

# Index

*Note:* References are to pages within chapters, thus 51.10 is page 10 of Chapter 51. Tables and/or Figures removed from the main text are in *italic*. Main entries are in **bold**. Alphabetical order is word-by-word, in which hyphens are given the filing role of a space.

- A**
- 1A4 antibodies (alpha-smooth muscle actin antibodies) 10.22
- AA *see* alopecia areata (AA)
- Ageneas syndrome 48.10
- abacavir 75.67
- hypersensitivity 35.7, 35.21, 72.30
- abatacept 74.9
- ABC method (avidin–biotin–peroxidase complex method) 10.17
- ABCA12 gene 11.13
- ABCB1 (*MDR-1*) gene 72.29
- ABCD dermatoscopy score 5.20
- ABCD mnemonic, melanoma 54.37
- abciximab 49.11, 49.13
- abdominal aortic aneurysm 47.2
- abdominal pain, in carcinoid syndrome 43.18
- abdominal wall, localized atrophy 45.12–13
- ablepharon–macrostomia syndrome 70.3
- abnormal sensitivity to cold 28.65–71
- abortion, spontaneous, in pseudoxanthoma elasticum 45.23
- abrasions
- accidental tattoo due to 58.57
- child abuse 28.34
- friction 28.9, 28.31
- infection following 4.5
- Abrikosoff's tumour *see* granular cell tumour
- abscess(es) 10.41
- in animals 2.12
- aseptic neutrophilic 50.82
- of Bartholin's gland 71.68
- breast *see* breast, abscess
- dental 69.109
- in HIV infection 35.24
- inguinal, chancroid 34.34
- intraoral 69.109
- metastatic tuberculous 31.10, 31.19–20
- oral cavity 69.109
- perianal/perineal 71.92
- periurethral 34.26
- pilonidal sinus 28.50
- subareolar 70.13
- sweat glands 17.43
- tubo-ovarian 34.26
- absence of skin *see* aplasia cutis congenita
- Absidia* 36.91
- vessel-invasive infection 49.35
- absorption, percutaneous 4.4–5
- in neonates 17.2
- absorption spectrum 29.3
- ABT-874, psoriasis 74.10
- Acacia melanoxylon* 26.80
- Acanthamoeba* 37.27
- acantholysis 10.36–7
- in complement-deficient mice 40.6
- defined 40.3
- in Hailey–Hailey disease 39.33
- mechanism 40.6
- in neonatal mouse model 40.5
- plasminogen activator 40.14
- urokinase block 40.14
- acantholytic dermatoses *see* Grover's disease (transient and persistent acantholytic dermatoses)
- acantholytic dyskeratotic epidermal naevi 19.83
- acanthoma
- clear cell 52.41
- Degos' 52.41
- pilar sheath 53.3
- spectacle-frame (acanthoma fissuratum) 28.29–30, 68.9
- acanthoma fissuratum 28.29–30, 68.9
- acanthome a 'cellules claires' 52.41
- acanthosis 10.37
- in eczema 23.4
- epidermal, Spitz naevus 54.22
- in viral warts 33.41, 33.42
- acanthosis nigricans 19.119–21
- acquired, pigmentation changes 58.25
- in animals 2.17
- congenital generalized lipodystrophy 46.37
- dermatomyositis and 58.27
- female genital region 71.80
- genitocrural dermatology 71.7
- hirsutism and 66.82
- HIV infection 35.12
- insulin resistance and 59.78, 66.82
- acne and 42.73
- male genital region 71.36
- oral involvement 69.34
- paraneoplastic 62.31, 69.34
- race and 9.15
- seborrhoeic keratosis association 52.38
- subtypes 69.34
- umbilical dermatology 71.101
- acanthosis palmaris (tripe palms) 19.120, 62.31–2
- Acari 38.33–54
- acarriasis
- canine sarcoptic 2.10
- otodectic 2.10
- Acaridae 38.46–7
- acarodermatitis urticarioides 38.48
- Acarus siro* 38.47
- accessory auricle 68.4
- accessory cells 4.8
- accessory digit 18.92
- accessory nerve 77.5
- accessory tragus (auricle) 18.84–5, 68.4
- ACE *see* angiotensin-converting enzyme (ACE)
- ACE inhibitors, adverse effects **75.92–4**
- angio-oedema 22.20, 22.21
- flushing 43.15–16
- pemphigus 75.38
- urticaria 22.10, 75.26
- acebutolol 75.91
- acetaldehyde, alcohol metabolism 43.16
- acetaminophen 75.72–3
- acetazolamide 75.97
- acetic acid 25.20
- acetone 25.20, 65.56
- N*-acetyl-4-*S*-cysteaminylphenol 73.27
- alpha-*N*-acetyl-galactosaminidase deficiency 59.34–5
- acetylacetone test 26.50, 26.99
- acetylated lanolin alcohol 27.13
- acetylcholine (ACh) 38.1, 44.3, 63.3, 80.7
- in atopic dermatitis 24.18
- peripheral nerves 4.10
- pruritus and 21.3, 21.4
- sweat gland control 3.12
- acetylcholinesterase 3.12
- N*-acetylcysteine 26.46, 47.11
- in microscopic polyangiitis 50.36
- ACh *see* acetylcholine (ACh)
- Achenbach's syndrome 28.27, 45.4, 45.5, 49.16
- Achillea* 25.21
- achondroplasia–hypochondroplasia, prenatal diagnosis 16.3
- achroordon *see* skin tags
- achromic naevus (naevus depigmentosus) 58.42, 58.44–5
- achromotrichia 66.94
- aciclovir
- action 74.49
- adverse effects 26.46, **75.66**
- in eczema herpeticum 33.36
- in erythema multiforme 76.7
- in herpes B virus infection 33.34, 33.35
- in herpes simplex 33.20, 33.21
- ocular involvement 67.26
- resistance 33.21
- in herpes zoster 33.27, 35.29, 63.6–7, 67.26
- corticosteroids with 33.28
- prophylactic 33.27
- in herpetic keratitis 67.16, 67.26
- mechanism of action 33.20
- in pityriasis rosea 33.81
- topical 73.15
- herpetic keratitis 33.21
- varicella prophylaxis 33.27
- varicella treatment 33.27, 35.29
- acid beta-glucosidase deficiency 59.39
- $\alpha_1$ -acid glycoprotein 13.19
- acid mucopolysaccharides, in scleroedema 51.119
- acid orcein–Giemsa stain 10.8
- acid phosphatase 3.52, 12.49, 38.14
- acids
- burns 25.11, 27.12
- as irritants 25.20
- Acinetobacter* 30.46
- axilla 30.4
- in cellulitis 30.18
- differential diagnosis 36.31
- in normal skin flora 30.2, 68.2
- perineum and groin 30.4
- toe clefts 30.4
- acini, sebaceous gland 42.1
- acipimox 75.156
- acitretin 74.35
- adverse effects **75.109**
- hair loss 66.29
- ocular 67.31
- in chloracne 27.14
- clinical indications 74.35
- in hidradenitis suppurativa 30.81
- in pemphigus 40.12
- in psoriasis 20.37, 74.35
- in psoriatic nail involvement 65.26
- in squamous cell carcinoma 52.28
- teratogenicity 72.28
- Ackerman syndrome 15.29
- acne
- adolescent *see* acne vulgaris
- childhood 42.75–6
- cosmetic 42.73
- drug-induced 9.5, 42.31, 42.71–3, 75.34
- ear 68.14
- endocrine 42.73
- external chemical origin (halogen acne) 27.12–15
- externally induced 42.73–4
- following spinal cord injury 63.17
- granulomatous/lymphoedematous 42.74, 42.75
- immobility 42.76
- infantile and juvenile 42.75–6
- irritant 25.2
- light-exacerbated 29.22
- 'Mallorca' 42.79
- mechanical 42.76–7
- naevi 18.11–13, 42.78
- Norwegian 42.79
- occupational 27.12–15, **42.77**
- oil and tar 27.6, 42.77
- penile 71.27
- pitch 27.14
- pomade 9.5, 42.31, 42.73–4
- post-acne osteoma cutis 59.70
- tropical/hydration 27.14, 42.79
- vasculitic/pyoderma gangrenosum 42.85
- virally induced 42.79
- see also* acne vulgaris
- acne aestivalis 42.79, **42.80**
- acne agminata 5.14, 31.25, **43.12–13**
- clinical features 43.13
- differential diagnosis 42.37, 61.10
- perioral dermatitis vs 43.11
- acne conglobata 42.32, 42.33, 42.71, **42.82–3**
- associated disorders 42.82–3
- isotretinoin treatment 42.62, 42.83
- treatment 42.83
- choice 42.40
- acne de jeune filles *see* acne excoriée
- Acne Disability Index 72.20
- acne excoriée 42.35, **42.70**, 64.29
- treatment 42.70
- acne fulminans 42.83–4
- bone and joint involvement 62.101
- erythema nodosum and 50.83
- inflammatory bowel disease and 62.52
- treatment 42.84
- isotretinoin 42.62
- acne mechanica 28.30, 28.31, 42.76–7
- acne necrotica miliaris 30.26
- acne necrotica varioliformis 30.26–7
- acne vulgaris vs 42.37
- acne nuchae keloidalis (acne keloid) 9.9, **30.26**
- Acne Quality of Life Scale (Acne-QOL; AQOL) 42.35, 72.20

- acne rosacea *see* rosacea  
acne venenata 27.12–15  
acne vermiculata (atrophoderma vermiculata) 45.8, 66.51  
acne vulgaris 42.17–70, 42.73–4  
adolescence 8.6  
aetiology/pathogenesis 42.17, 42.20–30  
cell-mediated immunity and scarring 42.26–7  
comedogenesis 42.22–4  
growth hormone and IGFs role 42.11  
hyperinsulinaemia 42.20–1, 42.34  
inflammation role 42.25–6  
innate immune reaction 42.25, 42.26  
*P. acnes* role 42.24–6  
seborrhoea 42.20–2  
topical drug effects on 42.40  
Apert's syndrome and 42.61, 42.70–1  
associated conditions 42.70–82  
associated features 42.33  
atopic dermatitis incidence and 42.18  
biological/evolutionary significance 42.27  
body dysmorphic disorder and 42.60, 42.71  
bone and joint involvement 62.99, 62.102  
calcification after (osteoma cutis) 42.78  
candidate genes 42.19  
childhood 42.75–6  
clinical features 42.30–8  
comedonal 42.18, 42.75  
treatment 73.35  
treatment choice 42.40  
cysts 42.18, 42.31  
Darier's disease and 42.71  
definition 42.17  
detergent 42.74  
diet and 42.33–4  
differential diagnosis 27.13, 42.36–8  
perioral dermatitis vs 42.36, 43.11  
rosacea 42.36, 43.5  
secondary syphilis vs 34.12  
drug-induced 9.5, 42.31, 42.71–3, 75.34  
ear 68.14  
endocrine 42.73  
endocrine investigations 42.22  
indications 42.21  
epidemiology and burden 42.19  
excess sebum production and 42.20  
females 42.18, 42.21–2  
genetic factors 42.18–19  
Global Alliance algorithm for outcome improvement 42.39, 42.40  
glycaemic index and 42.34  
grading scale 42.38, 42.38, 42.39  
haemorrhagic lesions 42.31, 42.32  
hidradenitis suppurativa and 42.74–5  
hirsutism and 42.20, 42.21  
hormonal control of sebaceous activity 42.9–14  
*see also* sebaceous glands  
hormonal treatments 42.52–4  
adrenal androgen production inhibitors 42.53  
androgen receptor blockers 42.53–4  
indication 42.52  
oral contraceptives 42.53  
ovarian androgen production inhibitors 42.53  
hyperprolactinaemia and 42.12  
inflammatory lesions 42.17, 42.30–1  
*P. acnes* role 42.24–5, 42.25–6  
scarring mechanisms 42.26–7  
steroids and isotretinoin 42.63  
topical antibiotics effect 42.43  
topical retinoids effect 42.40, 42.43  
treatment failure 42.57  
isotretinoin flare 42.62–3, 42.64  
predisposing risk factors 42.64  
isotretinoin treatment 42.14, 42.54, 42.57–66  
acne variants 42.62  
antibiotics with 42.63  
children under 12 years of age 42.60–1, 42.76  
clinical benefits 42.58–61  
cost-effectiveness 42.65  
dose schedules 42.61, 42.62  
drug interactions 42.64, 42.65  
duration of use 42.58, 42.62  
European Directive 42.59, 42.60  
initiation of therapy 42.59–60  
long-term treatment 42.58–9  
mechanism of action 42.57–8  
poor response 42.60  
resistance 42.62–3  
side effects 42.63–5  
in significant systemic disease 42.61  
slow response, reasons 42.62–3  
treatment recommendations 42.60  
US programme (iPLEDGE) 42.60  
itching 42.32  
keratins 42.23  
late-onset 42.18, 42.19  
lesion counts 42.38  
males 42.17–18  
mature 42.18, 42.19  
mild 42.38, 42.39  
mild to moderate 42.38  
moderate 42.39  
natural history 42.17–18  
nodular 42.71  
treatment choice 42.40  
nodules 42.31, 42.37  
non-inflammatory lesions 42.17, 42.30  
occupation and 42.34  
oral antibiotic treatment 42.46–9, 42.54  
adverse effects 42.47, 42.50–1, 67.31–2  
duration and dose 42.47–8  
mechanism of action 42.48  
topical agents with 42.48  
papular/pustular, treatment choice 42.40  
penile 71.27  
persistent 42.18  
isotretinoin use 42.61, 42.63  
physiological 42.18  
physiological/environmental factors affecting 42.33–5  
polycystic ovary syndrome and 42.20, 42.21–2, 42.73  
pomade 9.5, 42.31, 42.73–4  
premenstrual flare 42.24, 42.34  
prepubertal 42.18  
prevalence 42.17–18  
prognostic factors, poor 42.39  
psychosocial effects 42.35  
pyogenic granuloma 42.32, 42.79  
quality of life and 42.35, 64.10, 72.20  
race and 9.4–5, 42.19, 42.24  
resolution 42.18, 42.38  
mechanisms 42.27  
sandpaper 42.30  
treatment failure 42.56  
scarring 42.31–2, 42.32–3  
differential diagnosis 42.37  
mechanisms 42.26–7  
treatment 42.68–70  
types of scars 42.32–3  
scars 45.54  
keloid-like 45.54  
punch grafts 77.22  
sebaceous gland activity 42.15  
reduction/inhibition 42.14, 42.15  
seborrhoeic dermatitis and 23.29  
sebum excess 42.20–2  
sebum lipids and 42.22, 42.23  
secondary syphilis vs 34.12  
severe 42.39, 42.82–6  
severity assessment 72.10  
sinus formation 42.31, 42.32  
smoking and 42.34–5  
solar comedones with 42.79  
steroid 42.72  
stigma 64.6  
stress and depression 42.35  
sweating and 42.34  
topical treatment 42.39–46  
adapalene 42.39–40, 42.41, 73.36  
adverse effects 42.49–50  
antibiotics 42.39, 42.41–3, 73.9, 73.10  
azelaic acid 42.39, 42.43, 73.28  
benzoyl peroxide 42.39, 42.40, 42.41, 42.48, 42.67  
childhood acne 42.76  
complementary therapy 42.43  
dapsone 42.43  
nicotinamide 42.43, 73.51  
retinoic acid 73.34, 73.35  
retinoids 42.39–41, 42.48, 42.54  
salicylic acid 42.43  
selection 42.43–4  
tazarotene 73.37  
treatment 42.15–16, 42.38–70  
adverse effects 42.49–52  
antibiotics *see* acne vulgaris, oral  
antibiotic treatment  
choice 42.38–9, 42.43–4  
concordance with 72.6  
education of patients/doctors 42.55  
general principles 42.38  
hormonal *see* acne vulgaris, hormonal  
treatments  
isotretinoin *see* acne vulgaris,  
isotretinoin treatment  
oral 42.46–9, 42.66–7  
outcome measures 42.38  
*P. acnes* resistance 42.41–2, 42.43, 42.47, 42.55–6  
physical 42.67–8  
poor compliance 42.55  
retinoids 64.49  
slow response or failure 42.55–6, 42.56–7, 42.60  
topical *see* acne vulgaris, topical  
treatment  
UV radiation and 42.34  
variants, severe 42.82–6  
*see also* acne  
acneiform eruptions, drug-induced 42.71–3  
acnitis *see* acne agminata  
acquired digital fibrokeratoma 56.4, 65.31–2  
acquired epidermolysis bullosa *see* epidermolysis bullosa acquisita  
acquired generalized lipodystrophy (AGL) 46.37–9  
acquired idiopathic livedo reticularis 28.68, 49.49  
acquired immune deficiency syndrome *see* AIDS; HIV infection  
acquired perforating dermatosis 19.88–9  
acral arteriovenous tumour (cirroid aneurysm) 56.26–7, 65.35–6  
acral dermatitis, chronic 23.15  
acral dermatosis, acute, viral infections associated 33.76  
acral lentiginous melanoma 15.11, 54.35, 54.44, 54.45, 54.46, 65.40  
acral lick dermatitis 2.9  
acral peeling skin syndromes 19.66  
acral purpura 49.4, 49.32  
acral vascular syndrome, paraneoplastic 62.41  
*Acromonium* 36.8, 36.55, 36.73, 36.92  
acridinyl anisidide (AMSA) 75.133  
acrivastine 22.29  
in urticaria 22.28  
acro-dermato-ungual-lacrimal-tooth syndrome 15.29, 15.64  
acro-mammo-renal syndromes 70.2  
acro-osteolysis  
with keratoderma 19.115  
vinyl chloride-induced 45.52  
acroangiadermatitis of Mali 47.22, 49.17–18  
acrocephalosyndactyly *see* Apert's syndrome  
acrochordons *see* skin tags  
acrocyanosis 28.66–7  
cold-induced 49.33  
genetics 15.10  
neonatal 17.4  
reversible 49.34  
acrodermatitis chronica atrophicans 30.65, 45.9–11, 45.18  
acrodermatitis continua (of Hallopeau) 20.46, 65.25, 65.26, 79.4  
calcipotriol treatment 73.45  
acrodermatitis enteropathica 59.59, 59.72  
in animals 2.17  
Crohn's disease and 62.49  
genitocrural 71.5  
hair loss in 66.28–9  
oral involvement 69.31  
perianal/perineal 71.91  
in pregnancy 8.12  
acrodynia 69.83–4, 75.101–2  
acroerythrokeratoderma (Mal de Meleda) 19.3, 19.94, 19.100–1  
acrogeria 45.58, 45.59–60, 51.79, 51.106  
acrokeratoderma, aquagenic syringial 19.115  
acrokeratoelastoidosis of Costa 9.10  
acrokeratosis paraneoplastica *see* Bazex syndrome  
acrokeratosis verruciformis, Darier's disease vs and features in 19.82, 19.83, 19.88  
acrokeratosis verruciformis of Hopf 19.88, 65.18  
epidermodysplasia verruciformis vs 33.58  
plane warts vs 33.44  
acrokeratotic poikiloderma of Weary 15.82  
acrolein 25.21  
acromegaly 8.2, 62.2, 62.101  
ear involvement 68.18  
pigmentation 58.24  
sebum excretion rate 42.22  
acromelanosis 58.21  
acropachy 15.87–8  
acroparesthesiae 59.37  
acropigmentation, reticulate 58.21–2  
acropustulosis 65.25  
infantile 17.9–10, 50.62  
acropustulosis of Hallopeau, acitretin 74.35  
acrorenal field defect, ectodermal dysplasia, lipotrophic diabetes 15.29  
acrosclerosis 51.87  
vinyl chloride-related 62.47  
acrospiroma 53.22, 53.27–8  
malignant 53.34  
acrosvringium 53.23  
purpura around 49.21  
acryl ceramides, in sebum in acne 42.23  
acrylates 26.14, 26.72–3, 65.55–6  
acrylic fibres, sarcoidal reaction to 61.22–3  
ACTH  
administration, pigmentation changes 58.25  
adverse effects 69.97, 75.114–15  
in congenital adrenal hyperplasia 62.6  
in Cushing's syndrome/disease 58.24, 62.3–4  
ectopic secretion, pigmentation 58.25  
in lichen planus 41.18  
in place of systemic steroids 74.3–4  
at puberty 8.4  
sebaceous gland hypertrophy 42.11  
stimulation test 74.3  
*see also* ectopic ACTH syndrome  
actin 10.22  
Kindler syndrome 12.17  
polymerization, melanocyte dendrite formation 58.4  
actinic cheilitis *see* cheilitis, actinic  
actinic dermatitis, chronic *see* chronic actinic dermatitis (CAD)  
actinic elastosis 8.22  
actinic keratosis 52.2, 52.12, 52.30–2  
aetiology 52.30

- ageing and 80.2  
biological compensation in 52.31  
Bowenoid 52.31  
chromosome losses 52.29  
clinical features 52.30  
definition 52.30  
diagnosis 52.31  
epidermodysplasia verruciformis and 33.57  
eyelids 67.33  
flat type 52.31  
following chemotherapy 75.124  
hands 52.30  
in HIV infection 35.39  
incidence 52.2, 52.30  
lichenoid 52.31  
lip 52.30  
  *see also* cheilitis, actinic  
malignant melanoma risk 54.33  
new lesion development rate 52.31  
nodular 52.36  
pathology 52.30–1  
pigmented 52.31, 52.38  
pinna 68.30  
prevention by sunscreens 29.9  
progression to invasive SCC 52.29, 52.30, 52.31  
relapsing and/or remitting lesions 52.30  
skin biopsy 10.42  
treatment 52.31–2, 77.40, 77.42, 78.16  
  topical 5-FU 73.23  
  topical diclofenac 73.25  
  topical imiquimod 73.24
- actinic lentiginos *see under* lentiginos  
actinic prurigo (AP) 29.10, 29.13–15, 69.124  
  aetiology 29.13–14  
  clinical features 29.10, 29.14  
  definition 29.13  
  diagnosis and differential diagnosis 29.10, 29.14  
  pathology 29.14  
  polymorphic light eruption association 29.14  
  race and 9.19  
  treatment 29.10, 29.14–15
- actinic reticuloid (pseudolymphomatous chronic actinic dermatitis) 29.16, 29.17, 57.58
- $\alpha$ -actinin 40.2  
*Actinobacillus actinomycetem-comitans* 30.59  
*Actinomadura* 36.73  
*Actinomyces bovis* 30.75, 30.76  
*Actinomyces gerencseriae*, female genital infection 71.68  
*Actinomyces israelii* 30.74–5, 30.76  
  female genital infection 71.68  
*Actinomyces keratolytica* 30.39  
*Actinomyces naeslundii* 30.75  
*Actinomyces pyogenes* 30.37  
actinomycete infections 30.74–6, 68.25, 68.27  
  mycetoma due to 36.72–5  
actinomycetoma 36.72–5  
actinomycin D, adverse effects 75.127  
actinomycosis 30.74–6  
  abdominal 30.75  
  cervicofacial 30.75  
  pelvic 30.75  
  primary cutaneous 30.75  
  thoracic 30.75  
actinonin 12.50  
actinophytosis 30.67–8  
activated leukocyte cell adhesion molecule (ALCAM) 12.73  
activated partial thromboplastin time (aPTT) 49.9  
activated protein C (APC) 49.38  
  concentrates, in sepsis 49.40  
  resistance 14.13, 47.28, 47.42, 49.38–9  
activation-induced cytidine deaminase 13.10  
activator protein 1 (AP-1) 8.21, 8.22  
activin A, in lichen planus 41.1–2  
activin receptor-like kinase 1 (ACVRL) 47.17  
acupuncture 68.7, 72.32  
  blue macules at site of needles 58.54  
  in brachioradial pruritus 63.24  
  in post-herpetic neuralgia 63.7  
  for surgical procedures 77.11  
acute disseminated epidermal necrosis 76.1  
acute febrile neutrophilic dermatosis *see* Sweet's syndrome  
acute generalized exanthematous pustulosis 75.34–5  
  differential diagnosis 76.19  
acute genital ulceration 71.65–6  
acute haemorrhagic oedema of childhood/infancy 17.33–4, 49.18–19, 50.30  
acute leukaemia 55.31  
  genetics 15.14  
acute panniculitis, mechanical injury 28.27  
acute papular onychodermatitis 37.5  
acute-phase proteins 12.34, 13.19  
  C-reactive protein 12.28, 12.32, 13.4, 13.19  
acute retinal necrosis syndrome 33.26  
acute scrotum 71.28  
ACVRL1 gene mutations 47.17  
acyclovir *see* aciclovir  
acyl coenzyme A compounds 46.2  
AD *see* atopic dermatitis  
AD (autosomal dominant) inheritance 15.2, 15.5  
adalimumab 12.42, 13.25, 72.29, 74.5–7, 75.145  
  clinical indications 74.6  
  dose range and evidence level 74.6  
  and methotrexate, ADEPT study 74.7  
  origin 74.5  
  in psoriasis 20.41, 74.5  
Adam complex syndrome *see* amniotic bands/adhesions  
Adamantiades–Behçet's disease *see* Behçet's disease  
Adams–Oliver syndrome (scalp aplasia cutis congenita with limb reduction abnormalities) 15.96, 18.68, 18.99–100  
ADAMTS 3.41  
ADAMTS-1 gene 3.41  
ADAMTS-2 3.41  
ADAMTS13, deficiency 49.12, 49.31  
adapalene 73.35, 73.36  
  topical  
  acne treatment 42.39–40, 42.41  
  chloracne treatment 42.77  
Addison's disease 62.5–6  
  in autoimmune polyglandular syndrome 62.13  
  candidiasis and 36.58  
  ear involvement 68.18  
  genetics 15.81  
  hyperpigmentation 58.24  
  pigmentation 58.7  
  sarcoidosis and 61.17  
  sweat in 44.6  
  white 62.6  
Adema disease 59.72, 59.73  
ADEN (acute disseminated epidermal necrosis) 76.1  
adenine 11.2  
adenocarcinoma  
  aggressive digital papillary 53.33  
  female genitalia 71.77  
  perianal/perineal 71.91  
  sweat glands 53.40  
adenocarcinomatosis, perianal/perineal 71.91  
adenocystic carcinoma, primary cutaneous 53.37  
adenoid cystic carcinoma 53.37  
adenoma  
  apocrine tubular 53.21  
  ceruminous glands 68.29  
  papillary eccrine 53.26–7  
  sebaceous 42.87, 53.15–17, 68.28, 69.23  
  tubular apocrine 53.26  
adenosine arabinoside 74.48  
adenosine deaminase deficiency 17.60  
adenosine triphosphate (ATP) 46.2  
adenoviruses 33.2  
ADEPT study, adalimumab and methotrexate 74.7  
ADFN gene 58.44  
adherence to therapy *see* concordance  
  with therapy  
adherens junctions 3.23–4, 40.2  
  cadherins 40.2, 40.3  
  functions 3.23  
  gene mutations 3.23–4  
  *see also* desmosomes  
adhesion complex 40.1–2, 40.25  
  basement-membrane zone 40.1–2, 40.25  
  epidermis, desmosomes role 3.21–2  
  IgA antibodies 40.46  
adhesion molecules 12.68–75  
  on activated keratinocytes 12.75  
  in allergic contact dermatitis 26.6  
  in Behçet's disease 50.56  
  cell–cell adhesion, cadherins 40.5  
  CX3CR1, cell–cell adhesion and leukocyte trafficking 12.48  
  on desmosomes 40.2  
  ICAM-1 12.10, 12.16, 12.73  
  ICAM-2 12.73  
  leukocyte cell adhesion molecule (LEUCAM) subfamily 12.70  
  on neutrophils 12.21  
  platelet–endothelial cell adhesion molecule (PECAM-1 or CD31) 12.73  
  regulating leukocyte emigration 12.74  
  in vasculitis 50.4  
  vitamin D action 73.43  
adhesions  
  fibrinous 'violin-string' 34.30  
  heparan sulphate role 3.46  
  *see also* amniotic bands/adhesions  
adhesive plaster, salicylic acid in, wart treatment 33.48  
adhesives, in shoes 26.63, 26.68  
adipocytes 3.52  
  brown 46.1  
  hibernoma 46.45  
  development 46.3  
  differentiation inhibition by antiretrovirals 46.42  
  histology and cell structure 46.1–2  
  hyperplasia 46.6, 46.9  
  hypertrophy 46.6, 46.9  
  rimming 46.26  
  visceral adipose tissue (VAT) 46.4  
  dysfunction, in obesity 46.6, 46.6–7  
  white 46.1  
  *see also* lipocytes  
adipogenesis 46.3  
adipokines 46.2, 46.3  
adiponecrosis e frigore (cold panniculitis) 17.35, 46.21  
adiponectin 46.4  
  anti-inflammatory effects 46.4  
  low levels, inflammatory effects 46.4  
  receptors 46.4  
adipose tissue 46.2  
  atrophy *see* lipoatrophy  
  brown 8.16  
  hypertrophy 46.34, 46.41, 70.3, 70.4  
  intra-thoracic, increased 46.41  
  loss 46.34, 46.36  
    generalized lipodystrophy 46.37, 46.38  
    partial lipodystrophy 46.39–40  
    *see also* lipoatrophy; lipodystrophy  
  necrosis 46.44  
    *see also* subcutaneous fat, necrosis  
  omental, HIV lipodystrophy 46.42  
  pathology 46.10–12  
    *see also* panniculitis  
  perivascular 46.2  
  physiological function 8.16–17  
  visceral 46.4, 46.5  
  white 8.16–17  
    *see also* subcutaneous fat  
adiposid dolorosa (Dercum's disease) 8.17, 46.46, 46.47–9, 48.20  
adiposopathy 46.7  
adnexal polyp of neonatal skin 17.15, 70.8  
adnexal tumours 53.1–44  
  benign to malignant change 53.32  
  carcinoma  
    adenoid cystic 53.37  
    microcystic 53.35–6  
    mucinous 53.36  
  classification 53.2, 53.27  
  ductal differentiation 53.2  
  metastases 53.2  
  *see also specific tumours, anatomical structures*  
adolescence 8.4–8  
  career choice and skin disease 8.6, 8.7–8  
  dermatoses 8.6–8  
  difficulties and emotional problems 8.6  
  melanoma 54.48–9  
  normal bacterial skin flora 30.4  
  obesity 8.4  
  psychocutaneous disorders 64.30  
  quality of life assessment 72.23  
  striae 45.5, 45.6  
  *see also* puberty; individual conditions  
adrenal glands  
  androgen production, inhibition 42.53  
  carcinoma 66.83  
adrenal hyperplasia, late-onset, acne and 42.21  
adrenal insufficiency *see* Addison's disease  
adrenaline  
  in anaphylaxis 22.29, 38.15  
  in angio-oedema 22.29  
  in local anaesthetics 77.9, 77.10  
  in nail biopsy 65.42  
  skin biopsy and 10.2  
adrenallitis, autoimmune 62.5  
adrenarache 8.4  
 $\alpha$ -adrenoceptor blockers  
  in carcinoid syndrome 43.19  
  vibration injury 28.58  
adrenocortical disease, in Carney syndrome 58.14  
adrenocortical hormones, sebaceous gland activity and 42.11  
adrenocorticotrophic hormone *see* ACTH  
adrenoleukodystrophy 44.18  
adrenomedullin 4.5  
adriamycin *see* doxorubicin  
ADRs *see* drug reactions  
adult premature ageing syndrome *see* Werner's syndrome  
adult progeria *see* Werner's syndrome  
adult respiratory distress syndrome (ARDS), in toxic epidermal necrolysis 76.17  
ADULT syndrome 15.29, 15.64  
adult T-cell leukaemia–lymphoma (ATLL) 33.64–6, 57.37–9  
  clinical features 33.64–5  
  HTLV-1-association 57.37–9  
  race and 9.13  
adverse drug reactions *see* drug reactions  
AEC (ankyloblepharon-ectodermal dysplasia–clefing) syndrome 15.30, 15.61–3  
AECA *see* antiendothelial cell antibodies  
*Aeromonas* 30.59, 38.55  
  infections of reptiles/amphibia 2.12  
*Aeromonas hydrophila* 30.18, 30.59  
aerospace industry, occupational hazards 27.18  
AESOP syndrome 62.94  
aesthetic surgery, body dysmorphic disorder 64.19  
AF-6 (afadin) 3.23  
afadin 3.23

- affective disorder, in Hailey–Hailey disease 39.35
- afferent nerves 12.64
- African black walnut 26.81
- African blackwood 26.81
- African ebony 26.80
- African eye worm (loiasis) 37.11–12, 38.6
- African mahogany 26.81
- African teak 26.81
- African tick bite fever 38.35
- African tick typhus 30.73
- African trypanosomiasis 37.2, 37.29–31
- Afro–Caribbean children, circumscribed keratotic disorders 19.93
- agammaglobulinaemia
- autosomal recessive 17.71–2
  - X-linked 13.9, 13.13, 17.70–1, 69.117
- agammaglobulinaemia–dwarfism–ectodermal dysplasia 15.29
- age
- drug pharmacokinetics and pharmacodynamics 72.28–9
  - effect on normal bacterial skin flora 30.3–4
  - mechanical injury effects and 28.7, 28.18
- age spots 8.23
- see also* lentigo
- ageing 8.21–9
- allergic contact dermatitis and 26.8
  - bacterial skin flora and 30.3–4
  - biology of 8.21–2
  - dermis 8.22–3
  - Down's syndrome and 45.61
  - drug pharmacokinetics and pharmacodynamics 72.28–9
  - ear changes associated 68.5–6
  - eccrine sweat glands 8.24
  - epidermis 8.23
  - extrinsic 80.2, 80.3
  - hair colour changes 8.23
  - hair follicles 8.23–4
  - immune function and 8.24, 13.15
  - intrinsic 80.1–2
  - irritant contact dermatitis and 25.6–7
  - Langerhans' cells and 8.24
  - nail growth 8.24
  - nerves and sensation 8.24
  - occupational dermatoses and 27.2
  - pigmentation of skin 8.23
  - premature 45.15, 45.56–63
  - with short stature and pigmented naevi 45.60
  - prevention 80.3–4
  - pruritus and 21.12, 21.17
  - purpura 49.15
  - risk factor for skin disease 6.12
  - sebaceous and apocrine glands 8.24
  - skin
    - control of 8.21
    - photoageing 8.21–2
    - signs of 8.21
    - structural changes 8.22–5
  - stratum corneum 4.11
  - telangiectases due to 47.13
  - transepidermal water loss and 4.11
  - UVR effect (photoageing) 29.7
  - vascular changes associated 80.11
  - wound healing and 14.2, 14.9, 14.17–18
  - wrinkles and 45.2–3
- agglutinins, cold-induced injury 28.71
- aggrecan 3.48
- aggressive epidermotropic CD8+ (provisional) T-cell lymphomas 57.35–6
- aggressive house spider 38.32
- Agouti* gene 2.5, 2.6
- AGPAT enzymes 46.37
- agranulocytosis, oral involvement 69.56
- agriculture
- Bowen's disease associated 52.32
  - occupational hazards 5.6, 27.18
- AHEC (acute haemorrhagic oedema of childhood/infancy) 17.33–4, 49.18–19, 50.30
- Aicardi–Goutières syndrome 11.15
- AID (activation-induced cytidine deaminase) 13.10
- AIDS
- case definition 35.4–5
  - in pregnancy 8.13
  - rank order of diagnoses 35.4
  - see also* HIV infection
- AIN *see* anal intraepithelial neoplasia
- ainhum 45.69
- race and 9.12–13
- air flow, role in irritant contact dermatitis 25.8
- air-fluidized mattresses 28.20, 28.22
- air sampling, bacterial skin flora 30.2
- airbag dermatitis 28.14
- Aircast Walkers® foam boot 63.10
- aircrew, occupational hazards 27.18
- AIRE* gene 62.13
- defects 13.15
- AJCC staging system, melanoma, malignant 54.49, 54.50
- AL Test system 26.85
- Alagille's syndrome 62.62, 62.77
- alantolactone 26.75, 26.77
- alarmins 3.16
- Alatina moseri* 38.56
- albendazole 74.50–1
- in cutaneous larva migrans 37.17
  - in echinococcosis 37.25
  - in gnathostomiasis 37.18
  - in strongyloidiasis 37.16
  - in toxocarasis 37.18
  - in trichinosis 37.20
- albinism 58.39–41, 66.93–4
- classification 58.39
  - clinical features 58.40, 66.94
  - electron microscopy 10.29
  - genetics 66.94
  - incidence 58.40
  - ocular 58.39
  - oculocutaneous (OCA) 58.39
  - prenatal diagnosis 16.3, 16.6
  - race and 9.16
  - types 58.39
  - partial *see* piebaldism
  - prognosis and treatment 58.40–1
  - tyrosinase-negative 58.39, 58.40
  - tyrosinase-positive 58.40, 58.41
  - X-linked ocular 58.39
  - yellow mutant 58.40
- albinism–deafness syndrome (ADFN) 58.44
- albino 58.1
- albinoidism 58.41
- Albright's hereditary osteodystrophy 56.61–2, 62.12
- genetics 15.6
- Albright's sign 62.12
- Albright's syndrome *see* McCune–Albright syndrome
- albumin 13.19, 66.81
- albuterol 75.98
- Alcian blue reaction 10.8
- alcohol
- avoidance in carcinoid syndrome 43.19
  - flushing associated 43.16
  - intolerance 22.32
  - as irritant 25.19, 25.20
  - metabolism 43.16
  - misuse *see* alcohol abuse
  - multiple symmetrical lipomatosis associated 46.46
  - porphyria cutanea tarda and 45.52
  - sweating and 44.7
  - urticaria induced by 22.8
  - use in pregnancy *see* fetal alcohol syndrome
- alcohol abuse 64.46–7
- methotrexate 74.22
  - in psoriasis 20.4, 20.18
- alcohols
- antiseptics 73.14
  - in topical treatment 73.7
- alcuronium 75.153
- Alcyonidium diaphanum* 38.58
- aldehyde dehydrogenase 43.16
- aldehydes 25.21
- as antiperspirants 73.9
  - as antiseptics 73.14
- alefacept 13.25
- in lupus perniosis 61.21
  - origin 74.8–9
  - in psoriasis 20.41, 74.6, 74.8–9
- alemdronate 75.99
- Aleppo boil (Old World cutaneous leishmaniasis) 37.34–9
- aleuroconidia 36.4
- Alezzandrini's syndrome 58.46, 66.93
- alfalfa, antinuclear and anti-dsDNA antibodies 51.30
- alginate dressings 14.23–4
- alitretinoin (9-cis-retinoic acid) 73.36–7, 74.36
- clinical indications 74.36
  - topical 73.36–7
- ALK (anaplastic lymphoma kinase) 10.25
- ALK-1, and ALK-5 47.17
- alkali(s)
- burns 27.12
  - as irritants 25.9, 25.20
- alkali tests 27.11
- Alkaligenes*, toe clefts 30.4
- alkaline phosphatase 10.16
- in sarcoidosis 61.8
- alkaptonuria 44.21, 58.54, 59.98
- ear involvement 68.18
  - ochronosis in 44.21
  - see also* ochronosis
- alkyl bromides 25.21
- alkyl chlorides 25.21
- alkyl sulphonates 75.124
- alkyl tin compounds 25.21
- alkylating agents 75.124–5
- in necrobiotic xanthogranuloma 55.28
- all-*trans*-retinoic acid (ATRA) 42.14
- collagen gene expression control 3.39
  - male genital conditions 71.27
  - in melasma 73.27
  - photoageing reduction 29.7
  - receptors 73.35
  - sebocyte proliferation and lipids suppressed 42.14, 42.15
  - see also* retinoic acid (tretinoin; vitamin A acid)
- alleles, definition 15.3
- allergens 26.11, 26.30–84
- additional series, tests 26.92
  - airborne 22.9, 26.16–17, 26.20
  - assessment of sensitization potential 26.11–12
  - atopic dermatitis and 24.10–12, 24.30–1
  - avoidance 26.101
  - during pregnancy 24.34
  - binding to skin components 26.5
  - containment 26.99
  - eczema and 23.5
  - hand eczema and 23.13–14
  - injection by arthropods 38.1–2
  - leg ulcer 47.45
  - in lipsalves and lipsticks 69.119
  - in photoallergic contact dermatitis 26.23–4
  - pigmented purpuric dermatoses due to 49.23
  - replacement 26.99, 27.9
  - responses to 13.13
  - sources 26.14
  - standard series 26.2, 26.91–2
  - storage 26.86
  - systemic reactions to 26.22–3
  - urticaria due to 22.7–8
  - volatile 26.16–17
  - see also individual allergens*
- allergic contact dermatitis 26.1–106
- after arthropod bites/stings 38.2
  - age and 26.8
  - in animals 2.10
  - anogenital 26.18–19, 26.29
  - to antimicrobial agents 26.49–58
  - to applied medicaments 26.13, 26.18, 26.22, 26.43–7
  - arms 26.15–16, 26.29
  - atopic dermatitis and 24.22, 26.7, 26.13–14
  - axillae 26.18
  - to Bryozoa 26.10, 38.58
  - chronic 26.15
  - chronic venous insufficiency 47.34
  - clinical examination 26.14–22
  - clinical features 26.13–22
  - to clothing 26.18, 26.65–8
  - co-existence with other disorders 26.9
  - corticosteroids associated 73.17
  - to cosmetic vehicles 26.58–60
  - to cosmetics 26.14, 26.16, 26.17, 26.47–9
  - delayed (late) reaction time 26.6
  - differential diagnosis 26.28–30
  - differentiation from irritant contact dermatitis 25.6, 26.87–8
  - drug influences on 26.9
  - duration and behaviour 26.13
  - ear 26.17, 68.14
  - in elderly people 8.28
  - elicitation 26.6
  - environmental factors 26.10–11
  - epidemiology 26.2–5
  - exposed sites 26.20, 26.30
  - eyelids 23.11, 26.17, 26.22, 26.31, 67.5
  - facial 26.16–17, 26.29
  - feet 26.19, 26.29
  - female genitalia 71.58
  - to footwear 26.68–9
  - gender and 26.7–8
  - generalized 26.19, 26.30
  - gentamicin causing 73.10
  - in Hailey–Hailey disease 39.34–5
  - to hair dyes 26.10, 26.17, 26.60–2
  - hands 26.15–16, 26.29
  - history of 26.1–2
  - history-taking 26.13–14
  - hormones and 26.8
  - in infancy and childhood 26.8–9
  - Langerhans' cells regulating 55.4
  - legs 23.35, 23.36, 26.19, 26.29
  - lips 26.17
  - male genitalia 71.17–18
  - management 26.101–3
  - mechanical injury 28.22, 28.25, 28.52, 28.54
  - mucosal 26.20–1
  - nail involvement 65.28–9
  - to nail lacquer/polish 65.54–5
  - neck 26.18
  - neonatal 17.22
  - nipple 70.10
  - non-eczematous responses 26.25–8
  - occupational 26.4–5, 26.14, 26.20, 27.4, 27.5, 27.7
  - pathogenesis 26.5–6
  - pathology 26.13
  - perioral 26.17
  - periorbital oedema 67.5
  - persistent 29.17
  - pimecrolimus therapy 73.32
  - plant-induced 26.10, 26.15–16, 26.74–9
  - population studies 26.4–5
  - predisposing factors 26.6–13
  - to preservatives 26.49–58
  - prevalence 26.3–5
  - prevention 26.99–101
  - primary patterns 26.15–20
  - primary site 26.13
  - prognosis 26.103–4
  - race and 9.13, 26.8
  - to resins and plastics 26.16, 26.20, 26.69–74
  - to rubber 26.63–5
  - scalp 26.17–18
  - seasonal variation 26.13
  - secondary patterns 26.21–2
  - sensitization 26.1, 26.5–6, 26.6–7, 26.9–10

- sensitizing agents 73.39  
sources of allergy 26.14  
susceptibility to 26.6–7  
systemic non-eczematous 26.27  
systemically reactivated 26.22–3  
topical acne agents causing 42.49  
topical therapy causing 73.4  
truncal 26.18, 26.29–30  
to UV filters 26.62–3  
to woods, colophony and turpentine 26.79, 26.80–1, 26.82–4  
wound healing and 14.17  
allergic contact urticaria *see* urticaria  
allergic granulomatosis *see* Churg–Strauss syndrome  
allergic reactions  
canine 2.7  
to HRT 8.20  
to tattoo pigments 58.58  
to topical antibiotics 73.10  
allergy **13.12–14**  
to abacavir 72.30  
to aluminium 26.39–40, 26.46  
to antiperspirants 26.18  
to antiseptics 26.46  
to arthropod bites and stings 38.1  
to balsam of Peru 26.18, 26.22, 26.40, 26.41  
to chromium 26.15, 26.18, **26.34–6**  
compound 26.89  
contact urticaria and 22.19  
to cow's milk 22.6  
to detergents 26.18  
drug-induced 75.15–21  
to food additives 26.17, 26.22  
to gold 26.26, 26.38–9  
history of 26.1–2  
to nail polish/lacquer 26.16, 26.17, 26.18, 26.47, 26.48, 68.24  
to nickel *see* nickel  
to penicillin 26.46, 34.23  
to poison ivy 26.16, 26.17, 26.75  
to pollen *see* pollen allergy  
to retinol 26.46  
tests 13.16  
to tetracyclines 26.46, 75.53  
therapy 13.25–6  
to vitamin E 26.46  
to vitamin K 26.46  
Allgrove's syndrome 62.13  
*Allium* 25.21, 26.77  
*Allodermanyssus sanguineus* 30.74  
allodynia 33.26, 63.6  
allokinesis 21.1, 21.3, 21.13  
allopurinol 59.103  
adverse effects 75.78  
Stevens–Johnson syndrome 76.4, 76.11  
in American trypanosomiasis 37.32  
in palmar fibromatosis 45.46  
in sarcoidosis 61.21  
alloys, prosthetic implants 26.37  
allyl alcohol 25.21  
allylamines, topical 73.12  
allysines 3.43  
alopecia 66.13–14, **66.16–61**  
aetiology and 66.16–18  
age of onset and 66.16–17  
androgenetic 8.23  
in adolescence 8.6  
caffeine (topical) retarding 73.49  
female pattern 66.16, 66.17–18, 66.20, 66.22, 66.24, 66.25–6  
Hamilton–Norwood grading scale 66.16, 66.17  
inheritance 66.18–19  
limited frontoparietal 66.16  
nomenclature 66.16  
pathogenesis 66.19–21  
pathology 66.22–3  
role of androgens 66.13–14, 66.14–15, 66.16, 66.19–20  
treatment 66.23–7  
treatment, minoxidil 73.49–50  
in animals 2.18–19  
artefactual 66.53–6  
caused by irritants 25.2  
central centrifugal (follicular degeneration syndrome) 9.7, **66.46**, 66.68  
cicatricial  
acquired 66.38–9  
classification 66.39, 66.40  
non-specific 66.39  
primary 66.40  
secondary 66.40  
clinical features and 66.21–2  
congenital 66.59–60  
cosmetic 66.53  
Cronkhite–Canada syndrome 58.13  
definition 5.7  
in discoid lupus erythematosus 66.43–5  
in dogs and other animals 2.10  
drug-induced 66.29–30, 75.45  
due to medical trauma 66.53  
eating disorders 64.22  
in follicular lichen planus 41.11  
frontal fibrosing 41.11, 66.41, 66.42  
generalized non-Herlitz junctional EB 39.13  
in HIV infection 66.2  
in Hodgkin's disease 57.63  
hot comb (follicular degeneration syndrome) 9.7, **66.46**, 66.68  
in hypothyroidism 62.10, 66.28, 66.29  
in incontinentia pigmenti 66.51  
in lichen planus 41.11, 41.14, 41.17, 66.39, 66.41–3  
lipedematous 66.58–9  
neonatal occipital 17.4  
paraneoplastic, in cats 2.19  
pathological pulling/plucking 64.30–1  
post-inflammatory cicatricial, eyebrows 67.4  
in radiodermatitis 66.53–4  
sarcoidosis and 61.9, 61.14  
scarring 66.65  
differential diagnosis 66.36  
in dystrophic EB 39.18  
frontotemporal 9.7  
in SLE 66.29  
sulphur depletion 59.72  
in syphilis 66.29, 66.52  
syphilitic 34.11  
telogen, postpartum 8.10  
total (congenital) 66.59–60  
traction 9.7, 66.53  
treatment  
antiandrogens 74.2–3  
minoxidil 73.49–50  
Vogt–Koyanagi–Harada syndrome 58.45  
*see also* baldness  
alopecia areata (AA) 64.5, 66.16, **66.31–8**  
aetiology 66.31–3  
animal models 2.18  
in animals 2.18  
atopic dermatitis and 24.23  
atopy and 66.31  
as autoimmune disease 66.31–2  
in autoimmune polyglandular syndromes 62.13  
clinical features 66.34–5, 66.36  
diabetes mellitus and 66.32  
differential diagnosis 36.27, 66.35–6  
eyebrow hypoplasia 67.3  
genetics 15.10, 66.31  
genitocrural 71.8  
greying of hair and 66.92, 66.93  
in HIV infection 35.42, 66.2  
infection and 66.32  
management 66.36  
nail involvement 66.35, 66.36  
in other species 66.33  
pathology 66.33, 66.34  
prognosis 66.36  
skin biopsy 10.43  
stress and 66.32  
tacrolimus use and 73.32  
treatment 66.36–8  
minoxidil 73.50  
sensitizing agents 73.39  
topical mechlorethamine 73.24  
alopecia mucinosa 57.14, 59.26  
alopecia neoplastica 70.14  
alopecia totalis 66.35, 66.36, 66.37–8  
topical mechlorethamine treatment 73.24  
alopecia unguium 65.10  
alopecia universalis 66.36, 66.38  
in animals 2.18  
alopecia universalis–onychodystrophy–total vitiligo 15.30  
alopecia–anosmia–deafness–hypogonadism 15.30  
alopecia–onychodysplasia–hypohidrosis 15.30  
alopecia–onychodysplasia–hypohidrosis–deafness 15.30  
alpha-actinin 40.2  
alpha-hydroxy acids, in actinic elastosis 45.27  
 $\alpha$ -antitrypsin deficiency *see*  $\alpha$ -antitrypsin deficiency (*under antitrypsin*)  
 $\alpha$ -defensins 4.5, 13.4  
 $\alpha$ -fetoprotein 47.19, 63.16  
 $\alpha$ -keratin intermediate filaments ( $\alpha$ -KIF) 66.6  
 $\alpha_2$ -macroglobulin 13.4  
 $\alpha$ -tocopherol *see* vitamin E  
Alpine sunlamp 29.1  
*Alpinia galanga* 76.5  
Alport syndrome 3.27, 3.35  
alprazolam 75.81  
ALPS (autoimmune lymphoproliferative syndrome) 17.65–6  
*Astromeria* 26.26, 26.76  
Alstrom syndrome 69.12  
alteplase 75.23, 75.107  
altered self hypothesis, in vasculitis 50.6  
*Alternaria alternata* 36.77  
alternating pressure mattresses 28.20, 28.22  
alternative therapies *see* complementary and alternative therapy  
altitude injury, ear 68.11  
aluminium, allergy to 26.39–40, 26.46  
aluminium acetate 73.15–16  
in otitis externa 68.25  
aluminium chlorhydrate 44.11, 73.9  
aluminium chloride 25.19, 77.50  
in hyperhidrosis 44.10, 44.11  
in tinea pedis 36.49  
aluminium chloride hexahydrate 63.22–3, **73.9**, 77.47  
in epidermolysis bullosa simplex 39.31  
aluminium chlorohydrates 44.11, 73.9  
aluminium oxide, for calcinosis in a child 51.129  
alveolar fibrosis, systemic sclerosis 51.93  
alveolar ridges, bone loss in dystrophic EB 39.19  
amalgam *see* dental amalgam  
amantadine 26.46, 75.88  
amastia 70.2, 70.3  
amaurosis fugax 50.43  
amaurotic idiocy 44.18  
ambiguous external genitalia 71.56  
ambiphilic creams 73.7  
*Amblyomma* 30.58, 38.34, 38.35  
Ambras syndrome 66.76  
*Ambrosia* (ragweed) 26.10, 26.20, 26.75  
amelanosis 58.9  
amelo-cerebrohypohidrotic syndrome 15.30  
amelo-onychohypohidrotic dysplasia 15.30  
amelogenesis imperfecta 69.8  
amenorrhoea–galactorrhoea syndrome 66.83  
American trypanosomiasis (Chagas' disease) *see* trypanosomiasis, American/South-American  
amethocaine (tetracaine) 75.153, 77.10  
amfebutamone 75.88–9  
amicrobial pustulosis associated with autoimmune diseases 50.90  
amidopyrine 75.77  
amikacin 74.42  
amiloride, adverse effects 70.5  
amineptine 75.78  
acneiform eruptions due to 42.72  
*bis*(4-amino-3-methylcyclohexyl) methane 27.17  
3-amino-9-ethylcarbazole 10.16  
amino acid metabolism disorders 59.94–104  
with hypotrichosis 66.61  
amino penicillins, cutaneous adverse drug reactions 74.40  
amino-plastics 26.73, 26.74  
*p*-aminobenzoic acid 26.23, 26.62  
aminocaproic acid 75.107  
aminocyclitol antibiotic 74.42  
aminoglutethimide 75.128  
aminoglycoside antibiotics 74.42, 74.44  
in Hailey–Hailey disease 39.36  
topical 73.10  
5-aminolaevulinic acid (ALA)  
in non-melanoma skin cancer 52.16  
in photodynamic therapy 78.15  
topical, acne vulgaris 42.68  
aminopenicillins 74.40  
aminopeptidase N (APN) 12.50  
aminophenazone 75.77  
aminophylline 75.99  
aminopterin 20.33  
amiodarone 70.5, 75.31, 75.33, 75.89  
photosensitivity 29.23, 58.56  
pigmentation due to 58.56, 58.57  
amisulpiride 64.52  
amitriptyline 64.51  
adverse effects 75.78  
in dystrophic EB 39.30  
in erythromelalgia 47.10  
in hyperhidrosis 44.12  
in post-herpetic neuralgia 63.7  
ammonia, napkin dermatitis and 17.23  
ammonium chloride, in alkali burns 27.12  
ammonium persulphate 22.20, 26.17  
amniocentesis 16.2, 17.11  
amniotic bands/adhesions 17.15, **18.106–7**, 45.69  
lymphoedema 48.11  
amocazine 75.71  
amoebiasis **37.27–8**  
HIV infection 35.35  
perianal/perineal involvement 71.95  
amoeboma 37.27  
amorolfine 26.46, 36.48–9, 36.50, 36.55  
in onychomycosis 73.12  
in superficial white onychomycosis 36.55  
amoxicillin 75.50  
amoxicillin–clavulanate, adverse effect in HIV infection 35.21  
AMP-protein kinase A (AMP-PKA)  
pathway 46.3, 46.4  
amphetamines 44.18  
abuse 64.13, 64.14  
adverse effects 69.21, 70.5, **75.86–8**  
amphibia  
glands 2.4  
pigment cells 2.6  
skin 2.2  
skin infections 2.12  
amphotericin B 74.46  
adverse effects 75.64  
in blastomycosis 36.85  
in candidiasis 36.68, 36.69  
in chromoblastomycosis 36.76  
in coccidioidomycosis 36.86  
in cryptococcosis 36.90–1  
in histoplasmosis 36.83  
lipid-associated 74.46  
in penicilliosis 36.88

- ampicillin  
 adverse effects 75.22, **75.49–50**  
 fixed eruption 75.28  
 in infectious mononucleosis 33.30,  
 75.15, 75.49  
 in rosacea 43.6
- AMPs *see* antimicrobial peptides
- amputation  
 amputation stump neuroma 56.45  
 intrauterine *see* amniotic bands/  
 adhesions  
 in peripheral arterial disease 47.6, 47.8  
 stump pemphigoid 28.29  
 in thromboangiitis obliterans 47.8
- amputees, mechanical injury 28.27–9
- AMSA 75.133
- Amsler grid 45.23
- AMSTAR (Assessment of Multiple  
 Systematic Reviews) 7.16
- Amsterdam dwarf *see* de Lange  
 syndrome
- amyldimethyl-*p*-aminobenzoate 25.19
- amyloid proteins  
 non-fibrillar 59.42  
 in notalgia paraesthetica 63.23  
 staining 10.10, 59.43
- amyloidosis **59.42–57**, 62.45  
 anosacral 59.48  
 biochemical nature of fibril proteins  
 59.43  
 bone and joint involvement 62.105  
 cardiac involvement 62.78  
 clinical classification 59.46  
 cutaneous  
 anosacral 9.17  
 race and 9.17  
 cutis dyschromica 59.48  
 cutis laxa and 45.14  
 dialysis-related 59.57  
 differential diagnosis 50.54  
 ear involvement 68.15  
 electron microscopy 10.30  
 with familial Mediterranean fever  
 62.104  
 gelsolin amyloidosis (AGel) 59.57  
 inherited systemic 59.57  
 lichen amyloidosis 9.17, 59.46  
 macular amyloidosis 9.17, 58.28, 59.46  
 myeloma-associated **59.50–5**, 62.70,  
 62.93  
 treatment 59.55  
 oral involvement 69.114–15, 69.116,  
 69.117  
 pigmentation changes 58.28  
 primary **59.50–5**, 62.70  
 scleroderma-like lesions 51.79  
 treatment 59.55  
 primary localized cutaneous **59.44–9**  
 nodular PLCA 59.49  
 treatment 59.49  
 psoriasis and 20.19  
 purpura due to 49.15, 49.18  
 respiratory tract involvement 62.83  
 secondary localized cutaneous (PLCA)  
 59.50  
 secondary systemic 59.56  
 serum amyloid P component (SAP)  
 59.42–3  
 skin biopsy 10.42  
 systemic 59.50  
 in dystrophic EB 39.19–20  
 inherited 59.57
- anabolic steroids 74.32  
 acneiform eruptions due to 42.72  
 adverse effects 70.5, 75.119  
 keloids and 45.54
- Anacardiaceae 26.2, 26.75
- anaemia 62.85  
 aplastic 69.116  
 chronic, persistent parvovirus B19  
 infection 33.63  
 in dystrophic EB 39.29  
 Fanconi's *see* Fanconi's anaemia/  
 syndrome  
 haemolytic *see* haemolytic anaemia
- hypoplastic, Fanconi's anaemia 58.17
- iron deficiency 62.85  
*see also* iron, deficiency
- megaloblastic 62.85  
 pigmentation changes 58.27
- pernicious 62.85, 69.116
- pigmentation changes 58.17, 58.27,  
 62.85
- sickle cell *see* sickle cell disease
- sinus histiocytosis with massive  
 lymphadenopathy (SHML) 55.29
- anaerobic organisms  
 in normal skin flora 30.2  
 venous leg ulcers 47.44
- anaesthesia dolorosa 63.6
- anaesthetic, topical  
 in zoster and post-herpetic neuralgia  
 33.28  
*see also* local anaesthesia
- anaesthetic blockade, regional 47.11
- anagen 3.7, 3.13, 3.21, 66.7, 66.10  
 in androgenetic alopecia 66.20  
 duration 66.9  
 premature termination 66.16  
 short 66.60
- anagen effluvium 66.16
- anagrelide 49.29
- anakinra 22.24, 75.146  
 cryopyrin-associated autoinflammatory  
 syndromes 74.11  
 recombinant IL-1 receptor antagonist  
 74.11
- anal fissures 71.87, 71.89
- anal fistulae 71.87, 71.89
- anal intraepithelial neoplasia (AIN) 71.97  
 HPV and 33.54–5
- anal leakage 71.85
- anal lesions, syphilis 34.7
- analgesia  
 burns 28.79  
 venous leg ulcers 47.49
- analgesics, skin testing for reactions to  
 75.173
- analytical studies 6.19
- anamorph 36.2
- anaphylactoid reactions  
 drug reactions 75.12, 75.25–6  
 non-allergic 22.1, 22.8, 75.12, 75.25–6,  
 75.153
- anaphylatoxin C5a 12.24–5
- anaphylatoxins 13.2, 13.4
- anaphylaxis  
 to arthropod bites/stings 38.1, 38.3,  
 38.6, 38.14–15  
 definition 22.1  
 drug-induced 75.5, 75.8, 75.16–17,  
 75.17, 75.25–6, 75.48–9  
 atopic dermatitis and 24.23  
 topically applied drugs 26.44  
 in dystrophic EB 39.29
- exercise-induced 22.15
- food-dependent exercise-induced 22.8
- in general anaesthesia 75.153
- to latex 26.105
- in mastocytosis 22.35
- non-allergic 22.1, 22.8, 75.12, 75.25–6,  
 75.153
- prick testing and 22.26
- prodromal symptoms 22.8
- treatment 22.8, 22.29, 22.35, 75.176  
 antihistamines 74.31
- anaplasia 10.37
- Anaplasma phagocytophilum* 30.58, 30.59,  
 50.76
- anaplastic large cell lymphoma 57.31–3
- anaplastic lymphoma kinase 10.25
- anatomy, of skin 3.1–53
- Anatrichosoma cutaneum* 37.16
- ANCA *see* antineutrophil cytoplasmic  
 antibodies
- ANCA-related glomerulonephritis 51.111
- anchoring fibrils 3.26, 3.30, 3.32–3, 3.33  
 collagen type VII 3.32, 3.35–6  
 reduction, dystrophic EB 39.15–16,  
 39.16, 39.25
- anchoring filaments 3.26, 3.30  
 hemidesmosome complexes 3.32
- Ancylostoma brasiliense*, perianal/perineal  
 infections 71.96
- ancylostomiasis 22.10, 37.2, **37.14–15**,  
 37.16
- Anderson–Fabry disease (angiokeratoma  
 corporis diffusum) 59.34–8,  
 62.68–9, 62.77, 63.11  
 aetiology 59.35  
 bone and joint involvement 62.100  
 sweat gland cellular inclusions in 44.18
- Androctonus* 38.33
- androgen(s) 74.32  
 acne aetiology and 42.20–2  
 acneiform eruptions due to 42.72
- adrenal production, inhibition, in acne  
 42.53
- adverse effects 70.5, **75.119–20**  
 in androgenetic alopecia (baldness)  
 66.13–14, 66.14–15, 66.16,  
 66.19–20  
 circulating, mechanisms for reducing  
 42.15, 42.16  
 comedogenesis, role in 42.23  
 excess, acne aetiology and 42.20, 42.22,  
 42.76  
 in gynaecomastia 70.4  
 hair growth and 66.13–16  
 hirsutism and 66.81–2, 66.83  
 mechanism of action on hair follicles  
 66.14–15  
 ovarian production, inhibition, in acne  
 42.53
- prophylactic, in hereditary angio-  
 oedema 22.22
- sebaceous gland activity control 42.9–  
 11, 42.12  
 activity inhibition 42.15, 42.16  
 sweating and 44.5  
 synthesis and metabolism 66.14  
 acne and 42.20, 42.21  
 in skin 42.10, 42.12, 42.21  
 in women 66.81  
 transport proteins 66.81
- androgen insensitivity syndrome 66.14,  
 66.16
- androgen receptor(s) 42.21  
 in acne 42.21, 42.23  
 androgenetic alopecia and 66.14  
 blockers (antiandrogens), acne vulgaris  
 treatment 42.53–4  
 gene (*Stu1*) 8.23, 66.18–19  
 hair growth and 66.14  
 in sebaceous glands 42.4, 42.10
- androstenedione 8.8, 8.19, 42.10  
 hirsutism and 66.81
- 5 $\alpha$ -androsterol 44.2
- 5 $\alpha$ -androsterone 44.2
- Anemone* 25.21
- anethole 26.17
- anetoderma 45.17–19, 57.43  
 with granuloma annulare 60.7  
 of prematurity 17.11  
 primary 45.17  
 secondary 45.17
- aneuploidy 15.2
- aneurin 59.62
- aneurysm  
 abdominal aortic 47.2  
 cirsoid 56.26–7, 65.35–6  
 tertiary syphilis 34.14
- Angelman's syndrome, hypopigmentation  
 58.42
- angel's kiss (salmon patch) 18.62–3
- angina bullosa haemorrhagica 69.22,  
 69.84, 69.100  
 oral involvement 69.65
- angioblastoma 46.36  
 giant cell 56.32
- angiocentric lymphoma, EBV-positive  
 57.40–1
- angiodermatitis, disseminated  
 pruriginous 49.24–5
- angiodyskinesia 47.11
- angioendothelioma, papillary  
 intralymphatic (endovascular  
 lymphatic) 56.32–3
- angioendotheliomatosis  
 malignant 50.46–7  
 reactive 56.24
- angiofibroma 15.22  
 cellular 56.8  
 laser therapy 78.14
- angiogenesis 47.1  
 therapeutic, using gene therapy 47.6  
 VEGF increase and 8.21  
 in wound healing 14.6–7
- angiography 47.4  
 peripheral arterial disease 47.4
- angioblastic lymphadenopathy  
 (AILD) 57.51–3
- angioblastic T-cell lymphoma  
 57.51
- angiokeratoma **18.58–60**, 47.15  
 of Fabry 47.13  
 female genitalia 18.60, 71.55  
 of Fordyce 18.59, 47.13  
 genitocrural 71.7–8  
 lysosomal storage disorders and 59.35  
 male genitalia 18.59, 71.11, 71.12, 71.35  
 of Mibelli 18.58–9  
 solitary papular 18.59  
 of the vulva 18.60
- angiokeratoma circumscriptum 18.58
- angiokeratoma corporis diffusum *see*  
 Anderson–Fabry disease
- angioleiomyoma 56.54–5
- angiolipoma 46.44–5  
 infiltrating and non-infiltrating types  
 46.45
- angiolymphoid hyperplasia with  
 eosinophilia  
 epithelioid haemangioma 56.27–8,  
 68.15–16  
 foreign bodies 28.45–6
- angioma 49.2  
 cherry (Campbell de Morgan) 47.13,  
 47.15  
 eruptive 62.44  
 genetics 15.27  
 genitocrural 71.7–8  
 glomeruloid 62.44  
 hereditary neurocutaneous 18.79  
 sclerosing *see* fibrous histiocytoma
- spider *see* spider angioma
- sudoriparous 18.16, 44.9
- tufted 18.54–5, 18.56
- angioma serpiginosum 47.16–17
- angiomatoid fibrous histiocytoma  
 56.19–20
- angiomatosis  
 bacillary *see* bacillary angiomatosis
- diffuse dermal 5.10, 70.17
- angiofibroblastoma 56.7–8
- angiofibroma 15.22
- angiofibroma, aggressive 56.60  
 superficial 56.59
- angioneurotic oedema *see* angio-oedema
- angio-oedema  
 acquired 13.18–19  
 cholinergic 22.15  
 deficiency of C1 esterase inhibitor  
 (C1INH), 12.49  
 definition 22.1  
 differential diagnosis 26.29  
 drug-induced 75.26  
 episodic with eosinophilia 22.23  
 in hepatitis B virus infection 62.59  
 hereditary 22.21–2  
 erythema preceding 62.107  
 LE-like disease 51.17  
 oral involvement 69.33, 69.117  
 screening for 13.18, 22.26  
 idiopathic 22.20–1  
 kinin cascade and 13.4  
 in loiasis 37.11  
 management 22.29  
 antihistamines 74.31  
 oral involvement 69.107–8

- in ordinary urticaria 22.5  
 in parvovirus B19 infection 33.63  
 pathophysiology 22.5  
 periorbital oedema 67.5  
 ulcerative colitis and 62.50  
 in urticarial vasculitis 22.19  
 vibratory 22.13, 22.15, 28.58  
 without weals 22.2, 22.20–1
- angioplasty  
 claudication management 47.5  
 rest pain and gangrene 47.6
- angiopoietin-2 48.2
- angiosarcoma 56.37–40  
 epithelioid 56.40–1  
 pinna 68.34
- angiotensin 12.25
- angiotensin-converting enzyme (ACE)  
 3.52, 13.4, 63.2  
 inhibitors *see* ACE inhibitors, adverse effects
- in sarcoidosis 61.20
- angiotensin II receptor antagonists  
 adverse effects 75.94  
 in angio-oedema 22.21  
 in Marfan's syndrome 45.31
- angry back syndrome 23.6, 26.88, 26.95
- angular artery 77.2, 77.3
- anhidrosis 44.13–15  
 in Horner's syndrome 63.22
- anidulomycin 74.48
- animal(s)  
 acrodermatitis enteropathica 2.17  
 alopecia 2.18–19  
 chromatophores and melanocytes 2.5–6  
 colours and pigments 2.5–7  
 cutaneous features of systemic disease 2.17–18  
 disease relationship to human disease 2.7–8  
 differences from human diseases 2.9, 2.20–3, 2.22  
 similarities with human diseases 2.9, 2.9  
 without similar human disease 2.20–3, 2.21
- epidermis and dermis 2.3  
 glands 2.4  
 metabolism and reactions to therapeutics 2.9  
 pigment cells 2.5–7  
 skin diseases 2.8–19  
 atopic dermatitis 2.13–14  
 bacterial infection 2.11–12  
 bullous disorders 2.14–15  
 cicatricial pemphigoid 2.15  
 dermatitis 2.13–14  
 dermatomyositis 2.15–16  
 drug eruptions 2.17  
 epidermolysis bullosa acquisita 2.15  
 erythema multiforme 2.16  
 fungal infections 2.12–13  
 immune-mediated 2.14–16  
 lupus erythematosus 2.16  
 mast cell tumour 2.22–3  
 mechanobullous 2.17  
 neoplastic 2.19–20  
 parasitic diseases 2.9–11  
 pemphigus 2.15  
 pruritic diseases 2.9, 2.10, 2.11, 2.13  
 psoriasis 2.14  
 therapeutics, differences from humans 2.9  
 toxic epidermal necrolysis 2.16  
 vasculitis and panniculitis 2.16  
*see also* animal models; *individual types of animals*
- animal colours 2.5, 2.6–7
- animal models  
 alopecia areata 2.18  
 comedogenesis 42.23  
 human disease relationship 2.7–8  
 interleukin-8 (IL-8) synthesis 2.8  
 psoriasis 2.8  
 pyoderma gangrenosum-like disease 2.8
- skin grafts 2.7–8  
 topical corticosteroid efficacy assessment 73.16  
*see also* animal(s)
- animal testing 25.9, 26.12
- anisakiasis 22.8
- anistreplase 75.107
- ankle flare, venous 47.14, 47.33
- ankle-brachial Doppler pressure index 47.3  
 in neuropathic ulcers 63.9
- ankle-brachial index 47.3, 47.47
- ankle-brachial systolic gradient 47.3
- ankyloblepharon–ectodermal dysplasia–clefting (AEC) syndrome 15.30, 15.61–3
- ankyloglossia 69.36–7
- ankylosing spondylitis  
 genetics 15.9  
 radiotherapy and non-melanoma skin cancer due to 52.5
- ankylosymblepharon 76.18
- annelid worms, chaetae 2.2
- annelides 36.3, 36.4
- annexins II and IV, antibodies 49.6
- annular epidermolytic ichthyosis 19.31
- annular erythema 62.106–13  
 associated with extractable nuclear antigens 62.109  
 drug-induced 75.23–4  
 of infancy 62.108–9  
 neutrophilic and vascular 62.112–13  
 recurrent with purpura 62.112  
 in Sjögren's syndrome 62.109  
 Sweet's disease-like 51.135
- annular lichenoid dermatitis of youth 41.13
- annular purpura, mechanical injury 28.31
- annular scaling 5.7
- annulus migrans 69.94
- anodontia 69.6, 69.7
- anogenital intraepithelial neoplasia 33.46
- anogenital pilonidal sinus 28.49–50
- anogenital region  
 allergic contact dermatitis 26.18–19, 26.29  
 hidradenoma papilliferum 53.20–1  
 hyperpigmentation 71.2–3  
 hypopigmentation 71.2–3  
 intertrigo 71.2–3  
 itching 71.1–2  
 lesions 71.65  
 leukoplakia 71.3  
 mammary-like glands, tumours 53.37–8  
 Paget's disease 53.40–1  
 pruritus 71.1–2  
 trauma 28.37–8  
 ulcers 71.3–4  
 warts *see* wart(s), anogenital
- zoster 33.25
- anonychia 65.9  
 with bizarre flexural pigmentation 15.31  
 congenital 65.18–19  
 with ectrodactylia 65.18  
 following lichen planus 65.29
- anonychia–onychodystrophy with brachydactyly type b and ectrodactyly 15.31
- Anopheles* *see* mosquitoes
- anophthalmia 67.4
- anorexia nervosa 21.16, 64.21–2, 66.65  
 acne and 42.34  
 hypertrichosis in 66.78  
 pellagra 59.64
- ANOTHER syndrome 62.13
- anoxia 47.26
- ANP (atrial natriuretic peptide) 63.3
- anterior lid margin disease (ALMD) 67.12
- anthelmintics  
 adverse effects 75.71  
*see also* specific agents
- Anthemis* 25.21
- Anthocoridae 38.25
- Anthocoris* 38.25
- anthothecol 26.79
- Anthozoa 38.56
- anthralin *see* dithranol
- anthrax 30.25, 30.40–1
- Anthrenus* 38.27
- anthropometry, HIV lipodystrophy 46.42
- anthroquinone dyes 26.65–6
- anti-C1q antibodies 13.22, 22.81
- anti-CD3 antibodies 13.23
- anti-CTLA-4 antibodies, melanoma management 54.54
- anti-desmoglein antibodies 69.64–5
- anti-DNase 30.13
- anti-double-stranded DNA antibodies 13.19
- anti-EGF receptor inhibitors, acneiform eruptions due to 42.72
- anti-EGFR therapy 75.132–3
- anti-Hu antibodies 13.20
- anti-irritants 25.25
- anti-La/SSB antibodies 49.19  
 in neonatal lupus erythematosus 10.18, 17.16  
 in Sjögren's syndrome 51.137
- anti-Lag antibodies 55.4
- anti-Müllerian duct hormone (AMH) 8.2
- anti-myeloperoxidase antibodies 50.9
- anti-NADase 30.13
- anti-PR3 antibodies 50.9
- anti-Ri antibodies 13.20
- anti-RNP antibodies, prognosis in mixed connective tissue diseases 51.111
- anti-Ro/SSA antibodies 49.19, 51.49, 51.54, 51.105  
 annular erythema and 62.109  
 epitope 51.137  
 in neonatal lupus erythematosus 17.16  
 in pregnancy 51.50  
 in Sjögren's syndrome 51.22, 51.136  
 in subacute cutaneous lupus erythematosus 10.18  
 in vasculitis 51.136
- anti-SSA (Ro) antibodies *see* anti-Ro/SSA antibodies
- anti-SSB (La) antibodies *see* anti-La/SSB antibodies
- anti-TGF- $\beta$ 1 antibodies 66.20
- anti-TNF- $\alpha$  46.20  
 adverse effects 75.145  
 in toxic epidermal necrolysis 76.20–1
- anti-TNF agents  
 adverse effects 31.30, 50.49  
 genetic factors in response to 11.16
- anti-U1RNP antibodies 62.109
- anti-Yo antibodies 13.20
- antiandrogens 42.53, 74.32–3  
 acne vulgaris treatment 42.53–4  
 adverse effects 42.53, 75.120  
 allergy 26.46  
 gynaecomastia 70.4, 70.5  
 photosensitivity 75.31  
 in androgenetic alopecia 66.24, 66.25–6  
 in hirsutism 66.87–8
- antiapoptotic proteins 33.11
- antibiotics  
 in acrodermatitis chronica atrophicans 45.10  
 in actinomycosis 30.76  
 adverse effects 75.47–61  
 acute generalized exanthematous pustulosis 75.34  
 allergic contact dermatitis 26.45, 26.46  
 anaphylaxis 75.5, 75.25  
 epidermolysis bullosa acquisita 75.40  
 erythema multiforme 76.3, 76.4  
 oral antibiotics 42.47  
 pemphigus 75.38  
 photosensitivity 75.31  
 Stevens–Johnson syndrome 76.4, 76.11
- toxic epidermal necrolysis 76.13  
 urticaria 22.8, 22.10, 75.26  
 vasculitis 50.17, 50.18
- in anthrax 30.41  
 in atopic dermatitis 21.13, 24.29  
 in botryomycosis 30.68  
 in brucellosis 30.56  
 in candidiasis 36.68, 36.69  
 in cellulitis 30.19–20  
 in chancroid 30.47, 34.35  
 contraceptive pill interactions 42.51–2  
 cytotoxic 75.126–8  
 in diphtheria 30.37  
 in ecthyma 30.17  
 in erysipelas 30.19–20  
 in erythrasma 30.83  
 in furunculosis 30.24  
 in gas gangrene 30.44  
 in gonococcal infection 30.46  
 in gonorrhoea 34.28  
 in granuloma inguinale 30.62, 34.37  
 in Hailey–Hailey disease 39.35–6  
 'happenance' therapy, in syphilis 34.12  
 in hidradenitis suppurativa 30.81  
 in impetigo 30.16  
 inadvertent, syphilis decline due to 34.12  
 in invasive otitis externa 68.26  
 in leptospirosis 30.66  
 in Lyme disease 30.65–6, 62.106  
 in lymphoedema 48.24  
 in lymphogranuloma venereum 30.71, 34.33  
 mechanism of action, in acne 42.48  
 in melioidosis 30.50–1  
 in meningococcal infection 30.44  
 napkin dermatitis and 17.24  
 in nocardiosis 30.77  
 oral  
 acne vulgaris treatment 42.46–9, 42.54, 42.63  
 adverse effects 42.47  
 topical vs, in acne 42.41  
 in otitis externa 68.25  
*P. acnes* resistance 42.41–2, 42.43  
 prophylactic, in human bites 38.61  
 in psittacosis 30.72  
 in relapsing fever 30.64  
 resistance 30.9  
*P. acnes* 42.41–2, 42.43  
 in rhinoscleroma 30.53  
 in rickettsial infections 30.74  
 in rosacea 43.2, 43.6, 43.7  
 in *Salmonella* infection 30.48  
 in syphilis 30.25  
 in syphilis 34.22  
 topical 73.9–12  
 acne treatment 42.39, 42.41–3, 73.9, 73.10  
 adverse effects 75.61  
 benzoyl peroxide with, in acne 42.41  
 epidermolysis bullosa management 39.28  
 sebum production, effect 42.16  
 sensitization by 73.9  
 staphylococcal infections 73.9, 73.10, 73.11  
 wound healing and 14.21  
 in tularaemia 30.54  
 venous leg ulcers and 47.49  
 in wound infection 14.16
- antibodies  
 adverse drug reactions mediated by 75.17  
 autoimmunity *see* autoantibodies  
 defects of production 17.70–3  
 deficiencies 17.70, 17.84  
 idiotypic 13.10  
*in vivo* measurement of responses 17.56  
 maternal 13.15  
 monoclonal *see* monoclonal antibodies  
 tests for 13.18  
*see also* specific antibodies/antigens

- anticoagulant antibodies 49.29, 49.40, 51.63  
 in deep-vein thrombosis 47.28  
 detection 49.40  
 lupus anticoagulant and 51.63  
 in Sneddon's syndrome 49.43  
 transplacental transfer 49.51
- anticholinergics  
 adverse effects 26.17  
 topical 73.9  
 in hyperhidrosis 44.11, 73.9
- anticoagulant pathways 49.38
- antithrombin III-heparin/heparan 49.38  
 lupus anticoagulant 49.39  
 thrombomodulin-protein C/S 49.38–9
- anticoagulants  
 adverse effects **75.104–7**  
 in deep-vein thrombosis 47.29, 47.30  
 in Klippel-Trenaunay syndrome 47.24  
*see also specific drugs*
- anticonvulsant hypersensitivity syndrome  
*see* DRESS syndrome
- anticonvulsants  
 adverse effects **75.83–6**  
 acneiform eruptions 42.72  
 DRESS syndrome 23.47, 75.18–19, 75.26–7, 75.83, 76.10  
 erythema multiforme 76.3, 76.4  
 hyperpigmentation 69.97  
 pseudolymphoma 75.44  
 Stevens-Johnson syndrome 76.4, 76.11  
 toxic epidermal necrolysis 76.12–13  
 vasculitis 50.17, 50.18  
 in post-herpetic neuralgia 63.7
- antidepressants **64.50–1**  
 adverse effects 75.78–9  
 in post-herpetic neuralgia 63.7  
 psychocutaneous disorders  
 body dysmorphic disorder 64.20  
 lichen simplex 64.27  
 pruritus 64.23–4  
 skin picking 64.28  
 SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)  
 starting therapy 64.50  
 switching drugs 64.51  
 tricyclic *see* tricyclic antidepressants  
*see also* amitriptyline
- antidiuretic hormone (ADH) (vasopressin) 75.98  
 sweat production and 44.6
- antiendothelial cell antibodies 51.104, 51.111  
 in polyarteritis nodosa 50.33  
 in thromboangiitis obliterans 47.7  
 in vasculitis 50.7–8
- antiepileptic drugs *see* anticonvulsants
- antiepiligrin mucous membrane pemphigoid 40.39
- antifilarial drugs, filarial lymphoedema 48.24
- antifungal agents  
 adverse effects 26.46, **75.64–6**, 76.4  
 azelaic acid as 73.28  
 in candidiasis 36.67–8  
 in chromoblastomycosis 36.76  
 in dermatophytoses 36.47–9  
 in Hailey-Hailey disease 39.35  
 in lymphoedema 48.22  
 in otitis externa 68.25  
 in pityriasis versicolor 36.12  
 resistance to 36.50  
 systemic 74.46–8  
 topical **73.12–13**
- antigen(s)  
 acne pathogenesis 42.26, 42.27  
 in arthropod venom 38.1–2  
 complete/conjugated 26.5–6, 26.11  
 exogenous 4.8  
 immunoenzyme methods 10.15–16  
 immunofluorescence techniques 10.12, 10.13  
 nuclear 13.19–20  
 presentation 13.9–10, 17.50–1  
 abnormal, UVR effect 29.5  
 role in vasculitis 50.4–5  
 T-dependent 13.10  
 T-independent (TI) 13.10
- antigen 5 38.14
- antigen-presenting cells (APCs) 4.8, 13.6–7, 17.50, **55.4–5**  
 in atopic dermatitis 24.13–15  
 B cells as 13.7  
 dermal dendritic cells as 3.19, 55.4  
 effect of antimicrobials 74.25  
 effects of UV radiation on 13.28, 13.29  
 function 13.9–10  
 Langerhans' cells as 3.17, 3.18, 13.9, 55.4–5  
 in lymph nodes 13.8–9  
 macrophages as 3.19, 13.5, 55.4  
*see also* dendritic cells; histiocytes
- antigen-antibody reaction 49.18
- antihistamines 21.4, 21.17, 21.18, 74.31, 75.149–50, H<sub>1</sub>, H<sub>2</sub>  
 adverse effects 22.29, 26.17, 26.46, **75.148–50**  
 in atopic dermatitis 21.13, 24.29  
 in carcinoid syndrome 43.19  
 in delayed pressure urticaria 22.14  
 in dermatographism 22.14  
 dose range and evidence level 74.31  
 H<sub>1</sub>  
 adverse effects 75.148–9  
 second-generation 22.28, 22.29  
 in Hymenoptera stings 38.14  
 in lichen planus 41.18  
 as local anaesthetics 77.11  
 in mastocytosis 22.35  
 non-sedating (second-generation) 74.32  
 in pregnancy 22.29  
 in pruritus 21.17, 21.18  
 in psychogenic pruritus 64.23  
 in scombroid fish poisoning 43.16  
 in solar urticaria 29.19  
 topical 73.13  
 atopic eye disease treatment 67.15  
 in urticaria 22.28–9
- antihistone antibodies 51.54  
 minocycline-induced lupus-like reaction 42.51
- antihypertensives 75.92–7
- anti-inflammatory agents, systemic agents 74.2–3
- antilipoprotein antibodies 55.22
- antimalarials 74.25–6  
 adverse effects 51.20, **75.69–71**  
 hypermelanosis 58.30  
 hyperpigmentation 69.97, 75.33  
 nail colour changes 65.16  
 ocular 67.31
- antiphospholipid syndrome therapy 49.42
- discoid lupus erythematosus treatment 51.20–1  
 dose range and evidence level 74.26  
 in polymorphic light eruption 29.12
- antimetabolites 75.128–31  
 in cicatrizing conjunctivitis 67.23
- antimicrobial agents  
 as allergens 26.49–58  
 systemic agents **74.38–50**  
*see also* antibiotics; antifungal agents; antiviral agents
- antimicrobial dressings 14.24
- antimicrobial peptides (AMPs) 4.1, 4.5–6, 4.6, 12.5–7  
 cathelicidins 12.5  
 defensins 12.4–5  
 secreted by skin 3.16
- antimitochondrial antibodies 62.62
- antimony, pentavalent 74.51
- antineoplastic drugs, topical **73.23–6**
- antineutrophil cytoplasmic antibodies (ANCA) 51.104  
 atypical (X-/snowdrift-/a-ANCA) 13.20, 50.8  
 C-ANCA 13.20, 50.8, 50.9  
 detection 13.20  
 G-ANCA 50.8  
 lactoferrin-ANCA 50.9  
 in microscopic polyangiitis 50.36, 62.83  
 P-ANCA 13.20, 50.8, 50.9  
 in pyoderma gangrenosum 50.66  
 in Sweet's syndrome 50.76  
 in vasculitis 50.2, 50.3, 50.6, 50.7, 50.8–10  
 in Wegener's granulomatosis 50.39
- antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 74.8, 74.18
- antinuclear antibodies  
 detection 13.19–20, 13.21, 51.53  
 in lupus panniculitis 46.25  
 minocycline-induced lupus-like reaction 42.51  
 in Sneddon's syndrome 49.43  
 in systemic sclerosis 51.89  
 in Waldenström's macroglobulinaemia 49.19
- antinuclear antibody-negative SLE 51.56
- antinuclear factor, on Hep-2 cells 51.53
- antioestrogens 74.33, 75.119
- antioxidants 26.59, 26.63  
 in prevention of ageing 80.3  
 reduced levels, rosacea 43.2  
 in vegetable oils for topical therapy 73.6
- antiparasitic agents 74.50–1  
 topical 73.13–14
- antiparietal cell antibodies 62.85
- antiperspirants **73.9**  
 allergy to 26.18  
 types and indications 73.9
- antiphospholipid antibodies 49.40–2  
 in APLS/ lupus anticoagulant syndrome 49.40–2  
 in Degos' disease 49.45  
 detection 49.40  
 lupus anticoagulant 51.63  
 primary anetoderma and 45.17  
 in Sneddon's syndrome 49.43  
 in vasculitis 50.4
- antiphospholipid antibody syndrome (APLS) 49.39, **49.40–2**, 51.63  
 autoantigen 49.41  
 cardiac involvement 62.78  
 catastrophic 49.40, 49.41, 49.51  
 children 49.51  
 clinical features 49.41  
 coagulation mechanisms 49.40  
 cutaneous findings 49.41  
 diagnostic criteria 49.41  
 fibromuscular dysplasia with 49.48  
 idiopathic thrombocytopenic purpura and 49.9  
 primary, secondary 49.40  
 respiratory tract involvement 62.82  
 therapy 49.41–2
- antiplatelet agents  
 antiphospholipid syndrome therapy 49.41–2  
 claudication management 47.5  
 in dermatomyositis 51.129  
 in erythromelalgia 47.10  
 purpura due to 49.4
- antiplatelet antibodies 49.6
- antipolysaccharide antibody 13.15
- antiprothrombin antibodies, Sneddon's syndrome 49.43
- antipsychotic drugs **64.51–2**, 75.82  
 atypical 64.16, 64.52
- antiretroviral agents  
 action 74.49  
 adverse effects 35.6–7, 35.21, **35.21–2**, 70.4, **75.67–9**, 76.3, 76.4, 76.11, 76.13  
 oral 35.44  
 toxic neuropathy 63.12
- HIV-associated lipodystrophy 35.22, 46.42  
 in HIV infection 35.5–8  
 initiation 35.6  
 immune reconstitution (inflammatory) syndrome 35.46  
 novel, in HIV infection 35.6  
*see also* highly-active antiretroviral therapy
- antirheumatic drugs (DMARDs) 20.59
- anti-SRP (signal recognition particle) 51.128
- antiseptics **73.14–15**  
 allergy to 26.46  
 effect on normal bacterial flora 30.4  
 efficacy 73.14  
 in epidermolysis bullosa 39.28  
 in Hailey-Hailey disease 39.35  
 in impetigo 30.16  
 use before topical antibiotics 73.9  
 wound healing and 14.21
- antistreptolysin-O 30.13
- antisynthetase antibodies, 'mechanic's hands' 51.125
- antisynthetase syndrome 62.82
- antithrombin III 49.38  
 disorders 49.38
- antithymocyte globulin, familial haemophagocytic lymphohistiocytosis 55.26
- antithyroid antibodies 62.11  
 $\alpha_1$ -antitrypsin, urticaria and 22.4  
 $\alpha_1$ -antitrypsin deficiency  
 MZ phenotype 46.20  
 panniculitis 46.20–1  
 respiratory tract involvement 62.80  
 vasculitis and 50.11, 50.53  
 ZZ phenotype 46.20
- antituberculous drugs 74.44–5
- antitumour agents, hypermelanosis due to 58.30
- antiviral agents  
 adverse effects 26.46, **75.66–9**  
 antiretrovirals *see* antiretroviral agents  
 systemic 74.48–50  
 topical 73.15  
 wart treatment 33.50  
*see also specific agents*
- antlers 2.3
- Antoni A areas 56.46
- Antoni B areas 56.46
- ants 38.14
- anus  
 anomalous papillae 18.95  
*see also entries beginning anal, anogenital*
- anxiety  
 acne and 42.35  
 lichen planus association 41.3  
 anxiolytic drugs 64.52, 75.80–2  
 aortic aneurysm 45.30
- aortic arch syndrome (Takayasu's arteritis) **50.44–5**
- aortic incompetence 45.30
- aortitis  
 due to *Salmonella* 50.55  
 syphilis 34.14
- aortitis syndrome (Takayasu's arteritis) **50.44–5**
- aortofemoral bypass 47.5–6
- APAD (amicrobial pustulosis associated with autoimmune diseases) 50.90
- APCs *see* antigen-presenting cells
- APECED syndrome 13.13, 15.31, 36.64, 62.13
- Apert's syndrome **15.90**, 42.70–1, 68.4  
 acne and 42.61, 42.70–1  
 comedo naevus and 18.11  
 cutaneous changes 42.71
- aphthae 69.14  
 benign, female genitalia 71.65–6  
 definition 5.7  
 recurrent aphthous stomatitis **69.44–6**, 69.48  
 secondary syphilis vs 34.12

- see also oral cavity, ulcers; recurrent aphthous stomatitis
- aphthoviruses 33.71
- Apidae see bees
- apigenin 66.97
- Apis* see bees
- Apium graveolens* 75.162
- aplasia cutis congenita 18.98–106  
differential diagnosis 18.106  
with epidermolysis bullosa 18.101  
see also Bart's syndrome  
with fetus papyraceus 18.100–1  
following intrauterine infection 18.102  
isolated localized to the extremities 18.101–2  
in malformation syndromes 18.102–6  
overlying developmental malformation 18.100
- scalp  
with epidermal naevi 18.100  
with limb reduction abnormalities 18.68, 18.99–100  
non-syndromic 18.98–9  
teratogen-induced 18.102  
treatment 18.106
- Apligraf  
use in dystrophic EB 39.30  
see also skin equivalents
- APLS see antiphospholipid antibody syndrome
- apocrine sweat glands 3.12–13, 44.1, 44.2  
ageing and 8.24  
anatomy and physiology 44.18–19  
axillary 44.19  
carcinoma 53.21–2, 53.33–7  
control of 44.2  
cylindroma 53.28–9  
ectopic 44.18  
excretory duct 3.12, 53.1  
carcinoma 53.32  
functions 3.3, 44.2  
hidradenoma papilliferum 53.20–1  
hidrocystoma (cystadenoma) 53.18–19  
mixed tumour of skin 53.30–2  
of Moll 67.2  
in pregnancy 8.10  
secretory coil 3.12, 44.19  
cystic dilatation 53.18  
spiradenoma see spiradenoma  
structure 3.12  
syringocystadenoma papilliferum 53.19–20  
tubular adenoma 53.21  
tumours 53.18–22, 53.27
- apocrinitis see hidradenitis suppurativa
- Apocyanaceae 26.79, 26.80
- APOD (acute papular onychodermatitis) 37.5
- apoeccrine sweat glands 3.12, 44.1, 44.3
- Apoidea see bees
- apolipoprotein H ( $\beta_2$ -GPI) 49.40, 49.41
- apolipoproteins 59.82  
isoforms of apo E 59.89
- apomorphine 75.88
- apomucin, extramammary Paget's disease 53.40
- apopilosebaceous unit 3.13
- apoptosis 10.37  
in catagen 66.11  
defects 17.50  
and inflammation 12.11–12  
keratinocytes 12.12  
lymphocyte activation and 13.11  
necrosis vs 12.12  
sebocytes 42.15
- apoptotic cells (sunburn cells) 29.5
- appetite stimulants 75.89
- appetite suppressants 46.8, 75.89  
scleroderma-like lesions 51.81
- apraclonidine 26.46
- apronalide 75.17, 75.23
- APUDoma 43.17
- aquagenic syringal acrokeratoderma 19.115
- aquaplast 77.17
- Aqueous Cream BP 73.2, 73.7, 73.31, 73.48  
in eczema 23.38
- aqueous creams 73.7
- Araçatuba virus 33.8
- Araceae 25.21
- arachidonic acid  
metabolism, excessive, diclofenac action 73.25  
pathway 13.4  
synthesis 73.17
- arachis oil 73.6
- Arachnia propionica* 30.75
- Arachnida 37.2, 38.30–54
- arachnidism 38.30–2
- arachnodactyly  
congenital contractural 45.30–1  
in Marfan's syndrome 45.30
- Araneae (spiders) 38.30–3
- Arao-Perkins bodies 66.21
- arbor vitae 26.80
- Arcanobacterium haemolyticum* 30.37
- Archaeopsylla erinacei* 2.3
- Archives of Dermatology, Evidence-based Dermatology* 7.6
- area of burn assessment 28.77–9
- areca nut chewing 69.106–7
- AREDYLD syndrome 15.29, 70.3
- arenaviruses, and *Arenaviridae* 33.3, 33.66, 33.67, 33.68, 33.69
- areola 70.1  
atopic dermatitis 70.9–10  
basal cell carcinoma 70.15  
biopsy 10.32  
blue 70.13  
hyperkeratosis 70.8–9  
melanoma 70.15  
mucinosi 70.17  
neurofibromatosis 70.17  
in pregnancy 70.1  
sebaceous hyperplasia 70.13  
seborrhoeic warts 70.15  
supernumerary 18.92–3  
telangiectasia 70.13  
variations in 70.1
- Argasidae 38.33–5
- argentaffinoma 43.17
- Argonate-2 protein 11.7
- Argyll Robertson pupils 33.26, 63.15
- argyria 58.54, 75.33, 75.102  
earlobe 68.8  
nail colour in 65.16  
pigmentation due to 58.54  
skin biopsy 10.42
- ariboflavinosis 59.62
- aripiprazole 64.52
- aristolochic acid 75.160
- armadillo proteins 3.22
- 'armchair legs' 48.14, 48.21
- armed forces, skin disease and 8.8
- arms  
allergic contact dermatitis 26.15–16, 26.29  
lymphoedema 48.12, 48.13  
occupational dermatoses 27.3
- Arndt-Gottron syndrome see scleromyxoedema
- Arnold-Chiari malformation 18.95
- aromatherapy 26.40, 72.32, 75.160, 75.162
- arrector pili 3.1, 66.2, 66.3
- arsenic 75.99–100  
basal cell carcinoma due to 52.20  
Bowen's disease and 52.32, 52.33, 52.35  
hypermelanosis due to 58.29, 58.30  
as irritant 25.21  
non-melanoma skin cancers 52.4, 52.20  
pigmentation induced by 65.16
- arsenical keratosis 52.29, 52.34–5, 62.47
- arsenicism, chronic 52.33
- arterial disease, peripheral 47.1–12  
aetiology 47.1–2, 47.5  
clinical features 47.2–3  
differential diagnosis 47.4–5  
investigations 47.3–4  
prognosis 47.5  
risk factors 47.2  
treatment 47.5–6
- arterial dissections, lentiginosis with 58.14
- arterial priapism 71.51
- arterial ulceration 47.52–4
- arterial vessels 3.51  
venous vessels vs 3.52
- arteries  
calcification 47.8–9  
calibre-persistent 69.129  
occlusion, Degos' disease 49.45  
in pseudoxanthoma elasticum 45.21, 45.22  
thickening of walls 47.2  
venous vessels vs 3.52
- arteriogenesis 47.1
- arteriography, peripheral arterial disorders 47.4
- arteriolar disorders 47.1–12
- arterioles 3.51  
spider telangiectases 47.15
- arteriosclerosis 47.2
- arteriovenous abnormalities  
malformation see arteriovenous malformations (AVMs)
- periungual/subungual 65.35–6
- arteriovenous fistulae 47.3, 47.21  
acquired 47.21  
congenital 47.21  
iatrogenic 47.21  
pulmonary 47.17, 47.18  
signs and effects 47.21  
traumatic 47.21
- arteriovenous malformations (AVMs)  
18.61–2, 18.79, 47.21–3  
hepatic 47.18  
hereditary haemorrhagic telangiectasia 47.17
- arteriovenous shunts 47.21
- arteritic ulcers 51.132
- arteritis  
cranial see giant cell arteritis  
lymphocytic thrombophilic 50.51–2  
macular 50.51  
in rheumatoid arthritis 51.132  
Takayasu's 50.44–5
- arthralgia  
in connective tissue disorders 62.103  
in disseminated gonococcal infection 34.27  
in Henoch-Schönlein purpura 50.20  
in Lyme disease 62.105  
in palisading neutrophilic and granulomatous dermatitis 62.103  
in Reiter's syndrome 62.105  
in Sweet's syndrome 62.103  
in urticarial vasculitis 22.19  
vasculitis and 62.102  
in Whipple's disease 62.105
- arthritis  
in connective tissue disorders 62.103  
in Lyme disease 30.64, 30.65  
in multicentric reticulohistiocytosis 62.104  
nail dystrophy and 65.25  
psoriatic 62.103  
HIV infection 35.17  
rheumatoid see rheumatoid arthritis  
suppurative, gonococci causing 34.27–8  
in varicella 33.25  
vasculitis and 62.102
- arthritis mutilans 20.56, 62.104
- arthrochalasis multiplex congenita 45.32, 45.35
- arthroconidia 36.3, 36.4, 36.15, 36.16, 36.20, 36.37, 36.85
- Arthroderma* 36.18
- Arthroderma benhamiae* 36.2
- arthrogryposis and ectodermal dysplasia 15.31
- arthropods 37.2, 38.1–55  
bites/stings 38.1–5  
as disease vectors 38.2  
exoskeleton 2.2  
in the external auditory canal 68.11  
mechanism of skin injury 38.1–2  
pool feeders 38.1  
retained mouthparts 38.2  
susceptibility to infestation/attack 38.2  
vessel feeders 38.1  
see also specific classes and animals
- Arthus phenomenon/reaction 75.17
- artificial hair implantation 28.50
- artificial tears, in rosacea 43.7
- artists, occupational hazards 27.18
- aryl sulphatase deficiency 19.13
- asbestos, acnegenicity 27.13, 42.77
- Ascaris* 37.1, 37.2–3
- Ascher's syndrome 45.21, 69.38
- ascoma 36.3
- ascomycin see pimicrolimus
- Ascomycota 36.2, 36.3, 36.18
- ascorbic acid see vitamin C
- ascospores 36.3
- ascus 36.3
- ash-leaf-shaped macules 15.22
- ashy dermatosis 30.63
- ashy dermatosis of Ramirez 58.33–4
- L-asparaginase 75.132
- aspartame sweetener 75.159  
lobular panniculitis associated 46.14
- aspartate 22.11
- aspartylglucosaminuria 59.34
- aspergillosis, primary cutaneous 49.35
- Aspergillus*  
cutaneous lesions 36.92, 49.35  
identification 36.8  
oral infection 69.79–80, 69.118  
otitis externa 68.21  
invasive otitis externa 68.25  
otomycosis 36.17, 68.27  
sarcoidosis and 61.17
- Aspergillus fumigatus* 49.35
- Aspergillus penicilloides* 38.47
- Aspergillus terreus* 36.55
- asphyxia, purpura due to 49.14
- asphyxia reticularis multiplex see livedo reticularis
- aspirin  
adverse effects 75.72  
urticaria 22.8, 22.10, 75.26  
challenge test 22.26  
claudication management 47.5  
in Kawasaki disease 50.46  
low-dose 49.29  
in male genital conditions 71.27  
in mastocytosis 22.35  
in platelet function disorders 13.13  
surgical complications and 77.9  
in venous leg ulceration 47.49
- assassin bugs 37.31, 38.25–6
- Assessment of Multiple Systematic Reviews 7.16
- Assessment of the Psychosocial Effects of Acne (APSEA) 42.35
- Assessments of the Psychological and Social Effects of Acne questionnaire 72.20
- associations, skin disease 6.11, 6.18
- ASST (autologous serum skin test) 22.9
- asteatotic eczema (eczema craquelé) 8.27, 23.6–7, 47.34  
ear 68.14  
generalized 23.7  
hands 23.20  
old age and 8.27
- astemizole 22.29, 75.148–9
- Asteraceae see Compositae
- asteroid bodies 36.70, 36.71, 61.4
- asthma  
in carcinoid syndrome 43.18  
in Churg-Strauss syndrome 50.41
- astichiasis 67.4
- astringents 73.15–16
- astrocytosis, malignant 55.32–3

- AT *see* ataxia telangiectasia (AT; Louis-Bar syndrome)
- atabrine *see* mepacrine
- ataxia, in tabes dorsalis 63.15
- ataxia telangiectasia (AT; Louis-Bar syndrome) 13.13, 18.80, 47.18–19, 62.28, 69.117
- genetics 13.11
- immunodeficiency and 17.67–8
- necrobiosis lipoidica and 60.15
- respiratory tract involvement 62.80
- atazanavir, HIV infection 35.6
- atenolol 46.45, 75.91
- Atherix 38.6
- atherogenesis 46.6
- atheroma, abdominal/limb vessels 47.52
- atheromatous plaques 47.1
- atherosclerosis 49.36
- arterial ulceration 47.52
- inhibition,  $\beta_2$ -GPI role 49.41
- lipoproteins and 59.83
- lower limb vessels 47.2
- pathogenesis 47.1–2
- atherosclerotic plaques 49.36
- athlete's foot *see* tinea pedis
- athlete's nodules 28.31
- ATLL *see* adult T-cell leukaemia-lymphoma (ATLL)
- ATM gene mutations 47.18
- atopic blepharoconjunctivitis (ABC), clinical features 67.13
- atopic dermatitis (AD) 24.1–34
- acne incidence and 42.18
- acquired melanocytic naevi number 54.15
- in adolescence 8.7
- $\beta$ -adrenergic blockade theory 24.15
- adult phase 24.21
- aetiology 24.3–10, 24.19
- allergic contact dermatitis and 24.22, 26.7, 26.13–14
- allergy and 24.10–12, 24.30–1
- alopecia areata and 24.23
- in animals 2.12, 2.13–14
- antimicrobial peptide expression reduced 3.16
- associated disorders 24.22–3
- atopic eye disease management and 67.16
- atopy and 24.1, 24.22
- barrier function of skin 4.2, 24.4
- canine 2.7
- childhood 8.3
- concordance with therapy 72.6
- quality of life assessment 72.23
- childhood phase 24.20–1
- clinical features 24.19–22
- clinical trials and generalization of results 6.4
- complications 24.23–5
- costs (UK and USA) 6.5
- definition 24.1–2
- diagnosis 24.2, 24.26
- differential diagnosis 17.30, 24.26–7, 26.29
- actinic prurigo vs 29.14
- non-atopic dermatitis vs 24.1
- dry skin and 24.22
- ear 68.14, 68.23
- elderly people 8.28
- environmental factors 24.5–6
- eyelids 23.11
- female genitalia 71.58
- filaggrin in 4.2
- food allergy and 24.23
- genetics 15.1, 15.2, 15.10, 24.3–4
- growth delay and 24.24
- hands 23.14, 24.21–2
- herpes simplex and 33.35–6
- see also* eczema herpeticum
- HIV infection 35.16, 35.45
- house-dust mites and 38.47
- hygiene hypothesis 24.5–6, 24.7
- IgE in 24.3, 24.4, 24.5, 24.8–9
- IL-18 gene variations 33.35
- immune function and 24.6–10, 24.13–15
- immunodeficiency and 17.53
- infantile phase 24.19–20
- infantile seborrhoeic dermatitis and 24.22
- infection and 24.12–13, 24.24
- interleukins and 21.5
- intrauterine factors 24.5
- investigations 24.27–8
- light-exacerbated, differential diagnosis 29.12
- Malassezia* and 24.11, 36.13
- male genitalia 71.18
- mast cell role 3.20
- maternal factors 24.4
- mechanical injury 28.14
- menstrual cycle and 24.19
- migration and 24.2–3
- molluscum contagiosum with 33.11, 33.12
- mouse model 2.8, 2.14
- nail involvement 65.28–9
- natural history and prognosis 24.25–6
- neurogenic inflammation 12.63
- neuropeptides in 24.17
- nipple and areola 70.9–10
- occupation and 24.33–4
- ocular abnormalities in 24.24–5
- pathogenesis 24.10–19
- photosensitivity and 24.21
- pregnancy and 8.12, 24.19
- prevalence 23.3, 24.2–3
- prevention 24.33–4
- pruritus in 21.13–14, 24.17–18
- psychological factors associated 64.4, 64.9
- psychological factors in aetiology 24.19
- psychological morbidity 24.23–4
- quality of life assessment 64.10, 72.20, 72.23–4
- race and 9.13
- severity assessment 64.10, 72.9–10
- short stature and 8.3
- soap avoidance/use 73.31
- Staphylococcus aureus* and 24.8, 24.10, 24.12, 30.7, 30.8–9
- stress 12.63
- support groups 72.23
- sweat in 44.6
- sweating and 24.18–19
- terminology 24.1–2
- treatment 21.13, 24.28–33
- caffeine cream 73.49
- ciclosporin 74.16
- holistic, in adolescence 8.7
- immunomodulators 73.31, 73.32
- methotrexate 74.18–19
- tacrolimus 73.31
- topical sodium cromoglycate 73.51
- trigger factors and their reduction 24.28–9
- unresponsive 24.30
- urticaria and 24.23
- vascular abnormalities 24.15–17
- atopic eczema *see* atopic dermatitis (AD)
- atopic eye disease 67.13–16
- description and epidemiology 67.13, 67.15
- diagnosis 67.15
- immunopathogenesis 67.15
- management 67.15–16
- atopic dermatitis and 67.16
- atopic keratoconjunctivitis (AKC) 67.13, 67.14, 67.15, 67.16
- clinical features 67.13
- ocular mucous membrane pemphigoid vs 67.20
- atopy
- allergic contact dermatitis and 26.7
- alopecia areata and 66.31
- atopic dermatitis and 24.1, 24.22
- dermatophytosis and 36.21
- genetics 15.6
- hygiene hypothesis 24.5–6, 24.7
- irritant contact dermatitis and 25.7
- occupation and 27.2
- patch test 23.37
- perioral dermatitis and 43.11
- sarcoidosis and 61.6
- atorvastatin 75.157
- ATP2A2 gene, mutations in Darier's disease 39.32, 39.33
- ATP2C1 gene
- expression 39.33
- mutations in Hailey–Hailey disease 39.1, 39.32, 39.33
- segmental Hailey–Hailey disease 39.37
- atranol 26.77
- Atrax 38.31
- atrial myxoma 49.37
- cutaneous lentiginosis with 58.14
- see also* myxoma, cardiac
- atrial natriuretic peptide 63.3
- atrachia congenita 66.59–60
- atrichial sweat glands *see* eccrine sweat glands
- atrophic parapsoriasis 57.58
- atrophic polychondritis *see* relapsing polychondritis
- atrophic vulvovaginitis 8.20
- atrophie blanche 15.13, 23.35, 47.34, 49.44
- atrophoderma
- follicular 15.83, 45.7–8, 52.8–9, 62.29
- linear of Moulin 18.26
- skin biopsy 10.42–3
- verrucate 45.8, 66.51
- atrophoderma of Pasini and Pierini 45.8–9, 51.64, 51.69, 58.26
- morphoea and 51.78
- progression to systemic sclerosis 51.106
- atrophoderma reticulatum 45.8, 66.51
- atrophoderma vermiculata 45.8, 66.51
- atrophy
- corticosteroid-induced 73.17–18, 73.31
- tacrolimus and pimecrolimus safety 73.31
- atrophy, cutaneous 45.2–14
- corticosteroid-induced 45.3–4
- definition 5.7, 45.2
- generalized 45.2–6
- honeycomb (atrophoderma vermiculata) 45.8, 66.51
- localized 45.6–13
- macular *see* anetoderma
- in onchocerciasis 37.5, 37.6
- with rheumatoid disease 45.3
- varioliform 45.7
- atrophy, in hyperhidrosis 3.12, 44.12
- attributable risk 6.18
- atypical decubitus fibroplasia 56.5–6
- atypical facial dysmorphism 16.7
- atypical fibroxanthoma 56.20–2, 68.34, 79.18
- atypical lipomatous tumour 56.58
- atypical mole syndrome 54.28, 54.31–2
- melanoma risk 54.34, 54.47
- atypical spitzoid tumour of unknown malignant potential (STUMPs) 54.21, 54.24, 54.39
- Auchmeromyia* 38.8
- auramine–rhodamine stain 10.10
- auranofin 74.29–30
- auricle *see* pinna
- auriculotemporal syndrome 44.10, 44.11, 63.22
- Auspitz's sign 5.18
- psoriasis 20.11
- Australian blackwood 26.80
- Australian silky oak 26.81
- Austroconops* 38.6
- autoantibodies
- BP230 and BP180 40.42
- in bullous pemphigoid 40.30
- desmocollins 40.6
- detection 13.19–22
- in epidermolysis bullosa acquisita 40.52
- IgG 40.26, 40.30, 40.42, 40.47, 40.52
- in leprosy 32.7
- in lichen planus pemphigoides 41.21
- in mucous membrane pemphigoid 40.36
- organ-specific 13.21
- in pemphigus 40.8
- in SLE 51.29
- in thromboangiitis obliterans 47.7
- transplacental transfer 17.15–19
- type IV collagen ( $\alpha 3$  chain) 3.27
- in urticaria 13.21–2, 22.9
- see also* specific autoantibodies
- autoantigen complementarity hypothesis, in vasculitis 50.6
- autoantigens, desmosomes as 3.22
- autoeczematization 23.5, 26.21
- autoerythrocyte sensitization syndrome 49.16, 50.54, 64.33–4
- autofluorescence 10.14
- autoimmune acanthosis nigricans 19.120
- autoimmune adrenalitis 62.5
- autoimmune blistering disorders
- type VII collagen as autoantigen 3.36
- see also* pemphigus
- autoimmune conditions, adrenalitis 62.5
- autoimmune disease-associated reactive haemophagocytosis
- lymphohistiocytosis 49.6
- autoimmune disorders 13.14–15
- acquired generalized lipodystrophy (AGL) with 46.38
- adiponectin elevation 46.4
- alopecia areata as 66.31–2
- hepatitis C virus infection and 62.60
- leg ulceration 47.55
- lichen sclerosus and 51.113
- lipoatrophic panniculitis and 46.15
- lipomembranous fat necrosis and 46.22
- lobular panniculitis and 46.14
- in pregnancy 8.11, 8.12
- urticaria and 22.2, 22.9
- vitiligo as 58.46
- autoimmune lymphoproliferative syndrome 17.65–6
- autoimmune panniculitis 46.15
- autoimmune polyendocrinopathy syndrome, type I 15.31
- autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome 15.31
- autoimmune polyglandular (polyendocrine) syndrome (APECED syndrome) 13.13, 15.31, 36.64, 62.12–14
- autoimmune progesterone dermatitis 8.9, 8.15, 8.19, 75.119
- autoimmune thrombocytopenic purpura *see* idiopathic thrombocytopenic purpura (ITP)
- autoimmunity, Degos' disease 49.45
- autologous serum skin test 22.9
- automobile industry, occupational hazards 5.6, 27.18
- autonomic dysreflexia, following spinal cord injury 63.17
- autonomic functions of skin 4.9–10
- autonomic nervous system 4.9–10, 63.1, 63.3–4
- role in flushing 43.14
- autonomic neuropathy 44.7
- autoreactivity, urticaria and 22.2
- autosensitization 23.5
- autosomal dominant dyskeratosis congenita 15.36, 15.78–80
- autosomal dominant hypohidrotic ectodermal dysplasia 15.43, 15.58–60
- autosomal dominant ichthyosis (ichthyosis vulgaris) *see* ichthyosis vulgaris
- autosomal dominant (AD) inheritance 15.2, 15.5
- autosomal dominant lamellar ichthyosis 19.23–4
- autosomal dominant xeroderma pigmentosum 15.73

- autosomal genes  
 chromosomal abnormalities 15.10–12  
 definition 15.4
- autosomal recessive dyskeratosis  
 congenita 15.37, 15.78–80
- autosomal recessive hypohidrotic  
 ectodermal dysplasia 15.43,  
 15.58–60
- autosomal recessive (AR) inheritance 15.3
- avascular bone necrosis 51.47
- avidin 10.17
- avidin–biotin method 10.17
- avidin–biotin–peroxidase complex  
 method 10.17
- AVPR (atypical vascular proliferation  
 after radiotherapy) 56.41–2
- axilla  
 allergic contact dermatitis 26.18  
 bacterial flora 30.4  
 hidradenitis suppurativa 30.80, 30.81  
 hyperhidrosis 44.7–8, 44.12, 77.36–7  
 odour 44.8, 44.19, 44.20  
 Paget's disease 53.40–1  
 seborrhoeic dermatitis 23.31, 23.32  
 skin biopsy 10.32  
 sweat glands 44.1  
 apocrine 44.19
- axillary freckles 15.16, 15.17, 15.21
- axillary shave 44.20
- axillary web syndrome (AWS) 47.31–2,  
 48.29
- axon reflex 63.5
- axon reflex response 12.64
- ayan 26.80
- azapropazone 75.77
- azathioprine 13.24, 72.29, 74.14–16  
 adverse effects/reactions 13.24, 20.42,  
 26.46, 72.29, 75.128–9  
 in allergic contact dermatitis 26.102  
 in atopic dermatitis 24.31  
 clinical indications 74.15  
 complications of treatment 74.15  
 contraindications 74.15  
 in cytophagic histiocytic panniculitis  
 46.24  
 in dermatomyositis 51.129  
 in leprosy reactions 32.18  
 in linear IgA disease 40.51  
 long-term risk of malignancy 51.62  
 Merkel cell carcinoma association 53.42  
 in pemphigus 40.12, 40.16, 74.15  
 plus prednisolone, SLE 51.61  
 in polymorphic light eruption 29.12  
 in sarcoidosis 61.21  
 in systemic lupus erythematosus 74.15  
 in systemic sclerosis 51.108
- azelaic acid 73.13, 73.28  
 adverse effects 42.49  
 melasma treatment 73.28  
 topical, acne treatment 42.39, 42.43
- azidothymidine (AZT) *see* zidovudine
- azithromycin 26.46, 74.42, 75.58  
 acne vulgaris treatment 42.47  
 in atopic eye disease 67.16  
 in genital chlamydial infections 34.31  
 in granuloma inguinale 34.37  
 in lymphogranuloma venereum 34.33  
 in rosacea 43.6  
 syphilis management 34.22, 34.24
- azo dyes 26.26, 75.158
- azoles 74.47
- azone 73.7
- AZT *see* zidovudine
- aztreonam 75.51
- azul (pinta) 30.63–4
- azuurocin 13.4
- B**
- B-cell directed biological therapies  
 74.9–10
- B-cell lymphomas 57.41–51  
 actinic prurigo and 29.14  
 EBV association 33.30–1  
 in HIV infection 35.41
- primary 57.41–50  
 cytogenetic abnormalities, PCMZL/  
 PCFCL/PCLBCL 57.42  
 diffuse large B-cell (LBCL)  
 lymphoma 57.47–9  
 follicle centre (FCL) lymphoma  
 57.45–6  
 marginal zone (MZL) lymphoma  
 57.43–5  
 staging classification 57.42  
 WHO–EORTC classification 57.41
- secondary 57.50–1  
 intravascular large B-cell lymphoma  
 57.50–1  
 lymphomatoid granulomatosis 57.51  
 WHO–EORTC classification 57.2  
*see also* lymphoma(s)
- B-cell receptors 13.6–7, 17.49
- B-cell tumours, EBV association 33.30–1
- B lymphocytes 13.6–7, 17.49  
 activation 17.50  
 polyclonal 35.17  
 regulation of 13.10  
 affinity maturation 13.10  
 ageing effect 8.24  
 antigen presentation to 13.9–10,  
 17.50–1  
 as antigen-presenting cells 13.7  
 atopic eye disease 67.15  
 B1 13.7  
 B1a (CD5<sup>+</sup>) 13.6, 13.7  
 B1b (CD5<sup>+</sup>) 13.7  
 B2 13.7  
 $\beta_2$ -GPI antibody production stimulation  
 49.41  
 class switching 13.10  
 deficiency 13.9  
 development 13.7–8, 17.49  
 EBV infection 33.30  
 immunogenotyping 10.30  
 in lymph nodes 13.8–9  
 memory 13.10  
 microscopy 10.34  
 mucous membrane pemphigoid 67.20  
 naïve 13.10  
 polyclonal activation, psoriasis in HIV  
 infection 35.17  
 in spleen 13.8  
 trafficking 13.9  
 in Waldayer's ring 13.9  
 in wound healing 14.3
- B syndrome 69.37
- B19 parvovirus *see* parvovirus B19
- Baa bra 70.15
- baboon syndrome 26.22, 26.44, 75.36,  
 75.162
- bacillary angiomatosis 30.57, 38.11,  
 71.32–3  
 ear involvement 68.28  
 in HIV infection 35.25, 68.28  
 oral involvement 69.79
- bacillary peliosis 30.57
- Bacillus*, in normal skin flora 68.2
- Bacillus anthracis* 30.40–1
- bacillus Calmette–Guérin (BCG)  
 immunization *see* BCG  
 vaccination
- Bacillus cereus* 30.41
- Bacillus oleronius*, association with  
*Demodex* 43.3
- Bacillus pyocyaneus* *see* *Pseudomonas*  
*aeruginosa*
- Bacillus subtilis* 30.41
- bacitracin 26.46  
 adverse effects 75.61  
 allergic reactions to 73.10  
 in impetigo 30.16  
 topical, indications 73.10
- back, upper, surgical excision in area  
 77.15
- BACTEC system 31.6
- bacteria  
 adherence 30.5  
 aerobic, normal skin flora 30.2, 30.3  
 aeromonads 30.59
- anaerobic 30.59–62  
 normal skin flora 30.2, 30.3
- axilla 30.4
- barrier function of skin and 4.5–6, 30.5  
 colonization of skin 30.1, 30.2  
 hair follicles 42.24
- comedogenesis, role in 42.24
- coryneform (diphtheroid) 30.3,  
 30.35–40
- defences against 30.5
- dysgonic fermenters (DF) 30.59
- eugonic fermenters (EF) 30.59
- external auditory meatus 6.2, 30.4
- factors modifying populations 30.3
- flora (normal skin) 30.1, 30.2–6, 30.35–  
 6, 68.2  
 acne aetiology and 42.24  
 factors affecting 30.2, 30.3–4  
 genera/species 30.2–3  
 in HIV infection 35.24  
 hydration/dessication affecting 30.3,  
 30.5  
 quantitative studies 30.3  
 role 30.4, 30.5  
 sampling methods 30.2  
 semi- and quantitative data 30.2  
 by site 30.4–5  
 temporary residents 30.1, 30.2  
 transients 30.1
- Gram-negative 30.44–59
- Gram-positive 30.6–44
- groin 30.4
- growth inhibition by honey 73.48
- interference 30.5, 30.7
- isolation media 30.2
- nasal vestibule 30.4
- perineum 30.4
- quantitative studies 30.3
- removal, lymphatic vessels 48.5, 48.6  
 role 30.4
- sampling 30.2
- spiral 30.62–6
- strains 30.1
- temporary residents 30.1, 30.2  
 toe clefts 30.4  
 transients 30.1
- umbilicus 30.4–5, 30.6
- vulva 30.4
- bacterial infection 30.1–82  
 in animals 2.11–12, 2.22  
 in atopic dermatitis 24.8, 24.10, 24.12–  
 13, 24.24, 30.7, 30.8–9  
 of ears 68.19–20, 68.21  
 of eyes 67.26–7  
 female genitalia 71.68  
 following arthropod bites/stings 38.2,  
 38.3  
 following ear piercing 68.7  
 HIV infection and 35.24–8, 35.45  
 Kawasaki disease and 50.45  
 of lips 69.121  
 lymphoedema and 48.12, 48.15  
 napkin dermatitis and 17.23  
 necrotizing subcutaneous 30.68–9  
 neonatal 17.42–6  
 of oral cavity 69.77–9  
 otitis externa 68.21  
 purpura associated 49.20–1  
 sarcoidal reaction in 61.22  
 secondary, in varicella 33.25  
 skin barrier function and 4.5, 30.5  
 swimming and diving 28.53–4  
 vasculitis and 50.55  
 venous leg ulcers 47.44  
 vessel-invasive 49.34–5  
 wounds 14.16–17
- bacterial overgrowth, malabsorption  
 51.100
- bacterial pseudomycosis (botryomycosis)  
 30.67–8
- bacterid, panniculitic 46.32
- bacteriology reports 30.1
- Bacteroides* 30.60  
 in hidradenitis suppurativa 30.80
- Bacteroides fragilis* 30.59, 30.60
- Bactrian camel 66.8
- bad news consultation 72.4–5
- BADAS (bowel-associated dermatosis–  
 arthritis syndrome) 50.87–8,  
 62.51, 62.53
- Bafverstedt's lymphadenitis benigna  
 cutis 57.59
- 'bag of worms' appearance 56.48
- Bailey® nylon monofilament 63.9
- Baird–Parker classification system 30.2
- Baisch syndrome 15.31
- baking, occupational hazards 27.18
- balanitis 71.8–9, 71.13, 71.18, 71.19–20,  
 71.37–8, 71.40  
*Candida* 36.62, 36.68  
 circinate 34.30, 34.31, 71.18  
 lichen sclerosus and 51.113, 51.116  
 Zoon's 71.13, 71.18, 71.19–20
- balanitis xerotica obliterans 51.113, 51.116  
 corticosteroids 51.118
- balanitis xerotica obliterans (BXO) 71.21
- balanoposthitis  
 male genitalia 71.9, 71.21, 71.28, 71.34  
 non-specific 71.24  
 non-syphilitic spirochaetal ulcerative  
 71.31
- baldness  
 female pattern 66.16, 66.17–18, 66.20,  
 66.22, 66.24, 66.25–6  
 male pattern *see* alopecia, androgenetic  
 premature *see* alopecia, androgenetic  
 reversal 66.14–15  
*see also* alopecia
- Baller–Gerold syndrome (BGS) 15.80
- ballistometry 4.11
- balloon dilatation *see* angioplasty
- ballooning degeneration 10.38  
 herpes simplex 33.16
- balm of Gilead 14.21
- balsam of Peru  
 allergy to 26.18, 26.22, 26.40, 26.41  
 contact urticaria and 22.20  
 oral provocation tests 5.25  
 as scabicide 38.41
- balsam of spruce 26.40
- balsam of Tolu 26.40
- bandaging  
 compression 14.20–1, 38.31, 38.60  
 four-layer technique 14.20  
 'wet wrap' 73.4
- Bannayan–Riley–Ruvalcaba syndrome  
 (Bannayan–Zonana syndrome)  
 18.60, 62.26, 62.57, 69.38
- barbers, occupational hazards 27.19
- barber's hair sinuses 28.49
- Barber–Say syndrome 70.3
- barbiturates, adverse effects 75.80–1
- bare lymphocyte syndrome 17.60–1
- barium sulphide 73.29
- barley, as irritant 25.21
- barley itch 38.48
- Barmah Forest virus 33.67, 33.67–8
- Barraquer–Simons disease 46.39–40
- barrier creams 23.21, 25.25, 27.9
- barrier function of skin 3.2–3, 3.10–12,  
 4.1, 4.2–4, 4.3  
 in atopic dermatitis 4.2, 24.4  
 bacterial infection and 4.5, 30.5  
 fungal infection and 4.5  
 irritant contact dermatitis and 25.2–3  
 measurement 72.11  
 microorganisms and 4.5  
 neonatal 17.1–2  
 percutaneous absorption and 4.4–5  
 sebaceous lipids and 42.6–7  
 temperature regulation and 4.7  
 ultraviolet radiation and 4.6–7
- bartenders, occupational hazards 27.18
- Bartholin's duct, tumours 71.73
- Bartholin's gland, abscesses 71.68
- Bartonella* 30.56–8  
 vectors 38.5, 38.11
- Bartonella bacilliformis* 30.58  
 in HIV infection 35.25
- Bartonella elizabethae* 30.56

- Bartonella henselae* 38.11, 61.5  
in bacillary angiomatosis 30.57  
in cat scratch disease 30.56–7  
in HIV infection 35.25  
staining 10.10
- Bartonella quintana* 30.56, 30.57
- Bart–Pumphrey syndrome 19.108–9
- Bart's syndrome 18.101, 39.17, 39.18, 39.22
- basal cell(s)  
in basal cell carcinoma 52.20  
follicular atrophoderma and 52.8–9
- basal cell carcinoma (BCC) 52.2, 52.18–22  
advanced, features 52.19  
aetiology 52.18–19  
after chemotherapy 75.124  
aggressive, in naevoid basal cell carcinoma syndrome 52.7  
in animals 2.20  
arsenic-induced 52.20  
atypical 52.19  
basisquamous 52.22–3  
burns 28.91  
chemical carcinogens 52.4–5  
clinical course and natural history 52.20, 52.21  
clinical features 52.19–20  
as colostomy complication 62.54  
cytodiagnosis 10.29  
definition 52.18  
development in BCG scar 31.29  
diagnosis 52.21  
differential diagnosis 52.21  
Bowen's disease vs 52.33–4  
desmoplastic trichoepithelioma vs 53.9  
microcystic adnexal carcinoma vs 53.35  
sebaceous carcinoma vs 53.19  
dissemination/metastases 52.20  
early  
features 52.19  
pathology 52.20–1  
ears 68.32–3, 79.9, 79.10, 79.17  
with eccrine differentiation 53.36  
elderly people 8.28  
ethnic factors associated 52.18–19  
eyelids 67.10, 67.34–5, 79.9  
face 79.10, 79.11  
familial syndromes 52.6–9  
gene deletion 53.8  
*see also* naevoid basal cell carcinoma syndrome  
female genitalia 71.66, 71.77  
genetics 11.18, 52.19  
growth 52.20, 52.21  
head and neck 52.20  
histogenesis 52.19  
HIV infection and 35.39  
HPV infection and 52.6, 52.14  
incidence 52.2, 52.18–19  
infiltrative, microcystic adnexal carcinoma vs 53.35  
inflammatory reaction 52.21  
inner canthus 79.9  
invasive 52.19, 52.20, 52.21  
loss of heterogeneity events 52.12  
lupus vulgaris and 31.18, 31.19, 31.21  
male genitalia 71.48  
management principles 52.17  
mechanical injury 28.62  
melanocyte proliferation in 52.21  
metatypical 52.22–3  
mitotic figures 52.20  
morphoeic/sclerodermiform 52.19–20, 69.54  
diagnosis 52.21  
treatment 52.22  
mortality 52.2  
in naevoid basal cell carcinoma syndrome 52.6, 52.7, 52.8  
*see also* naevoid basal cell carcinoma syndrome  
nipple/areola 70.15
- nodular 69.54  
treatment 52.22, 73.24  
nose 79.10  
over histiocytoma 52.20  
p53 gene mutations 52.12  
pathology 52.20–1  
perianal/perineal 71.98  
perioral/lips 69.53–4  
prognosis and prognostic factors 52.21–2  
PUVA associated 52.4  
race and 9.18  
radiation-induced 52.5, 79.18  
recurrence 52.20, 79.17–18  
risk factors 52.18–19  
sclerosing  
desmoplastic trichoepithelioma vs 53.9  
eyelids 67.35  
skin damage and 52.19  
sporadic, gene deletion 53.8  
spread 52.19  
squamous cell carcinoma ratio 52.2, 52.26  
sun exposure patterns 52.3  
sunscreens use and 73.41  
superficial 52.20, 52.21, 52.33, 69.54  
treatment 73.24  
telangiectasia with 52.19  
in transplant recipients 62.74–5, 79.13  
treatment 52.8, 52.21–2, 78.14, 78.16  
aim 52.21  
curettage 77.40–1, 77.43, 77.44  
destructive therapies 52.22  
Mohs micrographic surgery 77.30, 77.32, 77.33  
principles 52.17  
radiotherapy 79.5–7, 79.8–12, 79.13  
surgery 52.22, 77.15, 77.19, 79.5  
topical 5-FU 73.23  
topical imiquimod 73.24  
ulcerated 52.19, 52.20, 52.21  
UVB phototherapy associated 52.4  
UVR exposure and 29.7, 52.3  
venous leg ulcers and 47.45–6  
*see also* non-melanoma skin cancer (NMSC)
- basal cell naevus syndrome *see* naevoid basal cell carcinoma syndrome
- basal cell papilloma *see* seborrhoeic keratosis
- basal lamina *see* basement membrane
- basalioma *see* basal cell carcinoma (BCC)
- basaloid cells  
in basaloid follicular hamartoma 53.11–12  
in trichoblastoma 53.10  
in trichoepithelioma 53.8
- Basan syndrome 15.29
- basement membrane 3.6, 10.37  
components 3.25–6  
mechanical injury 28.7  
sebaceous cells 42.3  
staining 10.8, 10.9  
vascular 3.52  
in wound healing 14.5
- basement membrane zone (BMZ) 3.25–3.33, 10.37  
adhesion complex 40.1–2, 40.25  
antibodies 40.27  
collagen type IV 3.25, 3.27  
components 3.25–6, 3.32  
structure and domain organization 3.31  
gene/protein systems involved in epidermolysis bullosa 3.26, 3.27  
heparan sulphate proteoglycans 3.29  
IgA, IgG, C3 deposits, mucous membrane pemphigoid 67.17  
laminins 3.27–9, 3.28  
*see also* laminin-5 (laminin-332)  
neutrophils 40.46  
subepidermal immunobullous diseases 40.27  
ultrastructure 3.25, 3.26
- basic fibroblast growth factor (bFGF)  
mechanism of action 58.7  
melanocyte mitogen 58.5  
pigmentation regulation 58.7  
scleroderma-like lesions, and cancer 51.79
- basic fuchsin *see* magenta paint
- basidiobolomycosis (subcutaneous zygomycosis) 36.78–9  
*Basidiobolus ranarum* 36.78, 36.79
- Basidiomycota 36.2, 36.3–4
- basidiospores 36.3, 36.89
- basidium 36.3
- basiliximab 75.146
- basisquamous basal cell carcinoma 52.22–3
- basophil(s) 12.20, 13.5–6  
in urticaria 22.5
- basophil degranulation test 75.174
- bastianido 28.32–3
- batbug 38.24
- Bateman syndrome 62.80
- bath itch 21.10
- bath oils 73.31
- bathing, in atopic dermatitis 24.29
- bathing attendants, occupational hazards 27.18
- bathing suit ichthyosis 19.24
- Bazex syndrome 45.8, 62.36, 62.48, 66.65  
ear involvement 68.18  
in Hodgkin's disease 62.89  
nail involvement 65.25
- Bazex–Dupré–Christol syndrome (atrophoderma follicular) 15.83, 45.7–8, 52.8–9, 62.29
- Bazin's disease *see* erythema induratum of Bazin
- BCG vaccination 31.28  
adverse effects 75.139, 75.141  
complications 31.6, 31.10, 31.28–9  
disseminated 17.58  
leprosy and 32.19  
mechanical injury 28.62  
therapeutic use 31.29
- bcl-2 10.25  
hair growth and 66.11
- bcl-6 10.25
- BCNS *see* naevoid basal cell carcinoma syndrome
- BCNU *see* carmustine
- BDC *see* Bazex–Dupré–Christol syndrome
- BDP (Bowen's disease of the penis) 71.38–9
- 'bean-bag' appearance, histiocytes 46.23–4
- Bean's syndrome *see* blue rubber-bleb naevus syndrome
- beard  
alopecia areata 66.35  
ringworm 36.28–9, 36.49  
weight, ageing effect 8.23–4
- bearded ghoul 38.59
- Beare type pili torti 15.50
- Beare–Stevenson cutis gyrata syndrome 15.91
- Beare–Stevenson syndrome 18.40
- beating injuries 28.32–3
- Beau's lines 59.75, 65.10, 65.12–13  
in childhood 65.7  
thumbnail 59.75
- becaplermin 14.27, 63.10
- Beck Depression Inventory 64.23
- Becker's naevus 18.17–19, 62.101, 66.77, 78.10  
with hypomastia 70.3
- Becker's naevus syndrome 18.27
- Becker's syndrome 58.21
- Beckwith–Wiedemann syndrome 18.69–70, 68.5, 68.6  
macroglossia in 69.113
- bedbugs 38.24
- bedsores *see* pressure ulcers
- Beer's law 78.3
- bees 38.13  
Africanized/'killer' 38.13  
hypersensitivity to 22.8, 38.1, 38.3, 38.14–15  
pheromones 38.2  
venom 38.14
- beeswax 26.82, 73.7
- beetles 38.26–8
- behavioural therapy 64.24, 64.28, 64.32  
obesity 46.8  
*see also* cognitive behavioural therapy
- Behçet's disease 50.56–62, 69.46–9  
acneiform eruption, acne vs 42.37  
aetiology and pathogenesis 50.56–7, 69.47  
bone and joint involvement 62.102  
clinical features 69.46, 69.47  
definition 50.56  
diagnosis 50.58, 50.60–1, 69.47–448  
differential diagnosis 42.37, 69.47  
genital involvement 50.58–9  
histopathology 50.57–8  
Koebner response 28.3–4  
male genitalia  
female genitalia 71.65  
male genitalia 71.24–5, 71.25  
neutrophilic eccrine hidradenitis and 44.17  
ocular involvement 50.59–60, 67.25  
oral involvement 50.58, 50.59, 69.44, 69.118  
overlap with other disorders 50.62  
perianal/perineal involvement 71.90  
renal involvement 62.71  
respiratory tract involvement 62.82  
skin lesions 50.59  
thrombophlebitis migrans in 47.30  
TNF antagonists 74.8  
treatment 50.61–2, 69.48  
vasculitis and 50.3, 50.49, 69.47
- Beighton score 45.34
- bejel (endemic syphilis) 30.63
- beliefs  
disorders of 64.12–17  
skin and skin disease 64.1–2, 64.6
- belimumab 74.10
- Bell's palsy 33.19
- Bence Jones protein 13.17, 49.32
- Beneckea chitiniivora* 2.12
- benign aphthae, female genitalia 71.65–6
- benign calcifying epithelioma of Malherbe 53.12–13
- benign epidermal tumours 52.38–45
- benign joint hypermobility syndrome 45.34
- benign lichenoid keratoses (BLKs) 41.6
- benign summer light eruption 29.12
- benign tumours 52.1  
female genitalia 71.72–4  
male genitalia 71.35–7  
perianal/perineal 71.83, 71.96  
*see also specific tumours*
- bentonite 73.8
- benzaldehyde 75.162
- benzalkonium chloride 26.17, 26.58, 67.22, 73.14
- Benzamycin®, acne vulgaris treatment 42.41
- benzathine penicillin G  
in non-venereal treponematoses 30.64  
syphilis management 34.22, 34.24
- benzene 25.19, 25.20
- benzimidazoles 74.50–1  
adverse effects 75.71  
in dracunculiasis 37.13  
in trichomoniasis 37.29
- 1,2-benzisothiazolin-3-one 26.15, 26.15, 26.53–4
- benznidazole 37.32
- benzoates 5.25
- benzocaine 26.45
- benzodiazepines 75.81
- benzoic acid 25.18, 36.47, 36.48, 36.49
- benzophenones 26.23, 26.24, 26.62  
photoallergic dermatitis due to 73.40

- benzo(a)pyrene 27.16  
benzopyrone drugs, in lymphoedema 48.25  
benzothiazinylalanine 58.6  
benzoyl peroxide (BPO)  
adverse effects 42.49  
antibiotics combined with 42.41, 42.48  
formulations 42.41  
indications 73.13  
as irritant 25.19, 25.21  
mechanism of action 42.40, 42.41  
topical, acne treatment 42.39–41, 42.41, 42.48, 42.67  
benzylamine 26.46, 75.78  
benzyl alcohol 26.58  
benzyl benzoate 38.41, 73.14  
in *Demodex* infection in rosacea 43.3  
benzyl penicillin *see* penicillin G  
Ber-H2 10.25  
Berardinella–Seip syndrome 46.37  
Berardinelli’s syndrome 66.76  
BerEP4 53.35  
Berloque dermatitis 26.18, 58.32  
beryllium reactions 61.22  
Besnier’s prurigo *see* atopic dermatitis (AD)  
bestatin 12.50  
Bet v.1 22.20  
 $\beta$ -blockers 64.52  
adverse effects 26.17, 26.46, 75.90–2  
flushing management 43.6, 43.15  
non-cardioselective 43.6  
 $\beta$ -catenin 66.10  
 $\beta$ -glucans 36.1  
 $\beta$ -haemolytic streptococci *see* *Streptococcus*  
betamethasone dipropionate 73.16  
calcipotriol with 73.45  
betamethasone valerate, glaucoma association 73.19  
 $\beta_2$ -microglobulin, in sarcoidosis 61.20  
beta-rays 79.1–2  
bété 26.81  
betel chewing 69.50, 69.96–7  
Bethyloidea 38.14  
*Betta splendens* 31.31  
bevacizumab, melanoma management 54.54  
bexarotene 57.23, 73.35, 73.36–7, 74.37  
bezafibrate 75.31  
bezoar 64.31  
bezoar by proxy 64.32  
bFGF *see* basic fibroblast growth factor (bFGF)  
BFS (burning feet syndrome) 63.25  
BGS (Baller–Gerold syndrome) 15.80  
bias 6.11, 6.18  
information 6.18  
language 7.7  
publication 7.7  
selection 6.18  
Bid (BH3-interacting death domain protein) 12.12  
bidi 69.90  
BIE *see* bullous ichthyosiform erythroderma (BIE)  
*Bifidobacterium eriksonii* 30.75  
bifonazole 73.12  
in dermatophytoses 36.50  
in otomycosis 36.17  
big foot disease *see* podoconiosis  
big leaf mahogany 26.81  
biglycan 45.33  
biguanides 75.156  
bile acid sequestrants 59.93  
bilharziasis *see* schistosomiasis  
biliary tract disorders 62.62  
bilirubin  
in sarcoidosis 61.8  
skin pigmentation 58.53  
bimatoprost 26.46, 66.79  
bindi 26.10  
bio-psycho-social approach 64.49  
biocides 27.5, 27.6  
as allergens 26.49–58  
bioengineering 4.10–11  
bioinformatics 11.8, 11.9  
biological compensation, in actinic keratosis 52.31  
biological false-positive reactions (BFP) in syphilis 34.20–1  
biological terrorism 33.5, 33.6  
biological therapies 74.4–13  
B-cell directed 74.9–10  
cytokine-directed 74.10–11  
interactions 72.29  
in melanoma 54.53–4  
naming conventions 74.5  
psoriasis 20.41–2, 72.14, 74.10  
in psoriatic arthritis 20.59  
recombinant proteins 74.4–5  
targeting tumour necrosis factor 74.5–6  
biomarkers  
lymphatic vessels 48.4–5, 48.19  
melanoma 54.51  
biostatistics 6.20  
biotin 10.17, 59.64  
biotinidase deficiency 59.64–5  
*Bipolaris* 36.77  
Birbeck granules 3.18, 55.3–4, 55.7  
electron microscopy 10.30  
lacking from indeterminate cells 55.3  
in Langerhans’ cell histiocytosis cells 55.6, 55.7, 55.7  
staining for 55.9  
structure and antigens 55.3–4  
birch 26.105  
birds  
aquatic, white colour 2.6  
glands 2.4  
mites 38.51–2  
pigment cells 2.6  
skin 2.3  
birth weight 17.1  
birthmarks  
simulation 64.42–3  
*see also individual birthmark types*  
Birt–Hogg–Dubé syndrome 53.14, 53.15, 62.57, 62.69  
*bis*(4-amino-3-methylcyclohexyl) methane 27.17  
bismuth subsalicylate 75.157  
bismuthia, pigmentation in 58.55  
bisphosphonates 75.99  
BIT (1,2-benzisothiazolin-3-one) 26.15, 26.15, 26.53–4  
bite marks, child abuse 28.34, 28.35  
bitemporal aplasia cutis 15.40, 15.83–4  
bitemporal forceps marks syndrome 15.40  
bites  
arthropod 38.1–5  
cat 38.60–1  
dog 38.60–1  
human 38.61  
child abuse 28.34, 28.35  
rodent 38.61  
seal 38.61  
snake 38.60  
bithionol 26.24  
Bittner’s syndrome 33.59  
Björnstad’s syndrome 66.64, 66.65  
BK mole syndrome 54.28, 62.20, 62.21–2  
BKH-S surveillance system 27.2  
black blowflies 38.8  
black death 30.55  
black dermatographism 28.92–3  
mechanical injury 28.26  
black heel 28.16, 28.31, 49.16  
black palm 28.16, 28.31  
black people, sarcoidosis 61.15–16  
black-widow spider 38.31  
blackflies 37.4, 38.5–6, 38.7  
blackheads 42.22, 42.24, 42.30, 42.77  
bladder, carcinoma 31.29  
BLAISE (Blaschkitis, adult) 18.26–7  
Blandford fly 38.5–6, 38.7  
*Blaps* 38.27  
Blaschkitis, adult 18.26–7  
Blaschko’s lines 15.6, 15.7, 18.2, 18.4  
blastic NK-cell lymphoma 57.39  
blastocystidia 36.16  
*Blastomyces dermatitidis* 36.83–5  
Blastomycetes 36.4  
blastomycosis 36.83–5  
aetiology 36.83  
bone and joint involvement 62.100  
clinical features 36.84  
definition 36.83  
differential diagnosis 31.10, 36.84  
disseminated 36.84  
histology 36.83–4  
keloidal (lobomycosis) 36.77–8  
laboratory diagnosis 36.84–5  
male genital dermatology 71.32  
oral involvement 69.80, 69.118, 69.121  
perianal/perineal 71.96  
primary cutaneous 36.84  
pulmonary 36.84  
South American *see* paracoccidioidomycosis  
treatment 36.85  
*Blatella* 38.28  
*Blatta* 38.28  
Blau syndrome 45.46, 60.4, 61.16, 62.104  
mutations in NOD2 12.12  
bleaches  
burns 25.11  
as irritants 25.21  
skin 9.8  
bleaching, of skin 73.27  
bleeding  
causes/abnormalities causing 49.6  
in Hermansky–Pudlak syndrome 58.41  
in idiopathic thrombocytopenic purpura 49.10  
intraoperative/postoperative 77.8, 77.9, 77.50  
neonates 49.49  
*see also* neonatal purpura  
occult, tests 49.5  
in thrombocytosis 49.5, 49.14  
bleeding time 49.5–6  
Blegvad–Haxthausen syndrome 45.17  
bleomycin  
adverse effects 75.126–7  
purpura 75.23  
scleroderma 27.17, 45.52  
intralesional  
administration method 33.50  
adverse effects 33.50  
wart treatment 33.50  
scleroderma-like changes 51.81  
topical 73.23  
blepharitis 67.4  
acute 67.6, 67.11  
associated conditions 67.7  
chronic 67.6–12  
causes 67.10  
epidemiology 67.6  
immunopathogenesis 67.6, 67.11  
treatment 67.11, 67.12  
classification 67.6, 67.7  
follicle mite infection and 38.53  
management 67.22  
*Phthirus pubis* causing 67.10  
seborrhoeic 67.7  
in seborrhoeic dermatitis 23.31  
staphylococcal 30.32, 67.6, 67.7, 67.8, 67.11  
atopic eye disease with 67.16  
clinical features 67.7  
treatment 67.11, 67.16  
streptococcal 30.32  
terminology problems 67.6  
ulcerative 67.8  
blepharochalasis 45.20–1, 45.33, 48.23–4, 67.4, 67.5  
blepharocheilodontic syndrome 15.31  
blepharoconjunctivitis  
atopic 67.13  
HSV 67.26  
blepharophyma 43.9  
blind loop syndrome 44.20, 50.87–8, 62.51, 62.53  
blinded trials 7.7  
blindness, mucous membrane  
pemphigoid 67.17, 67.18  
blinking 67.3  
blister beetles 38.2, 38.26  
blistering, acute drug-induced  
phototoxicity 29.21  
blistering agents, response in ageing skin 8.23  
blistering disorders, genetic *see* hereditary blistering disorders  
blisters  
after cryotherapy for warts 33.49  
cold-induced injury 28.64  
formation 39.1, 39.3, 40.29  
friction 28.2, 28.9, 28.12–13, 28.28, 28.30–1  
gingival 69.14  
during intensive care 28.39  
oral mucosa 69.22  
sucking 17.4  
suction 28.23–4  
transillumination 17.14  
*see also* bullae  
BLM (Bloom’s syndrome) 15.76–7, 62.27  
Bloch–Siemens syndrome *see* incontinentia pigmenti (IP)  
Bloch–Sulzberger syndrome *see* incontinentia pigmenti (IP)  
blood  
extravasated 49.2  
fetal sampling 17.12  
increased intravascular, in skin 49.2  
blood flow  
control, in capillaries 3.51  
in obesity 8.17  
blood pressure, claudication management 47.5  
blood samples, viral infection diagnosis 33.4–5  
two samples, timing 33.5  
blood supply, skin 3.2, 3.3, 3.50–2  
blood transfusion  
adverse effects 75.154–5  
CMV transmission 33.29  
in dystrophic EB 39.29  
intrauterine 17.12  
syphilis transmission 34.5  
blood urea nitrogen monitoring, burns 28.84  
blood vessels 3.50–2  
abnormal, purpura due to 49.14–15  
classification 47.13  
decreased support of, purpura due to 49.14–15  
remodelling 47.1  
thermoregulatory role 3.50–1  
Bloom–Richardson method 53.22  
Bloom’s syndrome (BLM) 15.76–7, 62.27  
genetics 15.76–7  
blowflies 38.8  
blue-ringed octopus 38.59  
blue rubber-bleb naevus syndrome 18.72–3  
hyperhidrosis and 44.9  
iron deficiency anaemia in 62.85  
oral involvement 69.30  
blue scrotum sign 62.65  
blue toe syndrome 49.36  
blueberry muffin baby 17.32–3, 49.20, 49.51  
‘blueberry muffin’ lesions 33.29  
bluebottle 38.8  
blushing *see* flushing  
BMP-2 49.47  
BMP-4, in lichen planus 41.2  
Bockenheimer’s syndrome 47.24  
body asymmetry 63.14  
body composition 3.52  
body dysmorphic disorder 42.60, 64.17–20, 64.48  
acne and 42.60, 42.71  
male genitalia 71.51–2  
perianal/perineal dermatology 71.99  
body image 1.1

- body mass index (BMI) 8.16, 46.5  
criticisms over and advantages 46.5
- body odour 44.19  
abnormal 44.19–20  
in adolescence 8.6, 8.7  
axillary 30.4, 44.8, 44.19, 44.20  
false beliefs 64.16  
production 44.2
- body piercing 58.57  
allergic contact dermatitis and 26.10  
ear 68.7–9  
complications 26.17, 61.23, 68.7–8  
nipple 70.11  
oral tissue 69.96  
ornamental 28.51–2
- body site, effect on mechanical injury 28.8
- body surface area, percentages 76.20
- body temperature  
limb, erythromelalgia 47.9  
monitoring, burns 28.83  
regulation *see* thermoregulation
- boil (furuncle) 30.23–4
- Bolivian haemorrhagic fever 33.69
- Bombay blackwood 26.80
- bombesin 4.10
- Bombidae *see* bees
- Bombus* *see* bees
- bone  
disorders 62.99–106  
fracture 62.99  
mineralization, inhibitors 49.48  
overgrowth, McCune–Albright syndrome 58.18
- bone involvement (in)  
congenital syphilis 34.16  
dystrophic EB 39.29  
Erdheim–Chester disease 55.18  
Langerhans’ cell histiocytosis (LCH) 55.12  
malignant histiocytosis 55.32  
McCune–Albright syndrome 58.18  
multicentric reticulohistiocytosis 55.23  
sarcoidosis 61.6–7, 61.11, 62.104  
systemic sclerosis 51.97  
venous leg ulcers 47.46  
xanthoma disseminatum 55.21
- bone marrow  
B cell development 13.7–8  
failure, Fanconi’s anaemia 58.17  
in Langerhans’ cell histiocytosis (LCH) 55.11  
in mastocytosis 22.30, 22.31, 22.32, 22.33, 22.34  
transplantation  
familial haemophagocytic lymphohistiocytosis 55.26  
oral complications 69.82–3  
*see also* haematopoietic stem cell(s), transplantation
- bone marrow aplasia, chloramphenicol 74.43
- bone marrow diseases, secondary thrombocytopenia due to 49.11–12
- bone morphogenetic proteins 3.3, 3.4, 3.7, 66.10  
BMP-2 49.47  
BMP-4, in lichen planus 41.2
- Bonnet–Dechaume–Blanc syndrome 18.62
- book dysplasia 15.31
- bookbinders, occupational hazards 27.18
- Böök’s syndrome 66.93
- boot, inflatable 48.23
- BOR syndrome (branchio-oto-renal syndrome) 18.83, 18.85, 18.90, 68.3
- Boraginaceae 26.80
- borax 75.163
- boric acid 75.163
- Bork syndrome 15.56
- Borrelia* 30.64  
male genital dermatology 71.22  
morphoea and 45.10  
*Borrelia afzelii* 45.9–10, 62.106  
*Borrelia balanitidis* 34.4  
*Borrelia burgdorferi* 30.64–6, 45.9, 62.106  
antibodies in morphoea 51.65  
female genital dermatology 71.62  
nodular panniculitis 46.14  
*Borrelia duttoni* 30.64  
*Borrelia garinii* 62.106  
*Borrelia gracilis* 34.4  
*Borrelia hermsi* 30.64  
*Borrelia lonestari* 38.35  
*Borrelia persica* 38.35  
*Borrelia recurrentis* 30.64  
*Borrelia refringens* 34.4  
*Borrelia vincentii* 26.46  
Borst–Jadassohn phenomenon 53.23  
appearance in Bowen’s disease 52.33  
bortezomib 50.17, 50.49, 75.133  
bosentan, cold-induced injury 28.70  
Boston eruption 33.73  
botryomycosis 30.67–8  
botulinum toxin  
adverse effects 80.7  
ocular 67.32  
in chromhidrosis 44.21  
cosmetic use 80.7–9  
combination treatments 80.7–8  
in genital osmidrosis 44.20  
in gustatory sweating 44.10, 44.11, 63.23  
in Hailey–Hailey disease 39.36  
in hyperhidrosis 44.11, 77.36, 77.37  
mode of action 80.7  
in notalgia paraesthetica 63.23  
products available 80.7  
in thelalgia 70.11  
type A (BTX-A) 80.7  
type B (BTX-B) 80.7
- bouba *see* yaws
- Bouchard’s nodes 45.70
- Bourneville’s disease *see* tuberous sclerosis complex
- bouton d’orient* (Old World cutaneous leishmaniasis) 37.34–9
- boutonneuse fever (tick typhus) 38.35
- bovine papillomaviruses (BPV) 2.21
- Bowdichia nitida* 26.80
- bowel-associated dermatosis–arthritis syndrome 44.20, 50.87–8, 62.51, 62.53
- bowel bypass syndrome 44.20, 50.87–8, 62.51, 62.53
- Bowenoid actinic keratosis 52.31
- Bowenoid papulosis 71.38–9, 71.74  
of genitalia 52.37  
male genitalia 71.38–9  
HPV and 33.54–5  
treatment 73.23
- Bowen’s disease 52.2, 52.12, 52.32–4  
aetiology 52.32  
arsenic exposure and 52.32, 52.33, 52.35  
clinical features 52.32–3  
definition and incidence 52.32  
diagnosis 52.33–4  
differential diagnosis  
extramammary Paget’s disease vs 53.41  
HPV infection vs 33.55  
epidermodysplasia verruciformis and 33.57  
HPV-2 infection 33.55  
internal malignancy and 62.47  
invasive carcinoma in 52.33  
palmoplantar 52.5  
pathology 52.33  
of penis 52.36  
progression to invasive SCC 52.29  
recurrences 52.34  
squamous cell carcinoma arising in 52.27  
treatment 52.34, 78.14, 78.16  
curettage 77.41  
radiotherapy 79.12  
topical 5-FU 73.23  
topical imiquimod 73.24  
vulval 71.74
- Bowen’s disease of the penis (BDP) 71.38–9
- box jellyfish 38.56, 38.57
- BP180 NC16a 8.14
- BP230 and BP180 *see* bullous pemphigoid antigens
- BPAG1 (bullous pemphigoid antigens, BP230) *see* bullous pemphigoid antigens, BP230 (BPAG1)
- BPAG2 *see* bullous pemphigoid antigens, BP180 (BPAG2; type XVII collagen); collagen, type XVII
- BPAG2 gene mutations 3.31
- brachial valve transplant 47.51
- Brachycera 38.6–8
- brachymetapody–  
anodontiahypotrichosis–  
albinoidism 15.31
- Brachypelma smithi* 38.30
- brachytherapy, interstitial 79.2, 79.5
- Braden system of risk assessment 28.20, 28.21
- bradykinin 13.4  
in angio-oedema 22.5, 22.21  
pruritus and 21.5
- brain  
lesions, hyperhidrosis associated 44.7  
melanoma metastases 54.54, 54.55  
thermosensitive receptors 44.5  
tumour, pruritus associated 62.34
- branchial arches, complex defects of first and second 18.80–7
- branchial (cleft) cyst 18.85–6
- branchio-oto-costal syndrome 18.85
- branchio-oto-renal syndrome 18.83, 18.85, 18.90, 68.3
- Branham’s sign 47.21
- Brassica* 25.21
- Brauer syndrome 15.40
- Brauer–Buschke–Fischer keratoderma 19.95, 19.112–13
- Brazil, prevalence of skin disease 6.9
- Brazilian pemphigus foliaceus 40.17–18
- Brazilian rosewood 26.81
- breast 70.1–17  
abscess 8.13, 70.10, 70.13, 70.15  
neonatal 17.43  
aplasia/hypoplasia 70.2, 70.3, 70.6, 70.7  
artefactual disease 70.11  
cancer *see* breast cancer  
Carney complex 70.17  
Cowden’s syndrome 70.17  
cutaneous larva migrans 70.17  
development 8.4, 70.1  
diffuse dermal angiomatosis 70.17  
duct ectasia/periductal mastitis complex 70.8  
enlargement, in pregnancy 8.9  
in Fox–Fordyce disease 70.17  
granular parakeratosis 70.17  
hair sinus 70.15  
hidradenitis suppurativa 70.17  
hypertrophy 70.3  
isolated enlargement 8.5  
lichen sclerosis et atrophicus 70.17  
lupus panniculitis 70.12  
lymphoedema 48.8, 48.17, 48.20  
management 48.23  
mammary duct fistula 70.13  
in menopause 8.19  
neurofibromatosis 70.17  
pityriasis rosea 70.17  
in pregnancy 70.1  
psoriasis 70.17  
pyoderma gangrenosum 50.70, 70.11  
roustabout’s 70.15  
sarcoidosis 70.12, 70.14  
scabies 70.17  
seborrhoeic warts 70.15, 70.16  
silicone implants 51.82, 51.90, 51.111  
autoimmune disease and 70.7–8  
supernumerary (accessory) 70.2–3  
telangiectasia 70.13  
vasculitis 70.11  
vitiligo 70.17
- breast bud 8.4
- breast cancer 62.15, 62.16, 70.13–14  
apocrine, apocrine carcinoma vs 53.21  
basal cell carcinoma 70.15  
carcinoma erysipelloides 48.31  
grading, Bloom–Richardson method 53.22  
inflammatory 48.31  
in Klinefelter’s syndrome 70.4  
lymphoedema associated 48.8, 48.17, 48.20  
male 70.14, 70.15  
melanoma 70.14, 70.15  
metastases from 70.14  
minoxidil use in 73.50  
Mondor’s disease and 70.16  
mucinous, mucinous axnaxal carcinoma vs 53.36  
Paget’s disease of nipple and 53.38, 53.39  
in Peutz–Jeghers syndrome 58.13  
radiotherapy, syringoma association 53.25
- breastfed infants, zinc deficiency 59.73–4
- breastfeeding  
atopic dermatitis and 8.12, 24.34  
cracked nipples 70.10  
gonorrhoea management 34.28  
immunity and 13.15  
prednisolone and 40.45  
scabicides and 38.42  
transfer of toxic substances 17.19
- breathing exercises, lymphoedema management 48.23
- Breslow thickness, melanoma 54.49, 54.52
- Brevibacterium* 30.3, 30.35, 30.36  
in normal skin flora 30.2, 30.3, 30.36, 68.2  
toe clefts 30.4  
*Brevibacterium epidermis* 30.3  
*Brevibacterium mcbrellneri* 30.3, 36.16
- brilliant green dye, topical therapy 73.48
- brilliantine 27.13, 27.14
- Brill–Zinsser disease 30.73
- brimonidine 26.46
- Brindle coat colour 2.5, 2.7
- British Association of Dermatologists 72.14
- British National Formulary (BNF), topical corticosteroids 73.16
- British Photodermatology Group (BPG) 29.2
- British Red Cross, cosmetic camouflage 43.6
- broad thumb–hallux syndrome 15.92–3
- Brocq, pigmented peribuccal pigmentation of 58.35–6
- Brodex’s classification 52.26
- bromhidrosis 8.7, 44.19–20
- bromides, acneiform eruption due to 42.73
- bromism 75.152
- 2-bromo-2-nitropropane-1,3-diol 26.50, 26.52
- 1-bromo-3-chlor-5,5-dimethylhydantoin 75.163
- bromocriptine  
adverse effects 75.88  
in gigantostasia 70.3  
bromodeoxyuridine 75.133  
bromoderma 75.21, 75.152  
bromoderma tuberosum 75.152  
bromofluorene 76.5  
bromophenol blue 44.4
- bronchial carcinoid tumours 43.18
- bronchiolitis, respiratory syncytial virus (RSV) 33.76
- bronchogenic (presteral ciliated) cyst 18.87–8
- bronze baby syndrome 17.12–13, 58.53
- bronze diabetes *see* haemochromatosis
- bronzed pigmentation *see* pigmentation
- bronzing of skin 58.53
- Brooke’s tumour *see* trichoepithelioma

- Brooke-Spiegler syndrome 53.9, 53.28, 53.29
- brown adipocytes 46.1
- brown adipose tissue 8.16  
see also brown fat
- brown dog tick 38.35
- brown fat 3.52, 8.16, 46.1  
hibernoma 46.45  
thermogenic 46.1
- brown recluse spider 38.32
- brown snakes 38.60
- brown-tail moth 38.28, 38.29
- brown-widow spider 38.31
- brucella, antigen 5.24
- Brucella abortus* 30.55
- Brucella melitensis* 30.55
- Brucella suis* 30.55, 30.56
- brucellosis 30.55–6  
nodular panniculitis 46.14  
sarcoidal reaction in 61.22  
sweating in 44.7
- Bruch's membrane 67.4
- Brugia malayi* 37.9–10
- Brugia timori* 37.9–10
- bruises  
child abuse 28.34–6  
differential diagnosis 28.36
- bruising see ecchymoses/bruising
- Brunauer-Fuhs-Siemens syndrome 19.105–6
- Brunsting Perry pemphigoid 40.35, 40.39
- Brunzell syndrome 46.37
- Bruton tyrosine kinase 17.71
- Bruton's disease (X-linked agammaglobulinaemia) 13.9, 13.13, 17.70–1, 69.117
- Brya ebenus* 26.80
- Bryant's sign 62.65
- Bryozoa (sea mats) 26.10, 38.58
- BSCL2* gene 46.37
- buba see yaws
- bubo  
in chancroid 30.47, 34.34, 34.35  
climatic see lymphogranuloma venereum (inguinale)  
in lymphogranuloma venereum 34.33  
in plague 30.55
- Bubostomum phlebotomum* 37.16
- buccal fat-pad herniation 69.110
- buccal mucosa  
lichen planus 41.8, 41.9  
pigmentation, Laugier-Hunziker syndrome 58.14
- Buckley's syndrome see hyper-IgE syndrome
- Budd-Chiari syndrome 49.29, 49.30
- budesonide 26.45
- Buehler test 26.11
- Buerger's disease see thromboangiitis obliterans
- Buerger's sign 47.2, 47.3
- buffalo gnats 38.7
- buffalo hump lipohypertrophy 46.41, 46.42
- buffalopox 33.8
- buffered phosphate solution 27.11–12
- bugs (Hemiptera) 38.23–6
- building-related illness 64.26
- building trades, occupational hazards 5.6, 27.2, 27.3, 27.18
- bulbar palsy 69.119
- bulimia nervosa 64.21–2  
oral manifestations 69.115
- bullae  
arthropod bites inducing 38.3, 38.6  
in bullous impetigo 30.15  
in carbon monoxide poisoning 28.93–4  
in congenital syphilis 34.16  
definition 5.8  
drug-induced 75.37–40  
in drug overdose 75.37  
in epidermolysis bullosa 39.6, 39.7, 39.8, 39.13, 39.14, 39.18  
see also epidermolysis bullosa (EB)  
in Hailey-Hailey disease 39.33
- histopathology 10.37–8  
in incontinentia pigmenti (IP) 58.16
- intraepidermal 10.38
- in otitis externa 68.22
- subepidermal 10.38
- in urticaria 22.5  
see also blisters
- bullous dermolysis of the newborn 39.23–4, 39.25
- bullous disorders 40.1–62  
in animals 2.14–15  
childhood see linear IgA disease  
in elderly people 8.28  
electron microscopy 10.29  
female genitalia 71.65–7  
herpes simplex in 33.15  
immunopathology 10.18–19  
intraepidermal 40.3–24  
neutrophilic 50.95  
ocular involvement 67.29  
subepidermal 40.25–62
- bullous eruption, measles 33.75
- bullous eruptions, fixed drug eruptions, female genitalia 71.66
- bullous ichthyosiform erythroderma (BIE) 15.6, 19.3, 19.29–34  
epidermolytic verrucous epidermal naevus and 18.5, 18.7–8  
genetics 15.6  
histopathology 10.39, 10.40  
naevoid 19.31  
prenatal diagnosis 16.3, 16.5  
see also ichthyosis bullosa of Siemens; ichthyosis hystrix
- bullous impetigo, differential diagnosis 40.50
- bullous myringitis 68.24
- bullous pemphigoid 40.26–35, 71.28  
aetiology 40.28  
IgG autoantibodies 40.30  
agents inducing 40.32–3  
amputees 28.29  
in animals 2.14–15  
associated diseases 40.32–3  
autoantibodies 35.19  
BP230 and BP180 40.28, 40.30, 40.36  
carcinoma and 40.32–3  
children, differential diagnosis 40.50  
clinical features 40.31–2  
defined 40.26  
differential diagnosis 40.34  
drug-induced 40.32, 75.38  
elderly people 8.27  
immunizations and 40.32  
immunopathology 10.18, 10.19  
induced (various agents) 40.32  
ocular features 67.20  
oral involvement 69.65  
paraneoplastic 62.45  
pathogenesis 40.28  
pathology 40.30  
prognosis 40.34  
renal involvement 62.71  
treatment 40.35  
methotrexate 74.18–19  
UV and PUVA inducing 40.32
- bullous pemphigoid antigens 3.30, 3.31  
antibodies to 39.25  
BP180 (BPAG2; type XVII collagen) 3.36, 3.37, 40.28, 40.30, 40.36  
and ectodomain 40.46  
in junctional EB 39.10, 39.25  
monoclonal antibodies to 39.25  
see also collagen, type XVII  
BP230 (BPAG1) 40.28, 40.30, 40.36  
antibodies to 39.25, 40.42  
desmoplakin and 40.30
- bullous pemphigoid-like eruption, orf 33.9
- bullous porphyria 59.5–6  
see also porphyria, cutaneous disease
- bullous systemic lupus erythematosus 40.56–8  
associated disease 40.57  
clinical features 51.41  
differential diagnosis 40.57
- bumblebees see bees
- bumetanide 75.97
- bungarotoxin 38.60
- Bungarus candidus* 38.60
- bunyaviruses, and *Bunyaviridae* 33.3, 33.66, 33.67, 33.68, 33.70
- buphthalmos 18.66
- bupivacaine 75.153, 77.10  
in nail biopsy 65.41–2
- buprenorphine 75.87
- burden of skin disease 6.1, 6.5  
data used in 6.5–6  
developed countries 6.8, 6.9  
developing countries 6.8, 6.9–10  
estimating 72.14
- Bureau-Barrière syndrome (acro-osteolysis with keratoderma) 19.115
- Burkholderia cepacia* 30.48
- Burkholderia mallei* 30.51
- Burkholderia pseudomallei* 30.50–1
- Burkitt's lymphoma 33.30
- burn scar carcinomas 28.91
- burning feet syndrome 63.25
- burning mouth syndrome 26.20, 26.39, 62.85, 69.86–7
- burns 28.74–92  
abuse of the elderly 28.91–2  
applied utensils 28.35  
area of burn assessment 28.77–9  
assessment in hospital accident department 28.76–7  
chemical 14.1, 25.1, 27.11–12  
clinical features 25.10–11  
management 25.22–3  
neonatal 17.14  
child abuse 28.34, 28.35, 28.90, 28.91–2  
cigarette 28.33, 28.34, 28.92  
clinical aspects 28.75–88  
cutaneous sequelae 28.88  
decompression 28.79–80, 28.81–2  
depth 14.10, 25.10–11  
burn classification 28.75, 28.76–7, 28.84–5  
differential diagnosis 28.36  
documentation 28.80  
electrical see electrical burns  
epidemiology 25.2  
fourth-degree 25.11  
full-thickness 14.10, 14.11, 25.11  
gastrointestinal tract decompression 28.78  
healing 14.10–11  
hypertrophic scarring 28.84, 28.88–9  
laser 28.90  
Erbium:YAG 53.7  
Lund and Bowder charts 28.77, 28.79  
malignant neoplasms 28.90–1  
management  
dressings 14.1  
early management 14.11  
first aid and prehospital management 28.75–6  
fluid resuscitation 28.77–8, 28.80–4  
general care 28.86  
immediate wound care 28.78  
pain relief 28.79  
referral/transfer of the patient 28.80, 28.82  
surgical interventions 28.84–6  
triage 28.80  
wound management 28.84–6  
microwave radiation 28.90  
monitoring response to resuscitation 28.83–4  
oral cavity 69.43, 69.88  
partial-thickness 14.10  
deep 14.10, 25.11  
superficial 14.10, 25.10–11  
pathophysiology 28.74–5  
prevention and epidemiology 28.74  
primary survey 28.75–6  
*Pseudomonas aeruginosa* infection 30.49, 30.50  
Rule of Nines 28.77, 28.78
- rule of nines 14.10
- secondary assessment 28.76
- specialized burns units 28.80, 28.82
- stem cell strategies 28.86–7
- torture injuries 28.33
- triage 28.80  
urine output 28.78
- Burow's solution 73.15–16  
in eczema 23.37–8
- burrow, definition 5.7
- bursa of Fabricius 13.7
- bursitis 24.25
- Buruli ulcer  
in HIV infection 35.26  
*Mycobacterium ulcerans* 12.9, 31.6, 31.33–5
- Buschke-Löwenstein tumour 33.46, 33.55, 33.55, 52.26  
female genitalia 71.76–7  
male genitalia 71.44–6  
perianal/perineal 71.95  
treatment 33.55
- Buschke-Ollendorf syndrome 45.50, 45.68  
bone and joint involvement 62.99, 62.100, 62.102  
juvenile elastoma and 18.32–3
- Buschke's sclerodema 51.79
- buserelin 75.117  
in acne vulgaris 42.53
- bush dermatitis 26.75
- bush tea essential oil, in scabies 38.41
- buspirone 64.52
- busulfan (busulphan) 69.97, 70.5, 75.124  
hypermelanosis due to 58.30
- butchers  
occupational hazards 25.21, 27.18  
warts 33.47
- butenafine 73.12
- Buthidae 38.33
- buthionine sulphoxime 73.27
- Buthus* 38.33
- buttercup 25.21
- butterflies 38.28–30
- butterfly itch 38.29
- N-butyl-4-chlorosalicylamide* 26.62, 73.40
- butylated hydroxyanisole 22.11, 75.159
- butylated hydroxytoluene (BHT) 22.11, 73.6, 75.159
- butylhydroxyanisole (BHA) 73.8
- butylhydroxytoluene (BHT) 73.8
- Bwamba virus 33.67
- BXO (balanitis xerotica obliterans) 71.21
- bypass procedures, in lymphoedema 48.25
- bystander activation hypothesis, in vasculitis 50.6
- C
- C1 esterase inhibitor (C1INH) 12.49, 13.3, 13.4  
deficiency 13.13, 22.1, 22.2, 22.20, 69.107  
acquired 22.22–3  
hereditary angio-oedema and 22.21–2  
kinins and 22.4, 22.5  
screening 13.18, 22.26
- C1 inhibitor, decreased, in necrobiotic xanthogranuloma 55.28
- C1q, C1r, C1s see complement
- C2 see complement
- C3 see complement
- C3H/HeJ mouse 2.18
- C4-binding protein 13.3  
deficiency 13.13
- C5a peptidase 30.11
- C8-binding protein 13.4
- C-fibres see nerves, C fibres
- c-Kit 3.21  
*c-kit* mutation 54.4  
*c-Myc* 3.5  
in wound healing 14.4

- C-PAN (cutaneous polyarteritis nodosa) 50.37–9
- C-reactive protein (CRP) 12.28, 12.32, 13.4, 13.19
- C-type lectins 12.10
- C-reactive protein 13.4, 13.19
- cabergoline, in restless legs syndrome 63.25
- cabinet makers, occupational hazards 26.20, 26.79, 27.18–19
- cachectin *see* tumour necrosis factor
- caecostoma 64.26
- CADASIL 50.47
- cadexomer-iodine, in wound cleansing 14.21
- cadherins 40.1–2
- adherens junctions 3.23, 40.2
- desmosomal 3.22
- maintaining cell–cell adhesion 40.5
- paraneoplastic pemphigus 40.23
- transmembranous 3.22
- Caenorhabditis elegans*, genetics 15.1
- caeruloplasmin
- elevated levels 49.9
- in occipital horn syndrome 45.39
- Caesalpinaceae 26.80
- café-au-lait macules (CALMs) 15.16–18
- café-au-lait spots 62.23, 62.33
- differential diagnosis 54.9
- laser therapy 78.10
- McCune–Albright syndrome 58.18
- neurofibromatosis 58.23
- skin biopsy 10.42
- caffeine, topical therapy 73.49
- CAGE questionnaire 64.47
- CAH *see* congenital adrenal hyperplasia
- CAHMR syndrome 15.33
- caine mix 68.24
- Calabar swelling 37.11
- calamine 21.17, 73.2, 73.8
- in miliaria 44.16
- Calymmatobacterium granulomatis* 34.36
- calcaneal petechiae 28.16, 28.31
- calcific uraemic arteriopathy *see* calciphylaxis
- calcification
- after acne 42.78
- dystrophic 62.45
- iatrogenic dystrophic neonatal 17.14
- metastatic 62.45
- calcifying panniculitis with renal failure 46.16
- osteoma cutis 42.78
- pinnal 59.69, 62.5
- of skin 59.68–70
- small vessel 47.8–9
- subcutaneous 49.47
- venous leg ulcers 47.46
- calcifying chondrodysplasia 45.8
- calcifying fibrous tumour/pseudotumour 56.6–7
- calcineurin inhibitors 73.31–4, 74.16–17
- in dermatomyositis 51.129
- female genital dermatology 71.64
- in psoriasis 20.25
- treatment, psoriasis 20.25, 20.42
- calcineurin pathway 13.6
- calcinosis
- calcifying panniculitis vs 46.16
- penile 71.36
- post-phlebitis subcutaneous 47.46
- scrotal 71.35–6
- in systemic sclerosis 51.95
- calcinosis cutis 62.44, 62.72
- calciphylaxis 50.54
- calciphylaxis (calcific uraemic arteriopathy) 46.17, 47.8–9, 49.47–8, 62.12, 62.70–1
- calcifying panniculitis with renal failure 46.16
- differential diagnosis 47.9
- hyperparathyroidism and 49.47
- male genital dermatology 71.25
- perianal/perineal dermatology 71.90
- risk factors 49.47
- calcipotriol (calcipotriene) 73.43, 73.45–6
- adverse effects 26.46, 73.45, 75.163
- combination therapies 73.45
- indications 73.45–6
- in lichen sclerosus 51.118
- maximum recommended rate of use 73.45
- metabolism 73.45
- occlusion with 73.45
- in psoriasis 20.26, 73.45
- combined with PUVA 20.30
- in psoriatic nail involvement 65.26
- structure 73.44
- topical, in lichen planus 41.18
- calcitonin, in complex regional pain syndrome 63.21
- calcitonin gene-related peptide (CGRP) 4.10, 12.25, 12.63, 12.64, 63.2, 63.3
- in atopic dermatitis 24.17
- immune function and 63.4
- pruritus and 21.3, 21.4
- in Raynaud's phenomenon 63.4
- triple response of Lewis and 63.5
- in wound healing 63.4
- calcitriol 29.6, 73.43, 73.45
- doses and efficacy 73.45
- morphoea, localized 51.75
- in psoriasis 73.45
- structure 73.43, 73.44
- calcium
- abnormal oscillations, in Hailey–Hailey disease 39.33
- absorption increased by vitamin D 73.43
- deposition in external ear 68.18
- Hailey–Hailey disease pathogenesis 39.32–3
- metabolism changes 46.16
- in nail plate 65.3
- calcium channel blockers
- adverse effects 69.21, 75.94–5
- in hyperhidrosis 44.12
- oedema associated 48.6
- platelet function abnormalities 49.13
- telangiectasia with 47.15–16
- in vibration injury 28.58
- in wound healing 14.24
- calcium hydroxyapatite 80.4–5
- calcium pyrophosphate deposition disease 59.102
- calculus, cutaneous 56.2
- calf muscle pump 47.25
- calf vein, thrombosis 47.29
- caliciviruses 33.2
- Calliphora* 38.8
- Calliphoridae 38.8
- callosities
- mechanical injury 28.10–12, 28.25, 28.26
- painful hereditary 19.102
- calluses
- definition 5.7
- mechanical injury 28.2, 28.10–12, 28.31
- plantar warts vs 33.44
- CALMs (café-au-lait macules) 15.16–18
- Calocedrus decurrens* 26.80
- calomel 75.160
- caloric restriction, obesity management 46.8
- calponin 10.22
- Calymmatobacterium granulomatis* 30.61–2
- female genital infection 71.71
- CAM 5.2 10.12, 10.20–1
- Cam 5.2 10.12, 53.39, 53.40, 53.43
- Camarena syndrome 15.32
- Camisa's syndrome (loricrin keratoderma) 19.3, 19.19, 19.94, 19.98
- camouflage
- in androgenetic alopecia 66.24
- animals 2.5, 2.6
- cAMP *see* cyclic AMP (cAMP)
- Campath 13.25
- Campbell de Morgan spots (cherry angioma) 47.13, 47.15
- camphor 73.48
- hair regrowth and 73.39
- campodactyly 45.46–7
- Campylobacter jejuni* 22.8
- in erysipelas/cellulitis 30.18
- CAMs *see* adhesion molecules
- Canale–Smith syndrome 13.11, 13.23
- canaleta 26.80
- cancer
- familial syndromes 52.6
- as genetic disease 52.12
- recurrent, lymphoedema 48.14
- risk, communicating 72.2
- see also* carcinogenesis; malignant disease; *specific cancers*
- cancer surveillance programme, in Peutz–Jeghers syndrome 58.13
- cancer susceptibility modifying genes 52.10–11
- cancerphobia 64.24–5
- cancrem oris 69.14
- candesartan 75.94
- Candida*
- folliculitis 42.36
- identification 36.8
- immunodeficiency and 17.53
- intralesional use, wart treatment 33.50
- in otitis externa 68.21
- in otomycosis 36.17
- septicaemia 36.68
- see also* candidiasis
- Candida africana* 69.105
- Candida albicans* 36.56
- adherence 36.57
- allergy to 36.63–4
- anogenital infections 71.2
- cutaneous carriage 36.56
- in denture-related stomatitis 6.103
- drug resistance 36.68
- ecology 36.56–7
- ectodermal dysplasias 15.70
- female genital infections 71.68
- gastrointestinal tract carriage 36.56, 36.58
- genitocrural infections 71.6–7
- in HIV infection 69.105
- identification 36.9, 36.66–7
- in infantile gluteal granuloma 17.27
- intravenous drug abuse 28.53
- male genital infections 71.9, 71.17, 71.18, 71.24, 71.32
- napkin dermatitis and 17.23–4
- in onycholysis 65.10
- oral carriage 36.56, 36.58, 69.88
- in otomycosis 68.27
- persorption 36.56
- polymorphism 36.56, 36.57
- strains 36.57
- vaginal carriage 36.56
- virulence 36.57
- see also* candidiasis
- candida antigen test 5.24
- Candida dubliniensis* 36.56, 36.67, 36.68, 69.105
- Candida glabrata* 36.56, 36.67, 36.68, 68.25
- in HIV infection 69.105
- Candida inconspicua* 69.105
- Candida krusei*
- drug resistance 36.67, 36.68
- fungaemia, in HIV/AIDS 35.32
- in HIV infection 35.32, 69.105
- identification 36.9, 36.66
- Candida lusitanae* 36.56, 36.68
- Candida parapsilosis* 36.56
- in HIV infection 69.105
- Candida tropicalis* 36.56
- in HIV infection 69.105
- identification 36.9, 36.66
- Candida zeylanoides* 36.56
- candidiasis 36.56–69
- acute erythematous (atrophic oral) 36.60, 69.8, 69.88, 69.89, 69.104–5
- acute pseudomembranous 36.60, 36.64, 36.68, 69.88–9
- aetiology 36.56–7
- angular cheilitis and 26.21, 69.122
- balanitis due to 36.62, 36.68
- chronic erythematous/atrophic 36.60, 69.88, 69.102–4
- chronic hyperplastic 69.88, 69.89
- chronic mucocutaneous 13.13, 36.64–6, 69.26, 69.88
- autosomal dominant 36.65
- autosomal recessive 36.65
- clinical features 36.64–5
- diagnosis 36.66
- with endocrinopathy 36.65
- hypoparathyroidism and 62.12
- idiopathic 36.65
- immunodeficiency and 17.66–7
- immunology 36.65–6
- late onset 36.65
- treatment 36.69
- chronic nodular 36.61
- chronic oral multifocal (glossitis) 36.61, 69.88, 69.105–6
- chronic plaque-like/hyperplastic (leukoplakia) 36.60–1, 69.89, 69.90, 69.91
- chronic pseudomembranous 36.60
- congenital 17.47, 36.63, 36.69
- corticosteroids and 36.59, 36.61
- Cushing's syndrome and 36.58
- cutaneous 36.61–3, 36.64
- definition 36.56
- in diabetes mellitus 36.58
- diabetic dermopathy 59.78
- differential diagnosis 36.33, 50.55
- flexural (intertriginous) 36.61, 36.64, 36.68
- genitocrural 71.5, 71.6
- histology 36.60
- in HIV infection 35.32, 35.45, 36.59–60, 69.105
- host factors 36.58–9
- hypothyroidism and 36.58, 36.65
- immunodeficiency and 36.59
- interdigital 36.61
- laboratory diagnosis 36.8, 36.66–7
- male genital 71.32
- napkin (diaper) 36.62, 36.68–9
- neonatal 17.25, 17.46–7
- nodular/granulomatous of napkin area 36.63
- oesophageal, in HIV infection 35.32
- onychomycosis due to 36.63, 36.64, 36.65, 36.69
- oral 36.60–1, 36.64, 69.13, 69.22, 69.88–889
- in HIV infection 35.32, 35.43
- treatment 36.68
- paronychia due to 9.18, 36.63, 36.64, 36.69, 65.21
- pathogenesis 36.57–60
- perianal/perineal 36.62, 71.92
- scrotal 36.62
- systemic 36.91
- treatment 36.67–9
- urticaria and 22.10
- vulvovaginal 36.61–2, 36.68
- see also* *Candida*
- candidide 23.9, 36.63–4
- canicola fever 30.66
- canine oral papillomavirus 33.42
- canities *see* hair, greying
- canker sores (recurrent aphthous stomatitis) 69.44–6, 69.48
- cannabinoid receptors 21.2
- cannabis
- adverse effects 70.5
- mechanical injury 28.53
- canning industry, occupational hazards 27.18
- Cannon's disease (white-sponge naevus) 35.43, 69.23–4
- Cantagalo virus 33.8
- cantharides, hair regrowth and 73.39
- cantharidin 25.4, 38.26
- molluscum contagiosum 33.12
- wart treatment 33.49

- canthaxanthin 75.162  
Cantú's syndrome 58.20  
Canvaxin whole-cell vaccine 54.54  
CAP fluoroimmunoassay 5.24, 13.16, 22.19, 22.26  
acute urticaria 22.26  
occupational dermatoses 27.7  
CAP syndrome 45.46  
capacitance images 72.11  
capecitabine 75.129  
capillaries 3.50–1  
in angioma serpiginosum 47.16–17  
chronically dilated 47.12  
formation 47.1  
fragility, testing 49.5  
leakage from 49.5  
malformations 18.62–70, 18.79  
pressure 49.5  
raised pressure, venous disorders 47.26, 47.27, 47.42  
stasis, venous microcirculatory disturbance 47.26, 49.15  
thrombosis, venous leg ulceration and 47.42  
capillaritis 49.4, 49.22, 75.23  
classification 49.3  
capillaroscopy, in rosacea 43.1  
capillary malformation–arteriovenous malformation syndrome 18.79  
capillary malformations 47.23, 47.25  
capillary microscopy 47.26, 49.2  
purpura 49.6  
*Capnocytophaga canimorsus* 38.60  
CAPS (cryopyrin-associated periodic syndrome) 22.24–5, 50.53, 62.69  
capsaicin 12.65–6, 73.49  
action at vanilloid receptors 21.2, 63.2  
in atopic dermatitis 24.18  
in chromhidrosis 44.21  
dermatitis due to 9.13  
in notalgia paraesthetica 63.23  
in post-herpetic neuralgia 63.7  
in pruritus 21.17  
topical, in zoster and post-herpetic neuralgia 33.28  
capsaicin-sensitive C-fibres 12.64  
capsule endoscopy 48.27  
captan 26.58  
captopril 75.93  
car assemblers, risk of occupational dermatoses 27.2  
carate (pinta) 30.63–4  
carba mix 26.64  
carbamazepine 64.52  
adverse effects 75.84  
erythroderma 23.47  
in complex regional pain syndrome 63.21  
eccrine gland secretion 44.18  
isotretinoin interaction 42.65  
carbapenems 74.40, 75.51–2  
carbaryl (carbaril) 38.19, 38.20, 73.14  
lice infestations 73.14  
carbidopa 75.88  
carbimazole 18.102  
carbohydrate recognition domains (CRDs) 12.10  
Carbomer BP 73.2  
carbon, in tattoo pigments, allergic reactions 58.58  
carbon dioxide laser 78.13  
in juvenile xanthogranuloma 55.16  
in lichen planus 41.18  
pulsed, eruptive vellus cyst 53.7  
in steatocystoma multiplex 42.88  
in vulval lichen sclerosus 51.118  
wart treatment 33.49  
in xanthoma disseminatum 55.21  
*see also* laser therapy  
carbon disulphide 25.20  
carbon monoxide poisoning 28.93–4  
nails in 65.15  
carboplatin 75.133–4  
carboxypeptidase 12.25  
carboxypeptidase N 13.4  
carboxypolyethylene (Carbomer BP) 73.2  
carbomol 75.81  
non-thrombocytopenic purpura due to 49.21  
carbuncle 30.24–5  
ear 68.19  
carcinoembryonic antigen (CEA) 10.21, 62.16  
extramammary Paget's disease 53.40  
malignant eccrine poroma 53.32  
Paget's disease of nipple 53.39  
carcinogenesis  
initiation phase 52.12–13  
multistage 52.29  
murine model 52.12–13, 52.15, 52.29  
photoproduct formation and 52.14  
progression phase 52.12, 52.13  
promotion phase 52.12, 52.13  
thermal injury 28.72  
carcinogens  
chemical 52.4–5  
multistage carcinogenesis in murine model 52.12  
exposure to 62.46–7  
carcinoid crisis, acute 43.19  
carcinoid syndrome 43.17–20, 62.40, 62.43  
clinical features 43.17–18  
diagnosis 43.19  
flushing 43.14, 43.17–18  
foods associated 43.18, 43.19, 43.19  
morphoea and 51.78  
pigmentation 58.25  
prognosis 43.19  
rosacea vs 43.5  
treatment 43.19  
tumours associated 43.17, 43.18  
carcinoid tumours 43.17  
surgical excision 43.19  
carcinoma  
adenocystic, primary cutaneous 53.37  
adenoid cystic 53.37  
basal cell *see* basal cell carcinoma (BCC)  
basosquamous basal cell 52.22–3  
breast *see* breast cancer  
burn scar 28.91  
cervical, HPV association 33.39, 33.54  
dyskeratosis congenita 15.79  
eccrine, eyelids 67.36  
genetics 15.27  
lymphoepithelioma-like 53.41–2  
Merkel cell *see* Merkel cell carcinoma  
microcystic adnexal 53.35–6  
mucinous 53.36–7  
mucoepidermoid, external auditory canal 68.33  
multicentric, male genitalia 71.42  
nasopharyngeal, EBV association 33.30  
oat cell, of bronchus, pigmentation changes 58.25  
penile 71.40–3  
primary neuroendocrine of skin *see* Merkel cell carcinoma  
pruritus, in old age and 8.27  
scrotal 27.15–16, 52.4, 52.25, 71.43–4  
sebaceous 42.87–8, 67.10  
eyelids 67.35–6  
spindle-cell 97.18  
squamous cell *see* squamous cell carcinoma (SCC)  
superficial spreading, male genitalia 71.41–2  
syringoid eccrine 53.36  
trichilemmal 53.6, 68.34  
verrucous *see* verrucous carcinoma  
vertical growth, male genitalia 71.42  
*see also* malignant disease  
carcinoma cuniculatum 33.55  
carcinoma en cuirasse 62.15–16  
carcinoma erysipelloides (telangiectatica) 48.31, 62.15, 62.16, 70.14  
genitocrural dermatology 71.8  
carcinoma *in situ*  
female genitalia 71.74  
male genitalia 71.37–9, 71.46  
perianal/perineal 71.90, 71.97  
carcinoma simplex 71.74  
carcinoma telangiectoides 62.15  
carcinoma, ear 68.34  
CARD15 gene 62.48  
in Blau syndrome 61.16  
cardiac arrhythmias  
pimozide therapy 64.16  
in sarcoidosis 61.7  
cardiac disease 62.75–80  
keratoderma and woolly hair and 19.94, 19.107  
*see also* specific diseases  
cardiac failure, venous leg ulcers and 47.47  
cardiac monitoring, burns 28.83  
cardiac myxoma 49.37, 50.54  
cardiac pacemakers 62.79  
cardiac rhabdomyomas 15.23  
Cardiff Acne Disability Index (CADI) 42.35, 72.20  
Cardiff Human Mutation Database 15.1, 15.5  
cardiofaciocutaneous syndrome 15.32, 18.70, 62.77  
cardiolipin 51.63  
cardiovascular disease  
Degos' disease 49.46  
Erdheim–Chester disease 55.18  
oral manifestations 69.117  
venous leg ulcers and 47.43  
cardiovascular system  
drugs acting on 75.89–98  
in Kawasaki disease 50.46  
in Marfan's syndrome 45.30  
in pseudoxanthoma elasticum 45.21, 45.22  
in SLE 51.43, 62.78  
in syphilis 34.14  
care pathways 72.26  
careers, skin disease in adolescence and 8.6, 8.7–8  
Carey syndrome 15.32  
Caripito itch 38.29  
carmustine (BCNU) 57.23  
adverse effects 26.46, 75.126  
Carney complex (Carney's syndrome) 54.3–4, 58.14, 62.25, 62.33, 62.78–9, 69.28  
breast involvement 70.17  
with endocrine autoimmune conditions 62.13  
carotenaemia 59.60, 62.64  
pigmentation 58.53  
carotene 75.33  
excess 58.53  
β-carotene, oral supplements 58.53  
carotenoids 2.5, 5.15, 58.2  
carpal tunnel syndrome 63.11, 63.14  
due to tuberculous gumma 31.20  
carpenters, occupational hazards 26.20, 26.79, 27.18–19  
Carpenter's syndrome 62.13  
carpet beetles 25.21  
Carpoglyphidae 38.47  
*Carpoglyphus passularum (lactis)* 38.47  
carprofen 75.74  
carrion's disease (Oroya fever) 30.57–8, 35.25  
cartilage–hair hypoplasia syndrome 13.13, 15.32, 15.93  
*Carukia barnesi* 38.56  
caruncles, urethral 71.73  
Carvajal disease/syndrome 19.94, 19.107, 66.70  
l-carvone 26.17  
*Carybdea rastoni* 38.56  
Casal's necklace 59.63  
case definition 26.3  
case reports 7.3, 7.4  
case series 7.3  
case–control studies 6.3, 6.19, 7.3, 7.4, 26.2  
appraisal 7.14–15, 7.15  
cashew nut oil 26.18, 26.75  
cashew nuts 26.22  
caspases  
activation 12.12  
deficiency 13.15  
caspofungin 36.68, 74.48  
Castellani's paint 36.48, 36.49, 73.48  
Castleman's disease  
HHV-8 and 33.34  
in HIV infection 35.41  
multicentric 56.24  
Castleman's tumour  
lichen planus and 41.16  
paraneoplastic pemphigus 40.23  
pemphigus 40.4  
castor oil 73.6  
castration and hair loss 66.13–14, 66.14–15  
cat(s)  
alopecia 2.18, 2.19  
atopic dermatitis 2.13–14  
bites from 38.60–1  
bullous pemphigoid 2.14–15  
cowpox infection association 33.7  
*Demodex* infestation 2.10  
fungal infections 2.12–13  
lice 2.10  
lupus erythematosus 2.16  
*Malassezia dermatitis* 2.14  
mast cell tumours 2.22  
melanomas 2.20–1  
neoplastic skin disease 2.19–20, 2.20–1  
sarcoids 2.22  
scabies 2.10  
staphylococcal skin infections 2.12  
superficial necrolytic dermatitis 2.17  
vitiligo 2.23  
white, SCC in 2.19, 2.20  
cat bites 38.60–1  
cat scratch disease 30.56–7, 38.11, 38.60, 61.5  
cat scratch fever antigen 5.24  
cat-scratch fever antigen 5.24  
catagen 3.7, 3.13, 66.7–8, 66.11  
cataract  
in atopic dermatitis 24.24–5  
corticosteroid-induced 67.15, 67.16, 67.31, 74.3  
in NF2 62.23  
cataract, hypertrichosis, mental retardation syndrome 15.33  
cataract–alopecia–sclerodactyly syndrome 15.33  
catecholamines 12.65, 63.3  
biosynthesis, defect in vitiligo 58.47  
menopausal flushing and 8.20  
β-catenin 3.4, 3.23, 66.10  
hair-follicle tumours 53.2  
pilomatricarcinoma 53.14  
pilomatricoma 53.13  
catenins 40.1–2, 66.10  
catering industry, occupational hazards 27.19  
caterpillars 25.21, 38.28–30  
catfish 38.59  
cathelicidin peptides 12.5, 12.6, 12.12  
cathelicidins 3.2–3, 3.16, 3.17, 4.5, 30.4, 30.5, 36.21, 43.2  
increased expression in rosacea 3.16, 43.2  
*see also* LL-37  
cathepsins 13.4  
cathepsins B, C and D 12.49  
cattle  
fungal infections 2.12  
photosensitivity 2.23  
*Trichophyton verrucosum* 2.9, 2.12  
cauda equina 63.16  
causalgia *see* complex regional pain syndrome  
causation of skin disease 6.11, 6.13, 6.17–18, 6.18  
caustics 77.47–8  
wart treatment 33.49

- cautery  
actinic keratosis 52.31  
Bowen's disease 52.34  
non-melanoma skin cancer 52.16  
*see also* electrocautery
- cave tick 38.35
- caviuna vermelha 26.81
- cayenne pepper spots 49.24
- CBT *see* cognitive behavioural therapy (CBT)
- CCI-CC27 12.45–6  
*see also* chemokines
- CCAAT-enhancer-binding proteins (C/EBPs) 46.3
- CCL5/RANTES mRNA 12.11
- CCL18 12.46
- CCL21 48.4, 48.5, 48.6
- CCL27 12.46
- CCR1-CCR11, chemokine receptors 12.47–8
- CCR5 55.3  
inhibition, HIV infection treatment 35.6
- CCR6 55.1, 55.3
- CCR7 48.6, 55.3
- CD nomenclature 10.25
- CD1 13.10
- CD1 complex 55.1, 55.3
- CD1a 10.24, 55.3  
antibodies 55.9  
Langerhans' cell histiocytosis (LCH) cells 55.7  
sinus histiocytosis with massive lymphadenopathy 55.29
- CD1b, CD1c 55.3
- CD2 10.25
- CD3 10.25, 13.8
- CD4 13.7, 13.8  
HIV receptor 35.3
- CD4+/CD56+ haematodermic neoplasm (blastic NK-cell lymphoma) 57.39–40
- CD4+ small/medium sized pleomorphic T-cell lymphomas 57.36–7
- CD4 T-cells *see* T lymphocytes, helper (Th/CD4<sup>+</sup>)
- CD5 10.25
- CD7 10.25
- CD8 13.7, 13.8
- CD8+ aggressive epidermotropic T-cell lymphomas (provisional) 57.35–6
- CD8+ class I pathway, T cells 12.13
- CD8 T-cells *see* T lymphocytes, cytotoxic (Tc/CD8<sup>+</sup>)
- CD10 10.26
- CD13 55.31
- CD14 13.5, 55.31
- CD16 13.6
- CD18 *see* complement receptors, CR3
- CD19 13.3, 13.8
- CD20 10.25
- CD21 *see* complement receptors, CR2 (CD21)
- CD23 13.3
- CD25 13.8
- CD27 13.10
- CD28 13.10–11
- CD28 agonist, 'cytokine storm' 74.4
- CD30 10.25
- CD30+ lymphoproliferative disorders 57.29–34  
lymphomatoid papulosis 57.29–30  
primary cutaneous (anaplastic) CD30+ large cell lymphoma 57.31–3  
T-cell lymphomas 57.29–30
- CD31 10.23  
platelet-endothelial cell adhesion molecule (PECAM-1) 12.73
- CD33 55.31
- CD34 10.22, 10.23, 13.7
- CD34 cells 55.1, 55.3
- CD35 13.3
- CD40 13.10, 13.11  
deficiency 13.10
- ligand *see* CD154  
in vasculitis 50.4
- CD44 13.8
- CD45 10.25
- CD45RA 13.10
- CD45RO 13.10
- CD46 13.3  
measles virus receptor 33.75
- CD54, expressed by dermal dendrocytes 55.4
- CD55 13.3
- CD56 10.21, 10.25, 13.6, 53.43
- CD59 14.4
- CD68 10.24, 55.18  
histiocytes 55.15, 55.20, 55.22
- CD70 13.10
- CD79a 10.25
- CD80 13.11, 55.3, 55.4
- CD81 13.3
- CD86 13.11, 55.3, 55.4
- CD88  
receptor for anaphylatoxin C5a 12.24–5  
*see also* complement, C5a
- CD95 13.11
- CD117 (Kit) 3.19–20  
*see also* KIT gene mutations
- CD150, measles virus receptor 33.75
- CD154 (CD40 ligand) 13.8, 13.10, 13.11  
deficiency (X-linked hyper-IgM syndrome) 13.10, 13.12, 13.23, 17.50, 17.63–4  
idiopathic thrombocytopenic purpura 49.9
- CD207 10.24
- CDAGS syndrome 15.91
- CDH3 gene mutations 3.24
- CDKN2A gene 54.33, 54.48, 62.21
- CEA *see* carcinoembryonic antigen (CEA)
- CEAP classification, chronic venous insufficiency 47.32
- cefaclor 74.41
- cefalexin 74.41
- celecoxib 75.77
- cell adhesion 12.68–75  
cell-cell adhesion, CX3CR1 12.48  
*see also* adhesion molecules
- cell apoptosis  
and inflammation 12.11–12  
*see also* apoptosis
- cell markers  
analysis 13.22–3  
panels 10.12
- cell-mediated immunity (CMI)  
acne scarring 42.26–7  
in HIV infection 35.3–4  
to HPV 33.42  
in measles 33.75  
in pregnancy 8.11  
in varicella and zoster 33.23
- cell wall antagonists (antifungals) 74.48
- cellist's chest 28.25–6
- cellular adhesion molecules *see* adhesion molecules
- cellular components of inflammation 12.14
- cellular retinoic acid binding proteins (CRABP-1 and -II) 73.34–5, 73.35
- cellular retinol binding proteins (CRBP-I and -II) 73.34–5, 73.35
- cellulite 46.9–10  
classification and stages 46.9  
hard vs flaccid types 46.9  
management 46.10  
oedematous 46.9
- cellulitis 4.5, 30.17–21  
acute 48.24  
*see also* erysipelas  
after arthropod bites/stings 38.2  
bacteriology 30.17–18  
clinical features 30.18, 30.19, 30.20  
clostridial 30.68  
complications 30.18  
definition 5.7, 30.17  
diagnosis 30.18–19  
differential diagnosis 26.29, 30.19
- dissecting 9.9–10
- ear 68.19
- eosinophilic (Well's syndrome) 46.12, 46.33–4, 62.87
- facial 30.18
- gangrenous 30.68
- HIV infection 35.24
- in lymphatic filariasis 37.9
- lymphoedema and 48.12, 48.15, 48.17  
management 48.24
- male genital dermatology 71.29–30
- necrotizing 30.68
- neuropathic ulcer and 63.9
- orbital 30.18  
neonatal 17.44
- perianal/perineal 30.32–3, 71.91–2
- periobital 30.18
- preorbital, neonatal 17.44
- preseptal 67.4
- racial influences 9.18
- recurrent 30.18, 30.20, 48.29  
lymphoedema 48.12, 48.24
- scalp *see* perifolliculitis capitis  
abscedens et suffodiens
- tongue 30.18
- treatment 30.19–20  
isotretinoin 74.34
- venous leg ulcers 47.50
- cement  
allergic contact dermatitis to 26.15  
burns 25.11, 25.12, 27.12  
as irritant 25.20, 27.6
- centipedes 38.54
- central nervous system (CNS)  
in Erdheim-Chester disease 55.18  
in juvenile xanthogranuloma 55.16  
in Langerhans' cell histiocytosis 55.11–12  
lesions, hyperhidrosis and 44.9, 44.10  
in primary angiitis 50.47  
in sarcoidosis 61.7  
in secondary syphilis 34.11  
in sinus histiocytosis with massive lymphadenopathy (SHML) 55.29  
in xanthoma disseminatum 55.21
- Centre of Evidence-Based Dermatology 6.14
- centrofacial lentiginosis syndrome 69.28
- Centruroides* 38.33
- CEP *see* congenital erythropoietic porphyria (CEP)
- Cephalonomia gallicola* 38.14
- cephalosporins 74.40–1  
adverse effects 75.50–1  
urticaria 22.8  
gonorrhoea management 34.28
- ceramides 3.10, 4.2, 4.3, 12.14–15  
accumulation 59.36  
in atopic dermatitis 24.22
- Cerapterus concolor* 38.27
- Ceratophyllidae 38.11
- Ceratopogonidae 38.6, 38.7
- cercariae 37.20–1, 37.23
- cercarial dermatitis 28.55, 37.20, 37.22–3, 38.56, 38.57
- cercopithecine herpesvirus 1 (CeHV-1) 33.34–5
- cerebellar syndrome, Langerhans' cell histiocytosis (LCH) 55.12
- cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) 50.47
- cerebral cavernous malformation 18.74
- cerebral palsy 69.119
- cerebrospinal fluid (CSF)  
in sarcoidosis 61.7  
in secondary syphilis 34.11  
syphilis diagnosis 34.21  
viral infection diagnosis 33.4
- cerebrotendinous xanthomatosis 59.91
- cernunnos deficiency 17.58
- certolizumab, psoriasis 74.5
- ceruloderma 58.36
- cerumen 68.2–3  
in alkaptonuria 68.18  
dry/wet 68.2  
impacted 68.11, 68.21, 68.25  
lack of 68.21  
removal 68.2–3
- cerumenolytics 68.3, 68.25
- ceruminous glands 68.2  
tumours 68.28–9, 68.29–30
- cervical auricle/tab 18.84, 18.85
- cervical carcinoma, HPV association 33.39, 33.54
- cervical examinations 71.53
- cervical infection, gonococcal 34.25
- cervical intraepithelial neoplasia (CIN) HPV and 33.54  
treatment 73.24
- cervical rib 63.14, 63.24
- cervical spinal involvement, psoriatic arthritis 20.57
- cervicitis  
anterior, chlamydial 34.29, 34.30  
gonococcal 34.26
- cervix, syphilitic chancre 34.7, 34.18
- cestodes 37.2, 37.3, 37.24–7
- cetamolol 75.91
- cetearyl (cetostearyl) alcohol 26.58–9
- cetirizine 22.29, 74.31  
adverse effects 75.149  
in urticaria 22.28
- cetomacrogols 73.7
- cetostearyl alcohol 73.2, 73.7
- cetrimide 73.14
- cetuximab 75.132
- Ceylon ebony 26.80
- CFS (cutaneous field stimulation) 62.23
- CGD *see* chronic granulomatous disease
- CGRP *see* calcitonin gene-related peptide
- CH3/HeJ mouse 66.33
- chaetae, annelid worms 2.2
- Chagas' (Chagas-Mazza) disease *see* trypanosomiasis, American/South-American
- chagoma, inoculation 37.32
- chalcone 67.11, 67.34
- chalk, as irritant 25.20
- chalone hypothesis 66.9
- chamomile 66.97
- Chanarin-Dorfman syndrome (neutral lipid storage disease with ichthyosis) 19.52–4
- chancere  
lymphogranulomatous 30.70  
soft *see* chancroid  
syphilitic 34.6–7, 69.78  
lips 69.121  
trypanosomal 37.30  
tuberculous 31.8, 31.10, 31.11–12
- Chancre redux 34.7
- chancroid 30.47, 34.34–5, 71.71, 71.93  
HIV co-infection 34.34–5  
syphilitic chancre vs 34.7
- CHANDS 15.35, 15.63, 15.65
- Channa striata* 31.31
- charcoal, in fish odour syndrome 44.20
- Charcot neuroarthropathy 47.58
- Charcot-Leyden crystal protein 13.5
- Charcot's joints 63.15
- CHARGE syndrome 68.3
- Charles' operation 37.10
- Charles' procedure 48.25
- Chediak-Higashi syndrome 12.23, 13.6, 13.13, 17.79–80, 58.41–2, 62.28, 62.95  
bacterial infection and 30.8  
neutrophils in 17.78–9  
oral involvement 69.33, 69.117
- cheeks  
biting 69.87–8  
sebaceous glands 42.1  
spontaneous atrophic scarring 45.7
- cheilitis 69.119–28  
actinic 52.37, 69.123–4, 78.14  
treatment 73.23, 73.24  
aetiology 69.119

- allergic 26.17, 26.41, 26.48  
angular 26.17, 26.21, 36.61, 36.68, 64.22, 69.122–3  
  in Down's syndrome 69.38–9  
contact 69.119–20  
drug-induced 69.121  
eczematous 69.119  
exfoliative (factitious) 69.127–8  
factitious 64.39–40  
glandular 69.124–5  
granulomatous (Miescher's) 48.16, 61.23, 69.60, 69.125–7  
infective 69.121  
irritant dermatitis and 25.16  
lip-lick 23.3, 24.22, 24.23  
plasma-cell 69.128  
retinoid 42.63  
Volkman's 69.124  
cheiloplasty 69.126  
cheilosis 69.122  
  solar *see* cheilitis, actinic  
cheiroarthropathy 45.62  
cheiropompholyx 23.16  
chemical carcinogens 52.4–5  
  multistage carcinogenesis in murine model 52.12  
  *see also* chemicals  
chemical damage, self inflicted 64.37–8  
chemical depigmentation 58.50–1  
chemical/gas/petroleum plant  
  operatives, risk of occupational dermatoses 27.2  
chemical industry, occupational hazards 27.19  
chemical peels 80.9–10  
  in acne vulgaris 42.68, 42.69  
  in actinic keratosis 52.32  
chemical pigmentation, eyelids 67.5  
chemicals  
  acne induced by 27.12–15  
  assessment of dermatitic potential 27.10–11  
  burns due to 27.11–12  
  contact purpura due to 49.21  
  definition 75.1  
  exposure to 75.162–3  
  leukoderma due to 27.15  
  photosensitivity in animals and 2.23  
  pigmentation due to 58.54, 58.56–7  
  pigmented purpuric dermatoses due to 49.23  
  scleroderma due to 45.52, 75.43  
  skin tumours, retinoic acid therapy 73.36  
  *see also* chemical carcinogens  
chemokines 12.44–8  
  in atopic dermatitis 24.7  
  CC1–CC27 12.45–6  
  classic role 12.44  
  CXCL chemokine/receptor family (CXCL1–15) 12.45, 12.46–7  
  Langerhans' cells migration 55.3, 55.4  
  leukocyte–endothelial interactions 12.44  
  in lichen planus 41.1  
  modulation of angiogenesis during tumour growth 12.48  
  nomenclature, systematic names and ligands 12.45  
  receptors 12.47–8  
  subfamilies 12.44  
chemosurgery 77.29  
  tattoo removal 58.59  
  *see also* Mohs' micrographic surgery  
chemotherapy  
  adverse effects 75.121–36  
  acral erythema 75.122–3  
  alopecia 75.45  
  extravasation 75.122  
  hyperpigmentation 75.33  
  internal malignant disease 75.124  
  mucositis 69.82  
  neutrophilic eccrine hidradenitis 44.16–17, 75.123  
  skin cancer 75.124  
  syringosquamous metaplasia 75.123  
  carcinoid tumours 43.19  
  combination, male genital dermatology 71.44  
  juvenile xanthogranuloma 55.16–17  
  malignant histiocytosis 55.33  
  melanoma induction 54.48  
  sinus histiocytosis with massive lymphadenopathy 55.30  
  squamous cell carcinoma 52.28  
  topical, nitrogen mustard and carmustine (BCNU) 57.23  
  *see also* cytotoxic drugs; *specific chemotherapeutic drugs*  
chest X-ray, burns 28.84  
chest–abdomen sign 62.80  
cheveux incoiffables 66.71–2  
*Cheyletiella* 38.4, 38.49–50  
  animal infestation 2.10  
chi-square test 7.20  
Chiari's syndrome 63.14  
'chicken skin' appearance 45.21, 45.22  
chickenpox *see* varicella  
Chiclero's ulcer 37.35, 37.39–41  
chigger 38.50, 38.51  
chigoe 38.12–13  
Chikungunya virus 33.66, 33.67  
  male genital infection 71.33  
chilblain lupus 51.11–12  
chilblains *see* perniosis  
child abuse  
  anogenital signs 71.15  
  bites 38.61  
  burns 28.34, 28.35, 28.90, 28.91–2  
  clinical features 28.34–5  
  differential diagnosis 28.36  
  emotional abuse 28.34, 28.38–9  
  female genital dermatology 71.57  
  mechanical injury 28.34–9  
  mouth ulcers and 69.43  
  neglect 28.34, 28.38–9  
  perianal/perineal dermatology 71.84  
  physical abuse 28.34–7  
  sexual 8.3, 28.34, 28.37–8, 71.57, 71.84  
  anogenital warts 33.40, 33.41  
  differential diagnosis 8.3  
  molluscum contagiosum 33.11  
CHILD syndrome 18.27, 19.3, 19.57–8  
childbirth 8.9–16  
childhood  
  definition 8.2  
  *see also* children; infancy and childhood  
childhood cancer, melanoma risk 54.15  
children  
  acne 42.75–6  
  AIDS case definition 35.5  
  anogenital warts 33.46  
  transmission 33.40–1  
  antiphospholipid antibody syndrome 49.51  
  atopic dermatitis  
  concordance with therapy 72.6  
  quality of life assessment 64.10, 72.23  
  drug responses and metabolism 72.28  
  frictional dermatitis 28.14  
  granulomatous perioral dermatitis 43.12, 43.13  
  herpes simplex 33.15, 33.20  
  HIV infection 33.44–5  
  medication errors 72.26  
  melanomas 54.15, 54.48–9  
  molluscum contagiosum 33.12  
  obesity and BMI 46.5–7  
  prevalence studies of skin disease 6.7–8  
  psoriasis, treatment 73.45  
  psychocutaneous disorders  
  factitious 64.38, 64.39  
  skin picking 64.28  
  trichotillomania 64.30–1  
  purpura fulminans 49.51  
  quality of life assessment 64.10, 72.23–4  
  rubella 33.70  
  skin 8.3  
  stigmatization 64.6–7  
  suction purpura 28.24  
  topical therapy, quantities 73.3, 73.4  
  UVR exposure and standard erythema dose 29.4  
  *see also* infancy and childhood  
Children's Dermatology Life Quality Index 72.23  
Children's Life Quality Index 72.23  
Chilopoda (centipedes) 38.54  
CHIME syndrome 19.60  
chimera (human), with pigment anomalies 58.23  
chimeric animals 2.8  
chimerism 18.1  
chimney sweeps, scrotal carcinoma 27.15–16, 52.25  
chin, swelling (gnathophyma) 43.9, 43.10  
chin crease, in pseudoxanthoma elasticum 45.22  
Chinese folk medicine, coin-rubbing 28.25  
Chinese herbal medicine  
  adverse effects 26.45, 26.46, 75.160–1  
  carcinogens in 52.5  
  systemic agents 74.52  
'Chinese letter pattern,' pigmentation in incontinentia pigmenti 58.16  
Chinese restaurant syndrome 43.16  
Chinese traditional medicine 72.31, 72.32  
*Chiracanthium* 38.32  
*Chironex fleckeri* 38.56, 38.57  
Chironomidae 38.7  
chiropractic 72.32  
chitin 36.1  
*Chlamydia* 30.70–2  
*Chlamydia psittaci* 30.71–2  
*Chlamydia trachomatis* 30.70–1  
  A-C strains 34.29  
  abscesses of Bartholin's gland 71.68  
  D-K strains 34.29  
  developmental cycle 34.29  
  direct fluorescent antibody test 34.30, 34.31  
  elementary bodies 34.29  
  genital infections 34.29–32  
  perianal/perineal infections 71.93, 71.97  
  persistence 34.31  
  reticulate bodies 34.29  
  serovars L1, L2, L3 34.32, 34.33  
  vaginal discharge 71.53  
chlamydial infections, genital 34.29–32  
  clinical features and complications 34.29–30  
  diagnosis 34.30–1  
  epidemiology 34.2, 34.29  
  management 34.31  
  chlamydoconidia 36.3, 36.4, 36.74  
  chloasma 58.25, 58.34–5, 75.33  
  differential diagnosis 36.11  
  pigmentation in pregnancy 8.10  
  chloracetamide 26.58  
  chloracne 27.12–15, 42.31, 42.34, 42.77  
  chemicals causing 42.77  
  ophthalmic 42.77  
  treatment 42.77  
  chloral hydrate 75.81  
  chlorambucil  
  adverse effects 75.124–5  
  in necrobiotic xanthogranuloma 55.28  
  in systemic sclerosis 51.108  
  chloramphenicol 26.17, 26.46, 74.43  
  adverse effects 75.5, 75.59, 75.61  
  bone marrow aplasia 74.43  
  chlordane 75.163  
  chlordiazepoxide 75.81  
  chlorhexidine 14.21, 26.58, 30.7, 73.14  
  adverse effects 75.164  
  in impetigo 30.16  
  use in neonates 17.2, 17.44  
  chloride, in sweat 44.5  
  chlorinated aromatic hydrocarbons, acne associated *see* chloracne  
  chlorinated salicylanilides 26.23  
  4-chloro-3,5-dimethylphenol (chloroxylenol) 26.56, 73.14  
  17 $\alpha$ -chloro steroids 42.16  
  chloroacetate esterase reaction 10.9  
  chloroatranol 26.77  
  chlorobenzene 25.20  
  chlorobiphenyl oxides 27.12  
  chlorobiphenyls 27.12  
  chlorocresol 26.56–7, 73.8  
  2-chlorodeoxyadenosine  
  juvenile xanthogranuloma 55.16  
  Langerhans' cell histiocytosis (LCH) 55.13  
  chloroform 25.3, 25.19  
  chloronaphthalenes 27.12  
  chlorophenols 27.12  
  *Chlorophora excelsa* 26.81  
  Chloropidae 38.6  
  chloroquine 74.25–6  
  adverse effects 75.69–70  
  hair colour changes 66.94  
  hypermelanosis 58.30  
  nail colour changes 65.16  
  ocular 67.31  
  pruritus 37.27  
  in discoid lupus erythematosus 51.20  
  in sarcoidosis 61.21  
  in Sjögren's syndrome 51.138  
  chloroxylenol 26.56, 73.14  
  chlorphenamine 74.31  
  chlorphenesin 26.58  
  chlorpheniramine 22.29  
  chlorpromazine 64.52, 75.82  
  adverse effects, hyperpigmentation 58.29, 75.33  
  chlorpropamide, adverse effects 75.156  
  chlorpropamide–alcohol flushing 43.16  
  chlortalidone (chlorthalidone) 75.98  
  chlortetracycline 74.41  
  chocolate, acne and 42.33–4  
  cholecalciferol *see* vitamin D  
  cholera 6.11  
  cholestasis  
  pruritus in 21.9–10  
  recurrent in pregnancy 8.13  
  cholestasis–lymphoedema syndrome 48.10  
  cholesteatoma, external auditory canal 68.28, 68.35  
  cholesterol  
  biosynthesis, inhibition, in sebocytes 42.5  
  embolism 50.54  
  in epidermis 3.11  
  LDL of standard lipid profile, Friedewald formula 59.84  
  metabolism 66.83  
  reverse transport 59.82–3  
  in sebum 42.5  
  cholesterol clefts 52.45  
  in necrobiotic xanthogranuloma 55.28  
  cholesterol crystals 46.16  
  cholesterol embolization syndrome (CES) 49.37  
  cholesterol ester transfer protein (CETP) 59.83  
  cholesterol esters  
  in sebum 42.5  
  in Tangier disease 59.91  
  cholesterol sulphatase, deficiency 19.9, 19.11–12  
  cholesterol sulphate, in epidermis 4.2  
  cholesterosis, extracellular 50.26  
  cholinesterase inhibitor,  
  organophosphorus 73.14  
  chondritis, ear 45.42, 45.43, 68.7, 68.19–20  
  chondrocytes, origin 12.30  
  chondrodermatitis nodularis 68.12–13, 77.36, 77.37  
  chondrodermatitis nodularis helioides 51.95, 62.99, 62.102  
  chondrodysplasia  
  calcifying 45.8  
  metaphyseal, of McKusick 15.93

- chondrodysplasia punctata (variant CDPX2) 19.50, 19.51
- chondroectodermal dysplasia 69.10, 69.37, 69.118
- chondroectodermal dysplasia, mesoectodermal dysplasia (Ellis-van Creveld syndrome) 15.39, 15.65
- chondroid syringoma 53.2, 53.30–2  
malignant 53.31
- chondroitin 4-sulphate, structure 3.47
- chondroitin 6-sulphate, structure 3.47
- chondroitin sulphate 3.46  
in wound healing 14.3
- chondroma, pinna 68.28
- chondromalacia  
idiopathic cystic (ear/endochondral pseudocyst) 24.25, 68.13–14  
systemic *see* relapsing polychondritis
- chondylomata acuminata 71.94
- chondylomata lata, perianal/perineal dermatology 71.93, 71.94
- chordoma cutis, perianal/perineal dermatology 71.84
- choreoathetosis 69.119
- chorionic gonadotrophin 8.9  
adverse effects 70.5
- chorionic villus sampling 16.1–2
- Choriptes* 38.46
- Choriptes bovis* 2.10
- choristia, periumbilical 71.100
- choristoma 18.88  
cartilaginous 68.29  
osseous (osteoma mucosae) 69.108–9
- Christianson-Fourie type hidrotic ectodermal dysplasia 15.42
- Christmas tree pattern, lesions 33.79
- Christ-Siemens-Touraine (CST) syndrome 15.28, 15.43
- chromate *see* chromium
- chromatin modification 11.16
- chromatophores 2.5–6
- chrome, in tattoo pigments, allergic reactions 58.58
- chrome ulcers 25.11
- chromhidrosis 44.20–1
- chromic acid  
burns 25.23, 27.12  
as irritant 25.20
- Chromista 36.1
- chromium  
allergy to 26.15, 26.18, 26.34–6  
in alloys 26.37  
avoidance of 26.35–6  
diphenylcarbazine test 27.8  
EU directive 26.35, 26.100, 27.3  
occupational exposure to 27.3  
occurrence 26.35  
oral provocation tests 5.25  
patch tests 26.36  
in shoes 26.68
- chromoblastomycosis 31.10, 36.75–6
- chromogranin A 10.21
- chromomycosis (chromoblastomycosis) 31.10, 36.75–6
- chromophores 29.3, 78.3, 78.4  
absorption spectra 29.3  
DNA as 29.4, 29.5  
in epidermis 29.4
- chromophytosis *see* pityriasis versicolor
- chromosomal instability 52.12
- chromosomal translocation  
malignant histiocytosis 55.32  
monocytic leukaemia 55.31
- chromosome 4, short-arm deletion syndrome 15.12, 18.2, 18.103
- chromosome 5, short-arm deletion syndrome 15.12
- chromosome 12, long-arm deletion syndrome 15.12
- chromosomes  
abnormalities 15.2, 15.9–14  
drug-induced damage 75.15
- chronic, infantile, neurological, cutaneous, articular syndrome 15.95–6
- chronic actinic dermatitis (CAD) 26.24, 29.10, 29.16–19  
aetiology 29.16–17  
clinical features 29.10, 29.17–18  
contact dermatitis association 29.16, 29.17  
definition 29.16  
diagnosis 19.17, 29.23  
differential diagnosis 29.10, 29.17  
erythrodermic 29.18  
pathology 29.17  
pseudolymphomatous form 29.16, 29.17, 57.58  
treatment 29.10, 29.18  
tacrolimus 73.32
- chronic bullous dermatosis of childhood 5.12–13  
oral involvement 69.69  
*see also* linear IgA disease
- chronic genetic ulceration 71.66
- chronic granulomatous disease 13.13, 17.48–9, 17.73–5  
with DLE-like lesions 51.16  
oral involvement 69.33, 69.117  
Sweet's syndrome and 50.76
- chronic illness, psychological impact 64.4
- chronic lymphocytic leukaemia, perianal/perineal dermatology 71.99
- chronic mucocutaneous candidiasis *see* candidiasis
- 'chronic obesity lymphoedematous mucinosis' 8.17
- chronic pain syndromes  
male genital dermatology 71.51–2  
perianal/perineal dermatology 71.99
- chronic papular onychodermatitis 37.5
- chronic penile oedema 71.30
- chronic renal failure  
gynaecomastia and 70.4  
hypopigmentation 58.27  
oral involvement 69.116  
pigmentation changes 58.27  
pruritus in 21.7–9
- chronic superficial scaly dermatitis 57.57
- chronic ulcerative stomatitis with epithelial antinuclear antibodies 69.64
- chronic venous insufficiency (CVI) 47.12, 47.26, 47.32–6  
classification 47.32, 47.33  
clinical features 47.33–5  
investigations 47.35–6
- chronic vulvar purpura 71.61–2
- chronicity 6.11
- chrysalis babies 19.27
- chrysarobin 66.94
- chrysiasis 58.54–5, 67.5, 75.33, 75.100
- chrysoderma 58.54–5
- Chrysomya* 38.8
- Chrysops* 37.11
- Churg-Strauss syndrome 50.9, 50.41–3, 50.52, 71.29  
cardiac involvement 62.78  
differential diagnosis 50.40  
eosinophilia in 62.86–7  
respiratory tract involvement 62.83
- chyle 48.27
- chylomicrons 59.82  
clearance 59.90  
restriction of production 59.90
- chylous reflux 48.27
- chymase 3.20, 12.25, 12.49  
in urticaria 22.4
- chymotrypsin, pruritus and 21.5
- chymotrypsin, in atopic dermatitis 24.18
- cicatrical pemphigoid 71.28, 71.91  
scalp 66.49  
vegetating 69.68  
*see also* mucous membrane pemphigoid
- cicatrizing palmoplantar keratodermas 19.94, 19.95, 19.101–2, 19.108–9
- ciclopirox olamine  
in seborrhoeic dermatitis 23.33  
topical, indications 73.12
- ciclosporin 13.24, 73.31, 74.16  
in actinic prurigo 29.15  
adverse effects 69.21, 75.136–8  
hypertrichosis 66.79  
in allergic contact dermatitis 26.102  
in atopic dermatitis 24.31  
in atopic eye disease 67.16  
in chronic actinic dermatitis 29.18  
clinical indications 74.16  
in cytophagic histiocytic panniculitis 46.24  
in dermatomyositis 51.129  
in dyslipidaemias 59.93  
female genital dermatology 71.64  
in granuloma annulare 60.10  
in Hailey-Hailey disease 39.36  
in hand eczema 23.22  
interactions 72.28–9  
in leprosy reactions 32.18  
in lichen sclerosis 51.118  
in linear IgA disease 40.51  
in pemphigus 40.12  
in pigmented purpuric dermatosis 49.26  
in polymorphic light eruption 29.12  
in psoriasis 20.38–9, 74.16  
in HIV infection 35.17  
in psoriatic arthritis 20.59  
in sarcoidosis 61.21  
in SLE 51.62  
in solar urticaria 29.20  
in subcutaneous panniculitis-like T-cell lymphoma 57.33  
in systemic sclerosis 51.108  
topical 73.32–3  
adverse effects 67.16  
in atopic eye disease 67.16  
in cicatrizing conjunctivitis 67.22  
in lichen planus 41.18  
in urticaria 22.30
- cidofovir  
in herpes simplex 33.21  
in molluscum contagiosum 33.13  
in monkeypox 33.7  
in orf 33.9  
wart treatment 33.50
- cigarette burns  
child abuse 28.34, 28.92  
torture injuries 28.33
- 'cigarette face' 45.2
- cigarette smoking *see* smoking
- cilazapril 75.93
- cilia *see* eyelashes
- cimetidine  
adverse effects 75.149–50  
erythroderma 23.47  
gynaecomastia 70.4, 70.5  
sebaceous gland activity inhibition 42.16  
wart treatment 33.50
- Cimex* 38.24
- Cimicidae 38.23–5
- cinacalcet hydrochloride 49.48
- CINCA syndrome 15.95–6, 50.53
- cinnabar 26.39, 75.160, 75.162
- cinnamates 25.18, 26.17, 26.23, 26.62
- cinnamic aldehyde 22.20, 25.18, 25.21
- cinnarizine 75.88
- CIPA (congenital insensitivity to pain with anhidrosis) 15.34
- ciprofloxacin, eccrine gland secretion 44.18
- circinate balanitis 34.30, 34.31, 71.18
- circinate ulcerative vulvitis 71.59
- circulatory disorders  
mechanical injury 28.28–9  
palmoplantar keratodermas 19.118
- circumcision 77.35  
chancroid risk reduction 34.35  
female 28.38, 71.57  
lichen sclerosis and 51.113, 51.118  
male 71.13, 71.20, 71.24, 71.39
- circumscribed keratotic disorders 19.93  
hypokeratosis of palms and soles 19.116
- cirrhosis  
alcoholic 69.115  
hepatic 62.60–2, 70.4  
*see also* primary biliary cirrhosis
- circoid aneurysm 56.26–7, 65.35–6
- 13-cis-RA *see* isotretinoin
- cisplatin 26.46, 75.134
- citalopram 64.20, 64.24, 64.28, 64.50
- Citrobacter freundii* 2.12
- citronella 38.5, 38.20
- citrulline 66.6  
in basal cell carcinoma 52.21
- Citrus* 25.21
- Citrus hystrix* 75.162
- Civatte bodies *see* colloid bodies
- CK7 10.21
- CK15 53.35
- CK20 *see under* cytokeratins
- CLA (cutaneous leukocyte antigen) 13.4, 55.1, 76.9
- Cladophialophora bantiana* 36.77
- Cladophialophora carrionii* 36.75, 36.76
- cladribine 13.24
- clam digger's itch 37.22, 38.56
- clamp connection 36.4
- clarinettist's cheilitis 28.26
- clarithromycin 32.17, 74.42, 75.58
- Clark levels, melanoma 54.38
- Clarkson's syndrome (systemic capillary leak syndrome) 22.23
- claudication 47.2  
intermittent 47.2, 47.7  
pain, differential diagnosis 47.5  
spinal 47.5  
treatment 47.5–6  
venous 47.5
- claudin 1, gene mutation 3.25
- claudin 16 (paracellin-1), gene mutations 3.25
- claudins 3.24, 25.2, 56.49
- cleaning work, occupational hazards 5.6, 27.19
- clear cell acanthoma 52.41
- clear-cell hidradenoma 53.27–8
- clear cell papulosis, genitocrural 71.6
- clear cell sarcoma 54.48, 56.53–4
- clearance rates, real vs apparent 6.13
- left lip/palate 18.91, 69.37–8  
with mucous cysts of the lower lip 15.93–4  
with syndactyly and ectodermal dysplasia 66.52
- cleft lip/palate-ectodermal dysplasia syndrome 15.33
- clefting, ectropion and conical teeth syndrome 15.31
- clefts, needle-shaped 46.16
- clegs 38.6
- cleidocranial dysostosis 66.73
- Clematis* 25.21
- CLEPDI syndrome 15.46
- climacteric 8.19
- climate/climatic factors  
in allergic contact dermatitis 26.10  
risk factor for skin disease 6.12
- 'climatic bubo' 30.70
- clindamycin 26.46, 74.42–3, 75.58–9  
acne vulgaris treatment 42.47  
in folliculitis decalvans 42.74  
in Fox-Fordyce disease 44.22  
*Propionibacterium acnes* resistance 42.56  
topical  
in acne vulgaris 42.41, 73.10  
in rosacea 43.6, 73.10
- cling film, for occlusion 73.4
- clinical deception 64.35
- clinical decisions  
factors influencing 72.4  
quality of life measures and 72.2, 72.14, 72.24  
risk-benefit analysis 72.3–4  
shared 72.1
- Clinical Evidence* 7.6
- Clinical Pathology Accreditation 13.15
- clinical questions, well-built 7.2–3

- clinical trials  
 drug reactions 75.2  
 generalizing results for treatments 6.4  
 cloquinoxol 26.32, 26.45  
 topical corticosteroids with 73.20  
 clitoridectomy 71.57  
 clitoris  
 benign tumours 71.72  
 congenital and developmental abnormalities 71.56  
 lichen sclerosus 71.62–3  
 structure and function 71.54–5  
 trauma and artefact 71.57  
 cloacal membrane 71.83, 71.98  
 clobazam 75.81  
 clobetasol propionate  
 female genital dermatology 71.63  
 lupus erythematosus profundus 51.15  
 pyogenic granuloma in acne 42.79  
 clofazimine 74.26, 74.45  
 acne vulgaris treatment 42.66  
 adverse effects 75.33, 75.62–3  
 pigmentation due to 58.55  
 clinical indications 74.26  
 in leprosy 32.16–17, 32.18  
 clofibrate 75.156  
 clomiphene (clomifene) 75.119  
 in gynaecomastia 70.5  
 clomipramine 64.28, 64.32, 64.51, 75.78  
 clonazepam, in hyperhidrosis 44.12  
 clonidine 26.46, 75.95–6  
 flushing management 43.15  
 in rosacea 43.6  
 cloning 11.4, 11.9–10  
 positional 11.1, 11.12  
*Clonorchis sinensis* 37.3  
 clopidogrel 75.108  
 claudication management 47.5  
 in erythromelalgia 47.10  
 platelet function abnormalities 49.13  
 Cloquet's node 54.53  
*Clostridium*  
 cellulitis due to 30.68  
 in gas gangrene 30.43–4  
*Clostridium difficile* colitis 74.42–3  
*Clostridium histolyticum* 30.43  
*Clostridium oedematis* 30.43  
*Clostridium perfringens* (*C. welchii*) 30.43  
 perianal/perineal dermatology 71.93  
*Clostridium septicum* 30.43  
*Clostridium sordellii* 30.43  
*Clostridium tetani*, intravenous drug abuse 28.52  
 clothing  
 allergens in 26.18, 26.65–8  
 protective 25.24, 25.25, 27.9  
 against jellyfish stings 38.57  
 rubber in 26.64  
 sun protection 73.41  
 UVR exposure minimisation 29.8  
 clotrimazole  
 in candidiasis 36.68  
 in dermatophytosis 36.47, 36.48  
 in otomycosis 36.17  
 topical 73.12  
 in trichomoniasis 37.29  
 Clouston's syndrome (hidrotic ectodermal dysplasia) 15.42, 15.67, 15.68–9, 19.94, 19.106, 53.23  
 alopecia 66.59  
 oral mucosa and lips 69.23  
 teeth 69.11  
 cloxacillin 75.49  
 clozapine 64.52, 75.82  
 CLSM (confocal laser scanning microscopy) 5.20  
 clubbing of fingers *see* finger(s), clubbing  
 clubbing of toes 15.87–8  
 clumping factor 36.58  
 clusterin 14.4  
 Clutton's joints 34.16  
 CMV infection *see* cytomegalovirus (CMV) infections  
 CNC (Carney complex) 58.14  
 Cnidaria 28.55, 38.55–8  
 co-cyprindiol  
 acne vulgaris treatment 42.53  
 effect on sebum composition 42.6  
 sebaceous activity inhibition 42.15–16  
 in sebaceous gland hyperplasia 42.87  
 co-morbidity, factitious skin disease 64.41  
 co-occurrence of diseases 6.13  
 co-polymers 26.74  
 co-trimoxazole 74.38, 74.39  
 adverse effects 75.57  
 fixed eruption 75.28, 75.29  
 in HIV infection 35.22  
 in head louse infection 38.20  
 male genital dermatology 71.27  
 non-thrombocytopenic purpura due to 49.21  
 photosensitive drug eruption 57.53  
 in Wegener's granulomatosis 50.41  
 coagulation  
 in antiphospholipid syndrome 49.40  
 cascade 49.38  
 changes, in deep-vein thrombosis 47.28  
 coagulation defects/disorders 49.2, 49.7  
 cytophagic histiocytic panniculitis 46.24  
 in Degos' disease 49.45  
 echymoses due to 49.4  
*see also* coagulopathy  
 coagulation screen  
 burns 28.84  
 purpura 49.6  
 coagulopathy  
 HIV infection 35.12–13  
 systemic, cutaneous features 49.38–42  
 vascular 49.42–7  
*see also* coagulation defects/disorders  
 coal mining  
 accidental tattoos in miners 58.57  
 occupational hazards 27.19  
 coal tar 20.22, 73.42  
 adverse effects 25.21, 26.46, 75.31, 75.164  
 carcinogenicity 27.16, 73.42  
 content and types 73.42  
 cytostatic effect 73.42  
 distillates, acnegenicity 27.13  
 in eczema 23.38  
 in hand eczema 23.22  
 high-temperature 73.42  
 low-temperature 73.42  
 mechanism of action and effects 73.42  
 in pityriasis amiantacea 66.57  
 in pityriasis capitis 66.56–7  
 UV light with 73.42  
 coalminers, accidental tattoos 58.57  
 cobalt  
 allergy to 26.33–4  
 in alloys 26.37  
 as irritant 25.21  
 patch tests 26.34  
 in tattoo pigments, allergic reactions 58.58  
 Cobb syndrome 18.62, 18.96  
 cobblestone skin appearance 45.21, 45.22  
 cocaine, eccrine gland secretion 44.18  
 cocamidopropylbetaine 26.18  
*Coccidioides immitis* 36.2, 36.85, 36.86  
*Coccidioides posadasii* 36.85, 36.86  
 coccidioidin 36.85  
 coccidioidin test 5.24, 36.86  
 coccidioidomycosis 36.85–7, 69.118  
 in HIV infection 35.34  
 coccygeal dimples 63.15  
*Cochliomyia* 38.8  
 Cochrane, Archie 7.1  
 Cochrane Collaboration 6.16, 7.1, 7.5, 7.8  
 Cochrane Database of Systematic Reviews 7.5  
 Cochrane Library 7.5  
 Cochrane Skin Group 6.16  
 Cockayne's syndrome 15.75–6, 45.61  
 childhood melanoma 54.48  
 Cockett's operation 47.39  
 Cockett's syndrome 47.32  
 cockroaches 38.2, 38.28  
 cocoa butter 73.6  
 coconut beetles 38.27  
 coconut oil, in scabies 38.41  
 cocus 26.80  
 codeine, adverse effects 75.26, 75.87  
 codeine phosphate, in carcinoid syndrome 43.19  
 coeliac disease 62.55  
 dermatitis herpetiformis and 40.58  
 erythema nodosum and 50.83  
 oral involvement 69.116  
 psoriasis and 62.55  
 transglutaminases 40.59  
 urticaria and 22.2  
 Coelomycetes 36.4  
 coenzyme Q-10 80.3  
 Coffin–Siris syndrome 15.33  
 cognitive behavioural therapy (CBT) 64.53  
 body dysmorphic disorder 64.20  
 in dystrophic EB 39.30  
 pathological skin picking 64.28  
 theory of 64.53  
 trichobezoar 64.32  
 cohort studies 6.19, 7.3–4  
 appraisal 7.14–15, 7.15  
 coin-rubbing 9.8  
 injuries 28.25  
 COL1A1 gene 45.35, 45.40  
 COL1A2 gene 45.35, 45.40  
 COL3A1 gene 45.34  
 COL5A1 gene 45.33  
 COL7A1 gene 3.32, 3.35  
 mutations 39.1  
 Bart's syndrome 39.22  
 bullous dermolysis of newborn 39.24  
 dystrophic EB 39.15–17, 39.22, 39.24, 39.27  
 EB simplex superficialis 39.5  
 molecular diagnosis of EB 39.27  
 COL17A1 gene mutations 3.36–7  
 in junctional EB 39.10  
 colchicine  
 action 74.27  
 adverse effects 75.134  
 clinical indications 74.27  
 in cutaneous small vessel vasculitis 50.16  
 dose range and evidence level 74.27  
 in pyoderma gangrenosum 50.72  
 in relapsing polycondritis 45.43  
 in systemic sclerosis 51.108  
 in urticarial vasculitis 50.23  
 cold (cold temperature) 28.63–5  
 ear injury 62.99, 62.102, 68.5, 68.8, 68.10  
 effect on peripheral nerves 63.14  
 hyperhidrosis induced by 44.7, 44.8  
 occlusion syndromes due to 49.32  
 vasoconstriction induced by 63.4  
 vasodilatation induced by 63.4–5  
*see also* cold-induced injury  
 cold agglutinins 13.18, 28.71, 49.34  
 cutaneous occlusion due to 49.34  
 in infectious mononucleosis 33.30  
 monoclonal and polyclonal types 49.34  
 cold creams 73.7  
 cold flexed fingers 51.112  
 cold-induced injury 28.63–71  
 abnormal sensitivity to cold 28.65–71  
 acrocyanosis 28.66–7  
 cold agglutinins 28.71  
 cold exposure 28.63–5  
 cryoglobulinaemia 28.71  
 ear injury 62.99, 62.102, 68.5, 68.8, 68.10  
 erythrocyanosis 28.67  
 frostbite 28.63–4  
 hyperhidrosis and 44.8  
 livedo reticularis 28.66, 28.67–8  
 neonatal 17.35–6  
 perniosis 28.65–6  
 physiological reactions 28.63  
 trench foot 28.64  
*see also* cold (cold temperature); Raynaud's phenomenon  
 cold-induced sweating syndrome 44.7, 44.8  
 cold nociceptors 4.9  
 cold panniculitis 17.35, 46.21  
 cold receptors 4.9  
 cold sores (reactivated herpes simplex) 33.3  
 Coleoptera 38.26–8  
 colistin 74.43  
 colitis  
*Clostridium difficile* 74.42–3  
 collagenous 62.53  
 ulcerative *see* ulcerative colitis  
 collagen 3.2, 3.33, 3.34–42  
 ageing and 8.22, 80.1, 80.2  
 $\alpha$ -chains 3.34, 3.37  
 in anchoring fibrils 3.32, 3.35–6  
 bovine dermal, acne scar treatment 42.69  
 as chromophore 78.3  
 cross-linking 3.39  
 defects in Ehlers–Danlos syndrome 3.35, 3.36  
 degradation 3.40–2, 47.27, 47.54  
 ageing and 8.22  
 regulation 3.41  
 dermal fillers 80.4  
 dermis, ageing and 8.22  
 disorders 45.31–44  
*see also*  
 connective tissue disorders/disease  
 dissection pattern 56.38, 56.39  
 dressings 14.24  
 effects of corticosteroids on 45.4, 73.17  
 FACIT (fibril-associated) 3.34  
 fibrillar 3.34  
 synthesis 3.37  
 formation in scleroderma 12.31  
 gene expression regulation 3.39  
*trans-/cis*-acting 3.39  
 genetic heterogeneity 3.34  
 hydroxylation reactions 3.37–8  
 hydroxyproline and hydroxylysine residues 3.37  
 implants, foreign body reactions 28.46–7  
 in irritant contact dermatitis 25.5  
 in keloids 45.54  
 lysine residues 3.37, 3.38  
 mechanical properties of skin and 4.8  
 mRNA formation, control 3.39  
 number of types 3.34  
 oxidative deamination reaction 3.39  
 periodicity in fibres 3.27, 3.28  
 pro- $\alpha$ -chains 3.37  
 procollagen type III (PIIINP) 20.33, 20.35  
 prolyl hydroxylation reaction 3.37  
 remodelling 78.13  
 resistance to proteolytic degradation 3.40  
 in scars 14.7–8  
 in striae 45.5  
 structural organization 3.34  
 subunit polypeptide 3.34  
 synthesis 3.37–8  
 by fibroblasts 3.49  
 increased by retinoic acid 73.35  
 increased in photodamaged dermis 3.39  
 inhibition by corticosteroids 45.4, 73.17  
 in scleroderma 12.31  
 uncontrolled 3.39  
 transepithelial elimination 45.64, 45.65  
 triple-helical conformation 3.34, 3.37–8, 3.40  
 type I 3.2, 3.35, 14.7, 80.1  
 biosynthesis 3.37  
 cross-linking 3.39  
 decorin binding 3.46  
 degradation 3.40–1  
 mutations in Ehlers–Danlos syndrome 3.35

- type III 3.2, 3.35, 14.7, 80.1  
 biosynthesis 3.37, 3.49  
 in Ehlers–Danlos syndrome 3.35, 45.34  
 in systemic sclerosis 51.92
- type IV 3.2, 3.27, 3.34  
 $\alpha$ -chains 3.27, 3.35  
 antibodies 39.25  
 assembly 3.27, 3.28  
 autoantibodies 3.27  
 basement membrane zone 3.25, 3.27  
 degradation 3.41  
 inclusions in multicentric reticulohistiocytosis 55.23  
 lymphatic vessels 48.4  
 mutations in renal diseases 3.27, 3.35  
 structure 3.35  
 vascular basement membrane 3.52
- type V 3.35  
 biosynthesis 3.37  
 in Ehlers–Danlos syndrome 3.35, 45.33
- type VI 3.35
- type VII 3.31, 3.34, 3.35–6, 39.16  
 absence, dystrophic epidermolysis bullosa 3.32  
 in anchoring fibrils 3.32, 3.35–6  
 assembly 3.27, 3.28  
 biosynthesis 3.37  
 in bullous dermolysis of newborn 39.23  
 in dystrophic epidermolysis bullosa 39.15, 39.25  
 in epidermolysis bullosa acquisita 3.36, 40.51  
 gene encoding (*COL7A1*) *see* *COL7A1* gene  
 Gly-X-Y repeats 39.16  
 monoclonal antibodies to 39.25  
 mutations in epidermolysis bullosa 3.36  
 structure 39.16
- type XII 14.7
- type XIV 14.7
- type XVI, expressed by dermal dendrocytes 55.4
- type XVII 3.36–7  
 biosynthesis 3.37  
 BPAG2 gene mutations 3.31  
 ectodomain and 40.46  
 in junctional epidermolysis bullosa 3.36–7  
*see also* bullous pemphigoid antigens, BP180 (BPAG2; type XVII collagen)
- type XXIX 3.37
- types in skin 3.34–7  
 in wound healing 14.1, 14.7  
 xenogeneic bovine 80.4
- 'collagen disease' 51.1
- collagen (vascular) disease *see* connective tissue disorders/disease
- collagen (vascular) diseases *see* connective tissue disorders/disease
- collagen dressings 14.24
- collagenases 12.52, 14.11  
 abnormalities, dystrophic EB 39.16  
 ageing and 80.2  
 interstitial (MMP1) 3.40  
 neutrophil 3.41  
 in sarcoidosis 61.20  
 in wound debridement 14.22
- collagenoma 18.31–2, 45.50  
 eruptive 18.31, 45.50  
 familial cutaneous 18.31, 45.50  
 plantar cerebriiform 18.31  
 storiform 56.3  
 verrucous perforating 45.65
- collagenosis  
 perforating (folliculitis) 59.80  
 reactive perforating 19.89
- collagenous colitis 62.53
- collagenous fibroma 56.10–11
- collarette scale 5.7
- 'collarettes,' fibrinous, staphylococcal blepharitis 67.8
- collateral vessels/circulation  
 claudication management 47.5  
 'corkscrew' 47.5, 47.7
- Colles' fracture 63.20, 63.21
- collier's stripes 58.57
- colloid (vehicle for topical therapy) 73.2  
 composition 33.48  
 wart treatment 33.48
- colloid baby 17.19–21, 19.13–17, 59.39
- colloid bodies 10.38  
 in lichen planus 41.4, 41.5  
 Russell bodies 30.52
- colloid degeneration *see* colloid milium (pseudomilium)
- colloid milium (pseudomilium) 10.38, 45.66–7, 73.27  
 electron microscopy 10.30
- colloid–amyloid bodies  
 Naegeli's syndrome 58.19  
 vitiligo 58.47
- Vogt–Koyanagi–Harada syndrome 58.45
- coloboma 67.4
- colony-stimulating factors 5.1  
 adverse effects 75.141–2  
 cells secreting 5.1
- colophony (Colophonium) 26.20, 26.79, 26.82–3, 33.48
- Colorado tick fever 38.34, 38.35
- colostomy *see* stoma
- colostrum 8.9
- colour  
 in animals 2.5, 2.6–7  
 disorders 2.22  
 hair *see* hair  
 hair coat, in animals 2.6  
 skin *see* pigmentation
- colour developing agents, lichen planus-like contact dermatitis 41.23
- coma, eccrine sweat gland necrosis induced by 44.18
- combination chemotherapy, male genital dermatology 71.44
- combined oral contraceptives (COCs)  
 acne treatment 42.53  
 failure rate, antibiotics affecting 42.54  
 melanoma and 54.57  
 melasma and 58.34  
 oral antibiotic interactions 42.51–2
- comedo, definition 5.7
- comedo naevus 42.78, 53.4
- comedo naevus syndrome 18.27
- comedogenesis  
 in acne 42.22–4  
 animal models 42.23  
 mechanical causes 42.76  
 reduced by antiandrogens 42.23–4  
 reduced by isotretinoin 42.58  
 topical drugs affecting 42.40
- comedones  
 in acne 42.18  
 in chloracne 27.13, 27.14, 42.77  
 closed (whiteheads) 42.22, 42.30, 42.36  
 corticosteroids associated 73.19  
 cyclical growth 42.24  
 familial 42.78  
 familial diffuse 18.11  
 familial dyskeratotic 18.11, 19.76  
 formation *see* comedogenesis  
 in hidradenitis suppurativa 30.81  
 midfacial 42.30  
 open (blackheads) 42.22, 42.24, 42.30, 42.77  
 pathogenesis 42.22–3  
 removal and extraction 42.67  
 rupture, reduction by topical retinoids 42.40  
 sandpaper 42.30, 42.56  
 secondary 42.31  
 solar/senile 42.79  
 retinoic acid therapy 73.36
- submarine 42.31  
 treatment 78.14
- Commission Internationale de l'Eclairage L\*a\*b\* system 25.22
- commissural pits 69.40–1
- Committee on Safety of Medicines 75.4
- common peroneal nerve 77.5
- common variable immunodeficiency 13.13, 17.72–3, 69.117
- communication 72.1–5  
 amongst clinicians 72.26  
 bad news 72.4–5  
 risks of therapy 72.3–4  
 training in 72.2
- community diagnosis 6.2
- comparative dermatology 2.8–19  
*see also* animal(s)
- comparative genomic hybridization (CGH) 54.24, 57.20
- compartment syndrome, following arthropod bites/stings 38.2
- compensation, in occupational dermatoses 27.1–2
- complement 13.1, 17.48  
 abnormalities associated with DLE 51.17  
 absence from dermal–epidermal junction, systemic sclerosis 51.92  
 activation 13.2, 13.3  
 assays 13.18–19, 17.55  
 C1q 13.2, 22.81  
 deficiency 17.83  
 C1r, deficiency 17.83  
 C1s, deficiency 17.83  
 C2  
 in angio-oedema 13.19  
 deficiency 13.13, 13.18, 17.84  
 C3 13.2, 13.3  
 deficiency 13.22, 17.84  
 increased, oedematous scarring vasculitis panniculitis 46.32  
 measurement 13.18  
 C3 nephritic factor, partial lipoatrophy and 46.39–40  
 C3a 13.2, 13.4  
 in vasculitis 50.4  
 C3b 13.3  
 C3d 13.18  
 C4 13.3  
 deficiency 13.18, 13.22, 17.83–4, 22.22  
 measurement 13.18  
 C4a 13.2  
 C4b 13.3  
 C5 deficiency 17.84  
 C5a 13.2, 13.4  
 in vasculitis 50.4  
 C6 deficiency 17.84  
 C7 deficiency 17.84  
 C8 deficiency 17.84  
 C9 deficiency 13.18, 17.84  
 deficiency 13.4, 13.15, 13.18–19, 17.53, 17.82–4, 51.54  
 interaction with antibody deficiencies 17.84  
 management 17.85  
 in mice, acantholysis 40.6  
 panniculitis with 46.27  
 formation of blisters 40.28  
 lysis, sensitivity 49.30  
 patterns of abnormalities 13.18  
 role in vasculitis 50.4–5, 50.5  
*Treponema pallidum* movement inhibition 34.20
- complement-deficient mice, acantholysis 40.6
- complement receptors 13.3  
 CD88 13.2  
 CR1 (CD35) 13.3  
 CR2 (CD21) 13.3, 13.8  
 EBV infection 33.30  
 CR3 12.10, 13.3  
 deficiency 17.84  
 CR4 13.3
- complementary and alternative therapy 64.2, 72.31–3  
 acne vulgaris treatment 42.43  
 adverse effects 75.160–2  
 forms of 72.32  
 potential risks 72.31, 72.32–3  
 in psychocutaneous disorders 64.54  
 rates of use 72.2, 72.31  
 reasons for use 72.32
- complex of myxomas, spotty pigmentation and endocrine overactivity *see* Carney complex (Carney's syndrome)
- complex rearrangements 15.2
- complex regional pain syndrome (CRPS) 44.8, 47.10–11, 62.101, 63.20–2  
 differential diagnosis 47.9
- complex traits 11.14–16
- complexion, concept of 64.1–2
- compliance *see* concordance with therapy
- Compositae 25.21, 26.10, 26.18, 26.20, 26.24, 26.75–6, 26.77
- Compound A (Cmpd A) 12.62
- compound F 73.16
- compression bandaging 14.20–1, 38.31, 38.60  
 complex regional pain syndrome 47.11  
 infantile haemangioma 18.52  
 long-stretch and short-stretch 47.48  
 multilayer 47.48  
 lymphoedema management 48.22  
 short-stretch bandaging 47.48, 48.22  
 venous leg ulcers 47.47, 47.48
- compression of skin 4.8
- compression stockings  
 deep-vein thrombosis 47.29  
 graduated elastic 47.38  
 lymphoedema management 48.22  
 post-thrombotic syndrome 47.40  
 varicose veins 47.38  
*see also* elastic stockings; medical elastic compression stockings (MECS)
- compression therapy  
 lymphoedema management 48.22–3  
 pneumatic, lymphoedema management 48.22–3  
 varicose veins 47.38  
 venous leg ulcers 47.47–8, 47.51
- compression ultrasound (CUS), deep-vein thrombosis 47.29
- computed tomography (CT)  
 foreign bodies 28.42  
 invasive otitis externa 68.26  
 lymphoedema 48.17  
 melanoma relapse 54.50  
 Sturge–Weber syndrome 18.66  
 venous malformations 18.71
- computer palms 28.27
- computers, disorders related to use 25.16–17
- concanavalin A 13.23
- conception, and drug therapies 72.28
- conchoid bodies 61.4
- concordance with therapy 72.5–7, 72.25–6  
 influences on 72.6–7, 72.13  
 monitoring 72.5  
 strategies to improve 72.7, 72.26
- conditioned hyperirritability 23.6
- conditioners 66.96
- condom chancr 34.7
- condoms  
 allergic contact dermatitis due to 26.19  
 male genital dermatology 71.17
- conductive deafness with ptosis and skeletal anomalies 15.33
- condyloma  
 giant *see* Buschke–Löwenstein tumour  
 malignant, anogenital warts vs 33.42
- condylomata acuminata 33.44
- giant 52.26  
 in pregnancy 8.11  
*see also* wart(s), anogenital
- condylomata lata 34.10, 34.11, 69.121
- cone-nose bug 38.25
- cone shells 38.59

- confidence intervals 6.18, 7.9, 7.17–18, 7.20–2
- confluent and reticulate papillomatosis 19.121–2
- confocal laser scanning microscopy 5.20
- confounding 6.18
- confounding factors 6.11
- congenital abnormalities 18.1
- definition 15.2
- female genital dermatology 71.56
- male genital dermatology 71.13–14
- perianal/perineal dermatology 71.83–4
- umbilical dermatology 71.100
- see also* developmental abnormalities; *specific abnormalities/conditions*
- congenital absence of skin *see* aplasia cutis congenita
- congenital adrenal hyperplasia 62.6–7, 66.83
- children, acne and 42.76
- late-onset
- acne and 42.21–2, 42.73
- acne fulminans and 42.83
- congenital adrenogenital syndrome, acne and 42.73
- congenital autonomic dysfunction with universal pain loss 44.7
- congenital CMV infection 33.29
- congenital dermal melanocytosis *see* Mongolian spot
- congenital erosive and vesicular dermatosis healing with reticulated supple scarring 17.11, 18.104, 50.62
- congenital erythropoietic porphyria (CEP) 59.10
- hypertrichosis in 66.79
- prenatal diagnosis 16.3
- congenital fascial dystrophy 45.50–1
- congenital generalized lipodystrophy (CGL) 46.37
- congenital haemolytic anaemia, pigmentation in 58.53
- congenital heart block (CHB), neonatal lupus erythematosus 51.49
- congenital hypertrichosis, perianal/perineal 71.84
- congenital hypertrophic lip of the hallux 65.7
- congenital hypotrichosis with juvenile macular dystrophy (HJMD) 15.33
- congenital ichthyosiform erythroderma (CIE) 19.17, 19.18
- see also* lamellar ichthyosis
- congenital ichthyosis with fine/focal scaling (CIFS; ichthyosis prematurity syndrome) 19.18–19
- congenital insensitivity to pain with anhidrosis (CIPA) 15.34
- congenital livedo reticularis 28.68
- congenital localized absence of skin (Bart's syndrome) 18.101, 39.17, 39.18, 39.22
- congenital nodular calcification of Winer 68.18
- congenital palmoplantar and perioral keratoderma 19.94, 19.101–2
- congenital palmoplantar and periorificial keratoderma with corneal epithelial dysplasia 69.25
- congenital reticular ichthyosiform erythroderma 19.18
- congenital ring constrictions *see* amniotic bands/adhesions
- congenital rubella 17.41–2, 18.2, 33.71
- congenital scalp defects with distal limb anomalies 15.96
- congenital syphilis *see* syphilis, congenital
- congenital telangiectatic erythema and stunted growth (Bloom's syndrome) 15.76–7, 62.27
- congestive heart failure, in sarcoidosis 61.7
- Congo floor maggot 38.8
- Congo red 10.10
- conical teeth, ectodermal dysplasias 15.58–9
- conidia 36.2, 36.3, 36.4, 36.9, 36.18
- conidiobolomycosis 36.78–9
- Conidiobolus coronatus* 36.78–9
- conjunctiva
- in atopic dermatitis 24.24
- biopsy 61.19
- ocular mucous membrane pemphigoid 67.19
- bulbar 67.2
- lentigo maligna 54.40–1
- naevus 54.18
- normal 67.14
- ocular rosacea 67.7
- palpebral 67.2
- bulbar, fusion in mucous membrane pemphigoid 67.18
- papilloma 33.47
- scarring 67.20
- ocular mucous membrane pemphigoid vs 67.20
- Stevens–Johnson syndrome 67.21
- shortening 67.21
- ulceration, mucous membrane pemphigoid 67.18
- conjunctivitis
- acute follicular (chlamydial) 34.29, 34.31
- adverse effects of treatment 26.46
- chronic blepharitis with, treatment 67.12
- cicatrizing 67.16–24
- autoimmune 67.17–20
- diseases causing 67.19, 67.20
- epidemiology and description 67.16–17
- non-autoimmune 67.19, 67.20
- in Stevens–Johnson syndrome 67.21
- treatment 67.22–3
- see also* mucous membrane pemphigoid (MMP)
- due to Lepidoptera 38.29
- follicular 67.8, 67.25
- gonococcal 34.25
- in graft-versus-host disease 67.22
- iatrogenic, ocular mucous membrane pemphigoid vs 67.20
- infective 67.19, 67.20
- in mucous membrane pemphigoid 67.18
- perennial allergic 67.13, 67.15
- in psoriasis 67.5
- in rosacea 43.4, 43.5
- in sarcoidosis 61.7
- seasonal allergic 67.13, 67.15
- in Stevens–Johnson syndrome 67.21, 76.16
- subepithelial immunobullous diseases and 67.20
- in toxic epidermal necrolysis 67.21
- vectors 38.6
- connective tissue, loss, topical corticosteroids causing 73.17
- connective tissue disorders/disease 45.1–70, 51.1–139
- age of onset 51.27
- bone and joint involvement 62.103
- cardiac involvement 62.78
- classification 45.1
- cryoglobulinaemia with 49.32
- deposition disorders 51.79
- dermatomyositis 51.120–9
- discoid lupus erythematosus 51.4–22
- ear involvement 68.17
- eosinophilic fasciitis 51.86
- erythromelalgia with 47.9
- genetic disorders 51.79
- graft-versus-host disease 51.83–6
- lupus erythematosus 51.1–62
- metabolic disorders 51.79
- mixed 51.110–12
- morphoea 51.64–78
- occupational causes 51.80
- ocular involvement 67.29
- oral involvement 69.117
- overlap syndromes 51.110–12, 51.126
- panniculitis in 46.31–2
- pigmented purpuric dermatoses and 49.23
- in pregnancy 8.11, 8.12
- respiratory tract involvement 62.80, 62.82
- rheumatoid disease 51.130–9
- sarcoidosis and 61.17
- scleroderma 51.64
- scleroedema 51.118–20
- secondary mucinosis 59.29
- silicone breast implants and 70.7–8
- skin biopsy 10.42–3
- subacute cutaneous lupus erythematosus 51.2, 51.22–7
- systemic lupus erythematosus 51.27–63
- systemic sclerosis 51.87–110
- see also specific disorders and diseases*
- connective tissue growth factor (CTGF) 14.3
- gene expression 51.65
- connective tissue panniculitis 46.15, 51.14–15, 51.87
- connexins 3.24
- ectodermal dysplasias 15.67–8
- gap junctions 3.24
- homotypic and heterotypic 3.24
- mutations in fish 2.6
- scar formation and 14.8
- connexons 3.24
- connubial/consort allergy 26.41, 26.48
- connubial dermatitis 26.18
- conotruncal anomaly face syndrome 13.8
- Conradi–Hünemann syndrome 62.100
- Conradi–Hünemann–Happle syndrome 19.3, 19.49–52
- prenatal diagnosis 16.3
- Conradi's syndrome (calcifying chondrodysplasia) 45.8
- consent
- to skin biopsy 10.2
- to surgery 77.13
- Consolidated Standards of Reporting Trials 7.16
- CONSORT (Consolidated Standards of Reporting Trials) 7.16
- CONSORT guidelines 6.16
- constipation, in dystrophic EB 39.19, 39.28
- constitutive skin colour 58.1, 58.7, 58.9–10
- constricting bands of the extremities *see* ainhum; pseudo-ainhum
- consultation *see* dermatology consultation
- contact dermatitis
- allergic *see* allergic contact dermatitis
- amputees 28.29
- chronic actinic dermatitis association 29.16, 29.17
- ear 68.23
- in elderly people 8.28
- eyelids 67.5
- female genitalia 71.58
- genitocrural 71.5
- insult (cumulative irritant contact dermatitis) 25.1, 25.5, 25.12–13, 25.14, 25.15
- irritant *see* irritant contact dermatitis
- lanolin causing 73.6–7
- lichen planus-like 41.23
- male genitalia 71.17–18
- mechanical injury 28.13–14, 28.22, 28.25, 28.29, 28.52, 28.54
- occupational 27.2
- in palmoplantar hyperhidrosis 44.8
- perianal/perineal 71.84
- perioral dermatitis vs 43.11
- photoallergic 26.23–5
- pigmented 26.26
- protein 27.5
- race and 9.13, 26.8
- venous leg ulcers 47.44–5
- contact hypersensitivity response (CHS) 13.27, 13.28
- UVR effect 29.5
- contact immunotherapy, alopecia areata 66.37
- contact irritants, pigmented purpuric dermatoses due to 49.23
- contact lens, corticosteroid contraindication 67.31
- contact sensitization
- corticosteroids causing 73.17
- lanolin causing 73.6–7
- by sunscreens 29.9
- by topical antibiotics 73.10
- wart treatment 33.49
- see also* contact dermatitis
- contact urticaria *see* urticaria, contact
- contagion, beliefs 64.6
- contamination, measurement of 27.11
- contiguous gene syndromes 15.6
- contingency tables 7.20
- contraceptive pill *see* combined oral contraceptives (COCs)
- contractures, in dystrophic EB 39.29
- Control of Substances Hazardous to Health legislation 26.100
- contusion, ear 68.6–7
- Conus* (cone shells) 38.59
- conversion disorder 64.25–6
- converting enzymes 12.49
- convulsions, febrile, in roseola infantum 33.32
- cooks, occupational hazards 5.6, 27.19
- Cook's syndrome 15.34
- coolants, synthetic 27.5
- cooling, skin surface 80.10–11
- cooling pastes 73.2
- Copenhagen Psoriasis Severity Index 72.9
- coping strategies 64.4
- copper
- as allergen 26.40
- deficiency 3.44, 66.94
- green hair induced by 66.95
- metabolism 59.76
- in occipital horn syndrome 45.39
- copper chlorophyllin, in fish odour syndrome 44.20
- copra itch 38.47
- coproporphyrin, hereditary 59.19
- coproporphyrin III 30.38
- coral bead sign 62.41
- corals 38.55–8
- Cordia* 26.80
- Cordylobia* 38.8, 38.9, 38.10
- corium *see* dermis
- cornea
- in atopic eye disease 67.16
- drug-induced pigmentation 58.29, 58.30
- in dystrophic EB 39.19
- epithelial defects, in toxic epidermal necrolysis 67.21
- ocular rosacea 67.7
- perforation, management 67.22
- persistent epithelial defect management 67.22
- mucous membrane pemphigoid 67.17, 67.18
- Stevens–Johnson syndrome 67.21
- in psoriasis 67.5
- statue eye 40.39
- transplant 67.9
- ulceration, management 67.23
- corneal arcus 59.86
- Cornelia de Lange syndrome *see* de Lange syndrome
- corneocytes 3.1, 3.8, 4.2, 12.14
- changes with ageing 4.11, 8.23, 80.2
- corneodermatosis syndrome 15.34
- corneodesmosin 66.60
- corneodesmosomes 12.14
- cornifin 3.10
- corns
- mechanical injury 28.10–12, 28.31
- plantar warts vs 33.44

- coromandel 26.80  
 corona phlebotactica paraplanaris 47.14, 47.33  
 corona seborrhoeica 23.30  
 corona veneris 34.11  
 coronary artery disease 47.5, 62.78  
 Frank's sign 68.6  
 coronaviruses 33.2  
 corpus luteum 8.8, 8.9  
 corrosion, tests for 25.9  
 Corrositex™ 25.9  
 corticosteroids 57.23, 74.2–3  
 in acne vulgaris 42.53  
 acneiform eruptions due to 42.72  
 adverse effects 28.46, 74.3  
 cataracts 67.15–16, 67.31  
 delays in wound healing 14.19  
 in elderly people 8.28  
 glaucoma 67.15–16, 67.31  
 hypertrichosis 66.79  
 ocular 67.31  
 purpura 49.15  
 rosacea 43.10  
 topical use 26.18, 26.45, 45.3–4, 45.5, 73.17–20, 75.116–17  
 anti-inflammatory effects 13.23–4, 73.16–17  
 antimitotic actions 73.16  
 in balanitis xerotica obliterans 51.118  
 candidiasis and 36.59, 36.61  
 in carcinoid syndrome 43.19  
 in chronic actinic dermatitis 29.18  
 collagen gene expression control 3.39  
 in congenital syphilis 34.16  
 in dermatomyositis 51.129  
 development 73.16  
 fluorinated 73.23  
 imidazoles with 73.12  
 immunosuppressive effects 13.23–4  
 induction of TLR-2 activation on keratinocytes 12.9  
 inhaled, perioral dermatitis and 43.11  
 intralesional 73.20, 77.48  
 adverse effects 45.3–4  
 in alopecia areata 66.36–7  
 in discoid lupus erythematosus 51.20  
 in Fox–Fordyce disease 44.22  
 in granuloma annulare 60.10  
 in infantile haemangioma 18.50  
 in keloids/hypertrophic scars 14.15  
 in Langerhans' cell histiocytosis 55.13  
 in lichen planus 41.18  
 needleless injection 77.48  
 in psoriasis 20.25  
 in pyoderma gangrenosum 50.72  
 mechanical injury 28.53  
 mechanism of action 73.16–17, 74.2  
 mode of action 74.2  
 in pemphigus 40.11–12, 74.2–3  
 perianal/perineal dermatology 71.99  
 in pregnancy 74.3  
 purpura due to 49.15  
 in pyoderma faciale 43.14  
 rosacea due to 43.10  
 route of administration 74.2  
 sebaceous gland activity and 42.11  
 in SLE 51.61  
 structure 73.16  
 systemic 74.2–3  
 aciclovir with in zoster 33.28  
 in acne vulgaris 42.63, 42.66  
 in actinic prurigo 29.14  
 adverse effects 45.3–4, 75.115–16  
 in alopecia areata 66.37  
 in atopic dermatitis 24.31  
 in atopic eye disease 67.16  
 in Churg–Strauss syndrome 50.42  
 in cutaneous small vessel vasculitis 50.15  
 in cytophagic histiocytic panniculitis 46.24  
 in dermatophytoses 36.49  
 in dystrophic EB 39.29  
 in eczema 23.38  
 in erythema multiforme 69.70, 76.7  
 in erythroderma 23.49  
 in giant cell arteritis 50.44  
 in Hailey–Hailey disease 39.35  
 in Henoch–Schönlein purpura 50.21  
 in herpes zoster 63.6  
 in hidradenitis suppurativa 30.81  
 in hirsutism 66.88  
 in idiopathic thrombocytopenic purpura 49.10  
 indications 74.2  
 in infantile haemangioma 18.49–50  
 in Kasabach–Merritt syndrome/phenomenon 18.56–7  
 in leprosy reactions 32.18  
 in lichen planus 41.18  
 in mastocytosis 22.36  
 in morphea, localized 51.74–5  
 in multicentric reticulohistiocytosis 55.24  
 in necrobiosis lipoidica 60.16  
 in osteoporosis 74.3  
 in polyarteritis nodosa 50.35  
 in pyoderma gangrenosum 50.72  
 in relapsing polychondritis 45.43  
 route of administration 74.2–3  
 in sarcoidosis 61.21  
 in Sweet's syndrome 50.79  
 in toxic epidermal necrolysis 76.20  
 toxicity 74.3  
 in urticaria 22.29  
 in urticarial vasculitis 22.29, 50.22  
 in Wegener's granulomatosis 50.40–1  
 tinea incognito and 25.15, 36.35–6, 36.50, 73.18  
 topical 57.23, 64.25, 72.6, 72.7, 73.16–23  
 abuse for skin lightening 73.26  
 acne vulgaris treatment 42.43  
 acnegenicity 27.13  
 adverse effects 26.18, 26.45, 45.3–4, 45.5, 73.17–20, 75.116–17  
 in allergic contact dermatitis 26.101  
 in alopecia areata 66.36  
 in atopic dermatitis 21.13, 24.29, 24.30  
 in atopic eye disease 67.15–16  
 calcipotriol with 73.45  
 in cicatrizing conjunctivitis 67.22  
 classification by potency 73.16, 73.18  
 clinical efficacy measurement 73.16  
 combination therapies 73.20  
 diffusion through stratum corneum 73.16  
 in eczema 23.38  
 effect on patch test reactions 26.9  
 in erythroderma 23.49  
 fear of (steroid phobia) 64.25, 72.6, 73.17  
 formulations 73.20  
 in Fox–Fordyce disease 44.22  
 frequency of application 73.3  
 glaucoma/cataract due to 67.15–16, 67.31  
 in Hailey–Hailey disease 39.35  
 in hand eczema 23.22  
 in HSV infection of eye 67.26  
 indications 73.20–1, 73.21  
 in infantile haemangioma 18.50  
 infection exacerbation 73.18  
 in irritant contact dermatitis 25.23  
 labelling 72.7  
 in lichen planus 41.17–18, 41.18  
 local adverse effects 73.17–20  
 in mastocytosis 22.36  
 mechanism of action 73.16–17  
 monitoring use 24.29  
 in napkin dermatitis 17.26  
 in necrobiosis lipoidica 60.16  
 occlusion 73.20  
 in otitis externa 68.25  
 perianal/perineal conditions 71.99  
 perioral dermatitis and 43.11  
 potencies 73.16, 73.18  
 in pruritus 21.17  
 in psoriatic nail involvement 65.26  
 in pyoderma faciale 42.84  
 rebound phenomena 73.19  
 receptor and binding affinity 73.16–17  
 rosacea induced by 73.19  
 in sarcoidosis 61.21  
 in seborrhoeic dermatitis 23.33  
 side effects 73.17–20  
 stability 73.20  
 systemic adverse effects 73.20  
 unlicensed 73.20  
 vascular effects 73.19–20  
 vasoconstrictor assay 73.16  
 vehicles 73.20  
 vitiligo 58.48–9  
 weekly dosage 73.20  
 withdrawal 73.19  
 withdrawal  
 in perioral dermatitis 43.12  
 in steroid-induced rosacea 43.10  
 corticotrophin-releasing hormone (CRH) 64.9  
 cortisol 73.16  
 in atopic dermatitis 24.19  
 in Cushing's disease/syndrome 62.4  
 hirsutism and 66.83  
 see also hydrocortisone  
 Corynebacterium  
 female genital infections 71.67  
 male genital infections 71.31  
 in normal skin flora 30.2, 30.3, 30.36, 68.2  
 in pitted keratolysis 30.39  
 taxonomy/classification 30.3  
 in trichomycosis axillaris 30.39  
 Corynebacterium acnes see Propionibacterium acnes  
 Corynebacterium bovis 30.3  
 Corynebacterium diphtheriae 30.35, 30.36  
 diphtheria 30.36–7  
 female genital dermatology 71.67  
 Corynebacterium haemolyticum 30.37  
 Corynebacterium hofmani 30.3  
 Corynebacterium minutissimum 30.3, 30.36, 30.37–8  
 genitocrural infections 71.6  
 in HIV infection 35.26  
 Wood's light examination 5.19  
 Corynebacterium pyogenes 30.37  
 Corynebacterium tenuis 30.36  
 Corynebacterium xerosis 30.3  
 coryneforms, in normal skin flora 30.3  
 COSHH legislation 26.100  
 cosmeceuticals 80.3  
 cosmetic advertising 64.1–2  
 cosmetic camouflage 72.31  
 acne scars 42.69  
 in hypermelanosis 58.38  
 in rosacea 43.6  
 in sarcoidosis 61.10, 61.21  
 cosmetic fillers, sarcoidal reaction to 61.22  
 cosmetic industry, ageing and 8.25  
 cosmetic surgery/treatment  
 congenital naevi 54.14  
 varicose veins 47.37  
 cosmetic units, head and neck 77.2  
 cosmetics  
 acnegenicity 27.13, 42.73  
 advertising 64.1–2  
 allergic contact dermatitis to 26.14, 26.16, 26.17, 26.47–9  
 avoidance 26.48  
 comedogenic and acne due to 42.73  
 EU directive 26.100  
 eyelid contact dermatitis due to 67.5  
 eyelid pigmentation due to 67.5  
 facial melanosis due to 58.34  
 hair 66.95–100  
 ingredient labelling 26.100  
 irritant contact dermatitis due to 25.15  
 nail 65.54–7  
 patch testing 26.48–9  
 perioral dermatitis and 43.11  
 photodynamic substance in 58.35  
 vehicles 26.58–60, 73.2–3  
 'costal fringe' 47.14  
 Costello syndrome 45.15, 45.16  
 costunolide 26.75, 26.77  
 cotton-seed dermatitis 38.48  
 coumadin see coumarins; warfarin  
 coumadin necrosis 49.39  
 coumarins  
 adverse effects 62.92, 75.105  
 in lymphoedema 48.25  
 necrosis 49.39  
 in secondary thrombocytopenia 49.11  
 therapeutic effects 49.39  
 counselling  
 genetic see genetic counselling  
 interpersonal 64.53  
 counterstaining  
 in immunoenzyme methods 10.17  
 in immunofluorescence methods 10.14  
 cowage 21.4  
 Cowden's syndrome 62.25–6, 62.57  
 breast involvement 70.17  
 genetics 15.26–7  
 oral involvement 69.38  
 palmpoplantar punctate keratoses and 62.21  
 PTEN gene mutations 53.5  
 renal involvement 62.69  
 trichilemmoma 53.5–6  
 cowpox 30.41, 33.7–8  
 cow's milk allergy 22.6  
 COX-1, and COX-2 see cyclooxygenases  
 coxsackieviruses 33.71–3  
 atopic dermatitis and 24.24  
 A and B strains, and diseases 33.71–2, 33.73  
 congenital infections 33.72  
 Gianotti–Crosti syndrome 33.77  
 oral infection 69.76, 69.118  
 purpura 49.20  
 rashes/exanthems 33.72, 33.73  
 CP (cicatricial pemphigoid) see mucous membrane pemphigoid  
 CPA (Clinical Pathology Accreditation) 13.15  
 CPA (cyproterone acetate) see cyproterone acetate  
 CpG oligodeoxynucleotides (ODN) 12.9  
 CPOD (chronic papular onychodermatitis) 37.5  
 crabs (pubic lice) see under lice  
 cradle cap 17.11, 17.30  
 Crandall's syndrome 66.65  
 cranial arteritis see giant cell arteritis  
 cranial nerves  
 ear innervation 68.1  
 palsy 61.7, 69.118  
 herpes simplex recurrence 33.18  
 cranio-ectodermal dysplasia 15.91–2, 69.10  
 cranio-ectodermal syndrome 15.34  
 cranio-osteopathopathy 15.88  
 craniofacial dysostosis 15.90–1  
 craniofacial features, ectodermal dysplasias 15.59, 15.62, 15.64–6, 15.69  
 craniomandibular dermatodysostosis (familial mandibulo-acral dysplasia) 45.61–2  
 craniosynostoses 15.90–2  
 craniosynostosis and porokeratosis (CDAGS syndrome) 15.91  
 cranium bifidum 18.95  
 Cre/lox recombination 11.11  
 creams 73.2  
 quantity applied 73.3–4  
 creatine, urinary 24-h 51.127  
 creatinine monitoring, burns 28.84  
 creeping eruption, cutaneous see larva migrans  
 creeping hair 28.49  
 Creole dyschromia 9.16  
 creosote 27.13  
 Crescis acicula 38.59

- cresol 25.21  
 CREST/CRST syndrome 47.14, 51.104, 62.48, 62.99  
   bone and joint involvement 62.99  
   pigmentation changes 58.26  
   respiratory tract involvement 62.82  
 cretinism 62.10, 62.11  
 Creutzfeldt–Jakob disease, new variant, sterilization of surgical equipment and 77.7  
 crevicular fluid 69.3  
 CRH (corticotrophin-releasing hormone) 64.9  
 cri du chat syndrome 15.12, 66.93  
 Crimean Congo haemorrhagic fever 33.67, 33.70  
 crinkles 45.2  
 crisantaspase 75.132  
 Crisponi syndrome 45.46  
 crocodiles 2.3  
 Crohn's disease **62.48–50**  
   acrodermatitis enteropathica and 62.49  
   cutaneous 62.48, 62.49  
   differential diagnosis 61.5  
   direct skin and mucosal involvement 62.48–9  
   epidermolysis bullosa acquisita and 62.49  
   erythema multiforme and 62.50  
   erythema nodosum and 62.50  
   female genitalis involvement 71.65  
   lichen nitidus association 41.22  
   lymphoedema 48.13, 48.16  
   male genitalia involvement 71.28, 71.30  
   metastatic 62.49, 68.17  
   necrobiosis lipidica and 60.15  
   oral 62.49, 69.116  
   oral intraepidermal IgA pustulosis and 62.49  
   perianal/perineal involvement 71.82, 71.87, **71.89–90**, 71.91, 71.95  
   polyarteritis nodosa and 62.49  
   porokeratosis and 62.49  
   psoriasis and 62.49  
   purpura and 62.51  
   pyoderma faciale and 42.84  
   pyoderma gangrenosum and 50.65, 62.50–1  
   reactive dermatoses associated 62.49  
   reactive lesions 62.50  
   sarcoidosis and 61.23  
   sexual abuse 28.38  
   subcorneal pustular dermatosis and 62.49  
   Sweet's syndrome and 50.75, 62.51  
   vasculitis and 62.51  
 cromones, atopic eye disease treatment 67.15  
 Cronkhite–Canada syndrome 15.50, **58.13–14**, 62.57–8  
 cross-sectional studies 6.19, 26.2  
 cross-sensitization 26.44–5, 26.96  
 Cross' syndrome 58.42  
 crossing-over 15.7–8  
 Crosti's lymphoma 57.45  
 croton oil 25.3  
 crotonaldehyde 25.21  
 Crozon's syndrome **15.90–1**, 68.4  
 Crow–Fukase syndrome 51.80, 58.29  
   *see also* POEMS syndrome  
 Crow–Fukase–Takatsuki syndrome *see* POEMS syndrome  
 'crow's feet' 45.2  
   botulinum toxin therapy 80.7, 80.8  
 CRP (C-reactive protein) 12.28, 12.32, 13.4, 13.19  
 CRPS *see* complex regional pain syndrome  
 Cruciferae 25.21  
 crust 10.38  
   *see also* scab  
 cryofibrinogen 13.17–18, 22.16, 49.33  
 cryofibrinogenemia 49.33–4  
 cryogelling, microvascular occlusion due to 49.32–4  
 cryoglobulin(s) **49.32–4**  
   classification 49.32  
   composition and associations 13.17  
   detection/investigations 49.32, 49.33  
   in HCV infection 33.61, 49.32, 49.33, 50.24, 50.25, 62.59  
   measurement 13.17–18  
   type I (single molecule) 49.32, 49.33  
   type II and III (mixed) 49.32  
 cryoglobulinaemia **28.71**, 49.32–3, 51.54  
   cold urticaria and 22.16  
   diagnosis 49.32, 49.33  
   in hepatitis B virus infection 62.59  
   in hepatitis C virus infection 33.61, 49.32, 49.33, 50.24, 50.25, 62.59  
   lymphoproliferative disease with 49.32  
   mixed 49.32, 50.24  
   purpura in 49.4, 49.5, 49.19  
   treatment 49.33  
   type I 49.32, 50.23–4, 62.93–4  
   type II 49.32, 50.24, 62.94  
   type III 49.32, 50.24, 62.94  
   vasculitis and 49.33, 50.23–5  
 cryopyrin-associated autoinflammatory syndrome (Muckle–Wells syndrome) **15.95–6**, 22.3, 59.57, 74.11  
 cryopyrin-associated periodic syndrome 22.24–5, 50.53, 62.69  
 cryosurgery **77.39–40**  
   adverse effects 77.39–40  
   clinical methods 77.39  
   clinical uses 77.39, 77.40  
   epidermolytic/non-epidermolytic epidermal naevi 18.7  
   granuloma annulare 60.10  
   infantile haemangioma 18.52  
   nail unit 65.48  
   non-melanoma skin cancer 52.16  
   sarcoidosis 61.21  
   *see also* cryotherapy  
 cryotherapy  
   acne vulgaris 42.68  
   actinic keratosis 52.31  
   Bowen's disease 52.34  
   molluscum contagiosum 33.12  
   warts 33.49–50  
   disadvantages and sequelae 33.49  
   *see also* cryosurgery  
 cryptococcosis **36.89–91**  
   aetiology 36.89–90  
   bone and joint involvement 62.100  
   definition 36.89  
   external ear 68.28  
   female genitalia involvement 71.69  
   in HIV infection 35.24, 35.33, 36.89, 68.28  
   meningitis 35.33  
   oral involvement 69.80, 69.118  
   sarcoidosis and 61.17  
*Cryptococcus neoformans* 36.89–91, 69.80  
   female genitalia infections 71.69  
   in HIV infection 35.33  
 cryptosporidiosis, HIV infection 35.35  
 crystal deposition, panniculitis with 46.16–17  
 crystal globulin vasculopathy 49.38  
 crystal-storing histiocytosis 46.17  
 crystal violet 10.10  
   *see also* gentian violet  
 crystalline folliculitis, necrotizing crystalline 19.89  
 crystals, lipid-containing 46.16  
 CS *see* Cockayne's syndrome  
 CSS *see* Churg–Strauss syndrome  
 CST syndrome 15.28, 15.43  
 CSVV (cutaneous small vessel/leukocytoclastic vasculitis) **50.4, 50.13–17**  
 CT *see* computed tomography  
 CTACK, in atopic dermatitis 24.7  
 CTCL (cutaneous T-cell lymphoma) *see under* lymphoma  
*Ctenocephalides canis* 38.4, 38.11–12  
*Ctenocephalides felis* 38.11–12  
*Ctenodactylus gondii* 37.44  
 CTGF (connective tissue growth factor) 14.3  
 CTLA4 13.11  
 Cuban laurel thrips 38.26  
 Cubozoa 38.56  
 Culicidae *see* mosquitoes  
*Culicoides* 38.6  
   skin disease in animals 2.11  
 Cullen's sign 62.65  
 cultural factors 64.1–2, 64.6, 64.18  
   in allergic contact dermatitis 26.10  
   communication 72.2  
 cultural remedies, bruising/purpura due to 49.16  
 culture, history-taking 5.5  
*Cunninghamella bertholletiae* 36.91  
 cupping 9.8  
   therapeutic 28.24  
 Cupressaceae 26.80  
*x Cupressocyparis leylandii* 26.80  
 curettage **77.40–4**  
   actinic keratosis 52.31, 77.40, 77.42  
   benign lesions 77.40  
   Bowen's disease 52.34  
   keratoacanthoma 52.43  
   molluscum contagiosum 33.12  
   non-melanoma skin cancer 52.16, 77.40–1, 77.43, 77.44  
   pyogenic granuloma 77.40, 77.41  
   skin biopsy 10.4  
   wart treatment 33.49, 77.40  
 curlicue pattern 10.38  
 curly hair–ankyloblepharon–nail dysplasia (CHANDS) 15.35, 15.63, 15.65  
 Curry–Hall syndrome 69.11  
 Curry–Jones syndrome **15.91**  
 Curth–Macklin ichthyosis hystrix 19.99  
 Curth's angle/modified profile sign 65.7, 65.8  
*Curvularia* 36.55, 36.73  
 Cushing's syndrome/disease 8.18, **62.3–4**  
   acne and 42.73  
   candidiasis and 36.58  
   dermatophytosis and 36.22  
   hair in 66.83  
   hair loss in, in animals 2.18  
   hyperpigmentation 58.24  
   pityriasis versicolor and 36.10  
   purpura 49.15  
   sarcoidosis and 61.17  
   sebaceous gland activity and 42.11  
   striae in 45.5  
 cutaneous mucosal venous malformation 18.74  
 cutaneous adenopathy complex 37.32  
 cutaneous afferent nerves 12.64  
 cutaneous field stimulation, in notalgia paraesthetica 63.23  
 cutaneous gaseous exchange 4.11  
 cutaneous Hodgkin's disease 57.63  
 cutaneous horn **52.36**, 53.13  
 cutaneous larva migrans *see* larva migrans, cutaneous  
 cutaneous leukocyte antigen (CLA) 13.4, 55.1, 76.9  
 cutaneous lupus erythematosus *see* discoid lupus erythematosus; lupus erythematosus (LE); subacute cutaneous lupus erythematosus  
 Cutaneous Lupus Erythematosus Disease Area and Severity Index 72.10  
 cutaneous lymphomas **57.1–64**  
   *see also* lymphoma(s); *specific lymphomas*  
 cutaneous microvascular occlusion *see* microvascular occlusion  
 cutaneous necrosis *see* necrosis  
 cutaneous neurofibromas 15.17  
 cutaneous porphyrias *see under* porphyria  
 Cutaneous Reactions Database 75.3  
 cutaneous sarcoidosis *see* sarcoidosis, cutaneous  
 cutaneous T-cell lymphoma (CTCL) *see under* lymphoma  
 'cutaneous' vessel network 3.50  
 cutaneous–intestinal syndrome with oropharyngeal ulceration 49.46  
 cute (pinta) 30.63–4  
*Cuterebra* 38.9  
 cuticle 3.14, 65.2  
   insects 2.2  
   marine worms 2.2  
   removers 65.56  
 cutis *see* dermis  
 cutis gyratea 18.40  
 cutis hyperelastica *see* Ehlers–Danlos syndrome  
 cutis laxa 8.21, 8.22  
   acquired 45.14, 45.16, 45.18  
   autosomal dominant 45.15  
   autosomal recessive 45.15  
   congenital 45.16  
   ear 68.18  
   elastin gene mutations 3.44  
   generalized 45.14–17  
   hereditary 45.15  
   localized abdominal wall 45.12–13  
   post-inflammatory elastolysis and 45.19–20  
   syndromes 45.15  
   X-linked (occipital horn syndrome) 3.44, 45.14, 45.15, 45.36, **45.39**  
 cutis marmorata 17.4, 28.68, 62.11  
   in infancy 49.48  
 cutis marmorata telangiectatica congenita 17.4, 18.67–8, 28.68, 49.48  
   with macrocephaly 18.68  
 cutis rhomboidalis nucae 45.26  
 cutis verticis gyratea (CVG) **15.89**, 62.39, **66.58**  
   with mental deficiency 15.89  
   prenatal diagnosis 16.7  
   retinitis pigmentosa and sensorineural deafness 15.89  
 CVID (common variable immunodeficiency) 13.13, 17.72–3, 69.117  
 CVS (chorionic villus sampling) 16.1–2  
 CX3CR1, cell–cell adhesion and leukocyte trafficking 12.48  
 CXCL chemokine/receptor family (CXCL1–15) 12.45, 12.46–7  
 CXCR2 14.3  
 CXCR4, inhibition, HIV infection treatment 35.6  
 cyanamide 75.88  
 cyanoacrylates 26.72, 65.28  
 cyanocobalamin *see* vitamin B<sub>12</sub>  
 cyanosis  
   nails in 65.15  
   neonatal peripheral 17.4  
 cyclamates 75.159  
 cyclic AMP (cAMP) 67.31  
   in atopic dermatitis 24.15–16  
 cyclic citrullinated peptide, antibodies to 13.21  
 cyclic GMP (cGMP)  
   in malakoplakia 55.27  
   in psoriasis, dithranol action 73.29  
 cyclist's nipple 70.10–11  
 cyclizine 75.149  
 cyclobutane pyrimidine dimers (CPD) 29.4, 29.5, 58.7  
 cyclocyclopaquinonimine 58.6  
 cycloclodopa 58.6  
 cyclohexanone peroxide 25.21  
 cyclohexylthiophthalimide 26.65  
 cyclooxygenases 12.60  
   COX-1 12.60  
   inhibition 49.13  
   COX-2 12.60  
   inhibition 49.13  
   lichen planus 41.15

- cyclophosphamide 13.24, 74.17–18  
adverse effects 75.125  
  hypermelanosis 58.30  
  in cicatrizing conjunctivitis 67.23  
  in dermatomyositis 51.129  
  dose range and evidence level 74.17–18  
  in microscopic polyangiitis 50.36  
  in mucous membrane pemphigoid 40.40  
  in multicentric reticulohistiocytosis 55.24  
  in pemphigus 40.12  
  in polyarteritis nodosa 50.35  
  in Wegener's granulomatosis 50.40–1
- Cyclops* 37.12, 37.13, 37.18, 37.26  
cycloserine 75.61  
cyclosporin *see* ciclosporin  
cycobemine *see* vitamin B<sub>12</sub>  
CYLD gene mutations 53.9, 53.28  
cylindroma 53.2, 53.28–9  
  benign eccrine 68.30  
  malignant 53.33–4  
  spiradenoma overlap 53.29
- Cylindrothorax melanocephala* 38.26  
cypriopterin acetate (CPA) 74.32  
  acne vulgaris treatment 42.53  
  adverse effects 66.88, 70.5, 75.120  
  in androgenetic alopecia 66.25–6  
  hair growth and 66.13  
  in hirsutism 66.87–8  
  sebaceous activity inhibition 42.15–16
- 'Cyrano nose' 18.46  
cysdopaquinone 58.6  
cyst(s) 52.45–8  
  acne vulgaris 42.18, 42.31  
  branchial (cleft) 18.85–6  
  bronchogenic (presteral ciliated) 18.87–8  
  cervical 18.85–6  
  definition 5.7  
  dental, in naevoid basal cell carcinoma syndrome 52.7  
  dermoid  
    congenital 18.88–9  
    oral cavity 69.34–5  
  epidermal, vulval 71.72  
  epidermoid ('sebaceous') *see* epidermoid ('sebaceous') cysts  
  epidermoid ('sebaceous') cysts  
  epidermoid plantar 33.47  
  epithelial (epidermoid) 52.45–6  
  eruptive vellus 53.7  
  eyelids 67.33  
  female genital 71.72, 71.73  
  in Gardner's syndrome 52.45  
  genitoperineal raphe 18.94–5  
  glands of Zeis 67.33  
  hair germ 53.6–12  
  horn 53.35  
  hydatid 37.24–5  
  keratinous 52.45  
  lateral cervical 18.85–6  
  male genital 71.35  
  marsupialized 52.46  
  median raphe 71.35  
  of Moll 67.33  
  mucinous 71.73  
  mucoid, male genitalia 71.35  
  mucous/mucous retention (mucocele) 69.22, 69.65, 69.84, 69.110  
  myxoid  
    nail 65.17, 65.36–7  
    surgery 77.36, 77.38  
  'onion-skin' 46.29  
  oral 69.107  
  parameatal 18.94–5  
  perianal/perineal 71.83, 71.87  
  phaeomycotic subcutaneous 36.77  
  pilonidal 71.87  
  preauricular 18.83–4  
  sebaceous 52.45  
    *see also* epidermoid ('sebaceous') cysts; steatocystoma multiplex  
  subepidermal keratin *see* milia  
  thyroglossal 18.86–7, 62.11  
  traumatic inclusion 52.45  
  trichilemmal *see* trichilemmal cyst  
  vulval epidermal 71.72
- cystadenoma, apocrine 53.18–19, 68.30  
cystamine 73.27  
cystatin 4.5  
5-cystdopa 58.6  
cysteinyl-dopa 58.5, 58.6  
cystic eyelids–palmo-plantar keratosis–hypodontia–hypotrichosis 15.52  
cystic fibrosis 69.116  
  of pancreas 59.59  
  skin wrinkling 28.93  
  sweat in 44.6  
  vasculitis and 50.53  
cystic hygroma 48.26–7  
  fetal 48.27  
cysticercosis 37.3, 37.24, 37.25  
cysticercosis cellulosa cutis 37.25  
*Cysticercus cellulosae* 37.25  
cystine 66.5  
cytarabine 75.129  
cytochrome P450 enzymes 72.27, 72.28–9  
  CYP2S1 and CYP26 73.35  
  CYP26A1, in sebaceous glands 42.15  
  retinoid metabolism 73.35  
cytodiagnosis 10.28–9  
cytokeratins  
  antibodies to 10.19–21  
  CK-7 10.21  
  CK-15 53.35  
  CK-20 10.20–1  
    extramammary Paget's disease 53.40  
    Merkel cells 53.31, 53.43  
cytokine antagonists 12.35, 12.43  
cytokine-directed biological therapies 74.9–11  
'cytokine storm' 74.4  
  virus-associated haemophagocytic syndrome 55.30  
cytokines 12.34–5, 17.49, 64.9  
  in acute wounds 14.5  
  antagonists 12.35, 12.43  
  assays 13.23  
  in atopic dermatitis 24.18  
  ATP2C1 gene expression down-regulation 39.33  
  brain 64.8  
  collagen gene expression control 3.39  
  ductal keratinocytes, in acne 42.24  
  inflammatory, lichen planus 41.1  
  in irritant contact dermatitis 25.5, 25.6  
  Langerhans' cell development 55.2, 55.1, 55.3  
  NF-AT mediated transcription 74.18  
  in polymorphic light eruption 29.11  
  proinflammatory  
    acne pathogenesis 42.25, 42.26  
    activation by UV radiation 8.21, 8.22  
    keratinocytes 12.15–17  
  proteoglycan binding 12.31  
  pruritus and 21.3, 21.5  
  recombinant 12.35  
  role in inflammation 12.34–5  
  sebocytes expressing 42.4–5  
  stress and 64.9  
  suppressor of cytokine signalling (Socs) protein pathway 12.35  
  suppressors and inhibitors 12.43  
  synthesized by cells of the dermis 12.76–7  
  T helper cells, acne pathogenesis 42.26  
  therapeutic 13.25  
  adverse effects 75.141–6  
  UV-induced 4.7  
  UVR-induced damage and 29.5  
  in vasculitis 50.4, 50.5, 50.6, 50.10–11  
  in wound healing 14.5  
  *see also* interleukin(s)
- cytomegalovirus (CMV) infections 33.29, 33.29–30  
  alopecia areata and 66.32  
  clinical features 33.29  
  conditions associated 33.29  
  congenital 33.29  
  diagnosis 33.29  
  disseminated 33.29  
  female genitalia 71.70  
  in HIV infection 35.28, 35.29  
  immune restoration and 35.29, 35.46, 35.47  
  HSV co-infection 35.28, 35.29  
  in immunosuppressed patients 33.29  
  intrauterine 18.2  
  isolation and detection 33.29  
  juvenile xanthogranuloma 55.15  
  mononucleosis 33.29  
  neurological complications 33.29  
  neuropathy associated 63.12  
  oral 69.75–6  
  perianal/perineal 71.95  
  perinatal and neonatal 33.29  
  reactivation  
    in GVHD 62.97  
    in HIV infection 35.29  
  retinitis 33.29  
  TORCH syndrome 33.76–7  
  transmission 33.29  
  treatment 33.29  
  vasculitis and 50.55  
cytophagocytosis 55.25  
cytosine 11.2  
cytosine arabinoside 75.129  
cytosine-phosphate-guanine (CpG) DNA sensor 12.9  
cytoskeleton of cells 3.9  
cytostatic drugs, hypermelanosis due to 58.30  
cytotoxic drugs  
  adverse effects 26.46, 70.5  
  cytophagic histiocytic panniculitis 46.24  
  isolated limb perfusion in recurrent melanoma 54.54  
  Langerhans' cell histiocytosis 55.13  
  topical 73.23–6  
    *see also* 5-fluorouracil  
    *see also* chemotherapy  
cytotoxic T cells *see* T lymphocytes, cytotoxic
- D**  
D2-40 *see* podoplanin  
Dabska's tumour 56.32–3  
dacarbazine (DTIC) 75.126  
  melanoma management 54.54  
daclizumab (anti-CD25 IL2 receptor), psoriasis in HIV infection 35.17  
dactinomycin, adverse effects 75.127  
dactylitis  
  blistering distal 30.33  
  syphilitic 34.16  
DAF (CD55) 13.3  
daffodil 25.21  
Daflon® 48.25  
Daivobet® 73.45  
*Dalbergia* 26.80–1  
DALYs (disability adjusted life years), leprosy 32.2  
danaparoid 49.28  
danazol 74.32  
  adverse effects 75.119  
  erythema multiforme 76.3, 76.4  
  in angio-oedema due to C1 esterase inhibitor deficiency 22.22  
  in gigantostasia 70.3  
  in gynaecomastia 70.5  
  prophylactic, in hereditary angio-oedema 22.22  
  in SLE 51.62  
  in urticaria 22.29  
dandruff  
  pityriasis capitis 66.56–7  
  seborrhoeic dermatitis and 23.29, 23.30  
  treatment 23.32–3  
  'walking'/'mobile' 38.49  
Dandy-Walker syndrome 69.29  
Dane particle 33.60  
Danoff syndrome 62.79  
danthron (dantron) 75.158  
danthron erythema 71.87  
dapsone 74.28, 74.45  
  adverse effects 75.63  
  in bullous systemic lupus erythematosus 40.56  
  in cicatrizing conjunctivitis 67.23  
  in cutaneous small vessel vasculitis 50.16  
  in dermatitis herpetiformis 40.62  
  in dermatomyositis 51.129  
  dose range and evidence level 74.28  
  in erythema elevatum diutinum 50.27  
  in Henoch-Schönlein purpura 50.21  
  in leprosy 32.16, 32.17  
  in linear IgA disease 40.50  
  in mucous membrane pemphigoid 40.40  
  oral, acne vulgaris treatment 42.66  
  in pemphigus foliaceus 40.16  
  in pyoderma gangrenosum 50.72  
  resistance to 32.16  
  in subcorneal pustular dermatosis 40.22  
  topical, acne vulgaris 42.43  
  in urticaria 22.29  
  in urticarial vasculitis 50.22, 50.23  
dapsone syndrome (lymphadenopathy and hepatitis) 40.62  
DARE (Database of Abstracts of Reviews of Effectiveness) 7.5  
Darier's disease 19.3, 19.81–6, 39.32, 39.33, 64.48  
  acne and 42.71  
  differential diagnosis 23.32, 40.11  
  Hailey-Hailey disease vs 39.35  
  ear 68.14  
  female genital involvement 71.66, 71.81  
  genitocrural involvement 71.5–6  
  in HIV infection 35.28  
  linear 18.24  
  male genital involvement 71.28  
  nail involvement 65.17–18, 65.27–8  
  oral involvement 69.25–6  
  related disorders 19.86–8  
  respiratory tract involvement 62.80  
  treatment 73.23, 79.4  
  retinoic acid 73.36  
Darier's sign 5.18, 21.10, 22.14  
  in urticaria pigmentosa 22.14, 22.31–2  
Darier-White disease *see* Darier's disease  
darkling beetles 38.27  
Darling's disease *see* histoplasmosis  
dart hairs 38.28  
dartoic myoma 56.54–5  
Darwin's tubercle 68.4  
Database of Abstracts of Reviews of Effectiveness 7.5  
*Datura metel* 75.160  
daunorubicin 75.127  
D-dimer 47.29  
de Barsey syndrome 45.15  
de Lange syndrome (Cornelia de Lange) 15.92, 69.38  
  hypertrichosis in 66.76  
De-Nol 75.157  
de Sanctis-Cacchione syndrome 15.73  
deafness  
  ear pits and 18.83  
  eighth-nerve, congenital syphilis 34.16  
  erythrokeratoderma with 19.71–2  
  keratodermas with 19.94, 19.98, 19.108–10  
  KID/HID syndrome 19.54–7, 19.60  
  with onychodystrophy 15.35  
death fever (visceral leishmaniasis) 37.41–3  
débridement, venous leg ulcers 47.48  
DEC *see* diethylcarbamazine  
decay-accelerating factor (CD55) 13.3  
decision making *see* clinical decisions  
deCODE 11.15  
decompression, burns 28.79–80, 28.81–2  
decongestive lymphatic therapy 48.21–4  
decorin 3.46, 14.7, 45.33

- decubitus ulcer 47.57  
 decubitus ulcers *see* pressure ulcers  
 deep-sea diving 28.55  
 deep-vein bypass 47.51  
 deep vein incompetence 47.41  
 deep-vein insufficiency 47.33  
 deep-vein obstruction 47.32  
 deep-vein thrombosis (DVT) 47.7, 47.26, 47.28–30  
   aetiology and pathogenesis 47.28  
   antiphospholipid syndrome 49.41  
   clinical features 47.28–9  
   cyproterone acetate causing 42.53  
   diagnosis 47.29  
   differential diagnosis 30.19  
   epidemiology 47.28  
   paraneoplastic 62.43  
   post-thrombotic syndrome 47.40  
   in pregnancy 8.11  
   treatment 47.29–30  
   venous ulceration and 47.42  
   *see also* venous thrombosis  
 deer flies 37.11, 38.6  
 DEET 38.5  
 defence mechanisms *see* host defence  
 defensins 3.2–3, 3.16, 3.17, 4.5, 12.5–7, 13.4, 14.5, 30.5  
    $\alpha$ -defensins 4.5, 13.4  
   deferoxamine 75.102  
   deficiency diseases 6.13  
   deformations 18.1  
 Degos' acanthoma 52.41  
 Degos' disease (malignant atrophic papulosis) 49.45–7, 50.54, 71.25  
   benign cutaneous (skin-limited) variant 49.45, 49.46  
   male genital involvement 71.25  
 Degos' syndrome 51.105  
 Degos–Touraine syndrome 45.13  
 7-dehydrocholesterol 29.6, 73.43  
 dehydrocostus lactone 26.75, 26.77  
 dehydroepiandrosterone  
   acne aetiology and 42.21, 42.35  
   in pregnancy 8.9  
 dehydroepiandrosterone sulphate (DHEAS) 42.10, 42.21  
   acne aetiology and 42.21, 42.22  
   comedogenesis and 42.23  
   hirsutism and 66.81  
 dehydrotestosterone, acne aetiology and 42.20  
 delavirdine 74.50, 75.68  
 delayed blanch phenomenon 24.15  
 delayed-type bacterial antigen tests 5.24  
 delayed-type hypersensitivity (DTH) *see* hypersensitivity, type IV (delayed-type)  
 Delhi boil (Old World cutaneous leishmaniasis) 37.34–9  
 deliberate self-harm, adolescents 8.7  
 Delleman's (Delleman–Oorthuys) syndrome (oculocerebrocutaneous syndrome) 18.37, 18.104  
 deltanoids 73.43–8  
 delusions 64.12  
   olfactory 64.16–17  
   of parasitosis 21.12, 64.13–16, 65.50, 68.16  
 demeclocycline, lichenoid eruptions due to 41.24  
 Demodex 38.52–4  
   dog infestations 2.9, 2.10  
   folliculitis  
     acne vs 42.36–7  
     rosacea vs 43.5  
     in HIV infection 35.36  
 Demodex brevis  
   eradication/treatment 43.3  
   rosacea pathogenesis 43.2–3  
 Demodex cati 2.10  
 Demodex folliculorum  
   eradication/treatment 43.3, 43.6  
   rosacea pathogenesis 43.2, 43.3, 43.5, 43.6  
 Demodex gatoi 2.10  
 demodicosis 2.10  
 demography, skin disease in old age 8.25–7  
 denaturing gradient gel electrophoresis (DGGE) 57.12  
 dendrite surveillance extension and retraction cycling habitude (dSEARCH) 3.17  
 dendrites, melanocyte, formation of 58.4  
 dendritic cells 5.1  
   antigen presentation 55.4  
   in atopic dermatitis 24.13–15  
   defensins 12.7  
   dermal 3.19, 48.6  
   epidermal modulation of function 24.14  
   follicular 13.9  
   HIV infection 35.8  
   in lymph nodes 13.9  
   lymphoid 4.8  
   migration 48.6  
   role in immune system 13.5, 13.9  
   subtypes 24.13  
   *see also* histiocytes; Langerhans' cells  
 dendrocytes  
   dermal *see* dermal dendrocytes  
   fat-storing hamartoma of 46.45  
 dengue 33.67, 33.68  
   virus serotypes 33.68  
 dengue fever (DF) 33.68, 38.5, 49.20  
 dengue haemorrhagic fever (DHF) 33.68, 49.20  
 dengue shock syndrome (DSS) 33.68, 49.20  
 denileukin diftitox 13.25  
 subcutaneous panniculitis-like T-cell lymphoma 57.33–4  
 Dennie–Morgan fold 24.24  
 dense bodies 3.51  
 dental amalgam 75.101  
   allergic contact dermatitis and 26.21, 26.39  
   lichen planus pathogenesis 41.3  
   tattoos 69.95–6  
   urticaria associated 22.11  
 dental aplasia 69.6, 69.7  
 dental care, in severe generalized dystrophic EB 39.28  
 dental caries, in dystrophic EB 39.19  
 dental cysts, in naevoid basal cell carcinoma syndrome 52.7  
 dental follicle 69.2  
 dental papilla 69.2  
 dental preparations 69.120  
 dental sinus 42.37  
 dental technicians, occupational hazards 27.19  
 dentifrice 69.119–20  
 dentine 69.2  
 dentinogenesis imperfecta 45.40, 45.41, 69.8  
 dentists, occupational hazards 27.19  
 dentition 69.2, 69.3  
   deciduous/milk 69.2, 69.3  
   examination 69.6  
   permanent/adult 69.2, 69.3  
   *see also* teeth  
 dentogingival junction 69.3  
 dentooculocutaneous syndrome 15.29  
 denture sore mouth (chronic erythematous/atrophic candidiasis) 36.60, 69.88, 69.102–4  
 dentures  
   allergic contact dermatitis and 26.21  
   hyperplasia induced by 69.109–10  
   mouth ulcers due to 69.43  
   oral changes related to 69.102–3  
   stomatitis 36.60, 69.88, 69.102–4  
 DEPA 38.5  
 dependency syndrome 48.14  
 depigmentation 58.9  
   chemical 27.15, 58.50–1  
   halo, halo naevus 54.19  
   hypermelanosis treatment 58.39  
 occupational 27.15  
   in onchocerciasis 37.5–6  
   post-inflammatory 5.16–17  
   *see also* hypopigmentation; leukoderma  
 depigmenting agents  
   cosmetic use 73.26, 73.27  
   topical 73.26–9  
 depilation 73.29  
   in hirsutism 66.85, 66.87  
 depilatories 73.29  
 depilatory creams 73.29  
 deposition disorders 51.79  
   paraneoplastic 62.44, 62.45  
 depression 64.3, 64.7, 64.47–8  
   acne and 42.35  
   isotretinoin treatment and 42.63  
   concordance with therapy and 72.6  
   isotretinoin therapy and 42.63, 64.49  
   lichen planus association 41.3  
   major 64.47–8  
   in psoriasis 64.4  
   in psychocutaneous disorders 64.15, 64.18, 64.28, 64.30  
   screening instruments 64.48  
 depressive ruminations 64.12  
 depth of burn classification 28.75, 28.76–7, 28.84–5  
 dequalinium, male genital dermatology 71.27  
 dequalinium chloride 25.12, 75.164  
 Der f1 38.47  
 Der p1 38.47  
 Dercum's disease 8.17, 46.46, 46.47–9, 48.20  
 dermabrasion  
   acne scars 42.69  
   actinic keratosis 52.32  
   congenital naevi treatment 54.14  
   post-inflammatory hypermelanosis after 58.31  
   skin flap scars 77.26  
   tattoo removal 58.59  
 Dermacentor 30.53, 30.58, 30.73, 38.34, 38.35  
 dermal-associated linear IgA disease 40.49  
 dermal collagen, hyalinization 51.114  
 dermal dendrocytes 55.3  
   fat-storing hamartoma 55.19  
   fate 55.4  
   histiocytoses involving 55.6, 55.14–22  
   juvenile xanthogranuloma 55.15–16  
   origin and development 55.3  
   phenotype 55.4  
   subepidermal 55.3  
   surface markers 55.3, 55.4  
 dermal erythropoiesis (blueberry muffin baby) 17.32–3, 49.20, 49.51  
 dermal fillers 80.4–6  
   in combination with botulinum toxin 80.7–8  
   foreign body reactions 28.46–7  
 dermal leishmanoid 37.41–2  
 dermal melanocytosis 58.36–8  
 dermal papilla 3.13, 66.3, 66.4, 66.7, 66.15  
 dermal sheath 66.4  
 dermal–epidermal basement membrane zone (BMZ) 3.25–33  
   *see also* basement membrane zone (BMZ); dermal–epidermal junction (DEJ)  
 dermal–epidermal junction  
   deposition of IgG, IgM and C3 in scleroedema 51.119  
   systemic sclerosis 51.92  
 dermal–epidermal junction (DEJ) 3.6, 3.25–33, 40.24–5  
   ageing and 80.2  
   biopsy in epidermolysis bullosa 39.24  
   ear 68.1  
   hemidesmosomes 3.30–2  
   keratinocyte proliferation, signalling 3.6  
   in lichen planus 41.4  
   mechanical function 4.8  
   melanocytes 54.1, 54.2, 54.4, 54.15, 54.18  
 molecular components 3.25–6  
   *see also* anchoring fibrils; collagen, type IV; hemidesmosome(s); laminin(s)  
   regional variations in 3.3  
   structure 3.1–2, 3.25–6  
   in wound healing 14.5  
 Dermanyssidae 38.51  
 Dermanyssus 38.51  
 derman sulphate 3.46, 4.8  
   structure 3.47  
   in wound healing 14.3  
 dermatitic potential 27.10–11  
 dermatitis  
   acral lick 2.9  
   airbag 28.14  
   allergic contact *see* allergic contact dermatitis  
   in animals 2.13–14  
   annular lichenoid, of youth 41.13  
   asteatotic 47.34  
   atopic *see* atopic dermatitis (AD)  
   atopic vs non-atopic 24.1  
   autoimmune progesterone 8.9, 8.15, 8.19, 75.119  
   berloque 26.18, 58.32  
   bush 26.75  
   canine metabolic necrolytic 2.17  
   cercarial 37.20, 37.22–3, 38.56, 38.57  
   chronic acral 23.15  
   chronic actinic *see* chronic actinic dermatitis (CAD)  
   chronic superficial (persistent) scaly 23.7–8, 57.57  
   connubial 26.18, 29.10  
   contact *see* contact dermatitis  
   contagious pustular *see* orf  
   cotton-seed 38.48  
   definition 23.1  
   discoid 64.47  
   eczematous, impetiginization 47.34  
   erosive pustular *see* erosive pustular dermatitis  
   exfoliative *see* erythroderma  
   factitial 71.56  
   fibreglass 25.17, 27.6, 28.47–8  
   flea bite, in animals 2.10  
   flee allergy 2.10  
   food-mite 38.46–7  
   frictional, of children 28.14  
   frictional sweat 28.14  
   genitocrural 71.5  
   granulomatous perioral, in children 43.12, 43.13  
   granulomatous periorificial 43.12, 43.13  
   halo 23.12–13  
   hand *see under* hand(s)  
   hearing-aid 26.17, 68.23–4  
   housewives 23.20–3, 26.15, 27.2, 27.3  
   Indian sandal 26.68  
   infantile eczematoid 68.19  
   infective 23.23–5, 47.34, 68.19  
   of (Jamaican) children associated with HTLV-1 infection 23.25  
   eczematoid 68.19  
   infra-auricular 24.23  
   interstitial granulomatous 50.52  
   intrinsic 24.1  
   irritant  
     topical acne agents causing 42.49  
     *see also* irritant contact dermatitis  
   Jacquet's 17.24  
   juvenile plantar 28.14  
   khaki 26.26, 26.66  
   lichenoid 41.5–6  
   lipstick 26.17  
   meadow 58.32  
   meadow/stripper/weedwacker 5.15, 58.32  
   moth 38.29  
   napkin (diaper) 17.22–7, 17.30, 25.16, 71.5  
   congenital syphilis vs 34.16  
   psoriasiform 17.31  
   nipple, mechanical injury 28.14

- nummular, mechanical injury 28.14  
 pachydermatous eosinophilic 24.27  
 palisaded neutrophilic and granulomatous 50.52  
 papular 23.44  
 of pregnancy 8.15  
 perianal 25.16  
 periorcular 43.11  
 corticosteroids associated 73.19  
 perioral 43.11–12  
 peristomal 25.16  
 persistent postirritant (postoccupational) 25.26  
 photoallergic, sunscreens causing 73.40  
 photocontact 75.32  
 photosensitivity 29.17  
 pigmented contact 26.26  
 pigmented cosmetic 58.35  
 pityrosporal *see* seborrhoeic dermatitis  
 pretibial pruritic papular 28.15  
 progesterone-induced, tamoxifen 74.33  
 protein contact 26.105–6, 27.5  
 recurrent granulomatous with eosinophilia *see* Well's syndrome  
 retinoid 73.27  
 rubber, male genitalia 71.17  
 sarcoid-like granulomatous 43.12, 43.13  
 schistosomal 37.21  
 seborrhoeic *see* seborrhoeic dermatitis  
 soluble oil 27.4, 27.5, 27.6  
 spectacle-frame 26.16, 26.17  
 stasis 47.34, 49.23  
 strimmer's 29.21, 58.32  
 sunscreens causing 73.40  
 superficial necrolytic (SND) 2.17, 2.20  
 systemic contact-type 75.36  
 tidemark 17.24  
 treatment, tacrolimus 73.32  
 uncinarial 37.14  
 verrucous 31.10, 36.75–6  
 wear and tear 23.20  
 cumulative irritant contact dermatitis 25.1, 25.5, 25.12–13, 25.14, 25.15  
 woodcutters' 26.77  
*see also* atopic dermatitis (AD); contact dermatitis; eczema  
 dermatitis artefacta 5.11, 46.29  
 acne excoriée and 42.70  
 ear 68.7, 68.16  
 male genital dermatology 71.15  
 dermatitis artefacta (dermatitis factitia) 64.35–42, 71.56  
*see also* factitious skin disease  
 Dermatitis Family Impact questionnaire 72.23  
 dermatitis gangrenosa infantum 30.78  
 dermatitis herpetiformis 5.14, 40.58–62, 59.59  
 aetiology 40.58  
 associated autoimmune diseases 40.61  
 cicatricial conjunctivitis 67.20  
 clinical features 40.61  
 coeliac disease and 40.58  
 defined 40.58  
 differential diagnosis 40.62  
 acne vs 42.37  
 ear 68.16  
 elderly people 8.28  
 gastrointestinal investigations. 40.60  
 immunopathology and immunogenetics 10.18, 10.19  
 iron deficiency anaemia in 62.85  
 linear IgA disease 40.45–9  
 lymphoma and 40.61  
 oral involvement 69.65, 69.68–9  
 paraneoplastic 62.46  
 pathogenesis 40.59  
 prognosis 40.61–2  
 treatment, gluten-free diet 40.61–2  
 dermatitis medicamentosa 23.11, 75.35–7  
 dermatitis palmaris sicca 23.20  
 dermatitis passivata 64.43  
 dermatitis plantaris sicca 23.26  
 dermatitis simulata 64.42–3  
 dermatitis vegetans 30.77–8, 50.89  
 dermatitis veinuse 47.34  
 dermatitis–arthritis syndrome, gonococci causing 34.27  
 dermatoarthritis, lipoid *see* multicentric reticulohistiocytosis  
*Dermatobia hominis* 38.9, 38.10  
 dermatochalasis 67.4  
 generalized 45.14–17  
 dermatoeidemiology 6.1  
 information resources 6.19  
 dermatofibroma *see* fibrous histiocytoma (FH)  
 dermatofibrosarcoma protuberans (DFSP) 56.12–14  
 diagnosis 10.23, 56.13  
 treatment 56.13, 79.13  
 dermatofibrosis, nodular, in dogs 2.17–18  
 dermatofibrosis lenticularis disseminata 18.32  
 dermatogenic enteropathy 23.27  
 dermatoglyphics 3.3  
 dermatoheliosis 45.27  
 dermatological care  
 maldistribution globally 6.16  
 need, supply and demand for 6.15–16  
*see also* health services  
 dermatological non-disease  
 male genital dermatology 71.51–2  
 perianal/perineal dermatology 71.99  
*see also* body dysmorphic disorder  
 dermatological pathomimicry 64.42  
 dermatology  
 comparative clinical 2.8–19  
*see also* animal(s)  
 definition 1.1  
 evolution of 1.1–5  
 historical bibliography 1.8–10  
 scope and patterns of work 1.5–8  
 services 1.6  
 training in 1.4  
 dermatology consultation 72.1–5  
 prognosis/bad news 72.4–5  
 psychocutaneous disorders 64.15, 64.19, 64.34–5  
 Dermatology Index of Disease Severity (DIDS) 72.8–9  
 Dermatology Life Quality Index (DLQI) 1.1, 20.41, 42.35, 64.10, 72.9, 72.14, 72.17, 72.18  
 use in adolescents 72.23  
 dermatology nurse specialist 72.26  
 dermatology research, animals, role 2.7–8  
 dermatome 63.1  
 dermatomycosis furfuracea *see* pityriasis versicolor  
 dermatomyofibroma 56.7  
 dermatomyositis 51.120–9  
 aetiology 51.120–1  
 autoantibodies 51.121  
 cytokines 51.121  
 drug-associated 51.120–1  
 immunological abnormalities 51.121  
 infections associated 51.121  
 penicillamine 51.121  
 relationship with malignancy 51.121  
 in animals 2.15–16, 2.20  
 association with other disorders 51.127  
 childhood 62.99  
 in childhood 51.126  
 clinical features 51.123–5  
 calcification 51.125  
 in Chinese 51.121, 51.124  
 'mechanic's hands' 51.125, 51.127  
 muscle symptoms 51.125  
 oesophageal diverticula 51.125  
 panniculitis 51.124  
 differential diagnosis 26.29, 26.30, 51.120, 51.127, 51.128  
 drug-induced 75.42  
 hair loss in 66.29  
 hypertrichosis and 66.78  
 incidence 51.120  
 investigation of associated malignancy 51.128  
 juvenile, acquired generalized lipodystrophy with 46.38  
 oral involvement 69.71  
 panniculitis with 46.31  
 paraneoplastic 62.36–8  
 pathology 51.122  
 muscle involvement 51.122  
 pigmentation changes 58.27  
 in pregnancy 8.12, 51.127  
 prognosis 51.128  
 respiratory tract involvement 62.82  
 treatment 51.129  
 azathioprine 74.15  
 methotrexate 74.18–19  
 protein therapeutics 74.12  
 vasculitis and 50.48  
 vs systemic sclerosis 51.128  
 dermatomyositis-like syndrome, echovirus infections 33.73  
 dermatopathia pigmentosa reticularis *see* livedo reticularis  
 dermatopathology 10.1  
 dermatopathy, in dogs 2.15  
*Dermatophagoides* *see* house-dust mite (HDM)  
 dermatophilosis, in horses 2.12  
*Dermatophilus congolensis* 2.12, 30.39  
 dermatophytes 36.18–20  
 adherence 36.20  
 anthrophilic 36.18–19  
 classification and nomenclature 36.18, 36.37  
 factors affecting infection 36.21–2  
 female genital infections 71.68–9  
 geophilic 36.18, 36.19  
 host resistance and immunology 36.21  
 identification 36.5, 36.8, 36.37, 36.38, 36.39–42, 36.43, 36.44–6  
 pathogenesis of infection 36.20–1  
 penetration 36.20–1  
 zoophilic 36.18–19  
*see also* dermatophytosis; *specific dermatophytes*  
 dermatophyte reactions 23.8–9, 23.17, 36.36–7  
 dermatophytosis 36.18–51  
 in animals 2.12–13  
 atopy and 36.21  
 Cushing's syndrome and 36.22  
 diabetes mellitus and 36.22  
 erythroderma and 23.48  
 factors affecting incidence 36.21–2  
 female genital infections 71.68–9  
 histopathology 36.22–3  
 in HIV infection 35.32–3, 35.45  
 homosexual men 35.32  
 laboratory diagnosis 36.5, 36.8, 36.37, 36.38, 36.39–42, 36.43, 36.44–6  
 malnutrition and 36.22  
 molecular diagnosis 36.9  
 pathogenesis 36.20–1  
 prevention 36.46–7  
 reinfection 36.50  
 secondary infection 36.50  
 tinea barbae 36.28–9, 36.49  
 tinea capitis (tinea tonsurans) 9.8, 36.25–8, 36.47, 36.49, 66.16, 66.35, 66.53–4, 79.4  
 tinea corporis (tinea circinata) 5.12–13, 36.23–5, 36.49  
 tinea cruris 36.33–4, 36.49–50  
 tinea faciei (tinea faciale) 36.28, 36.29–30, 36.49  
 tinea imbricata 36.24, 36.25, 36.29  
 tinea incognito 25.15, 36.35–6, 36.50  
 topical corticosteroids causing 73.18  
 tinea manuum 26.29, 36.32–3, 36.50  
 tinea pedis *see* tinea pedis  
 tinea unguium 36.34–5, 36.50  
 treatment and management 36.46–51, 73.28  
 treatment failure 36.50–1  
*see also* dermatophytes  
 dermatoscopy *see* dermatoscopy  
 dermatoses  
 acantholytic, transient and persistent 19.86–8  
 digitate 57.57  
 inflammatory, acitretin 74.36  
 intercellular IgA 40.19–22  
 methotrexate 74.20  
 neutrophilic, TNF antagonists 74.7  
 occupational *see* occupational dermatoses  
 pruritic, fleas on animals causing 2.9–10  
 subcorneal pustular 40.19–22  
 treatment, acitretin 74.36  
*see also specific dermatoses*  
 dermatosis papulosa nigra 9.11, 52.40  
 dermatosis pustulosa cruris et atrophicans 9.13  
 dermatosparaxis 45.32, 45.35–6  
*Dermestes* 38.27  
 Dermestidae 38.27  
 dermicidin 4.5  
 dermicin 36.21  
 dermis 2.2, 4.4  
 absorption through 4.4–5  
 ageing 8.22–3, 45.2, 80.1  
 anatomy 3.2  
 blood supply 4.7  
 collagen 8.22  
 corticosteroid-induced atrophy 73.17  
 degenerations 10.38  
 ear 68.1  
 embryology 3.3–5, 3.5  
 evolution 2.1–4  
 extracellular matrix 3.33–50  
 immune surveillance 3.18–19  
 macrophage 3.19  
 mechanical injury 28.5, 28.7, 28.8  
 mechanical properties 4.8  
 'pseudohemiation' of fat into 46.10  
 structure 3.34  
 synthesis of cytokines 12.21–2, 12.76–7  
 T cells 3.18–19  
 upper, hypermelanosis 58.31  
 vertebrate evolution 2.2–3  
 dermite ocre of Favre 49.17–18  
 dermo-chondro-corneal dystrophy 15.96  
 dermo-odonto-dysplasia 15.35  
 dermoepidermal junction *see* dermal-epidermal junction (DEJ)  
 Dermograft® 63.10  
 dermatographism 5.11, 21.6, 22.5  
 black 22.14  
 challenge test 22.13  
 cholinergic 22.13  
 cold urticaria and 22.16  
 delayed 22.13  
 immediate symptomatic 22.12–13, 22.14  
 male genital dermatology 71.16  
 red 22.13  
 treatment 22.14  
 white 22.14  
 dermatographometer 22.13, 22.14  
 dermoid cysts  
 congenital 18.88–9  
 oral cavity 69.34–5  
 dermolytic pemphigoid *see* epidermolysis bullosa acquisita  
 dermatoscopy 5.20, 49.2  
 melanoma vs acquired melanocytic naevi 54.19, 54.38  
 scabies 38.41  
 Spitz naevus 54.24  
 subungual haematoma 65.49  
 dermatotrichic syndrome 15.35  
 Dermovate®, pyogenic granuloma in acne 42.79  
 des-arg-bradykinin 13.4  
 descriptive studies 6.19  
 desensitization 13.26  
 in atopic dermatitis 24.31  
 to drug reactions 75.176–7  
 in urticaria 22.9  
 desert rheumatism (coccidioidomycosis) 35.34

- desert sore 47.56  
desferrioxamine 75.102  
desimipramine 75.33  
  in post-herpetic neuralgia 63.7  
desloratadine 22.29  
desmin 10.22  
desmocollins 3.22, 40.2  
  autoantibodies 40.6  
desmogleins 3.22, 40.2, 40.4  
  antibodies 40.5, 40.23  
  antidesmoglein 1 ELISA assays 40.8  
  desmoglein-3 40.5  
    gene 40.3  
    Dsg1 disruption, disorders 3.22  
    in pemphigus vulgaris 69.64  
    recombinant (DG1 and DG3) 40.8  
desmoid tumours, genetics 15.26  
Desmon's syndrome 19.62  
desmoplakin 3.11  
  and BP230 40.30  
desmoplakins-1 and 2 40.2, 40.4  
desmoplasia 10.38  
desmoplastic fibroblastoma 56.10–11  
desmosines 3.43  
desmosome junctions, splitting 40.8  
desmosomes 3.21–2  
  adhesion components 40.2  
  antibodies to 3.22  
  as autoantigens 3.22  
  components 3.22, 3.23  
  electron microscopy 3.22, 10.30  
  gene mutations 3.22, 3.23  
  in Hailey–Hailey disease 39.33  
  hemidesmosomes, dermoepidermal junction 40.25  
  immunobullous diseases 3.22, 3.23  
  intercellular adhesion 3.21–2  
  loss in pemphigus 40.15  
  ultrastructure 3.21–2  
desogestrel, acne treatment 42.53  
desquamation 3.9  
desquamation en aires 23.19  
detergent acne 42.74  
detergents  
  allergy to 26.18  
  as irritants 25.8–9, 25.20  
  in shampoos 66.96  
  skin barrier function and 25.3  
Detol 26.56  
Deuteromycota 36.2, 36.3, 36.4  
developing countries  
  burden of skin disease 6.8, 6.9–10  
  dermatological care availability 6.16  
  World Bank report on skin diseases 6.16  
development of skin 3.3–5  
  *see also* embryology  
developmental abnormalities 18.1–107  
  ears 68.3–5  
  female genital dermatology 71.56  
  male genital dermatology 71.13–14  
  perianal/perineal dermatology 71.83–4  
  umbilical dermatology 71.100  
  *see also* congenital abnormalities  
devil's pinches 49.16  
dew itch 37.14  
Dewar classification, sentinel node biopsy 54.52  
Dewar photoproducts 29.4  
dexamethasone, in acne vulgaris 42.53  
dexpanthenol 26.46  
dextran, IV I.m.w. 51.108  
DFNB29 3.25  
DFSP *see* dermatofibrosarcoma protuberans  
Dhobie itch *see* tinea cruris  
DHT *see* 5 $\alpha$ -dihydrotestosterone (DHT)  
Di-HETE 12.32  
diabetes insipidus  
  infective otitis externa and 68.26  
  in Langerhans' cell histiocytosis 55.11, 55.12  
  sarcoidosis and 61.7, 61.17  
diabetes mellitus 59.77–81  
  alopecia areata and 66.32  
  bullae 59.80–1  
  candidiasis in 36.58, 59.78  
  dermatophytosis and 36.22  
  ear involvement 68.18  
  foot care 47.58  
  foot ulcers 47.57–8, 63.8–9  
  furunculosis and 30.23  
  granuloma annulare and 60.9  
  gustatory hyperhidrosis in 44.10  
  large vessel disease 59.77–8  
  lichen planus and 41.9, 41.16  
  lipoatrophic 46.37  
  mastopathy 50.49  
  maternal 18.2  
  necrobiosis lipoidica and 60.12, 60.13, 60.15  
  neuroischaemic foot 47.57  
  neuropathic foot/ulcers 47.57, 47.58, 63.8–9  
  neuropathy 44.7, 59.78  
  non-insulin-dependent *see* diabetes mellitus, type 2  
  obesity associated 46.5, 46.7  
  oral lichen planus and 41.9  
  perforating dermatoses and 45.63  
  periodontitis and 69.18  
  peripheral arterial disease 47.2, 47.4, 47.5  
  investigations 47.3  
  polycystic ovary syndrome and 66.82  
  pruritus 21.11  
  secondary dyslipidaemias 59.92  
  shin spots 59.77  
  thick skin 45.62  
  type 1  
    insulin antibodies and lipodystrophy 46.35  
    partial lipodystrophy 46.40  
  type 2  
    flushing associated with chlorpropamide–alcohol 43.16  
    insulin resistance 46.4  
    obesity and 8.17  
    ulcers 14.1, 14.13, 47.57–8  
    venous leg ulcers 47.43  
  diabetic dermopathy 59.77–8  
  diabetic embryopathy syndrome 68.3  
  diabetic neuropathy 44.7, 59.78  
  diabetico-dermatogenic syndrome 62.67  
  diagnosis 5.1–26  
  diagnosis-related groups 5.2  
  Diagnostic and Statistical Manual of Mental Disorders (DSM) 64.11  
    body dysmorphic disorder 64.17–18  
    factitious skin disorders 64.35  
  diagnostic criteria 5.2  
  importance in epidemiology 6.4–5  
  diagnostic tests  
    evaluation 7.13, 7.13–14  
    immunological and allergic disease 13.15–26  
  dialectical behaviour therapy 64.46  
  diallyl disulphide 26.77  
  diallylglycol carbonate monomer 25.21  
  diallylphthalate 25.21  
  dialysis and related therapies  
    calcifying panniculitis with renal failure 46.16  
    dialysis-related amyloidosis 59.57  
    treatment of psoriasis 20.44  
    *see also* haemodialysis  
  Diamond's triad 62.8, 62.9  
  diamorphine  
    in dystrophic EB 39.30  
    eccrine gland secretion 44.18  
  Dianette® 42.15–16, 42.53  
  diapers *see* napkin(s)  
  *Diaptomus* 37.26  
  diarrhoea  
    in carcinoid syndrome 43.18, 43.19  
    in Langerhans' cell histiocytosis 55.11  
    management 43.19  
    napkin dermatitis and 17.24  
  diascopy 5.19  
  diastematomyelia 18.96  
diathermy  
  artefact due to 10.31  
  cutting 77.44  
  HPV-associated dysplasia/neoplasia 33.55  
  surgical *see* electrosurgery  
  unipolar/monoterminal/bipolar 77.45  
  *see also* electrosurgery  
  diazacholesterol 75.157  
  diazepam, adverse effects 70.5, 75.81  
  diazolidinyl urea 26.50, 26.51  
  diazoxide, adverse effects 75.96  
    hypertrichosis 66.79  
  dibenzoylmethanes 26.23  
  Dicer 11.7  
  dichloroacetic acid 77.48  
  2,6-dichlorobenzonitrile 27.13  
  dichlorodiphenyltrichloroethane (DDT),  
    acne associated 42.77  
  dichlorophene 26.58  
  2,4-dichlorophenoxyacetic acid 27.13  
  diclofenac  
    actinic keratosis 52.31  
    adverse effects 73.25, 75.75  
    male genital dermatology 71.27  
    topical 73.25  
  dictyocoonidia 36.4  
  Dictyoptera (cockroaches) 38.2, 38.28  
  didanosine, adverse effects 35.22  
  dideoxycytidine 75.67  
  DIDMOHS *see* DRESS syndrome  
  *Dieffenbachia* 25.21, 26.16  
  diesel oil 27.13  
  diet  
    acne vulgaris and 42.33–4  
    in allergic contact dermatitis 26.22,  
      26.32, 26.102  
    in atopic dermatitis 24.30–1  
    in dystrophic EB 39.28  
    elimination/exclusion/challenge 5.25  
    history-taking 5.5  
    risk factor for skin disease 6.13  
  dietary fatty acids, ichthyoses 19.5–6  
  neutral lipid storage disease with 19.54  
  Refsum's disease 19.46  
  Sjögren–Larsson syndrome 19.44  
  diethyl- $\beta$ -chloroethylamine 26.46  
  diethyl toluamide 25.19  
  diethylcarbamazine (DEC) 74.51  
    in loiasis 37.11–12  
    in lymphatic filariasis 37.10  
    in onchocerciasis 37.7  
  diethylpropion, adverse effects 70.5  
  dieting, lipoedema and 48.19  
  differentiated vulval intraepithelial  
    neoplasia 71.75  
  diffraction of light, colours in animals  
    and 2.5  
  diffuse and macular atrophic dermatosis  
    45.13  
  diffuse large B-cell lymphoma (PCLBCL)  
    57.47–9  
  diffuse neurofibroma 15.21  
  diffuse palmoplantar keratodermas 19.3,  
    19.94, 19.95–7  
  diflunisal 75.72  
  DiGeorge's syndrome 13.8, 17.50, 17.61–2,  
    62.12, 69.117  
  digital arteries 65.4  
  digital nerve block 65.42, 77.10  
  digital papillary adenocarcinoma,  
    aggressive 53.33  
  digital subtraction angiography 47.4  
  digitalis, adverse effects 70.5  
  digitate dermatosis *see* dermatitis, chronic  
    superficial (persistent) scaly  
  digitate dermatosis (chronic superficial  
    scaly dermatitis) 23.7–8, 57.57  
  DigiTrac 72.10  
  digoxin 75.89–90  
  dihydropteridine reductase (DHPR),  
    deficiencies 59.96  
  5 $\alpha$ -dihydrotestosterone (DHT) 42.10,  
    42.16, 66.14  
    synthesis 8.2  
dihydroxyacetone (DHA), false tanning  
  73.49  
dihydroxyanthranol *see* dithranol  
1,3-dihydroxybenzene *see* resorcinol  
1,4-dihydroxybenzene *see* hydroquinone  
1,24-dihydroxycholecalciferol *see* tacalcitol  
1,25-dihydroxycholecalciferol *see* calcitriol  
1 $\alpha$ -25 dihydroxycholecalciferol 73.43  
5-6-dihydroxyindole (DHI) 58.5, 58.6  
5-6-dihydroxyindole carboxylic acid  
  (DHICA) 58.5, 58.6  
  diiodohydroxyquin 58.28  
  Dikaryomycota 36.4  
  Dilantin *see* phenytoin  
  dilated pore 53.3  
  diloxanide furoate 37.28  
  diltiazem  
    adverse effects 45.52, 75.94–5  
    in hyperhidrosis 44.12  
  dilute Russell's viper venom time  
    (dRVVT) 49.40  
  D-dimer 47.29  
  dimethyl acetamide 25.19  
  dimethyl formamide 25.19  
  dimethyl phthalate 25.19  
  dimethylbenzanthracene (DMBA) 52.13  
  dimethylfumarate 74.29  
  dimethylglyoxime test 26.99, 27.8  
  dimethylsulphoxide 25.3, 25.7, 25.10,  
    25.19, 47.11, 75.164  
    histamine release 73.7  
    as penetration enhancers 73.7  
  dimethylthiazolidiphenyl tetrazolium  
    bromide assay 25.9  
  dimeticone 38.20, 73.14  
  dimples 69.40  
    coccygeal 63.15  
    lumbosacral 63.15  
  dinitrochlorobenzene (DNCEB) 66.37  
    contact sensitization, susceptibility in  
      polymorphic light eruption  
      29.11  
    mutagenicity 73.39  
    sensitization by 73.39  
    wart treatment 33.49  
  dinitrophenol, pigmentation due to  
    58.56–7  
  Diogenes syndrome 64.43  
  *Diospyros* 26.80  
  dioxins 75.162  
    chlorinated 27.12  
  dipeptidyl peptidase IV (DP IV) 12.50  
  diphenacyprone (diphenylcyclopropenone)  
    66.37, 75.147  
    sensitization by 73.39  
  diphenhydramine, adverse effects 22.29  
  diphenylcarbazide test 27.8  
  diphenylcyclopropenone 76.5  
  diphenylhydantoin *see* phenytoin  
  diphenylthiourea 26.26  
  diphtheria 30.36–7  
    *see also Corynebacterium diphtheriae*  
  diphtheroid organisms *see*  
    *Corynebacterium*  
  *Diphyllobothrium latum* 37.24  
  dipivefrine 26.46  
  Diplopoda (millipedes) 38.54–5  
  Diptera 38.5–11  
    *see also specific insects*  
  direct fluorescent antibody test, *Chlamydia*  
    34.30, 34.31  
  direct immunofluorescence (IMF)  
    lichen planus 41.5  
    mucous membrane pemphigoid 67.17,  
      67.19  
  Directives on Dangerous Substances  
    and Dangerous Preparations  
    26.100  
  directly observed therapy in tuberculosis  
    31.27  
  *Dirofilaria* 37.16, 37.19  
  dirofilariasis 37.19  
  dirt phobias 64.24  
  disability 6.5  
    magnitude in skin disease 6.5

- disability adjusted life years, leprosy and 32.2
- disappearing bone disease 48.27
- discoid eczema 23.7, 23.9–11, 64.47
- dry 23.10
- in elderly people 8.28, 23.10
- hands 23.10
- isotretinoin causing 42.64
- prevalence 23.3
- discoid lupus erythematosus 51.4–22
- aetiology 51.4
- Blaschko's lines 51.11
- childhood 51.14
- complement abnormalities 51.17
- differential diagnosis 51.7
- disseminated DLE (DDLE) 51.10–11
- immunocytochemistry 51.7
- immunopathology 51.5–6
- incidence and clinical features 51.8–14
- laboratory abnormalities 51.17
- neoplastic change 51.18
- pathology 51.5–7
- treatment 51.18–20
- antimalarials 51.20–1
- oral agents 51.20
- topical therapy 51.19–20
- discoid lupus erythematosus (DLE) 5.12–13, 51.4–22
- alopecia in 66.43–5
- anetoderma in 45.17
- differential diagnosis 36.29
- systemic lupus erythematosus vs 51.2
- ear involvement 68.14–15, 68.17
- eyelids 67.10
- facial, rosacea vs 43.5
- lichen planus with 41.20
- lip involvement 69.128
- oral involvement 69.65, 69.71
- race and 9.15
- see also lupus erythematosus (LE)
- disease associations, measures of 6.18
- disease co-occurrence 6.13
- disease definition 5.1–3, 6.4–5
- disease-modifying antirheumatic drugs (DMARDs) 20.59
- disfigurement, psychological impact 64.2
- disinfectants, antiseptics vs 73.14
- disodium cromoglycate 13.26
- disomy, uniparental 15.7
- disruptions 18.1
- disseminate and recurrent
- infundibulofolliculitis 9.4, 19.76, 30.28
- disseminate lenticular leukoderma 58.52
- disseminated DLE (DDLE) 51.10–11
- disseminated intravascular coagulation (DIC)
- haemorrhage 49.39
- sepsis-related purpura fulminans with 49.39–40
- disseminated lipogranulomatosis 62.100
- disseminated porokeratoses 19.90–1
- distal sensory polyneuropathy 63.12
- distal 'wing' block 65.42
- Distemonanthus benthamianus* 26.80
- distichiasis 67.4
- disulfiram 26.32, 75.88
- dithiodimorpholine 26.65
- dithranol 73.29–31
- adverse effects 25.21, 26.46, 66.94, 75.163
- in alopecia areata 66.37
- burns 27.11
- calcipotriol with 73.45
- in clobetasol propionate 20.24
- indications 73.29
- in Lassar's paste 20.23
- mechanism of action 73.29
- pastes/creams and formulations 73.30
- in psoriasis 20.22, 20.23–4
- PUVA and 20.30
- safety 73.29
- structure 73.29
- diuretics
- adverse effects 75.97–8
- erythema multiforme 76.3, 76.4
- lichenoid tissue reaction 41.24, 41.25
- vasculitis 50.17, 50.18
- lymphoedema management 48.24–5
- diving, mechanical injury 28.53–6
- Divry–van Bogaert syndrome 18.79
- DKC see dyskeratosis congenita
- DKC1 gene 58.21
- DLE see discoid lupus erythematosus (DLE)
- DLQI see Dermatology Life Quality Index
- DMDM hydantoin 26.50, 26.52
- DMSO see dimethylsulphoxide
- DNA
- amplification, normal bacterial skin flora 30.2
- as chromophore 29.4, 29.5
- complementary (cDNA) 11.4, 11.5, 11.10
- damage see DNA damage
- extraction 11.3–4
- free fetal 16.9–10
- homologous replication 2.8
- instability 15.70–7
- interaction with UVR 29.4
- LE cell factor 51.52
- lesions induced by UV radiation 13.32
- library 11.4, 11.5
- manipulation 11.3–5
- methylation 11.16
- microsatellite 11.11–12
- mitochondrial 11.3
- mutations 8.21
- non-coding (junk) 11.1, 11.2
- nuclear 11.3
- photoproducts 29.4
- prenatal diagnosis based on 16.1–3, 16.4, 16.9–10
- repair 52.14
- UV-induced damage 52.13–14
- repair defects 47.18, 52.12, 52.13–14
- immunodeficiency and 17.67–70
- in xeroderma pigmentosum 52.10
- replication, repair of photoproducts 52.14
- sensitivity to, painful bruising syndrome 49.16
- sequencing 11.6–7, 11.8
- structure 11.2–3
- synthesis, reduced by tar plus UV light 73.42
- DNA antibodies 51.54
- DNA damage
- 'molecular fingerprint' 52.13
- repair 52.14
- UV-induced damage 52.13–14
- repair defects 47.18, 52.12
- immunodeficiency and 17.67–70
- in xeroderma pigmentosum 52.10
- tanning and 58.31
- UV-induced 8.21, 29.4, 29.5, 52.13–14, 58.7
- melanin protection from 58.8, 58.10
- DNA hydration products 29.4
- DNA photoproducts 29.4
- DNA polymerases 11.6, 52.14
- DNA viruses see virus(es), DNA
- DNCB see dinitrochlorobenzene
- dobutamine 75.98
- docetaxel 75.135
- dock workers, occupational hazards 38.2
- 'doctor shoppers' 64.19
- doctor–patient relationship 72.1–2, 72.25
- psychocutaneous disorders 64.36, 64.41, 64.52–3
- documentation, burns 28.80
- dog(s)
- acanthosis nigricans 2.17
- acrodermatitis enteropathica 2.17
- allergic reactions 2.7
- alopecia 2.18
- atopic dermatitis 2.7, 2.13
- bacterial skin diseases 2.11–12
- bites from 38.60–1
- bullous pemphigoid 2.14–15
- coat colour and mutations affecting 2.6–7
- colour blindness 2.6
- Demodex mite infestation 2.9, 2.10
- demodicosis 2.10
- dermatomyositis 2.15, 2.20
- erythema multiforme 2.16
- flea allergy dermatitis (FAD) 2.10
- fungal infections 2.12–13
- lice 2.10
- lupus erythematosus 2.16
- mast cell tumours 2.22
- mechanobullous diseases 2.17
- melanomas 2.20–1
- merle pattern ('blue merle') 2.7
- neoplastic skin disease 2.19–20, 2.20–1
- nodular dermatofibrosis 2.17–18
- parasitic infections 2.9, 2.10, 2.11
- pemphigus foliaceus 2.15
- psoriasis 2.14
- sarcoptic acariasis 2.10
- skin diseases 2.9
- staphylococcal infections 2.11–12
- superficial necrolytic dermatitis 2.17
- sweating and temperature control 2.20
- vitiligo 2.23
- dog bites 38.60–1
- Dogger Bank itch 26.10, 38.58
- Dohi (keratosis follicularis squamosa) 19.76
- Dokumentationszentrum schwerer Hautreaktionen 6.6
- dolichocephaly 45.30
- domestic pets
- arthropod infestation 38.2, 38.4, 38.11–12
- bites from 38.60–1
- Cheyletiella* mites 38.4, 38.49–50
- scabies 38.46
- see also cat(s); dog(s)
- dominant alleles 15.2, 15.3–4
- dopamine, adverse effects 70.5
- Dong Ling Hou Tong Pian 76.3
- Donohue's syndrome (leprechaunism) 45.62–3, 46.37
- Donovan bodies 30.61–2, 34.37
- Donovania granulomatis* see *Calymmatobacterium granulomatis*
- donovanosis see granuloma inguinale
- DOOR syndrome 15.35
- dopachrome 58.5, 58.6
- dopachrome tautomerase 58.5, 58.6
- dopamine
- adverse effects 75.98
- restless legs syndrome and 63.24
- transport 64.13
- dopaminergic neurotransmission 47.12
- dopaquinone 58.5, 58.6
- Doppler duplex ultrasound
- arterial 47.47
- chronic venous insufficiency 47.35
- venous leg ulceration 47.47
- dorsal perforation of the prepuce 71.9
- dorsal root ganglion 63.2
- dorzalamide 26.46
- dose rate, UVR 29.1
- DOT in tuberculosis 31.27
- double-bind strategy 64.41
- Dovobet® 73.45
- Dowling–Degos disease 15.94–5, 58.21, 58.22
- female genital dermatology 71.80
- genitoural dermatology 71.7
- Dowling–Meara EB simplex 39.3, 39.6–8
- Down's syndrome 18.2, 53.25
- ageing and 45.61
- angular cheilitis and 69.38–9
- crusted scabies and 38.43
- ear defects 68.3, 68.4
- genetics 15.10–11
- macroglossia in 69.113
- oral involvement 69.119
- periodontitis 69.17, 69.18
- scrotal tongue and 69.37
- doxepin 64.23, 64.27, 64.28, 73.13, 74.32
- adverse effects 26.46, 75.164
- in mastocytosis 22.35
- in pruritus 21.17, 21.18
- in urticaria 22.29
- doxorubicin 57.26, 65.16, 75.127–8
- hypermelanosis due to 58.30
- doxycycline 74.41
- acne vulgaris treatment 42.46–7, 42.48
- adverse effects 42.50
- ocular 67.31–2
- in genital chlamydial infections 34.31
- in lymphogranuloma venereum 34.33
- in rosacea 43.6, 43.7
- in sarcoidosis 61.21
- DPCE (digital papular calcific elastosis) 45.28
- DPCP see diphenylproprone (diphenylcyclopropenone)
- dracunculiasis (dracontiasis) 37.12–13
- Dracunculus medinensis* 37.1–2, 37.3, 37.12–13
- dragon worm 37.12–13
- Draize test 25.9, 26.12
- DRESS syndrome (drug hypersensitivity) 23.47, 46.34, 75.18–19, 75.26–7, 75.83, 76.10
- in HIV infection 35.20, 35.21
- minocycline causing 42.51
- dressings 14.22–4
- alginates 14.23–4, 77.17
- antimicrobial 14.24
- burns 14.1
- collagen 14.24
- compression bandaging 14.20–1, 38.31, 38.60
- debriding 14.24
- epidermolysis bullosa management 39.28
- foams 14.24, 77.17
- following nail biopsy 65.42–3
- following surgery 7.17–18
- haemostatic 77.50
- hyaluronic acid 14.24
- hydrocolloids 14.23, 77.17
- hydrofibre 14.23
- hydrogels 14.23, 77.17
- low adherence 14.23
- multitape 77.17
- occlusive 73.4
- odour-absorbing 14.24
- pressure 77.17
- pressure ulcers 28.22–3
- saline 14.21
- selection 14.23
- self-adhesive hydrocolloid 73.4
- semipermeable films 14.23
- skin grafts 77.17, 77.20
- venous leg ulcers 47.48
- wet-to-dry 14.22
- xerogel 77.17
- drilling fluid, perforating dermatosis due to 45.64
- drinking, flushing associated 43.15
- 'drip-sign' 64.37–8
- Drosophila melanogaster*, genetics 15.1
- drosperinone, acne treatment 42.53, 42.54
- drug(s)
- acetylation 75.14
- acneiform eruptions due to 42.71–3
- chronic ulcerative panniculitis due to 46.28
- concentrations, conventions defining 73.1–2
- conditions induced by see drug reactions (ADRs) (and drug-induced conditions)
- costs of unused/unwanted 72.25
- definition 75.1
- distribution 72.27, 72.28
- eruptions due to see drug reactions (ADRs) (and drug-induced conditions)

- excretion 72.27  
5-HIAA excretion changes due to 43.19  
hydrolysis 75.14  
to improve peripheral circulation, systemic agents 74.51  
interactions **72.28–9**  
with herbal remedies 72.33  
labelling 7.27, 72.7  
lobular panniculitis with crystals after 46.17, 46.18  
metabolism 72.27, 72.28–9  
genetic factors 72.29–30  
naming 75.2  
overdosage 75.37  
oxidation 75.13–14  
pharmacodynamics 72.27–8  
pharmacogenetics 72.29–30  
photosensitizing 29.20, 29.21  
in pregnancy 72.28  
prescription errors 72.26–7  
reactions due to *see* drug reactions (ADRs) (and drug-induced conditions)  
risk–benefits 72.3–4  
routes of administration 72.27  
special manufacture 72.26  
targets, genetic polymorphism 72.29  
teratogenic 72.28, 75.11  
topical *see* topical therapy  
*see also specific drug groups*  
drug abuse  
HIV infection and 35.45–6  
lymphoedema association 48.13  
mechanical injury 28.45, 28.52–3  
venous leg ulcers and 47.47  
*see also specific drugs of abuse*  
drug eruptions with eosinophilia and systemic symptoms (DRESS) *see* DRESS syndrome  
drug history 75.168  
drug hypersensitivity syndrome *see* DRESS syndrome  
drug-induced conditions *see* drug reactions (ADRs) (and drug-induced conditions)  
drug rash with eosinophilia and systemic symptoms syndrome *see* DRESS syndrome  
drug reactions (ADRs) (and drug-induced conditions) 6.13, 75.1–177, 75.10  
acanthosis nigricans 19.120  
acne/acneiform eruptions 9.5, 42.71–3, 75.34  
acute generalized exanthematous pustulosis 75.34–5  
affecting eyes 67.31–2  
allergic contact dermatitis 26.13, 26.18, 26.22, 26.43–7  
anaphylactoid 75.12, 75.25–6  
anaphylaxis 24.23, 75.5, 75.8, 75.16–17, 75.17, 75.25–6, 75.48–9  
angio-oedema 75.26  
in animals 2.17  
annular erythema 75.23–4  
antibody-mediated (type II) 75.17  
aquagenic pruritus 21.11  
assessment criteria 75.2  
in atopic dermatitis 24.23  
bullous 75.37–40  
bullous pemphigoid 40.32–3, 75.38  
and associated diseases 40.32–3  
cell-mediated (type IV) 75.17–21  
challenge tests 75.175  
cheilitis 69.121  
chromosomal damage 75.15  
chronic ulcerative panniculitis due to 46.28  
in cicatrizing conjunctivitis treatment 67.22  
classification 75.9  
clinical trials and 75.2  
costs of 75.2  
co-trimoxazole, photosensitive eruption 57.53  
cutaneous 75.7–9, 75.17–18  
amino penicillins 74.40  
definition 75.1–2  
dermatomyositis 75.42  
diagnosis 75.167–75  
differential diagnosis 26.29  
disease exacerbation 75.12  
DRESS syndrome 23.47, 75.18–19, 75.26–7, 76.10  
drug elimination 75.168  
drug history 75.168  
due to human error 75.2  
ear involvement 68.18  
eczematous 23.11, 75.35–7  
effects on spermatogenesis 75.11  
elderly patients 75.6  
eosinophilia–myalgia syndrome 75.43  
epidermolysis bullosa acquisita 75.40  
eruptions  
pityriasis rosea vs 33.80  
secondary syphilis vs 34.11, 34.12  
erythema multiforme 76.3, 76.4  
erythema nodosum 50.83–4, 75.43–4  
erythroderma 23.47, 75.24–5  
erythromelalgia 75.44–5  
exanthematous (maculopapular) 75.22–3  
facultative 75.10  
female genital involvement 71.66  
fixed eruptions 75.20, 75.28–30  
in animals 2.17  
female genital region 71.66  
histopathology 75.21  
HIV infection 35.21, 35.22  
hyperpigmentation 58.30, 58.31  
incidence 75.8  
perianal/perineal region 71.91  
flushing 43.15–16  
genetic mechanisms 76.10–11  
hair discoloration 66.94, 75.45  
hair loss 66.29–30, 75.45  
hirsutism 75.45  
histopathology 75.21–2  
in HIV infection 35.20–4, 75.6–7  
in children 35.45  
HLA associations 75.14–15  
hypermelanosis 58.29–30  
hyperpigmentation 75.28, 75.32–3, 75.52–3  
hypertrichosis 66.79, 75.45  
hypopigmentation 75.33  
ichthyosis 19.63–4  
idiopathic thrombocytopenic purpura (ITP) 49.9  
idiosyncratic 75.12–13  
IgE-dependent (type I) 75.16–17  
immune complex-mediated (type III) 75.17  
immunological 75.15–21  
in immunosuppression 75.6–7  
incidence 75.3–9  
in infancy and childhood 75.6  
interactions 75.10–11  
intolerance 75.12–13  
lichenoid eruptions 41.23–5, 75.19–20, 75.30  
histopathology 75.21  
linear IgA disease 40.49, 75.39–40, 76.7  
lipodystrophy 35.22  
*see also* lipodystrophy  
livedo 49.21  
localized lipoatrophy 46.34–5  
lupus erythematosus-like syndrome 75.20, 75.41–2  
male genital dermatology 71.27–8  
mechanisms 35.22, 75.9–21  
metabolic 75.11  
mortality due to 75.2, 75.5  
mycophenolate mofetil causing 20.42, 74.24  
nail changes 65.16, 65.38–9, 75.46  
non-immunological 75.10–15  
ocular complications 67.31–2  
ocular drugs 67.15, 67.16  
oral 69.83, 69.97, 69.116, 75.46–7  
in HIV infection 35.44  
overdosage manifestations 75.10  
pemphigoid 67.20  
perianal/perineal 71.91  
photosensitivity 29.20–2, 75.30–2, 75.52  
pigmentation 58.55–7  
pigmented purpuric dermatoses 49.23  
pityriasis rosea 33.79, 33.80, 75.24  
platelet function disorders 49.12–13  
pseudolymphoma 57.53–4, 75.27, 75.44  
psoriasisiform eruptions 75.24  
purpura 49.9, 49.11, 49.21, 75.23  
pustular 50.62, 75.34  
reporting 5.2–3, 75.2, 75.3–4  
risk of 75.6–7  
scleroderma/scleroderma-like 45.52, 75.42–3  
serum sickness-like syndrome 22.18  
skin testing 75.168–73  
sources of data 7.7, 7.8  
Stevens–Johnson syndrome 76.4, 76.11–12  
sulphonamides 74.38–9  
Sweet’s syndrome 50.74, 50.75  
teratogenesis 72.28, 75.11  
thrombocytopenia 49.9, 49.11  
toxic epidermal necrolysis 76.12–15  
toxicity  
cumulative 75.10  
delayed 75.10  
treatment 75.175–7  
urticaria 22.8, 22.10, 75.16–17, 75.17, 75.25, 75.26  
vasculitis 49.21, 50.17–19, 50.49, 75.17, 75.40–1  
drug transporters 72.29  
drusen 45.22  
dry cleaning solvents, scleroderma-like lesions 51.80  
dry eyes *see* eye(s), dry  
dry skin  
in atopic dermatitis 24.22  
in the elderly 4.11  
in old age 8.27  
dry zone mahogany 26.81  
drying pastes 73.2  
DSAP1 gene 52.35  
DSAP2 gene 52.35  
dSEARCH 3.17  
DTIC *see* dacarbazine  
Duane’s retraction syndrome 68.4  
Dubovitz syndrome 15.36  
duck-hunter’s itch *see* larva migrans, cutaneous  
Ducrey’s disease *see* chancroid  
duct ectasia/periductal mastitis complex 70.8  
‘Dudley nose’ 2.23  
Dufouriellus ater 38.25  
Dühring–Brocq disease *see* dermatitis herpetiformis  
duloxetine 64.51  
dum-dum fever (visceral leishmaniasis) **37.41–3**  
Dundee Experimental Bald Rat (DEBR) 2.18, 66.33, 73.32  
Duplex ultrasound scanning 47.4  
Dupuytren’s disease/contracture (palmar fibromatosis) 45.45–6, **56.11**  
dusting powders 73.2  
dutasteride, in androgenetic alopecia 66.24, 66.25  
DVT *see* deep-vein thrombosis  
dwarfism *see* short stature  
DX-88 22.22  
Dyera costulata (jelutong) 26.79, 26.80  
dyers, occupational hazards 27.19  
dyes  
anthraquinone 26.65–6  
azo 26.60, 26.61, 26.65–6  
disperse 26.65–6, 26.67  
eyebrows and eyelashes 26.60  
hair 66.96–8  
allergic contact dermatitis and 26.10, 26.17, 26.60–2  
depigmentation and 26.26  
open patch testing 26.97  
topical therapeutic 73.48  
dynamic psychotherapies 64.53–4  
dynein, melanosome transfer along melanocyte dendrites 58.4  
dynorphins 21.4  
dysaesthesia  
in HIV infection 63.12  
male genitalia 71.51–2  
in peripheral neuropathy 63.11  
scalp 63.23  
dysaesthetic vulvodynia 71.82  
dyschondroplasia with haemangioma *see* Maffucci’s syndrome  
dyschromatosis symmetrica hereditaria **15.95**, 58.21–2  
dyschromatosis universalis hereditaria **15.95**  
dysecdysis 2.9  
dysencephalic syndrome of François (Haller–Streiff syndrome) 15.41, **18.81–2**, 45.8  
dysfibrinogenaemia, acquired 49.33  
dyshidrosis in syringomyelia 63.14  
dyskeratoma, warty, subungual 65.18  
dyskeratosis 10.39  
genital papular acantholytic, female genitalia 71.81  
pagetoid, male genitalia 71.46  
dyskeratosis congenita (DKC) **15.78–80**, 59.48, 62.28–9, 62.95  
genetics 15.36–7  
immunodeficiency 13.13  
oral involvement 69.24  
pigmentation 58.20–1  
dyslipidaemias 59.83–94  
cerebrotendinous xanthomatosis 59.91  
combined 59.84, 59.88–90  
drug-associated 59.92  
familial hypercholesterolaemia 59.86–8  
insulin resistance 59.92  
lipodystrophy-associated 59.92  
primary 59.86–92  
secondary 59.92–3  
sitosterolaemia 59.91  
Tangier disease 59.91  
treatment 59.93–4  
working classification 59.84  
*see also* hyperlipoproteinaemias  
dysmorpohobia *see* body dysmorphic disorder  
dysostosis multiplex 59.31  
dysplasia 10.39  
dysplastic naevi *see* naevus, atypical/dysplastic  
dysplastic naevus syndrome (familial melanoma syndrome) 54.28, 62.20, 62.21–2  
dysproteinaemia 49.7  
purpura in 49.19–20  
dysthymia 64.48  
dystrophia bullosa hereditaria 58.20  
dystrophic epidermolysis bullosa *see* epidermolysis bullosa (EB), dystrophic  
**E**  
E-selectin, deficiency 13.9  
EAC *see* erythema annulare centrifugum  
ear(s) **68.1–35**  
acne 68.14  
in acromegaly 68.18  
in Addison’s disease 68.18  
ageing changes 68.5–6  
in alkaptonuria 68.18  
allergic contact dermatitis 26.17, 68.14  
altitude injury 68.11  
in amyloidosis 68.15  
anatomy and physiology 68.1–2  
angiolympoid hyperplasia with eosinophilia 68.15–16  
asteatotic eczema 68.14  
atopic dermatitis 68.14, 68.23

- avulsion 68.7  
 bacillary angiomatosis 68.28  
 bacterial flora 6.2, 30.4  
 basal cell carcinoma 68.32–3, 79.9, 79.10, 79.17  
 bat 68.4  
   in Bazex syndrome 68.18  
 benign tumours 68.28–30  
 bullous diseases 68.16  
   calcium deposition 68.18  
   cauliflower 68.6  
   cold injury 62.99, 62.102, 68.5, 68.8, 68.10  
   collagen vascular diseases 68.17  
   contact dermatitis 68.23  
   contusion 68.6–7  
   cryptococcosis 68.28  
   cutis laxa 68.18  
   Darier's disease 68.14  
   delusions of parasitosis and 68.16  
   dermatitis artefacta 68.7, 68.16  
   developmental defects 68.3–5  
   in diabetes mellitus 68.18  
   drug-related disorders 68.18  
   elastotic nodules 45.28  
   elephantiasis 68.16, 68.24  
   examination 68.3  
   foreign bodies 68.11  
   fungal infection 36.7–8, 36.17, 68.20, 68.21, 68.27–8  
     investigation 36.6  
   furunculosis 68.19, 68.27  
   gouty tophi 68.17  
   granuloma annulare 60.7, 68.15  
   granuloma faciale 68.16  
   granulomatous disorders 68.17, 68.20  
   haematoma 68.6–7  
   hairy 66.13, 68.1, 68.2, 68.5, 68.18, 68.21  
     genetics 15.4  
   herpes simplex 68.20, 68.28  
   herpes zoster 68.20, 68.28  
   in HIV infection 68.28  
   hot-weather 68.2, 68.21  
   hypertrophy of retro-auricular folds 68.18  
   infection 68.18–28  
   irritant contact dermatitis 68.14  
   Jessner's benign lymphocytic infiltration 68.15  
   laceration 68.7  
   Langerhans' cell histiocytosis (LCH) 55.11  
   large 68.4  
   length 68.6  
   leprosy 68.17, 68.20  
   lichen planus 68.15  
   lichen simplex 68.23  
   lop 6.2  
   low-set 68.4  
   in lupus erythematosus 68.14–15, 68.17  
   in lupus vulgaris 68.17, 68.20  
   in lymphocytoma cutis 68.15  
   lymphoedema 48.12, 48.16  
   malignant tumours 68.18, 68.28, 68.30–4  
   molluscum contagiosum 68.28  
   Mozart's 68.4  
   mudi-chood 68.16  
   *Mycobacterium marinum* infection 68.17, 68.20  
   Page's disease 68.30  
   peri-auricular anomalies 68.4  
   petrified 68.18, 68.35  
   piercing 68.7–9  
     complications 26.17, 61.23, 68.7–8  
   pityriasis versicolor 68.20  
   porphyria cutanea tarda 68.17–18  
   pre-malignant lesions 68.30  
   pseudocyst 68.13–14  
   psoriasis 68.14, 68.23  
   purpura 49.4, 68.18  
   pyoderma gangrenosum 68.17  
   radiation injury 68.11  
   radiotherapy 79.9, 79.10  
   railroad track abnormality 68.4–5  
   referred pain 68.35  
   in relapsing polychondritis 45.42, 45.43  
   sarcoidosis 61.9, 68.17  
   scrofuloderma 68.20  
   seborrhoeic dermatitis 68.14, 68.23, 68.28  
   self-healing epitheliomas 52.9  
   in SLE 51.46–7, 68.17  
   small 68.4  
   solar damage 68.10–11  
   swelling (otophyma) 43.9  
   swimmer's 68.21  
   syphilis 68.20  
   transepithelial elimination disorders 68.14  
   trauma 68.6–14  
     turkey 61.9  
     verruciform xanthoma 68.16  
     wedge excision 77.35  
     Wildemuth's 68.4  
     xanthogranuloma 68.16  
     xanthoma 68.17  
     see also external auditory canal/meatus; pinna  
 ear pits 18.83–4, 68.4  
 ear tag (accessory tragus) 18.84–5, 68.4  
 earlobe  
   pendulous 68.18  
   skin crease 68.6  
   split 77.36  
 earplugs, allergic contact dermatitis due to 26.17  
 earrings  
   allergic contact dermatitis due to 26.17  
   embedded 68.7, 68.8  
   sensitization to 68.7–8  
 East Indian ebony 26.80  
 East Indian rosewood 26.80  
 Eastern equine encephalitis virus 33.66, 33.67  
 easy bruising syndrome 49.15–16  
 eating disorders 21.16, 64.21–2  
   hypertrichosis in 66.78  
   obesity and 46.6  
   oral manifestations 69.115  
   see also anorexia nervosa  
 EB see epidermolysis bullosa (EB)  
 EBA see epidermolysis bullosa acquisita (EBA)  
 Ebenaceae 26.80  
 EBM see evidence-based medicine  
 Ebola virus/disease 33.67, 33.69–70  
 EBV see Epstein-Barr virus  
 EBV-associated post-transplant lymphoproliferative disorder (PTLD) 57.51  
 EBV-positive angiocentric lymphoma 57.40–1  
 EBV receptor see complement receptors, CR2 (CD21)  
 ecchymoses/bruising 49.1, 62.90  
   aetiology 49.3  
   definition 5.7, 49.2  
   easy bruising syndrome 49.15–16  
   factitious 64.38  
   large, causes 49.7  
   non-thrombocytopenic vascular causes 49.14–21  
   pigments and colour changes 49.2  
   size of lesions 49.4  
   syndrome of painful 64.33–4  
   trauma causing 49.14, 49.16  
   see also purpura  
 eccrine carcinoma, eyelids 67.36  
 eccrine hidradenitis, neutrophilic see neutrophilic eccrine hidradenitis  
 eccrine sweat glands 3.1, 3.12–13, 44.1, 44.2, 53.1  
   in adolescence 8.7  
   ageing and 8.24  
   anatomy and physiology 44.3–4, 44.5  
   assessment of functioning 44.4, 44.5  
   carcinoma 53.32, 53.32–3, 53.33–7  
     syringoid 53.36  
   coma-induced necrosis 44.18  
   control of activity 44.5–7  
   dermal duct tumour 53.22, 53.24  
   development 3.5  
   disorders 44.7–16  
     with abnormal histology 44.16–17  
     with cellular inclusions 44.18  
   drug concentration and secretion 44.17–18  
   duct (excretory) 3.12, 44.4, 53.1  
     dilatation 53.22  
     tumours 53.23  
   duct-blocking agents 44.11  
   epithelioma 53.36  
   hidradenoma 53.22  
     malignant 53.34  
   hidroacanthoma simplex 53.22–3  
   hidrocystoma 53.22  
   innervation 44.5–6  
   intraepidermal sweat unit 44.4  
   isolation of 44.4  
   neonatal 17.2  
   papillary adenoma 53.26–7  
   poroid hidradenoma 53.24  
   poroma 53.22, 53.23–4  
     intra-dermal 53.22–3  
     malignant 53.32–3  
   in pregnancy 8.10  
   radiation-induced damage 44.18  
   secretory coil 3.12, 44.3, 44.4  
   sites and number 3.12  
   spiradenoma 53.29–30  
     malignant 53.30, 53.34  
   structure 3.2, 3.12  
   syringofibroadenoma 53.22, 53.24–5  
   syringofibroadenomatous hyperplasia 53.24  
   thermoregulation 3.3  
   tumours 53.2, 53.22–7  
     apocrine differentiation and 53.27  
     malignant 53.22  
     see also eccrine sweat glands, carcinoma  
 ECG see electrocardiogram (ECG)  
 Echelle de Cotation des Lésions d'Acne 72.10  
 Echelle d'Evaluation Cliniques des Cicatrices d'Acne 72.10  
*Echiichthys vipera* 38.59  
*Echinacea* 75.162  
 echinocandins 74.48  
 echinococcosis 37.1, 37.3, 37.24–5  
 Echinoidea (sea urchins) 61.22  
 echoviruses 33.73, 69.118  
 eclabion 17.20  
 ECM (erythema chronicum migrans) see erythema migrans  
 econazole  
   in candidiasis 36.68  
   in dermatophytosis 36.47, 36.48  
   in *Scopulariopsis brevicaulis* infection 36.54  
   in tinea nigra 36.15  
   topical 73.12  
 economic burden of disease 72.14  
 ECP (eosinophil cationic protein) 13.5, 13.16  
 ecstasy pimples 28.53  
 ectasizing endocapillaritis 49.22  
 ethyma 30.17  
 ethyma contagiosum see orf  
 ethyma gangrenosum 30.49, 49.34–5  
   in HIV infection 35.25  
   male genital involvement 71.30  
   neonatal 17.45  
   perianal/perineal involvement 71.92  
 ectoderm 2.2  
 ectodermal defect with skeletal abnormalities 15.37  
 ectodermal dysplasia  
   adrenal cyst with 15.38  
   anhidrotic (X-linked hypohidrotic) 13.13, 17.81–2, 44.13  
   autosomal recessive 69.10  
   classification 15.27–8, 15.57  
   dental involvement 69.10–12  
   with distinctive facies and preaxial polydactyly 15.38  
   with ectrodactyly and macular dystrophy 15.38  
   gap junction protein defects 15.67–70  
   genetics 15.27–70  
   hidrotic see Clouston's syndrome (hidrotic ectodermal dysplasia)  
   hypermelanosis 58.19  
   with hypodontia and taurodontism 69.10  
   hypohidrotic 66.60  
     prenatal diagnosis 16.7  
   with mental retardation and syndactyly 15.37  
   mutations in TNF-like/NF-kB signalling pathways 15.57–61  
   with natal teeth 15.37  
   and neurosensory deafness 15.47  
   with palatal paralysis 15.37  
   pure hair and nail type 15.38  
   with severe mental retardation 15.37  
   and skin fragility syndrome 15.46  
   with syndactyly 15.38  
   with syndactyly and cleft lip/palate 66.52  
   syndrome with tetramelic deficiencies 15.38  
   TP63-related phenotypes 15.61–5  
   X-linked hypohidrotic 69.10  
 ectodermal dysplasia–ectrodactyly–macular dystrophy (EEM) 3.24  
 ectodermal dysplasia–skin fragility syndrome, preimplantation diagnosis 16.7  
 ectodysplasin signalling pathway 66.11  
 ectoparasite infections  
   animal infestations 2.9–11  
     treatment 2.9  
   elderly people 8.29  
 ectoparasites 37.1  
 ectopic ACTH syndrome 62.3, 62.33  
   pigmentation 58.25  
 ectopic CRH syndrome 62.3  
 ectrodactyly, with anonychia 65.18  
 ectrodactyly, ectodermal dysplasia, clefting (EEC) syndrome 15.28, 15.38, 15.63–4  
 ectrodactyly–ectodermal dysplasia 15.39  
 ectropion 67.4  
   collodion baby 17.20  
   following skin grafting 77.20  
   following surgery 77.3, 77.5  
 ecilizumab 49.30  
 eczema 23.1–39  
   acute 23.2, 23.3–4, 23.37–8  
   apron 23.15  
   asteatotic see asteatotic eczema (eczema craquelé)  
   atopic see atopic dermatitis (AD)  
   autosensitization 47.34  
   chronic 23.2, 23.4, 23.38  
   chronic infective, adult T-cell leukaemia–lymphoma 33.64  
   in chronic venous insufficiency 47.34  
   classification 23.1–2  
   definition 23.1  
   diagnostic tests 23.36–7  
   discoïd see discoïd eczema  
   drug-induced 23.11, 75.35–7  
   dry palmar see wear and tear dermatitis  
   dyshidrotic see pompholyx  
   in elderly people 8.28, 23.10  
   endogenous contact 75.36  
   endogenous 23.1, 23.2, 23.3  
   erythroderma and 23.47  
   exogenous 23.1, 23.2  
   eyelid 23.11  
   fat 23.16  
   female genital involvement 71.52, 71.58, 71.68  
   fingertip 23.15–16  
   forefoot 23.26  
   genetics 15.12  
   genitocrural 71.5

- gravitational *see* eczema, venous gut 23.16  
hand *see under* hand(s)  
histopathology 23.3–5  
hyper-IgE syndrome and 23.27  
hyperkeratotic palmar 23.16, 26.29  
hypogammaglobulinaemia and 23.27  
hypopigmentation after 58.51  
hypostatic (venous) 47.34  
infected 23.23, 23.24, 23.25  
infective *see* dermatitis, infective  
malabsorption and 23.27  
male genital involvement 71.16  
management 23.36–9  
microbial *see* dermatitis, infective  
neonatal 17.22–31  
nummular *see* discoid eczema  
patchy vesiculosquamous 23.16  
pathogenesis 23.5  
pellagra and 23.27  
perianal/perineal involvement 71.86  
perioral/lick 23.3, 24.22, 24.23  
phenylketonuria and 23.27  
photosensitive 29.17  
post-traumatic 23.28–9  
prevalence 23.3  
ring 23.19–20  
seborrhoeic *see* seborrhoeic dermatitis  
secondary dissemination 23.5–6  
slaughterhouse 23.16  
stasis *see* eczema, venous  
subacute 23.4, 23.38  
terminology 24.1–2  
treatment  
  corticosteroids and antimicrobial agents 73.20  
  wood tars 73.42  
tylotic 23.16, 26.29  
umbilical 71.101  
unclassified 23.2  
varicose 26.19  
  differential diagnosis 26.29  
venous (gravitational) 23.35–6, 26.21, 26.44  
  in elderly people 8.28  
venous disturbances causing 47.34  
venous leg ulcers 47.45  
vesicular of palms and soles 26.32  
  occupational 27.4, 27.5  
winter 8.27  
  *see also* asteatotic eczema (eczema craquelé)  
  *see also* dermatitis  
Eczema Area and Severity Index 72.10  
eczema craquelé *see* asteatotic eczema (eczema craquelé)  
eczema herpeticum 24.24, 33.35–7, 69.72–3  
  aetiology 33.35  
  clinical features 33.35  
  cowpox infection vs 33.7  
  diagnosis and treatment 33.35–6  
  herpes simplex recurrence 33.18  
  recurrence 33.35  
eczema marginé/marginatum of Hebra *see* tinea cruris  
Eczema Severity Score 72.14  
eczema vaccinatum 33.6, 33.35  
eczematide-like purpura of Doucas and Kapetanakis 49.22, 49.24–5  
EDA gene 15.58  
edicol ponceau 44.4  
EDS *see* Ehlers–Danlos syndrome  
EDTA 26.17, 26.58  
Edwards' syndrome (trisomy 18) 15.11  
*Edwardsiella lineata* 38.56  
EDXA (electron dispersive X-ray analysis) 28.42  
EEC syndrome  
  ear defects 68.3  
  prenatal diagnosis 16.3, 16.7  
EEC syndrome (ectrodactyly, ectodermal dysplasia, clefting) 15.28, 15.38, 15.63–4  
EED (erythema elevatum diutinum) 50.25–7, 50.62, 62.51  
EELS (electron energy loss spectroscopy) 28.42  
efalizumab 13.25, 72.14, 74.9, 75.146  
  in granuloma annulare 60.11  
efavirenz 74.50, 75.68  
  photosensitivity due to 35.22  
eflornithine 66.89  
eflornithine hydrochloride 73.29  
Ehlers–Danlos syndrome 3.27, 3.35, 45.31–9  
  aetiology 45.32  
  associated syndromes 45.37  
  autosomal dominant, collagen type V mutations 3.35  
  bone and joint involvement 62.100, 62.104  
  capillary fragility 49.5  
  clinical and molecular subtypes 45.32  
  clinical features 45.32  
  definition 45.32  
  diagnosis 45.37  
  differential diagnosis 45.16  
  genetics 15.5  
  mechanical injury 28.2, 28.8, 28.38  
  molecular defects 3.35  
  pathology 45.32–3  
  pregnancy in 8.12, 45.34  
  prenatal diagnosis 16.3  
  progeroid 45.32, 45.36  
  purpura due to 49.14, 49.15  
  tenascin-X-deficient 45.32, 45.37  
  treatment 45.37  
  type I (gravis/classical) 45.32, 45.33–4  
  type II (mitis/classical) 45.32, 45.33–4  
  type III (hypermobility) 45.32, 45.34  
  type IV (vascular) 45.32, 45.34–5, 45.37  
  type V (X-linked) 45.32, 45.35  
  type VI (kyphoscoliosis/ocular-scoliotic) 45.32, 45.35  
  type VIIA (arthrochalasia) 45.32, 45.35  
  type VIIB (dermatosparaxis) 45.32, 45.35–6  
  type VIII (periodontitis) 45.32, 45.36, 69.17, 69.18  
  type IX (occipital horn syndrome) 3.44, 45.14, 45.15, 45.36, 45.39  
  type X (fibronectin-deficiency) 45.32, 45.36  
  vascular type, collagen type III mutations 3.35  
ehrlichiosis 30.58–9, 38.35  
eighth-nerve deafness, congenital syphilis 34.16  
*Eikenella corrodens* 30.59  
  male genital infection 71.34  
Ekbohm's syndrome 64.52  
ELAM-1 49.22  
elastases 3.44, 13.4, 50.10  
elastic fibres 3.2, 3.33, 3.42–5  
  ageing effects 8.22–3, 45.2, 80.1, 80.2  
  biosynthesis in fibroblasts 3.49  
  components 3.42  
  *see also* elastin; elastin-associated microfibrils  
  disorders 45.14–31  
  effects of corticosteroids on 45.4  
  in Ehlers–Danlos syndrome 45.32  
  functions 45.14  
  mechanical properties of skin and 4.8  
  in striae 45.5  
elastic microfibrils 3.2  
  *see also* elastin-associated microfibrils  
elastic stockings  
  sclerosing panniculitis (lipodermatosclerosis) 46.30–1  
  venous leg ulcers 47.47–8, 47.51  
  *see also* compression stockings  
elastic wave propagation, mechanical injury 28.5  
elasticity of skin 45.14  
elastin 3.2, 3.42, 3.43–4  
  ageing and 8.22, 45.2, 80.1, 80.2  
  cross-linking 3.43–4  
  in cutis laxa 45.14, 45.15  
  in elastosis perforans serpiginosa 45.65  
facial skin 45.2  
  formation 3.43–4  
  gene 3.44  
  metabolic turnover and degradation 3.44  
  mRNA and alternative splicing 3.44  
  in wound healing 14.8  
elastin-associated microfibrils 3.2, 3.42, 3.44–5  
  formation 3.45  
  function and as scaffold 3.42  
  proteins 3.44–5  
elastoderma 45.29–30  
elastofibroma 45.29, 56.8–9  
elastolysis  
  generalized *see* cutis laxa  
  idiopathic mid-dermal 45.19  
  with granuloma annulare 60.7  
  localized 45.17–20  
  perifollicular 45.20  
  post-inflammatory 45.16, 45.19–20  
  upper dermal 45.19  
elastoma 18.33  
  juvenile 18.32–3  
  perforating *see* elastosis perforans serpiginosa  
elastorrhexis  
  generalized (generalized cutis laxa) 45.14–17  
  papular 18.33, 45.68  
elastosis 8.27  
  actinic/solar 8.22, 45.26–8  
  ear 68.10  
  digital papular calcific 45.28  
  late onset focal dermal 45.26  
  linear focal 45.25–6  
  perforating calcific 45.24–5  
elastosis colloidalis conglomerata *see* colloid milium (pseudomilium)  
elastosis perforans serpiginosa 19.89, 45.63, 45.65–6  
  ear involvement 68.14  
  in Ehlers–Danlos syndrome 45.35  
  genetics 15.10  
  elastotic degeneration 10.38  
elaunin fibres 3.42  
elderly people 8.21–8.29  
  abuse 28.91–2  
  acne with solar comedones 42.79  
  adverse drug reactions 75.6  
  basal cell carcinoma 8.28  
  bullous disorders 8.28  
  clothing lice 8.29  
  cutaneous atrophy 45.2  
  Diogenes syndrome 64.43  
  discoid eczema 23.10  
  drug responses 72.28  
  dry skin 4.11  
  eccrine glands 8.24  
  ectoparasite infections 8.29  
  eczema 8.28  
  greying of hair 8.23  
  hair follicles 8.23–4  
  immune system 13.15  
  leg ulcers 8.28  
  malignant melanoma 8.28–9  
  nails 61.7  
  normal bacterial skin flora 30.4  
  pigmentation changes 8.23  
  post-herpetic neuralgia 8.28  
  pruritus 8.27, 21.12, 21.17  
  psoriasis 8.28  
  purpura of lower leg 49.17  
  scabies 8.29, 38.40  
  sebaceous and apocrine glands 8.24  
  skin cancer 8.28–9  
  skin disease 8.25–7  
  causes/risk factors 8.26  
  epidemiology 8.25, 8.26  
  skin senescence 8.21  
  topical therapy, absorption 73.4  
  wound healing 14.2, 14.9, 14.17–18  
  zoster 8.28, 33.25, 33.26, 33.28  
  *see also* ageing; *specific conditions*  
elective lymph node dissection (ELND), melanoma 54.51  
*Electra pilosa* 38.58  
electrical burns 28.33, 28.75, 28.88–90  
  child abuse 28.90  
  first aid 28.75  
  torture injuries 28.33  
electricians, occupational hazards 27.19  
electrocardiogram (ECG)  
  abnormalities, pimozone therapy 64.16  
  complications following neonatal monitoring 17.14  
  sarcoidosis 61.7, 61.20  
electrocautery 77.44–5  
  *see also* electrocautery  
electrochemotherapy 77.49  
electrocoagulation, wart treatment 33.49  
electrodesiccation 77.44, 77.45–6  
electrofulguration 77.44, 77.45–6  
electrolysis 77.44  
  in hirsutism 66.87  
electrolyte monitoring, burns 28.84  
electromagnetic radiation  
  skin ageing and 8.21  
  spectrum 29.1, 29.2  
electron beam therapy 57.24–5  
electron dispersive X-ray analysis (EDXA), foreign bodies 28.42  
electron energy loss spectroscopy (EELS), foreign bodies 28.42  
electron microscopy 10.29–30  
  epidermolysis bullosa 39.24–5  
electronic compliance monitoring 72.5  
electronic prescribing 72.26  
electronics industry, occupational hazards 27.19  
electrophoresis, DGGE 57.12–13  
electroplating (electroforming), occupational hazards 27.20  
electroresection 77.44  
electrosurgery 77.44–7  
  pacemakers and 77.46  
  rhinophyma 77.46  
  spider naevi 77.46  
  warts 77.46  
  xanthelasma 77.46  
  *see also* diathermy  
elementary bodies, *Chlamydia* 34.29  
elephantiasis 48.15, 48.17  
  ear 68.16, 68.24  
  infection prevention 48.22  
  in lymphogranuloma venereum 34.33  
  non-filarial 9.8, 48.13  
  perianal/perineal involvement 71.83  
  tropical 37.8–10, 48.12  
  vulval 30.71  
elephantiasis neurofibromatosa 48.21  
elephantiasis verrucosus nostras 48.14  
elephants 2.3  
ELISA *see* enzyme-linked immunosorbent assay  
ELISpot 31.6  
elkonyxis 65.13  
Ellis–van Creveld (EvC) syndrome 15.39, 15.65  
EMA *see* epithelial membrane antigen (EMA)  
EMBASE 7.5, 7.6  
embolectomy, balloon-catheter 47.6  
emboli  
  cardiac sources 49.37–8  
  cholesterol 49.36–7, 50.54  
  fat 49.38  
  microvascular occlusion due to 49.36–8  
  oxalate crystal 49.37  
  *see also* embolism  
embolia cutis medicamentosa 75.155  
embolism  
  acute limb ischaemia vs 47.5  
  cardiac myxoma 49.37, 50.54  
  platelet, in ischaemic disease 47.2  
  *see also* emboli

- embolization  
arterial 18.61  
arteriovenous fistulae 47.21  
  infantile haemangioma 18.51  
embryo, wounds 14.2, 14.9  
embryology  
  lymphatic system 48.1–2  
  sebaceous glands 42.3  
  of skin 3.3–5  
    melanoblasts and melanocyte development 58.3–4  
    miRNA role 3.50  
    vasculogenesis 47.1  
  *see also individual skin structures*  
emedastine 67.15  
eMelanoBase 54.33  
EMILIN1 48.4  
emilins 3.45  
emissary veins 77.2, 77.3  
EMLA® cream 77.10  
  adverse effects 75.153–4  
  in notalgia paraesthetica 63.23  
  in skin biopsy 10.2  
emollients 73.5, 73.31  
  in atopic dermatitis 24.29  
  in bullous ichthyosiform erythroderma 19.33  
  in CHILD syndrome 19.58  
  in colloidion babies 19.14–16  
  in Darier's disease 19.85  
  in eczema 23.38  
  in erythroderma 23.49  
  formulations 73.31  
  frequency of application 73.3  
  frostbite and 68.10  
  in hand eczema 23.22  
  in harlequin ichthyosis 19.29  
  in IBIDS/PIBIDS syndrome 19.49  
  in ichthyosis hystrix 19.37  
  in ichthyosis vulgaris 19.7–8  
  in irritant contact dermatitis 25.23, 25.25  
  in lamellar ichthyosis 19.25  
  in lymphoedema 48.22  
  napkins impregnated with 17.26  
  in Netherton's syndrome 19.41  
  in non-bullous ichthyosiform erythroderma 19.19  
  in pachyonychia congenita 19.104  
  in pityriasis rubra pilaris 19.79  
  in pruritus of senescence 21.12, 21.17  
  quantity applied 73.3–4  
  in senile xerosis 8.27  
  in Sjögren–Larsson syndrome 19.44  
  use in neonates 17.2  
  in X-linked recessive ichthyosis 19.12  
emotional abuse, mechanical injury 28.34, 28.38–9  
emotions, influence on skin disease 64.2–3  
emperipolesis, in sinus histiocytosis with massive lymphadenopathy 55.29  
emulsification tendency 73.7  
emulsifiers 25.20, 73.7  
  in ointments 73.2  
Emulsifying Ointment BP 73.31  
emulsions 73.2  
  definition 73.2, 73.7  
  determination of nature of 73.7  
  oil-in-water (O/W) 73.7  
  stable 73.7  
  water-in-oil (W/O) 73.7  
EN *see* erythema nodosum (EN)  
*en cocarde* (cockade) 5.7  
enalapril 75.93  
enamel 69.2  
enamel organs 69.2  
enamel workers, occupational hazards 27.19  
encephalitis 33.67  
  eastern equine 33.67  
  herpes B virus infection 33.34  
  herpes simplex 33.17, 33.19  
  HHV-6 associated 33.32  
  Japanese 33.67  
  in loiasis 37.11, 37.12  
  measles 33.75  
  postvaccinal, cowpox 33.7  
  roseola infantum 33.32  
  tick-borne 33.67, 38.34, 38.35  
  varicella 33.24  
  Venezuelan equine 33.67  
  western equine 33.67  
  zoster 33.26  
encephalocoele 18.95  
encephalomyelitis, vaccinia vaccination 33.6  
enchondroma 65.34  
endarterectomy, surgical 47.5  
endarteritis obliterans, syphilis 34.5  
endocannabinoids 21.2  
endocardial fibrosis 43.18  
endocarditis  
  foreign bodies 28.51  
  infective 49.37–8  
  marantic 49.37  
  subacute bacterial 44.7, 62.78  
  vasculitis and 50.55  
endocrine acne 42.73  
endocrine disorders 62.2–14  
  genetics 15.23  
  hypermelanosis in 58.24–5  
  purpura in 49.18  
  *see also individual diseases*  
endocrine system, Langerhans' cell histiocytosis (LCH) 55.11, 55.12  
endoglin, gene mutations 47.17  
endometriosis, female genital dermatology 71.81  
endoparasites 37.1  
β-endorphin, UVR exposure associated 29.7  
endorphins 21.4, 64.23  
endothelial cells  
  in infantile haemangioma 18.41  
  lymphatic 48.2  
  migration, in angiogenesis 47.1  
  in sclerosing panniculitis 46.30  
  in vasculitis 50.8  
endothelin(s), pigmentation regulation 58.8  
endothelin 1 (ET1) 12.75  
  keratinocyte production 58.26  
  melanocyte growth and 58.5  
  pigmentation regulation 58.8  
endothelin 3 (ET3), pigmentation regulation 58.8  
*endothelin 3* gene, in mice 2.7  
*endothelin-B* receptor gene, mutation 2.7  
endothelium 3.51  
  antigens 3.52  
  initial lymphatics 48.2, 48.3–4  
  injury, arterial disease pathogenesis 47.1  
  microscopy 10.35  
  structure 3.51  
endothelium derived relaxing factor (EDRF) *see* nitric oxide (NO)  
endotoxins, atopy and 24.5–6, 24.7  
endovascular treatment, varicose veins 47.39  
endovascularitis, lymphocytic 50.48  
energy  
  excess, lipogenesis 46.3  
  homeostasis 46.2–3, 46.3  
  need, lipolysis 46.3  
  negative balance, weight loss 46.7  
  positive balance, in obesity 46.6  
  reduced intake, obesity management 46.8  
  storage in adipose tissue 46.2  
enfuvirtide (T20), HIV infection 35.6, 35.22  
ENG gene mutations 47.17  
enhanced green fluorescent protein (EGFP) 3.17  
enkephalins 21.4, 64.23  
enophthalmos, in Horner's syndrome 63.22  
entactin (nidogen) 3.28–9, 3.31  
*Entamoeba*, perianal/perineal infections 71.95  
*Entamoeba histolytica* 37.2, 37.27–8  
  female genital infections 71.69  
enterobiasis 37.13–14  
*Enterobius vermicularis* 37.3, 37.13–14  
  perianal/perineal infection 71.92  
  vaginal discharge 71.53  
enterochromaffinoma 43.17  
enterococci 30.13, 30.69  
enteroviruses 33.71–3  
  oral infection 69.76–7  
entropion 67.4, 67.21  
environmental factors 6.12  
in allergic contact dermatitis 26.10–11  
envoplakin 3.11  
envoplakin BP230 40.4  
enzyme immunoassays, *Treponema pallidum* 34.20  
enzyme-linked immunosorbent assay (ELISA) 5.24, 13.19  
  serodiagnosis of pemphigus 40.8  
enzyme replacement therapy (ERT) 59.38, 59.39–40  
enzymic panniculitis 46.18–20  
eosin 26.17, 26.24  
  topical therapy 73.48  
eosinophil(s) 12.20, 13.5  
  in atopic eye disease 67.15  
  in Churg–Strauss syndrome 50.42  
  in incontinentia pigmenti 58.15  
  infiltration in panniculitis 46.12  
  in Langerhans' cell histiocytosis 55.8  
  in mast cell tumours, in dogs 2.22  
  microscopy 10.34  
  receptors 13.5  
  in urticaria 22.3, 22.5  
  in vasculitis 50.6–7  
eosinophil cationic protein (ECP) 13.5, 13.16  
eosinophil-derived neurotoxin 13.5  
eosinophil peroxidase 13.5  
eosinophilia 62.86–8  
  aetiology 5.21, 62.87  
  in cholesterol embolization syndrome (CES) 49.37  
  with episodic angio-oedema 22.23  
  in loiasis 37.11  
  recurrent granulomatous dermatitis with (Well's syndrome) 46.12, 46.33–4, 62.87  
eosinophilia-myalgia syndrome 45.52, 62.87, 75.43  
  secondary mucinosis 59.29  
eosinophilic cellulitis (Well's syndrome) 46.12, 46.33–4, 62.87  
eosinophilic fasciitis 51.64, 51.86, 62.87  
lipodermatosclerosis overlap 46.30, 46.31  
  paraneoplastic 62.40  
eosinophilic folliculitis, HIV infection 35.18–19  
eosinophilic globules (Kamino bodies) 10.40, 54.22, 54.24, 54.24  
eosinophilic granules, fragmented *see* flame figures  
eosinophilic granuloma *see under* granuloma(s); Langerhans' cell histiocytosis (LCH)  
eosinophilic inclusions, epidermal cells in warts 33.41  
eosinophilic panniculitis 46.12  
eosinophilic pustulosis 17.10, 30.29  
eosinophilic (idiopathic) sclerosing lipogranuloma 46.29, 46.30  
eosinophilic spongiosis 40.11, 40.15  
eotaxin 12.46, 13.5, 35.18  
  in atopic dermatitis 24.7  
epheides *see* freckles  
EphrinB2 48.2  
epicanthal fold 67.4  
epicanthus inversus 67.4  
*Epicauta* 38.26  
Epicheck 26.85  
epichlorohydrin 25.21, 27.11  
epicuticle 66.5  
epidemic hysteria syndrome 64.25–6  
epidemiological study 6.3  
  disease definition needed 6.4–5  
  reading checklist 6.19  
  types 6.19  
epidemiology 6.1–21  
  allergic contact dermatitis 26.2–5  
  analytical 6.3, 6.19  
  case definition 26.3  
  clinical 6.1  
  comparisons and inferences from 6.2–3  
  computer software, information resources 6.20  
  data collection 26.2–3  
  definition 6.1–2  
  diagnostic criteria importance 6.4–5  
  historical aspects 6.1–2  
  information resources 6.19, 6.20–1  
  methodologies 26.2–3  
  occupational dermatoses 26.3, 27.1–4  
  pellagra 6.1  
  populations vs individuals 6.2–4  
  sarcoidosis 61.2  
  scabies 6.2, 38.37–8  
  scurvy 6.1  
  skin disease in old age 8.25, 8.26  
  skin diseases as 'entities' in population 6.2  
  standardization 26.3  
  terminology and glossary 6.18–19  
  *see also other specific diseases*  
EPIDERM surveillance system 6.6, 26.3, 26.4, 27.2  
epidermal attachment complexes 3.21–5  
  adherens junctions 3.23–4  
  desmosomes 3.21–2  
  gap junctions 3.24  
  tight junctions 3.24–5  
epidermal barrier, formation by keratinocytes 12.14  
epidermal basement membrane *see* basement membrane  
epidermal cells, lipids 42.5  
epidermal cysts, vulval 71.72  
epidermal development, fetal 12.15  
epidermal growth factor (EGF)  
  keratinocytes 12.16  
  response to 12.31  
  sebaceous cell activity control 42.12  
  in wound healing 14.3, 14.4, 14.27  
epidermal growth factor receptor (EGFR) 3.4, 3.6  
  inhibitors, acneiform eruptions due to 42.72  
  ligands 12.11  
epidermal hyperplasia 52.44  
  mechanical injury 28.11  
  persistent and excessive 52.44  
  wound healing response 52.44  
epidermal melanin unit 58.2  
epidermal naevus syndrome 18.27–30, 54.11  
epidermal necrosis, acute disseminated 76.1  
epidermal proliferation units 3.6  
epidermal sheets 4.4  
epidermal tumours, benign 52.38–45  
epidermis 3.7–16, 4.4, 12.14  
  absorption through 4.4–5  
  adhesion complex, desmosomes role 3.21–2  
  ageing 8.23, 45.2, 80.1–2  
  anatomy 3.1, 3.2  
  atrophy, retinoic acid therapy 73.35  
  barrier function 4.2, 4.3  
  cell turnover, ageing and 8.23  
  cells, lipids in 42.5  
  composition 3.1  
  corticosteroid-induced atrophy 73.17  
  degenerations 10.38  
  differentiation 3.6, 3.8, 3.11  
  ear 68.1  
  embryology 3.3–5  
  evolution 2.1–4

- function 3.2–3  
hyperplasia *see* epidermal hyperplasia  
hyperproliferation, keratins expressed 3.10  
hypertrophy, in actinic keratosis 52.30  
immunological function 4.8–9  
interfollicular  
  development 3.4, 3.5  
  signalling in 3.4  
  stem cells and proliferation 3.6–7  
invertebrate derivatives 2.1–2  
  as ‘itch receptor’ 21.2  
lipids 3.9, 3.11  
mechanical function 4.1, 4.8  
melanocyte distribution 58.2–3  
in porokeratosis 52.36  
post-inflammatory hypermelanosis 58.31  
proliferation of cells 3.6  
racial variations 9.2  
spongiotic, incontinentia pigmenti 58.15  
stem cell proliferation 3.6  
structure and ultrastructure 3.7–9  
  *see also individual layers*  
thickness  
  ageing and 8.23  
  increased by retinol 73.35  
  vertebrate evolution 2.2–3  
  vertebrates 2.2–3  
  water content, ageing and 8.22, 8.27  
epidermis–dermal junction *see* dermal–epidermal junction  
epidermodysplasia verruciformis (EV)  
  33.57–8  
  aetiology and gene mutations 33.57  
  clinical features 33.57–8  
  diagnosis and treatment 33.58  
  in HIV infection 35.30  
  pathology 33.57  
  in transplant recipients 33.59  
  viral warts and non-melanoma skin cancer with 52.5  
epidermodysplasia verruciformis (EV)-like syndromes 33.58, 33.59  
epidermoid (‘sebaceous’) cysts 42.88, 52.45–6  
  acne vs 42.37  
  excision 77.36  
  following ear piercing 68.8  
  genetics 15.26  
  implantation 65.34  
  lipoma vs 46.44  
  mechanical injury 28.28  
  plantar 33.47  
  sites 52.45  
  trichilemmal cysts vs 52.46  
  *see also steatocystoma multiplex*  
epidermolysis 39.1  
epidermolysis bullosa (EB) 39.1, 39.1–32  
  albopapuloid (Pasini) 39.21–2, 45.50  
  with aplasia cutis congenita 18.101  
  classification 39.1–2  
  definition 39.1  
  dermolytic cleavage 39.2  
  diagnosis and investigations 39.1–2, 39.24–7  
    antigen mapping 39.25  
    electron microscopy 39.24–5  
    molecular 39.26–7  
    skin biopsy 39.21, 39.24  
    specific antibody probes 39.25–6  
  differential diagnosis 15.82, 39.27  
  dystrophic 39.2, 39.15–24  
    albopapuloid (Pasini) variant 39.21–2, 45.50  
    in animals 2.17  
    autosomal dominant 39.15, 39.16, 39.17, 39.21–4  
    autosomal recessive 39.15, 39.18–20  
    Bart’s syndrome 39.17, 39.18, 39.22  
    bullous dermolysis of newborn 39.23–4, 39.25  
    classification 39.2  
    clinical subtypes 39.18–24  
    crusted scabies and 38.43  
    diagnosis 39.24, 39.25  
    dominant 39.2, 39.27  
    ear 68.16  
    electron microscopy 10.29  
    generalized dominant 39.21–2  
    generalized recessive (non-Hallopeau–Siemens) 3.32, 39.20, 39.21  
    hyperplastic (Cockayne–Touraine) 39.21–2  
    inverse recessive 39.16, 39.20, 39.21  
    localized, recessive 39.15–16  
    management 39.28–30  
    molecular pathology 39.15–18  
    oral involvement 39.18–19, 69.32  
    pretibial 39.17, 39.22  
    recessive 39.2, 39.16, 39.27  
    recessive, centripetalis 39.24  
    scalp involvement 39.19  
    severe generalized recessive (Hallopeau–Siemens) 39.16, 39.18–20, 39.28–30, 39.30  
    sporadic dominant, diagnosis 39.27  
    squamous cell carcinoma in 39.17, 39.19, 39.30  
    squamous cell carcinoma prevention 39.31  
  epidermal basement membrane zone role 3.26  
  epidermolytic cleavage 39.2  
  *see also* epidermolysis bullosa (EB) simplex  
  female genital involvement 71.66  
  gastrointestinal involvement 62.48  
  generalized atrophic benign (GABEB) 3.36–7, 39.13, 66.52  
  genetics 15.5, 15.82  
    genes/proteins involved in 3.27  
  hypertrichosis associated 66.78  
  junctional 39.2, 39.9–15  
    in animals 2.17  
    autosomal recessive 39.9  
    cicatricial 39.13, 39.15  
    clinical subtypes 39.11–15  
    diagnosis 39.24, 39.25  
    electron microscopy 10.29  
    generalized non-Herlitz 39.13  
    genetics 3.28, 3.31, 3.36, 39.9–11  
    Herlitz 39.9, 39.10, 39.11–13  
    indeterminate 39.9  
    laminin 332 gene mutations 3.28, 39.10  
    late-onset 39.15  
    localized (non-Herlitz) 39.14  
    molecular pathology 39.9–11  
    non-Herlitz type 3.36–7, 39.4, 39.9, 39.10, 39.13, 39.31, 66.52  
    non-Herlitz type, *BPAG2* gene mutations 3.31, 3.36, 39.10  
    oral involvement 69.32  
    progressive 39.15  
    pyloric stenosis with 39.9–10, 39.11, 39.14  
  lamina lucidolytic cleavage 39.2, 39.9  
  *see also* epidermolysis bullosa (EB), junctional  
  oral involvement 39.13, 39.18–19, 69.31–2  
  preimplantation diagnosis 16.7–8, 39.31  
  prenatal diagnosis 16.2–3, 16.4, 16.5, 16.7, 16.10, 39.27, 39.31  
  prevalence and incidence 39.3  
  pseudojunctional 39.4  
  renal involvement 39.20, 62.71  
  screening 39.27  
  treatment 39.27–32  
    gene therapy 39.31  
    neonates and infants 39.27–8  
    severe generalized recessive dystrophic EB 39.28–30  
epidermolysis bullosa acquisita (EBA) 40.51–6  
  aetiology 40.52  
  in animals 2.15  
  associated diseases 40.55  
  autoantigen (collagen type VII) 3.36  
  cicatricial conjunctivitis 67.20  
  clinical features 40.54  
  collagen type VII in 3.36, 40.51  
  Crohn’s disease and 62.49  
  defined 40.51  
  differential diagnosis 40.55  
  drug-induced 40.55, 75.40  
  ear 68.16  
  EBA mucous membrane pemphigoid 40.54  
  electron microscopy 10.29  
  IgA EBA 40.55  
  immunopathology and immunogenetics 10.18, 10.19  
  oral 69.68  
  paraneoplastic 62.46  
  pathogenesis/pathology 40.52–3  
  prognosis 40.55  
  treatment 40.55–6  
epidermolysis bullosa (EB) atrophicans 39.9  
epidermolysis bullosa (EB) atrophicans generalisata gravis (Herlitz junction EB) 39.9, 39.10, 39.11–13  
epidermolysis bullosa (EB) atrophicans generalisata mitis 39.13  
epidermolysis bullosa (EB) dystrophica–neutrophica 39.15  
epidermolysis bullosa herpetiformis *see* epidermolysis bullosa (EB) simplex, Dowling–Meara form  
epidermolysis bullosa (EB) letalis 39.9, 39.11–13  
epidermolysis bullosa (EB) progressiva 39.15  
epidermolysis bullosa (EB) pruriginosa 39.17, 39.22–3  
epidermolysis bullosa (EB) simplex 39.3–9  
  autosomal dominant, Oagna form 39.4, 39.8  
  autosomal recessive 39.4  
    diagnosis 39.25  
    lethal 39.8  
    muscular dystrophy with 39.4, 39.8  
    neuromuscular disease with 39.8  
  basal type 39.2, 39.6–9  
  classification 39.2  
  clinical subtypes 39.5–9  
  diagnosis 39.24, 39.25  
  Dowling–Meara form 39.3, 39.6–8, 39.30–1  
    diagnosis 39.25  
  electron microscopy 10.29, 39.4  
  generalized 39.6  
  of hands and feet (Weber–Cockayne) 39.4, 39.6, 39.30–1  
    friction blisters in 28.13  
  keratin gene mutation 3.10  
  Koebner 39.4, 39.6  
  lethal acantholytic 39.4, 39.5–6  
  lethal autosomal recessive 39.8  
  localized (Weber–Cockayne) 39.4, 39.6, 39.30–1  
  mechanical injury 28.13  
  migratory circinate 39.9  
  molecular pathology 39.3–5  
  mottled pigmentation with 39.4, 39.8  
  non-Dowling–Meara generalized variant 39.4, 39.6  
  pyloric stenosis with 39.4, 39.8  
  suprabasal subtypes 39.2, 39.5–6  
  treatment 39.30–1  
epidermolysis bullosa (EB) simplex superficialis 39.5  
epidermolytic ichthyosis, annular 19.31  
epidermolytic palmoplantar keratoderma 19.3, 19.94, 19.95–7  
epidermolytic toxins 30.7  
*Epidermophyton floccosum* 36.18, 36.21  
  female genital infection 71.68–9  
  identification 36.8, 36.46  
  in tinea corporis 36.23, 36.24  
  in tinea cruris 36.33  
  in tinea incognita 36.36  
  in tinea manuum 36.32  
  in tinea pedis 36.30, 36.31  
  in tinea unguium 36.34  
epidermotropic CD8+ (provisional) T-cell lymphomas 57.35–6  
EpiDerm™ 25.9  
epididymitis, in lymphatic filariasis 37.9  
epididymo-orchitis, chlamydial infections 34.29  
epigenetics 11.16–17  
epilation 73.29  
  X-ray 66.53–4  
epilepsy  
  genetics 15.23, 15.24  
  Lafora’s myoclonic 44.18  
  oral involvement 69.119  
  in Sturge–Weber syndrome 18.66  
epiloia *see* tuberous sclerosis complex  
epinephrine *see* adrenaline  
epiphora 67.4  
epipodophyllin, Langerhans’ cell histiocytosis (LCH) 55.13  
episcleritis 67.4  
EpiSkin™ 25.9  
epistasis, hereditary haemorrhagic telangiectasia (HHT) 47.17  
epithelial membrane antigen (EMA) 10.21  
  malignant eccrine poroma 53.32  
epithelial neutrophil activating peptide 78 (CXCL5, ENA-78) 12.46–7  
epithelioid angiomas *see* bacillary angiomas  
epithelioma  
  eccrine 53.36  
  eyelid 67.35–6  
  radiation-induced 79.18  
  sebaceous (old terminology) 53.15  
  self-healing 52.9–10  
  squamous, venous leg ulcers vs 47.45  
  superficial with sebaceous differentiation 53.17  
epithelioma adenoides cysticum *see* trichoepithelioma  
epithelioma cuniculatum 52.26, 65.38  
epithelium, oral cavity 69.1  
epitope, anti-Ro antibodies 51.137  
epitope spreading 40.5  
epitrichial sweat glands *see* apocrine sweat glands  
epitrichium 17.20  
eponychium *see* cuticle  
epoxy resins *see* resins, epoxy  
Eppendorf Itch Questionnaire 21.16  
epratuzumab 74.10  
epsilon aminocaproic acid, in hereditary angio-oedema 22.22  
Epstein–Barr virus (EBV) 33.30–2  
  acne fulminans and 42.83–4  
  antibodies to 33.30  
  dermatoses associated 33.31  
  diagnosis 33.30  
  epidemiology 33.30  
  female genital dermatology 71.65, 71.69  
  Gianotti–Crosti syndrome 33.31  
  haemophagocytic syndrome 33.31  
  hairy leukoplakia 33.31, 69.90, 69.91, 69.93  
  Hodgkin’s disease and 35.41  
  hydroa vacciniforme association 29.15  
  infectious mononucleosis 33.30  
  Kikuchi’s histiocytic necrotizing lymphadenitis 33.31, 33.77  
  latency and persistence 33.30  
  lymphomas and lymphoproliferative disorders 33.30–1  
  oral infection 33.30, 69.75, 69.118  
  perianal/perineal dermatology 71.94  
  primary infection 33.30  
  reactivation in GVHD 62.97  
  recessive dystrophic, non-melanoma skin cancer and 52.11  
  shedding 33.30

- sinus histiocytosis with massive lymphadenopathy (SHML) 55.29
- urticaria following infection 22.8
- vasculitis and 50.49
- Epstein's pearls 17.5, 69.17
- epitfibatide 49.13
- EPUAP scheme 14.13, 14.14
- epulis
- congenital 69.17
  - giant cell 69.20
  - pregnancy 8.11, 69.20–1
- epulis fissuratum 69.109–10
- Epyris californicus* 38.14
- EQ *see* erythroplasia of Queyrat
- equina (glands) 30.51
- Erbium:YAG laser *see under* laser therapy
- Erb's point 77.3
- Erdheim–Chester disease 55.18–19
- ergosterol 36.2, 73.12
- erisipela de la costa 37.5
- ERK1 and ERK2 mitogen-activated protein kinases 12.11
- erlotinib 75.132
- erosiointerdigitalis blastomycetica 36.61
- erosion
- definition 5.7
  - mulberry-like 36.87
- erosive adenomatosis of the nipple 70.12–13
- erosive pustular dermatitis
- legs 50.89–90
  - treatment 73.32
- erosive pustular dermatosis
- legs 47.44
  - scalp 66.49–50
- erucism 38.28
- eruptive vellus hair cyst (EVHC) 42.88
- ERX1/2 51.65
- erysipelas 30.17–21
- bacteriology 30.17–18
  - clinical features 30.18, 30.19
  - coastal *see* onchocerciasis
  - complications 30.18
  - definition 30.17
  - diagnosis 30.18–19
  - differential diagnosis 26.29
  - ear 68.19
  - in HIV infection 35.24–5
  - lymphoedema and 48.12, 48.15, 48.24
  - management 48.24
  - ocular involvement 67.27
  - recurrent 30.18, 48.29
  - treatment 30.19–20
- erysipelas-like erythema 59.77
- erysipeloid 30.42–3
- Erysipelothrix rhusiopathiae (insidiosa)* 30.35, 30.42–3
- erythema
- acral 75.122–3
  - acute drug-induced phototoxicity 29.21
  - annular *see* annular erythema
  - carbon monoxide poisoning 28.93
  - cold-induced injury 28.64
  - danthron 71.87
  - definition 5.7
  - erysipelas-like 59.77
  - gingival 69.13
  - granulomatous slack-skin disease 57.15
  - gyrate 62.110
  - in hepatitis B virus infection 62.59
  - in irritant contact dermatitis 25.22
  - measurement 72.11
  - mechanical injury 28.27, 28.39
  - morbiform toxic, drug reaction in HIV infection 35.20
  - necrolytic migratory *see* necrolytic migratory erythema
  - oral cavity 69.22
  - palmar
    - paraneoplastic 62.41
    - in pregnancy 8.10  - palmar crease 62.85
  - papular 51.135
  - perianal/perineal 71.86, 71.87
  - peripheral ischaemic disorders 47.2
  - persistent cholinergic 22.15
  - post-inflammatory, in acne 42.33
  - pressure 47.33
  - quantification 25.22
  - radiation spectrum for induction 29.5, 29.9
  - recurrent scarlatiniform 30.34
  - recurrent toxin-mediated perineal 30.32
  - in rosacea 43.3, 43.4, 43.6
  - SCLE-like marginally scaled 51.135
  - skin colour and 5.16
  - Sweet's disease-like annular erythema 51.135
  - in sympathetic nerve injury 63.20
  - thermal injury 28.72–3
  - in triple response 22.12
  - see also* erythema annulare centrifugum
- erythema ab igne 28.72–3, 52.24
- erythema annulare centrifugum 5.12, 26.26, 62.38, 62.106, 62.110–12, 75.23–4
- molluscum contagiosum with 33.12
- erythema annulare rheumaticum 62.107
- erythema chronicum migrans *see* erythema migrans
- erythema circinatum 69.94
- erythema dyschromicum perstans 30.63, 58.33–4
- lichen planus vs 41.17
  - race and 9.16–17
- erythema elevatum diutinum 50.25–7, 50.62, 62.51
- erythema gydatum repens 62.107–8
- paraneoplastic 62.38
  - tuberculosis and 31.21
- erythema induratum of Bazin and of Whitfield 31.10, 31.24, 47.57, 50.31
- see also* vasculitis, nodular
- erythema infectiosum (fifth disease) 5.10, 33.62, 33.63
- see also* parvovirus B19 infection
- erythema marginatum (rheumaticum) 62.107
- rheumatic fever 51.138
- erythema migrans 30.64–6, 62.106–7
- acrodermatitis chronica atrophicans and 45.10
  - lingual *see* tongue, geographical
- erythema multiforme (EM) 76.2–8
- aetiology 69.69, 76.2–5
  - allergic contact dermatitis resembling 26.25–6, 26.76
  - in animals 2.16
  - atypical 76.7
  - clinical features 69.69, 76.6–7
  - in coccidioidomycosis 36.86
  - coxsackievirus infections and 33.72
  - Crohn's disease and 62.50
  - definition 76.1
  - diagnosis 69.69
  - differential diagnosis 40.11, 76.7
  - drug-induced 76.3, 76.4
  - HIV infection 35.20
  - female genital involvement 71.66
  - following streptococcal infection 30.16
  - genitocrural 71.6
  - in hepatitis B virus infection 62.59
  - herpes-associated (HAEM) 33.18–19
  - in herpes simplex 33.18–19, 33.76
  - histopathology 76.6
  - immunology 76.2
  - localized vesiculobullous 76.7
  - in lymphogranuloma venereum 30.71
  - major 69.69, 76.7
  - male genital involvement 71.25, 71.27
  - minor/papular/simplex form 69.69, 76.6–7
  - molluscum contagiosum with 33.12
  - oral involvement 69.65, 69.69–70
  - orf association 33.9
  - paraneoplastic 62.46
  - pathology 76.5–6
  - persistent 76.7
  - post-herpetic 33.19
  - predisposing factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50.82–3
  - diagnosis 50.86
  - drug-induced 50.83–4, 75.43–4
  - enzymic (pancreatic) panniculitis mimicking 46.19
  - following jellyfish stings 38.56
  - following streptococcal infection 30.12
  - histopathology 50.85–6
  - history and nomenclature 50.83
  - in lymphogranuloma venereum 30.70
  - pregnancy and 50.83
  - in psittacosis 30.72
  - in sarcoidosis 50.83, 61.2, 61.6, 61.8, 61.9
  - septal panniculitis 46.12
  - treatment 50.86–7
  - tuberculous 31.8
  - ulcerative colitis and 62.50
  - as vasculitis 61.17
  - in viral infections 33.76
- erythema nodosum leprosum *see* lepra reactions, type 2
- erythema nodosum migrans *see* erythema nodosum
- erythema toxicum neonatorum 17.6–7
- erythema response 58.10
- erythralgia *see* erythromelalgia
- erythralgia *see* erythromelalgia
- erythrasma 30.37–9
- differential diagnosis 26.29, 36.11
  - genitocrural dermatology 71.6
  - perianal/perineal dermatology 71.95
  - treatment 73.10
  - Wood's light examination 5.19
- erythrocytosis
- cold-induced injury 28.67
  - with nodules 50.32
  - vibration injury 28.58
- erythrocyte sedimentation rate (ESR) 13.19
- chronic urticaria 22.26
  - sarcoidosis 61.20
  - in thromboangiitis obliterans 47.7
- erythrocytes
- agglutination (cold-related) 49.34
  - P antigen 33.63
- erythroderma 23.32, 23.46–51
- adult T-cell leukaemia–lymphoma 33.64
  - aetiology 23.46
  - bullous ichthyosiform *see* bullous ichthyosiform erythroderma (BIE)
  - clinical features 23.46–9
  - complications 23.49–50
  - congenital ichthyosiform (CIE) 19.17–21
  - predominant factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50.82–3
  - diagnosis 50.86
  - drug-induced 50.83–4, 75.43–4
  - enzymic (pancreatic) panniculitis mimicking 46.19
  - following jellyfish stings 38.56
  - following streptococcal infection 30.12
  - histopathology 50.85–6
  - history and nomenclature 50.83
  - in lymphogranuloma venereum 30.70
  - pregnancy and 50.83
  - in psittacosis 30.72
  - in sarcoidosis 50.83, 61.2, 61.6, 61.8, 61.9
  - septal panniculitis 46.12
  - treatment 50.86–7
  - tuberculous 31.8
  - ulcerative colitis and 62.50
  - as vasculitis 61.17
  - in viral infections 33.76
- erythema nodosum leprosum *see* lepra reactions, type 2
- erythema nodosum migrans *see* erythema nodosum
- erythema toxicum neonatorum 17.6–7
- erythema response 58.10
- erythralgia *see* erythromelalgia
- erythralgia *see* erythromelalgia
- erythrasma 30.37–9
- differential diagnosis 26.29, 36.11
  - genitocrural dermatology 71.6
  - perianal/perineal dermatology 71.95
  - treatment 73.10
  - Wood's light examination 5.19
- erythrocytosis
- cold-induced injury 28.67
  - with nodules 50.32
  - vibration injury 28.58
- erythrocyte sedimentation rate (ESR) 13.19
- chronic urticaria 22.26
  - sarcoidosis 61.20
  - in thromboangiitis obliterans 47.7
- erythrocytes
- agglutination (cold-related) 49.34
  - P antigen 33.63
- erythroderma 23.32, 23.46–51
- adult T-cell leukaemia–lymphoma 33.64
  - aetiology 23.46
  - bullous ichthyosiform *see* bullous ichthyosiform erythroderma (BIE)
  - clinical features 23.46–9
  - complications 23.49–50
  - congenital ichthyosiform (CIE) 19.17–21
  - predominant factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50.82–3
  - diagnosis 50.86
  - drug-induced 50.83–4, 75.43–4
  - enzymic (pancreatic) panniculitis mimicking 46.19
  - following jellyfish stings 38.56
  - following streptococcal infection 30.12
  - histopathology 50.85–6
  - history and nomenclature 50.83
  - in lymphogranuloma venereum 30.70
  - pregnancy and 50.83
  - in psittacosis 30.72
  - in sarcoidosis 50.83, 61.2, 61.6, 61.8, 61.9
  - septal panniculitis 46.12
  - treatment 50.86–7
  - tuberculous 31.8
  - ulcerative colitis and 62.50
  - as vasculitis 61.17
  - in viral infections 33.76
- erythema nodosum leprosum *see* lepra reactions, type 2
- erythema nodosum migrans *see* erythema nodosum
- erythema toxicum neonatorum 17.6–7
- erythema response 58.10
- erythralgia *see* erythromelalgia
- erythralgia *see* erythromelalgia
- erythrasma 30.37–9
- differential diagnosis 26.29, 36.11
  - genitocrural dermatology 71.6
  - perianal/perineal dermatology 71.95
  - treatment 73.10
  - Wood's light examination 5.19
- erythrocytosis
- cold-induced injury 28.67
  - with nodules 50.32
  - vibration injury 28.58
- erythrocyte sedimentation rate (ESR) 13.19
- chronic urticaria 22.26
  - sarcoidosis 61.20
  - in thromboangiitis obliterans 47.7
- erythrocytes
- agglutination (cold-related) 49.34
  - P antigen 33.63
- erythroderma 23.32, 23.46–51
- adult T-cell leukaemia–lymphoma 33.64
  - aetiology 23.46
  - bullous ichthyosiform *see* bullous ichthyosiform erythroderma (BIE)
  - clinical features 23.46–9
  - complications 23.49–50
  - congenital ichthyosiform (CIE) 19.17–21
  - predominant factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50.82–3
  - diagnosis 50.86
  - drug-induced 50.83–4, 75.43–4
  - enzymic (pancreatic) panniculitis mimicking 46.19
  - following jellyfish stings 38.56
  - following streptococcal infection 30.12
  - histopathology 50.85–6
  - history and nomenclature 50.83
  - in lymphogranuloma venereum 30.70
  - pregnancy and 50.83
  - in psittacosis 30.72
  - in sarcoidosis 50.83, 61.2, 61.6, 61.8, 61.9
  - septal panniculitis 46.12
  - treatment 50.86–7
  - tuberculous 31.8
  - ulcerative colitis and 62.50
  - as vasculitis 61.17
  - in viral infections 33.76
- erythema nodosum leprosum *see* lepra reactions, type 2
- erythema nodosum migrans *see* erythema nodosum
- erythema toxicum neonatorum 17.6–7
- erythema response 58.10
- erythralgia *see* erythromelalgia
- erythralgia *see* erythromelalgia
- erythrasma 30.37–9
- differential diagnosis 26.29, 36.11
  - genitocrural dermatology 71.6
  - perianal/perineal dermatology 71.95
  - treatment 73.10
  - Wood's light examination 5.19
- erythrocytosis
- cold-induced injury 28.67
  - with nodules 50.32
  - vibration injury 28.58
- erythrocyte sedimentation rate (ESR) 13.19
- chronic urticaria 22.26
  - sarcoidosis 61.20
  - in thromboangiitis obliterans 47.7
- erythrocytes
- agglutination (cold-related) 49.34
  - P antigen 33.63
- erythroderma 23.32, 23.46–51
- adult T-cell leukaemia–lymphoma 33.64
  - aetiology 23.46
  - bullous ichthyosiform *see* bullous ichthyosiform erythroderma (BIE)
  - clinical features 23.46–9
  - complications 23.49–50
  - congenital ichthyosiform (CIE) 19.17–21
  - predominant factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50.82–3
  - diagnosis 50.86
  - drug-induced 50.83–4, 75.43–4
  - enzymic (pancreatic) panniculitis mimicking 46.19
  - following jellyfish stings 38.56
  - following streptococcal infection 30.12
  - histopathology 50.85–6
  - history and nomenclature 50.83
  - in lymphogranuloma venereum 30.70
  - pregnancy and 50.83
  - in psittacosis 30.72
  - in sarcoidosis 50.83, 61.2, 61.6, 61.8, 61.9
  - septal panniculitis 46.12
  - treatment 50.86–7
  - tuberculous 31.8
  - ulcerative colitis and 62.50
  - as vasculitis 61.17
  - in viral infections 33.76
- erythema nodosum leprosum *see* lepra reactions, type 2
- erythema nodosum migrans *see* erythema nodosum
- erythema toxicum neonatorum 17.6–7
- erythema response 58.10
- erythralgia *see* erythromelalgia
- erythralgia *see* erythromelalgia
- erythrasma 30.37–9
- differential diagnosis 26.29, 36.11
  - genitocrural dermatology 71.6
  - perianal/perineal dermatology 71.95
  - treatment 73.10
  - Wood's light examination 5.19
- erythrocytosis
- cold-induced injury 28.67
  - with nodules 50.32
  - vibration injury 28.58
- erythrocyte sedimentation rate (ESR) 13.19
- chronic urticaria 22.26
  - sarcoidosis 61.20
  - in thromboangiitis obliterans 47.7
- erythrocytes
- agglutination (cold-related) 49.34
  - P antigen 33.63
- erythroderma 23.32, 23.46–51
- adult T-cell leukaemia–lymphoma 33.64
  - aetiology 23.46
  - bullous ichthyosiform *see* bullous ichthyosiform erythroderma (BIE)
  - clinical features 23.46–9
  - complications 23.49–50
  - congenital ichthyosiform (CIE) 19.17–21
  - predominant factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50.82–3
  - diagnosis 50.86
  - drug-induced 50.83–4, 75.43–4
  - enzymic (pancreatic) panniculitis mimicking 46.19
  - following jellyfish stings 38.56
  - following streptococcal infection 30.12
  - histopathology 50.85–6
  - history and nomenclature 50.83
  - in lymphogranuloma venereum 30.70
  - pregnancy and 50.83
  - in psittacosis 30.72
  - in sarcoidosis 50.83, 61.2, 61.6, 61.8, 61.9
  - septal panniculitis 46.12
  - treatment 50.86–7
  - tuberculous 31.8
  - ulcerative colitis and 62.50
  - as vasculitis 61.17
  - in viral infections 33.76
- erythema nodosum leprosum *see* lepra reactions, type 2
- erythema nodosum migrans *see* erythema nodosum
- erythema toxicum neonatorum 17.6–7
- erythema response 58.10
- erythralgia *see* erythromelalgia
- erythralgia *see* erythromelalgia
- erythrasma 30.37–9
- differential diagnosis 26.29, 36.11
  - genitocrural dermatology 71.6
  - perianal/perineal dermatology 71.95
  - treatment 73.10
  - Wood's light examination 5.19
- erythrocytosis
- cold-induced injury 28.67
  - with nodules 50.32
  - vibration injury 28.58
- erythrocyte sedimentation rate (ESR) 13.19
- chronic urticaria 22.26
  - sarcoidosis 61.20
  - in thromboangiitis obliterans 47.7
- erythrocytes
- agglutination (cold-related) 49.34
  - P antigen 33.63
- erythroderma 23.32, 23.46–51
- adult T-cell leukaemia–lymphoma 33.64
  - aetiology 23.46
  - bullous ichthyosiform *see* bullous ichthyosiform erythroderma (BIE)
  - clinical features 23.46–9
  - complications 23.49–50
  - congenital ichthyosiform (CIE) 19.17–21
  - predominant factors 69.69
  - pregnancy and 8.12
  - in psittacosis 30.72
  - reactions resembling 26.25, 76.5
  - terminology 76.1
  - treatment 69.69–70, 76.7
  - triggering factors 76.2, 76.3
  - ulcerative colitis and 62.50
  - in varicella 33.25
  - in viral infections 33.76, 76.2
- erythema multiforme-like syndrome 51.14
- erythema multiforme major 67.20–1
- ocular complications 67.20–1
  - ocular mucous membrane pemphigoid vs 67.19
  - see also* Stevens–Johnson syndrome (SJS)
- erythema necroticans (Lucio reaction/phenomenon) 32.13, 49.35
- erythema neonatorum 17.4
- erythema nodosum (EN) 31.24, 46.12, 50.82–7
- aetiology and pathogenesis 50.83–5
  - childhood 61.16
  - chronic 50.86
  - clinical features 50.86
  - in coccidioidomycosis 36.86
  - Crohn's disease and 62.50
  - definition 50

- female genital infection 71.68, 71.70  
genitocrural infection 71.5  
in HIV infection 35.24  
in malakoplakia 55.27  
in paronychia 65.21  
pyoderma gangrenosum and 50.65  
*Escherichia coli* O157:H7 49.31  
escitalopram 64.50  
esomeprazole 75.157  
espundia 37.39  
ESR *see* erythrocyte sedimentation rate (ESR)  
essential fatty acid deficiency 3.11  
hair loss and 66.29  
Estelle 35® 42.15–16, 42.53  
esthiomene 30.70  
estrone 42.12  
etanercept 13.25, 72.14  
adverse effects 75.145  
clinical indications 74.6  
dose range and evidence level 74.6  
in granuloma annulare 60.11  
in hidradenitis suppurativa 74.7  
origin, genetically engineered fusion protein 74.5  
in pemphigus 40.12  
in psoriasis 20.41, 74.5  
in HIV infection 35.17  
in sarcoidosis 61.21  
ethacrynic acid 75.97  
ethambutol 74.44  
adverse effects 31.27, 75.61  
in tuberculosis 31.27  
ethanol  
as antiseptic 73.14  
*see also* alcohol  
ethchlorvynol 75.81  
ethics, prenatal diagnosis and 16.10–11  
ethinyloestradiol 74.33  
acne treatment 42.53, 42.54  
ethionamide 74.45, 75.61  
Ethiopia, prevalence of skin disease 6.10  
ethnic groups and ethnicity 6.12  
allergic contact dermatitis and 26.8  
atopic dermatitis and 24.2–3, 24.21  
hair growth and 66.80  
head louse infection and 38.19  
history-taking 5.5  
irritant contact dermatitis and 25.6  
pigmentation 58.1  
pigmentation significance 58.9  
risk factor for skin disease 6.12  
sarcoidosis and 61.2, 61.3, 61.15–16  
tuberculosis and 31.2  
*see also* race  
2-ethoxyethyl-*p*-methoxycinnamate 25.19  
ethyl acetate 25.20  
ethyl chloride 77.10  
2-ethyl,1,3-hexanediol 25.19  
ethylene diaminetetraacetate 73.8  
ethylene glycol monomethylether 25.20  
ethylene oxide 25.21, 27.11  
ethylenediamine  
adverse effects 26.18, 26.44  
as allergen 26.59  
ethylenediamine tetracetate (EDTA) 26.17, 26.58  
etoposide 75.131–2  
familial haemophagocytic lymphohistiocytosis 55.26  
etretinate  
adverse effects 75.109–10  
hair loss 66.29  
in granuloma annulare 60.10  
in hidradenitis suppurativa 30.81  
in lichen sclerosus 51.118  
in non-melanoma skin cancer 52.18  
squamous cell carcinoma 52.28  
in psoriasis 20.37  
in psoriatic nail involvement 65.26  
Eucerin 73.7  
eumelanins 3.20, 66.90  
in animals 2.5, 2.6  
formation 58.5, 58.6  
synthesis 3.21, 3.21  
eumelanosomes 66.91  
eumycetoma 36.72, 36.73, 36.74  
eunuchs 66.13–14, 66.16  
sebum secretion 42.10  
Euphorbiaceae 25.21  
*Euphyllia picteti* 38.56  
*Euproctis* 38.28, 38.29  
*Euroglyphus* 38.47  
European Pressure Ulcer Advisory Panel classification scheme 14.13, 14.14  
EuroQol EQ-5D 72.17  
*Eurysolen gracilis* 75.160  
*Eutrombicula* 38.50  
EV *see* epidermodysplasia verruciformis (EV)  
Evans' syndrome 49.9  
evaporimeter 4.11  
EvC (Ellis–van Creveld syndrome) 15.39, 15.65  
evening primrose oil, in atopic dermatitis 24.31  
*Evernia prunastri* 26.77  
evidence-based dermatology, information resources 6.20  
evidence-based medicine 6.18, 7.1–23  
evidence  
appraisal and evaluation 7.7–23  
finding 7.5–6  
hierarchy of 7.3–4  
need for 7.1–2  
practice of 7.2  
question formulation 7.2–3  
evolution  
epidermis and dermis 2.1–4  
glands 2.4–5  
pigmentation role 73.40  
significance of melanin and pigmentation 58.8–9  
skin components 2.1  
Ewing's sarcoma, extrasosseous 56.54  
examination of skin 5.6–22  
exanthem subitum (roseola infantum) 33.32  
exanthems  
viral infection 33.3–4, 33.4  
*see also* rash(es)  
excisions *see* surgery  
excited skin syndrome 26.88, 26.95  
excoriations  
definition 5.7  
neurotic 23.46  
self inflicted 64.14, 64.19, 64.27–9, 64.37  
exercise  
anaphylaxis and 22.15  
lymphoedema management 48.22  
purpura due to 49.18  
urticaria and 22.8  
vasculitis induced by 49.18, 50.23  
exfoliation, definition 5.7  
exfoliative dermatitis *see* erythroderma  
exfoliative toxins 30.14, 30.30  
exocytosis 10.39  
exogen 66.8, 66.11, 66.20  
exomphalos–macroglossia–gigantism syndrome *see* Beckwith–Wiedemann syndrome  
*Exophiala dermatitidis* 36.77, 36.92  
*Exophiala jeanselmei* 36.77  
*Exophiala werneckii* 36.8, 36.14  
exoskeleton 2.2  
exostosis  
external auditory canal 68.28, 68.29  
subungual 62.101, 65.33–4  
expert opinion 7.3, 7.4  
exposure dose 29.1  
external auditory canal/meatus  
altitude injury 68.11  
anatomy and physiology 68.1–2  
bacterial flora 6.2, 30.4  
basal cell carcinoma 68.32–3, 79.9  
benign tumours 68.28–9  
cholesteatoma 68.28, 68.35  
eosinophilic granuloma 68.28  
examination 68.3  
exostosis 68.28, 68.29  
foreign bodies 68.11  
hypertrichosis 68.18, 68.21  
infantile haemangioma 18.46  
infection 68.20–8  
keratosis obturans 68.28, 68.35  
lichen planus 68.15  
mucoepidermoid carcinoma 68.33  
normal bacterial flora 30.4  
osteoma 68.28, 68.29  
papillomatosis 68.29  
squamous cell carcinoma 68.32–3  
verrucous carcinoma 68.33  
*see also* ear(s)  
external jugular vein 77.2, 77.3  
external otitis *see* otitis externa  
extracellular matrix (ECM) 3.33–3.50  
components 3.33–4  
*see also* collagen; elastic fibres; proteoglycan(s)  
function and cell types 3.49  
lymphatic capillaries 48.4  
PDGF upregulating in mucous membrane pemphigoid 67.20  
*see also* dermis  
extracellular matrix protein 1 gene (ECM1) 3.50  
extracorporeal photopheresis (ECP) 57.27  
in pemphigus 40.12  
in systemic lupus erythematosus (SLE) 51.62  
in systemic sclerosis 51.108  
extramammary Paget's disease (EMPD) *see* Paget's disease  
extranodal NK/T-cell lymphoma (nasal type) 57.40–1  
extravasation, in chemotherapy 75.122  
exudative discoid and lichenoid chronic dermatosis 23.11–12  
eye(s) 67.1–37  
anatomy and physiology 67.1–3  
apocrine hydrocystoma 53.18  
appendages 67.1–3  
in atopic dermatitis 24.24–5  
autoinoculation with gonococci 34.25  
in Behçet's disease 50.59–60  
bullous disorders 67.29  
caterpillar setae in 38.29  
in congenital syphilis 34.16  
in connective tissue disorders 67.29  
in Degos' disease 49.46  
drug-induced disorders 67.15, 67.16, 67.31–2  
dry 67.21  
management 67.22  
in dystrophic EB 39.19, 39.29  
in Ehlers–Danlos syndrome 45.35  
in herpes simplex 67.25–6  
hypopigmentation, in Chédiak–Higashi syndrome 58.41  
infections 67.24–8  
inherited disorders 67.28–31  
in juvenile xanthogranuloma 55.16  
in keratinization disorders 67.29–30  
in leprosy 32.13–14  
in loiasis 37.11  
in Marfan's syndrome 45.30  
in molluscum contagiosum 67.24–5  
in necrobiotic xanthogranuloma 55.28  
in onchocerciasis 37.4  
parasitic diseases involving 67.27  
in pseudoxanthoma elasticum 45.21, 45.22  
in pyoderma gangrenosum 50.70  
in relapsing polycondritis 45.43  
in rosacea 43.4, 43.5, 43.7  
in sarcoidosis 61.7  
in SLE 51.46–7, 67.25  
in Stevens–Johnson syndrome 76.16  
in Sturge–Weber syndrome 18.66  
in systemic diseases 67.24, 67.25  
in systemic sclerosis 51.103  
topical corticosteroid exposure, effects 73.19  
in toxic epidermal necrolysis 76.18  
in trypanosomiasis 37.32  
tumours affecting 67.33–4  
viral infection 67.25–6  
in xeroderma pigmentosum 15.73  
in zoster 33.25–6, 33.26, 67.26  
*see also* entries beginning ocular  
eye flies 38.6  
eye sign 37.32  
eyebrows 67.1  
ageing and 8.24  
alopecia areata 66.35  
bushy 67.3  
disorders 67.3–4  
dyes 26.60  
fusion 67.3  
hypoplasia 67.3–4  
inflammatory disorders 67.4  
inherited disorders 67.29  
loss and scarring 67.4  
plucking 67.4  
trichotillomania 67.4  
eyelashes 67.2  
alopecia areata 66.35  
disorders 67.4  
dyes 26.60  
inherited disorders 67.29  
loss 67.4, 67.8  
louse infection 38.22, 38.23  
phthiriasis 67.27  
trichomegalia, in HIV infection 35.41  
eyelids  
abnormalities 67.5–6  
actinic keratosis 67.33  
allergic contact dermatitis 23.11, 26.17, 26.22, 26.31, 67.5  
anatomy and physiology 67.1–2  
atopic dermatitis 23.11  
basal cell carcinoma 67.10, 67.34–5, 79.9  
benign cysts 67.33  
benign tumours 67.33–4  
blepharochalasis *see* blepharochalasis  
blood supply 67.2  
chalazion 67.34  
chronic oedema 48.16  
contact dermatitis 67.5  
cysts, keratoderma with 19.95, 19.111  
dermatitis, tacrolimus therapy 73.32  
discoid lupus 67.10  
eccrine carcinoma 67.36  
eczema 23.11  
epithelioma 67.35–6  
impetigo 67.26  
inflammation of margin 67.6–12  
*see also* blepharitis  
irritant contact dermatitis 25.13, 25.15  
juvenile xanthogranuloma 67.33  
Kaposi's sarcoma 67.36  
keratoacanthoma 67.34  
louse infestation 67.27  
lymphoedema 77.2  
malignant tumours 67.34–6  
margin  
intraepidermal carcinoma 52.37  
ulcers 67.6, 67.8, 67.9  
melanoacanthoma 67.34  
melanoma 67.35, 67.36  
Merkel cell carcinoma 67.36  
metastatic carcinoma 70.14  
milia 67.33  
millet-seed nodules 61.7  
occupational dermatoses 27.4  
ocular rosacea 67.7  
oedema, in rosacea 43.6  
periorbital oedema 67.5  
pigmentation 67.5  
pigmented naevi 67.34  
port-wine stain 67.34  
psoriasis 67.5  
purpura diagnosis 49.4  
radiotherapy 79.8–9  
in sarcoidosis 61.7  
sebaceous carcinoma 42.87–8, 53.17, 67.10, 67.35–6  
sebaceous glands 67.2  
seborrhoeic dermatitis 23.11  
seborrhoeic keratosis 52.39, 67.33

- shortening 67.21  
skin diseases 67.5–6  
squamous cell carcinoma 67.35, 67.36  
surgery 77.3, 77.5  
sweat glands 67.2  
swelling (blepharophyma) 43.9  
syringomas 67.33  
tarsal plate 67.2  
topical corticosteroid use, effects 73.19  
trichoepithelioma 67.33  
tricholemmoma 67.33  
vascular naevi 67.34  
warts 67.24  
wedge excision 77.35  
xanthelasma 67.33  
ezetimibe 59.93
- F**  
F granules 3.10  
fabric conditioners/softeners 25.25, 26.18  
fabricated and induced illness 64.44–5  
Fabry's disease *see* Anderson–Fabry disease (angiokeratoma corporis diffusum)
- face  
allergic contact dermatitis 26.16–17, 26.47, 26.48  
basal cell carcinoma 79.10, 79.11  
cellulitis 30.18  
*Demodex folliculorum* in rosacea 43.2  
differential diagnosis of dermatoses 26.29  
embryonic development 18.80, 18.85  
erythromelanosis follicularis of 58.36  
fibrous papule 56.2–3  
flushing *see* flushing  
focal facial dermal dysplasia 45.6, 45.8  
hemiatrophy 45.11–12, 51.70  
Herlitz junctional EB 39.12  
intra-dermal elastic tissue 45.2  
necrobiosis 68.17  
piercings 69.96  
purpura 49.4  
radiotherapy 79.10, 79.11  
rejuvenation techniques 80.4–14  
rosacea features 43.3  
sebaceous carcinoma 53.17  
seborrhoeic dermatitis 23.31  
skin biopsy 10.33  
spontaneous atrophic scarring of the cheeks 45.7  
telangiectases 47.14  
vascular tone 43.14  
warts 33.41
- facial Afro-Caribbean childhood eruption (FACE) 9.12, 43.12, 43.13  
facial artery 77.2  
facial ectodermal dysplasia 15.40  
facial hemiatrophy 46.39  
facial hyperpigmentation 58.12, 58.34–8  
management 73.28  
facial idiopathic granulomas with regressive evolution *see* acne agminata  
facial lipotrophy 46.39–40  
HAART-induced 35.22  
HIV-associated 46.42  
facial lymphoedema 48.12, 48.13, 48.16, 48.23  
management 48.23  
facial nerve 77.4–5, 77.10  
facial oedema, solid 42.74, 48.13, 48.16, 48.23  
facial palsy, zoster 33.25, 33.26  
facial skin, ageing 8.21–2  
facies, in naevoid basal cell carcinoma syndrome 52.7  
facioauriculovertebral spectrum 18.82–3, 68.4  
factitious skin disease 64.11, 64.34–46  
co-morbidity 64.41  
dermatitis artefacta (dermatitis factitia) 64.35–42, 71.56  
dermatology consultation 64.34–5  
diagnostic criteria 64.35  
investigations 64.40–1  
management 64.41–2  
medicolegal issues 64.45  
factor V Leiden mutation 14.13, 49.38, 49.39, 49.44  
factor VIII-related antigen 10.23  
factor XIa 13.4  
factor XIIIa 10.23  
expressed by dermal dendrocytes 55.4, 55.15, 55.18  
histiocytosis (class IIa) 55.15, 55.18, 55.20, 55.22  
sinus histiocytosis with massive lymphadenopathy 55.29  
factor B 13.18  
factor H 13.3  
deficiency 13.3  
factor I 13.3  
factory visits 27.8–9  
FAE *see* fumaric acid esters  
faecal contamination 71.85  
faecal impaction 39.28–9  
faeces, napkin dermatitis and 17.23  
falanga 28.32–3  
famciclovir  
action 74.49  
therapy  
herpes simplex 33.20, 33.21  
herpes zoster 33.27, 33.28, 63.6, 67.26  
familial atypical multiple mole and melanoma 62.20, 62.21–2  
familial cancer syndromes 52.6  
familial cold autoinflammatory syndrome 15.95–6  
familial cold urticaria 74.11  
familial disorders  
analysis 15.7  
definition 15.2  
*see also specific familial disorders*  
familial dysautonomia 44.7, 62.80, 63.18  
type II 15.34  
familial dyskeratotic comedones 19.76  
familial glomus tumour, genetics 15.6  
familial haemophagocytic lymphohistiocytosis (FHL) 55.25–6  
familial Hibernian fever 22.25, 50.53, 62.69, 62.104  
familial histiocytic dermoarthritis 62.104  
familial hypercholanemia 3.25  
familial hypercholesterolaemia 59.86–8  
pseudo familial hypercholesterolaemia 59.92  
familial hypomagnesaemia 3.25  
familial male-lethal type incontinentia pigmenti 15.45  
familial mandibulo-acral dysplasia 45.61–2  
familial Mediterranean fever 22.25  
with amyloidosis 62.104  
bone and joint involvement 62.104  
with urticaria 62.69  
vasculitis and 50.53–4  
familial melanoma syndrome 54.28, 62.20, 62.21–2  
familial multiple tumour syndromes 15.15–27  
familial partial lipodystrophy (FPLD) 46.40–1  
familial peeling skin syndromes 19.66–8  
familial polyendocrinopathy syndrome 36.58, 36.65  
familial polymorphous light eruption 29.13  
family(ies)  
bad news communication 72.5  
clinical decisions and 72.4  
history-taking regarding 5.5  
quality of life assessment 64.10, 72.23–4  
Family Dermatology Life Quality Index 72.23  
FAMMM syndrome (familial atypical multiple mole melanoma syndrome) 54.28  
famotidine 75.150  
Fanconi's anaemia/syndrome 58.17–18, 62.29, 62.95  
anaemia in 58.17  
immunodeficiency and 17.68–70  
*Fammia canicularis* 38.6, 38.8  
fansidar, adverse effects 37.27  
Farber's disease 59.41  
farcy 30.51  
farmer's lung 61.23  
Faroe Islands, prevalence of skin disease 6.9  
Fas (CD95), deficiency 13.15  
Fas ligand (FasL)  
in apoptosis 12.11, 40.6  
toxic epidermal necrolysis and 74.11  
facial hernias, legs 45.68–9  
'facial' network 3.50  
fasciitis, eosinophilic *see* eosinophilic fasciitis  
fasciitis–panniculitis syndrome 46.31  
fascin 55.9  
*Fasciola hepatica* 37.3  
fat  
accumulation, buffalo hump 46.42  
autologous transfer 46.39, 46.43, 80.5–6  
loss *see* lipotrophy  
metabolism, regulation 46.2–3  
subcutaneous *see* subcutaneous fat  
fat cells *see* adipocytes  
fat embolism 49.38, 62.99, 62.101  
fat granuloma 61.22  
fat necrosis *see* subcutaneous fat, necrosis  
fat tissue 46.2  
as organ 46.2  
*see also* subcutaneous fat  
fatty acid(s) 46.2  
energy source 46.3  
free *see* free fatty acids  
in ichthyoses 19.5–6  
neutral lipid storage disease with 19.52, 19.54  
Refsum's disease 19.45–6  
Sjögren–Larsson syndrome 19.42–3, 19.44  
non-esterified (NEFA) 46.3  
in sebum 42.5, 42.6  
in topical treatment 73.7  
fatty acid esters 73.35  
acnegenicity 27.13  
fatty alcohol oxidation (FAO), Sjögren–Larsson syndrome 19.42, 19.44  
fatty aldehyde dehydrogenase (FALDH), Sjögren–Larsson syndrome 19.42, 19.43, 19.44  
faun tail 18.96, 53.6, 63.15  
favourable skin tension lines, scar orientation and 77.2, 77.11, 77.13  
Favre–Chaix's purpura 49.22  
Favre–Racouchot syndrome 42.79, 45.27  
favus 36.26, 36.27  
FDH *see* focal dermal hypoplasia (FDH)  
FDS (follicular degeneration syndrome) 9.7, 66.46, 66.68  
feathers 2.3  
febrile convulsions, in roseola infantum 33.32  
febrile ulceronecrotic Mucha–Habermann disease (FUMHD) 50.50–1  
feet  
aggressive digital papillary adenocarcinoma 53.33  
allergic contact dermatitis 26.19, 26.29  
atopic dermatitis 8.7  
atopic winter *see* juvenile plantar dermatosis  
burning feet syndrome 63.25  
care in diabetes 47.58  
diabetic ulcers 47.57–8, 63.8–9  
in dystrophic EB 39.18  
erythromelalgia 47.9  
hair as foreign body 28.49  
hyperhidrosis 44.8  
localized EB simplex (Weber–Cockayne EBS) 39.6  
hyperkeratosis  
Dowling–Meara EB simplex 39.7  
localized junctional EB 39.14  
hyperpigmentation, acromelanosis 58.21  
ischaemic disease 47.2  
localized EB simplex (Weber–Cockayne EBS) 39.6  
localized junctional EB 39.14  
mechanical injury 28.10–12, 28.14, 28.16, 28.31, 28.61  
microbial eczema 23.25  
moccasin 36.31  
neuropathic ulcers 47.57  
in obesity 8.17  
occupational dermatoses 27.3  
pitted keratolysis 44.8  
psoriasis of soles 20.15  
rocker-bottom 63.8  
soles of *see* soles  
symmetrical lividity 44.8  
tropical immersion 30.49  
wrinkling 28.93  
Felty's syndrome  
leg ulceration associated 47.55  
oral involvement 69.32–3  
pyoderma gangrenosum of perianal area 51.132  
female(s)  
acne vulgaris 42.18  
sexual development 8.2  
female genital dermatology 71.52–82  
benign tumours and tumour-like lesions 71.72–4  
congenital and developmental abnormalities 71.56  
general approaches 71.1–4, 71.52  
inflammatory dermatoses 71.58–65, 71.66  
lichen planus 41.9  
lichen simplex and lichenification 71.52–3  
malignant neoplasms 71.76–9  
miscellaneous conditions 71.79–82  
non-sexually transmitted infections 71.67–70  
normal flora and variants 71.55  
precancerous dermatoses 71.74–6  
sexually transmitted diseases 71.70–2  
trauma and artefact 28.38, 71.56–7, 71.66  
ulcerative and bullous disorders 71.65–7  
vaginal discharge 71.52, 71.53–4, 71.69  
*see also individual conditions*  
female genital mutilation (FGM) 71.56–7  
female genitalia, structure and function 71.54–6  
femoropopliteal vein bypass 47.6  
fenbufen 75.74  
fenestrations 3.52  
fenofibrate 46.47, 75.31  
fenoprofen 75.74  
fentanyl 26.46  
fentichlor 26.24  
fenticonazole, topical 73.12  
Ferguson–Smith syndrome 69.54  
fermitin, Kindler syndrome 12.17  
Fernandez reaction 32.15  
ferric chloride, tattoos 58.57  
ferric sulphate, tattoos 58.57  
ferritin 49.6, 59.70  
ferrous sulphate, in restless legs syndrome 63.25  
ferulic acid 80.3  
fetal alcohol syndrome  
ear anomalies 68.3, 68.4–5  
haemangioma in 18.2  
hypertrichosis in 66.77  
fetal development, drug exposure 72.28  
fetal hydantoin syndrome, ear anomalies 68.3  
fetal hydrops 33.63  
fetal varicella syndrome 17.40–1, 18.2, 18.102

- $\alpha$ -fetoprotein 47.19, 63.16  
 fetoscopy 16.5–7  
 fetuin A 49.48  
 fetus  
   brown fat 46.1  
   free DNA 16.9–10  
   influence of environment 6.12  
   medical procedures 17.11–12  
   melanoma metastases 54.57  
   rhabdomyoma 18.37  
   RNA 16.9–10  
   sebaceous glands 42.3  
   skin biopsy 16.5–7  
   testis and testosterone secretion 8.2  
   ultrasound 16.7  
   wound healing 14.2, 14.9  
 fetus papyraceus, with aplasia cutis  
   congenita 18.100–1  
 Feuerstein–Mims syndrome 18.27–30,  
   54.11  
 fever  
   eczema herpeticum 33.35  
   hyperhidrosis and 44.7  
 fexofenadine 22.29, 74.31  
   in urticaria 22.28  
 FFDD (focal facial dermal dysplasia)  
   15.40, 15.83–4, 18.103, 45.6, 45.8  
 FG syndrome-1 15.96  
 FGF2 *see* basic fibroblast growth factor  
   (bFGF)  
 FGFR2 gene mutations 42.78  
 FGFR3 gene 18.6  
   mutations in seborrhoeic keratosis  
   52.38  
 FGM (female genital mutilation) 71.56–7  
 FH *see* fibrous histiocytoma  
 FHL (familial haemophagocytic  
   lymphohistiocytosis) 55.25–6  
 fibrates 59.93  
 fibreglass dermatitis 25.17, 27.6, 28.47–8  
 fibrillin(s) 3.2, 3.45  
   ageing and 80.2  
   lymphatic capillaries 48.4  
   in Marfan's syndrome 45.30  
 fibrillin 1 (FBN1) 3.45  
 fibrillin 2 (FBN2) 3.45  
 fibrin 49.38  
   cuff 47.26–7, 47.27  
   in venous eczema 23.35  
 fibrin cuff theory 47.26–7, 47.27  
 fibrinogen 49.38  
   in wound healing 14.3  
 fibrinoid necrosis/degeneration 10.38,  
   51.1  
 fibrinolysin/deoxyribonuclease 14.22  
 fibrinolysis 47.28  
   inhibition 49.45  
 fibrinolytic agents, platelet function  
   disorders 49.13  
 fibro-osseous pseudotumour of the digits  
   56.5  
 fibroblast(s) 3.49–50, 12.30–2  
   age-related changes 8.22  
   ageing 45.60, 80.1, 80.2  
   allogeneic human-derived 80.5  
   in chemical-induced scleroderma 45.52  
   collagen synthesis 3.49  
   cultured  
     gene expression patterns 3.49–50  
     transduction by transcription factors  
     3.50  
   dermal sheath 66.4  
   dermal subsets 3.7  
   elastin synthesis 3.44, 3.49  
   in embryonic dermis 3.3  
   functions 3.49  
   keloid 3.50, 14.15, 45.54  
   lipoid proteinosis 3.50  
   microscopy 10.35  
   MMPs synthesis/secretion 3.41  
   in palmar fibromatosis 45.45  
   pluripotent stem cell induction 3.50  
   proteoglycan synthesis 3.46  
   in wound healing 14.1, 14.7–8  
 fibroblast-derived matrix molecules 12.30  
 fibroblast growth factor (FGF) 3.3, 12.31  
   hair growth and 66.11  
   mucous membrane pemphigoid  
     pathogenesis 67.20  
   receptors, *FGFR*-2 mutation 42.71  
   wound healing and 14.3, 14.5, 14.27  
 fibroblastic rheumatism 51.133, 62.103  
 interphalangeal joints 51.133  
 fibroblastoma  
   desmoplastic 56.10–11  
   giant cell 56.14–15  
 fibrocystic disease, of pancreas 59.59  
 fibroepithelial polyp  
   oral 69.20  
   *see also* skin tags  
 fibroepithelioma of Pinkus 52.48  
   as trichoblastoma variant 53.10  
 fibrofolliculoma 53.14–15  
 fibrohistiocytic tumours 56.15–23  
   diagnosis 10.22–3  
 fibrokeratoma, acquired digital  
   (periuogal) 56.4, 65.31–2  
 fibrolipoma, neural 18.40  
 fibroma(s)  
   calcifying aponeurotic 56.7  
   collagenous 56.10–11  
   female genital dermatology 71.72  
   Gardner-associated 56.11  
   garlic clove 65.31–2  
   genetics 15.26  
   nuchal 56.11  
   oral cavity 69.20  
   perifollicular 53.14  
   periuogal 65.32  
   pinna 68.28  
   pleomorphic 56.3–4  
   sclerotic 56.3  
   storiform perineural 56.49  
   tendon sheath 56.10  
   trichoblastic 53.10–11  
   trichogenic 53.10–11  
 fibroma molluscum 62.2  
 fibromatosis 45.44–50  
   bone and joint involvement 62.101  
   congenital generalized 56.9  
   deep (non-metastasizing) 45.44  
   dermal plaque-like 56.7  
   hereditary gingival 69.14–15  
   inclusion body (digital/infantile  
     digital) 56.9–10, 65.32  
   juvenile hyaline 45.49–50, 69.15  
   palmar 45.45–6, 56.11  
   penis 45.47–8, 56.11–12  
   plantar 45.47, 56.11  
   radiation 97.18  
   subcutaneous pseudosarcomatous  
     45.50, 56.4–5, 69.112  
   superficial  
     fascial 45.44–8  
     palmar and plantar 45.45–6, 45.47,  
     56.11  
 fibromodulin 45.33  
 fibromuscular dysplasia, peripheral  
   arteries 49.48  
 fibronectin 3.2, 49.33  
   in Ehlers–Danlos syndrome 45.32,  
   45.36  
   in sarcoidosis 61.20  
   in wound healing 14.1, 14.3, 14.4, 14.7  
 fibronectin-binding proteins 30.7  
 fibropapillomas, in cats 2.22  
 fibrosarcoma 79.18–19  
 fibrosis  
   in chronic radiodermatitis 79.16  
   definition 5.7  
   oral submucous 69.106–7  
   subcutaneous fat injury leading to  
   46.11  
 fibrous dysplasia, McCune–Albright  
   syndrome 58.18  
 fibrous histiocytoma (FH) 56.16–18  
   aneurysmal 56.16–17, 56.17, 56.18  
   angiomatoid 56.19–20  
   atrophic 56.16  
   atypical 56.16, 56.17  
   cellular 56.16, 56.17  
   epithelioid 56.16, 56.17–18  
   malignant 56.22  
   myxoid malignant 56.22  
   nail involvement 65.32  
   plexiform 56.20  
 fibrous lump 69.20  
 fibrous papule of the face/nose 56.2–3  
 fibrous tumours 56.2–14  
   *see also specific types*  
 fibroxanthoma, atypical 56.20–2, 68.34,  
   79.18  
 fibulin(s) 3.2, 3.45, 45.14  
 fibulin-4 3.45  
   mutations 3.44  
 fibulin-5 3.45  
   mutations 3.44  
 fiddleback spider 38.32  
 'fiddler's neck' 28.25, 42.76  
 'field effect'  
   lentigo maligna 54.41  
   melanoma 54.36  
 fievre boutonneuse 30.73  
 fifth disease (erythema infectiosum) 5.10,  
   33.62, 33.63  
   *see also* parvovirus B19 infection  
 FIGURE (facial idiopathic granulomas  
   with regressive evolution) 43.13  
 filaggrin 3.1, 3.8, 3.10, 12.15, 12.50  
   in atopic dermatitis 24.4  
   defect, knockout mice 2.8  
   gene mutations 3.8  
   in stratum corneum 4.2  
 filariasis  
   blinding *see* onchocerciasis  
   Loa loa 37.11–12, 38.6  
   lymphatic 37.8–10, 48.12  
   lymphoedema 48.12, 48.24  
   ocular involvement 67.27  
   vectors 38.5  
 filiform keratodermas 19.114  
 filiform keratoses 19.92–3  
 filling materials, acne scars 42.69  
*Filobasidiella* 36.89  
 filopodia, melanosome transfer to  
   keratinocytes 58.4  
 filoviruses 33.3, 33.66, 33.67, 33.68,  
   33.69–70  
 filter-paper test 27.8  
 finasteride 74.32  
   adverse effects 66.25, 70.5, 75.120  
   in androgenetic alopecia 66.24–5  
   in hirsutism 66.88  
 fine-needle aspiration cytology,  
   melanoma 54.53  
 fine-needle aspiration of lymph nodes  
   5.21  
 fine-tooth comb 38.20  
 finger(s)  
   clubbing 15.87–8, 62.35, 65.7–8  
   with acanthosis palmaris 62.32  
   in inflammatory bowel disease 62.52  
   cold flexed 51.112  
   congenital onychodysplasia of index  
   fingers 65.20  
   digital nerve block 65.42, 77.10  
   fibro-osseous pseudotumour 56.5  
   myxoma 56.59  
   nails *see* nail(s)  
   nicotine staining 62.46  
   paroxysmal haematoma 28.27, 45.4,  
   45.5, 49.16  
   tulip 26.16  
   wrinkling 28.93  
 finger pebbles 59.79  
 finger tip unit 73.3, 73.4  
 fingernails  
   lichen planus 41.14, 41.15  
   torture injuries 28.33  
 fingerprints 3.3  
 Finkelstein's disease 17.33–4, 49.18–19,  
   50.30  
 Finlay–Marks syndrome 15.52  
 Finn chamber 26.85, 26.86  
 fir 26.81  
 fire ants 38.14  
 fire jelly 38.56  
 fire sponge 38.59  
 firjal (endemic syphilis) 30.63  
 first aid, burns 28.75–6  
 Fischer syndrome 15.39  
 Fischer–Volavsek syndrome 15.39  
 fish  
   colour, patterns and genetics 2.6  
   as irritants 25.21  
   pigment cells 2.5–6  
   mutations affecting 2.6  
   scales 2.2  
   skin infections 2.12  
   venomous 38.59–60  
 fish odour syndrome 44.20  
 fish scale collagen (FSC) 2.2  
 fishing, occupational hazards 27.19  
 fissure, definition 5.7  
 fissures of Santorini 68.1  
 fistula  
   branchial (cervical) 18.85–6  
   congenital auricular 18.83–4, 68.4  
   definition 5.7  
   mammary duct 70.13  
   parastomal 62.54  
   perianal/perineal 71.83, 71.87, 71.89  
   umbilical 71.100  
 fistulectomy 70.13  
 fistulotomy 70.13  
 Fitz–Hugh Curtis syndrome 34.26, 34.30  
 fixatives  
   in perfumes 26.40  
   in skin biopsy 10.4–5  
 fixed drug eruptions *see* drug reactions  
   (ADRs) (and drug-induced  
   conditions), fixed eruptions  
 fixed effects models 7.9  
 FK-506 *see* tacrolimus (FK506)  
 flag sign 66.94  
 flagellation 28.33  
 flame figures 46.33  
   conditions with 46.33  
   in eosinophilic cellulitis (Well's  
   syndrome) 46.12, 46.33–4  
   in eosinophilic panniculitis 46.12  
 flare, in triple response 22.12  
 flash burns 28.90  
 flashlamps 78.5  
   in hypertrichosis 78.12–13  
   in port-wine stains 78.7  
   in telangiectases 78.8  
 flat flies 38.6  
 'flat seborrhoeic keratosis' 54.3  
 flatworms 37.2, 37.3, 37.20–3  
 flautist's chin 28.26  
 flaviviruses 33.2, 33.61, 33.66, 33.67, 33.68  
 flavonoid drugs, venous leg ulcers 47.49  
*FLCN* gene mutations 53.14  
 flea(s) 38.11–13  
   animal 2.9–10, 38.4  
   control agents 2.10  
   diagnosis of infestation 38.4, 38.11–12  
   hedgehog 2.3  
   human (*Pulex irritans*) 2.10  
   survival 38.4  
 flea allergy dermatitis (FAD) 2.10  
 Flegel's disease (hyperkeratosis  
   lenticularis perstans) 10.39,  
   19.89–90  
 Fleisher syndrome 70.2  
 flesh flies 38.8  
 Flexible Collodion BP 73.2  
 Fli-1 10.23, 10.24  
 floor layers, occupational hazards 27.19  
 flora, skin *see* bacteria, flora (normal skin)  
 florid cutaneous papillomatosis 19.93  
 Florida horse leech 36.92  
 florists, occupational hazards 27.19  
 flour  
   as irritant 25.21  
   mites in 38.46–7  
 flow cytometry 13.16, 13.19, 13.22, 13.23,  
   17.56  
 flower cells 33.64, 33.65

- flucloxacillin 30.19–20, 75.49  
 fluconazole 74.47  
 adverse effects 75.64  
 in candidiasis 36.68, 36.69  
 in coccidioidomycosis 36.86  
 in dermatophytoses 36.48, 36.49  
 eccrine gland secretion 44.18  
 in ectodermal dysplasias 15.70  
 failure to respond to 36.50–1  
 in histoplasmosis 36.83  
 flucytosine  
 adverse effects 75.64  
 in candidiasis 36.68  
 in chromoblastomycosis 36.76  
 in cryptococcosis 36.90–1  
 fludarabine 13.24  
 in paraneoplastic pemphigus 40.23  
 fludroxycortide (flurandrenolone) 73.20  
 fluence (energy) 29.1  
 fluid balance monitoring, burns 28.83–4  
 fluid resuscitation, burns 28.77–8, 28.80–4  
 flukes 37.2, 37.3, 37.20–3  
 fluocinonide 73.37  
 fluorescein 10.12, 47.26, 75.155  
 fluorescence micro-lymphangiography 48.19  
 fluorescent treponemal antibody absorption (FTA-ABS) test 34.20, 51.52  
 fluoride  
 tooth discoloration and 69.8  
 toxicity 75.162  
 fluorochrome dyes 10.12  
 fluoroquinolones 32.17, 74.41  
 5-fluorouracil (5-FU)  
 in actinic keratosis 52.31  
 adverse effects 26.46, 75.129  
 pellagra 59.63  
 in Bowen's disease 52.34  
 intralesional 77.49  
 wart treatment 33.49  
 in non-melanoma skin cancer 52.17–18  
 squamous cell carcinoma 52.28  
 in systemic sclerosis 51.108  
 topical 73.23  
 photocarcinogenesis control 29.7  
 wart treatment 33.49  
 in xeroderma pigmentosum 15.74  
 fluoxetine 64.20, 64.28, 64.50, 74.52, 75.79  
 adverse effects, hyperhidrosis 44.7  
 flupentixol 64.52  
 flushing 8.20, 43.14–17  
 alcohol intake associated 43.16  
 carcinoid syndrome 43.14, 43.17–18, 43.19  
 causes 43.15, 43.16  
 chlorpropamide–alcohol 43.16  
 drug-induced 43.15–16  
 dry (without sweating) 43.14  
 emotionally triggered 43.15  
 food associated 43.16  
 in carcinoid syndrome 43.18, 43.19  
 gustatory 43.16  
 management 43.6  
 nicotinic acid 73.51  
 in mastocytosis 22.32, 22.35  
 mediators and pathogenesis 43.2  
 menopausal 8.20, 43.15  
 neurally activated 43.14  
 paraneoplastic 62.43–4  
 persistent 43.16  
 physiological 43.15  
 premenstrual 8.8  
 pyoderma faciale 42.84  
 in rosacea 43.1, 43.2, 43.3  
 scombroid fish poisoning 43.16  
 unilateral gustatory 43.16  
 wet (with sweating) 43.14  
 fluspirilene 75.82  
 flutamide 74.32  
 in acne 42.16, 42.54  
 adverse effects 42.54, 75.31, 75.134  
 in androgenetic alopecia 66.26  
 in hirsutism 66.89  
 fluticasone 73.16  
 fluvoxamine 64.20, 64.23–4, 64.28, 64.50  
 foam cells 46.11  
 foam dressings 14.24  
 foam sclerosant 47.39  
 focal acantholytic dyskeratosis 69.26  
 focal acral hyperkeratosis, race and 9.10  
 focal dermal hypoplasia (FDH) 15.39, 15.84–6  
 bone and joint involvement 62.100  
 oral involvement 69.33–4  
 focal epithelial hyperplasia 33.47, 69.111–12  
 focal facial dermal dysplasia (FFDD) 15.40, 15.83–4, 18.103, 45.6, 45.8  
 focal keratoderma with oral leukokeratosis 19.103  
 focal palmoplantar and oral hyperkeratosis syndrome 69.25  
 focal palmoplantar keratodermas 19.3, 19.94, 19.95, 19.102–5  
 fogo selvagem (wild fire) 40.13, 40.17–18  
 see also pemphigus foliaceus  
 folate see folic acid  
 foliate papillitis 69.107  
 folic acid 59.63  
 deficiency 62.85, 69.56, 69.85–6, 69.116, 69.117  
 pigmentation changes 58.27  
 supplementation in methotrexate therapy 74.22–3  
 folie à deux 64.15, 64.36  
 follicle centre primary B-cell lymphoma 57.45–6  
 follicle mites see *Demodex*  
 follicle-stimulating hormone (FSH) 8.4  
 in adolescence 8.4  
 in menopause 8.19  
 in menstrual cycle 8.8  
 in polycystic ovary syndrome 66.82  
 follicle unit 12.63  
 follicles, hair see hair follicle(s)  
 follicular atrophoderma, basal cell carcinoma and 52.8–9  
 follicular carcinoma 53.32  
 follicular casts 42.22  
 follicular degeneration syndrome 9.7, 66.46, 66.68  
 follicular dendritic cell(s) 13.9  
 follicular dendritic cell sarcoma 55.31  
 follicular ichthyosis 19.73  
 ichthyosis follicularis with alopecia and photophobia 19.58–9, 19.60  
 follicular infundibulum  
 comedo naevus 53.4  
 expanded, dilated pore 53.3  
 trichoadenoma 53.3–4  
 tumour 53.3  
 follicular keratosis  
 inverted 53.2–3  
 scarring 66.50–1  
 follicular mucinosis 57.14, 59.26  
 immunophenotype 57.14  
 T-cell lymphomas 57.14  
 urticaria-like 59.28  
 follicular occlusion triad/tetrad 30.79, 42.33, 42.74  
 follicular units 66.3  
 folliculitis 30.21–30, 59.80  
 acneiform oil 42.34  
 actinic 30.27–8  
 agminate 36.27  
*Candida* 42.36  
 causes 25.2  
 chronic, of legs 30.22  
 chronic verrucous, in VZV infection 35.28  
*Demodex*  
 acne vs 42.36–7  
 rosacea vs 43.5  
 in dermatophytosis 36.22  
 differential diagnosis, acne vs 42.36–7  
 dissecting  
 acne and 42.33  
 scalp see perifolliculitis capitis abscedens et suffodiens  
 eosinophilic, in HIV infection 35.18–19  
 eosinophilic pustular 17.10, 30.28–9  
 Gram-negative 30.49, 42.84  
 acne and 42.74  
 isotretinoin treatment 42.62  
*Propionibacterium acnes* antibiotic resistance 42.56  
 in HIV infection 35.24  
 isotretinoin 42.62, 42.84, 74.34  
*Malassezia* (seborrhoeic/pityrosporal) 23.34, 36.13  
 mechanical injury 28.29  
 necrotizing crystalline infundibular 19.89  
 oil 27.14, 27.16  
 perforating see perforating collagenosis (folliculitis)  
 perianal/perineal 71.91  
*Pityrosporum*, acne vs 42.37  
 pruritic of pregnancy 8.15  
 in scabies 38.39  
 scalp 42.74  
 staphylococcal 67.6, 67.11  
*Staphylococcus epidermidis* 42.36  
 superficial 30.21–2  
 trunk 30.27  
 tufted 42.74, 66.46–7  
 folliculitis decalvans 30.25, 42.74, 66.46–7  
 acne conglobata with 42.82  
 treatment 42.74  
 folliculitis keloidalis 9.9, 30.26  
 folliculitis ulerythematosus reticulata 66.51  
 folliculocentric keratotic disorders 19.72–6, 19.84  
 folliculosebaceous-apocrine tumours 53.30–2  
 Folling's disease see phenylketonuria (PKU)  
 follow-up studies 26.2  
 fondaparinux 49.27  
 Fong syndrome 15.8, 15.86–7  
*Fonsecaea* 36.75  
*Fonsecaea compacta* 36.75  
*Fonsecaea pedrosoi* 36.75, 36.76  
 food  
 consumption, obesity and 46.6  
 contact cheilitis due to 69.120  
 flushing associated 43.16  
 in carcinoid syndrome 43.19  
 histamine/histamine-releasing substances in 22.8  
 urticarial reactions to 22.8, 22.10–11, 26.105  
 food additives  
 adverse effects 75.158–60  
 allergy to 26.17, 26.22  
 challenge testing 22.26  
 chronic urticaria due to 22.10–11  
 contact urticaria due to 22.20  
 oral provocation tests 5.25  
 pigmented purpuric dermatoses due to 49.23  
 pseudoallergic reactions to 22.10  
 St John's challenge test 22.11  
 food allergy  
 atopic dermatitis and 24.23, 24.30–1  
 tests for 5.25  
 food diary, in urticaria 22.26  
 food industry, occupational hazards 27.19  
 food mites 38.46–7  
 food preservatives 75.159  
 foot see feet  
 foot and mouth disease 33.74  
 footwear  
 allergens in 26.63, 26.68–9  
 nail trauma from 65.51, 65.52, 65.53–4  
 'vegetarian' 26.69  
*Forcipomyia* 38.6  
 Fordyce spots 42.1, 42.86, 45.21, 69.2, 69.5, 69.22–3  
 Fordyce's condition 71.11  
 isotretinoin treatment 42.62  
 foregut carcinoid tumours 43.18  
 forehead  
 sebaceous glands 42.1  
 swelling (metophyma) 43.9  
 foreign bodies 28.39–52  
 aetiology 28.40, 28.41  
 clinical features 28.42  
 definition 28.39–40  
 diagnostic tools 28.42  
 ear 68.11  
 male genital dermatology 71.14  
 penetration injury 28.40, 28.49–52  
 reactions and complications 28.43–52  
 sarcoïdal reactions to 61.22  
 in sarcoidosis 61.3–4  
 treatment 28.42–3  
 in wounds 14.17  
 foreign-body granulomas, localization of tattoos 58.58  
 foreign-body reaction 61.5  
 to lipids 61.22  
 forelock, white 66.93  
 foreskin 71.9, 71.12–13  
 circumcision 71.13, 71.20, 71.24, 71.39  
 Forest Plot 7.9  
 forestry, occupational hazards 38.2  
 formaldehyde  
 acetylacetone test 26.50, 26.99  
 adverse effects 26.46, 75.164  
 as allergen 26.49–51  
 as antiseptic 73.14  
 avoidance 26.50  
 chromotropic acid test 26.50  
 in clothes 26.65, 26.67  
 in hyperhidrosis 73.9  
 as irritant 25.21  
 in leather tanning 26.68  
 lutidine test 27.8  
 nail hardeners 65.56  
 onycholysis due to 65.28  
 patch testing 26.50  
 releasers 26.49, 26.50, 26.51–3  
 resins 26.49, 26.65, 26.68, 26.69, 26.73–4  
 sources 26.50  
 formaldehyde solution BP 73.9  
 formalin 26.49  
 as fixative 10.4, 10.6  
 pigment artefact 10.31  
 soaks 44.11  
 wart treatment 33.49  
 see also formaldehyde  
 Formicidae (ants) 38.14  
 Forschheimer's sign 33.70  
 foscarnet 74.50, 75.67  
 genital ulceration in HIV-infected patients and 71.27  
 for herpes simplex 33.21  
 foundry work, occupational hazards 27.19  
 four-hoof disease 26.21  
 4p-syndrome 18.2, 18.103  
 Fournier's gangrene 71.30–1, 71.95  
 foreign bodies 28.51  
 in HIV infection 35.25  
 foveal hypoplasia 58.40  
 Fowler's solution 52.4  
 Fox–Fordyce disease 44.21–2, 70.17  
 in adolescence 8.7  
 in pregnancy 8.10  
 treatment 73.36  
 FOXC2 48.2  
 FOXC2 gene 47.37, 47.41, 62.77  
 mutation 48.9, 48.10  
 Fox–Fordyce disease 71.72  
 FOXP-1 10.26  
 Fox's sign 62.65  
 fractalkine 13.9  
 fractional photothermolysis 80.11–12  
 striae 45.6  
 fraena 69.6  
 fragile X syndrome 68.4  
 genetics 15.14  
 fragility disorders, skin see epidermolysis bullosa (EB)

- fragrance(s)  
 as allergens 26.40–3, 27.2  
 in cosmetics 26.47  
*see also* perfumes  
 Fragrance mix I 26.42  
 Fragrance mix II 26.42  
 framboesia *see* yaws  
 framycetin 26.17, 26.45, 26.46, 68.24  
 topical 73.10  
 Franceschetti–Klein syndrome 18.80–1, 68.4  
*Francisella tularensis* 30.53–4  
 François dyscephalic syndrome 15.41  
 François' syndrome 15.96  
 Franklin's disease 69.114  
 Frank's sign 68.6  
 freckles 54.1–2, 54.10, 58.1, 58.10–11  
 axillary 15.16, 15.17, 15.21  
 in neurofibromatosis 58.23  
 comparison with related disorders 54.2, 54.4  
 flexural 62.23  
 inherited and acquired disorders with 58.11  
 laser therapy 78.10  
 in Peutz–Jeghers syndrome 58.13  
 skin biopsy 10.42  
 free fatty acids  
 production by skin flora 30.4, 30.5  
 in sebum 42.5, 42.7, 42.22  
 in acne 42.22, 42.23  
 free radical(s)  
 scavengers 47.11  
 UV-induced damage and 8.21  
 freeze-induced injury 28.64  
 freezing, of tissue *see* cryotherapy  
 Frei intradermal test 34.33  
 frei jorge 26.80  
 Frei test 5.24  
 freijo 26.80  
 French paradox 47.2  
 frequency of skin disease 6.11–13, 6.18  
 Freund's complete adjuvant test 26.12  
 Frey's syndrome 44.10, 44.11, 63.22  
 friction  
 dermatitis and 25.17  
 napkin dermatitis and 17.23  
 purpura and 49.5  
 reaction to 27.6  
 friction injury 28.9–16  
 amputees 28.28  
 black heel and palm 28.16, 28.31  
 blisters 28.2, 28.9, 28.12–13, 28.28, 28.30–1  
 callosities, corns and calluses 28.2, 28.10–12  
 dermatitis 28.13–14  
 miscellaneous dermatoses 28.15–16  
 pressure ulcers 28.17, 28.21  
 frictional dermatitis of children 28.14  
 frictional melanosis 28.15  
 frictional sweat dermatitis 28.14  
 frictional ulcers 33.18  
 fried tooth and nail syndrome 15.40  
 Friedewald formula, standard lipid profile, LDL cholesterol 59.84  
 frit flies 38.6  
 Frizzled5 3.21  
 frontal emissary vein 77.2  
 frontalis muscle 77.4  
 frontonasal dysplasia and dilated Virchow–Robin spaces 15.52  
 frostbite 28.63–4  
 ear 68.8, 68.10  
 fruit acids, in actinic elastosis 45.27  
*Frullania* 26.77  
 frusemide (furosemide) 17.12, 75.31, 75.97  
 FSH *see* follicle-stimulating hormone (FSH)  
 FTA-ABS DS test 34.20  
 FTA-ABS test 34.20, 34.21  
 fucosidosis 59.33–4  
 sweat gland cellular inclusions in 44.18  
 fugitive swellings 37.11–12, 38.6  
*fumurate hydratase* (FH) gene 2.17  
 fumaric acid, in psoriasis 20.40, 74.29  
 fumaric acid esters  
 dose range and evidence level 74.29  
 flushing associated 43.15  
 in psoriasis 74.29  
 in sarcoidosis 61.21  
 fumarylacetoacetic hydroxylase (FAH), deficiencies 59.97  
 FUMHD (febrile ulceronecrotic Mucha–Habermann disease) 50.50–1  
 functional mosaicism 15.6  
 functions of skin 3.2–3, 4.1–11  
 fungal infections 36.1–93  
 in animals 2.12–13  
 collection of material 36.5–7  
 ear 36.7–8, 36.17, 68.20, 68.21, 68.27–8  
 investigation 36.6  
 endemic 36.80  
 female genital dermatology 71.68–9  
 glossary 36.93  
 in HIV infection 35.32–5, 35.45  
 laboratory investigation 36.5–10, 36.69–70, 36.80  
 lips 69.121  
 lymphoedema and 48.15, 48.22  
 male genitalia 71.32, 71.48  
 nails *see* onychomycosis  
 neonatal 17.46–8  
 nomenclature 36.5  
 opportunistic 36.80  
 oral cavity 69.79–80, 69.118  
 otitis externa 68.21  
 perianal/perineal 71.92  
 race and 9.12  
 sarcoidal reaction in 61.22  
 sarcoidosis and 61.3, 61.17  
 skin barrier function and 4.5  
 skin biopsy 10.42  
 subcutaneous 36.69–79  
 superficial and cutaneous 36.5–69  
 systemic 36.79–92, 62.80  
 vasculitis and 50.55  
 venous leg ulcers and 47.44  
 vessel-invasive 49.35–6  
*see also specific fungal infections*  
 fungi 36.1–5  
 classification 36.2–4  
 culture 36.7–9  
 dematiaceous 36.4, 36.70  
 dikaryotic 36.3–4  
 dimorphic 36.2, 36.80  
 direct examination 36.7  
 glossary 36.93  
 heterothallic 36.2  
 homothallic 36.2  
 keratinophilic 36.18, 36.19  
 moniliaceous 36.4  
 nomenclature 36.4–5  
 normal skin flora 36.10, 36.13, 36.56  
 polymorphism 36.4, 36.56  
 reproduction 36.2  
 sampling 36.5–7  
 staining 10.8, 10.9, 10.10, 36.7, 36.70  
*see also* moulds; *specific fungi*  
 funisitis, congenital syphilis 34.15  
 funnel anus 71.85  
 funnel-web spiders 38.31  
 furaltadone 26.46  
 furfuraceous scale 5.7  
 N6-furfuryladenine 80.3  
 furocoumarins, phytophotodermatitis 58.32  
 furosemide 17.12, 75.31, 75.97  
 furuncle 30.23–4  
 furuncular myiasis 38.8, 38.9  
 furunculosis 30.23–4  
 ear 68.19, 68.27  
 perianal/perineal dermatology 71.91  
*Fusarium*  
 cutaneous lesions 36.92, 49.35, 49.36  
 differential diagnosis 36.31  
 identification 36.8  
 in mycetoma 36.73  
 superficial white onychomycosis and 36.55  
 fusidic acid 26.46, 74.43  
 adverse effects 73.10, 75.59  
 in impetigo 30.16  
 ophthalmic, in rosacea 43.7  
 resistance to 30.9  
 topical, indications 73.10  
*Fusidium coccineum*, fusidic acid from 73.10  
 fusiform cells, in basal cell carcinoma 52.21  
 fusion inhibitors (HIV), side-effects 35.21  
*Fusobacterium* 30.60, 69.77  
 in tropical ulcer 30.60  
 Futch's lines 5.17, 9.2, 9.3  
 FVS (fetal varicella syndrome) 17.40–1, 18.2, 18.102  
 G  
 G-CSF *see* granulocyte colony-stimulating factor (G-CSF)  
 G-proteins 62.99  
 $\alpha$ -subunit, McCune–Albright syndrome 58.18  
 G syndrome 69.37  
 gabapentin  
 adverse effects 75.86  
 in brachioradial pruritus 63.24  
 in complex regional pain syndrome 63.21  
 in erythromelalgia 47.10  
 in post-herpetic neuralgia 63.7  
 in pruritus 21.8, 21.17, 21.18  
 in restless legs syndrome 63.25  
 in zoster and post-herpetic neuralgia 33.28  
 GABEB (generalized atrophic benign epidermolysis bullosa) 3.36–7, 39.13, 66.52  
 gadolinium 75.151  
 gadolinium-based contrast agents, nephrogenic systemic fibrosis (NSF) 51.82  
 GAGs *see* glycosaminoglycans (GAGs)  
 galactorrhoea, black 70.6  
 galactosidase A, deficiencies 59.36  
 galactosyltransferase 3.38  
 galanin 63.3  
 gallamine 75.153  
 gallates 73.8  
 GALT (gut-associated lymphoid tissue) 69.3  
 gamma benzene hexachloride *see* lindane  
 gamma/delta (provisional entity) T-cell lymphomas 57.36  
 gammopathy, benign monoclonal 49.13  
 ganciclovir  
 action 74.49  
 herpes B virus infection 33.35  
 gangrene  
 bacterial synergistic 47.57  
 causes 47.5  
 clostridial 30.68  
 cold-induced injury 28.64  
 cutaneous, varicella complication 33.25  
 definition 5.7  
 female genital region 71.67  
 foreign bodies 28.51  
 Fournier's 30.68, 30.69  
 gas 30.43–4  
 non-clostridial 59.78  
 ischaemic foot 47.2  
 male genital region 71.15, 71.30–1  
 management 47.6  
 in mixed connective tissue diseases 51.111  
 perianal/perineal region 71.93, 71.95  
 in peripheral arterial disease 47.2, 47.5  
 progressive bacterial synergistic 30.68–9  
 spontaneous 71.100  
 ulcerative colitis and 62.51  
 umbilical dermatology 71.100  
 venous limb 49.28  
 gap junction protein defects, ectodermal dysplasias 15.67–70  
 gap junctions 3.24  
 functions 3.24  
 gene mutations 3.24  
 structure 3.24  
 GAPO syndrome 15.41, 69.12  
 gardeners, occupational hazards 5.6, 27.19  
 Gardner–Diamond syndrome 49.16, 50.54, 64.33–4  
*Gardnerella vaginalis*, vaginal discharge 71.53  
 Gardner's syndrome 46.44, 62.57  
 bone and joint involvement 62.100  
 cysts in 52.45  
 epidermoid cysts in 52.45  
 fibroma in 56.11  
 genetics 15.25–6  
 oral involvement 69.39  
 garlic  
 allergic contact dermatitis due to 26.16, 26.22, 26.77  
 as irritant 25.21  
 as photoallergen 26.24  
 garlic clove fibroma 65.31–2  
 gas exchange, neonatal 17.2  
 gas gangrene 30.43–4  
 non-clostridial 59.78  
*Gasterophilus* 37.16, 38.9, 38.10  
 gastric banding, vertical 46.8  
 gastric carcinoma tumours 43.18  
 gastrinoma 62.67–8  
 gastrointestinal tract (GIT)  
 bleeding 62.55–6  
*Candida albicans* carriage 36.56, 36.58  
 cutaneous markers of disorders 62.47–58  
 decompression due to burns injury 28.78  
 in Degos' disease 49.46  
 disorders 62.47–58  
*see also specific disorders and anatomical structures*  
 drug interactions in 75.10  
 in hereditary angio-oedema 22.21  
 Langerhans' cell histiocytosis (LCH) 55.11  
 malignancies  
 carcinoid syndrome associated 43.18  
 Muir–Torre syndrome and 53.15  
 malignant histiocytosis 55.32  
 oral manifestations of disease 69.116  
 polyps 62.56–8  
 in rosacea 43.2  
 in SLE 51.44–5  
*Staphylococcus aureus* carriage 30.7  
 tumours  
 genetics 15.23  
*see also specific types*  
 in urticarial vasculitis 22.19  
 gastrostomy, in severe generalized dystrophic EB 39.29  
 gastrula 3.3  
 Gaucher cells 59.39  
 Gaucher's disease 19.60, 59.39  
 acute infantile 58.24  
 bone and joint involvement 62.100, 62.105  
 pigmentation 58.24  
 gel electrophoresis 57.12–13  
 gelatinase(s) 3.41, 12.52, 14.11  
 ageing and 80.2  
 granules 13.4  
 gelatine matrix implant, acne scar treatment 42.69  
 gels, topical therapy 73.2  
 gelsolin amyloidosis (AGel) 59.57  
 gemcitabine 75.129  
 gemfibrozil 75.156  
 GEMSS syndrome 45.53, 51.79  
 gender  
 allergic contact dermatitis and 26.7–8  
 bacterial skin flora and 30.3–4

- body dysmorphic disorder and 64.18, 64.19  
 effect on normal bacterial skin flora 30.3–4  
 irritant contact dermatitis and 25.7  
 mechanical skin properties and 28.7  
 psychocutaneous skin disease and 64.25, 64.29, 64.35  
 risk factor for skin disease 6.12
- gene(s) 11.1  
 cancer 'modified' 52.13  
 cancer susceptibility modifying 52.10–11  
 candidate 11.11–14  
 acne vulgaris 42.19  
 disease-causing, identification 11.11–14  
 expression 11.2–3  
 mapping 11.12  
 microarrays 11.7–8, 11.9  
 mismatch repair 11.18  
 mutation, transfection 11.10  
 mutator 52.12  
 oncogenes 11.17–18  
 positional cloning 11.1, 11.12  
 promoter region 11.3  
 reporter 11.10  
 sexual development 8.2  
 stable transfection 11.10  
 studies of expression and function 11.9–11  
 transcription 11.2–3  
 transient transfection 11.9–10  
 translation 11.3  
 tumour-suppressor 11.17–18
- gene therapy 11.20–2  
 angiogenesis using 47.6  
 in epidermolysis bullosa 39.31  
 gene tracking 15.7  
 general anaesthesia 75.153, 77.11  
 general anaesthetic agents 75.153  
 skin testing for reactions to 75.172  
 General Health Questionnaire (GHQ) 42.35
- General Household Survey, UK 6.5  
 general practitioners (GPs) 6.14–15  
 with special interest in dermatology 72.2
- generalized atrophic benign epidermolysis bullosa (GABEB) 3.36–7, 39.13, 66.52
- generalized eruptive keratoacanthoma 52.44
- generalized folded skin 18.36, 18.40, 18.107
- generalized idiopathic ischaemic dermatopathy (GIID), in dogs 2.15
- generalized pustular psoriasis (GPP) 20.48–50  
 acute (von Zumbusch) 20.49–50  
 calcipotriol treatment 73.45  
 localized forms 20.52  
 in pregnancy 20.50–1
- genetic counselling 15.9, 15.18, 15.24, 16.1  
 congenital naevi 54.13  
 Ehlers–Danlos syndrome 45.37  
 familial melanoma 54.34  
 Peutz–Jeghers syndrome 58.13
- genetic diseases  
 blistering disorders 39.1–37  
 see also epidermolysis bullosa (EB); Hailey–Hailey disease  
 cancer as 52.12  
 connective tissue diseases 51.79  
 obesity in, cutaneous features 8.18  
 see also specific genetic diseases  
 genetic factors 6.12  
 acne vulgaris 42.18–19  
 adverse drug reactions 75.12–13  
 albinism 66.94  
 alopecia areata 66.31  
 androgenetic alopecia 66.18–19  
 atopic dermatitis 24.3–4  
 basal cell carcinoma 11.18  
 developmental defects 18.2–3  
 drug reactions 76.10–11  
 harlequin ichthyosis 11.13  
 Henoch–Schönlein purpura 50.11  
 immunodeficiency disorders 17.51  
 irritant contact dermatitis 25.6  
 Kawasaki disease 50.11  
 leprosy 32.2  
 lichen planus 41.2  
 malignant disease 11.17–19  
 malignant melanoma 11.18  
 mastocytosis 22.30, 22.31  
 pigmentation variations 58.9–10  
 pseudoxanthoma elasticum 45.21  
 sarcoidosis 61.3  
 squamous cell carcinoma 11.18  
 urticaria 22.3  
 vasculitis 50.11–12  
 Wegener's granulomatosis 50.11  
 see also genetics  
 genetic imprinting 24.5  
 genetic instability 52.12  
 genetic linkage 11.11–14  
 genetic mosaicism see mosaicism  
 genetic stability, genetic factors affecting 52.12
- genetics 15.1–97  
 acrokeratotic poikiloderma of Weary 15.82  
 analysis of inherited disorders 15.7  
 autosomal genes 15.4, 15.10–12  
 Bazex–Dupré–Christol syndrome 15.83  
 Bloom's syndrome 15.76–7  
 cartilage–hair hypoplasia syndrome 15.32, 15.93  
 chromosomal abnormalities 15.2, 15.9–14  
 CINCA syndrome 15.95–6  
 clubbing of fingers and toes 15.87–8  
 Cockayne's syndrome 15.75–6  
 congenital scalp defects with distal limb anomalies 15.96  
 contiguous gene syndromes 15.6  
 Cornelia de Lange syndrome 15.92  
 Cowden's disease 15.26–7  
 craniosynostoses 15.90–2  
 cutis verticis gyrata 15.89  
 dermo–chondro–corneal dystrophy 15.96  
 DNA instability 15.70–7  
 Dowling–Degos disease 15.94–5  
 drug responses 72.29–30  
 dyschromatosis symmetrica hereditaria 15.95  
 dyschromatosis universalis hereditaria 15.95  
 dyskeratosis congenita 15.36–7, 15.78–80  
 ectodermal dysplasias 15.27–70  
 familial cold autoinflammatory syndrome 15.95–6  
 familial multiple tumour syndromes 15.15–27  
 FG syndrome-1 15.96  
 focal dermal hypoplasia syndrome 15.39, 15.84–6  
 focal facial dermal dysplasia 15.40, 15.83–4  
 Gardner's syndrome 15.25–6  
 genetic counselling see genetic counselling  
 genodermatoses 15.1, 15.2, 15.3–4  
 genomic imprinting 15.6  
 heterogeneity 15.5  
 high-throughput analysis 15.6  
 histocompatibility antigens 15.8–9  
 human genome organization 15.4  
 inheritance patterns 15.2, 15.3–4  
 Kindler's syndrome 15.82–3  
 lines of Blaschko 15.6, 15.7  
 linkage disequilibrium 15.7–8  
 lyonization 15.6  
 mosaicism 15.6, 15.11  
 Muckle–Wells syndrome 15.95–6  
 mutations and disease 15.5, 15.6  
 nail–patella syndrome 15.8, 15.86–7  
 neurofibromatosis 15.2, 15.6, 15.14, 15.15–21  
 Noonan's syndrome 15.14–15, 15.20–1  
 nosology in skin disease 15.2, 15.3–4  
 nucleotide excision repair 15.71–2, 15.75–6  
 online databases 15.1  
 pachydermoperiostosis 15.87, 15.88–9  
 poikilodermatous syndromes 15.78–83  
 polymorphisms 15.6, 15.7  
 principles of medical genetics 15.2–8  
 Rothmund–Thomson syndrome 15.51, 15.80–2  
 Rubinstein–Taybi syndrome 15.92–3  
 sex-linked genes 15.4, 15.12–14  
 tuberous sclerosis complex 15.6, 15.21–5  
 twin spotting 15.7  
 two-hit progression to tumour formation 15.5–6  
 uniparental disomy 15.7  
 van der Woude syndrome 15.93–4  
 Werner's syndrome 15.77  
 xeroderma pigmentosum 15.5, 15.70–5  
 see also genetic factors
- genital chancres 34.6–7  
 genital dermatology  
 female see female genital dermatology  
 male see male genital dermatology  
 genital herpes see herpes simplex, genital infections  
 genital lentiginosis 54.6–7  
 genital lymphangiectasia 48.28  
 genital lymphoedema 30.70, 48.12, 48.16  
 management 48.23  
 genital mucosa, verrucous carcinoma 52.26  
 genital mutilation 71.15  
 female 71.56–7  
 genital papular acantholytic dyskeratosis 71.81  
 genital warts see wart(s), anogenital
- genitalia  
 acute ulceration 71.65–6  
 in Behçet's disease 50.58–9  
 Bowenoid papulosis of 52.37  
 female  
 atrophy, in menopause 8.19  
 structure and function 71.54–6  
 see also female genital dermatology  
 male see male genital dermatology  
 melanoma 54.47  
 pyoderma gangrenosum 50.70  
 scabies 38.39  
 sebaceous glands 42.1  
 warts see wart(s), anogenital
- genitocrural dermatology 71.4–8  
 candidosis 71.5, 71.6  
 dermatitis 71.5  
 erythrasma 71.6  
 general approaches 71.1–4  
 infections 71.6–7  
 inflammatory dermatoses 71.4–6  
 intertrigo 71.4–5, 71.7  
 tinea cruris 71.6–7  
 genitogingival syndrome 71.23  
 genitoperineal raphe, congenital sinuses and cysts 18.94–5  
 genitourinary tract, in dystrophic EB 39.29  
 genodermatoses 15.1  
 associated with internal malignancy 62.19–29  
 bony changes in 62.99  
 inheritance patterns 15.2, 15.3–4  
 prenatal diagnosis 16.1–11  
 synophrys 67.3  
 genome-wide screens, high-throughput  
 genetic analysis 15.6  
 GenoMEL 54.33, 54.34  
 genomic hybridization, comparative (CGH) 57.20  
 genomic imprinting 15.6  
 genomics 11.7–8, 11.9  
 genophotodermatoses, investigations 29.24  
 gentamicin 26.17, 26.45, 26.46, 30.9, 68.24, 74.42, 75.58  
 topical therapy 73.10  
 gentian violet 10.10, 25.12, 25.21  
 accidental tattoos 58.57  
 topical therapy 73.48  
 geographic factors 6.12  
 in diagnosis 5.5  
 geographical tongue see tongue, geographical  
 geotrichosis 69.80  
 gerbils 2.9  
 geroderma (geroderma) osteodysplastica 45.15, 45.60–1  
 gestational pemphigoid see pemphigoid gestationis  
 gestrione 75.119  
 GF see granuloma faciale  
 GH see growth hormone (GH)  
 Ghon focus 31.8  
 Gianotti-type perioral dermatitis (granulomatous perioral dermatitis) 43.12, 43.13  
 Gianotti–Crosti-like syndrome 33.77–8  
 coxsackievirus infections and 33.72  
 diagnosis and treatment 33.78  
 hepatitis A and 33.74  
 non-viral causes 33.77  
 pathology and clinical features 33.77–8  
 viral causes 33.77  
 Gianotti–Crosti syndrome  
 EBV infection and 33.31, 33.77  
 HBV infection and 33.61, 33.77, 62.59, 62.64  
 giant cell(s)  
 foreign-body, in rosacea 43.4  
 herpes simplex 33.16  
 in juvenile xanthogranuloma 55.15  
 microscopy 10.34–5  
 multinucleate see multinucleate giant cells  
 in necrobiotic xanthogranuloma 55.28  
 septal panniculitis 46.12  
 giant cell angioblastoma 56.32  
 giant cell arteritis 50.43–4, 61.17  
 granuloma annulare and 60.9  
 oral involvement 69.81–2, 69.117  
 giant cell tumour, tendon sheath 56.15–16, 65.36  
 giant condyloma  
 female genital dermatology 71.76–7  
 male genital dermatology 71.44–6  
 perianal/perineal dermatology 71.95  
 giant condyloma acuminatum 52.26  
 giant hogweed 26.16  
 giant porokeratoses 19.91  
 giant rhinophyma, with symmetrical lipomatosis 46.46  
 giant trichoblastoma 53.10  
 gigantism 62.2  
 Gigantobilharzia 37.22  
 gigantomastia 70.3  
 Gilchrist's disease see blastomycosis  
 gingivae 69.2  
 bleeding 69.12  
 blisters 69.14  
 erythema 69.13  
 examination 69.6  
 haemangioma 69.13  
 hyperplasia 69.12–13  
 drug-induced 69.21, 75.47  
 in hypoplasminogenaemia 69.15  
 inflammation see gingivitis  
 in juvenile hyaline fibromatosis 69.15  
 in Noonan's syndrome 15.14  
 pigmentation 69.13  
 in scurvy 69.21  
 telangiectases 69.13  
 ulcers 69.14  
 white patches 69.13  
 gingival crevice 69.2, 69.3  
 gingival cysts of the newborn 17.5, 69.17  
 gingival fibromatosis 15.27  
 hereditary 69.14–15  
 hypertrichosis and 15.40

- gingival fibromatosis—sparse hair—malposition of teeth 15.40
- gingivitis 69.12
- acute ulcerative (necrotizing) 69.14, 69.77–8
- allergic 26.21, 26.41
- chronic 69.17
- desquamative 69.13, 69.19, 69.67, 69.106
- plasma cell 69.13
- in pregnancy 8.11, 69.20–1
- gingivostomatitis
- allergic (atypical/plasma-cell) 69.19
- herpetic 33.16
- white folded 35.43, 69.23–4
- Ginkgo biloba* 26.22, 26.75, 75.162
- GIT *see* gastrointestinal tract (GIT)
- glabrous skin 3.3
- Merkel cells 3.16
- glanders 30.51
- glands
- apocrine 44.1, 44.2
- in mammals 2.4
- atrial 2.4
- eccrine 44.1, 44.2
- evolution 2.4
- in mammals 2.4
- epitrichial 2.4
- evolution 2.1, 2.4–5
- 'generation' 2.4
- holocrine 44.1
- merocrine 2.4, 44.1
- sebaceous, in mammals 2.4
- specialized 44.1–2
- urophygial (green), in birds 2.4
- see also specific types*
- glands of Montgomery 70.1
- glandular fever *see* infectious mononucleosis
- Glasgow seven-point check-list, melanoma 54.37
- glassy membrane 66.7
- glatiramer acetate 50.83–4, 75.155
- lobular panniculitis at injection site 46.14
- glaucoma
- adverse effects of treatment 26.46
- corticosteroid-induced 67.15, 67.16, 67.31, 73.19
- earlobe creases and 68.6
- in Sturge–Weber syndrome 18.66
- glaziers, occupational hazards 27.19
- Gleich syndrome *see* hypereosinophilic syndrome
- Gli-1, overexpression 53.2
- glial filament acidic protein (GFAP) 3.9
- glibenclamide 75.156
- glioma, nasal 18.89–90, 56.52
- glipizide 75.156
- Global Alliance algorithm, for acne outcome improvement 42.39, 42.40
- Global Alliance for the Elimination of Lymphatic Filariasis 37.10
- global warming 26.10
- globoside 33.63
- glomangioma/glomangiomyoma *see* glomus tumour
- glomerulonephritis
- in dystrophic EB 39.20
- ear involvement 68.17
- following streptococcal infection 30.12, 30.15–16
- in loiasis 37.11
- mesangiocapillary, partial lipotrophy and 46.39–40
- glomus bodies 65.4
- glomus cells 56.43
- glomus tumour 56.43–4, 65.15, 65.17, 65.34–5
- diagnosis 10.23, 56.43
- familial 15.6
- female genital dermatology 71.73
- hyperhidrosis and 44.9
- jugulare 68.29
- multiple 18.73–4
- solitary plaque-like telangiectatic glomangioma 47.20
- glomouvenous malformation 18.73–4
- Glossinidae (tsetse flies) 37.2, 37.29, 38.6
- glossitis 69.22
- benign migratory *see* tongue, geographical
- deficiency 69.85–6
- median rhomboid 36.61, 69.88, 69.105–6
- tertiary syphilis 34.14
- glossodynia/glossopyrosis 26.20, 26.39, 62.85, 69.86–7
- gloves
- in hand eczema 23.21–2
- latex 26.105
- protective 5.3, 5.4, 25.25, 26.72–3
- recommended materials 25.24
- rubber 26.63
- glucagonoma syndrome *see* necrolytic migratory erythema
- glucan, adverse effect in HIV infection 35.21
- $\beta$ -glucans 36.1
- glucocorticoid receptor alpha (GR $\alpha$ ) 73.16–17
- glucocorticoid receptor beta (GR $\beta$ ) 73.17
- glucocorticoid response elements (GREs) 73.17
- glucocorticoids *see* corticosteroids
- glucose
- intolerance 8.28
- in sweat 44.6
- glucose-6-phosphate dehydrogenase 73.30
- glucose-6-phosphate dehydrogenase deficiency 74.39
- treatment for linear IgA disease 40.50
- glucose transporter receptor 4 (GLUT-4) 46.2
- glue, application to skin 64.38, 64.39
- glutaraldehyde
- as allergen 26.58
- as antiseptics 73.14
- in epidermolysis bullosa simplex 39.31
- in hyperhidrosis 44.11, 73.9
- wart treatment 33.48–9
- glutathione S-transferase (GST),  $\pi$  isoform 2.20
- gluten-free diet 40.61–2
- treatment of psoriasis 20.43
- glutethimide 75.81
- glyburide 75.156
- glycaemic index, acne and 42.34
- glycerol, anti-irritant effect 25.25
- glycerol suppositories 39.28
- glyceryl monoacetate 26.79, 26.82
- glyceryl monothioglycolate 26.17–18
- glyceryl trinitrate 75.97
- cold-induced injury 28.70
- glycine, in elastin 3.43
- glycine-X-Y sequence 3.32, 3.34
- glycolic acid 80.9
- glycolic aciduria 49.37
- glycolipids, stratum corneum 3.11
- glycopeptide antibiotics 74.43
- glycoprotein 11b–111a (GP11b–111a), platelet-specific integrin 12.32
- $\beta_2$ -glycoprotein I ( $\beta_2$ -GPI) 49.40, 49.41
- antibodies 49.40, 49.41
- glycoproteinoses 59.33
- acroparesthesiae 59.37
- degradation disorders 59.33–5
- storage disorders, classification 59.33
- glycoproteins, non-collagenous 3.34
- glycopyrrolate cream 73.9
- glycopyrronium bromide 44.10, 44.11, 63.23, 73.9
- glycosaminoglycans (GAGs) 3.2, 3.34, 3.45–9, 59.21, 59.30
- ageing and 80.1
- degradation enzyme deficiencies 59.30–1
- functions 3.46–7
- postassembly modification 3.45–6
- structure and synthesis 3.45–6
- glycosylation
- blood vessels, ageing and 8.21
- collagen 3.38
- glycosylphosphatidylinositol (GPI) anchor 49.30
- Glycyphagidae 38.47
- Glycyphagus* 38.47
- glycyrrhetic acid 73.49
- glyoxal 26.58
- glypican family of proteoglycans 3.45
- GM-CSF *see* granulocyte–macrophage colony-stimulating factor
- Gnaphosidae 38.32
- gnathophyma 43.9, 43.10
- Gnathostoma* 37.16, 37.18–19
- gnathostomiasis 37.18–19
- goblet cells
- eyelids 67.2
- loss, Stevens–Johnson syndrome 67.21
- Goeckerman regimen 73.42
- gold, metallic, contact allergy 26.26, 26.38–9, 68.7–8
- gold therapy 74.29–30
- adverse effects 75.100–1
- chrysiasis 58.54–5, 75.33, 75.100
- erythroderma 23.47
- eyelid pigmentation 67.5
- flushing 43.15
- lichenoid eruptions 41.24
- oral pigmentation 69.97
- pityriasis rosea 75.24
- dose range and evidence level 74.30
- Goldenhar syndrome 18.82–3, 68.4
- Golgi zones, sebaceous cells 42.3
- golimumab 74.5
- psoriasis 74.5
- Goltz syndrome *see* focal dermal hypoplasia (FDH)
- Goltz–Gorlin syndrome *see* focal dermal hypoplasia (FDH)
- Golubatz fly 38.5
- Gomm–Button disease *see* Sweet's syndrome
- Gomori's silver impregnation technique 10.9
- gonadal mosaicism 15.6
- gonadotrophin(s) 8.4
- adverse effects 75.117
- acneiform eruptions 42.72
- sebaceous gland activity and 42.11, 42.12
- gonadotrophin-releasing hormone (GnRH) 8.4
- agonists
- in acne vulgaris 42.53
- in hirsutism 66.89
- pulsatile output, menstrual cycle 8.8
- receptor 8.4
- release, neurokinin B role 8.20
- Gongylonema pulchrum* 37.18
- gonococcal infection 30.45–6
- arthritis and 62.105
- disseminated (DGI) 34.26–8
- vasculitis and 50.55
- see also* gonorrhoea
- gonococci *see* *Neisseria gonorrhoeae*
- gonorrhoea 30.45–6, 34.24–9
- clinical features 34.25
- complications 34.26–8
- diagnosis 34.28
- epidemiology 34.25, 34.28
- management 34.28
- oropharyngeal 69.78–9, 69.118
- in pregnancy and breastfeeding 34.28
- prevalence 34.2
- trichomoniasis and 37.29
- see also* gonococcal infection; *Neisseria gonorrhoeae*
- Goodpasture's syndrome 3.27, 3.35
- Gorham's (Gorham–Stout) disease 18.76, 48.27
- bone and joint involvement 62.99, 62.100
- gorilla, lice 38.15
- Gorlin–Chaudhry–Moss syndrome 15.40
- Gorlin's syndrome *see* naevoid basal cell carcinoma syndrome
- Gottron's papules, dermatomyositis 51.123–4
- Gottron's syndrome (progressive symmetrical erythrodermatoderma) 19.70–1, 45.58, 45.59–60
- Gougerot–Carteaud syndrome 19.121–2
- Gougerot–Houwer–Sjögren syndrome 51.134
- see also* Sjögren's syndrome
- gout 59.101, 62.101, 62.105
- lobular panniculitis 46.17
- sarcoidosis and 61.18
- sweating and 44.7
- see also* tophi, gouty
- GPP (generalized pustular psoriasis), calcipotriol treatment 73.45
- GPR54 receptor 8.4
- GPs (general practitioners) 6.14–15
- with special interest in dermatology 72.2
- graft-versus-host disease (GVHD) 17.53, 51.83–6, 62.96–9
- acute 51.83–6, 62.96–7, 67.22
- autoantibodies to Merkel cells 3.16
- chronic 51.83–6, 62.97, 62.98, 67.22
- hypermelanosis after 58.31
- clinical features 51.84–5
- cutaneous histological changes grading 51.83
- following blood transfusion 75.154
- hyperacute 62.96
- incidence and aetiology 51.83
- localized morphea and 51.65
- materno-fetal 17.59
- ocular involvement 67.22
- oral involvement 69.83
- pathology 51.83–4
- prognosis 51.85
- treatment 62.97–8
- graft-versus-leukaemia reaction 62.96
- grafts, tattoo removal 58.59
- Graham–Little–Piccardi–Lassueur syndrome 41.11, 66.42–3
- grain/grain-shoveller's itch 38.48
- Gram-negative bacteria
- normal skin flora 30.2
- overgrowth, folliculitis 42.84
- Gram-positive cocci, normal skin flora 30.2
- Gram-positive rods, normal skin flora 30.2
- Gram stain 10.10
- granisetron 75.79
- granular cell tumour 56.50–1, 71.73
- congenital epulis 69.17
- dermal non-neural (primitive polypoid/primitive non-neural) 56.59
- oral 69.55
- pinna 68.28
- granular degeneration 10.39–40, 42.78
- granular parakeratosis 70.17
- granule defects, in Chédiak–Higashi syndrome 58.41
- granule deficiencies 12.23
- granulocyte colony-stimulating factor (G-CSF) 46.32
- adverse effects 50.74, 50.76, 75.141–2
- localized reaction to 50.90
- granulocyte–macrophage colony-stimulating factor (GM-CSF) 12.16
- adverse effects 75.142
- histiocyte ontogeny 55.3
- polymorphonuclear granulocytes 12.20
- skin barrier function and 25.3
- granulocytes, polymorphonuclear 12.20–4
- granuloma(s) 52.44
- actinic/Miescher's/O'Brien's 45.28–9, 50.85, 60.1, 60.13–14

- actinic/O'Brien's 45.28–9  
 in allergic contact dermatitis 26.26–7  
 annular elastolytic giant cell 60.13–14  
*Candida* 36.65  
 Churg–Strauss 50.42, 50.52  
 cutaneous extravascular necrotizing 50.52  
 denture 69.109–10  
 eosinophilic  
 external auditory canal 68.28  
 pregnancy and 8.12  
 traumatic 69.43  
*see also* Langerhans' cell histiocytosis (LCH)  
 facial idiopathic  
 aseptic 43.14  
 with regressive evolution *see* acne agminata  
 fat 61.22  
 fibrin ring 50.24  
 fish-tank *see Mycobacterium marinum*  
 foreign-body 36.75  
 localization to tattoos 58.58  
 histopathology 10.39  
 in HIV infection 35.26  
 immunization 28.45  
 infantile gluteal 17.27–8, 71.91, 73.18  
 insulin, zinc-induced 28.46  
 juvenile giant-cell *see* juvenile xanthogranuloma  
 lethal midline 69.57  
 lick 2.9  
 lipophagic 46.13  
 mineral oil 46.29  
 necrobiotic 60.3–4  
 oil 46.29–30  
 perifollicular, in lichen nitidus 41.22  
 pseudopyogenic 56.27–8, 68.15–16  
 pulse 69.109  
 pyogenic *see* pyogenic granuloma  
 radial (Miescher) 46.12  
 reticulohistiocytic *see* multicentric reticulohistiocytosis  
 sarcoid 61.3, 61.4–5  
 localization to tattoos 58.58  
 in schistosomiasis 37.21  
 sea urchin 38.58  
 silica 61.22  
 swimming-/diving-associated 28.55  
 swimming pool *see Mycobacterium marinum*  
 telangiectaticum *see* pyogenic granuloma  
 tuberculoid 31.8–10, 32.4, 32.5  
 ulcerating of the pudenda *see* granuloma inguinale  
 umbilical 18.93, 71.100  
 xanthomatous, with necrobiosis 55.27–9  
 zirconium 61.22  
*see also specific types*  
 granuloma annulare 5.12, 59.79, 60.1–12  
 aetiology 60.1–3  
 associations 60.9–10  
 autoimmune thyroiditis and 60.9  
 bone and joint involvement 62.101  
 clinical features 60.5, 60.6, 60.7–9  
 diabetes mellitus and 60.9  
 differential diagnosis 60.9  
 ear 60.7, 68.15  
 follicular pustulous 60.7  
 generalized/disseminated 60.5, 60.6, 60.7  
 giant cell arteritis and 60.9  
 histopathology 60.3–5  
 in HIV infection 35.19–20, 60.1, 60.7  
 linear 60.7  
 localized 60.5, 60.6  
 malignant disease and 60.9  
 Mauriac's syndrome and 60.9  
 morphea and 60.9  
 necrobiosis lipoidica and 60.9, 60.15  
 papular umbilicated 60.7  
 paraneoplastic 62.38–9  
 'patch' 60.7  
 perforating 60.4, 60.7, 60.9  
 pustular generalized perforating 60.7  
 sarcoidosis and 60.9, 61.17  
 scalp 66.5  
 seasonal recurrence 60.1  
 skin biopsy 10.43  
 subcutaneous 60.7, 60.9  
 treatment 60.10–12  
 tuberculosis and 60.1  
 uveitis and 60.9  
 viral infection and 60.1  
 granuloma faciale 50.28–30  
 in dermatophytosis 36.22  
 ear 68.16  
 treatment 50.29, 78.9, 78.14  
 granuloma gluteale infantum 36.63  
 granuloma gravidarum 8.11, 56.25  
 granuloma inguinale 30.61–2, 34.36, 34.36–7, 71.93  
 female genital dermatology 71.71  
*see also Calymmatobacterium granulomatis*  
 granuloma multiforme 60.14, 60.17  
 granuloma multiplex haemorrhagicum *see* Kaposi's sarcoma  
 granuloma telangiectaticum *see* pyogenic granuloma  
 granuloma venerum *see* granuloma inguinale  
 granulomatosis  
 Langerhans' cell *see* Langerhans' cell histiocytosis (LCH)  
 lipoid, Erdheim–Chester disease 55.18–19  
 orofacial 48.16  
 Wegener's *see* Wegener's granulomatosis  
 granulomatosis disciformis 61.5, 61.17  
 granulomatous cheilitis, Miescher's 48.16, 61.23, 69.60, 69.125–7  
 granulomatous dermatitis 51.131  
 granulomatous disease(s)  
 chronic *see* chronic granulomatous disease  
 disseminated lipogranulomatosis 59.41  
 leg ulcers in 47.57  
 lethal midline granuloma 57.40  
 lymphoedema in 48.13, 48.23  
 secondary B-cell lymphomas 57.51  
 slack-skin disease 45.20, 57.15–16  
*see also specific diseases*  
 granulomatous perioral dermatitis in children 43.12, 43.13  
 granulomatous reactions  
 to foreign bodies 28.47, 28.48  
 to injected oils 46.29–30  
 TNF antagonists 74.8  
 granulomatous slack skin 45.20, 57.15–16  
 granulosis rubra nasi 44.18  
 granzyme 10.26, 13.11  
 grasshoppers 38.28  
 Graves' disease 53.22, 62.7–8  
 gravity, pigmented purpuric dermatoses and 49.22  
 gravity stasis, purpura due to 49.14  
 grease-gun injury 46.29–30  
 greases, in topical treatment 73.6  
 great auricular nerve 77.3  
 'the greater patient' concept 72.23  
 green shield bug 38.25  
 green tea extract, wart treatment 33.50  
 greenbottle fly 14.22, 38.8  
 Greither's syndrome 19.94, 19.98–9  
 grenadil 26.81  
 grenadilla 26.81  
 Grenz rays  
 in allergic contact dermatitis 26.102  
 guidance on use 79.4  
 non-melanoma skin cancer associated 52.5  
 Grenz zone 10.39, 50.29  
*Grevillea* 26.75, 26.81  
 grey syndrome 75.64  
 Grey Turner sign 62.65  
 Griscelli syndrome 13.13, 17.78–9, 17.80–1, 58.42, 62.95  
 griseofulvin 74.47–8  
 adverse effects 75.64–5  
 in dermatophytoses 36.48, 36.49, 36.50  
 eccrine gland secretion 44.18  
 pigmented purpuric dermatosis 49.26  
 GRO-alpha (CXCL1) 12.46  
 Grocott's silver staining technique 10.10  
 groin, bacterial flora 30.4  
 Grönblad–Strandberg syndrome *see* pseudoxanthoma elasticum (PXE)  
 gross cystic disease fluid protein-15 (GCDFP-15) 53.22  
 extramammary Paget's disease 53.40  
 ground itch 37.2, 37.14–15  
 stronglyloid *see* stronglyloidiasis  
 group/mass populations reactions 64.25–6  
 group therapy 64.53  
 Grover's disease (transient and persistent acantholytic dermatoses) 19.86–8  
 differential diagnosis 40.11  
 treatment 73.44  
 growth  
 abnormal or delayed 8.3  
 delay in atopic dermatitis 24.24  
 intrauterine retardation 17.1  
 postnatal 8.1–2  
 somatic 8.1–2  
 spurts 8.4  
 growth factors  
 from cells other than keratinocytes 12.76  
 collagen gene expression control 3.39  
 exogenous, in wound healing 14.27  
 for melanocytes 58.5  
 mucous membrane pemphigoid pathogenesis 67.20  
 pressure ulcers 28.23  
 trapped, venous ulcers and 47.27  
*see also specific factors*  
 growth hormone (GH) 8.1  
 in breast development 70.1  
 concentration in plasma 8.2  
 deficiency 8.2, 8.4, 62.3  
 Langerhans' cell histiocytosis (LCH) 55.12  
 excess secretion 8.2, 62.2  
 gene expression 8.1  
 hair growth and 66.13  
 in hypopituitarism 62.3  
 recombinant, in erythromelalgia 47.10  
 replacement, localized lipohypertrophy 46.35  
 sebaceous gland activity and 42.11  
 growth hormone-releasing hormone 8.2  
 growth-regulated gene/melanoma growth stimulating activity (GRO/MGSA) 12.74  
 growth retardation–alopecia–pseudoanodontia–optic atrophy (GAPO) 15.41  
 Guanarito virus 33.67, 33.69  
 guanethidine 75.96  
 systemic sclerosis 51.108  
 Guanieri bodies 33.5  
 guanine 11.2  
 Guillain–Barré syndrome, zoster 33.26  
 guinea pig maximization test 26.11, 27.10  
 guinea pig model 73.32  
 guinea worm 37.12–13  
 guitar nipple 28.25, 70.11  
 gum benzoin 26.40  
 gum rosin 26.79  
 gumma  
 syphilitic 34.5, 34.13–14, 66.52, 69.78  
 tuberculous 31.10, 31.19–20  
 gummatous neurosyphilis 34.14  
 gums *see* gingivae  
 Günther's disease *see* congenital erythropoietic porphyria (CEP)  
 gut-associated lymphoid tissue 69.3  
 Guthrie test 59.95  
 guttate morphea *see* lichen sclerosus  
 GVHD *see* graft-versus-host disease  
 gynaecomastia 70.3–6  
 aetiology 70.4  
 drug-induced 70.4–5  
 in endocrine disorders 70.4  
 haemodialysis and 62.72, 70.4  
 management 70.5–6  
 physiological 70.4  
**H**  
 H-caldesmon 10.22  
 H-ras proto-oncogene 52.13  
 Haarscheibe 53.14  
 hamartomatous proliferation of mesodermal component 53.14  
 HAART *see* highly-active antiretroviral therapy (HAART)  
 Haber's syndrome 52.41  
 habit disorders 64.26–34  
 A-B-C model 64.28  
*Hadronyche* 38.31  
 haem 59.2–5  
 biosynthesis 59.3  
 six key structural changes 59.4  
 enzyme deficiencies 59.5  
*see also* porphyria  
 haemangioendothelioma  
 epithelioid 56.40  
 kaposiform (Kaposi-like infantile) 18.55–6, 56.31–2  
 malignant *see* angiosarcoma  
 retiform (hobnail) 56.32  
 spindle cell 56.30–1  
 haemangioma  
 acquired elastotic 56.28–9  
 capillary, eyelids 67.34  
 congenital 18.54  
 cutaneous arteriovenous 56.26–7, 65.35–6  
 epithelioid (histiocytoid) 56.27–8, 68.15–16  
 gingivae 69.13  
 glomeruloid 56.24–5  
 haemosiderotic 49.17  
 hepatic 18.52–3  
 hobnail (targetoid haemosiderotic) 56.29  
 infantile/capillary 18.40–52, 18.96  
 associated anomalies 18.47–8  
 clinical features 18.42–3  
 definition and classification 18.40–1  
 diagnosis and complications 18.44–7  
 management 18.48–52  
 pathogenesis and pathology 18.41–2  
*see also* naevus, strawberry  
 laser therapy 78.6  
 lobular capillary *see* pyogenic granuloma  
 lumbosacral 18.47  
 microvenular 56.29–30  
 oral cavity 69.13, 69.22, 69.29, 69.30  
 pinna 68.28  
 in pregnancy 8.10  
 sinusoidal 56.30  
 spinal dysraphism and 63.15  
 spindle cell 56.30–1  
 symplastic 56.31  
 thrombocytopenia 49.12  
 verrucous 18.74–5  
 haemangioma–haemorrhage syndrome *see* Kasabach–Merritt syndrome/phenomenon  
 haemangiomas  
 multifocal/benign neonatal 18.53  
 multifocal/diffuse (miliary) neonatal 18.53–4  
 haemangiopericytoma 18.58  
 adult 56.42  
 infantile 56.9, 56.42  
 haemangiosarcoma *see* angiosarcoma  
*Haemaphysalis* 38.34, 38.35  
*Haematobia* 38.6  
 haematocrit monitoring, burns 28.84  
 haematodermic neoplasms, blastic  
 NK-cell lymphoma 57.39–40

- haematological disorders **62.85–96**  
 in dyskeratosis congenita 15.79  
 eye and skin involvement 67.30  
 leg ulcers and 47.56  
 pigmented purpuric dermatoses and 49.23  
*see also specific disorders*  
 haematological tests, purpura 49.6  
 haematology 69.116  
 haematoma  
 definition 5.7  
 ear 68.6–7  
 paroxysmal finger 49.16  
 penile 71.14  
 post-surgical 77.8, 77.9  
 subungual 65.49–50  
 wound healing and 14.17  
 haematopoietic stem cell(s) 55.1  
 transplantation 13.26, 62.96–8, 76.7  
 in familial haemophagocytic lymphohistiocytosis 55.26  
 herpes-associated erythema multiforme and 33.19  
 oral complications 69.82–3  
*see also stem cell(s)*  
*Haematopota* 38.6  
*Haematosiphon* 38.24  
 haematosiphoniasis 38.24  
 haematoxylin and eosin 10.8, 10.9, 10.10  
 haematoxylin bodies, heart valves, SLE 51.34  
 haemochromatosis 59.71, 62.61–2  
 arthropathy associated 62.105  
 pigmentation changes 58.28  
 skin biopsy 10.42  
 haemodialysis  
 bacterial infection and 30.7  
 complications 62.72–3, 75.155  
 gynaecomastia and 62.72, 70.4  
 nephrogenic systemic fibrosis and 45.53  
 perforating dermatoses and 45.63  
 pruritus and 21.7–8, 62.72  
 restless legs syndrome and 63.24  
*see also dialysis and related therapies*  
 haemoglobin  
 as chromophore 78.3  
 skin colour and 2.5, 5.15  
 haemoglobin monitoring, burns 28.84  
 haemoglobinuria  
 paroxysmal nocturnal 49.30  
 sleep-associated 49.30  
 haemolymphangiomas, diffuse 48.31  
*see also Maffucci's syndrome*  
 haemolysis, intravascular, paroxysmal nocturnal haemoglobinuria 49.30  
 haemolytic anaemia  
 congenital, pigmentation in 58.53  
 Coombs-positive, ITP with 49.9  
 haemolytic disease of newborn 69.116  
 haemolytic-uraemic syndrome (HUS) 13.3, 49.12, 49.31  
 atypical 49.31  
 haemophagocytic lymphohistiocytosis (haemophagocytic syndrome) 17.78–9, 46.23–5, 49.12  
 cutaneous manifestation 46.23–5  
 virus-associated 55.30–1  
 EBV 33.31  
 haemophilia 49.2  
 bleeding time 49.6  
 haemophiliacs, HIV infection 35.45  
*Haemophilus ducreyi* 30.47, 34.7, 34.34  
 female genital dermatology 71.71  
*see also chancroid*  
*Haemophilus influenzae* 15.60  
*Haemophilus influenzae* type b 13.15  
 in cellulitis 30.18  
 haemopoietic stem cells *see* haematopoietic stem cell(s)  
 haemorrhage  
 abnormal platelet function and 49.12–14  
 disseminated intravascular coagulation 49.39  
 inflammatory 49.18–19  
 purpura due to 49.2, 49.3, 49.4  
 Lassa fever 33.69  
 macular 62.90  
 simple, purpura due to 49.2, 49.3, 49.4–7  
 splinter, nails 49.7  
 venous leg ulcers 47.45  
 haemorrhagic disease of the newborn 49.51  
 haemorrhagic effects, sporting activities 28.31  
 haemorrhagic fever  
 diagnosis 33.5  
 tick-borne 38.35  
 viral **33.66–70**  
 diagnosis 33.68  
 haemorrhagic fever with renal syndrome (HFRS) 33.70  
 haemorrhagic oedema of childhood *see* acute haemorrhagic oedema of childhood/infancy  
 haemorrhoids 71.96  
 anal fissure 71.87  
 syphilis vs 34.8, 34.12  
 haemosiderosis 62.85  
 hypostatic 58.53  
 skin pigmentation 58.53  
 haemosiderotic fibrohistiocytic lipomatous lesion (haemosiderotic fibrolipomatous tumour) 56.19  
 haemostasis, in surgery 77.50  
 Hageman factor 13.4  
 Hailey–Hailey disease 39.1, 39.32–7  
 aetiology 39.32  
 clinical features 39.34  
 complications 39.34–5  
 cytodiagnosis 10.29  
 differential diagnosis 39.35, 40.11  
 female genital dermatology 71.66, 71.81  
 genitocrural 71.5–6  
 histopathology 39.33, 39.35  
 investigations 39.35  
 linear 18.25  
 male genital dermatology 71.25  
 prognosis 39.35  
 segmental 39.37  
 squamous cell carcinoma and 39.35  
 treatment 39.35–6, 79.4  
 Haim–Munk syndrome 19.3, 19.110, 69.16  
 hair  
 African 9.2  
 anatomy and physiology **66.1–16**  
 artificial 28.50  
 Asian 9.2  
 aural *see* ear(s), hairy  
 axillary 66.13  
 ageing and 8.24  
 bamboo (trichorrhexis invaginata) 19.37, 19.38, 19.39–40, 66.65–7  
 bayonet 66.62  
 bleaches 66.85, 66.98  
 body, grading schemes 66.80  
 braiding 66.74  
 brush end 66.62  
 bubble 66.62  
 bulb *see* hair bulb  
 casts 66.62  
 Caucasian 9.2  
 chest, ageing and 8.24  
 circle 66.62  
 colour, in animals 2.6–7  
 conditioners 66.96  
 congenital abnormalities, in animals 2.18  
 cortex 3.13, 66.2, 66.6  
 cosmetics **66.95–100**  
 curly, curvature 3.14  
 cuticle 3.13, 66.2, 66.5–6  
 cycle *see* hair cycle  
 defects  
 folliculocentric keratotic disorders 19.72–3, 19.74–5  
 IBIDS/PIBIDS syndrome 19.47–9  
 ichthyosis follicularis with alopecia and photophobia 19.58–9, 19.60  
 keratoderma and cardiac disease and 19.94, 19.107  
 Netherton's syndrome 19.37, 19.38, 19.39–40  
 differentiation 3.13–14  
 discs 3.16  
 disorders 3.14  
 in animals, comparison with humans 2.21  
 ocular involvement 67.29  
*see also specific disorders*  
 drug-induced discoloration 66.94, 75.45  
 dyes 66.96–8  
 allergic contact dermatitis and 26.10, 26.17, 26.60–2  
 depigmentation and 26.26  
 open patch testing 26.97  
 ectodermal dysplasias 15.58, 15.64–6, 15.68–9  
 embryology 3.3  
 evolution 2.6, 66.1  
 examination in fungal infection 36.5–6  
 exclamation mark 66.34, 66.35  
 external root sheath *see* hair, outer root sheath (ORS)  
 facial 8.4, 66.13  
 management 73.29  
 follicles *see* hair follicle(s)  
 as foreign body 28.49–51  
 functions 4.1  
 greasy, menstrual cycle and 8.8  
 greying 3.21, 8.23, 66.92–3  
 alopecia areata and 66.92  
 Notch signalling 3.21  
 pernicious anaemia and 62.85  
 premature 66.92–3  
 premature, in vitiligo 58.48  
 growth  
 androgens and 66.13–16  
 congenital naevi 54.11  
 ethnic factors 66.80  
 excessive 66.75–89  
 increased by minoxidil 73.50  
 normal 3.13–14  
 in pregnancy 8.10  
 rate 66.11  
 rate increased by caffeine 73.49  
 synchronous 66.27  
*see also hair cycle*  
 guard 66.2  
 heterochromia 66.91–2  
 in HIV infection 35.41–2, 35.42  
 inner root sheath (IRS) 3.13, 66.3, 66.4–5, 66.7  
 keratins 3.13–14  
 knotting 66.74  
 lanugo 66.91  
 laser-assisted removal 78.12–13  
 length, in animals 2.6–7  
 lichen planus 41.14  
 in liver disease 62.64  
 loss *see* hair loss  
 mammals 2.3  
 matrix  
 hamartoma 53.12–13  
 'mummified ghost' cells 53.12  
 tumours **53.12–14**  
 mechanoreceptor function in animals 2.6  
 medulla 3.13, 66.2, 66.6  
 moult waves 66.8  
 multiple 66.73  
 oral 69.37  
 outer root sheath (ORS) 3.13, 66.3, 66.4, 66.5  
 tumours **53.4–6**  
 permanent waving 66.98–9  
 pigmentation **66.89–95**  
 effects of physical phenomena 66.91  
 variations 66.91–5  
 plucking 66.9, 66.85  
 Pohl–Pinkus constriction 66.62  
 in pregnancy 8.10, 66.9, 66.27  
 proteins 3.13–14  
 pubic 8.4, 66.13  
 ageing and 8.24  
 louse infection 38.22  
 waxing 38.22  
 race and 9.2, 66.13  
 red 3.21, 66.91  
 regrowth, sensitizing agent action 73.39  
 retinoid 66.65  
 ringed 66.69–70, 66.91  
 scalp, ageing effect 8.23  
 seasonal growth 66.8–9  
 animals 2.3  
 setting 66.100  
 sexual, secondary 8.6  
 shaft  
 abnormalities 66.61–75  
 fracture 66.16  
 shampoos *see* shampoos  
 shaving 66.11, 66.85  
 silvery 58.42  
 in SLE 51.38, 66.29, 66.30  
 spun-glass 66.71–2  
 sternal 66.13  
 straightening/relaxing 66.99  
 structure 3.2, 3.13, 66.6  
 styling practices, race and 9.7  
 styling products 26.18  
 swallowing 64.31–2  
 tapered 66.62  
 terminal 66.2, 66.13  
 in congenital naevi 54.11  
 minoxidil effect 73.50  
 terminal differentiation of cortical cells 3.13  
 terminal-to-vellus ratio, ageing and 8.23  
 tiger tail 66.62  
 transplantation 66.23–4  
 in trichofolliculoma 53.7–8  
 types 66.2  
 variants 3.14  
 vellus 3.13, 66.2, 66.13, 66.91  
 ageing and 8.23  
 occlusion/cystic dilatation 53.7  
 waxing 66.87  
 weathering 66.74–5, 66.91  
 white 8.23, 66.35, 66.91, 66.92–3  
 forelock, in piebaldism 58.42  
 woolly 66.70–1  
 hair-bearing skin 3.3  
 surgical incisions 77.5  
 HAIR-AN syndrome 19.120, 42.73, 66.82  
 hair artefact 64.40  
 hair bulb 66.2–3, 66.3–4  
 in albinism 58.39, 58.40  
 matrix 66.4  
 hair collar sign 18.95, 18.98  
 hair cycle 3.7, 3.13–14, 66.7–13  
 in alopecia areata 66.33  
 disturbances 66.27–31  
 dynamics 66.20  
 melanogenesis and 66.90  
 hair follicle(s)  
 abnormalities in follicular atrophoderma 52.8–9  
 ageing/elderly people 8.23–4  
 in alopecia areata 66.33, 66.34  
 in anagen 66.7, 66.8  
 anatomy 3.1, 3.2, 66.2–67  
 areola periphery 70.1  
 bacterial flora 30.2, 30.3  
 bulge stem cells 3.6  
 carcinoma **53.32, 53.33–7**  
 in catagen 66.7–8  
 degeneration/regeneration cycle 3.7  
 density 66.2  
 distribution 66.2  
 embryonic development 3.3, 3.4, 3.5, 42.3, 66.2  
 defective, in comedo naevus 42.78  
 follicular infundibulum tumour 53.3  
 immune privilege and 66.32  
 inflammatory diseases **30.21–30**  
*see also folliculitis*

- infundibulum 66.3  
innervation 66.6  
isthmus 66.3  
loss 66.16  
mechanism of androgen action  
66.14–15  
mechanoreceptor (*Haarscheibe*) 53.14  
melanocytes 3.21, 58.3  
melanogenesis 3.20, 66.90–1  
mesenchymal lesions **53.14–15**  
miniaturization 66.18, 66.20–1  
mites *see Demodex*  
naevus 53.6  
prominent 9.4  
regional variations in density 3.3  
scars and 14.8  
stem cells 3.7  
suprabulbar region 66.3, 66.4, 66.6  
transplantation 66.15  
tumours **53.2–4**, 53.27
- hair follicle unit 12.63  
hair germ 3.5  
hamartoma 53.8–9  
tumours and cysts **53.6–12**
- hair loss  
eating disorders 64.22  
pathological pulling/plucking 64.30–1  
*see also alopecia*  
hair muffs 38.60  
hair peg 3.5  
hair pull test 66.28, 66.30  
hair sinus, breast 70.15  
hair-thread tourniquet syndrome 28.50  
hairdressers, occupational hazards 5.6,  
22.20, 26.47, 27.2, 27.3, 27.19  
hand dermatitis 8.8  
*hairless* mouse 66.11  
hairline 66.16, 66.17  
surgery across 77.5  
hairy leukoplakia 69.90, 69.91, **69.93–4**  
EBV association 33.31, 35.43  
in HIV infection 35.43  
hairy pinnae *see* ear(s), hairy  
HAL DRB1\*04 (DR4), actinic prurigo and  
29.14  
half-moon lunule *see* lunula  
halides 75.152–3  
Hallermann–Streiff syndrome 15.41,  
**18.81–2**, 45.8  
Hallopeau, acrodermatitis continua of *see*  
acrodermatitis continua (of  
Hallopeau)  
Hallopeau–Siemens dystrophic  
epidermolysis bullosa (EB)  
39.16, 39.18–20  
hallux valgus, mechanical injury 28.10–11  
halo, formation, venous microcirculatory  
disorders 47.27  
halo naevus 58.49–50  
halogen acne 27.12–15  
halogenated acetophenones 25.21  
halogenated aromatic hydrocarbons,  
acnegenicity 27.12–13  
halogenated salicylanilides 26.24  
haloperidol 64.52, 75.83  
HAM56 55.15  
hamartoma 47.12, 52.1, **53.6–12**  
apocrine gland 18.14  
basaloid follicular 53.11–12  
congenital midline/rhabdomyomatous  
mesenchymal 18.37  
congenital smooth-muscle (arrector  
pili) 18.35–6  
congenital vellus 18.10–11  
cutaneous *see* naevus  
diffuse smooth-muscle 18.36–7  
eccrine angiomatous 18.16  
fat-storing of dermal dendrocytes  
**46.45**, 55.19  
fibrolipomatous of nerve  
(neurolipomatosis) 18.40  
fibrous of infancy **18.34–5**, 56.6  
folliculosebaceous cystic 53.7–8  
generalized follicular 66.51–2  
hair germ 53.8–9
- hair matrix 53.12–13  
linear basaloid follicular 18.13  
medallion-like dermal dendrocytic  
17.15, 56.18–19  
meningotheial 18.95  
neuromuscular 18.37, 56.44  
nodular proliferative neurocristic 54.13  
pilosebaceous follicle 53.7–8  
sclerosing epithelial 53.9–10  
striated-muscle 18.37  
sudoriferous 18.15–16  
HAMP gene 62.61  
Han Chinese patients 72.30  
hand(s)  
actinic keratosis 52.30  
aggressive digital papillary  
adenocarcinoma 53.33  
annular lesions of discoid LE 51.14  
cold flexed fingers 51.112  
collagenous and elastotic marginal  
plaques 45.28  
dermatitis 72.10  
career choice and 8.8  
dermatitis/eczema **23.13–23**, 42.10  
alitretinoin 74.36  
allergic contact dermatitis 26.15–16,  
26.29  
asteatotic 23.20  
atopic dermatitis 8.7, 23.14, 24.21–2  
career choice and 8.8  
chronic, lymphoedema after 48.13  
classification 23.13–14  
constitutional 24.22  
diagnosis 27.4  
differential diagnosis 23.20, 23.21,  
25.15, 25.16  
discoid 23.10  
irritant contact dermatitis 25.2, 25.13,  
25.14, 25.15, 25.24  
nail involvement 65.28–9  
nickel allergy and 26.31–2  
as occupational dermatosis 27.2  
plant-induced 26.76  
prevalence 23.3  
prognosis 23.21  
severity assessment 72.10  
tacrolimus therapy 73.32  
treatment 23.21–3  
disinfection 77.5, 77.7  
in dystrophic EB 39.18  
eating disorder manifestations 64.22  
erythromelalgia 47.9  
factitious disorders 64.40  
finger pebbles 59.79  
hyperpigmentation, acromelanosis 58.21  
lichen planus 23.20, 23.21  
mechanical injury 28.10–12, 28.14,  
28.16, 28.27, 28.31  
mechanic's 62.82  
milium 25.15, 25.16  
neutrophilic dermatosis of the (dorsal)  
hands 50.80–1  
occupational dermatoses 27.2, 27.3  
pityriasis rubra pilaris 23.20  
psoriasis 23.20, 25.15, 25.16  
of palms 20.15  
scabies 25.15, 25.16  
tinea incognita 25.15  
*Trichophyton* infection 23.20, 23.21,  
25.15  
tripe palms 19.120  
varices 47.16  
wrinkling 28.93  
*see also* palms  
hand, foot and mouth disease **33.71**,  
69.76–7  
electron microscopy 10.30  
hand cooling test 63.4–5  
Hand Eczema Severity Index 72.10  
hand-foot syndrome 38.14  
hand washing, compulsive 64.24  
hand-arm vibration syndrome (HAVS)  
27.17, 28.26, 28.56, **28.57–8**  
handicap, in skin disease 6.5  
magnitude 6.5
- Hand-Schüller-Christian syndrome *see*  
Langerhans' cell histiocytosis  
(LCH)  
handymen, occupational hazards 27.20  
HANES-1 study 6.7, 6.15  
hang nails 65.51  
hanging groin 37.5  
Hanovia sunlamp 29.1  
Hanseman cells 55.27  
Hansen's disease *see* leprosy  
hantavirus pulmonary syndrome 33.70,  
49.20  
hantaviruses 33.67, 33.70, 49.20  
*Haplochlarna maculosa* 38.59  
haplotype 11.7  
Happle's syndrome (Conradi–  
Hünemann–Happle syndrome)  
19.3, 19.49–52  
prenatal diagnosis 16.3  
haptens 26.11, 26.23, 75.16  
harara 38.5, 38.7  
hard palate 69.2, 69.6  
hardness tests, mechanical injury 28.5  
harlequin colour change 17.4  
harlequin ichthyosis 19.25–9  
harm, critical appraisal of paper about  
7.15  
Hartnup disease 59.100–1  
harvest mites 30.74, 38.2, **38.50–1**  
harvester ants 38.14  
Hashimoto–Pritzker syndrome *see*  
Langerhans' cell histiocytosis  
(LCH)  
Hashimoto's thyroiditis 62.10  
sarcoidosis and 61.17  
Haverhill fever 30.67  
HAVS (hand-arm vibration syndrome)  
27.17, 28.26, 28.56, **28.57–8**  
Hawaiian box jellyfish 38.56  
Haxthausen's disease (keratoderma  
climactericum) 19.117–18, 46.21  
Hayden syndrome 15.42  
Hay–Wells syndrome 15.28, **15.61–3**  
hazard ratio 6.18  
HBV *see* hepatitis B virus (HBV)  
hCAP18 *see* LL-37  
HCV *see* hepatitis C virus (HCV)  
HD1 39.25  
HDAC (histone deacetylase inhibitors)  
57.28  
HDM *see* house-dust mite  
H&E (haematoxylin and eosin) 10.8, 10.9,  
10.10  
head, basal cell carcinoma 52.20  
head and neck  
blood vessels 77.2, 77.3  
cosmetic units 77.2  
local anaesthesia 77.2–4, 77.10  
lymphatic system 69.4, 77.2, 77.3  
lymphoedema 48.12, 48.13, **48.16**, 48.23  
motor nerves 77.4–5  
oedema 48.12  
sensory nerves 77.2–4  
surgery 77.2–5  
*see also* neck; *specific areas*  
head injury, hypertrichosis following  
66.78  
head lice *see* under lice  
head load, in tropics, pigmentation effect  
58.9  
headache  
in giant cell arteritis 50.43  
herpes simplex 33.17  
in traction alopecia 66.53  
headsets, dermatitis due to 26.17  
Heaf test 5.24, 13.22  
health-related groups 5.2  
health-related quality of life *see* quality of  
life (QOL)  
health services  
audit 72.13  
boundaries between primary/  
secondary care 6.15  
need, supply and demand relationship  
6.15–16
- needs assessment 6.14  
primary care 6.14–15  
referral rates 6.15  
research **6.14–17**, 72.13  
secondary care 6.15  
uptake and number of patients using  
6.14  
Health Technology Assessment Database  
7.5  
health workers, occupational hazards 5.6  
hearing-aids, dermatitis due to 26.17,  
68.23–4  
hearing impairment *see* deafness  
heart  
in carcinoid syndrome 43.18  
disorders **62.75–80**  
keratoderma and woolly hair and  
19.94, 19.107  
*see also specific disorders*  
in infantile haemangioma 18.45  
in sarcoidosis 61.7  
in systemic sclerosis 51.101, 62.78  
in trypanosomiasis 37.32  
*see also entries beginning cardiac*  
heart failure, venous leg ulcers and 47.47  
heart valves, haematoxylin bodies in SLE  
51.34  
heat  
sensitivity, rosacea 43.2  
wart treatment 33.50  
heat-associated carcinomas 28.73  
heat cautery 77.44–5  
heat injury *see* thermal injury  
heat nociceptors 4.9  
heat pain threshold 4.9  
heat shock proteins 51.54  
hsp90 73.17  
polymorphic light eruption and 29.11  
in vasculitis 50.5  
in wound healing 14.5  
heavy-chain disease 69.114  
heavy water distillate, acne associated  
42.77  
Heberden's nodes 45.70  
Heck's disease 33.47, 69.111–12  
HED *see* hypohidrotic ectodermal  
dysplasia (HED)  
Hedgehog signalling  
in follicular atrophoderma 52.9  
importance during development 52.6  
in naevoid basal cell carcinoma  
syndrome 52.6, 52.7  
Heerfordt's syndrome 61.7  
Heidenhain's Susa 10.31  
Heimler syndrome 15.52  
*Helicobacter pylori* 62.48  
eradication, effect on rosacea 43.2, 43.6,  
43.7  
rosacea pathogenesis and 43.2  
urticaria and 22.2, 22.10  
*Helleborus* 25.21  
HELLP syndrome 49.12, 49.31  
helminth infection, eosinophilia in 62.86  
heloma *see* corns  
hemi-hypertrophy 63.14  
hemiatrophy, facial 46.39  
hemidesmosome(s) 3.26, 3.30–2  
components (HD1–HD5) 3.30  
gene mutations 3.31  
in junctional epidermolysis bullosa  
39.9, 39.25  
ultrastructure 3.30  
hemidesmosome-anchoring filament–  
anchoring fibril adhesion  
complex 3.3, 3.30–2  
hemidesmosome-anchoring filament  
complexes 3.3  
hemifacial atrophy 51.70  
hemifacial microsomia **18.82–3**, 68.4  
hemilipodystrophy 46.39  
Hemiptera (bugs) **38.23–6**  
hemizygous genes, definition 15.3  
hemojuvulin gene 62.61  
henna 66.97, 75.162  
tattoos 26.60

- Hennekam lymphangiectasia-lymphoedema syndrome 48.10, 48.27
- Henoch-Schönlein purpura 49.18-19, 50.19-21
- aetiology and pathogenesis 50.4, 50.5, 50.7, 50.20
  - bone and joint involvement 62.102
  - classification 50.2
  - clinical features 50.20
  - genetic factors 50.11
  - male genital dermatology 71.28-9
  - renal involvement 62.71
- Hep-2 cells 13.19, 13.20
- antacentromere antibodies 51.103
- Sci-70 antibodies 51.104
- hepadnaviruses 33.2
- heparan, structure 3.47
- heparan sulphate 3.46
- in wound healing 14.3
- heparan sulphate proteoglycans (HSPGs) 3.29
- heparin
- adverse effects 45.52, 62.92, 75.105-7
  - haemorrhage 49.28
  - necrosis 49.27-9
  - purpura 75.23
  - thrombocytopenia 49.11, 49.27-9
  - LMWH *see* low-molecular-weight heparin (LMWH)
  - skin testing for reactions to 75.173
  - structure 3.47
- heparin-reactive antibodies 49.27
- hepatic artery ligation/embolization, in carcinoid tumours 43.19
- hepatic vein thrombosis (Budd-Chiari syndrome) 49.29, 49.30
- hepatitis 62.58
- chronic active, lichen planus and 41.16
  - following ear piercing 68.7
  - herpes simplex virus and 33.17
  - prevention of spread during surgery 77.7
  - viruses 33.60-2
  - see also specific viruses*
- hepatitis A 33.74
- nodular panniculitis and 46.14
- hepatitis A virus (HAV) 33.74, 62.59
- hepatitis B virus (HBV) 33.60-1
- aetiology and epidemiology 33.60
  - angio-oedema and 62.59
  - cryoglobulinaemic vasculitis and 62.59
  - cutaneous manifestations of infection 33.60, 62.59
  - erythema and 62.59
  - erythema multiforme and 62.59
  - Gianotti-Crosti syndrome and 33.61, 33.77, 62.59, 62.64
  - HbcAg (core antigen) 33.60
  - HBeAg (e antigen) 33.60
  - HbsAg (Australia antigen) 33.60
  - immune response 33.60
  - lichen planus and 41.16, 62.59
  - polyarteritis nodosa and 33.60-1, 50.33, 50.34, 50.35, 62.59
  - prophylaxis 33.61
  - pyoderma gangrenosum and 62.59
  - replication 33.60
  - serum sickness and 33.60, 62.59
  - transmission 38.24
  - by human bites 38.61
  - urticaria and 22.8, 62.59
  - vaccination 33.61, 62.59, 75.139
  - conditions after 33.61
  - lupus panniculitis and 46.25
  - vectors 38.24
- hepatitis C virus (HCV) 33.61-2
- antibodies 49.32
  - autoimmune disorders and 62.60
  - cold-induced injury 28.71
  - conditions associated with 33.62
  - cryoglobulins and 33.61, 49.32, 49.33, 50.24, 50.25, 62.59
  - cutaneous features of infection 33.61, 62.59-60
  - lichen planus pathogenesis 41.2-3, 41.16
  - necrolytic acral erythema and 62.59
  - oral manifestations of infection 69.115
  - pigmented purpuric dermatoses and 49.23
  - polyarteritis nodosa and 50.33, 62.59
  - porphyria cutanea tarda and 33.61-2, 62.59-60
  - pruritus and 21.9
  - red fingers syndrome and 62.59
  - replication 33.61
  - tattoos 28.48
  - transmission 38.24
  - treatment 33.62
  - vasculitis and 33.61
- hepatitis D virus 62.60
- hepatitis E virus 62.60
- hepatitis F virus 62.60
- hepatitis G virus 62.60
- HIV infection with 35.5
- hepatocutaneous syndrome, in dogs 2.17
- hepatocyte growth factor (HGF) 3.21
- hair growth and 66.10
  - melanocyte mitogen 58.5
- hepatocyte growth factor activator inhibitor-1 (HAI-1) 12.50
- hepatoerythropoietic porphyria 59.13-15
- hepatolenticular degeneration syndrome 59.76
- hepatosplenomegaly
- in sarcoidosis 61.10
  - in trypanosomiasis 37.32
- hepatovirus 33.71, 33.74
- heptachlor 75.163
- herald patch
- differential diagnosis 33.80, 33.81
  - pityriasis rosea 33.79, 33.80
- herbal remedies 64.54, 72.32, 72.33
- acne vulgaris 42.43
- platelet function disorders 49.13
- potential risks 72.29, 72.33
- herd immunity and scabies 38.37
- hereditary angio-oedema *see* angio-oedema, hereditary
- hereditary benign intraepithelial dyskeratosis 69.25
- hereditary benign telangiectasia 47.19
- hereditary blistering disorders 39.1-37
- see also* epidermolysis bullosa (EB); Hailey-Hailey disease
- hereditary coproporphyrin 59.19
- hereditary epidermal polycystic disease *see* steatocystoma multiplex
- hereditary haemorrhagic telangiectasia (HHT) 18.79-80, 47.13, 47.17-18, 49.5
- aetiology and pathogenesis 47.17-18
  - iron deficiency anaemia in 62.85
  - mutations in HHT1 and HHT II 49.7
  - oral cavity 69.29, 69.117
  - portal hypertension and 62.63
  - purpura and bleeding 49.15
- hereditary leiomyomatosis and renal cell carcinoma syndrome 2.17, 62.29, 62.69
- hereditary mucoepithelial dysplasia 15.42, 69.31
- hereditary non-polyposis colorectal cancer (HNPCC) 52.10
- sebaceous adenoma association 42.87
- hereditary onycho-osteodysplasia (Hood) syndrome 15.8, 15.86-7
- hereditary osteo-onychodysplasia 15.8, 15.86-7
- hereditary polymorphous light eruption 29.13
- hereditary progressive mucinous histiocytosis 59.25
- hereditary sclerosing poikiloderma 15.82
- hereditary sensory autonomic neuropathy (HSAN)
- type I 63.18
  - type II 63.18
  - type III 44.7, 62.80, 63.18
- type IV 63.18-19
- type V 63.19
- heregulin-a 62.16
- Herellea see Acinetobacter*
- Hermansky-Pudlak syndrome 9.16, 17.78-9, 17.81, 49.12, 58.41, 62.52, 62.95
- hernias
- fascial, legs 45.68-9
  - muscular 28.61-2
- heroin 75.28, 75.87
- herpangina 33.71, 69.76
- herpes-associated erythema multiforme (HAEM) 33.18-19
- herpes B virus (B virus; CeHV-1) 33.34-5
- herpes gestationis *see* pemphigoid gestationis
- herpes gladiatorum 33.17
- herpes iris of Bateman 76.7
- herpes labialis 69.72-3
- herpes simplex 5.14, 33.14, 33.14-22, 69.118
- aetiology 33.14-15
  - antibodies 33.19, 33.35
  - atopic eczema and 33.35-6
  - autoinoculation/inoculation 33.15, 33.17
  - children 33.15, 33.20, 35.45
  - clinical features 5.4, 33.16-20
  - cytodiagnosis 10.28, 10.29
  - diagnosis 33.19
  - differential diagnosis 26.29
  - ear involvement 68.20, 68.28
  - electron microscopy 10.30
  - erythema multiforme and 33.18-19, 76.2
  - genital infections 33.15, 33.17, 33.18
  - females 71.57, 71.70
  - in HIV infection 35.28
  - males 71.33
  - maternal primary 33.15, 33.21
  - prevalence 34.2
  - primary 33.16, 33.17
  - recurrent 33.17, 33.18
  - treatment 33.20, 33.21
- gingivostomatitis 33.16
- Hailey-Hailey disease vs 39.35
- in HIV infection 33.15, 35.28, 35.45, 68.28
- immune restoration and 35.28, 35.46, 35.47
- immune response 33.15, 33.21
- immune restoration disease 35.28, 35.46, 35.47
- in immunodeficiency 33.15, 33.17, 33.18, 33.20
- intrauterine infection 17.39, 18.2, 33.15, 33.21
- keratoconjunctivitis 33.17, 33.18
- latent infections 33.14
- in malaria 37.27
- neonatal infection 17.39-40, 33.15, 33.17, 33.20
- non-primary first-episode 33.15
- ocular 67.16, 67.25-6
- oral 33.16, 69.13, 69.72-4
- in HIV infection 35.43
  - primary 33.15, 33.16
  - prophylaxis 33.21
  - recurrent 33.17-18, 33.20, 33.21
- paronychia due to 65.22-3
- pathology 33.16
- perianal/perineal disease 71.95
- in HIV infection 35.28
- primary infection 33.16-17
- complications 33.17
  - HSV-1 33.14-15, 33.16
  - HSV-2 33.15, 33.16
  - recurrence comparison 33.18
  - treatment 33.20
- prophylaxis 33.20, 33.21
- recurrent infection 33.15, 33.17-19
- complications 33.18-19
  - intraoral 69.73
  - labial 69.72-3
  - treatment 33.20-1
- stomatitis 33.16, 69.13, 69.72-4
- TORCH syndrome 33.76-7
- trauma facilitating 33.15, 33.18
- treatment 33.20-1
- topical agents 73.15
  - vesicles 33.16, 33.18
  - whitlow 33.17
- herpes simplex virus (HSV) 33.14, 33.14-22
- blepharoconjunctivitis 67.26
  - DNA detection 33.19
  - HSV-1 33.14, 33.16, 33.17, 33.18
  - eczema herpeticum 33.35
  - HSV-2 33.14, 33.16, 33.17, 33.18
  - Well's syndrome and 46.33
  - mutants, drug resistance 35.28
  - reactivated 67.25
  - oral 33.3
  - prevention 33.20, 33.21
  - shedding 33.14, 33.17
  - subclinical 33.18
  - transmission 33.14, 33.15
  - vaccines 33.21
- herpes zoster *see* zoster
- herpes zoster oticus 33.25, 33.26
- management 33.28
- herpes zoster sine eruptione 33.25, 67.26
- Herpesvirus hominis* 33.24
- see also* herpes simplex virus (HSV)
- Herpesvirus varicellae* 33.22, 33.24
- see also* varicella zoster virus (VZV)
- herpesviruses 33.2, 33.14-37
- classification 33.14
  - electron microscopy 10.30
  - oral infection 69.76
  - transmission by human bites 38.61
  - see also specific viruses*
- herring brine 25.21
- Hertog's sign 62.10
- HES *see* hydroxyethyl starch (HES)
- Hess test 49.5
- hetastarch *see* hydroxyethyl starch (HES)
- heterochromia 66.91-2
- heterogeneity, genetic 15.5
- heterophile antibodies, EBV infection 33.30
- heterozygosity, loss of 11.18
- heterozygous genes, definitions 15.3-4
- Heubner's arteritis 34.5
- HEV (high endothelial venule) 13.9, 13.10
- hexachlorophene (hexachlorophane) 14.21, 25.21, 26.24, 73.15, 75.164
- 2,4-hexadienoic acid 25.18, 26.58, 73.8
- Hexathelidae 38.31
- HF *see* hydrofluoric acid
- HFE gene 62.61
- HFEA (Human Fertilization and Embryology Authority) 16.8-9
- HGU (Human Genetics Unit) 15.1
- HHF35 10.22
- HHV-1 *see* herpes simplex virus (HSV), HSV-1
- HHV-2 *see* herpes simplex virus (HSV), HSV-2
- HHV-3 *see* varicella zoster virus (VZV)
- HHV-4 *see* Epstein-Barr virus (EBV)
- HHV-5 *see* cytomegalovirus (CMV) infections
- HHV-7 *see* human herpesvirus 7 (HHV-7)
- HHV-8 *see* human herpesvirus 8 (HHV-8)
- hibernian fever 22.25, 50.53, 62.69, 62.104
- hibernoma 46.45
- HID (hystrix ichthyosis and deafness) syndrome 15.46, 19.36, 19.37, 19.54-7
- hidradenitis
- in adolescence 8.7
  - idiopathic recurrent palmoplantar 44.17
  - neutrophilic eccrine *see* neutrophilic eccrine hidradenitis
- hidradenitis suppurativa 30.79-82, 42.74-5, 64.7
- acne and 42.33
  - acne conglobata and 42.82
  - aetiology 30.79-80

- bone and joint involvement 62.102  
breast 70.17  
clinical features 30.80–1  
complications 30.81  
diagnosis 30.81  
genitocrural dermatology 71.5  
isotretinoin treatment 42.62  
pathology 30.80  
perianal/perineal dermatology 71.88–9  
TNF antagonists 74.7  
treatment 30.81–2, 77.36
- hidradenocarcinoma 53.34  
hidradenoma 53.27–8  
clear-cell 53.27–8  
eccrine 53.22  
malignant 53.34  
nodulocystic 53.27–8  
papillary 71.72  
poroid 53.24  
hidradenoma papilliferum 53.20–1, 68.30  
hidradenomas eruptifs *see* syringoma  
hidroacanthoma simplex 53.22–3  
hidrocystoma  
apocrine 53.18–19  
eccrine 53.22, 67.33  
eyelid 67.33
- hidrotic ectodermal dysplasia 15.42,  
15.67, **15.68–9**, 19.94, 19.106  
*see also* Clouston's syndrome (hidrotic  
ectodermal dysplasia)
- HIES *see* hyper-IgE syndrome  
high-density lipoprotein (HDL)  
cholesterol, retinoids 74.37  
high endothelial venule 13.9, 13.10  
high-resolution comparative genomic  
hybridization 11.13  
high-throughput genetic analysis 15.6  
higher bacterial infections, female genital  
dermatology 71.68  
highly-active antiretroviral therapy  
(HAART) 35.1, 35.5  
adverse effects 35.21, 75.67  
in children 35.45  
gynaecomastia 70.4, 70.5  
lipotrophy 35.22  
sarcoidosis 61.6  
anogenital wart regression 35.30  
CD4 T-cell reconstitution 35.4  
immune reconstitution (inflammatory  
syndrome) 35.46  
indications 35.17, 35.18, 35.32  
in Kaposi's sarcoma 35.37  
lipodystrophy association 46.41, 46.42  
skin cancer warning 35.40  
success and survival improvement 35.6
- hip circumference 46.5  
*Hippelates* 30.14, 38.6  
Hippoboscidae 38.6, 38.7  
Hippocrates 72.5, 72.25  
Hippocratic fingers **15.87–8**  
*Hippomane manchinella* 25.21  
hippopotamus 2.3, 2.4  
hirsutism **66.80–9**  
acne association 42.20, 42.21  
in acromegaly 62.2  
antiandrogens 74.32  
definition 66.75, 66.80  
diagnostic approach 66.84–5  
drug-induced 75.45  
endocrine factors 66.80–4  
grading 66.80  
idiopathic 66.83  
investigations 66.85  
perianal/perineal 71.85  
in pregnancy 8.10, 66.82  
treatment 66.85, 66.86, 66.87–9  
*see also* hypertrichosis
- Hirudinea 38.55  
histamine **12.57–9**  
in arthropod saliva/venom 38.1  
atopic eye disease 67.15  
in cholinergic urticaria 22.15  
cold urticaria and 21.4  
electromagnetic radiation inducing  
release 8.21  
in flushing 43.14, 43.16  
food and 22.8  
in Hymenoptera venom 38.14  
intra-dermal injection 22.5  
liberators 22.8  
mast cell release 67.15  
pruritus and 21.3–4  
release by DMSO 73.7  
triple response of Lewis and 63.5  
urticaria and 22.4, 22.8, 22.9  
histamine receptors 74.31  
cloning 12.26  
H<sub>1</sub> 21.3, 22.4  
H<sub>2</sub> 21.3, 22.4  
H<sub>3</sub> 21.3, 22.4  
H<sub>4</sub> 21.3, 22.4  
pruritus and 21.3  
histamine-release test 75.174  
histatins 12.6–7  
histiocytes  
in benign cephalic histiocytosis 55.15  
cytotoxic 46.23–5  
differentiation/development 5.1–3  
in familial haemophagocytic  
lymphohistiocytosis 55.25  
foamy 55.21  
juvenile xanthogranuloma 55.15  
function 55.2, 55.4–5  
in granuloma annulare 60.4  
microscopy 10.34  
in multicentric reticulohistiocytosis  
55.23  
ontogeny 55.1–3  
phagocytosis by 55.4, 55.26  
proliferation  
cytotoxic histiocytic panniculitis  
46.23–4  
haemophagocytic syndrome 46.23  
malignant 55.32, 55.33  
in sinus histiocytosis with massive  
lymphadenopathy 55.29  
in solitary giant xanthogranuloma 55.15  
*see also* histiocytosis
- histiocytic markers 10.24  
histiocytic sarcoma 55.31  
histiocytoma  
aneurysmal fibrous 49.17  
basal cell carcinoma over 52.20  
fibrous *see* fibrous histiocytoma  
generalized eruptive 55.15, 55.19  
giant-cell *see* multicentric  
reticulohistiocytosis  
progressive nodular 55.20  
solitary (solitary epithelioid) 55.23,  
55.24
- histiocytoma cutis *see* fibrous  
histiocytoma (FH)
- histiocytosis **55.1–34**  
benign cephalic (papular of the head)  
55.15, **55.17–18**  
bone and joint involvement 55.12,  
55.21, 55.23, 55.32, 62.101  
class I (Langerhans' cell involvement)  
55.6, **55.6–14**  
*see also* Langerhans' cell histiocytosis  
(LCH)  
class IIa (dermal dendrocyte  
involvement) 55.6, **55.14–22**  
histopathology/diagnosis 55.15  
*see also* juvenile xanthogranuloma  
class IIb (non-Langerhans' cell, non-  
dermal dendrocytes) 55.6,  
**55.23–31**  
class III (malignant) 38.7, 55.6, **55.31–4**  
immunohistochemistry 55.31, 55.32,  
55.33  
of LCH type 55.7, 55.32  
malignant reticulohistiocytosis  
55.32–3  
monocytic leukaemia 55.31–2  
true histiocytic lymphoma 55.33–4  
virus-associated haemophagocytic  
syndrome vs 55.30  
classification 55.5–6  
crystal-storing 46.17
- familial sea-blue 55.26  
generalized eruptive 55.15, 55.19  
hereditary progressive mucinous 55.27  
histiocyte function changes causing  
symptoms 55.2  
intravascular (intra-lymphatic)  
associated with rheumatoid  
arthritis 62.103  
oral involvement 69.58–9  
papular, of head 55.15, **55.17–18**  
progressive nodular 55.20  
pure cutaneous *see* Langerhans' cell  
histiocytosis (LCH)  
regional, cytotoxic histiocytic  
panniculitis 46.23  
sea-blue 55.26  
self-healing *see* Langerhans' cell  
histiocytosis (LCH)  
self-limiting types 55.17  
virus-induced, with  
erythrophagocytosis 55.30–1  
histiocytosis X *see* Langerhans' cell  
histiocytosis (LCH)
- histology technicians, occupational  
hazards 27.19  
histone deacetylase inhibitors 57.28  
histone modification 11.16  
histopathological techniques, foreign  
bodies 28.42  
histopathology **10.1–43**  
*Histoplasma capsulatum* 36.2, 36.80–3  
in HIV infection 35.34  
histoplasmin test 5.24, 36.86  
histoplasmosis **36.80–3**  
acute disseminated 36.82  
acute pulmonary 36.82  
aetiology 36.81  
chronic disseminated 36.82  
chronic pulmonary 36.82  
clinical features 36.81–2  
definition 36.80–1  
diagnosis 36.82–3  
disseminated 35.33  
histology 36.81  
in HIV infection 35.33–4  
large-form (African) 36.81, 36.83  
male genital dermatology 71.32  
oral involvement 69.80, 69.118  
perianal/perineal 71.96  
primary cutaneous 36.82  
small-form 36.81  
treatment 36.83  
history-taking 5.3–6  
HIV (human immunodeficiency virus)  
35.1  
attachment and infection process 35.3  
circulating recombinant forms (CRFs)  
35.2  
genetic variability and error rate 35.2,  
35.5  
gp41 protein 35.3, 35.6  
group M 35.2  
groups, subtypes (clades) and sub-  
subtypes 35.2–3  
immunosuppressive effects 35.4  
receptors and co-receptors 35.3, 35.6  
recombination 35.2  
*rev*, *tat*, *nef*, *vpr*, *vpu* genes 35.3  
reverse transcription 35.3, 35.6  
structure 35.3  
types 35.2  
viral load 35.5  
HIV-1 35.2  
HIV-2 35.2  
HIV-associated adipose redistribution  
syndrome (HARS) 46.41–2  
HIV infection **35.1–47**  
abscesses 35.24  
acanthosis nigricans 35.12  
actinic keratosis 35.39  
acute primary/seroconversion 35.10–11  
differential diagnosis 35.11  
alopecia areata 66.2  
American trypanosomiasis (Chagas'  
disease) 35.35
- amoebiasis 35.35  
anal cancer 35.30, 35.39  
angiolioma 46.45  
anogenital warts 35.29–30  
antibody response 35.3  
arthropod bites/stings 38.2, 38.7  
atopic dermatitis 24.24, 35.16, 35.45  
atypical mycobacterial infections  
35.25–6  
bacillary angiomatosis 35.25, 68.28  
bacterial infection 35.24–8, 35.45  
basal cell carcinoma 35.39  
breast hypertrophy and 70.3  
candidiasis 35.32, 35.43, 35.45, 36.59–60,  
69.105  
cell count monitoring 13.22  
cellulitis 35.24  
chancroid co-infection 34.34–5  
in children 35.44–5  
chronic actinic dermatitis and 29.16  
clinical features 35.10  
co-infections 35.5  
coagulopathies 35.12–13  
coccidioidomycosis 35.34, 36.86  
*Corynebacterium minutissimum* 35.26  
cryoglobulinaemia and 28.71  
cryptococcosis 35.24, 35.33, 36.89,  
36.90–1, 68.28  
cryptosporidiosis 35.35  
cutaneous larva migrans 35.36  
cytomegalovirus (CMV) infection  
35.28, 35.29  
*Demodex* infection 35.36  
dermatological manifestations **35.8–47**  
*see also specific manifestations*  
dermatophytosis 35.32–3, 35.45  
diagnosis 35.8, 35.11  
early, benefits 35.6, 35.8–9  
differential diagnosis 35.11  
drug reactions 35.20–4  
non-antiretroviral drugs 35.20  
oral 35.44  
duct ectasia/periductal mastitis  
complex and 70.8  
ear involvement 68.28  
eosinophilic folliculitis 35.18–19  
epidemiology 35.1–2  
erythema elevatum diutinum and 50.25  
erythroderma 35.13, 35.16  
eyelash disorders (trichomegaly) 67.4  
fungal infections 35.32–5, 35.45  
furunculosis and 30.23  
global trends 35.2  
granuloma annulare and 35.19–20,  
60.1, 60.7  
granuloma inguinale (donovanosis)  
and 34.37  
gynaecomastia and 70.4  
haemophagocytic syndrome and 46.23  
haemophilias 35.45  
hair changes 35.41–2, 35.42, 66.2  
hairy ears and 68.5  
hairy leukoplakia and 35.43, 69.93–4  
hepatitis G and 35.5  
herpes simplex 33.15, 35.28, 35.45,  
68.28  
oral 35.43  
histoplasmosis 35.33–4, 36.81  
HLA associations 35.3, 35.4, 35.5  
homosexual men 35.2, 35.5, 35.13,  
35.15, 35.30, 35.32  
HPV infections and 33.59, 35.29–30  
hyperpigmentation 35.12  
ichthyosis 35.11–12  
immune evasion 35.6  
immune restoration disease 35.28,  
35.29, 35.46, 35.47  
immunology 35.3–4  
incidence 34.2  
indicator conditions 35.1, 35.4, 35.8  
infections **35.24–36**  
*see also specific infections*  
infective otitis externa and 68.26  
inflammatory dermatoses 35.13–15  
intravenous drug users 35.45–6

- investigations 35.9  
 Kaposi's sarcoma and 56.34  
 leishmaniasis 35.35, 37.43  
 leprosy and 32.2, 35.26  
 lichen planus and 41.12  
 lipodystrophy syndrome 46.41–3  
 long-term non-progressors 35.3, 35.5  
 long-term survivors 35.5  
 lymphoma 35.41  
 malakoplakia 35.36  
 male genital dermatology 71.34, 71.39, 71.40–1, 71.48  
 melanoma 35.39–40  
 microsporidiosis 35.35  
 molecular epidemiology 35.2–3  
 molluscum contagiosum 33.11, 35.30–1, 35.45, 68.28  
 of eyelids 67.24–5  
 mortality 34.2, 35.2  
 MRSA infections 35.24  
 mucocutaneous involvement 35.1, 35.8  
*Mycobacterium avium* complex infection and 31.7, 35.25–6  
*Mycobacterium chelonae* infection and 31.7  
*Mycobacterium fortuitum* infection and 31.7  
*Mycobacterium gordonae* infection and 31.7  
*Mycobacterium kansasii* infection and 31.7  
*Mycobacterium scrofulaceum* infection and 31.7  
*Mycobacterium terrae* infection and 31.7  
*Mycobacterium tuberculosis* infection and 31.2, 31.7, 35.25  
*Mycobacterium xenopi* infection and 31.7  
 nail involvement 35.41–2, 35.42, 65.16, 65.23  
 natural history 35.5  
 neonatal 17.42  
 neoplasms 35.36–41, 35.40  
   *see also* Kaposi's sarcoma  
 neuropathy associated 63.12  
 neutrophilic eccrine hidradenitis and 44.17  
 non-AIDS defining cancers 35.39  
 oncocerciasis 35.36  
 onychomycosis 35.33, 35.41  
 oral manifestations 35.42–4, 69.19, 69.56, 69.81, 69.97–8, 69.118  
   ulceration 35.42  
 oropharynx in 35.42–4  
 parvovirus B19 35.31  
 pathogenesis 35.4, 35.6  
 penicilliosis 35.34, 36.88  
 perianal/perineal dermatology 71.83, 71.94, 71.95, 71.97–9  
 periodontal disease 35.43  
 pigmentary disorders 35.12  
*Pneumocystis carinii* pneumonia 35.4–5, 35.21, 35.35  
 porphyria cutanea tarda in 35.20  
 prevention of spread during surgery 77.7  
 prognostic indicators 35.11  
 progression rates 35.5  
 protozoal infections 35.35–6  
 pruritic papular eruption 35.19, 35.45  
 pruritus 21.14, 35.11–12  
 psoriasis 20.4, 35.17–18  
 rapid progressors 35.5  
 Reiter's syndrome 35.17  
 resistance to infection 35.3  
 risk of adverse drug reactions 75.6–7  
 rosacea 43.3  
 sarcoidosis and 61.6  
 scabies and 35.36  
   crusted (Norwegian) 38.44  
 seborrhoeic dermatitis and 23.29, 23.30, 23.32, 35.15–16, 35.45, 36.13, 68.28  
 seroconversion 35.3, 35.8, 35.10  
   dermatological manifestations 35.10  
 sexual transmission 35.2  
 soft-tissue infections 35.24  
 sporotrichosis 35.26  
 squamous cell carcinoma 35.39  
*Staphylococcus aureus* and 30.7, 30.8, 35.24, 35.45  
 survival improvements 35.5, 35.6  
 syphilis co-infection 34.3, 34.14, 34.23, 35.25  
 testing, 'normalization' 35.9  
 time to AIDS development 35.5  
 tinea corporis/faciei 35.32  
 toxic epidermal necrolysis and 76.8–9  
 transmission 35.5  
   resistance 35.6  
   sexually transmitted infections and 34.1  
   side-effects 35.6–7  
   vertical 35.44  
 treatment 35.5–8  
   failure, causes 35.5  
   guidelines 35.6  
   initiation 35.6  
   *see also* antiretroviral agents  
 tuberculosis and 31.2, 31.7, 31.8, 31.20, 31.27  
 varicella zoster virus (VZV) infection 35.28–39  
 vasculitis and 50.55  
 vectors 38.24  
 viral infections 35.28–32  
 vitiligo 35.12  
 warts 33.59  
 in women 35.44  
   genital involvement 71.57, 71.67, 71.71  
 xerosis 35.11–12  
 yaws in 35.25  
 zoster 33.25, 68.28  
   *see also* AIDS  
 HIV-wasting syndrome 46.42  
 hives *see* urticaria  
 HJMD (congenital hypotrichosis with juvenile macular dystrophy) 15.33  
 HLA-3, in lichen planus 41.2  
 HLA-5, in lichen planus 41.2  
 HLA associations 12.13–14, 15.8–9  
   adverse drug reactions 72.30, 75.14–15, 75.100  
   alopecia areata 66.31  
   Behçet's disease 50.56, 69.47  
   chemical-induced scleroderma 45.52  
   erythema multiforme 69.69, 76.2  
   geographical tongue 69.100  
   giant cell arteritis 50.43  
   granuloma annulare 60.1  
   hidradenitis suppurativa 30.80  
   HIV infection 35.3, 35.4, 35.5  
   psoriasis 35.17  
   idiopathic thrombocytopenic purpura 49.10  
   lichen planus 41.2  
   pityriasis rosea 33.78  
   sarcoidosis 61.3, 61.18  
   scabies 38.38  
   Stevens-Johnson syndrome 76.10–11  
   toxic epidermal necrolysis 76.10–11  
   urticaria 22.3  
 HLA-B8 40.45  
 HLA-CW7 40.45  
 HLA-Cw0602, psoriasis in HIV infection 35.17  
 HLA-DQB1\*0301 40.36  
 HLA-DQB1\*0503 40.3  
 HLA-DR, expressed by dermal dendrocytes 55.4  
 HLA-DR typing  
   HLA-B8 51.2  
   HLA-B8 and -DRw3 51.54  
   systemic sclerosis 51.90  
 HLA-DR2 40.41  
 HLA-DR3 40.45  
 HLA-DRB1\*0102 40.17  
 HLA-DRB1\*0402 40.3  
 HLA-DRB1\*1401 40.3  
 HLRCC syndrome 2.17, 62.29, 62.69  
 HMB45 10.21, 58.3  
 HNPs (human neutrophil peptides) 4.5  
 hoarseness, as a sign of systemic disease 62.84  
 hobbies  
   allergic contact dermatitis and 26.14  
   disorders associated with 5.6  
   history-taking 5.5  
 hobnail cells 56.29, 56.32, 56.33  
 hobo spider 38.32  
 Hodgkin's disease 57.63, 62.89–90  
   allergic contact dermatitis and 26.9  
   cutaneous 57.63  
   dyskeratosis congenita 15.79  
   EBV association 35.41  
   erythroderma and 23.48  
   exfoliative dermatitis 57.63  
   hair loss in 66.29  
   in HIV infection 35.41  
   HPV infections 33.59  
   ichthyosis with 19.63  
   pigmentation changes 58.26  
   pruritus in 21.11, 62.89  
   Reed-Sternberg cells 57.29  
   sarcoidal reaction in 61.23  
 Hoigne reaction 34.23  
 Holmes-Adie syndrome 44.14  
 holocarboxylase synthetase deficiency 59.64  
 holocrine glands 42.1  
 holoderma *see* knuckle pads  
 holomorph 36.2  
 Homans' procedure 48.25  
 homeopathy 72.32, 75.162  
 homeostasis, of skin 3.5–7  
 homocysteinurias (homocystinurias) 45.30, 59.99  
   hair colour in 66.95  
 homogentisic acid 73.27  
   accumulation in ochronosis 58.54  
 homogentisic acid oxidase 73.27  
 homologous recombination 11.10–11  
 homologous restriction factor protein 13.4  
 homosexual men *see* men who have sex with men (MSM)  
 homozygous genes, definitions 15.3–4  
 honey, in wound treatment 14.21, 73.48  
 honeybees *see* bees  
 HOOD syndrome 15.8, 15.86–7  
 hookworm disease 22.10, 37.2, 37.14–15, 37.16  
 hordeolum (stye) 67.6, 67.26–7  
 hormonal therapy, acne *see under* acne vulgaris  
 hormone replacement therapy (HRT) 8.19  
   complications 8.20  
   female genital dermatology and 71.52  
   flushing management 8.20  
   melasma rarity 58.34  
 hormone-sensitive lipase (HSL) 46.3  
 hormones  
   acne aetiology and 42.20–2  
   allergic contact dermatitis and 26.8  
   collagen gene expression control 3.39  
   fat and energy metabolism control 46.2  
   in menopause 8.19  
   menstrual cycle 8.8  
   pregnancy 8.9–10  
   at puberty 8.4–5  
   sebaceous gland activity and *see* sebaceous glands  
 horn, cutaneous 52.36, 53.13  
 horn cysts 53.35  
 horn flies 38.6  
 Horner's syndrome 63.22  
 hornets 38.14  
 horns (rhino) 2.3  
 Hornstein-Knickenberg syndrome 53.14, 53.15, 62.57, 62.69  
 horse botfly 38.9, 38.10  
 horse flies 37.11, 38.6, 38.7  
 horseradish peroxidase 10.15, 10.16  
 horses  
   alopecia 2.18  
   bullous pemphigoid 2.14–15  
   fungal infections 2.12  
   hypertrichosis 2.18, 2.19  
   melanoma 2.20  
   photosensitivity 2.23  
   pruritic skin disease 2.11  
   sarcoids 2.21–2  
   skin infections 2.12  
*Hortaea werneckii* 36.8, 36.14  
 Horton's disease *see* giant cell arteritis  
 hosiery, support/compression 14.20  
 hosiery workers, occupational hazards 27.6  
 hospital workers, occupational hazards 27.19–20  
 host defence  
   bacterial infections 30.1–2  
   innate 12.5  
   *see also* immunity, innate  
   role of normal skin flora 30.4, 30.5  
   *see also* immune system; immunity  
 host-parasite relationships 30.2  
 hot combing 9.7, 66.46, 66.99  
 hot flushes/flushes *see* flushing  
 hot-tubs 28.54–5  
 house-dust mite (HDM) 38.47–8  
   atopic dermatitis and 24.10, 24.31  
 house flies 38.6, 38.8  
 house mouse mite 38.51  
 housewives' dermatitis 23.20–3, 26.15, 27.2, 27.3  
 housework, occupational hazards 26.14, 26.15, 27.2, 27.3, 27.20  
 Howel-Evans syndrome 19.94, 19.106, 19.107, 62.20–1, 62.48  
 HOX gene expression, fibroblasts 3.50  
 Hoyeraal-Hreidarrson syndrome 17.70  
 HPS *see* haemophagocytic lymphohistiocytosis (haemophagocytic syndrome)  
 HPV *see* human papillomavirus (HPV)  
 HRF 13.4  
 HRT *see* hormone replacement therapy  
 HSAN *see* hereditary sensory autonomic neuropathy  
 HSCT (haematopoietic stem cell transplantation) *see under* haematopoietic stem cell(s)  
 HSP *see* Henoch-Schönlein purpura  
 HSV *see* herpes simplex virus (HSV)  
 5-HT *see* serotonin (5-HT)  
 HTA (Health Technology Assessment Database) 7.5  
 HTLV *see* human T-lymphotropic virus(es) (HTLV)  
 HTLV-1 *see* human T-lymphotropic virus type 1 (HTLV-1)  
 HTLV-2 33.64  
 HTLV-3 33.64  
 HTLV-4 33.64  
 human adjuvant disease, induced by silicone or paraffin implants 51.82  
 human androgen receptor (HUMARA) gene *see* HUMARA gene  
 human  $\beta$ -defensins (hBDs) 3.17, 4.5, 13.4, 14.5, 36.21  
   in acne pathogenesis 42.25  
 human bites 38.61  
 human bocavirus infections 33.62  
 human botfly 38.9, 38.10  
 human chorionic thyrotrophin (hCT) 8.9  
 Human Fertilization and Embryology Authority 16.8–9  
 Human Genetics Unit (HGU) 15.1  
 human genome organization 15.4  
 Human Genome Project 11.1, 15.1  
 human granulocytic anaplasmosis 30.58  
   Sweet's syndrome and 50.76  
 human herpesvirus 1 (HHV-1) *see* herpes simplex virus (HSV), HSV-1  
 human herpesvirus 2 (HHV-2) *see* herpes simplex virus (HSV), HSV-2

- human herpesvirus 3 (HHV-3) *see* varicella zoster virus (VZV)
- human herpesvirus 4 (HHV-4) *see* Epstein-Barr virus (EBV)
- human herpesvirus 5 (HHV-5) *see* cytomegalovirus (CMV) infections
- human herpesvirus 6 (HHV-6) **33.32–3**, 62.97  
antibodies 33.32, 33.33  
clinical features 33.32–3  
diagnosis and treatment 33.33  
pityriasis rosea and 33.79, 33.81  
reactivation 33.33
- human herpesvirus 7 (HHV-7) **33.33**, 62.97  
pityriasis rosea and 33.79, 33.81
- human herpesvirus 8 (HHV-8) **33.33–4**, 35.36, 56.33  
latent infection 33.34  
latent nuclear antigen-1 (LNA-1) 56.36  
pityriasis rosea and 33.79  
primary infection 33.34  
tumour development and 33.34
- human immunodeficiency virus *see* HIV (human immunodeficiency virus)
- human immunoglobulin *see* immunoglobulin(s)
- human leukocyte antigens, disease associations *see* HLA associations
- human neutrophil peptides 4.5
- human papillomavirus (HPV) **33.37–60**  
anal carcinoma and 35.30, 35.39  
anogenital intraepithelial neoplasia and 33.54–5, 33.59, 35.30  
antibodies 33.54  
Bowenoid papulosis and 33.54–5  
Buschke-Löwenstein tumour and 33.46, **33.55**  
cervical carcinoma and 33.39, 33.54, 35.30  
cervical infection 33.39  
cervical intraepithelial neoplasia and 33.54  
clinical conditions by HPV type 33.38  
diagnosis 33.39  
DNA 33.37  
integration into host chromosome 33.39, 33.54  
in skin cancers 33.55, 52.6  
E6 and E7 proteins 33.39, 33.42, 52.14  
electron microscopy 33.39  
in epidermal dysplasia and neoplasia 33.37, 33.39, **33.54–7**  
treatment 33.55  
epidermodysplasia verruciformis and *see* epidermodysplasia verruciformis (EV)  
expression of signals in keratinocytes 12.16  
genital infection 33.39  
in females 71.55, 71.69, 71.70–1, 71.76  
in males 71.9, 71.20, 71.34, 71.36, 71.38–46  
*see also* wart(s), anogenital genotypes 33.37, 33.38  
in epidermodysplasia verruciformis 33.57  
in Hailey-Hailey disease 39.35  
high-risk HPVs 33.54, 33.55, 52.5  
in HIV/AIDS 33.59, 35.29–30  
HPV-1 33.37, 33.40, 33.41, 33.43  
HPV-2 33.40, 33.42, 33.47, 33.59  
HPV-3 33.44  
HPV-4 33.59  
HPV-6 33.44, 33.47, 33.55, 35.30  
HPV-7 33.47  
HPV-10 33.44  
HPV-11 33.37, 33.44, 33.47, 33.55, 35.30  
HPV-13 33.47  
HPV-16 33.37, 33.42, 33.54  
HPV-18 33.54  
HPV-32 33.47  
HPV-57 33.47
- HPV-116 35.30  
immunity to 33.42  
in immunodeficiency 17.52, 33.58–9  
in immunosuppression **33.58–60**  
infection sites 33.38, 33.39  
inverted follicular keratosis and 53.2  
latent infection 33.39, 33.47  
in lichen sclerosis 51.116  
low-risk HPVs 52.5  
non-melanoma skin cancer and 52.5–6, 52.14  
occupational infections 33.47  
oncogenesis 33.39  
oral cavity 69.118  
malignant disease 69.50  
papilloma 69.110–11  
papillomas and 33.37–8  
penile cancer and 35.30  
penile intraepithelial neoplasia and 33.54–5  
perianal intraepithelial neoplasia 33.54–5  
perianal/perineal dermatology and 71.83, 71.94, 71.95, 71.97  
persistent infections 33.57  
in pregnancy 8.11  
prevalence, non-melanoma skin cancers and 52.14  
reactivation, with lichen planus treatment 41.18  
replication in keratinocytes 33.37  
squamous cell carcinoma and 33.55, 52.5, 65.37  
subclinical infection 33.39  
tissue culture difficulties 33.37  
in transplant recipients 33.59  
trichilemmoma and 53.5  
tropism for stratified squamous epithelium 33.37  
tumours associated with 33.37, 33.39, **33.54–7**  
*see also specific tumour types*  
typing 33.37, 33.41, 52.5–6  
vaccination 33.42  
vulvar intraepithelial neoplasia and 33.54–5  
warts 33.39–54, 65.31  
*see also* warts
- human parvovirus B19 *see* parvovirus B19
- human placental lactogen (hPL) 8.9
- human secretory-pathway  $\text{Ca}^{2+}/\text{Mn}^{2+}$ -ATPase isoform 1 (hSPCA1) 39.32
- human T-lymphotropic virus(es) (HTLV) **33.64–6**  
HTLV-1 *see* human T-lymphotropic virus type 1 (HTLV-1)  
HTLV-2 33.64  
HTLV-3 33.64  
HTLV-4 33.64
- human T-lymphotropic virus type 1 (HTLV-1) 33.64–6  
adult T-cell leukaemia-lymphoma (ATLL) and 33.64–6, 57.37–9  
atopic dermatitis and 24.24  
clinical features of infections 33.64–5  
crusted scabies and 38.44  
diagnosis and treatment of infection 33.65  
infective dermatitis of children associated 9.12, 23.25  
myelopathy/tropical spastic paraparesis (HAM/TSP) and 33.64–6  
transmission and replication 33.64
- HUMARA gene  
Erdheim-Chester disease 55.18  
Langerhans' cell histiocytosis 55.7
- humblebees *see* bees
- humectants 26.59, 73.7
- humidity, role in irritant contact dermatitis 25.8
- humoral response, HIV infection 35.3
- Hunter's syndrome *see* mucopolysaccharidoses
- huntspiders 38.32
- Huriez syndrome (keratoderma with scleroatrophy) 19.94, 19.99–100
- Hurler's syndrome *see* mucopolysaccharidoses
- Hutchinson-Gilford syndrome *see* progeria
- Hutchinsonian incisors 69.8, 69.78
- Hutchinson's lupus 28.65
- Hutchinson's melanotic freckle *see* lentigo maligna
- Hutchinson's sign 33.26, 54.45, 65.39, 65.40, 67.26
- Hutchinson's teeth 34.17
- Hutchinson's triad 34.17
- HUUS (hypocomplementaemic urticarial vasculitis syndrome) 13.22, 22.19, 50.22
- HV *see* hydroa vacciniforme (HV)
- hyaline bodies 33.11
- hyaline degeneration 10.38
- hyalinization, dermal collagen 51.114
- hyalinizing spindle cell low-grade fibromyxoid tumour with giant rosettes *see* sarcoma
- hyalinosis, systemic  
infantile 45.50  
juvenile hyaline fibromatosis 45.49–50, 69.15
- Hyalomma* 38.34
- hyaluronic acid 3.2, 3.46  
ageing and 80.1  
dermal fillers 80.4, 80.5, 80.6  
dressings 14.24, 63.10  
functions 3.46, 3.49  
structure 3.45–6, 3.47  
synthesis 3.45–6  
in wound healing 3.49
- hyaluronic acid derivatives, foreign body reactions 28.47
- hyaluronidase 38.1, 38.14
- hydantoin, hypermelanosis due to 58.29–30
- hydatid disease 37.1, 37.3, **37.24–5**
- hydralazine, adverse effects 75.96  
vasculitis 50.17, 50.18
- hydration, measurement 25.22
- hydrazines 25.21
- hydroa vacciniforme (HV) 29.10, **29.15–16**, 29.23, 46.32–3  
diagnosis 29.23
- hydrochloric acid  
as irritant 25.19, 25.20  
neutralization 25.23
- hydrocoele, in lymphatic filariasis 37.9–10
- hydrocolloid dressings 14.23, 47.48
- hydrocortisone 73.16  
contact sensitivity due to 73.17  
development 73.16  
in lichen planus 41.18  
relative absorption levels 73.4  
sebaceous gland activity and 42.11  
*see also* cortisol
- hydrodissection 77.2, 77.34
- hydrofibre dressings 14.23
- hydrofluoric acid  
burns 25.11, 25.23, 27.11, 27.12  
as irritant 25.20
- hydrogel dressings 14.23
- hydrogen peroxide  
as antiseptic 73.14–15  
bleaching hair 66.85, 66.98  
in hair dyes 66.97  
in otitis externa 68.25  
in wound cleansing 14.21
- 15-hydroperoxyabietic acid 26.79
- hydrophilic lipophilic balance (HLB) 73.7
- hydropic degeneration 10.38, 10.39
- hydroquinone 27.15, **73.26–7**  
abuse for skin lightening 73.26, 73.27  
adverse effects 75.33, 75.164–5  
exogenous ochronosis and 73.27  
for freckles 58.11
- hypermelanosis treatment 58.38–9  
monobenzylether of 73.27
- Hydrous Ointment BP 73.7
- hydroxprolinuria, in sarcoidosis 61.20
- 4-hydroxyanisole 73.27
- hydroxybenzoates 22.26, 73.8  
*see also* parabens
- hydroxycarbamide (hydroxyurea) therapy 47.54–5, 62.86, 74.18  
adverse effects 75.134–5  
lichenoid tissue reaction 41.25  
nail colour changes 65.16, 65.38  
pigmentation 58.55  
ulcer development in sickle cell anaemia 49.47  
dose range and evidence level 74.18  
in myeloproliferative disorders 49.29  
in psoriasis 20.36, 74.18
- hydroxychloroquine 13.24, 74.25–6  
adverse effects **75.69–70**  
hypermelanosis 58.30  
ocular 67.31  
in discoid lupus erythematosus 51.20  
in pemphigus foliaceus 40.16  
in SLE 51.61  
in urticarial vasculitis 50.23
- 25-hydroxycholecalciferol 73.43
- hydroxyethyl starch (HES) 21.15, 75.155  
pruritus 28.44
- 5-hydroxyindole acetic acid (5-HIAA), carcinoid syndrome diagnosis 43.19
- 11-hydroxylase deficiency 62.7
- 21-hydroxylase deficiency 62.6–7, 66.83  
partial 42.21
- hydroxylysine 3.37, 3.38
- hydroxyproline, excretion, collagen degradation 3.40
- hydroxyquinolones 26.18
- 3 $\beta$ -hydroxysteroid dehydrogenase 42.10, 42.12, 66.14
- 17 $\beta$ -hydroxysteroid dehydrogenase 42.10, 42.12, 66.14
- hydroxysteroid dehydrogenases 42.3
- 5-hydroxytryptamine *see* serotonin (5-HT)
- hydroxyurea therapy *see* hydroxycarbamide (hydroxyurea) therapy
- hydroxyzine 64.23  
adverse effects 22.29, 75.149  
in urticaria 22.28
- Hydrozoa 38.55, 38.56–7
- hyfrecation, macrocomedones 42.63, 42.67
- hygiene hypothesis 6.17–18, 24.5–6, 24.7
- Hylesia* 38.29
- hymen 71.55, 71.56
- Hymenoptera **38.13–15**  
hypersensitivity to 22.8, 38.1, 38.3, 38.14–15  
pheromones 38.2  
venom 38.14
- hyper-IgD syndrome 13.7, 22.25  
vasculitis and 50.53
- hyper-IgE syndrome 13.13, 17.76–7  
bacterial infection and 30.8  
bone and joint involvement 62.100, 62.104  
differential diagnosis 24.26–7  
eczema and 23.27  
in HIV infection 35.16  
oral involvement 69.33, 69.117
- hyper-IgM syndrome, X-linked 13.10, 13.12, 13.23, 17.50, 17.63–4
- hyperaemia, management 67.22–3
- hyperandrogenism 66.20
- hyperbaric oxygen therapy *see* oxygen, hyperbaric therapy
- hyperbilirubinaemia 62.64  
phototherapy 58.53  
pigmentation in 58.53
- hypercalcaemia 59.68–9  
in HTLV-1 infection 33.65  
in pseudoxanthoma elasticum 45.23  
in sarcoidosis 61.8, 62.71

- subcutaneous fat necrosis of the newborn and 17.36  
 vitamin D causing 73.43  
 hypercalciuria, in sarcoidosis 61.8  
 hypercholanemia, familial 3.25  
 hypercholesterolaemia 59.84, 59.86–8  
 hypercoagulation, thrombophlebitis migrans and 47.31  
 hypercorticism *see*  
 Cushing's syndrome/disease  
 hypercytokinaemia 55.26  
 hyperelasticity 4.8  
 hypereosinophilic syndrome 62.41, 62.87–8  
 differential diagnosis 24.27  
 eosinophilic vasculitis and 50.27  
 oral involvement 69.59  
 vasculitis and 50.53  
 hyperferritinaemia 49.6  
 hypergammaglobulinaemia 49.19  
 hyperglucagonaemia 62.66–7  
 hyperglycaemia, in congenital generalized lipodystrophy 46.37  
 hypergranulosis 10.39  
 hyperhidrosis 44.7–13  
 in adolescence 8.7  
 asymmetrical 44.8–9  
 axillary 44.7–8, 44.12, 77.36–7  
 compensatory 44.9, 44.12, 44.13–14  
 craniofacial 44.7–8, 44.9, 44.11  
 emotional 44.7–8, 44.9  
 flushing and 43.15  
 following spinal cord injury 63.17  
 generalized 44.7  
 gustatory 44.10–11, 63.22–3  
 idiopathic circumscribed 44.9, 44.11  
 inguinal 71.6  
 localized 44.8–9  
 mechanical injury 28.30  
 nail–patella syndrome and 44.8  
 olfactory 44.10  
 palmoplantar 44.7–8, 77.37  
 palmoplantar keratoderma and 19.95, 44.8  
 paraneoplastic 62.35–6  
 in syringomyelia 63.14  
 treatment 44.10, 44.11–13, 73.9, 77.36–7  
 hyperhomocysteinaemia 50.54  
*Hypericum perforatum* 72.29, 75.160, 75.162  
 hyperimmunoglobulin D and periodic fever syndrome 62.104  
 hyperinsulinaemia 46.7  
 acne aetiology and 42.20–1, 42.34  
 hyperirritable skin 27.11  
 hyperkeratosis  
 actinic keratosis 52.30  
 in dermatophytosis 36.22  
 disseminated superficial 'actinic' porokeratosis 52.35  
 in eczema 23.4  
 epidermolytic 10.39–40, 42.78  
 follicular 10.40, 42.74  
 histopathology 10.39–40  
 mechanical injury 28.11, 28.14, 28.15, 28.24, 28.28  
 nipple and areola 19.93, 70.8–9  
 oil 27.16  
 palmar 26.29  
 palmoplantar, in dermatopathia pigmentosa reticularis 58.20  
 subungual 51.12, 65.12, 65.15, 65.24  
 in syphilis 34.11  
 in viral warts 33.41, 33.42  
 hyperkeratosis follicularis et parafollicularis in cutem penetrans *see* perforating collagenosis (folliculitis)  
 hyperkeratosis lenticularis perstans (Flegel's disease) 10.39, 19.89–90  
 hyperkeratotic psoriasis 15.11  
 hyperlipoproteinaemias  
 Fredrickson classification 59.83  
 HIV lipodystrophy 46.42  
 type I 59.90  
 type III 59.88–9  
 type IV 59.91  
 type V 59.90  
 WHO classification 59.83  
 hypermelanosis *see* hyperpigmentation  
 hyperoxaluria 49.37, 50.54  
 absorptive 49.37  
 primary 49.37  
 secondary 49.37  
 hyperparakeratosis 69.93, 69.94  
 hyperparathyroidism 62.12  
 calciphylaxis (calcific uraemic arteriolopathy) 47.8  
 pruritus and 21.8  
 secondary/tertiary, in calciphylaxis 49.47  
 hyperphenylalaninaemia syndromes 59.94–6  
 non-PKU 59.96  
*see also* phenylketonuria (PKU)  
 hyperpigmentation 58.9, 58.10–39  
 acquired 58.38  
 in acromegaly 62.2  
 in acromelanosis 58.21  
 ACTH administration and 58.25  
 in actinic lichen planus 41.12–13  
 in Addison's disease 58.7, 58.24, 62.5–6  
 aetiology 9.4, 25.2  
 in amyloidosis 58.28  
 in anaemia 58.27  
 anogenital 71.2–3  
 in Becker's syndrome 58.21  
 in Cantú's syndrome 58.20  
 in carcinoid syndrome 58.25  
 in Carney complex 69.28  
 in chronic venous insufficiency 47.33  
 in contact dermatitis 26.26  
 in Cronkhite–Canada syndrome 58.13  
 in Cushing's syndrome 58.24  
 cutaneous lesion associated 58.38  
 in dermatomyositis 58.27  
 in dermatopathia pigmentosa reticularis 58.20  
 differential diagnosis 58.38  
 diffuse progressive, in mycosis fungoides 58.26  
 in disseminated superficial 'actinic' porokeratosis 52.35  
 drug-induced 58.29–30, 75.28, 75.32–3, 75.52–3  
 in dyskeratosis congenita 58.21  
 in endocrine diseases 58.24–5  
 ephelides *see* freckles  
 facial 58.12, 58.25, 58.34–8  
 management 73.28  
*see also* melasma  
 familial progressive 58.19  
 in Fanconi's anaemia 58.17  
 female genital dermatology 71.79–80  
 following chemical peel 80.9  
 following cryosurgery 77.40  
 in Gaucher's disease 58.24  
 generalized, in HIV infection 35.12  
 genetic causes 58.9, 58.38  
 gingival 69.13  
 in haemochromatosis 58.28  
 hands and feet, acromelanosis 58.21  
 hereditary disorders with 58.19  
 in HIV infection 35.12  
 in hyperthyroidism 58.24, 62.8  
 hypomelanosis occurring with 58.31, 58.33  
 incontinentia pigmenti *see* incontinentia pigmenti (IP)  
 interscapular skin 58.31  
 lentiginos *see* lentiginosis  
 lichen planus 41.13  
 in liver disease 62.64  
 in lymphomas 58.26  
 in malabsorption syndromes 58.28  
 in McCune–Albright syndrome 58.18  
 mechanical injury 28.15, 28.28, 28.31  
 in megaloblastic anaemia 62.85  
 melasma-like 58.34  
 in Mendes da Costa–van der Valk syndrome 58.20  
 menstruation and 58.25  
 in morphea 58.26  
 mucocutaneous 58.12  
 in multiple organ failure 58.27  
 in Naegeli's syndrome 58.19  
 in Nelson's syndrome 62.4  
 in neoplastic diseases 58.25  
 in nervous system diseases 58.26  
 in neurofibromatosis 58.23  
 in Niemann–Pick disease 58.24  
 oral cavity 9.3, 58.12, 69.21–2, 75.47  
 oral contraceptives and 58.25, 75.33  
 palms and soles 9.2, 9.3  
 paraneoplastic 62.33, 62.34  
 in pellagra 58.28  
 periorbital 58.19  
 persistent post-inflammatory, in acne 42.33  
 in Peutz–Jeghers syndrome 58.12  
 in pheochromocytoma 58.25  
 photodynamic and phototoxic reactions 58.32  
 in pityriasis versicolor 36.11  
 post-inflammatory 5.16–17, 9.4, 9.5, 26.26, 58.7, 58.29, 58.30–1, 58.35, 71.2–3  
 treatment 73.26, 73.27  
 in pregnancy 58.25  
 in primary biliary cirrhosis 58.28  
 progressive cribriform and zosteriform 18.18  
 in prurigo pigmentosa 23.44–5  
 in renal failure 58.27, 62.72  
 reticulate  
 acropigmentation 58.21–2  
 poikiloderma of Civatte 58.35  
 zosteriform 58.22–3  
 in rheumatoid arthritis 58.26  
 in sarcoidosis 61.14  
 in scleroderma 58.26  
 in SLE 58.27  
 in Still's disease 58.26  
 in systemic disorders 58.25–9  
 in systemic sclerosis 58.26  
 tanning *see* tanning  
 treatment 58.38–9  
 acquired hypomelanosis due to 58.50  
 retinoic acid 73.36  
 urticaria pigmentosa with 58.38  
 in Vagabond's disease 58.28–9  
 in vitamin A deficiency 58.28  
 in Werner's syndrome 58.23  
 in xeroderma pigmentosum 58.24  
*see also* melanosis; pigmentation  
 hyperpituitarism 62.2  
 sweating in 44.7  
 hyperplasia  
 intravascular papillary endothelial 69.102  
 mechanical injury 28.11  
 sebaceous gland, female genital dermatology 71.55  
 squamous, male genital dermatology 71.37  
 UVR-induced 29.5  
 verrucous, mechanical injury 28.28  
 hyperprolactinaemia 66.83  
 acne 42.12  
 hyperpyrexia  
 in anhidrosis 44.13  
 in HSN V 63.19  
 hypersensitivity angitis 50.4, 50.13–17  
 hypersensitivity reactions  
 in animals, comparison with humans 2.21  
 classification 13.12, 13.14  
 tattoos 28.48  
 type I (immediate)  
 in atopic eye disease 67.15  
*see also* allergy  
 type II 13.14  
 type III (immune complex) 13.14  
 urticaria as 22.18  
 urticarial vasculitis as 50.22  
 in viral infections 33.3  
 type IV (delayed-type) 13.14, 26.25  
 acne pathogenesis 42.25, 42.27  
 actinic prurigo 29.14  
 chronic, acne scarring and 42.27  
 induction phase 29.11  
 polymorphic light eruption 29.9, 29.11  
*Propionibacterium acnes* role/effect 42.7  
 reduced in obesity 8.17  
 role of macrophages 13.5  
 tests 13.22  
 types 26.5  
 types 26.5  
 hypersplenism, in sarcoidosis 61.7  
 hypertelorism 67.4  
 hypertension  
 raised leptin levels and 46.7  
 in SLE 51.43  
 in Takayasu's arteritis 50.45  
 venous 23.35–6  
 venous leg ulcers and 47.43  
 hypertensive ulcers 47.52–4  
 hyperthyroidism 62.7–10  
 flushing associated 43.16  
 hair in 66.28, 66.78  
 hyperpigmentation in 58.24–5  
 pruritus in 21.11  
 sarcoidosis and 61.17  
 sweating in 44.7  
 hypertrichosis 66.75–80  
 acquired generalized 66.77–9  
 acquired localized 66.79–80  
 in Berardinelli's syndrome 66.76  
 congenital 71.84  
 congenital generalized 66.75–7  
 lipodystrophy 46.37  
 congenital localized 66.77  
 congenital macrogynivae and 66.76  
 in Cornelia de Lange syndrome 66.76  
 definition 66.75  
 dermatomyositis and 66.78  
 drug-induced 66.79, 75.45  
 minoxidil 73.49, 73.50  
 in eating disorders 66.78  
 with epidermolysis bullosa 66.78  
 equine 2.18, 2.19  
 external auditory canal/meatus 68.18, 68.21  
 in fetal alcohol syndrome 66.77  
 in hyperthyroidism 66.78  
 in hypothyroidism 66.78  
 iatrogenic 66.79  
 laser therapy 78.12–13  
 lumbosacral 66.77  
 in malnutrition 66.78  
 in mucopolysaccharidoses 66.76  
 naevoid 66.77  
 pinna 68.1, 68.2, 68.5  
*see also* ear(s), hairy  
 in porphyria 66.79  
 in pregnancy 8.10  
 in spinal dysraphism 63.15  
 in trisomy 18 66.77  
 universal 66.76  
 in Winchester syndrome 66.76  
*see also* hirsutism  
 hypertrichosis and dental defects 15.42  
 hypertrichosis lanuginosa 66.75–6  
 acquired 66.77–8  
 paraneoplastic 62.35  
 hypertriglyceridaemia(s) 59.84  
 in congenital generalized lipodystrophy 46.37  
*see also* hyperlipoproteinaemias  
 hypertrophic osteoarthropathy 15.87, 15.88–9  
 hypertrophic scarring, burns 28.84, 28.88–9  
 hyperviscosity disorders, purpura in 49.4, 49.5  
 hyphae 36.2, 36.3  
 aerial 36.9  
 extrapillary 36.20  
 Hyphomycetes 36.4

- hypnosis 64.54  
for surgical procedures 77.11  
wart treatment 33.50
- hypnotics 75.80–2
- hypoadrenalism *see* Addison's disease
- hypoalbuminaemia, in erythroderma 23.49
- hypocalcaemia 62.12
- hypochlorous acid 13.4
- hypochondriasis 64.12
- hypocomplementaemia  
partial lipoatrophy and 46.39  
in urticarial vasculitis 22.18, 22.19, 50.22
- hypocomplementaemic urticarial vasculitis syndrome (HUVS) 13.22, 22.19, 50.22
- hypocorticism *see* Addison's disease
- Hypoderma* 38.9, 38.10
- hypodermatitis sclerodermaformis 46.30–1
- hypodontia 69.6, 69.7  
nail dysgenesis with 69.6  
taurodontism and sparse hair with 69.10
- hypogammaglobulinaemia  
echovirus infections and 33.73  
eczema and 23.27
- hypoglossal palsy 69.6
- hypoglycaemia, sweating in 44.7
- hypogonadism 8.5  
delayed puberty 8.6  
genetics 15.81
- hypohidrosis 44.13–15
- hypohidrotic ectodermal dysplasia (HED) 15.28, 15.43  
deafness and 15.44  
differential diagnosis 15.81  
in dogs 2.18, 2.20  
hypothyroidism and agenesis of the corpus callosum and 15.44  
hypothyroidism and ciliary dyskinesia and 15.44
- immune deficiency, osteopetrosis and lymphoedema with 15.44, 15.60
- immune deficiency and 15.43, 15.60  
mutations in TNF-like/NF-kB signalling pathways 15.58–60
- papillomas and acanthosis nigricans with 15.44
- hypomagnesaemia, familial 3.25
- hypomastia 70.2, 70.3
- hypomelanosis *see* hypopigmentation
- hypomelanosis of Ito 58.45, 62.100
- hypomelanotic macules of tuberous sclerosis 58.44
- hypomelia–hypotrichosis–facial haemangioma syndrome 18.70, 66.61
- hyponychium 3.15, 65.2, 65.46
- hypoparathyroidism 62.12  
candidiasis and 36.58
- hypophosphatasia 69.117
- hypopigmentation 58.9, 58.39–53  
acquired 58.50–3  
causes 58.51  
chemical depigmentation 58.50–1  
in actinic lichen planus 41.12–13  
aetiology 9.4, 25.2  
along Blaschko's lines 58.45  
anogenital 71.2–3  
in Chédiak–Higashi syndrome 58.41  
in contact dermatitis 26.26, 26.27  
corticosteroid-induced 73.17  
in disseminated superficial 'actinic' porokeratosis 52.35  
drug-induced 75.33  
eyelids 67.5  
female genital dermatology 71.79  
following chemical peel 80.9  
following cryosurgery 77.40  
following patch/photopatch testing 26.94, 26.95  
genetic and naevoid disorders 58.39–50  
halo, in halo naevus 58.49–50
- hypermelanosis occurring with 58.31, 58.33
- idiopathic guttate 9.11, 58.52  
in inflammatory disorders 58.52  
of Ito 58.45, 62.100  
in liver disease 62.64  
male genital dermatology 71.49  
in mycosis fungoides 9.7  
in napkin dermatitis 17.25  
occupational 27.1, 27.15  
in onchocerciasis 37.5–6  
paraneoplastic 62.34  
in pityriasis versicolor 36.11  
post-inflammatory 9.5–6, 26.26, 58.51–2, 71.2–3  
in sarcoidosis 61.14
- hypopituitarism 62.2–3  
in sarcoidosis 61.7
- hypoplasminogenaemia 69.15, 69.59
- hypoproteinaemia 66.29  
venous leg ulcers 47.43
- hypopyon 67.4
- hypopyon ulcers 67.9
- hyposensitization  
adverse effects 75.140–1  
in allergic contact dermatitis 26.102
- hyposteatorosis 23.6
- hypotension, pressure ulcers 28.18
- hypothalamic–pituitary–adrenal (HPA) axis 64.8, 64.9
- hypothalamo–pituitary–gonadal axis  
normal 8.4  
premature puberty 8.5
- hypothernar hammer syndrome 28.26, 28.56, 50.54
- hypothermia, erythroderma and 23.49
- hypothyreosis erythema migrans 62.106
- hypothyroidism 62.10–12  
candidiasis and 36.58, 36.65  
hair loss in 62.10, 66.28, 66.29  
in animals 2.18  
hypertrichosis in 66.78  
palmoplantar keratoderma with myxoedema 19.118  
pruritus in 21.11  
sarcoidosis and 61.17  
thermal injury 28.72–3
- hypotrichosis  
congenital 66.60–1  
disorders of amino acid metabolism and 66.61  
eyelid cysts and hypodontia with 66.61
- hypomelia–hypotrichosis–facial haemangioma syndrome 66.61
- keratosis pilaris with 66.60  
lentiginosis and 66.60–1  
localized autosomal recessive 66.67  
Marie–Unna hereditary 66.60  
resulting from short anagen 66.60
- hypotrichosis–osteolysis–periodontitis–palmoplantar keratoderma syndrome 15.45
- hypotrichosis simplex 66.60
- hypotrichosis–lymphoedema–telangiectasia syndrome 48.10
- hypovolaemic shock, burns 28.77
- hypoxanthine guanine phosphoribosyl transferase (HGPRT) 59.102, 74.14
- hypoxia-inducible factor-1a 14.6
- hystrix-like ichthyosis with deafness (HID) syndrome 15.46
- I**
- I cell disease 59.32
- iatrogenic swelling, male genital dermatology 71.49–50
- iatrogenic vaginal discharge 71.53
- IBIDS/PIBIDS syndrome 19.47–9
- ibuprofen 26.46, 75.74
- ibuprofen 26.46
- ICAM-1 *see* intercellular adhesion molecule-1
- icatibant 22.21, 22.22
- ICDRG (International Contact Dermatitis Research Group) 26.2
- ICE (IL-1alpha converting enzyme) 12.43, 12.49
- 'ice-pick' marks 52.8
- ice provocation test 27.17
- ICE syndrome 19.61
- ICF syndrome 17.65
- ichthammol (Ichthyol) 73.42  
in eczema 23.38
- ichthyoses, congenital 19.3–63  
bullous ichthyosiform erythroderma 19.3, 19.29–34  
*see also* bullous ichthyosiform erythroderma (BIE)  
CHILD syndrome 18.27, 19.3, 19.57–8  
CHIME syndrome 19.60  
collodion babies 17.19–21, 19.13–17, 59.39  
Conradi–Hünemann–Happle syndrome 16.3, 19.3, 19.49–52  
harlequin 19.25–9  
HID syndrome 19.36, 19.37, 19.54–7  
IBIDS/PIBIDS syndrome 19.47–9  
ichthyosis bullosa of Siemens 19.3, 19.34–5  
ichthyosis follicularis with alopecia and photophobia 19.58–9, 19.60  
ichthyosis hystrix 19.3, 19.35–7, 19.99  
ichthyosis vulgaris 19.6–9  
KID syndrome 19.54–7, 19.60  
lamellar 19.3, 19.21–5  
multiple sulphatase deficiency 19.13  
Netherton's syndrome 19.3, 19.37–42  
*see also* Netherton's syndrome (NS)  
Neu–Laxova syndrome 19.59–60  
neutral lipid storage disease with 19.52–4  
non-bullous ichthyosiform erythroderma 19.17–21  
Refsum's disease 19.3, 19.45–7  
Sjögren–Larsson syndrome 16.3, 19.3, 19.42–5  
sporadic genetic syndromes with 19.60–3  
X-linked recessive 19.3, 19.9–13
- ichthyosis  
acquired (late-onset) 19.63–5, 62.32  
anhidrosis and 44.13  
autosomal dominant, genetics 15.5  
congenital *see* ichthyoses, congenital (*above*)  
harlequin 11.13, 17.20  
prenatal diagnosis 16.3, 16.6, 16.7  
in HIV infection 35.11–12  
ichthyosiform atrophy 57.63  
lamellar *see* lamellar ichthyosis (LI)  
malabsorption 59.58  
X-linked *see* X-linked ichthyosis
- ichthyosis bullosa of Siemens 19.3, 19.34–5
- ichthyosis follicularis, atrichia and photophobia (IFAP) syndrome 15.45
- ichthyosis follicularis with alopecia and photophobia (IFAP) 19.58–9, 19.60
- ichthyosis hystrix 19.3, 19.35–7, 19.99  
HID (hystrix ichthyosis and deafness) syndrome 19.36, 19.37, 19.54–7  
of Rheydt 19.37
- ichthyosis linearis circumflexa (ILC) 19.37, 19.39, 19.40, 19.41  
*see also* Netherton's syndrome (NS)
- ichthyosis prematurity syndrome 19.18–19
- ichthyosis vulgaris 3.8, 4.2, 19.6–9, 24.22  
genetics 15.5  
skin biopsy 10.42  
ichthyotic scale 5.7  
icodextrin 75.99
- ICOS (inducible co-stimulator) 13.11
- icterus *see* jaundice
- 'id' eruption 47.34
- idiopathic acquired anhidrosis 44.13
- idiopathic facial aseptic granuloma 43.14
- idiopathic guttate hypomelanosis 58.52
- idiopathic lipogranuloma, male genital dermatology 71.50
- idiopathic midline destructive disease 69.58
- idiopathic multiple pigmented sarcoma *see* Kaposi's sarcoma
- idiopathic nodular panniculitis 46.13–14
- idiopathic sclerosing lipogranuloma 46.29, 46.30
- idiopathic thrombocytopenic purpura (ITP) 49.1, 49.9–11  
drug-induced 49.9  
in pregnancy 49.12  
remission and treatment 49.10  
viral infection associated 49.9, 49.10
- idoxuridine 73.15  
action 74.49  
adverse effects 26.46, 75.66  
orf 33.9  
topical, herpes simplex 33.21
- IFAP syndrome 15.45
- Ig *see* immunoglobulin(s)
- IGF-1 *see* insulin-like growth factor-1 (IGF-1)
- IGF-2, sebaceous gland activity and 42.11
- Iggo discs 3.16
- ileostomy *see* stoma
- ileumbilical fistula 71.100
- iliac compression syndrome 47.32
- iliac thrombosis 47.28
- iloprost 14.24, 47.6
- ILVEN (inflammatory linear verrucous epidermal naevus) 18.19–21, 20.17
- imatinib 66.94, 75.132
- imidazoles  
adverse effects 26.46  
in candidiasis 36.68, 36.69  
corticosteroids with 73.12  
in dermatophytosis 36.47, 36.48, 36.49  
in otitis externa 68.25  
topical 73.12
- imidazolidinyl urea 26.50, 26.51–2
- iminodipeptiduria 47.54
- imipenem 74.40
- imipramine 64.51, 75.33, 75.79
- imiquimod  
adverse effects 75.147–8  
lip ulceration 54.43  
in basal cell carcinoma in HIV infection 35.39–40  
in Bowen's disease 52.34  
in granuloma annulare 60.10  
in infantile haemangioma 18.52  
in lentigo maligna 54.43  
topical therapy 73.24  
wart treatment 33.49–50
- immediate pigment darkening (IPD) 58.31
- immersion foot 28.64
- immigrants, latent syphilis diagnosis 34.12
- immobility acne 42.76
- immobilization  
lymphoedema and 48.14  
pressure ulcers and 28.18, 28.21
- immune complex(es) 26.25  
adverse drug reactions mediated by 75.17  
circulating, viral infections 33.3  
in cutaneous small vessel vasculitis 50.13  
in hepatitis B virus infection 62.59  
hypersensitivity *see* hypersensitivity reactions, type III (immune complex)  
in leprosy 32.7  
pigmented purpuric dermatoses and 49.22  
in polyarteritis nodosa 50.33  
role in purpura 49.18  
role in vasculitis 22.18, 22.19, 49.18, 50.4–5, 50.5

- type II/III cryoglobulins 49.32  
vasculitis *see* vasculitis
- immune-mediated disease  
in animals 2.14–16  
*see also specific diseases*
- immune privilege, alopecia areata and 66.32
- immune reconstitution (inflammatory) syndrome/immune restoration disease (IRIS/IRD) 35.46
- immune response  
adaptive  
suppression by UVR 29.6  
*see also* immunity, acquired  
ageing and 8.24  
in HIV infection 35.3–4  
innate  
stimulation by UVR 29.6, 29.7  
*see also* immunity, innate  
modifiers, topical, non-melanoma skin cancer 52.17  
primary 13.6  
secondary 13.6  
stimulation, molluscum contagiosum therapy 33.13  
wound healing and 14.2–4
- immune surveillance 3.18–19  
altered, malignancy after lymphoedema 48.15
- immune system 17.48–51  
adaptive  
activation 3.18  
*see also* immunity, acquired  
ageing and 13.15  
in atopic dermatitis 24.6–10, 24.13–15  
defects  
ichthyosis 19.61  
pityriasis rubra pilaris 19.79  
deficiency *see* immunodeficiency  
dynamic nature of 13.6  
hair cycle and 66.11  
hygiene hypothesis 24.5–6, 24.7  
immune surveillance 3.18–19  
in infancy and childhood 13.15  
innate (non-adaptive) *see* immunity, innate  
integration of parts 13.2  
interaction with nervous system 63.4  
Langerhans' cells 3.17–18  
lichen planus pathogenesis 41.1–2  
lymphatic system function 48.6, 48.29  
malignant disease and 13.15  
mast cell functions 3.20  
microbial recognition 12.8–9  
oral cavity 69.3  
psychological effects 64.8–9  
skin 2.8, 3.16–19  
structure and function 13.1–11  
suppression *see* immunosuppression  
UVR-induced changes 29.5–6, 52.14  
*see also* immunity
- immune thrombocytopenic purpura *see* idiopathic thrombocytopenic purpura (ITP)
- immunity  
acquired 13.6–11, 17.49–51  
adverse drug reactions and 75.17–21  
in candidiasis 36.58  
components 13.6–7  
disorders 17.57–70  
in leprosy 32.3, 32.7  
in sarcoidosis 61.5–6  
tests of 17.56–7  
to arthropod bites/stings 38.1  
innate 3.16–17, 12.5, 13.1–6, 17.48–9  
in acne pathogenesis 42.25, 42.26  
in atopic dermatitis 24.13–14  
cellular components 13.4–6  
defects 17.73–82  
non-specific defence mechanisms 13.1–2  
soluble factors 13.2–4  
tests of 17.55–6  
in pregnancy 8.11  
immunization granulomas 28.45
- immunoabsorption 13.25  
pemphigus 40.12
- immunoblotting 10.18
- immunobullous diseases 40.1–62  
desmosomes as autoantigens 3.22, 3.23  
intraepidermal 40.3–24  
intraepithelial 67.17  
mixed 40.49  
ocular complications 67.17  
treatment 67.22–3  
subepidermal *see* subepidermal immunobullous diseases  
subepithelial 67.17  
conjunctivitis 67.20
- immunocytochemistry 13.16–19
- immunocytochemistry, sebaceous glands 42.3–5
- immunocytoma 57.43
- immunodeficiency 13.11–12  
candidiasis and 17.66–7, 36.59  
cellulitis/erysipelas and 30.18  
classification of disorders 17.51  
CMV infection in 33.29  
diagnosis 17.51–7  
DNA repair defects and 17.67–70  
due to abnormal B-cell development 13.8  
examination 17.54  
genetics 17.51  
herpes simplex in 33.15, 33.17, 33.18, 33.20  
history-taking 17.51–3  
HPV infections in 17.52, 33.58–9  
infection and 17.54–5  
*see also specific infections*  
laboratory investigation 17.54–5  
mice 2.7–8  
non-infectious non-specific manifestations 17.53–4  
oral manifestations 69.117  
primary 13.11, 13.12, 13.13  
cutaneous features 17.54  
neonatal disorders 17.48–85  
warts and HPV infections in 33.59  
secondary 13.11, 13.12, 13.14  
short-limbed dwarfism and 17.64–5  
varicella and zoster in 33.23, 33.24, 33.25, 33.27  
warning signs 17.55  
warts in 17.52, 33.58–9  
*see also specific immunodeficiency disorders*
- immunolectron microscopy 10.18
- immunoenzyme (immunoperoxidase) methods  
applications 10.18–28  
techniques 10.15–18
- immunofluorescence mapping, epidermolysis bullosa (EB) 39.1–2
- immunofluorescence methods 13.19  
applications 10.18–28  
techniques 10.12–15
- immunofluorescence microscopy  
EB simplex 39.4  
junctional EB 39.10
- immunogenotyping 10.30
- immunoglobulin(s) 13.7  
absence from dermal–epidermal junction 51.92  
assay 17.56  
C domains 17.49  
D (diversity) segment 17.49  
heavy (H) chains 17.49  
intravenous *see* intravenous immunoglobulin (IVIg)  
joining (J) segment 17.49  
light (L) chains 17.49  
measurement 13.16–17  
monoclonal 13.17  
patterns 13.17  
receptors  
FceR1, in atopic dermatitis 24.14  
FceR1a 22.4  
FceR1b, in atopic dermatitis 24.3  
in sarcoidosis 61.5, 61.6
- structure 17.49  
superfamily 12.73–5  
V domains 17.49
- immunoglobulin A (IgA) 13.7  
adhesion complex 40.46  
in atopic dermatitis 24.9–10, 24.12  
deficiency 13.7, 17.73, 69.3  
selective 69.117  
in dermatitis herpetiformis 40.59  
dermatosis 40.19–22  
clinical features 40.4, 40.20  
pathogenesis 40.19–20  
pathology 40.19  
treatment 40.20  
*see also* linear IgA disease
- in Henoch–Schönlein purpura 50.20
- IgA1 13.7  
IgA2 13.7  
immune complexes 49.18  
myeloma 49.13
- immunoglobulin A (IgA)-mediated epidermolysis bullosa acquisita 40.55
- immunoglobulin D (IgD) 13.7
- immunoglobulin E (IgE) 13.7  
allergen-specific 13.16  
anti-IgE antibodies 51.104  
in atopic dermatitis 24.3, 24.4, 24.5, 24.8–9  
in atopic eye disease 67.15  
in contact urticaria 27.5  
detection of antibodies 5.23–4  
mast cell activation 3.20  
measurement 13.16  
receptors 13.5  
in sweat 44.6  
synthesis, dysregulation in HIV infection 35.16  
tests for drug-specific antibody 75.173–4  
total level 13.16  
urticaria and 22.7–8
- immunoglobulin G (IgG) 13.7  
anticardiolipin antibody, SLE 51.63  
in atopic dermatitis 24.9  
autoantibodies 40.26, 40.47, 40.52  
in bullous pemphigoid 40.30  
in epidermolysis bullosa acquisita 40.52  
in mucous membrane pemphigoid 40.36  
in heparin-induced thrombocytopenia 49.27  
receptors, IgG–antigen complexes 12.32  
in Sjögren's syndrome 13.7  
subclasses 13.7
- immunoglobulin M (IgM) 13.7  
cold agglutinin-related cutaneous occlusion 49.34
- immunohistochemistry, melanoma 54.49
- immunological functions of skin 4.1, 4.8–9
- immunological tolerance 13.29–30, 26.12
- immunomodulators 73.31–4, 74.25–30, 75.136–8  
topical, wart treatment 33.49–50
- immunopathology 10.11–28
- immunophilins 73.17, 74.18
- immunorestitution, in HIV infection 35.46
- immunosuppression  
adverse drug reactions and 75.6–7  
in atopic dermatitis 21.13  
in atopic eye disease 67.16  
cicatrizing conjunctivitis 67.22–3  
cold-induced injury 28.71  
crusted scabies and 38.43–4  
cutaneous manifestations 75.123–4  
eczema herpeticum and 33.35  
for eyelid diseases 67.5  
female genital dermatology and 71.64, 71.69  
follicle mite infection and 38.53
- for idiopathic thrombocytopenic purpura 49.10
- internal malignancy and 62.47
- male genital dermatology and 71.39, 71.41
- Merkel cell carcinoma association 53.42
- molluscum contagiosum and 33.11
- mucous membrane pemphigoid and 67.20
- non-melanoma skin cancer association 52.11, 52.14
- in ocular features of immunobullous disorders 67.22–3
- reaction to arthropod bites/stings and 38.2
- in sarcoidosis 61.21
- seborrhoeic dermatitis and 23.29
- squamous cell carcinoma and 52.26–7
- systemic 13.27–8, 13.29  
UV-induced 8.22, 13.26–34, 26.10  
reduced by sunscreens 73.41
- immunosuppressive therapy  
Darier's disease 19.85  
Netherton's syndrome 19.41  
non-bullous ichthyosiform erythroderma 19.19  
non-specific 74.14–24  
pityriasis rubra pilaris 19.79  
SLE 51.61
- immunotherapy 13.23–6  
adverse effects 26.46, 75.138–41  
alopecia areata 66.37  
in hand eczema 23.22  
Hymenoptera venom 38.15  
in latex sensitivity 26.106  
melanoma metastatic to brain 54.55–6  
urticaria 22.29–30
- Impact of Psoriasis Questionnaire (IPSO) 72.20
- impairment 6.5
- imperforate hymen 71.56
- impetiginization, eczematous dermatitis 47.34
- impetigo 4.5, 30.14–17  
bacteriology 30.14  
bullous 30.14  
bacteriology 30.14  
clinical features 30.15  
desmoglein 1 (Desgl1) disruption 3.22  
epidemiology 30.14  
neonatal 17.42, 30.14  
pathology 30.14–15  
canine 2.11–12  
clinical features 30.15  
complications 30.15–16  
definition 30.14  
differential diagnosis 36.27  
epidemiology 30.14  
eyelids 67.26  
follicular of Bockhart 30.22  
herpes labialis and 69.72, 69.73  
non-bullous (impetigo contagiosa of Tilbury Fox) 30.14, 30.15  
pathology 30.14–15  
renal involvement 62.71  
in scabies 38.39  
treatment 30.16, 73.10
- impetigo herpetiformis 8.12  
genitocrural dermatology 71.5
- implantable defibrillators 62.79
- implantation, foreign body reactions 28.46–7, 28.50, 28.52
- imprinting, genomic 15.6
- in situ* hybridization 11.9
- incense cedar 26.80
- INCI (International Nomenclature of Cosmetic Ingredients) 26.24, 26.41, 26.48
- incidence 6.11, 6.18  
definition 26.2
- incisional biopsy, panniculitis 46.11
- inclusion bodies  
eosinophilic 10.29  
sarcoidosis 61.4

- incontinentia pigmenti (IP) 15.45, 17.81–2, 48.10, 58.15, 58.15–17, 58.16  
 aetiology and genetics 58.15  
 alopecia in 66.51  
 bone and joint involvement 62.100  
 clinical stages and features 58.15–16  
 dental involvement 69.6  
 extra-cutaneous features 58.16, 58.17  
 familial male-lethal type 15.45  
 gene 58.15  
 genetics 15.6, 15.13  
 histopathology 10.41  
 oral involvement 69.95  
 pathology 58.15  
 subungual keratotic tumours 65.38  
 treatment 58.16
- incontinentia pigmenti achromians of Ito 58.45
- indandiones 75.105
- indentation tests, mechanical injury 28.5
- indentometry 4.11
- indeterminate cells 55.3
- Indian sandal dermatitis 26.68
- Indian tick typhus 30.73
- indinavir 75.68–9  
 adverse effects 45.5  
 photosensitivity 35.22
- indirect immunofluorescence, ocular  
 mucous membrane pemphigoid 67.19
- indium 26.40
- indometacin (indomethacin) 75.76  
 dermatomyositis 51.129  
 isotretinoin interaction 42.65
- inducible co-stimulator 13.11
- infancy and childhood  
 acute haemorrhagic oedema of childhood/infancy 17.33–4, 50.30  
 adverse drug reactions 75.6  
 allergic contact dermatitis 26.8–9  
 atopic dermatitis 24.19–21  
 bacterial skin flora 30.4  
 dermatomyositis 62.99  
 fibrous hamartoma 56.6  
 immune system 13.15  
 longitudinal melanonychia 65.39  
 myofibromatosis 56.9  
 nails 65.6–7  
 ingrowing 65.6–7, 65.53  
 nomenclature 17.1  
 periodontitis 69.18  
 psoriasis 17.31–2  
 sarcoidosis 61.16  
 scabies 38.39–40, 38.42  
 seborrhoeic dermatitis 17.28–31, 23.29, 23.34, 24.22, 24.26  
 subcutaneous fat necrosis following hypothermic cardiac surgery 17.37–8  
 Sweet's syndrome 50.63  
 urticaria 22.6–7  
 wound healing 14.2  
*see also* children; infant(s)
- infant(s)  
 epidermolysis bullosa (EB)  
 Herlitz junctional 39.12  
 management 39.27–8  
 epidermolysis bullosa (EB) simplex  
 Dowling-Meara form 39.7  
 generalized 39.6  
 normal bacterial skin flora 30.4  
 skin and skin disease 8.1–4  
 topical therapy  
 corticosteroid adverse effects 73.20  
 quantities 73.3, 73.4  
*see also* infancy and childhood
- infantile acne 42.75–6
- infantile gluteal granuloma 17.27–8, 71.91, 73.18
- infantile neuronal ceroid lipofuscinosis, prenatal diagnosis 16.3
- infantile Refsum's disease 19.46
- infantilism 8.3
- Infant's Dermatitis Quality of Life Index (IDQOL) 72.23
- infection(s)  
 in animals 2.9–13, 2.21  
 atopic dermatitis and 24.12–13, 24.24  
 Behçet's disease and 50.56  
 bone and joint involvement 62.100, 62.105  
 children 8.3  
 cryoglobulinaemia with 49.32  
 diabetic foot ulcers 47.57–8  
 ear 68.18–28  
 exacerbation, corticosteroids associated 73.18  
 eyes 67.24–8  
 Henoch-Schönlein purpura and 50.20  
 in HIV infection 35.24–36  
*see also* individual infections
- immunodeficiency and 17.54–5
- intrauterine 18.2, 18.102
- leg ulcers due to 47.56–7
- in lymphoedema 48.12, 48.15, 48.24  
 prevention 48.22, 48.24
- microvascular occlusion due to 49.34–6
- neonatal 17.39–48
- panniculitis 46.27–8
- pigmented purpuric dermatoses due to 49.23
- in pregnancy 8.11
- purpura associated 49.20–1
- respiratory tract 62.80
- risk factors 6.12–13
- secondary thrombocytopenia due to 49.11
- Sweet's syndrome and 50.75
- tattoos and 58.58
- in transplantation recipients 62.74
- urticaria and 22.2, 22.8, 22.10, 22.11
- vasculitis and 50.5–6, 50.49, 50.55–6
- venous leg ulcers 47.44, 47.49  
*see also* bacterial infection; fungal infections; viral infection; *specific infections*
- infection phobias 64.24
- infectious mononucleosis  
 acne after 42.79  
 ampicillin reaction 75.15, 75.49  
 CMV causing 33.29  
 EBV causing 33.30  
 HHV-6 associated 33.32
- infective eczematoid dermatitis 68.19
- infective vaginal discharge 71.53
- infertility, sexually transmitted diseases causing 34.1
- inflammasome NALP-3 12.4
- inflammation 12.1–77  
 acne pathogenesis 42.24, 42.25–6  
 topical drugs affecting 42.40  
 adiponectin action 46.4  
 cell apoptosis and 12.11–12  
 cellular components 12.14–15  
 clinical features 12.2–5  
 cryopyrin-associated autoinflammatory syndromes 74.11  
 drug absorption increase 73.4  
 histopathological features 12.3  
 hypermelanosis after 58.29, 58.30–1  
 hypomelanosis and 58.51–2  
 lipotrophia semicircularis and 46.36  
 lymphoedema and 48.8, 48.12–13  
 major histocompatibility complex and 12.13  
 mechanical injury 28.31  
 mediators of 12.33–67  
 acute-phase proteins 12.34  
 keratinocytes 12.15–17  
 lysosomal 12.53  
 in pigmentation regulation 58.7  
 tumour necrosis factor 74.5  
 UVR-induced damage and 29.5  
*see also* *specific mediators*
- neurogenic 63.2
- atopic dermatitis 12.63
- non-specific post-inflammatory pigmentation 58.29
- phases 12.1–4
- platelets in 12.33
- recurrent episodes (recurrent cellulitis) 48.29
- of subcutaneous fat 46.10–11  
*see also* panniculitis
- UVR exposure as cause 29.5
- vasculature and 12.68
- wound healing and 14.2–4  
*see also* inflammatory dermatoses; inflammatory response; *specific inflammatory disorders*
- inflammatory bowel disease  
 ocular involvement 67.25  
 TNF antagonists 74.7
- inflammatory bubo 34.7
- inflammatory dermatoses  
 acitretin therapy 74.36  
 female genitalia 71.58–65, 71.66  
 genitocrural 71.4–6  
 in HIV infection 35.13–15  
 male genitalia 71.16–29  
 perianal/perineal 71.84–91  
 in pregnancy 8.13–15  
 umbilical 71.101  
*see also* *specific inflammatory dermatoses*
- inflammatory linear verrucous epidermal naevus (ILVEN) 18.19–21, 20.17
- inflammatory myxohyaline tumour of the distal extremities with virocyte or Reed-Sternberg-like cells 56.15
- inflammatory response 12.1–2  
 acute phase (first 6 h) 12.2–3  
 in basal cell carcinoma 52.21  
 chronic phase 12.4  
 exaggerated, complex regional pain syndrome 47.10, 47.11  
 in premalignant epithelial lesions 52.29  
 in squamous cell carcinoma 52.25, 52.26  
 to *Treponema pallidum* 34.4, 34.7  
 vasodilatation 12.4  
*see also* inflammation
- inflammatory vaginal discharge 71.53–4
- infiximab 13.25, 74.5  
 adverse effects 75.145
- chimeric human-murine monoclonal antibody 12.42, 74.5  
 clinical indications 74.6  
 in cutaneous small vessel vasculitis 50.16  
 dose range and evidence level 74.6  
 in granuloma annulare 60.11  
 in pemphigus 40.6, 40.12  
 in psoriasis 20.41, 72.14, 74.5  
 in HIV infection 35.17  
 in pyoderma gangrenosum 50.72  
 in sarcoidosis 61.21
- influenza viruses 33.75
- information technology, prescribing pathway 72.26
- infraorbital nerve 77.2, 77.4, 77.10
- infrared coagulation 77.47  
 nail unit 65.48  
 wart treatment 33.49
- infrared radiation  
 erythema ab igne 28.72–3  
 experimental effects 28.72  
 heat-associated carcinomas 28.73  
 thermal injury 28.71–4
- infundibular crystalline folliculitis, necrotizing 19.89
- infundibulofolliculitis, disseminate and recurrent 9.4, 19.76, 30.28
- infundibuloma (dilated pore) 53.3
- ingrowing nails *see* nail(s), ingrowing
- inguinal hyperhidrosis 71.6
- inguinal lymph node dissection (ILND) 48.8
- inguinal syndrome, lymphogranuloma venereum 30.71, 34.33
- inhaled drugs 72.27
- inherited disorders  
 analysis 15.7  
 definition 15.2  
*see also* *specific inherited disorders*
- injury  
 mechanical *see* mechanical injury  
 thermal *see* thermal injury  
*see also* trauma
- ink-spot lentigo 54.2, 54.5
- innate immunity *see* immunity, innate
- inner canthus, radiotherapy 79.9
- inner root sheath (IRS) 3.13, 66.3, 66.4–5, 66.7
- innervation  
 autonomic 63.3–4  
 blood vessels 63.3  
 immune system and 63.4  
 motor 77.2  
 head and neck 77.4–5  
 neurophysiological testing 63.4–5  
 sensory 63.1–3  
 head and neck 77.2–4  
 surgery and 77.2  
 skin 3.2, 3.12, 3.15–16, 63.1–6  
 wound healing and 63.4
- inocoterone 42.16
- inoculation chagoma 37.32
- inoculation sites, sarcoidosis 61.13
- insect(s) 37.2, 38.5–30  
 cuticle 2.2  
*see also* arthropods; *specific insects*
- insect bite reactions  
 actinic prurigo vs 29.14  
 hypersensitivity, in HIV infection 35.19  
 purpura and bleeding 49.17
- insect repellents 38.5
- insecticides 38.5
- insulin  
 adverse effects 75.120  
 antagonism by growth hormone 8.1–2  
 antibodies 46.35  
 cross-reaction 46.35  
 in breast development 70.1  
 fat hypertrophy and 46.35  
 functions 46.4  
 lipodystrophy 46.34, 46.35, 59.80  
 in polycystic ovary syndrome 66.82  
 reactions 59.80  
 resistance 8.17, 46.4, 46.6, 66.82  
 acanthosis nigricans and 59.78  
 acne and 42.73  
 in dyslipidaemias 59.92  
 in HIV lipodystrophy 46.42  
 sensitivity 46.4
- insulin-like growth factor-1 (IGF-1)  
 growth and 8.2  
 hair growth and 66.10  
 in hyperpituitarism 62.2  
 sebaceous gland activity and 42.11
- insulin-like growth factor-2 (IGF-2), sebaceous gland activity and 42.11
- insulinoma 62.67–8  
 flushing association 43.16
- integrins 3.2, 12.68–70, 13.9  
 $\alpha$ - $\beta$  pathways 51.65  
 $\alpha$ 6 $\beta$ 4 3.6, 3.28, 3.30, 3.31, 39.11  
 functions 3.30  
 reduced expression in junctional EB  
 with pyloric stenosis 39.11
- avidity 12.70
- basal cell-basement-membrane interface 12.69
- $\beta$ -integrins 13.3  
 $\beta$ 4, in junctional EB 39.10
- cell binding of laminins via 3.28, 3.30, 3.32
- knockout mice studies 12.69
- leukocyte cell adhesion molecule (LEUCAM) subfamily 12.70
- leukocyte rolling 12.74
- platelet-specific, glycoprotein 11b–111a (GP11b–111a) 12.32
- very late antigens of activation 12.69

- in wound healing 12.69, 14.3, 14.4–5, 14.6
- intense pulsed light source (IPLS) therapy *see under* laser therapy
- intensive care, mechanical injury 28.39
- intent-to-treat design 7.7
- intention-to-treat analysis 7.11
- inter-quartile range 7.17, 7.18
- intercellular adhesion junctions *see* adherens junctions
- intercellular adhesion molecule-1 (ICAM-1) 8.21, 49.22
- ageing and 8.21
- effects of UV radiation on 13.28
- in lichen planus 41.2
- in polymorphic light eruption 29.11
- in sarcoidosis 61.20
- intercellular IgA dermatosis 40.19–22
- interdigital keratoderma 19.115–16
- interdigitating dendritic cell sarcoma 55.31
- interdigitating reticulum cells 3.17, 55.3, 55.4
- interference, colours in animals and 2.5
- interferon(s) **12.41**
- adverse effects, allergic contact dermatitis 26.46
- interactions 72.29
- receptors, in tuberculosis 31.4
- therapy, warts 33.49
- type I
- cells producing 41.1
- in lichen planus 41.1
- interferon-alpha (IFN- $\alpha$ ) therapy 13.25
- adverse effects 75.142–3
- sarcoidosis 61.3
- carcinoid syndrome 43.19
- cryoglobulinaemic vasculitis 50.25
- hepatitis C 33.62
- HTLV-1 infection 33.65
- infantile haemangioma 18.50–1
- intralesional 77.49
- warts 33.49
- Kasabach–Merritt syndrome/phenomenon 18.57
- mastocytosis 22.36
- melanoma 54.53–4
- orf 33.9
- squamous cell carcinoma 52.28
- interferon-beta (IFN- $\beta$ ) therapy, intralesional, warts 33.49
- interferon-gamma (IFN- $\gamma$ ) 17.49
- defects in IL-12-dependent pathway 17.81
- epitope, Langerhans' cell histiocytosis cells 55.8
- in leprosy 32.7
- in lichen planus 41.1
- receptor 13.5
- release assays 31.6
- therapy 13.25
- adverse effects 75.142–3
- granuloma annulare 60.10
- in vasculitis 50.4, 50.6
- in wound healing 14.3
- interferon-inducible protein 10 (CXCL10, IP-10) 12.46
- interleukin(s) **12.35–40**
- anti-IL12/23 74.10
- IL-17 to IL-35 12.38
- see also specific interleukins*
- interleukin-1 (IL-1) 12.35, 13.5, 64.9
- adverse effects 75.144
- electromagnetic radiation and 8.21
- receptor activation, UV radiation 8.21
- in sarcoidosis 61.5
- sebocytes expressing 42.4–5
- specific blocking agent 12.43
- in vasculitis 50.4, 50.6
- in wound healing 14.3
- interleukin-1 (IL-1) receptor antagonist (IL-1RA) 12.43, 74.11
- in vasculitis 50.10
- interleukin-1 $\alpha$  (IL-1 $\alpha$ ) 12.43
- in acne aetiology 42.25, 42.26
- comedogenesis in acne and 42.24
- hair growth and 66.11
- as inflammatory mediator 42.25
- skin barrier function and 25.3
- interleukin-1 $\alpha$  (IL-1 $\alpha$ ) converting enzyme (ICE) 12.43, 12.49
- interleukin-2 (IL-2) 12.35–6, 17.49
- in idiopathic thrombocytopenic purpura 49.10
- in leprosy 32.7
- pruritus and 21.5
- in sarcoidosis 61.5
- stress and 64.9
- therapy 13.25
- adverse effects 75.144
- intralesional 77.49
- lobular panniculitis at injection site 46.14
- melanoma 54.54
- vitamin D action 73.43
- interleukin-3 (IL-3) 12.36
- adverse effects 75.144
- interleukin-4 (IL-4) 12.36, 13.5–6
- adverse effects 75.144
- receptor 24.4
- in tuberculosis 31.4–5
- interleukin-5 (IL-5) 12.36
- interleukin-6 (IL-6) 12.36
- adverse effects 75.144
- electromagnetic radiation and 8.21
- in lichen planus 41.1
- interleukin-7 (IL-7), thymic stromal lymphopoietin (TSLP) and 12.36
- interleukin-8 (IL-8) 12.36–7, 12.46, 13.4
- in acne pathogenesis 42.25
- in pyoderma gangrenosum 50.65
- synthesis, animal model 2.8
- in vasculitis 50.10
- vitamin D action 73.43
- interleukin-9 (IL-9) 12.36–7
- interleukin-10 (IL-10) 12.37, 12.44, 20.42
- stress and 64.9
- in UV-induced immunosuppression 13.31, 52.14
- vitamin D action 73.43
- interleukin-11 (IL-11) 12.37
- interleukin-12 (IL-12) 12.37, 17.49
- receptor 13.5
- tuberculosis and 31.4
- in UV-induced immunosuppression 13.31, 52.14
- interleukin-13 (IL-13) 12.37, 13.5–6
- in tuberculosis 31.4
- interleukin-14 (IL-14) 12.37
- interleukin-15 (IL-15) 12.37
- interleukin-16 (IL-16) 12.37
- interleukin-18 (IL-18), in atopic eczema and eczema herpeticum 33.35
- interleukin-18 (IL-18) receptor antagonist (IL-18RA) 12.43
- interleukin-31 (IL-31), in atopic dermatitis 21.5, 24.18
- intermediate filaments 3.9
- endothelial cells 3.51
- genes and mutations 3.9
- see also* keratin intermediate filaments
- intermediate pigment darkening (IPD) 58.10
- intermittent claudication 47.2, 47.7
- internal mechanical injury 28.60–2
- internalin A 30.42
- International Agency for Research on Cancer (IARC), vitamin D, sunlight and cancer 29.6
- International Contact Dermatitis Research Group 26.2
- International Foundation for Dermatology 6.16
- International Nomenclature of Cosmetic Ingredients 26.24, 26.41, 26.48
- international normalized ratio (INR) 47.29, 49.13
- International Nosology of Heritable Disorders of Connective Tissue 45.32
- International Statistical Classification of Mental and Behavioural Disorders (ICD-10) 64.11, 64.21
- Internet, as resource for Münchausen patient 64.44
- interpapillary ridges, actinic keratosis 52.30–1
- interpersonal counselling 64.53
- interpersonal psychotherapy 64.53
- interphalangeal joints, fibroblastic rheumatism 51.133
- interscapular skin, hypermelanosis 58.31
- interstitial fluid
- excess 48.7, 48.7, 48.8
- see also* lymphoedema; oedema
- lymphatic drainage 48.5–6
- pressure 48.8
- reabsorption 48.5, 48.7
- interstitial granulomatous dermatitis 51.131, 62.103–4
- intertrigo
- acute erosive genitocrural, HIV infection 35.10
- anogenital 71.2–3
- Candida* 36.61, 36.64, 36.68
- differential diagnosis 36.33
- genitocrural **71.4–5**, 71.7
- sports injury 28.31
- streptococcal 30.33
- submammary 70.3
- intervention studies 6.19
- intestinal bypass arthritis–dermatitis syndrome 44.20, 50.87–8, 62.51, **62.53**
- intestinal lymphangiectasia 48.27–8
- intolerance reactions 22.8
- intra-abdominal pressure 8.17
- intracranial pressure, raised 54.11
- antibiotics causing 67.31
- intraepidermal bullous diseases 40.3–24
- intraepidermal carcinoma, of eyelid margin 52.37
- intraepidermal neutrophilic IgA dermatosis 50.62, 62.49
- intralesional corticosteroids, adverse effects 28.46
- intramuscular injections, complications 75.155–6
- intraocular pressure, elevated 73.19
- intrapartum injuries, mechanical injury 28.39
- intrauterine contraceptive devices 75.118
- intrauterine programming and atopic dermatitis 24.5
- intravascular large B-cell lymphoma 57.50–1
- intravascular papillary endothelial hyperplasia **56.23–4**, 69.102
- intravascular pressure, raised, purpura due to 49.14
- intravenous drug abuse, mechanical injury 28.45, 28.52–3
- intravenous immunoglobulin (IVIg) 13.25, 74.11
- adverse effects 75.138
- in idiopathic thrombocytopenic purpura 49.10
- in Kawasaki disease 30.79, 50.46
- in pemphigus 40.12
- rituximab and 74.9
- in toxic epidermal necrolysis 76.20
- in urticaria 22.30
- intravenous infusion, complications 75.154
- introital narrowing 71.57, 71.62
- intron 11.3
- inverse pattern psoriasis 71.18
- invertebrates, ectoderm, exoskeleton and cuticle 2.1–2
- involucrin 3.1, 3.8, 3.10, 4.2
- iodides 44.18
- acneiform eruption due to 42.73
- iodine
- adverse effects 75.152, 75.165
- as antiseptic 73.15
- hypersensitivity 73.15
- toxicity 73.15
- use in neonates 17.2
- iodine releasing agents, as antiseptic 73.15
- iodism 75.152
- iododerma 75.21, 75.152
- iodophores 73.15
- iodopropynyl butyl carbamate 26.58
- ionizing radiation 79.1
- damage to ears 68.11
- naevi due to 18.2
- squamous cell carcinoma associated with HPV and 33.55
- treatment modalities *see* radiotherapy
- iontophoresis
- in epidermolysis bullosa simplex 39.31
- in hyperhidrosis 44.11
- IP *see* incontinencia pigmenti (IP)
- IP-10 14.3
- IPD (intermediate pigment darkening) 58.10
- IPEX syndrome 13.11, 13.15, 17.67, 24.7, 62.13
- ipilimumab, melanoma management 54.54
- iPLEDGE, isotretinoin use 42.60
- iproniazid 75.79
- iridiophores 2.5
- iridium 26.40
- iridocyclitis 61.6, 61.7
- iris
- hamartomas 58.23
- lesions 76.1, 76.6, 76.7
- in sarcoidosis 61.7
- iris (plant) 25.21
- iroko 26.81
- iron
- adverse effects 75.101
- deficiency 59.70–1, 62.48, 62.85
- chronic diffuse telogen effluvium and 66.28
- differential diagnosis 40.50
- hair colour change in 66.94
- oral involvement 69.56, 69.85–6, 69.116
- pruritus in 21.10
- restless legs syndrome and 63.24
- wound healing and 14.18
- disorders, restless legs syndrome 47.12
- intoxication 59.71
- metabolism 59.70
- overload 59.71
- pigment, in skin 58.53
- supplements, in dystrophic EB 39.29
- iron salt tattoos 58.57
- irradiance 29.1
- spectral 29.3
- total 29.2
- irradiation monochromator 29.2
- irritant contact dermatitis **25.1–26**
- acute 25.1, 25.11–12
- after arthropod bites/stings 38.2
- clinical features 25.11–19
- to cosmetics 25.15
- cumulative (chronic) 25.1, 25.5, 25.12–13, 25.14, 25.15
- delayed 25.12
- differentiation from allergic contact dermatitis 25.6, 26.87–8
- ear 68.14
- epidemiology 25.1–2
- eyelids 25.13, 25.15
- female genitalia 71.58
- friction and 25.17
- hand 25.2, 25.13, 25.14, 25.15, 25.24
- histology 25.4–5
- history 25.1
- immunopathology 25.5
- investigations 25.21–2
- male genitalia 71.17
- management 25.23, 25.24
- mechanical 25.17–18, 28.13, 28.22
- models 25.9–10
- nail involvement 65.28–9

- neonatal 17.22–8  
occupational 25.13, 25.14, 27.4, 27.5–7  
pathogenesis 25.2–3  
pathology 25.3–6  
phototoxicity and 25.17  
physical 27.6–7  
predisposing factors 25.6–10  
prevention 25.24–5, 25.26  
prognosis 25.26  
site and vulnerability 25.7  
volatile/airborne 25.15  
see also burns, chemical
- irritants 6.12, 25.14, 25.19–21  
airborne 25.15  
avoidance 23.21  
contact responses to 25.2, 25.10  
delayed-type stinging sensation 25.19  
eczema and 23.5  
see also irritant contact dermatitis  
identification 25.9–10  
immediate-type stinging sensation 25.19  
mechanical 25.17–18, 25.21  
mechanism of action 25.3  
occupational 27.3, 27.18–21  
quantifying response to 25.22  
symptomatic (subjective) responses to 25.18–19, 25.24  
topical therapy agents as 73.4  
volatile 25.15  
see also specific irritants
- irritation  
acute, tests for 25.9–10  
chronic, tests for 25.10  
tests for 25.9  
threshold 27.11
- IRS (inner root sheath) 3.13, 66.3, 66.4–5, 66.7
- irukandji 38.56
- ischaemia  
acute limb 47.5  
management 47.6  
causes 47.5  
critical leg 47.2, 47.4  
peripheral disorders 47.1–9  
pressure ulcers 28.16–18  
see also arterial disease, peripheral
- ischaemic fasciitis 56.5–6
- isoconazole  
in dermatophytosis 36.48  
topical 73.12
- isocyanates 26.74
- isodesmosine 3.43–4
- isolated limb infusion, melanoma  
recurrence treatment 54.55
- isolated limb perfusion, melanoma  
recurrence treatment 54.54
- isomorphic phenomenon/response see  
Koebner phenomenon/response
- isoniazid 59.63, 74.44  
adverse effects 31.27, 70.5, 75.61–2  
acneiform eruptions 42.72  
prophylactic, in HIV infection 31.7  
resistance to 31.27  
in tuberculosis 31.27
- isopropanol (isopropyl alcohol) 25.20  
antiseptic 73.14
- isopropyl dibenzoylmethane 26.62
- isopropyl linoleate 27.13
- N*-isopropyl-*N'*-phenyl-*p*-phenylenediamine 26.15, 26.26, 26.64
- 4-isopropylcatechol, hypermelanosis  
treatment 58.39
- isosorbide, male genital dermatology  
71.27
- isothiazolinones 26.53–4
- isotretinoin 20.37, 42.57, 74.34–5  
in acne conglobata 42.62, 42.83  
in acne fulminans 42.62, 42.84  
in acne-related conditions 42.59  
in acne vulgaris see acne vulgaris,  
isotretinoin treatment  
adverse effects 42.63–5, 75.110–13  
discoid eczema 42.64
- ocular 67.31  
questionnaire on 42.63  
systemic 42.64
- apoptosis of sebocytes 42.15  
in cellulitis 74.34  
in chloracne 27.14  
clinical indications 74.34  
dose range and evidence level 74.35  
effect on sebum composition/synthesis 42.6  
effects in sebocyte culture 42.58  
European Directive on use 42.59, 42.60  
in folliculitis decalvans 42.74  
in Fordyce's condition 42.62  
in Gram-negative folliculitis 42.62, 42.84, 74.34  
in granuloma annulare 60.10  
in hidradenitis suppurativa 30.81  
mechanism of action 42.57–8  
metabolism 42.64, 42.65  
in sebaceous glands 42.14, 42.15, 42.58  
metabolites 42.58  
in miliaria profunda 44.16  
mood changes and 64.49  
in pyoderma faciale 42.84, 43.14  
in rhinophyma 43.9  
in rosacea 43.6, 74.34  
in rosacea fulminans 42.62  
in sarcoidosis 61.21  
in sebaceous gland hyperplasia 42.87  
in sebocyte proliferation reduction 42.14  
in sebum synthesis reduction 42.14  
in squamous cell carcinoma 52.28  
teratogenicity 42.59, 42.63, 72.28  
tetracycline contraindication 42.64, 42.65  
topical 42.39–40, 42.54  
benzoyl peroxide vs 42.41  
topical 5-FU with 73.23
- itch-scratch cycle 21.5, 21.13
- itching see pruritus
- ITGB4* and *ITGA6* mutations 39.11
- Ito, hypomelanosis of 58.45
- Ito, naevus of 54.9
- itraconazole 15.10, 74.47  
adverse effects 75.64  
in blastomycosis 36.85  
in candidiasis 36.68, 36.69  
in chromoblastomycosis 36.76  
in coccidioidomycosis 36.86  
in dermatophytoses 36.48, 36.49, 36.50  
failure to respond to 36.50–1  
in histoplasmosis 36.83  
in *Malassezia* folliculitis 36.13  
in otomycosis 36.17  
in paracoccidioidomycosis 36.88  
in penicilliosis 36.88  
in pityriasis versicolor 36.12  
in *Scopulariopsis brevicaulis* infection 36.54  
in *Scytalidium* infection 36.52  
in seborrhoeic dermatitis 23.33  
in sporotrichosis 36.72  
in yellow nail syndrome 65.16–17
- ITRF-4 10.25
- ITT (intention-to-treat)  
analysis 7.11  
design 7.7
- ivermectin 74.51  
adverse effects 75.71  
in dogs 2.11  
in animals 2.11  
in crusted scabies 38.44  
in cutaneous larva migrans 37.17  
in *Demodex* infection in rosacea 43.3  
in head louse infection 38.20  
in loiasis 37.12  
in lymphatic filariasis 37.10  
in onchocerciasis 37.7  
in phthiriasis palpebrarum 38.23  
in scabies 38.41–2  
in strongyloidiasis 37.15–16  
topical 73.14
- IVIg see intravenous immunoglobulin (IVIg)
- Ixodes* 30.58, 30.64, 30.73, 38.34, 38.35, 62.106
- Ixodidae* 38.33–5
- J  
jacaranda 26.81
- Jackson–Lawler syndrome (pachyonychia congenita type 2) 15.49, 19.3, 19.94, 19.103–4, 42.88, 65.20
- Jacob's disease 69.40
- Jadassohn–Lewandowsky syndrome (pachyonychia congenita type 1) 15.49, 19.3, 19.94, 19.103–4, 65.20
- Jadassohn's naevus phakomatosis 18.27–30, 54.11
- Jaffe–Lichtenstein disease 47.55
- JAK*-2 mutations, in myeloproliferative disorders 49.29, 62.86
- JAK*-3 13.11
- Jak*–*Stat*–*Socs* pathway 12.28, 12.35
- Jamaica ebony 26.80
- Janeway lesions 62.78
- Japanese encephalitis 33.67
- Japanese lacquer tree 26.75
- Jarisch–Herxheimer reaction 34.23, 75.15
- jaundice 62.58, 62.63–4  
in malaria 37.27  
pigmentation in 58.53
- jejunoileal bypass surgery  
adverse effects 8.17–18  
BADAS and 50.87  
necrobiosis lipoidica after 60.15  
vasculitis-associated panniculitis after 46.32
- Jellinek's sign 58.24–5, 62.8
- jellyfish 38.55–8
- jelutong 26.79, 26.80
- Jessner's (benign) lymphocytic infiltration 57.60  
differential diagnosis 51.7  
ear 68.15
- Jessner's peel 80.9
- jewellers, occupational hazards 27.20
- Jews, Ashkenazi 44.7
- jigger 38.12–13
- jigsaw-puzzle appearance, cylindroma 53.28
- jimble 38.56
- JMML (juvenile myelomonocytic leukaemia) 15.14–15, 15.20
- Job's syndrome see hyper-IgE syndrome
- jogger's nipples 28.31, 70.10–11
- Johanson–Blizzard syndrome 15.45, 18.103, 69.12
- Johnson neuroectodermal syndrome 15.30
- Joint Tuberculosis Committee 31.27
- joints  
Charcot's 63.15  
Clutton's 34.16  
disorders 62.99–106  
hypermobility 45.30, 45.34, 62.104  
neutrophilic dermatoses and 50.82  
in sarcoidosis 61.6–7  
in systemic sclerosis 51.102
- jojoba oil, in scabies 38.41
- Jorgenson syndrome 15.43
- joules (J) 29.1
- journals 7.5–6
- jugular lymph sac (JLS) 48.2
- jumping spiders 38.32
- Jun proteins, loss, in SCID mouse model 2.14
- junctional activity 54.10
- junctional adhesion molecules (JAMs) 3.24
- junctional epidermolysis bullosa see epidermolysis bullosa (EB), junctional
- junctional naevus see naevus, junctional
- Jung's disease 23.27
- Junin virus 33.67, 33.69
- juvenile acne 42.75–6
- juvenile chronic myeloid leukaemia 15.20
- juvenile dermatitis herpetiformis/pemphigoid see linear IgA disease
- juvenile dermatomyositis 51.126
- juvenile myelomonocytic leukaemia (JMML) 15.14–15, 15.20
- juvenile onset ischaemic dermatopathy, in dogs 2.15
- juvenile plantar dermatosis 23.26  
mechanical injury and 28.14
- juvenile rheumatoid arthritis 51.133–6
- juvenile spring eruption 29.12
- juvenile xanthogranuloma 15.20, 55.6, 55.15–17  
clinical features 55.16  
diagnosis, prognosis and treatment 55.16–17  
eyelids 67.33  
Langerhans' cell histiocytosis and 55.10  
neonatal 55.16  
non-xanthomatous 55.15  
spindle cell variant 55.15
- K  
*K* gene, in dogs 2.6
- Kabuki syndrome 68.4
- kala azar (visceral leishmaniasis) 37.41–3
- kallikrein 21.5
- Kallin's syndrome 39.9
- Kallmann's syndrome 19.11, 19.12, 70.2
- kambala 26.81
- Kamino bodies 10.40, 54.22, 54.24, 54.24
- kanamycin 26.45, 75.58
- Kangri cancer 52.5
- Kanzaki disease 44.18, 59.34
- Kaposi's sarcoma 35.36–8, 56.33–7  
aetiology 56.33–4  
African type 48.30  
AIDS-associated 33.33, 35.4, 35.36–8, 48.30, 48.31, 56.34  
in children 35.45  
differential diagnosis 35.37  
oral 35.43  
staging and diagnosis 35.37  
treatment 35.37, 35.38  
classic 48.30, 56.33–4  
clinical features 35.37, 56.34–5  
definition 56.33  
differential diagnosis 35.37, 56.36  
endemic 56.34  
external ear 68.28, 68.34  
eyelids 67.36  
iatrogenic 56.34  
immunodeficiency-associated 48.30, 48.31  
Koebner response 28.3  
lymphangiomas 56.35  
from lymphatic endothelium 48.30  
lymphatic origin of 48.30  
lymphoedema and 48.14, 48.30–1  
male genital dermatology 71.48  
markers 49.18  
Mediterranean type 48.30  
oral 35.43, 69.13, 69.22, 69.55, 69.99  
pathogenesis 35.36–7, 56.33–4  
pathology 56.35–6  
perianal/perineal dermatology 71.98–9  
in pregnancy 8.13  
promontory sign 56.35  
race and 9.18–19  
regression 56.36  
staging 56.35–6  
in transplant recipients 62.74–5  
treatment 35.37, 35.38, 56.36, 79.13  
alitretinoin see isotretinoin
- Kaposi's sarcoma-associated herpesvirus (KSHV) see human herpesvirus 8 (HHV-8)
- Kaposi's varicelliform eruption 24.24, 33.35–7  
aetiology 33.35  
clinical features 33.35

- dermatoses associated with 33.35  
diagnosis and treatment 33.35–6  
Kaposi–Stemmer sign 48.15  
karyorrhexis 10.40, 46.26  
Kasabach–Merritt syndrome/  
phenomenon 18.56–7, 56.31  
kaposiform haemangioendothelioma  
and 18.55  
thrombocytopenia and 49.12  
tufted angioma and 18.56  
Katayama fever 37.21  
kava dermopathy 59.64, 75.161–2  
Kawasaki disease 30.78–9, 50.45–6  
aetiology 30.78  
cardiac involvement 62.78  
differential diagnosis 76.7  
genetic factors 50.11  
oral involvement 69.84, 69.118, 69.121  
pathogenesis 50.5–6  
keds 38.6, 38.7  
keloids 14.2, 14.15, 45.54–6  
in acne 42.32  
treatment 42.69  
fibroblasts 3.50  
following ear piercing 68.8  
following surgery 77.8  
linear 45.54  
male genital dermatology 71.36  
race and 9.15  
treatment 45.55, 73.36, 77.49–50  
intralesional corticosteroids 14.15  
laser therapy 78.14  
radiotherapy 45.55, 79.4–5  
topical imiquimod 73.24  
kenogen 66.8, 66.20  
Kenya tick typhus 30.73  
keratan sulphate, structure 3.47  
keratin(s) 3.1, 3.9  
accumulation, keratoacanthoma 52.42,  
52.43  
acidic (type II) 3.10, 10.20  
in acne 42.23  
antibodies to 10.19–21, 39.25  
basic (type I) 3.10  
cuticular 66.5  
epidermal 3.1  
expressed by sebocytes 42.12  
genes 3.9–10, 3.10  
hair (*HaKRT1-6* and *HbKRT1-6*) 3.14  
mutations 3.10, 11.12  
hair 3.13–14, 66.6  
hard 65.2, 65.3  
K1/K10 pair 3.10  
K2e 3.10  
K5/K14 pair 3.10  
mutations in epidermolysis bullosa  
simplex 39.3–4  
K8/K18 pair 3.10  
K9 3.10  
K15 3.10  
K17 3.14  
mutations in steatocystoma multiplex  
42.88  
nail 65.3  
neutral-basic (type II) 10.20  
in pachyonychia congenita 65.3  
soft 65.3  
in stratum corneum 4.2  
structure 3.9, 3.31  
types 3.9, 3.10  
keratin-associated proteins 66.6  
keratin intermediate filaments 3.1, 3.9,  
3.10, 3.21–2, 3.30, 40.2  
desmosomes and 3.21–2, 40.1–2  
detachment in pemphigus 40.15  
hemidesmosomes and 3.30, 40.28  
 $\alpha$ -keratin intermediate filaments (a-KIF)  
66.6  
keratinization  
management 67.22  
in seborrhoeic keratosis 52.39  
trichilemmal 66.3  
keratinization disorders 19.1–122  
acanthosis nigricans 19.119–21  
acitretin therapy 74.36  
classification 19.1–2  
confluent and reticulate papillomatosis  
19.121–2  
Darier's disease and related disorders  
19.3, 19.81–8  
erythrokeratodermas 19.69–72  
filiform keratosis 19.92–3  
Flegel's disease 19.89–90  
folliculocentric keratotic 19.72–6, 19.84  
ichthyoses 19.3, 19.4–65  
isotretinoin therapy 74.34  
keratolytic treatments  
bullous ichthyosiform erythroderma  
19.33  
CHILD syndrome 19.58  
ichthyosis hystrix 19.37  
ichthyosis vulgaris 19.8  
lamellar ichthyosis 19.25  
Netherton's syndrome 19.41  
non-bullous ichthyosiform  
erythroderma 19.19  
non-epidermolytic palmoplantar  
keratoderma 19.97  
pachyonychia congenita 19.104  
Sjögren–Larsson syndrome 19.44  
X-linked recessive ichthyosis 19.12  
minute keratosis 19.92–3  
miscellaneous circumscribed keratotic  
19.93  
molecular genetics 19.1–4, 19.94–5  
ocular involvement 67.29–30  
palmoplantar keratodermas 19.93–119  
peeling skin syndromes 19.66–9  
perforating keratotic 19.88–9  
pityriasis 19.65, 19.76–81, 19.84  
porokeratosis 19.90–2  
retinoid therapy  
bullous ichthyosiform erythroderma  
19.33  
CHILD syndrome 19.58  
Darier's disease 19.85  
harlequin ichthyosis 19.29  
IBIDS/PIBIDS syndrome 19.49  
ichthyosis hystrix 19.37  
ichthyosis vulgaris 19.8  
KID/HID syndrome 19.56  
lamellar ichthyosis 19.25  
Netherton's syndrome 19.41  
neutral lipid storage disease with  
ichthyosis 19.54  
non-bullous ichthyosiform  
erythroderma 19.19  
non-epidermolytic palmoplantar  
keratoderma 19.97  
pachyonychia congenita 19.104  
pityriasis rubra pilaris 19.79  
Sjögren–Larsson syndrome 19.44  
X-linked recessive ichthyosis 19.12  
systemic treatments  
bullous ichthyosiform erythroderma  
19.33  
CHILD syndrome 19.58  
Darier's disease 19.85  
harlequin ichthyosis 19.29  
IBIDS/PIBIDS syndrome 19.49  
ichthyosis hystrix 19.37  
ichthyosis vulgaris 19.8  
KID/HID syndrome 19.56  
lamellar ichthyosis 19.25  
Netherton's syndrome 19.41  
non-bullous ichthyosiform  
erythroderma 19.19  
pityriasis rubra pilaris 19.79  
Sjögren–Larsson syndrome 19.44  
X-linked recessive ichthyosis 19.12  
topical treatments  
bullous ichthyosiform erythroderma  
19.33  
CHILD syndrome 19.58  
collodion babies 19.14–16  
Darier's disease 19.85  
harlequin ichthyosis 19.29  
IBIDS/PIBIDS syndrome 19.49  
ichthyosis hystrix 19.37  
ichthyosis vulgaris 19.7–8  
lamellar ichthyosis 19.25  
Netherton's syndrome 19.41  
non-bullous ichthyosiform  
keratoderma 19.97  
pachyonychia congenita 19.104  
pityriasis rubra pilaris 19.79  
Sjögren–Larsson syndrome 19.44  
X-linked recessive ichthyosis 19.12  
see also specific disorders  
keratinocyte(s) 3.1, 3.8, 3.9–10, 12.14–17,  
54.1  
adhesion between 3.22  
abnormal, in Hailey–Hailey disease  
39.33  
adhesion molecules 12.75  
ageing and 80.2  
androgen metabolic enzymes 42.12  
apoptosis 12.12  
Fas ligand (FasL) and 12.11  
TNF-receptors 12.42  
atypical, squamous cell carcinoma  
52.25  
barrier function and 4.2  
basal  
cleavage in epidermolysis bullosa  
simplex 39.2, 39.3  
epidermal proliferation units 3.6  
nail matrix 3.15  
stem cell activity, control 3.6  
structure 3.8  
in Bowen's disease 52.33  
chemokines 12.16–17  
in chronic wounds 14.11  
cultured 14.26  
use in dystrophic epidermolysis  
bullosa 39.29  
cytokines and pro-inflammatory  
mediators 12.15–17  
ductal  
cytokines produced 42.24  
proliferation abnormalities in acne  
42.22–3, 42.25–6  
topical retinoid effects 42.40  
endothelin-1 production 58.26  
epibasal 3.8  
epidermal barrier formation 12.14  
epidermal growth factor (EGF) 12.16  
growth factor, hair growth and 66.10  
human papillomaviruses (HPV) and  
12.16, 33.37  
hyperproliferation 3.16  
in acne 42.22–3, 42.25–6  
induction in acne 42.23  
reduced by isotretinoin 42.58  
topical retinoid effects 42.40  
immature, seborrhoeic keratosis 52.39  
induction of TLR-2 activation by  
glucocorticoids 12.9  
intercellular adhesion molecule-1  
(ICAM-1) 12.10, 12.16, 12.73  
in irritant contact dermatitis 25.5  
in junctional epidermolysis bullosa  
39.9  
keloid 14.15  
koilocytosis, in warts 33.41  
in lichen planus 41.1  
mediators of inflammation 12.15–17  
melanocyte contact 58.2, 58.7  
melanosome transfer to 58.4–5  
migration 3.2  
MMPs synthesis/secretion 3.41  
number served by melanocyte 58.2  
proliferation, lentigo 54.3  
receptor-blocking strategies 12.17  
in Stevens–Johnson syndrome 76.9–10  
structure 3.9–10  
surrounding melanocytes 54.18  
terminal differentiation 3.6, 3.10  
in toxic epidermal necrolysis 76.9–10  
ultraviolet radiation and 12.16,  
52.13–14  
vascular endothelial growth factor  
(VEGF), MHC and 12.16  
in vitiligo 58.47  
in wound healing 14.4–5  
keratinocyte transglutaminase 3.10  
keratitis 67.4  
bacterial 67.14  
chronic blepharitis with, treatment  
67.12  
dendritic 67.26  
epithelial, in molluscum contagiosum  
67.25  
filamentary 67.4  
geographical 67.26  
herpetic 33.17, 33.18, 33.21, 67.16, 67.26  
interstitial 67.4  
congenital syphilis 34.16  
rosacea 43.4, 43.5, 43.7  
stromal and endothelial 67.26  
keratitis, ichthyosis and deafness  
syndrome see KID syndrome  
keratoacanthoma 52.42–4  
aetiology and incidence 52.42  
clinical features 52.42–3  
diagnosis 52.43  
eyelids 67.34  
generalized eruptive 52.44  
growth and size 52.42  
oral cavity 69.54–5  
pathology 52.43  
recurrence 52.42  
sebaceous 53.15  
sites 52.42  
squamous cell carcinoma vs 52.26, 52.27  
subungual/periuveal 65.38  
surgery 77.15  
treatment 52.43–4  
keratoconjunctivitis  
atopic see atopic keratoconjunctivitis  
(AKC)  
in atopic dermatitis 24.24  
in herpes simplex 33.17, 33.18  
treatment 67.15–16  
vernal 67.13, 67.14, 67.15, 67.16  
keratoconjunctivitis sicca 67.4  
in sarcoidosis 61.7  
keratoconus 24.24, 67.4  
keratoderma  
climacteric (Haxthausen's disease)  
19.117–18  
definition 5.7  
filiform 19.114  
loricrin 19.3, 19.19, 19.94, 19.98  
palmoplantar see palmoplantar  
keratoderma  
palmoplantaris transgrediens see Mal  
de Meleda  
punctate, plantar warts vs 33.44  
race and 9.10  
Sybert's 19.94, 19.99  
keratoderma blenorrhagica 34.30, 34.31  
keratoderma climactericum 8.20  
keratoelastoidosis marginalis 45.28  
keratohyalin granules 3.8, 4.2  
clumped, warts 33.41  
in obesity 8.17  
keratolinin/cystatin 3.10  
keratolysis exfoliativa 19.66, 23.19  
keratolysis plantare sulcatum 30.39–40,  
44.8  
keratoma hereditarium mutilans 45.70  
keratomycosis nigricans palmaris 36.8,  
36.14–15  
keratopathy 67.4  
keratosis  
actinic see actinic keratosis  
arsenical 52.29, 52.34–5, 62.47  
benign lichenoid (BLKs) 41.6  
eyelids 67.33  
filiform 19.92–3  
inverted follicular 53.2–3  
lip  
leukokeratosis see cheilitis, actinic  
treatment 73.23  
oral 69.90–3  
post-ionizing radiation 52.37  
seed-like of the palms and soles 62.33

- smoker's 69.90  
snuff-dipper's 69.90  
stucco 52.40  
sublingual 69.91  
tar 52.37
- keratosis circumscripta 19.78  
keratosis follicularis *see* Darier's disease  
keratosis follicularis spinulosa decalvans 19.74–5, 19.84, 66.51  
keratosis follicularis squamosa (Dohi) 8.17, 19.76  
keratosis lichenoides chronica (Nékam's disease) 41.27–8, 73.44  
keratosis obturans 68.28, 68.35  
keratosis pilaris 19.72–4, 19.84, 24.22, 45.8  
  acne vs 42.37  
  hypotrichosis with 66.60  
  lentiginosis and 66.60–1  
  treatment 73.36  
keratosis pilaris atrophicans faciei 66.51  
keratosis punctata 9.10  
keratosis senilis *see* actinic keratosis  
keratosis spinulosa 19.75, 19.76  
keratosis spinulosa (lichen spinulosus) 19.75, 19.76  
keratouveitis, HSV 67.26  
kerion 30.25, 36.22, 36.27, 36.36, 36.49  
  *Trichophyton verrucosum* as cause 2.12  
kerosene 25.20  
ketanserin 74.52  
  in systemic sclerosis 51.108  
  in wound healing 14.24  
ketoconazole 74.47  
  adverse effects 70.5, 75.65  
  in blastomycosis 36.85  
  in candidiasis 36.68  
  in dermatophytoses 36.48, 36.49  
  eccrine gland secretion 44.18  
  in histoplasmosis 36.83  
  in *Malassezia* folliculitis 36.13  
  in paracoccidioidomycosis 36.88  
  in pityriasis capitis 66.56  
  in pityriasis versicolor 36.12  
  in seborrhoeic dermatitis 23.33  
  in tinea nigra 36.15  
  topical 73.12  
ketoprofen  
  adverse effects 26.46, 75.74  
  as photoallergen 26.24  
ketotifen, in rosacea 43.6  
khaki dermatitis 26.26, 26.66  
khat 69.50  
*Khaya* 26.81  
khaya mahogany 26.81  
khellin 58.48  
KHSV *see* human herpesvirus 8 (HHV-8)  
Ki-67 53.43  
  keratinocyte hyperproliferation in acne 42.22–3  
  in mast cell tumours, in dogs 2.22  
Ki-M1p 55.15  
kicking injuries 28.33  
KID syndrome 15.46, 15.68, 15.69–70, 19.54–7, 19.60  
  oral involvement 69.26  
kidneys  
  disorders 62.68–75  
  oral manifestations 69.116  
  *see also* chronic renal failure; renal disease; renal failure  
  drug elimination 72.27  
  in sarcoidosis 61.7, 62.71  
  in SLE 51.44  
  in systemic sclerosis 51.101  
  transplantation 69.116  
  nephrogenic systemic fibrosis and 45.53  
  non-melanoma skin cancer and 52.11  
  skin changes in recipients 62.74–5  
  in Wegener's granulomatosis 50.39–40  
  'wire-loop' lesions 51.34  
  *see also* entries beginning renal  
Kikuchi–Fujimoto disease 33.31, 33.77  
Kikuchi's disease 33.31, 33.77, 51.134  
  SLE and 51.58  
Kikuchi's histiocytic necrotizing lymphadenitis, EBV infection and 33.31, 33.77  
killer-inhibitory receptors 13.6  
Kimura's disease 46.34, 56.27, 68.15  
Kindler's syndrome 12.17, 15.82–3, 39.1, 39.2, 39.2, 45.13, 69.40  
  diagnosis 39.24–5, 39.25  
  Kindlin-1 39.25  
kinesin, melanosome transfer along melanocyte dendrites 58.4  
kinesiotaping, lymphoedema management 48.23  
kinetensin 12.25  
kinin(s) 38.1  
  cascade 13.2, 13.4  
  in urticaria 22.5  
kininase II *see* angiotensin-converting enzyme  
Kinmonth's lymphoedema praecox 48.10  
Kirghizian dermat-osteolysis 15.46  
KIRs (killer-inhibitory receptors) 13.6  
kissing bugs 37.2, 37.31, 38.25  
Kit (CD117) 3.19–20  
KIT gene mutations 3.20  
  in mastocytosis 22.30, 22.31  
  in piebaldism 58.42, 66.93  
Kit ligand (mast cell growth factor/stem cell factor (M/SCF)), melanocyte mitogen 58.5  
Kitamura's disease 58.21  
*Klebsiella oxytoca*, in invasive otitis externa 68.25  
*Klebsiella pneumoniae rhinoscleromatis* 30.51–3  
KLICK syndrome 19.19  
Kligman cream 73.27, 73.28  
Klinefelter's syndrome 47.42  
  breast cancer and 70.14  
  genetics 15.13–14  
  gynaecomastia and 70.4  
Klippel–Trenaunay syndrome (KTS) 18.76–8, 47.23–4, 47.37  
  acroangiokeratosis (of Mali) and 49.17  
  aetiology 18.77  
  bone and joint involvement 62.99, 62.100  
  clinical features 18.77  
  definition 18.76  
  differential diagnosis 18.77  
  lymphoedema and 48.10, 48.12, 48.21  
  nomenclature 18.76  
  oral involvement 69.30  
  treatment 18.77–8  
Kloos–Schleifer classification system 30.2  
knee, surgery 77.5  
*Knemidokoptes mutans* 38.46  
Knemidokoptidae 38.46  
knock-out animals 2.8, 11.11  
knock-out vector 2.8  
knuckle pads 19.93, 19.108–9, 45.48, 45.49  
  race and 9.15  
Kobberling–Dunnigan syndrome 46.40–1  
Köbner-like isomorphic phenomenon, common warts 33.43  
Koch phenomenon 31.3–4, 31.6  
Koeber epidermolysis bullosa (EB) simplex 39.4, 39.6  
Koeber phenomenon/response 5.8  
  eczema and 23.28–9  
  in erythema multiforme 76.7  
  friction and 25.17  
  in Hailey–Hailey disease 39.34  
  in lichen planus 41.6, 41.12  
  in mechanical/thermal injury 28.2–3, 28.15, 28.48, 28.73  
  in nails 65.24  
  in psoriasis 5.12, 20.8, 20.17  
  in reactive perforating collagenosis 45.64  
  in sarcoidosis 61.10  
  sexual abuse and 51.117  
  in vitiligo 26.26, 26.27, 58.47  
Koenen tumour 15.22, 65.31, 65.32  
koganbyo 37.22  
Kohlmeier–Degos' disease *see* Degos' disease  
koilocytosis, in viral warts 33.41  
koilonychia 62.85, 65.8  
  in childhood 65.6  
  kojic acid 73.28  
kokardennaevus 54.20–1  
Koplik's spots 33.75, 69.95  
koro syndrome 71.51  
Kostmann's syndrome 17.48, 17.75  
KP1 *see* CD68  
krala 26.81  
KRAS gene 15.15  
Kronmayer lamp 29.2  
KRT1 gene 18.5  
KRT5 gene mutation, epidermolysis bullosa simplex 39.3–4  
KRT10 gene 18.5  
KRT14 gene mutation, epidermolysis bullosa simplex 39.3–4  
KS *see* Kaposi's sarcoma  
KTS *see* Klippel–Trenaunay syndrome (KTS)  
*kua'sha* 28.25  
kumkum 26.10  
Kunjin virus 33.67  
Kveim test 5.24, 61.1, 61.19–20  
kwashiorkor 35.41, 59.67, 66.94  
Kyasanur forest disease 33.67  
kyphoscoliosis 45.30  
  in Ehlers–Danlos syndrome 45.34, 45.35  
Kyrle's disease *see* perforating collagenosis (folliculitis)
- L**  
L granules, sulphur-rich 3.10  
L-selectin *see* selectins  
La/SS-B antibodies 51.50  
Laband's syndrome 68.4  
labetalol 75.91  
labia majora 71.54, 71.56, 71.72, 71.79  
labia minora 71.54, 71.56, 71.62–3  
labial melanotic macules 54.2, 54.6, 54.7  
laboratory tests 5.21–2  
  immunological and allergic disease 13.15–26  
labour, delayed in X-linked ichthyosis 8.9  
*Lacazia loboi* 36.77, 36.78  
laceration, pinna 68.7  
lacrimal apparatus 67.3  
  cicatization 67.21  
lacrimal glands 67.2–3  
  in graft-versus-host disease 67.22  
  in sarcoidosis 61.7  
  in Stevens–Johnson syndrome 67.21  
lactate  
  as irritant 25.19  
  in sweat 44.5, 44.6  
lactation  
  drug therapy and 72.28  
  sebaceous gland activity 42.12  
lactic acid 80.9  
lactic acid stinging test 25.10  
lactiferous ducts 70.1, 70.8, 70.11  
lactoflavine 59.62  
lactogen 8.9  
lactucin 26.75  
lactucopicrin 26.75  
LAD *see* leukocyte adhesion deficiency (LAD)  
Lag antigen, Birbeck granules 55.4  
Laginel–Lavastine and Viard type, lipoatrophy 46.39  
*Lagochilascaris minor* 37.18  
lagophthalmos 32.14, 67.4, 67.21  
LAMA3 gene, mutations in junctional epidermolysis bullosa 39.10  
LAMB syndrome 49.37, 54.4, 58.14, 62.25, 62.79, 69.28  
LAMB3 gene, mutational hotspots and R42X and R635X 39.10  
*Lambdopsalis bulla* 66.1  
Lambeth study 6.6–7, 6.7, 6.15  
lamellar bodies/granules *see* membrane-coating granules  
lamellar desquamation/exfoliation of the newborn 17.19–21, 59.39  
lamellar ichthyosis (LI) 19.3, 19.21–5  
  prenatal diagnosis 16.3  
  treatment 73.36  
  *see also* non-bullous ichthyosiform erythroderma  
lamina densa 3.25, 3.26  
  cleavage below in dystrophic epidermolysis bullosa 39.2, 39.15  
lamina lucida 3.25, 3.26  
  cleavage in junctional epidermolysis bullosa 39.2  
  salt-split 40.47  
laminin(s) 3.27–3.29  
  cell binding mediated by integrins 3.28, 3.30  
  chain composition 3.27, 3.28  
  functions 3.28  
  G domain 3.27, 3.29  
  lymphatic vessels 48.4  
  subunits and structure 3.27–3.28, 3.29  
  in wound healing 14.6  
laminin-1, antibodies to 39.25  
laminin-5 (laminin-332) 3.6, 3.25–6, 3.27, 3.30, 40.36  
   $\alpha\beta 4$  integrin binding 3.28, 3.30, 3.32  
  in anchoring filaments 3.32  
  gene mutations 3.28  
  in junctional epidermolysis bullosa 3.28, 3.30, 39.10  
  antibody probes for diagnosis 39.25  
  monoclonal antibodies to 39.25  
  structure 3.27, 3.29, 3.31, 3.32  
lamins, nuclear 3.9  
  in partial face-sparing lipodystrophy 46.41  
lamivudine 26.46, 75.67  
  adverse effects 35.22  
lamotrigine 64.52  
  adverse effects 75.86  
  in complex regional pain syndrome 63.21  
*Lampona* 38.32  
lamprene *see* clofazimine  
Lamprene, pigmentation due to 58.55  
Lanette O 26.58–9  
Langer–Giedion syndrome 15.55, 15.65–6  
Langerhans' cell granulomatosis *see* Langerhans' cell histiocytosis (LCH)  
Langerhans' cell histiocytosis (LCH) 3.18, 55.6–14  
  aetiology 55.6–7  
  bone involvement 55.12  
  bone marrow 55.11  
  clinical features 17.25, 55.9–12  
  clonality 55.7  
  CNS involvement 55.11–12  
  cutaneous features 55.9–10  
  definition 55.6  
  diagnosis 55.7, 55.12  
  diagnostic markers 55.8–9  
  differential diagnosis 17.30, 55.12, 55.23  
  ears 55.11  
  endocrine system involvement 55.11, 55.12  
  female genital dermatology 71.79  
  gastrointestinal 55.11  
  Hashimoto–Pritzker variant 55.8, 55.9  
  immunocytochemistry 55.8–9  
  immunoglobulins 55.6  
  incidence 55.9  
  investigation 55.12–13  
  juvenile xanthogranuloma and 55.10  
  male genital dermatology 71.48  
  malignant 55.7, 55.32  
  multisystem 55.10, 55.11, 55.12  
  treatment 55.13  
  nails 55.11  
  oral involvement 55.11, 69.118  
  pathology 55.7–8  
  perianal/perineal dermatology 71.99

- pregnancy and 8.12  
prognosis 55.12  
pulmonary 55.7, 55.11  
reduced T-cell response 55.6, 55.7  
seborrhoeic dermatitis vs 55.9  
treatment 55.12, 55.13  
  topical mechlorethamine 73.24
- Langerhans' cell histiocytosis (LCH) cells  
55.6, 55.7, 55.7, 55.8  
  Birbeck granules 55.3–4, 55.6  
  CD1a 55.7  
  histology/ultrastructure 55.7, 55.7–8  
  surface markers 55.8–9  
  T cell response inhibition 55.6, 55.7
- Langerhans' cell sarcoma 55.31
- Langerhans' cells 3.1, 3.17–18, 4.8, 12.16  
abnormal *see* Langerhans' cell  
  histiocytosis (LCH) cells  
  in acne pathogenesis 42.26, 42.27  
  activated, surface markers 55.3, 55.4  
  ageing and 8.24, 8.02  
  in allergic contact dermatitis 26.6  
  antigen presentation by 55.3, 55.4–5  
  Birbeck granules 3.18, 55.3–4  
  culture 55.3  
  cytokines released 3.17, 55.3  
  deficiency 3.17–18  
  differentiation/development 55.1–3  
  effects of UVR on 13.28, 13.29, 29.5  
  embryology 3.5  
  functions 3.3, 3.17, 3.18, 13.9, 55.4–5  
  hair bulb 66.4  
  in HIV-associated psoriasis 35.17  
  in HIV infection 35.8  
  in HPV infection and warts 33.42  
  hyperplasia 10.24  
  in irritant contact dermatitis 25.5  
  in lichen planus 41.4  
  maturation 55.3  
  migration 3.17, 3.18, 55.3, 55.4  
  factors controlling 5.2, 5.3, 55.1  
  signals initiating 55.4  
  motion mechanism 3.17  
  in nail matrix 65.2  
  ontogeny 55.1–3  
  phenotype 55.3, 55.3–4  
  precursors 55.1, 55.2  
  structure and ultrastructure 3.17–18  
  surface markers 10.24–5, 55.3, 55.3–4,  
  55.5
- langerin 10.24
- Langer's lines 77.2, 77.13
- Langhans' giant cell 10.34–5  
  in lichen nitidus 41.21  
  in pancreatic panniculitis 46.18
- language  
  barriers 72.2  
  skin/skin disease and 64.1, 64.6
- language bias 7.7
- lanolin  
  as allergen 26.58  
  comedogenicity 27.13  
  composition 73.6  
  as emollient 73.6  
  in topical therapy 73.6–7
- lanreotide, in carcinoid syndrome 43.19
- lansoprazole 75.157
- lanugo 66.2
- large B-cell lymphoma (PCLBCL) 57.47–9
- large vessel disease 51.39
- larva currens *see* *Strongyloides stercoralis*
- larva migrans  
  cutaneous 37.16–17  
  breast involvement 70.17  
  in HIV infection 35.36  
  oral 69.101  
  visceral *see* toxocarasis
- larval therapy, pressure ulcers 28.22
- laryngo-onycho-cutaneous (LOC)  
  syndrome 39.15
- larynx, lichen planus 41.9
- laser burns 28.90  
  Erbium:YAG 53.7
- laser Doppler flowmetry, in erythema  
  25.22
- laser evoked potentials 63.5
- laser therapy 78.1–16  
  ablative resurfacing 78.13–15  
  acne 42.67, 42.69  
  actinic cheilitis 78.14  
  adverse effects 33.49  
  angiofibroma 78.14  
  argon 78.1  
  basal cell carcinoma 78.14  
  Becker's naevus 18.18, 78.10  
  Bowen's disease 78.14  
  café-au-lait spots 78.10  
  classification 78.2  
  CO<sub>2</sub> *see* carbon dioxide laser  
  in combination with botulinum toxin  
  80.7  
  continuous 78.2  
  cosmetic/rejuvenation 80.7, 80.10–13  
  epidermolytic/non-epidermolytic  
  epidermal naevi 18.7  
  Erbium:YAG laser 78.13  
  osteoma cutis 42.78  
  fractional ablative resurfacing 78.13  
  fractional photocoagulation 78.13  
  freckles 78.10  
  gain medium 78.2  
  granuloma faciale 50.29, 78.9, 78.14  
  haemangioma 78.6  
  hair removal 66.87, 78.12–13  
  history of 78.1  
  HPV-associated dysplasia/neoplasia  
  33.55  
  hypertrichosis 78.12–13  
  hypertrichosis lanuginosa 66.76  
  hypertrophic scars 78.8  
  incisional 78.13, 78.14  
  infantile haemangioma 18.51  
  intense pulsed light source (IPLS) 78.6,  
  78.10  
  acne 42.67  
  cosmetic use 80.10–11  
  hereditary haemorrhagic  
  telangiectasia 47.18  
  port-wine stains 18.64  
  telangiectasia 47.20  
  keloids 78.14  
  KTP 78.6  
  leg veins/venules 78.8  
  lichen planus 41.18  
  light 78.1–2  
  light-tissue interactions 78.4–5, 78.5–6,  
  78.9, 78.12, 78.13  
  low-level (LLLT) 78.15  
  lymphoedema management 48.23  
  melanocytic naevus 78.11  
  melasma 78.11  
  naevoid basal cell carcinoma syndrome  
  52.8  
  naevus of Ota 78.10, 78.11  
  nail unit 65.48  
  Nd:YAG 78.6, 78.9–10, 78.14  
  essential telangiectasia 47.19  
  lichen planus 41.18  
  telangiectasia 47.20  
  varicose veins 47.39  
  necrobiosis lipoidica 60.16  
  non-ablative photocoagulation 78.13,  
  78.14  
  non-melanoma skin cancer 52.17  
  optical cavity 78.2  
  osteoma cutis 42.78  
  peri-orbital syringoma 78.14  
  photothermal ablation 78.13–15  
  phymas 43.10  
  port-wine stain 18.64–5, 78.6–7  
  psoriasis 20.43, 78.8  
  pulsed 78.2–3  
  pulsed-dye (PDL) 47.20, 78.6–7  
  side-effects 18.64  
  warts 33.49  
  Q-switched 78.2, 78.3, 78.9–10  
  resurfacing 80.7, 80.11  
  rhinophyma 43.10, 78.14  
  sarcoidosis 61.21  
  seborrhoeic keratosis 78.10
- solar lentigines 78.10
- speckled and lentiginous naevus 78.10
- spot size 78.3, 78.4
- striae 45.6
- tattoos 58.59, 78.10
- telangiectases 47.19, 47.20, 78.7–8  
  in rosacea 43.6  
  tissue cooling 78.5  
  tissue optics 78.3–4  
  trichoepithelioma 78.14  
  varicose veins 47.39  
  vascular lesions 78.5–9  
  warts 33.49, 78.8  
  xanthelasma 78.14
- Lasiodiploidea theobromae* 36.55
- Lasiohelea* 38.6
- Lassa fever 33.67, 33.69
- Lassar's paste, dithranol 20.23
- latanoprost 26.46, 66.79, 66.94, 75.165
- late-infantile neuronal ceroid  
  lipofuscinosis, prenatal diagnosis  
  16.3
- late-onset (acquired) ichthyoses 19.63–5,  
  62.32
- latent transforming growth factor- $\beta$   
  (LTBP) 3.45
- lateral pterygoid muscle, examination  
  69.4–5
- latex 26.63  
  contact urticaria to 26.105, 27.5  
  sensitivity  
  immunotherapy 26.106  
  male genital dermatology 71.17  
  spina bifida and 63.16  
  testing for 26.106, 27.7  
  *see also* rubber
- latrosectism 38.31
- Latrodectus* 38.31
- Lattice System Global Assessment 72.9
- Laugier–Hunziker(–Baran) syndrome  
  58.14–15, 65.38, 69.28
- laurel oil 76.5
- lavender oil  
  adverse effects 70.5  
  in head louse infection 38.20  
  as insect repellent 38.5
- lawsone 66.97
- Lawsonia* spp. 66.97
- laxatives  
  adverse effects 75.158  
  in dystrophic epidermolysis bullosa  
  39.28
- laxity, skin 45.14  
  *see also* cutis laxa
- LBP (lipopolysaccharide-binding protein)  
  12.9
- LCH *see* Langerhans' cell histiocytosis
- LDF (laser Doppler flowmetry), in  
  erythema 25.22
- LE *see* lupus erythematosus (LE)
- le tic des levres 64.39–40, 69.127–8
- lead acetate hair dye 66.97
- lead poisoning 75.33
- lead subacetate 75.165
- lectins 13.23
- Ledderhose's disease 45.47, 56.11
- leeches 38.55
- Leeds acne grading system 72.10
- LEF1 3.4, 66.10
- leflunomide 13.24, 75.138
- leg(s)  
  allergic contact dermatitis 23.35, 23.36,  
  26.19, 26.29  
  atherosclerosis 47.2  
  burning pain 47.11  
  chronic folliculitis 30.22  
  disseminated superficial actinic  
  porokeratosis 52.35–6  
  erosive pustular dermatitis 50.89–90  
  erythromelalgia 47.9–10  
  fascial hernias 45.68–9  
  injuries, venous ulceration and 47.42  
  ischaemic disease 47.2  
  neurovascular disorders 47.9–12
- occupational dermatoses 27.3
- pustular dermatitis atrophicans 30.22
- red streaks 48.29
- surgery 77.5
- telangiectases 47.13
- ulcers *see* ulcer(s), leg  
  *see also* lower limb
- Leg Club Foundation 14.21
- legionellosis 30.67
- Leguminosae 26.80
- Leiden mutation 54.33
- leiomyoma 56.54–6  
  congenital 18.37  
  genetics 15.26  
  genital 56.54–5  
  in females 71.73  
  oral 69.113  
  pillar 56.54–5
- leiomyoma cutis 56.54–5
- leiomyomatosis, multiple cutaneous and  
  uterine 56.55
- leiomyosarcoma 56.56
- Leishmania* 37.2, 37.27, 37.33
- Leishmania aethiopicum* 37.34, 37.35, 37.36,  
  37.37, 37.39
- Leishmania brasiliensis*, ocular infection  
  67.27
- Leishmania brasiliensis brasiliensis* 37.34,  
  37.35, 37.39, 37.40
- Leishmania brasiliensis guyanensis* 37.34,  
  37.35, 37.39–40
- Leishmania brasiliensis panamensis* 37.34,  
  37.35, 37.40
- Leishmania brasiliensis peruviana* 37.34,  
  37.35, 37.39, 37.40
- Leishmania chagasi* 37.34
- Leishmania donovani*, ocular infection 67.27
- Leishmania donovani donovani* 37.41
- Leishmania donovani infantum* 37.34, 37.36,  
  37.39, 37.41
- Leishmania major* 37.34, 37.35, 37.36, 37.39
- Leishmania mexicana amazonensis* 37.34,  
  37.35
- Leishmania mexicana mexicana* 37.34, 37.35,  
  37.39
- Leishmania tropica* 37.34, 37.35–6, 37.37,  
  37.39
- female genital dermatology 71.69  
  ocular infection 67.27
- leishmaniasis 37.33–44  
  American (South American) cutaneous  
  37.34, 37.35, 37.39–41  
  differential diagnosis 31.10  
  diffuse/disseminated cutaneous 37.37,  
  37.38  
  epidemiology 37.34  
  genital involvement, in males 71.33  
  in HIV infection 35.35, 37.43  
  lip involvement 69.121  
  lupoid (chronic) 37.37, 37.39, 61.5, 61.13  
  mucosal 37.39–41  
  ocular involvement 67.27  
  Old World cutaneous 37.34–9  
  oral involvement 69.81  
  perianal/perineal involvement 71.96  
  post-kala-azar dermal 37.41–2  
  in returned travellers 37.41  
  ulcers in 47.57  
  vectors 38.5, 44.7  
  visceral 37.41–3  
  world distribution 37.33
- leishmaniasis cutis diffusa 37.37, 37.38
- leishmaniasis recidivans 37.37, 37.39
- leishmanin test 37.34, 37.37, 37.38, 37.42
- leisure activities, risk factor for skin  
  disease 6.13
- LEKTI 24.4, 66.65–6
- Leis's syndrome 15.44
- Lenner's lymphoma 57.64
- lentigines 8.23, 54.2–6, 54.10, 71.80  
  actinic (solar) 54.2, 54.4  
  laser therapy 78.10, 80.2, 80.11  
  lentigo maligna development from  
  54.4, 54.5, 54.41  
  management 58.39, 73.26, 73.27

- in Carney syndrome 58.14  
 definition 58.11  
 freckles vs 54.1, 54.4  
 ink-spot 54.2, 54.5  
 paraneoplastic 62.33  
 PUVA 54.2, 54.4–5, 58.33  
 senile (age spots) 8.23, 54.3, 58.39  
 simple 54.2, 54.3–4
- lentiginos neonatorum 17.8  
 lentiginosis 54.2–54.3, 58.11–15  
 arterial dissections with 58.14  
 centrofacial 58.12  
 cutaneous with atrial myxomas 58.14  
 eruptive 58.11  
 generalized 58.11  
 genital 54.6–7  
 hereditary 54.2, 54.3  
 inherited patterned 58.11, 69.28–9  
 keratosis pilaris and hypotrichosis with 66.60–1  
 multiple lentiginos syndrome 58.12  
 oral 69.28  
 periorificial *see* Peutz–Jeghers syndrome  
 segmental 54.2–54.3  
 unilateral (zosteriform) 58.11
- lentiginous melanocytic hyperplasia 54.30  
 lentigo maligna 8.28–9, 54.5, 54.40, 54.42  
 actinic (solar) lentigo progression to 54.4, 54.5, 54.41  
 ageing and 8.23, 80.2  
 differential diagnosis 54.41–2  
 seborrhoeic keratosis vs 52.38  
 mucosal melanosis similarity 54.7  
 periocular (conjunctival) 54.40–1  
 treatment 54.42–3  
 azelaic acid 73.28  
 radiotherapy 79.12–13  
 topical imiquimod 73.24
- lentigo maligna melanoma 54.35, 54.40–4, 79.12–13  
 development 54.41  
*in situ see* lentigo maligna  
 pathology 54.42  
 treatment 54.43, 54.44
- leonine facies 32.11, 43.5, 43.6  
 leopard skin 37.6  
 'leopard spotting' 45.22  
 LEOPARD syndrome 54.3, 58.12, 62.77, 69.12, 69.28  
 features 58.12
- Lepidoptera (butterflies/moths) 25.21, 38.28–30  
 lepidopterism 38.28  
 lepra reactions 32.3–4  
 distinction from relapse 32.17  
 treatment and 32.17–18  
 type 1 32.4, 32.6, 32.12  
 type 2 32.4, 32.6, 32.7, 32.12–13, 32.18, 75.43  
 thalidomide and 74.30
- leprechaunism (Donohue syndrome) 45.62–3, 46.37
- leproma 32.5  
 lepromin test 32.7, 32.15  
 leprosy 32.1–20  
 aetiology 32.1–2  
 anhidrosis and 44.13  
 bone and joint involvement 62.100  
 borderline 32.3–4, 32.5–6  
 features 32.9, 32.11–12  
 lepromatous 32.4, 32.6  
 tuberculoid 32.4, 32.5–6  
 classification 32.4  
 clinical features 32.8–12  
 definition 32.1  
 diagnosis 32.14–15  
 differential diagnosis 32.15–16, 60.17  
 ear involvement 68.17, 68.20  
 early lesions 32.8  
 eye involvement 32.13–14  
 female genital involvement 71.67  
 genetics 32.2  
 geographical distribution 32.2–3  
 histology 32.4–6, 32.7
- history 32.1  
 HIV infection and 35.26  
 immunology 32.6–7  
 indeterminate 32.6, 32.8  
 lepromatous 32.3, 32.5, 32.7  
 eyebrow hypoplasia 67.3  
 features 32.9–11  
 polar 32.8  
 subpolar 32.11
- Lucio reaction/phenomenon 32.13, 49.35  
 mechanisms of damage 32.4  
 nerve involvement 32.4, 32.5, 32.6, 32.12, 32.17  
 complications of damage 32.18  
 cranial nerve palsy 69.118  
 diagnosis 32.13, 32.14  
 lepromatous 32.10, 32.11  
 tuberculoid 32.8–9  
 ocular involvement 67.27  
 pathogenesis 32.3–4  
 patient education 32.18  
 in pregnancy 8.11  
 prevention and control 32.19  
 prognosis 32.14  
 pure neuritic 32.12  
 rehabilitation 32.18  
 relapse 32.17  
 serology 32.7–8  
 subclinical infection 32.2–3  
 treatment 32.16–19  
 clofazimine 74.26  
 tuberculoid 32.4, 32.5, 32.7  
 differential diagnosis 31.10, 61.5, 61.13  
 eyebrows 67.3–4  
 features 32.8–9  
 polar 32.8  
 ulcers 47.56  
 vaccination 32.19
- LEPs (laser evoked potentials) 63.5  
 leptin 46.3  
 in acquired generalized lipodystrophy 46.38  
 body mass index (BMI) and 46.6  
 congenital deficiency 46.3  
 in polycystic ovary syndrome 66.82  
 at puberty 8.4  
 resistance 46.3, 46.6–7  
 role in wound healing 14.1
- Leptocimex 38.24  
 Leptoconops 38.6, 38.7  
 Leptosphaeria senegalensis 36.73  
 Leptospira 30.62, 30.66  
 leptospirosis 30.66  
 Leptotrichia buccalis 30.60  
 Leptotrombidium 38.50  
 Lesch–Nyhan syndrome 59.102–3, 65.50, 69.43, 69.117
- Leser–Trélat sign 52.38, 53.38, 62.31, 62.32
- lesions  
 agminate 5.9  
 annular 5.8, 5.9, 5.12, 32.15, 62.106–13  
 arcuate 5.8  
 child abuse-associated 28.34–5  
 colour 5.15–17, 5.18  
 confluent 5.9  
 digitate 5.8  
 discoid 5.8, 23.10  
 distribution 5.15, 5.16, 5.17  
 in drug addicts 28.52–3  
 grouped/clustering 5.9, 5.14  
 guttate 5.7  
 intensive care-associated 28.39  
 linear 5.8, 5.9, 5.11, 5.12  
 livedo 5.8, 5.10  
 palpation 5.17–18  
 pattern 5.9, 5.14, 5.15  
 petaloid 5.8  
 polycyclic 5.8  
 reticulate 5.8, 5.10, 5.12  
 satellite 5.9, 5.15  
 scattered/disseminated/exanthematous 5.9, 5.15  
 serpiginous 5.8
- shape 5.8–9, 5.10, 5.11, 5.12–13  
 sparing 5.9  
 stellate 5.8  
 swimming-/diving-associated 28.55  
 symmetrical 5.15  
 target 5.8, 38.32  
 terminology 5.6–8  
 whorled 5.8  
*see also specific lesions*
- lesser occipital nerve 77.3  
 lesser weever fish 38.59
- lethal cutaneous and gastrointestinal arteriolar thrombosis *see* Degos' disease  
 lethal toxin 30.41
- Letterer–Siwe disease *see* Langerhans' cell histiocytosis (LCH)
- leu<sup>5</sup>-enkephalin 12.25  
 leucine-rich repeat (LRR) 12.9  
 proteoglycans 3.46
- leukaemia 62.88  
 acute myeloid (AML) 55.31  
 adult T-cell *see* adult T-cell leukaemia-lymphoma (ATLL)  
 chronic myeloid (granulocytic) juvenile 62.96  
 neutrophilic eccrine hidradenitis and 44.17  
 treatment of skin lesions 73.24  
 erythroderma and 23.48  
 genetics 15.14–15, 15.20  
 juvenile myelomonocytic (JMML) 15.14–15, 15.20  
 lymphatic 57.62  
 pigmentation changes 58.26  
 mast-cell 22.31, 22.33  
 monocytic 55.31–2  
 oral involvement 69.57, 69.116  
 perianal/perineal involvement 71.99
- leukaemia cutis 55.31–2, 57.61–2, 62.15, 62.88  
 leukaemia inhibitory factor (LIF) 58.5  
 leukaemia-lymphoma (HTLV-1-associated) *see* adult T-cell leukaemia-lymphoma (ATLL)  
 leukaemoid reaction 62.88  
 leukocidal toxins 30.8  
 leukocyte adhesion deficiency (LAD) 13.9, 17.48, 17.77–8  
 LAD-1 12.22, 17.77–8  
 LAD-2 17.78  
 LAD-3 17.78  
 oral involvement 69.16
- leukocyte cell adhesion molecule (LEUCAM) subfamily, integrins 12.70  
 leukocyte emigration, regulation by adhesion molecules 12.74  
 leukocyte function-associated antigens, LFA-1 13.9  
 leukocyte migration inhibition test 75.174  
 leukocyte procoagulant activity 26.98  
 leukocyte rolling 12.74  
 leukocyte trafficking, CX3CR1 12.48  
 leukocyte trapping, in venous disorders 47.27  
 leukocytoclasia, in vasculitis 50.7  
 leukoderma 58.9  
 disseminate lenticular 58.52  
 drug-induced 75.33  
 following allergic contact dermatitis 26.26  
 occupational 27.15, 58.50  
 post-inflammatory 58.48  
 syphilitic 58.31
- leukoderma acquisitum centrifugum (halo naevus) 58.49–50  
 leukoderma syphiliticum 34.10, 34.12  
 leukoedema 17.5, 69.23  
 leukokeratosis  
 genetics 15.14  
 lips *see* cheilitis, actinic  
 oral, focal keratoderma with 19.103  
 leukomelanoderma 73.27  
 leukonychia 65.14, 65.15
- apparent 65.15  
 post-inflammatory 65.29  
 punctate 65.15  
 subtotal 65.15  
 total 65.15  
 transverse 65.15
- leukopathy, symmetrical progressive 58.52  
 leukopenia, oral involvement 69.56  
 leukophores 2.5  
 leukoplakia 69.13, 69.22, 69.50, 69.89–94  
 anogenital 71.3  
 candidal 36.60–1, 69.89, 69.90, 69.91  
 female genital dermatology 71.52  
 genetics 15.79  
 hairy *see* hairy leukoplakia  
 heterogeneous/speckled 69.90, 69.91  
 homogeneous 69.90  
 malignant transformation 69.90–1, 69.92  
 oral, treatment 73.23  
 proliferative verrucous 69.90, 69.91  
 syphilitic 69.78, 69.90, 69.91
- leukotriene(s) 12.60–2, 13.4  
 modifiers 12.61  
 leukotriene antagonists 74.31  
 dose range and evidence level 74.31  
 in Sjögren–Larsson syndrome 19.44  
 in urticaria 22.29
- leukotriene B<sub>4</sub> (LTB<sub>4</sub>), inflammatory acne pathogenesis 42.26  
 leukotriene C<sub>4</sub> (LTC<sub>4</sub>) 12.25, 12.27, 12.32, 12.46, 12.61, 12.66, 12.74  
 in urticaria 22.4
- leuprolide, in acne vulgaris 42.53  
 leuprorelin 75.117  
 levamisole  
 adverse effects 68.18, 75.71  
 dermatomyositis 51.129
- levator palpebrae superioris 67.2  
 Levin syndrome I 15.34  
 levocabastine 67.15  
 levocetirizine 22.29  
 adverse effects 75.149
- levodopa  
 adverse effects 75.88  
 in restless legs syndrome 63.25  
 sebaceous gland activity 42.12  
 seborrhoeic dermatitis and 23.29
- levomepromazine (levopromazine) 75.82  
 levonorgestrel 75.118  
 acne treatment 42.53  
 levuride 23.9, 36.36–64  
 Lewar's disease 69.109  
 Leyland cypress 26.80  
 LH *see* luteinizing hormone  
 LH 7.2 monoclonal antibody 39.25  
 Lhermitte–Duclos disease 62.26  
 l'homme rouge 23.49  
 LI *see* lamellar ichthyosis
- liarazole  
 dose range and evidence level 74.37  
 in psoriasis 20.42
- Libman–Sacks endocarditis 51.33
- lice 38.15–23  
 clothing/body 38.2, 38.15, 38.16, 38.21–2  
 elderly people 8.29  
 dogs and cats 2.10  
 head 38.15, 38.16, 38.17–21  
 treatment 73.13, 73.14  
 pubic (crabs) 38.15, 38.16–17, 38.18, 38.22–3, 71.7, 71.34  
 blepharitis due to 67.10  
 eyelash infestation 67.27  
 treatment 73.13, 73.14  
 topical therapy 73.13–14
- lichen amyloidosus 59.46  
 lichen aureus 49.22, 49.23, 49.25  
 treatment 49.26  
 lichen myxoedematosus 59.21–3, 62.45  
 lichen nitidus 41.21–3, 65.29  
 clinical features and sites 41.22  
 histology 41.21–2  
 lichen planus with 41.22

- linear 41.22  
male genitalia 71.24  
papules 41.21, 41.22  
race and 9.5  
treatment 41.22–3
- lichen nuchae 23.40
- lichen planopilaris 41.7, 41.11–12, 41.14  
female genitalia 71.60  
scalp 41.11, 66.39, 66.41–3  
*see also* lichen planus, follicular lesions
- lichen planus 41.1–20, 59.79  
actinic (subtropical) 41.12–13  
erythematous 41.13  
acute, confluence of lesions 41.14  
allergic contact dermatitis and 26.26  
alopecia 41.11, 41.14, 41.17, 66.39, 66.41–3  
annular 5.12–13, 41.7, 41.13, 41.17  
associated conditions 41.16–17  
atrophic 41.13–14  
  histology 41.5  
buccal 5.10, 41.8, 41.9  
bullous 41.20–1, 41.25  
  histology 41.5  
cicatricial conjunctivitis 67.20  
clinical features 41.6–9  
complications 41.14–16  
dental amalgam association 41.3  
diabetes mellitus and 41.9, 41.16  
differential diagnosis 40.40, 41.17, 51.117  
discoid lupus erythematosus with 41.20  
ear 68.15  
epidermodysplasia verruciformis vs 33.58  
epitheliomatous transformation 41.8  
erosive 69.61, 69.62  
erythroderma and 23.48  
follicular lesions 41.11–12  
  histology 41.5  
genetic factors 41.2  
genital 41.9  
  in females 71.59–61, 71.76  
  in males 71.23–4  
genitocrural 71.5  
guttate 41.14  
hair involvement 41.14  
hands 23.20, 23.21  
hepatitis B virus and 41.16, 62.59  
hepatitis C virus and 41.2–3, 41.16  
histology 41.4–6  
HIV and 41.12  
hyperpigmentation 41.12, 41.13  
hypertrophic 9.5, 41.7, 41.10  
  histology 41.4–5  
  prognosis 41.17  
  treatment 41.18
- idiopathic 41.16  
immune system in 41.1–2  
incidence 41.4  
itching 41.9  
Koebner response 28.3, 28.48, 28.73  
laryngeal 41.9  
lichen nitidus with 41.22  
linear 18.23–4, 41.12  
  multiple lesions 41.12  
in liver disease 62.64  
localization to tattoos 58.58  
macular variant 41.17  
‘mixed’ with DLE 41.20  
mucosal 41.7–8, 41.9, 41.15, 41.17, 41.18  
  histology 41.5  
  treatment 41.18  
nails 41.14, 41.15, 65.25, 65.29–30  
Nékam’s disease as variant 41.27  
oesophageal 41.9  
oral 26.26, 41.9, 69.61–3, 69.65  
  complications 41.15  
  diabetes mellitus and 41.9, 41.16  
  differential diagnosis 41.9  
  drugs associated 41.25  
  histology 41.4  
  pathogenesis 41.1, 41.2, 41.3, 41.23  
  treatment 41.18, 73.37  
  oral erosive, ciclosporin therapy 73.33  
  palms and soles 26.29, 41.7, 41.8, 41.14  
  papules 41.4, 41.6  
  paraneoplastic 62.38  
  pathogenesis 41.1–3  
  perianal/perineal 71.90  
  pigmentation 41.7  
  plane warts vs 33.44  
  post-inflammatory hypermelanosis after 58.31  
  prognosis 41.17  
  pruritus in 41.9, 41.17  
  race and 9.5  
  relapses 41.17, 41.18  
  reticular 69.61  
  scalp 41.11, 66.39, 66.41–3  
  secondary syphilis vs 34.12  
  segmental 41.12  
  sites 41.7  
  ‘spiny’ lesion variant 41.7  
  subacute, confluence of lesions 41.14  
  tongue 41.8, 41.9  
  treatment 41.17–20, 73.36  
  ulceration of feet 41.14, 41.18  
  variants 41.9–14  
  viral infections associated with 41.2–3  
  without itching 41.17  
  zosteriform 41.12
- lichen planus follicularis 41.11  
tumid forms 41.14
- lichen planus-like contact dermatitis 41.23
- lichen planus pemphigoides 40.34, 41.20–1, 69.63  
  drugs causing/associated with 41.25  
  lichen planus pigmentosus 41.13, 41.17  
  lichen planus subtropicus 41.12–13  
  lichen planus/lichen sclerosus overlap syndrome 69.63
- lichen purpuricus *see* lichen aureus
- lichen ruber moniliformis (Nékam’s disease) 41.27–8, 73.4
- lichen ruber pemphigoides 41.20–1
- lichen sclerosus 40.40, 51.64, 51.112–18, 54.6, 71.87  
  aetiology 51.113  
  anogenital lesions in women 51.115  
  associations 51.113  
  *Borrelia* and 30.65  
  breast 70.17  
  child sexual abuse and 28.38  
  in children 8.3  
  female 51.117  
  clinical features 51.114–15  
  differential diagnosis 51.117  
  in elderly people 8.27  
  extragenital 45.18  
  female genitalia 51.115, 71.57, 71.62–5, 71.76, 71.77  
  human papilloma virus in 51.116  
  incidence 51.113  
  male genitalia 71.20–3, 71.40, 71.41  
  balanitis xerotica obliterans 51.113, 51.116  
  malignant changes 51.116  
  in menopause 8.20  
  morphoea in 51.77  
  nail involvement 65.29  
  oral 51.115, 69.63–4  
  pathology 51.114  
  perianal/perineal 71.87  
  prognosis 51.117  
  purpura and bleeding in 49.17  
  scalp 66.50  
  treatment 51.118  
  urethral stenosis in males 51.116  
  vasculitis and 50.49
- lichen scrofulosorum 31.10, 31.21–2, 31.29
- lichen nitidus vs 41.22
- lichen simplex 23.39–41, 64.27  
  clinical features 23.40  
  definition 23.39  
  diagnosis 23.40–1  
  ear 68.23  
  female genitalia 71.52–3  
  histopathology 23.39–40  
  male genitalia 9.14, 71.16  
  neck 23.32  
  perianal/perineal 71.84, 71.85  
  treatment 23.41
- lichen simplex chronicus 9.13–14, 23.40, 26.17
- lichen spinulosus (keratosis spinulosa) 19.75, 19.76
- lichen striatus 5.11, 23.41–2, 65.29  
  race and 9.5
- lichen verrucosus et reticularis (Nékam’s disease) 41.27–8, 73.44
- lichenification 23.39–42, 64.27  
  aetiology 23.39  
  in atopic dermatitis in animals 2.13  
  clinical features 23.39  
  definition 5.7, 23.39  
  in eczema 23.4  
  female genitalia 71.52–3  
  genetics 15.10  
  giant of Pautrier 23.40  
  histopathology 23.39  
  mechanical injury and 28.2, 28.28  
  pebbly 23.40  
  perianal/perineal 71.84–6
- lichenified onychodermatitis 37.4, 37.5, 37.6
- lichenoid, definition 41.1
- lichenoid eruptions  
  definition 41.1  
  drug-induced 41.23–5  
  melanoma and 41.6  
  post-inflammatory hypermelanosis 58.31  
*see also* lichen planus
- lichenoid melanodermitis 41.13
- lichenoid photoeruptions 41.25
- lichenoid reactions, symptomatic 41.23–7
- lichenoid tattoo reaction 58.58
- lichenoid tissue reaction  
  contact 26.26  
  histopathology 10.40
- lichens 26.24, 26.77, 26.82
- lick granuloma 2.9
- lidocaine 77.10  
  adverse effects 77.10  
  dosage 77.10  
  in nail biopsy 65.41–2  
  in post-herpetic neuralgia 63.7  
  in tick removal 38.36  
  topical, in oral lichen planus 41.18
- life quality index *see* Dermatology Life Quality Index (DLQI)
- ligands 26.11
- ligase IV deficiency 17.58
- light  
  amplification 78.1  
  laser 78.1–2  
  nature of 78.1–2  
  therapy *see* phototherapy  
  tissue interactions 78.4–5, 78.5–6, 78.9, 78.12, 78.13
- light cautery  
  comedones 42.67  
  macrocomedones 42.63
- light-emitting diodes (LEDs) 29.2
- light exposure  
  mechanical injury 28.8, 28.53  
  photodermatitis 28.92
- light-induced reactions, tattoo pigments and 58.58
- light-reflection rheography (LRR) 47.36
- light therapy, acne vulgaris 42.67, 42.68
- lightning burns 28.90
- lightning pains 34.14
- lignocaine *see* lidocaine
- likelihood ratio 7.13
- Liliaceae 26.76
- limb(s)  
  disproportionate growth 47.23  
  lower *see* lower limb  
  melanoma recurrence, management 54.54–5  
  overgrowth (hypertrophy) 48.21
- swelling  
  causes 48.20  
  differential diagnosis 48.19–21  
  investigations 48.17–19  
  as lymphoedema complication 48.15  
  *see also* lymphoedema  
  upper *see* upper limb
- limbal broadening 39.19
- limbitis  
  management 67.23  
  mucous membrane pemphigoid 67.18
- limb-mammary syndrome (LMS) 15.46, 15.64
- limbus 67.4
- lime burns 25.12
- limonene (dipentene) 26.41, 26.42, 26.82
- lincomycin 75.58–9
- lincosamides, side effects 74.42–3
- lindane  
  adverse effects 75.164  
  in scabies 38.41  
  withdrawal 73.14
- linea alba 8.10, 17.5, 69.87
- linear dermatitis herpetiformis *see* linear IgA disease
- linear epidermal naevus syndrome 62.100
- linear furrows 45.2
- linear IgA disease 40.45–51  
  acne vs 42.37  
  aetiology 40.45  
  cicatricial conjunctivitis and 67.20  
  clinical features 40.48–9  
  defined 40.45  
  dermal-associated 40.49  
  differential diagnosis 40.50, 76.19  
  drug-induced 40.49, 75.39–40, 76.7  
  immunoelectron microscopy 10.29  
  immunopathology 10.18  
  oral involvement 69.65, 69.68–9  
  paraneoplastic 62.46  
  pathogenesis/pathology 40.46–7  
  prognosis 40.50  
  treatment 40.50–1  
  ulcerative colitis and 62.51–2
- linear IgA mucous membrane pemphigoid 40.49
- linear lichenoid dermatosis *see* lichen striatus
- linear naevus syndrome *see* naevus, sebaceous
- linear porokeratosis 18.25–6, 19.91
- linear subcutaneous bands 51.131
- lines of Blaschko 15.6, 15.7
- linezolid 30.9
- lingual varices 69.6
- linkage disequilibrium 15.7–8
- linoleate 3.11
- linoleic acid 73.5  
  reduced in sebum in acne 42.23, 42.26
- Linton’s operation 47.39
- Limuche urguiculata* 38.56
- lip(s) 69.1–2  
  acquired lesions 69.119–28  
  actinic keratosis 52.30  
  allergic contact dermatitis 26.17  
  augmentation 80.4, 80.5  
  basal cell carcinoma 69.53–4  
  chancres 69.121  
  chapping 69.119  
  cleft *see* cleft lip/palate  
  in discoid lupus erythematosus 69.128  
  double lip 69.38  
  examination 69.5  
  fissure 69.129  
  staphylococcal 30.32  
  haemorrhagic crusting 69.121, 76.16  
  keratoacanthoma 69.54–5  
  in leishmaniasis 69.121  
  leukokeratosis *see* cheilitis, actinic  
  melanotic macule 69.27  
  myxoid cyst 69.22, 69.65, 69.84, 69.110  
  naevi 69.29  
  oedema 48.16  
  pigmentation, Laugier–Hunziker syndrome 58.14

- pits/sinuses 18.3, **18.90–2**, 69.40–1  
lip-pit syndrome **15.93–4**  
pseudocleft 69.37  
radiotherapy 79.10, 79.11  
in reactive perforating collagenosis 69.129  
in sarcoidosis 69.129  
secondary syphilis and 34.9  
senile haemangioma (venous lake) 47.16, 69.101  
squamous cell carcinoma 69.42, 69.49–50, 79.10, 79.11  
surgery 77.3, 77.5  
syphilitic chancre 34.7  
in systemic lupus erythematosus 69.128  
tattoos 69.96  
ulcers  
due to calibre-persistent artery 69.129  
imiquimod association 54.43  
vermillion zone 69.1–2  
vermilionectomy 77.36  
wedge excision 77.35
- lip-pit syndrome **15.93–4**  
lipid(s)  
antibacterial properties 4.5  
epidermal cells 42.5  
foreign-body reaction to 61.22  
photoprotective function 4.7  
polar, stratum corneum 3.11  
role in skin barrier function 3.11, 4.2, 25.2, 25.8  
sebaceous cells 42.3, 42.5  
sebum 42.5, 42.5, 42.6  
skin surface, abnormalities in HIV infection 35.15  
stratum corneum 3.10, 3.11  
synthesis in epidermis 3.10–11  
tear film 67.2, 67.3  
in vehicles for topical therapy 73.5, 73.6  
vernix caseosa 17.4
- lipid metabolism, disorders **59.81–93**  
dyslipidaemias *see* dyslipidaemias
- lipid pathway  
ATP binding cassette A-1 (ABCA1) 59.83  
endogenous/exogenous 59.82  
reverse cholesterol transport 59.82–3  
lipid storage disease 44.18, 59.81–93  
*see also specific diseases*
- lipid vacuolation, neutral lipid storage disease with ichthyosis 19.52–4
- lipidosis, lipoedema vs 48.19
- lipiodol 48.17
- lipoarabinomannan 31.1, 46.41–3, 70.3, 70.4
- lipoatrophia semicircularis 46.36
- lipoatrophic diabetes 46.37
- lipoatrophy 45.63, 46.11, 46.34  
facial *see* facial lipoatrophy  
generalized 46.37–9  
HIV-associated 35.22, 46.41  
insulin 46.34, 46.35  
lipoatrophic panniculitis 46.15  
localized 46.34–7  
'idiopathic' 46.35–7  
involutional vs inflammatory 46.35  
partial 46.31–2, 46.37, 46.39–40  
semicircular 28.27, 46.36  
trauma-related 46.36  
*see also* lipodystrophy
- lipoblastoma 18.38–9, 56.57
- lipoblastomatosis 56.57
- lipocortin 73.17
- lipocytes 46.2  
coagulative necrosis 46.18  
fat storage and metabolism 46.2–3  
'ghost' 46.18  
*see also* adipocytes
- lipodermatosclerosis 46.30–1, 47.27, **47.34**  
acute 46.30, 46.31  
chronic, lymphoedema with 48.13
- lipodystrophia centrifugalis abdominalis infantalis 46.36
- lipodystrophy **46.34–43**  
acquired 46.34  
generalized 46.37–9  
antiretroviral drug association 46.41–3  
breast 70.3, 70.4  
centrifugal 46.36  
congenital 46.34  
generalized 46.37  
cystic angiomatosis with 46.37  
drugs associated with 35.22  
generalized 46.34, 46.37–9  
acquired 46.37–9  
congenital 46.37  
HIV-associated 35.22, 46.41–3, 70.3, 70.4  
insulin 46.34, 46.35  
lipoedema vs 48.19  
metabolic abnormalities in 46.41, 46.42  
partial (progressive) 46.34, 46.36, 46.39–40, 62.70  
face-sparing 46.40–1  
familial (FPLD) 46.40–1  
treatment 35.22  
*see also* lipoatrophy
- lipodystrophy syndrome, HIV-associated 46.41–3, 70.3, 70.4
- lipoedema 48.19–20  
lipoedema–lymphoedema syndrome 48.19
- lipofibromatosis 56.12
- lipofuscins, in chromhidrosis 44.20–1
- lipogenesis 46.2, 46.3  
regulation in sebaceous glands 42.12  
sebaceous 42.5
- lipogranuloma  
idiopathic 71.50  
male genitalia 71.15, 71.50  
sclerosing 46.28, 46.29–30  
female genitalia 71.56  
foreign bodies 28.43–4  
idiopathic (eosinophilic) 46.29, 46.30  
*see also* paraffinoma
- lipogranulomatosis, disseminated 59.41
- lipohypertrophy, buffalo hump 46.42
- lipoid dermatoarthritis *see* multicentric reticulohistiocytosis
- lipoid proteinosis 59.41–2, 62.100  
abnormal fibroblasts 3.50
- lipolysis 46.2–3, 46.3, 46.3
- lipoma **46.43–9**  
aetiology and histopathology 46.44  
clinical features 46.44  
congenital 18.39  
diagnosis 46.44  
frontalis-associated 46.45  
in Gardner's syndrome 46.44  
genetics 15.26, 15.27  
granular cell (hibernoma) 46.45  
lumbosacral 18.39  
multiple 46.44, 46.46–7  
oral 69.113  
pleomorphic 56.57–8  
in spinal dysraphism 63.15, 63.16  
spindle cell 56.57–8  
tendon sheath 46.44  
treatment 46.44, 77.35  
variants 46.44
- lipomastia 70.3, 70.4
- lipomatosis **46.46–7**  
congenital 18.39–40  
congenital diffuse 46.47  
Dercum's disease 8.17, 46.46, 46.47–9, 48.20  
encephalocraniocutaneous 18.39, 46.46  
mediastinal 46.46  
mediastinoabdominal 46.46  
multiple symmetrical 46.46–7  
non-symmetrical 46.46  
pelvic 46.46  
physiological, racial form 46.46  
renal sinus and perirenal 46.46
- lipomatosis dolorosa (Dercum's disease) 8.17, 46.46, 46.47–9, 48.20
- Lipometer® 42.7
- lipomodulin 13.23–4
- lipomyelomeningocele 18.96
- Liponyssoides* 38.51
- lipophagic granuloma 46.13
- lipopolysaccharide(s)  
in atopic dermatitis 24.7  
receptor 13.5  
in vasculitis 50.5
- lipopolysaccharide-binding protein (LBP) 12.9
- lipoprostaglandin E<sub>1</sub>, livedoid vasculopathy 49.44
- lipoprotein lipase 46.7, 59.89  
enhanced activity, multiple symmetrical lipomatosis 46.46
- lipoproteins 46.2  
atherosclerosis and 59.83  
classification 59.82  
elevated levels *see*  
hyperlipoproteinaemias  
low-density (LDL)  
oxidised 49.41  
of standard lipid profile, Friedewald formula 59.84  
triglyceride rich (TRLs) 59.90
- liposarcoma 56.58  
well-differentiated 56.58
- liposomes 73.2  
T4 endonuclease V formulation 73.23  
unilamellar 4.2
- liposuction (lipectomy) 46.47  
in HIV lipodystrophy 46.43  
in lipoedema 48.20  
in lymphoedema 48.25
- lipoteichoic acid 30.7, 30.12
- β-lipotrophin 58.7
- lipoxins 12.61, 13.4
- 5-lipoxygenase (5-LO) 12.61  
inhibitor, acne vulgaris treatment 42.66
- lipsalves  
contact cheilitis due to 69.119  
possible allergens in 69.119
- Lipschütz-type ulcers, female genitalia 71.65–6
- Lipschütz ulcers  
CMV infection 33.29  
EBV infection and 33.31
- lipsticks 26.17  
contact cheilitis due to 69.119  
possible allergens in 69.119
- liquefaction degeneration 10.38, 10.39
- liquid nitrogen 33.49, 77.10, 77.39  
in acne vulgaris 42.68  
photocarcinogenesis control 29.7  
skin biopsy sample in epidermolysis bullosa 39.24  
*see also* cryotherapy
- Liquid Paraffin BP 73.6, 73.31
- liquiritin 73.28
- liquorice 73.28, 73.49, 75.160
- Lisch nodules **15.16**, 15.17, 58.18, 58.23, 62.23
- lisinopril 75.93
- Listeria monocytogenes* 30.35, 30.42
- listeriosis **30.42**  
neonatal 17.45, 30.42
- Listrophoridae 38.46
- Listrophorus gibbus* 38.46
- lithium 64.52  
adverse effects **75.80**  
acneiform eruption 42.73  
erythema multiforme 76.3, 76.4  
erythroderma 23.47  
lichenoid tissue reaction 41.25
- Lithraea* 26.75
- livedo 5.8, 5.10, **49.48**  
antiphospholipid syndrome 49.41  
'broken,' in cutaneous calciphylaxis 49.47, 49.48  
drug-induced 49.21
- livedo annularis *see* livedo reticularis
- livedo racemosa 49.48
- livedo reticularis 28.66, **28.67–8**, 49.48, 51.132, 58.20  
acquired, non-physiological 28.68, 49.49  
antiphospholipid syndrome 49.41  
cholesterol embolus and 49.36, 49.37  
in cryoglobulinaemia 49.33  
leg ulceration associated 47.55  
Sneddon's syndrome 49.42, 49.48  
summer ulceration with *see* livedoid vasculopathy
- livedo vasculitis *see* livedoid vasculopathy
- livedoid vasculopathy 47.34, 47.55, **49.44**  
leg ulceration associated 47.55
- liver  
disorders **62.58–65**  
acute yellow atrophy 27.11  
alcoholic liver disease, methotrexate contraindications 20.34, 74.21  
cirrhosis 62.60–2  
cutaneous features of chronic disease 62.61  
oral manifestations 69.115  
pruritus in 21.9–10  
schistosomiasis 37.22  
skin pigment changes in 62.63–4  
spider telangiectases 47.14, 47.15  
viral hepatitis, methotrexate contraindications 74.21  
drug metabolism 72.27, 72.28–9  
drug-related phenomena 62.62–3  
in echinococcosis 37.24  
metastases, carcinoid syndrome 43.17, 43.19  
in sarcoidosis 61.7–8  
systemic disease and 62.63  
in systemic sclerosis 51.101  
transplantation 47.18
- liver function tests, isotretinoin use and 42.64–5
- liver spots 8.23, 54.3, 58.39
- liverworts 26.77, 26.82
- lizard skin 37.5, 37.6
- lizards 2.4, 2.12  
epidermis, shedding 2.3  
pigment cells 2.6
- LKB1* gene 58.12, 58.13
- LL-37 3.16–17, 4.5, 43.2  
in eczema herpeticum 33.35  
*see also* cathelicidins
- LM *see* longitudinal melanonychia
- LMNA gene mutations 46.41
- LMS (limb–mammary syndrome) 15.46, **15.64**
- LMX1B* gene 15.86, 62.69
- Loa loa* 37.2, 37.3, 37.11–12, 37.16
- loath (endemic syphilis) 30.63
- lobomycosis **36.77–8**
- Lobo's disease **36.77–8**
- local anaesthesia **77.10–11**  
animals 2.9  
field block 77.10  
in laser therapy 78.6  
methods 77.10–11  
in nail biopsy/surgery 65.41–2  
nerve block 77.2–4, 77.10, 77.40  
in pregnancy 77.10  
principles 77.10  
ring block 65.42, 77.10  
in skin biopsy 10.2  
topical 77.10
- local anaesthetic agents  
adverse effects 26.17, **75.153–4**, 77.10  
artefacts in specimens due to 10.31  
in pruritus 21.17  
skin testing for reactions to 75.172–3  
surgical complications associated with 77.9  
types 77.10–11
- local lymph node assay 26.12
- locusts 38.28
- LOD (lichenified onychodermatitis) 37.4, 37.5, 37.6
- lod score 11.12

- l'œdème bleu 46.28  
 Löeffler's syndrome 37.14, 37.16  
 Loeys-Dietz syndrome 45.30  
 lofepramine 64.51  
 Lofgren's syndrome 61.7  
 logwood hair dye 66.97  
 loiasis 37.11–12, 38.6  
 lomustine 75.125  
 lone star tick 38.35  
 longitudinal melanonychia 58.55, 65.2,  
 65.14, 65.38–41  
 biopsy 65.40  
 in childhood 65.39  
 in HIV infection 65.16, 65.23  
 in lichen planus 65.29  
 race and 9.3  
 in SLE 58.27  
 loose anagen hair syndrome 66.72–3  
 loperamide, in carcinoid syndrome 43.19  
 lopinavir–ritonavir, adverse effect 35.22  
 loratadine 22.29  
 adverse effects 75.149  
 in urticaria 22.28  
 lorricrin 3.1, 3.10  
 lorricrin keratoderma 19.3, 19.19, 19.94,  
 19.98  
 lormetazepam 75.81  
 Lothian Atopic Dermatitis Study 6.5  
 lotions 73.2  
 thickened (gels) 73.2  
 Louis, Pierre Charles Alexander 7.1  
 Louis-Bar syndrome *see* ataxia  
 telangiectasia (AT; Louis-Bar  
 syndrome)  
 louse flies 38.6  
 lovastatin 75.156  
 love bites 28.24  
 Lovibond's angle/profile sign 65.7, 65.8  
 low-density lipoprotein (LDL)  
 oxidised 49.41  
 of standard lipid profile, Friedewald  
 formula 59.84  
 low-level laser therapy (LLLT) 78.15  
 lymphoedema management 48.23  
 low-molecular-weight heparin (LMWH)  
 in deep-vein thrombosis 47.29, 47.30  
 heparin-induced thrombocytopenia and  
 49.28  
 in superficial venous thrombosis 47.30  
 lower limb  
 bilateral whole-limb swelling 48.12  
 lymphangiectasia 48.28  
 lymphoedema 48.11–12, 48.20  
 oedema, rapid development 49.17  
 purpura 49.7, 49.17  
*see also* leg(s)  
 loxapine 75.82  
 LOXL1 gene 3.39  
 LOXL3 3.39  
*Loxosceles* 38.32  
 Loxoscelidae 38.31, 38.32  
 loxoscelism 38.31, 38.32  
 LPS *see* lipopolysaccharide(s)  
 LPS-binding protein (LBP) 12.9  
*Lucilia* 14.22, 38.8  
*Lucilia sericata*, larval therapy 28.22  
 Lucio reaction/phenomenon 32.13, 49.35  
 lues maligna 34.11, 34.14  
 lumbar sympathectomy, in systemic  
 sclerosis 51.108  
 lumbosacral dimples 63.15  
 lumican 45.33  
 lumpy scalp syndrome 18.104, 68.5  
 Lund and Bowder charts 28.77, 28.79  
 lungs  
 Erdheim–Chester disease 55.18  
 Langerhans' cell histiocytosis (LCH)  
 55.7, 55.11  
 in SLE 51.43, 62.82  
 in systemic sclerosis 51.98  
*see also* entries beginning pulmonary,  
 respiratory  
 lunula 3.14, 65.1  
 in nail–patella syndrome 65.19  
 red 65.17, 65.36  
 lupoid grains 61.10  
 lupoid sycosis 30.25  
 lupus anticoagulant 49.39, 49.40  
 lupus anticoagulant syndrome 49.40–2,  
 51.52, 51.63  
 clinical features 51.63  
 lupus band test 10.18  
 lupus erythematosus (LE) 51.1–62  
 aetiology, sunlight 12.12  
 in animals 2.16  
 antimalarials in 74.25  
 assessment 72.10  
 cell factor, deoxyribonucleoprotein  
 51.52  
 cell phenomenon 51.52  
 cell test 51.52  
 cold-induced injury 28.65  
 cutaneous 74.19  
 cutaneous atrophy 45.6  
 differential diagnosis 29.12, 61.10  
 discoid *see* discoid lupus erythematosus  
 (DLE)  
 drug-induced 29.21  
 drug-induced syndrome resembling  
 75.20, 75.41–2  
 ear involvement 68.14–15, 68.17  
 erythema multiforme-like syndrome  
 and 51.14  
 exfoliative cutaneous, in dogs 2.16  
 gyratus repens 51.11  
 hypomelanosis in 58.52  
 idiopathic thrombocytopenic purpura  
 and 49.9  
 immunopathology 10.18  
 keratoderma produced by 19.117,  
 19.118  
 leg ulceration and 47.55  
 localization to tattoos 58.58  
 matrix metalloproteinases (MMPs) and  
 12.52  
 methotrexate in 74.19  
 neonatal 17.16–18, 51.49–51, 62.78,  
 62.109  
 telangiectases in 47.14  
 neutrophilic dermatoses and 50.63  
 pigmentation changes 58.27  
 post-inflammatory hypermelanosis  
 after 58.31  
 subacute cutaneous 51.22–7  
 subcutaneous nodules 51.14–15  
 systemic *see* systemic lupus  
 erythematosus (SLE)  
 treatment  
 antimalarials 74.25  
 methotrexate 74.19  
 lupus erythematosus gyratus repens  
 62.39  
 lupus erythematosus profundus 46.25–7,  
 51.14–16  
 associated features 51.16  
 breast involvement 46.25–6, 70.12  
 clinical features 51.15  
 histopathology 51.15  
 hypertrophicus et profundus 51.14–15  
 telangiectases 51.16  
 treatment 51.15–16  
 lupus-like reaction, minocycline-induced  
 42.51  
 lupus mastitis 46.25–6, 70.12  
 lupus miliaris disseminatus faciei *see* acne  
 agminata  
 lupus nephritis 51.35  
 lupus panniculitis *see* lupus  
 erythematosus profundus  
 lupus pernio 61.1, 61.7, 61.9–10, 61.11  
 rosacea vs 43.5  
 treatment 61.21  
 lupus vulgaris 31.10, 31.16–19  
 clinical features 31.16–17  
 complications 31.17–18, 31.19  
 cutaneous atrophy 45.6  
 definition 31.16  
 diagnosis 31.18–19  
 differential diagnosis 61.5, 61.13  
 ear involvement 68.17, 68.20  
 following BCG vaccination 31.29  
 histopathology 31.9–10, 31.16  
 incidence 31.16  
 miliary 31.17  
 papular and nodular forms 31.17  
 pathogenesis 31.16  
 plaque form 31.16, 31.17  
 prognosis 31.17–18  
 treatment 31.19, 31.28  
 tumour-like forms 31.17, 31.18  
 ulcerative and mutilating forms 31.16,  
 31.18  
 vegetating form 31.16–17, 31.18  
 luteinizing hormone (LH) 8.4  
 in adolescence 8.4  
 LH:FSH ratio, acne aetiology and 42.22  
 menopausal flushing and 8.20  
 in menstrual cycle 8.8  
 in polycystic ovary syndrome 66.82  
 lutidine test 27.8  
*Lutzomyia* 37.33, 38.5  
*Lycopodium serratum* 75.160  
*Lycosa* 38.30  
 Lycosidae 38.32  
*Lyctocoris campestris* 38.25  
 Lyell's syndrome *see* toxic epidermal  
 necrolysis (TEN)  
 Lyme disease 30.64–6, 69.118  
 arthralgia in 62.105  
 erythema migrans 62.106–7  
 late-phase 30.65, 45.9–11, 45.18  
 ocular involvement 67.27  
 race and 9.18  
 syphilis serological cross-reactivity  
 34.21  
 vectors 38.35  
 lymecycline  
 in acne vulgaris 42.46, 42.47, 42.48  
 in rosacea 43.6  
 lymph 13.8–9  
 drainage 48.3  
 drainage failure 48.7, 48.8  
 causes 48.8  
 flow 48.6  
 increased load (capillary filtration)  
 48.7, 48.13  
 stasis 48.15  
 thrombosis 48.29  
 transport 48.5–6  
 lymph blisters 48.26, 48.28  
 lymph node-to-venous shunts 48.25  
 lymph nodes  
 fine-needle aspiration 5.21  
 head and neck 69.4, 77.2, 77.3  
 involvement in squamous cell  
 carcinoma 79.10–11  
 lymph drainage to 48.5  
 in melanoma *see* under melanoma,  
 malignant  
 radiotherapy, lymphoedema after  
 48.13  
 structure and function 13.8–9  
 lymph sacs, primitive 48.1  
 lymphadenectomy, melanoma 54.53  
 lymphadenitis  
 histiocytic necrotizing 33.77  
 in HIV infection 35.24–5  
 inguinal, chancroid 34.34  
 Kikuchi's histiocytic necrotizing, EBV  
 infection and 33.31  
 lower limb 48.29  
 tuberculous 35.25, 35.45  
 lymphadenoma, cutaneous 53.11  
 lymphadenopathy  
 in cat scratch disease 30.57  
 generalized, secondary syphilis 34.11  
 in Gianotti–Crosti-like syndrome 33.77  
 in granuloma inguinale (donovanosis)  
 34.36  
 in lymphogranuloma venereum 34.33  
 in rubella 33.70  
 in sarcoidosis 61.1, 61.7, 61.9, 61.13  
 sinus histiocytosis with massive  
 lymphadenopathy (SHML) 55.29  
 in SLE 51.48  
 lymphadenosis benigna cutis (of  
 Bafverstedt) 30.65, 57.59  
 lymphangiectasia 48.15, 48.25  
 cutaneous 48.28–9  
 genital 48.28  
 intestinal 48.27–8  
 vulval 71.81  
 lymphangioblasts 48.1, 48.2  
 lymphangioendothelioma, benign  
 (acquired progressive  
 lymphangioma) 48.30, 56.41  
 lymphangiogenesis 48.2  
 post-natal 48.2  
 lymphangiography 48.9, 48.19  
 magnetic resonance 48.19  
 lymphangioma 48.25, 48.25–7  
 acquired (cutaneous lymphangiectasia)  
 48.28–9  
 acquired progressive (benign  
 lymphangioendothelioma) 48.30,  
 56.41  
 cavernous 48.27  
 female genitalia 71.72  
 genitocrural 71.7–8  
 macrocystic 48.27  
 oral cavity 69.34  
 pinna 68.28  
 progressive 48.30, 56.41  
 secondary 48.28  
 term usage 48.25  
 lymphangioma circumscriptum 48.26  
 lymphangiomatosis, diffuse 48.27  
 lymphangiomyomatosis 48.30  
 lymphangions 48.4  
 lymphangiopericytoma 48.30  
 lymphangiosarcoma 48.15, 48.31  
*see also* angiosarcoma  
 lymphangiothrombosis 48.29  
 lymphangitis 5.12, 48.29  
 in lymphatic filariasis 37.9  
 milker's nodule 33.10  
 obliterative 48.8  
 in orf 33.9  
 recurrent 48.29  
 sclerosing 71.14  
 lymphatic capillaries 48.3–4  
 increased filtration 48.7, 48.13, 48.21  
 lymphatic cisterns 48.26  
 lymphatic endothelial cells (LECs) 48.2  
 lymphatic hyperplasia, dermal 48.2  
 lymphatic leukaemia 57.62  
 pigmentation changes 58.26  
 lymphatic malformations (LMs) 18.75–6,  
 48.25–7  
 cervicofacial 48.27  
 classification 48.26  
 localized congenital 48.25–6  
 macrocystic 48.26–7  
 microcystic 48.26  
 truncal 48.27  
*see also* lymphangioma  
 lymphatic network 3.52  
 lymphatic system 48.1  
 acquired abnormalities 48.29–30  
 anatomy 48.3  
 biomarkers 48.4–5, 48.19  
 congenital abnormalities 48.25–7  
*see also* lymphatic malformations  
 (LMs)  
 development 48.1–2  
 failure 48.25  
 disorders 48.1–31  
*see also* specific disorders  
 eyelids 67.2  
 function 48.5–6  
 lymphatic tumours 48.30–1, 56.41–2  
 lymphatic vessel(s)  
 acquired abnormalities 48.29–30  
 anatomy 48.3  
 aplasia 48.9  
 biomarkers 48.4–5, 48.19  
 blood vessels differentiation 48.4, 48.19  
 contractile collectors 48.3, 48.4, 48.6  
 malformations in 48.26  
 progressive distal failure 48.12

- decongestive therapy 48.21–4  
dendritic cell migration 48.6  
dermal backflow 48.3, 48.19  
development 48.1–2  
  failure 48.25  
  post-natal 48.2  
die-back phenomenon 48.12  
dilatation *see* lymphangiectasia  
disorders **48.1–31**  
  *see also specific disorders*  
distal hypoplasia 48.11  
dysfunctional, lymphoedema due to 48.14  
  failure, oedema 48.7, 48.8  
  function 48.5–6  
  hypoplasia and hyperplasia 48.9  
  immune function 48.6, 48.29  
  initial (non-contractile, terminal) 48.3–4  
  function and lymph transport 48.5–6  
  imaging 48.19  
  insufficiency 48.7–8, 48.29  
  manual drainage therapy 48.23  
  obliteration 48.8, 48.29  
  obstruction 48.8, 48.11, 48.28  
  pressure 48.6  
  recurrent acute inflammatory episodes 48.29  
  reduced number 48.8  
  reflux in 48.8  
  remodelling 48.2  
  separation from blood vessels 48.2  
  structure 48.3–5  
  thrombosis 48.29  
  transplantation 48.25  
  transport in 48.5–6  
  valves 48.3, 48.4  
lymphatic vessel endothelial hyaluronan receptor *see* LYVE-1  
lymphatic vessel-to-venous shunts 48.25  
lymphaticovenous anastomosis 48.25  
lymphocoele 48.29–30  
lymphocyst 48.29–30  
lymphocyte(s) 12.14, 12.17–30  
  activation, suppression by tacrolimus/pimecrolimus 73.31  
  infiltrates 57.60  
  band-like, in lichen planus 41.4, 41.5  
  infiltration  
  differential diagnosis 51.7  
  in familial haemophagocytic lymphohistiocytosis 55.25  
  in syphilis 34.5  
  nuclear dust, karyorrhexis and 46.26  
  proliferation, in cytophagic histiocytic panniculitis 46.23–4  
  subpopulation measurements 13.22–3  
  toxicity assay 75.174  
  transformation tests 26.98, 75.174  
  *see also* B lymphocytes; T lymphocytes  
lymphocyte function antigens, LFA-1 13.9  
lymphocytic lymphoma, differential diagnosis 51.7  
lymphocytoma  
  borreliol 62.106  
  solitary, in Lyme disease 30.65  
lymphocytoma cutis 57.59  
  differential diagnosis 51.7, 61.13  
  ear 68.15  
lymphoedema 3.52, 46.7, **48.7–48.19**  
  angiosarcoma and 56.38  
  assessment before treatment 48.21  
  breast 48.8, 48.17, 48.20  
  management 48.23  
  breast cancer-related 48.8, 48.17, 48.20  
  cellulitis and 48.12, 48.15, 48.17  
  management 48.24  
  classification and causes 48.9  
  clinical diagnosis/features 48.14–15  
  complications 48.15  
  congenital 48.9  
  eyelid 48.16  
  Crohn's disease and 48.13, 48.16  
  definition 48.7  
  dysfunctional lymphatics causing 48.14  
  ear 48.12, 48.16  
  epidemiology 48.7–8  
  eyelids 77.2  
  congenital 48.16  
  facial 48.12, 48.13, 48.16  
  management 48.23  
  familial, after puberty 48.10  
  filarial 48.12, 48.24  
  genetic forms 48.10–11  
  genital 30.70, 48.12, 48.16  
  management 48.23  
  germline forms 48.10  
  in granulomatous diseases 48.13, 48.23  
  head and neck 48.12, 48.13, **48.16**  
  management 48.23  
  hereditary type I 48.8, 48.9–10  
  hereditary type II 48.10  
  in herpes simplex 33.18  
  infection prevention 48.22, 48.24  
  infection treatment 48.24  
  infections after 48.15  
  infections causing 48.12  
  inflammation with 48.12–13  
  inherited forms 48.9–10  
  investigations 48.17–19  
  in Kaposi's sarcoma 48.14, 48.30–1  
  Klippel-Trenaunay syndrome and 48.10, 48.12, 48.21  
  localized 48.17  
  lower limb 48.11–12, 48.20  
  malignancy as complication 48.15  
  malignancy associated 48.8, 48.14, 48.30  
  management 43.6–7, **48.21–5**  
  best practice 48.21  
  drug therapy 48.24–5  
  efficacy evidence 48.23  
  of infections 48.24  
  intensive and maintenance 48.23  
  physical therapy 48.21–4  
  surgery 48.25  
  weight loss and oxygen 48.23  
  massive localized 48.17  
  mechanical injury and 28.1–2, 28.8, 28.31  
  melanoma and 48.8  
  midline 48.16  
  management 48.23–4  
  in Noonan's syndrome 15.14  
  obesity and 48.20–1  
  palmoplantar keratodermas and 19.118  
  pathology 48.8  
  pathophysiology 48.8–9  
  pelvic malignancy 48.8  
  penile 71.28, 71.49–50  
  periorbital oedema 67.5  
  pitting absence 48.14  
  in pregnancy 8.17  
  primary 48.7, **48.9–12**  
  causes 48.9  
  congenital 48.8, 48.9–10  
  genetic/inherited forms 48.9–11  
  phenotypes 48.11–12  
  proximal obstructive 48.11, 48.15  
  referrals 48.21  
  in rosacea 43.4, 43.6–7, 48.13, 48.16  
  sarcoidosis and 48.13, 48.23  
  scar 48.17  
  secondary 47.35, 48.7, **48.12–14**  
  soft stage and hard late-stage 48.8  
  trauma-induced 48.12, 48.13  
  truncal 48.15  
  management 48.23  
  upper limb 48.12, 48.13  
  venous disease association 48.12, 48.13  
  venous leg ulcers and 47.45  
  vulval 48.16, 71.81  
lymphoedema praecox 48.7, 48.9, 48.10  
lymphoedema tarda 48.7, 48.8, 48.9  
lymphoedema–distichiasis syndrome (LDS) 48.8, 48.9, 48.10, 62.77  
lymphoepithelioma, nasopharynx 53.41–2  
lymphoepithelioma-like carcinoma 53.41–2  
lymphogranuloma venereum (inguinale) **30.70–1, 34.32–4**, 48.12, 71.71–2, 71.93  
  clinical features 34.32–3  
  syphilis vs 34.7  
lymphography  
  indirect 48.19  
  isotope 48.17  
  X-ray contrast 48.17  
lymphohistiocytosis  
  autoimmune disease-associated reactive haemophagocytic 49.6  
  familial haemophagocytic (FHL) 55.25–6  
  lymphoid markers 10.25–6  
lymphoid tissue  
  primary 13.7–8  
  secondary 13.8–9  
lymphoma(s) **57.1–64**, 62.89–90  
  adult T-cell leukaemia/lymphoma *see* adult T-cell leukaemia–lymphoma (ATLL)  
  angiocentric, EBV-positive 57.40–1  
  angiotropic (intravascular) 33.65, 46.23, 50.46–7  
  B-cell *see* B-cell lymphomas  
  Burkitt's 33.30  
  CD30-positive large cell 33.65  
  cutaneous **57.1–64**  
  cutaneous B-cell 62.89  
  cutaneous T-cell (CTCL) 62.89  
  chronic actinic dermatitis vs 29.18  
  diffuse plane xanthomatosis in 55.22  
   $\gamma/\delta$  group (CGD-TCL) 46.23  
  in HIV infection 35.41  
  in hyperparathyroidism 62.12  
  hypopigmentation 58.52  
  ichthyotic variant 62.90  
  pigmented purpuric dermatoses and 49.23  
  radiotherapy 79.13  
  topical mechlorethamine treatment 73.23–4  
  treatment 73.36  
  dermatitis herpetiformis and 40.61  
  ear 68.18, 68.34  
  EBV association 33.30–1  
  erythroderma and 23.48  
  formation, chronic actinic dermatitis and 29.17  
  genital involvement  
  in females 71.79  
  in male 71.48  
  HIV infection and 35.41  
  hydroa-like 46.32–3  
  Ki-1 positive 55.32  
  large cell, EBV association 33.30–1  
  large cell anaplastic 57.31–3  
  malignant histiocytosis vs 55.32  
  Lennert's lymphoma 57.64  
  mucosa-associated lymphoid tissue (MALT) 57.2, 57.43  
  NK-cell  
  blastic 57.39  
  EBV association 33.31  
  oral 69.57–8, 69.116  
  perianal/perineal 71.99  
  pigmentation changes 58.26  
  plasmablastic 35.41  
  primary cutaneous  
  (anaplastic) CD30+ large cell lymphoma 57.31–3  
  hepatoerythropoietic porphyria 59.13–15  
  WHO–EORTC classification **57.2**  
  pseudolymphomas, ADRs 57.53–4  
  radiotherapy and non-melanoma skin cancer due to 52.5  
  sarcoidal reaction in 61.23  
  sarcoidosis and 61.17, 62.40  
  subcutaneous panniculitis-like T-cell (SPTL) *see under* T-cell lymphomas  
  sweating in 44.7  
  T-cell *see* T-cell lymphomas  
  true histiocytic 55.31, **55.33–4**  
  zoster complication 33.23, 33.25  
  *see also* B-cell lymphomas; non-Hodgkin's lymphoma; T-cell lymphomas  
lymphomatoid granulomatosis *see* polymorphic reticulosis  
lymphomatoid papulosis 57.29–30  
lymphopenia, HIV infection 35.10  
lymphophagocytosis, in sinus histiocytosis with massive lymphadenopathy 55.29  
lymphoproliferative disorders  
  cryoglobulinemia and 49.32  
  EBV association 33.30–1  
  primary cutaneous CD30+ 57.29–34  
  lymphomatoid papulosis 57.29–30  
  *see also specific lymphoproliferative disorders*  
lymphorrhoea 48.15, 48.26  
lymphosarcoma, pigmentation changes 58.26  
lymphoscintigraphy 5.22, 48.17  
  melanoma 54.51, 54.52  
  normal 48.18  
lymphostatic vasculopathy 48.8  
lymphovasculogenesis 48.2  
  failure/impairment 48.8  
lynx spiders 38.32  
lyonization 15.6  
lysine, in tropoelastin 3.43  
lysine residues  
  collagen 3.37, 3.38  
  elastin 3.43, 3.44  
lysosomal storage disorders **59.30–41**  
  angiokeratoma-associated 59.35  
  lysosomal trafficking regulator, gene mutation, in Chédiak–Higashi syndrome 58.41  
lysosomes  
  mediators of inflammation 12.53  
  sebaceous cell 42.3  
lysozyme 10.24, 13.1, 13.4, 30.4  
  in sarcoidosis 61.20  
lysyl hydroxylase 45.35  
lysyl oxidase (LOX) 3.39, 3.44, 45.35, 45.39  
lysyl oxidase-like genes/proteins 3.39  
*Lytta vesicatoria* 38.26  
LYVE-1 10.24, 48.19  
  lymphatic vessel marker 48.4, 48.5  
**M**  
M cells 13.9  
M-plasty 77.16  
M proteins 30.12, 30.13  
Maastricht model 47.27  
Mac387 10.24  
  antibodies 55.19  
macassar 26.80  
Machado–Guerreiro's test 37.32  
*Machaerium scleroxylon* 26.81  
machine tool operators/setters, risk of occupational dermatoses 27.2  
Machupo virus 33.67, 33.69  
macrocephaly, with cutis marmorata telangiectatica congenita 18.68  
macrocheilia 69.126  
macroclimate 6.12  
macrocomedones 42.22, 42.30, 42.57  
  isotretinoin flare and 42.63  
  removal 42.63, 42.67  
  treatment failure 42.56–7  
macroconidia 36.3, 36.4, 36.18, 36.41  
macrogingivae, congenital 66.76  
 $\alpha_2$ -macroglobulin 13.4  
  venous microcirculatory disorders 47.27  
macroglossia 62.2, 69.113, 69.114  
macrogols *see* polyethylene glycols  
macrolide antibiotics 74.42  
  acne vulgaris treatment 42.46–7  
macromastia 70.3  
macromelanosomes 58.23

- macronychia 65.9  
 macrophage(s) 12.4, 12.26–30, 13.9, 17.48  
   arterial disease pathogenesis 47.1  
   CD11b, UVR effects 29.5  
   cytokines released 46.4  
   dermal 3.19  
   in embryonic dermis 3.3  
   foamy 46.11  
   in granuloma inguinale 34.37  
   immature 55.4  
   intraepidermal *see* Langerhans' cells  
   in leprosy 32.7  
   malignancies involving 55.31–4  
   melanin in, incontinentia pigmenti 58.15  
   microscopy 10.34  
   phagocytosis 55.4  
     failure 55.27  
     receptors 55.4  
   in relapsing febrile nodular panniculitis 46.13  
   in subcutaneous fat 46.4, 46.6, 46.11  
   surface markers 55.29  
   tissue 55.2  
     phagocytic function 55.4  
     *see also* histiocytes  
   in visceral adipose tissue, in obesity 46.4  
   in wound healing 14.3  
   *see also* monocyte(s); monocyte–macrophage system  
 macrophage activation syndrome 49.6  
 macrophage inflammatory protein(s), in vasculitis 50.10  
 macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ) 12.16, 12.18, 12.25, 12.39, 12.45, 12.46, 13.4  
 macrophage inflammatory protein-1 $\beta$  (MIP-1 $\beta$ ) 12.46  
 macrophage migration inhibition assay 75.174  
   lichenoid eruptions due to drugs 41.23  
 macrophage migration inhibitory factor (MIF) 12.27  
 macrophage–monocytes *see* monocyte–macrophage system  
*Macrothefe* 38.31  
 macrotia 68.4  
 maculae caeruleae 38.22–3, 49.17  
 macular amyloidosis 9.17, 58.28, 59.46  
 macules  
   amelanotic, vitiligo 58.47–8  
   ash-leaf 15.22  
   blue, in argyria 58.54  
   definition 5.7  
   differential diagnosis 32.15  
   erythema dyschromicum perstans 58.33  
   erythematous, herpes zoster 67.26  
   freckles 58.10  
   genetics 15.16–18, 15.22  
   hypomelanotic 58.52  
   vitiligo 58.47  
   inflammatory, in acne 42.32  
   labial melanotic 54.2  
   Laugier–Hunziker syndrome 58.14  
   lentigo 54.3  
   in leprosy 32.9  
   melanotic *see* melanotic macules  
   Peutz–Jeghers syndrome 58.12  
   simple haemorrhage/purpura 49.2, 49.3, 49.4  
   tuberous sclerosis 58.44  
 maculopapular rash 5.7, 33.4  
 madarosis 32.11, 62.10, 67.4, 67.4  
 MAdCAM 13.9  
 Madelung's neck 46.46  
 Madura foot *see* mycetoma  
*Madurella grisea* 36.73  
*Madurella mycetomatis* 36.72, 36.73, 36.74  
 maduromycosis *see* mycetoma  
 madurosis 67.8  
 Maffucci's syndrome 18.72, 65.34  
   bone and joint involvement 62.100  
   lymphoedema 48.11, 48.31  
   oral involvement 69.13, 69.29, 69.30  
 magenta paint 36.48, 36.49  
   topical therapy 73.48  
 maggot therapy, venous leg ulcers 47.48  
 maggots 14.22, 38.8  
 MAGIC syndrome 45.44, 69.47  
 magnetic resonance angiography (MRA), peripheral arterial disease 47.4  
 magnetic resonance imaging (MRI) 5.22  
   foreign bodies 28.42  
   muscle hernias 28.62  
   sarcoidosis 61.7  
   Sturge–Weber syndrome 18.66  
   venous malformations 18.71  
 magnetic resonance lymphangiography (MRL) 48.19  
*Magnolia officinalis* 75.160  
*main succulente* 63.14  
 maintenance, of skin 3.5–7  
 Majocchi's disease (purpura annularis telangiectodes) 49.22, 49.25  
 Majocchi's granuloma, in HIV infection 35.32  
 major basic protein 13.5, 67.15  
   in urticaria 22.3  
 major complement components, deficiencies 51.54  
 major histocompatibility complex (MHC) 13.14  
   class I molecules 4.8, 13.10  
   deficiency 17.61  
   hair cycle and 66.11  
   class II molecules 4.8, 13.9–10  
   deficiency 17.60–1  
   expressed by phagocytes 55.4  
   dysfunction or genetic alteration of  
     MHC alleles 12.13–14  
   genetics 15.8–9  
   inflammation and 12.13  
   MHC class I chain-related gene B (MICB) 12.14  
   peptide-binding capacity 12.13  
 Mal de Meleda 19.3, 19.94, 19.100–1  
 mal de pinto (pinta) 30.63–4  
 mal morado 37.7  
 malabsorption 59.58–9, 69.116  
   bacterial overgrowth 51.100  
   causes 59.58  
   in children with HIV infection 35.45  
   eczema and 23.27  
   hair loss and 66.29  
   pigmentation changes 58.28  
   systemic sclerosis 51.99  
   vitamin B12 deficiency, systemic sclerosis 51.102  
 malaise, systemic, in photosensitivity disorders 29.23  
 malakoplakia 55.27  
   HIV infection 35.36  
   vulval 71.70  
 malaria 37.27, 38.2, 38.5, 44.7  
   pigmentation in black people and 58.9  
*Malassezia*  
   aberrant reaction to, HIV infection 35.15  
   antibody response to 36.11  
   atopic dermatitis and 24.11, 36.13  
   in confluent and reticulate papillomatosis 36.13–14  
   dermatitis in animals due to 2.14  
   folliculitis 23.34, 36.13  
   acne vs 42.37  
   genetics 15.10  
   identification 36.9  
   in invasive otitis externa 68.25  
   male genital infection 71.18, 71.33  
   in neonatal pustulosis 17.47–8  
   in normal skin flora 30.2, 36.10, 36.13  
   in pityriasis capitis 66.56  
   pityriasis versicolor and 36.10, 36.11, 36.12  
   seborrhoeic dermatitis and 17.29, 23.29, 23.30, 36.13, 66.56  
*Malassezia furfur* 42.24  
   acne aetiology and 42.24  
   folliculitis 42.37  
*Malassezia globosa* 42.75  
*Malassezia pachydermatitis*, in dogs 2.14  
*Malassezia sympodialis* 33.35, 42.75  
 malathion 73.14  
   in clothing/body louse infection 38.22  
   in head louse infection 38.19  
   resistance 38.20  
   in scabies 38.41  
 Malayan krait 38.60  
 male(s)  
   acne vulgaris 42.17–18  
   sexual development 8.2, 8.4  
   spermatogenesis 8.4  
 male angioyofibroblastoma-like tumour 76.8  
 male genital dermatology 71.8–52  
   circumcision 71.13, 71.20, 71.24, 71.39  
   congenital and developmental abnormalities 71.13–14  
   drug reactions 71.27–8  
   foreskin 71.9, 71.12–13  
   general approaches 71.1–4, 71.8–10  
   inflammatory dermatoses 71.16–29  
   lichen planus 41.9  
   malignant neoplasms 71.46–9  
   miscellaneous conditions 71.49–52  
   non-sexually transmitted infections 71.29–33  
   normal genital variants 71.11–12  
   pain and swelling 71.49–50, 71.51–2  
   pre-malignant dermatoses and carcinoma *in situ* 71.37–9  
   sexually transmitted diseases 71.33–5  
   squamous cell carcinoma 71.22, 71.39–46  
   structure and function of male genitalia 71.10–11  
   trauma and artefact 28.24, 28.39, 71.14–16  
   tumours 71.35–7  
   *see also* individual conditions  
 maleopimaric acid 26.79, 26.82  
 malformation sequence 18.1  
 malformation syndromes 18.1  
   aplasia cutis congenita in 18.102–6  
 malformations 18.1, 47.21–5  
   arteriovenous *see* arteriovenous malformations (AVMs)  
   capillary 47.23, 47.25  
   venous *see* venous malformations  
 Malherbe, benign calcifying epithelioma of 53.12–13  
 Mali, prevalence of skin disease 6.10  
 malignant atrophic papulosis *see* Degos' disease  
 malignant disease 52.1  
   acanthosis nigricans 19.120  
   in amputees 28.29  
   benign tumours vs 52.2  
   burns and 28.90–1  
   development *see* carcinogenesis  
   direct spread to skin 62.15–17  
   ear 68.30–4  
   female genital region 71.76–9  
   following chemotherapy 75.124  
   genetics 11.17–19  
   genodermatoses associated 62.19–29  
   granuloma annulare and 60.9  
   haematological 62.88–90  
   hyperpigmentation 58.25  
   ichthyoses 19.39, 19.55, 19.56, 19.61, 19.63  
   immune system and 13.15  
   immunopathology 10.19  
   internal  
     acquired acanthosis nigricans 58.25  
     Bowen's disease and 52.33  
     cutaneous markers 62.14–29  
     Muir–Torre syndrome 52.10, 53.15  
     multicentric reticulohistiocytosis 55.24  
     thrombophlebitis migrans and 47.30, 47.31  
   investigation 62.14  
   lymphoedema associated 48.8, 48.14  
   as lymphoedema complication 48.15  
   male genital region 71.46–9  
   mechanical injury 28.62–3  
   metastatic 52.1, 62.17–19  
     female genital involvement 71.79  
     immunopathology 10.24  
     male genital involvement 71.48  
     nail involvement 65.34  
     oral cavity 69.55–6  
     radiotherapy 79.13  
     telangiectatic 62.16  
     tumour-to-tumour 62.18  
     umbilical dermatology 71.101  
   neoplastic vaginal discharge 71.54  
   oral cavity 69.13, 69.22, 69.42, 69.49–456, 69.98–9  
     metastatic 69.55–6  
   palmoplantar keratodermas 19.106, 19.116–17  
   pigmented purpuric dermatoses and 49.23  
   pruritus and 21.11  
   radiotherapy and non-melanoma skin cancer due to 52.5  
   reduced by sunscreens 73.41  
   sarcoidosis and 61.17  
   scleroderma-like lesions and bFGF 51.79  
   sweating associated 44.7  
   Sweet's syndrome and 50.74, 50.75  
   TNM staging 69.51  
   transplacental transfer 17.19  
   tuberculosis and 31.18, 31.19, 31.21  
   umbilical dermatology 71.101  
   wound healing and 14.18  
   xeroderma pigmentosum and 15.72  
   *see also* carcinoma; tumour(s); specific tumours  
 malignant down 66.78  
 malignant melanoma *see* melanoma, malignant  
 malignant neoplasms *see* malignant disease  
 malignant peripheral nerve sheath tumours (MPNST) 15.18  
 malingering 64.43  
 'Mallorca' acne 42.79  
 malnutrition  
   child abuse 28.38–9  
   in children with HIV infection 35.45  
   dermatophytosis and 36.22  
   hair colour change in 66.94  
   hair loss in 66.29  
   hypertrichosis in 66.78  
   pityriasis versicolor and 36.10  
   pressure ulcers 28.18, 28.21–3  
   purpura in 49.18  
   wound healing and 14.18  
 malondialdehyde, increased levels, rosacea 43.2  
 Malpighian layer 3.8  
   ballooning of cells, VZV infection 33.23–4  
 MALT (mucosa-associated lymphoid tissue) 57.2  
 MALT lymphomas 57.2, 57.43  
 maltase deficiency 44.18  
 Malvaceae 26.81  
 mammalian target of rapamycin (mTOR) 74.5  
 mammals  
   glands 2.4  
   hair 66.1  
   pigment cells 2.6  
   mutations affecting 2.6–7  
   skin 2.3  
   *see also* animal(s); specific mammals  
 mammary glands 44.18, 70.1  
   ectopic, anogenital 53.37  
   *see also* breast  
 mammary-like glands, anogenital 53.37  
   tumours 53.37–8  
 mammary ridges 70.1  
 mammo-renal syndromes 70.2  
 mammoplasty, reduction 70.3

- mandible 69.2  
examination 69.5
- mandibulofacial dysostosis 18.80–1, 68.4
- manganese  
in Hailey–Hailey disease 39.33  
in tattoo pigments, allergic reactions 58.58
- mange  
demodectic 2.10  
dogs 2.10  
'head' (feline) 2.10  
sarcoptic 2.10  
sheep and cattle 2.10–11
- mango 26.75
- mangrove fly 37.11
- mannan-/mannose-binding lectin/  
protein 13.2, 13.3, 17.48  
deficiency 13.4  
measurement 13.18
- mannans 36.1, 36.58
- mannose receptor, and other C-type  
lectins 12.10
- mannosidoses 59.34
- Mansonella ozzardi* 37.8
- Mansonella perstans* 37.8
- Mansonella streptocerca* 37.8
- Mansonia altissima* 26.81
- Mantoux test 31.6
- manual lymphatic drainage therapy  
(MLD), in lymphoedema 48.23
- Manuka honey 73.48
- manzanillo tree 25.21
- MAP kinase pathway 3.16–17  
stem cell signalling 3.6
- maprotiline 75.79
- marasmus 59.67  
hair loss in 66.29
- marbling, neonatal 17.4
- Marburg disease/virus 33.67, 33.69–70  
diagnosis 33.5
- Marcanin *see* bupivacaine
- Marfan's syndrome 45.30–1  
aetiology 45.30  
bone and joint involvement 62.100  
clinical features 45.30  
definition 45.30  
diagnosis 45.30–1  
*FBN1* gene 3.45  
management 45.31  
mechanical injury 28.2  
pathology 45.30  
pregnancy and 45.31
- Margarita Island ectodermal dysplasia 15.46
- marginal papular acrokeratoderma 9.10
- marginal papular keratoderms 19.95, 19.114–15
- marginal zone lymphoma, primary B-cell 57.43–5
- marine worms, cuticle and epidermis 2.2
- Marjolin's ulcer 28.20, 28.91
- marking nut tree 26.75
- Marshall's syndrome 15.46, 46.20
- MART-1 *see* Melan-A
- martin bug 38.24
- mask of pregnancy *see* melasma
- masons, occupational hazards 27.20
- mass populations reactions 64.25–6
- massage, in lymphoedema 48.23
- masseter muscles, examination 69.4
- Masson's ammoniacal silver nitrate stain 10.8–9
- Masson's naevic corpuscles 54.19
- Masson's pseudoangiosarcoma  
(intravascular papillary  
endothelial hyperplasia) 56.23–4,  
69.102
- Masson's trichrome stain 10.9
- Masson's vegetant intravascular  
haemangioendothelioma  
(intravascular papillary  
endothelial hyperplasia) 56.23–4,  
69.102
- mast cell(s) 3.19–20, 12.24–6, 13.5  
activation 3.20, 22.4  
IgE-mediated 3.20  
in atopic dermatitis 3.20  
in atopic eye disease 67.15  
cathelicidins 12.7  
connective tissue type 3.19  
cytoplasmic granules 3.19  
degranulating triggers 22.35  
dermal 3.19  
in embryonic dermis 3.3, 3.19  
functions 3.20  
increased in ageing skin 8.22  
in infantile haemangioma 18.42  
inflammatory mediator release 3.20  
sodium cromoglycate action 73.51  
in mastocytosis 22.30, 22.34  
microscopy 10.35  
mucosal type 3.19  
nerve interactions 3.20  
neutral protease content 12.24  
origin and development 3.19  
products released 3.20  
pruritus and 21.4, 21.8  
receptors 12.25  
in rosacea 43.4  
secretory granule 12.25  
staining 10.9  
tumours, in animals 2.9, 2.22–3  
in urticaria 22.3, 22.4–5
- mast cell growth factor/stem cell factor  
(M/SCF), melanocyte mitogen 58.5
- mast cell tryptase 13.16
- mast cell tumours, in animals 2.9, 2.22–3
- mast-cell growth factor *see* stem-cell  
factor
- mastectomy, angiosarcoma following 56.38
- mastitis 8.13  
in breastfeeding 70.10  
duct ectasia/periductal mastitis  
complex 70.8  
granulomatous 31.25  
lupus 46.25–6  
neonatal 17.43
- mastocytoma 22.32  
in cats 2.22  
skin biopsy 10.43, 22.34
- mastocytosis 22.30–6, 62.43  
aetiopathogenesis 22.31  
aggressive 22.31, 22.33  
bone and joint involvement 62.99,  
62.101  
bullous 22.32  
classification 22.30–1  
clinical presentation 22.31  
cutaneous 22.30, 22.31, 22.31–3  
diffuse 22.33  
emergency management 22.35  
flushing associated 43.16  
genetics 22.30, 22.31  
histopathology 22.34  
investigation 22.34–5  
management 22.35–6  
prevalence 22.31  
prevention 22.35  
prognosis 22.36  
pruritus in 21.10, 22.32, 22.35  
systemic 22.30, 22.31, 22.33–4
- mastopathy, diabetic 50.49
- materia alba 69.87
- Matricaria* 25.21
- matrilysins 12.5, 12.52
- matriptase 12.50
- matrix Gla protein 49.48
- matrix metalloproteinases (MMPs) 3.40–  
1, 12.51–3  
ADAMs 12.51  
ageing and 80.1, 80.2  
in chronic wounds 14.11  
hair growth and 66.10  
inhibitors *see* tissue inhibitors of  
metalloproteinases (TIMPs)  
in Kawasaki disease 50.45
- matrilysin (MMP-7) 12.5, 12.52
- MMP1 3.40, 8.21–2, 47.27
- MMP2 47.27
- MMP3 (stromelysin-1) 3.41
- MMP8 3.41
- MMP9, in lichen planus 41.2
- MMP10 (stromelysin-2) 3.41
- synthesis and secretion 3.41
- tissue inhibitors *see* tissue inhibitors of  
metalloproteinases (TIMPs)
- UVR-induced 8.21, 8.22, 29.7
- in Winchester's syndrome 45.50
- in wound healing 14.4, 14.5
- wrinkles and 45.2
- Mauriac's syndrome 60.9
- Maurice's syndrome 33.18
- mauve stinger 38.56
- Max Joseph spaces, in lichen planus 41.4
- maxacalcitol 73.43, 73.46  
structure 73.44
- maxilla 69.2  
examination 69.5
- maximal skin tension lines 77.2, 77.11,  
77.13
- maximization test 26.11, 27.10
- May–Thurner syndrome 47.32
- Mazzotti's test 37.7
- MBL *see* mannan-/mannose-binding  
lectin/protein
- MBP *see* mannan-/mannose-binding  
lectin/protein
- MBT (mercaptobenzothiazole) 26.64
- MC1R (melanocortin 1 receptor) 3.21,  
29.5, 54.2, 54.33, 58.7
- MC1R* gene 2.5, 2.6, 54.33, 66.90–1
- MC903 *see* calcipotriol
- McCune–Albright syndrome 15.18, 58.18–  
19, 62.13, 62.99, 62.100
- neurofibromatosis vs 58.18
- McGrath syndrome 15.46
- MCP *see* CD46
- MCUS (multiple cutaneous and uterine  
leiomyomatosis) 56.55
- MDBGN (methylidibromo glutaronitrile)  
26.55
- MDS *see* myelodysplastic syndrome
- MDT (multidrug regimen), in leprosy  
32.16–17
- meadow dermatitis 58.32  
phytophotodermatitis 29.21, 58.32,  
75.162
- mean 7.17, 7.18
- measles 33.75–6, 69.95, 69.118  
aetiology and pathology 33.75  
antibodies 33.75  
atypical, in HIV infection 35.45  
clinical features 33.75  
diagnosis and prevention 33.75  
MMR vaccination 33.71  
neonatal purpura 49.20  
treatment 33.76
- measurement of disease 72.8–14  
correlation with QOL measures 72.14  
value of 72.8
- mebendazole 74.50–1  
in dracunculiasis 37.13  
in enterobiasis 37.14
- mechanical acne 42.76–7
- mechanical injury 28.1–63  
amputees 28.27–9  
biomechanical considerations 28.4–9,  
28.11  
child abuse 28.34–9  
determinants 28.2, 28.6–7  
evaluation methods 28.5–6  
foreign bodies 28.39–52  
friction 28.2, 28.9–16, 28.28  
hypothenar hammer syndrome 28.26,  
28.56  
internal 28.60–2  
Koebner response 28.2–3, 28.15, 28.48,  
28.73  
malignant neoplasms 28.62–3  
miscellaneous reactions to mechanical  
trauma 28.25–39
- musical instruments 28.25–6  
Nikolsky sign 28.4, 76.17  
overview 28.1–4  
pathological variation 28.8  
physiological variation 28.7, 28.18  
pressure ulcers 28.16–23, 28.27–8  
sexual abuse 28.34, 28.37–8  
skin function and properties 28.5–7  
skin lesions in drug addicts 28.52–3  
sports injuries 28.30–2, 28.53–6  
suction 28.23–5, 28.39  
swimming and diving 28.31, 28.53–6  
torture injuries 28.32–4  
vibration 28.56–60
- mechanical nociceptors 4.9
- mechanical properties of skin 4.7–8
- mechanics, occupational hazards 27.20
- 'mechanic's hands,' antisynthetase  
antibodies 51.125
- mechanobullous diseases 39.1  
in animals 2.17  
*see also* epidermolysis bullosa (EB)
- mechanoreceptors 4.9, 4.10, 63.2  
rapidly adapting 4.9  
slowly adapting 4.9
- mechlorethamine  
and carmustine (BCNU) 57.23  
hypersensitivity to 73.23  
topical 73.23–4  
*see also* nitrogen mustard
- Meckel's diverticulum 18.93
- meclufenamate sodium 75.76
- medial canthus 67.2  
basal cell carcinoma 67.35  
in mucous membrane pemphigoid 67.18
- medial pterygoid muscle, examination  
69.5
- median 7.17, 7.18
- median raphe cysts, male genital region  
71.35
- median umbilical ligament 18.94
- medical elastic compression stockings  
(MECS)  
deep-vein thrombosis 47.29, 47.30  
Klippel–Trenaunay syndrome 47.24  
thrombophlebitis migrans 47.31  
*see also* compression stockings
- medical literature  
appraisal and evaluation of research  
papers 7.10, 7.13, 7.15, 7.16–23  
databases 7.5–6  
keeping up with 7.2  
language bias 7.7–8  
publication bias 7.7, 7.8  
searching 7.5–6
- medical publications *see* medical  
literature
- MedicAlert bracelet 38.15  
in latex allergy 26.106
- medicolegal issues  
factitious skin disease 64.45  
occupational dermatoses 27.17–18
- Medina worm 37.12–13
- Mediterranean fever 30.73
- MEDLINE 7.5, 7.6
- medroxyprogesterone acetate 75.119
- MedWatch 75.3
- Mees' lines 65.15, 65.16
- mefenamic acid 75.76
- mefloquine 75.70
- Megalopyge* 38.29
- megalymphatics 48.12
- megestrol 75.89, 75.119
- meglumine antimoniate 37.39
- Meibomian ductules  
epithelial metaplasia 67.21  
keratinization 67.11
- Meibomian gland 42.1, 67.2  
dysfunction 67.7, 67.9  
epidemiology 67.6  
in Stevens–Johnson syndrome 67.21  
hypertrophy 27.13  
lipids, composition change in rosacea  
43.7  
normal, ducts 67.11

- Meibomian gland disease (MGD) 67.11  
 Meibomian lipids 67.11  
 Meibomian seborrhoea 67.7, 67.11  
 meibomitis 67.7, 67.9  
 meibum, abnormal production 67.11  
 Meige's disease 48.9, 48.10  
 meiosis, definition 15.3  
 Meirovsky phenomenon 58.10  
 Meissner's corpuscles 3.15, 4.9, 4.10, 63.2, 63.14  
 Mel-5 10.21, 20.22  
*Melaleuca alternifolia* oil see tea tree oil  
 Melan-A 10.21, 20.22  
 Melan-A mart melanoma antigen 53.39  
 melanin(s) 5.15, 54.1, 58.1  
 absence, vitiligo 58.47  
 in animals 2.5  
 in basal cell carcinoma 52.21  
 biological significance 58.8–9  
 as chromophores 78.3  
 evolution 2.1  
 forms/types 2.5  
 function 3.3  
 hair pigmentation and 3.20, 66.89–890, 66.90–1  
 in Hodgkin's disease 57.63  
 increased, Peutz–Jeghers syndrome 58.13  
 mixtures of eumelanins and pheomelanins 58.5, 58.6  
 mucocutaneous, Peutz–Jeghers syndrome 58.12  
 photoprotective role 4.7  
 pigment types 3.20  
 protective function 58.8, 58.10  
 synthesis/production 3.21, 4.7, 58.2, 58.5, 58.6  
 by *C. albicans* 36.57  
 delayed effect of tanning 29.5  
 genetic variation 58.2–3  
 inhibition by depigmenting agents 73.27  
 see also melanogenesis  
 types 58.5, 58.6  
 melanoacanthoma 52.39–40  
 eyelid 67.34  
 see also melanotic macules  
 melanoacanthosis see melanotic macules  
 melanoblasts 3.3  
 development in neural crest 58.3  
 migration and differentiation 58.3–4  
 melanocortin  
 in Addison's disease 58.7  
 MC1  
*Melanocortin-1* gene 2.5, 2.6  
 sebocytes expressing 42.4  
 MC5, sebocytes expressing 42.4  
*Melanocortin-1* gene 2.5, 2.6  
*Melanocortin-1* receptor genes 2.5, 2.6, 54.33, 66.90–1  
 melanocortin receptor(s)  
 MC5-R, sebocytes 42.4  
 melanocortin 1 receptor (MC1R) 3.21, 29.5, 54.2, 54.33, 58.7  
 MC1R gene 2.5, 2.6, 54.33, 66.90–1  
 melanocyte(s) 3.1, 3.20–1, 54.1, 54.10, 54.15, 58.1, 58.2–5  
 absence  
 lichen planus 41.4  
 piebaldism 58.42  
 vitiligo 58.47  
 age-related changes 80.2  
 age-related reduction in number 58.3  
 in alopecia areata 66.33  
 in animals 2.5–6, 2.6  
 autoantibodies, in vitiligo 58.46  
 in basal layer of epidermis 58.2, 58.3  
 birds 2.6  
 compound naevus, and cell types 54.18  
 in culture 58.2  
 culture of 58.5  
 response to UV 58.7  
 cytological atypia, atypical naevus 54.30  
 dendrite formation 58.4  
 dendritic, in dermal melanocytosis 58.36  
 dermal–epidermal junction 54.1, 54.2, 54.4, 54.15, 54.18  
 development 58.3–4  
 signalling and transcription factors 58.3  
 differentiated 3.21  
 distribution 58.2–3  
 regional 58.3  
 electron microscopy 10.29–30  
 embryology and affinities 3.3, 3.5, 3.21  
 evolution 2.5–6  
 G-protein-coupled receptors 3.21  
 grafts 77.22  
 in greying hair 66.92  
 hair bulb 66.4, 66.90  
 hair follicles 58.3  
 increased activity 58.31  
 increased number 58.9, 58.11, 58.31  
 tanning 58.31  
 see also lentiginosis  
 keratinocytes surrounding 54.18, 58.2, 58.7  
 large, reduced, piebaldism 58.42  
 lentiginous hyperplasia 54.30  
 lips 69.2  
 markers 3.21, 10.21–2  
 melanin synthesis 4.7, 58.2  
 genetic variation 58.2–3  
 migration into dermis 54.18  
 mitogens and growth factors 58.5  
 in nail matrix 3.15, 65.2, 65.14  
 number in skin 58.9  
 number of keratinocytes associated 58.2  
 in piebaldism 66.93  
 proliferation 54.2  
 atypical naevus 54.28  
 basal cell carcinoma 52.21  
 melanoma 54.35–6  
 seborrhoeic keratosis 52.39  
 race and 9.2  
 reduction in number  
 age-related 58.3  
 disorders 3.21  
 regulation 58.7–8  
 response to UV 58.7  
 signalling pathways 3.21  
 stem cells 3.21  
 UV-induced growth arrest 58.7  
 melanocyte lineage, development 58.3  
 melanocyte-specific antibody, HMB-45 58.3  
 melanocyte-stimulating hormone (MSH) 12.63–4  
 melanocyte mitogen 58.5  
 melanosome transfer to keratinocytes 58.4  
 MSH-2, in Muir–Torre syndrome 53.15  
 pigment cell regulation in fish 2.5–6  
 $\alpha$ -melanocyte-stimulating hormone ( $\alpha$ -MSH) 29.5  
 pigmentation and 66.90–1  
 sebaceous gland activity 42.12  
 $\beta$ -melanocyte-stimulating hormone ( $\beta$ -MSH)  
 in Cushing's syndrome and hyperpigmentation 58.24  
 hypermelanosis in systemic disorders 58.25, 58.27  
 melanocytic lesions, dermal 54.7–9  
 melanocytic naevi see naevus, melanocytic  
 melanocytoma 54.9  
 melanocytoma–acanthoma, in dogs 2.21  
 melanocytosis  
 dermal 58.36–8  
 disseminated dermal 58.38  
 leptomenigeal 54.13–14  
 oculodermal see naevus, of Ota  
 see also hyperpigmentation  
 melanodermatitis, lichenoid 41.13  
 melanoepithelioma, non-naevoid, type 1 52.39–40  
 melanogenesis 58.2  
 biochemistry 58.5–6  
 hair follicles 66.90–1  
 increased 58.9  
 oestrogen effect 58.7  
 UV-stimulated 58.31, 58.32  
 see also melanin(s), synthesis/production  
 melanogenuria, slaty-blue dermal melanosis 58.25  
 melanoleucoderma 15.47  
 melanoma, malignant 54.32–57  
 ABCD categories/mnemonic 54.37  
 acquired melanocytic naevi progression 54.37, 54.38  
 acral lentiginous 15.11, 54.35, 54.44, 54.45, 54.46, 65.40  
 aetiology 29.7, 54.32–3  
 AJCC staging system 54.49, 54.50  
 amelanotic 65.39  
 subungual 54.46  
 animal-type 54.48  
 in animals 2.20–1, 2.22  
 anorectal 54.47  
 antibodies, diagnostic use 54.39  
 'at risk' patients, identification 54.34  
 atypical mole syndrome 54.34, 54.47  
 atypical naevi progressing to 54.28, 54.29–30, 54.31  
 biomarkers 54.51  
 biopsy 54.38  
 breast 70.14, 70.15  
 Breslow thickness 54.49, 54.52  
 carcinoma erysipeloides 48.31  
 CDKN2A gene 54.33  
 childhood 54.48–9  
 Clark levels 54.38  
 clinical diagnostic aids 54.37  
 clinicopathological variants 54.35–6  
 communicating prognosis 72.5  
 congenital naevi progression 54.10, 54.13  
 CT scan after relapse 54.50  
 dermoscopy 54.19, 54.38  
 desmoplastic 54.42, 54.43  
 differential diagnosis 54.6, 54.38–9  
 acquired melanocytic naevi vs 54.19, 54.38–9  
 atypical melanocytic naevus vs 54.28, 54.38  
 basal cell carcinoma vs 52.21  
 halo naevus vs 54.20  
 malignant blue naevus vs 54.27  
 metastasizing Spitz naevus vs 54.22  
 Spitz naevus vs 54.22, 54.23–4, 54.39  
 ear 68.33–4  
 early, features 54.19  
 elective lymph node dissection (ELND) 54.51  
 equine, human melanoma comparison 2.20  
 evolving from congenital naevi 54.10, 54.13  
 eyelids 67.35, 67.36  
 familial 54.33–4, 54.48  
 family history 54.47–8  
 female sex hormones and 54.56–7  
 fine needle aspiration cytology 54.53  
 follow-up after surgery 54.53  
 following chemotherapy 75.124  
 generalized lentiginosis and 54.3  
 genetics 6.12, 11.18  
 genital 54.47  
 female genital region 71.77–8  
 male genital region 71.47  
 Glasgow seven-point check-list 54.37  
 growth phases 54.35–6  
 halo naevus with 58.49  
 histogenetic types/sites 54.37–49  
 in HIV infection 35.39–40  
 immunohistochemistry 54.49  
 in situ 54.29–30, 54.35–6, 54.39  
 incidence 54.32  
 increased with sunscreen use 73.41  
 intracerebral primary 54.13  
 invasive  
 elderly people 8.28–9  
 treatment 54.39  
 juvenile see naevus, Spitz  
 lentigo maligna see lentigo maligna melanoma  
 lichenoid tissue reaction association 41.6  
 lymph node involvement 54.47, 54.50  
 de novo origin 54.47  
 management 54.53  
 lymphoedema 48.8  
 lymphoscintigraphy 54.51, 54.52  
 management/treatment 54.49–56  
 after excision of primary 54.50–3  
 anti-CTLA-4 antibody therapy 54.54  
 azelaic acid 73.28  
 biological therapies 54.53–4  
 of brain metastases 54.55–6  
 follow-up after surgery (stage I/II) 54.53  
 interferon-alpha (IFN- $\alpha$ ) therapy 54.53–4  
 metastatic to lymph glands 54.53  
 palliative care 54.54, 54.55, 54.56  
 radiotherapy 54.55, 54.56, 79.12  
 recurrent disease in limb 54.54–5  
 stage IV disease 54.54, 54.55–6  
 topical imiquimod 73.24  
 metastasis 5.15  
 brain 54.54, 54.55–6  
 childhood melanoma 54.48  
 in transit 54.54–5, 54.55  
 to lymph glands, management 54.53  
 placental and fetal 54.57  
 in pregnancy 54.56  
 retarded in horses 2.20  
 sites 54.51, 54.54  
 solitary brain 54.54, 54.55  
 topical imiquimod 73.24  
 unknown primary site 54.47  
 minimal deviation 54.48  
 mortality 54.32  
 mucosal 54.46–7  
 multiple primary 54.47–8  
 myxoid 54.42  
 naevoid 54.48  
 neurotropic 54.42  
 nipple, Paget's disease vs 53.39  
 nodular 54.35, 54.36, 54.40, 54.54  
 elderly people 8.29  
 Notch signalling abnormality 3.21  
 obesity and 8.17  
 oral cavity 54.6, 69.98–9  
 palliative management 54.54, 54.55, 54.56  
 palmoplantar 54.35, 54.44, 54.45  
 phenotypic risk factors 54.33  
 photography, detection by 54.31  
 pre-pubertal 54.48–9  
 pregnancy and 8.12, 54.56–7  
 prevention 54.34  
 prognosis 54.49–50, 54.52  
 PUVA lentigo and 54.5  
 race and 9.18  
 radial growth phase 54.28, 54.36  
 early, vs atypical naevus 54.28  
 recurrence  
 local 54.54–5  
 risk factors 54.49  
 relapse, staging at 54.50  
 risk after childhood cancer 54.15  
 risk markers, atypical melanocytic naevi 54.28  
 secondary from occult primary site 54.47  
 sentinel node biopsy 54.39, 54.50, 54.51–2, 54.53  
 slaty-blue dermal melanosis 58.25  
 small cell 54.48  
 of the soft parts 54.48  
 solar (actinic) keratosis and 54.33  
 spitzoid 54.22, 54.23–4, 54.25  
 see also naevus, Spitz

- stage III disease, radiotherapy 54.56  
stage IV disease 54.51  
management 54.54, 54.55–6  
staging 54.49, 54.50–1  
subungual/peringual 54.44–6,  
65.39–41  
differential diagnosis 54.18  
*in situ* 54.46  
sun exposure and 6.12, 29.7, 54.32–3,  
54.34  
sunscreens use 54.34, 73.41  
superficial spreading 54.31, 54.35,  
54.36, 54.37, 54.37–40  
atypical naevi progression 54.28,  
54.29–30, 54.31  
congenital naevi complication 54.13  
differential diagnosis 54.38  
generalized lentiginosis and 54.3  
halo naevus vs 54.20  
pathology 54.38–9  
regression 54.37  
sites, colour 54.37  
verrucous variant 54.38–9  
surgical treatment of primary site 54.39  
survival rates 54.52  
susceptibility, in lentiginosis 54.3, 54.4,  
54.5  
TNM staging system 54.50, 54.50  
transplacental transfer 17.19  
umbilical 71.101  
vaccines 54.54  
vaginal 54.47  
verrucous 54.38–9  
vertical growth phase 54.36  
vulval 54.47
- Melanoma Genetics Consortium 54.33  
melanoma-inhibitory activity (MIA) 54.51  
melanoma-astrocytoma syndrome 62.20,  
62.22  
melanoma-nervous system tumours  
(NST) syndrome 62.20, 62.22  
melanonychia *see* longitudinal  
melanonychia  
melanophages 54.26  
in amyloidosis 58.28  
hyperpigmentation treatment 73.26  
melanophores 2.6  
melanophyllin 58.4  
melanosis  
Becker's *see* naevus, Becker's  
circum-/intra-oral 69.21  
frictional 28.15  
genital 54.2  
mucosal 54.6–7  
neurocutaneous 54.11  
penile 58.15, 71.49  
periobital 67.5  
post-inflammatory 47.33  
primary acquired 54.40–1  
smoker's 69.96  
transient neonatal pustular 9.12, 17.8–9  
universal acquired 58.22  
vulvovaginal 58.15, 71.79–80
- melanosis circumscripta precancerosa of  
Dubreuilh *see* lentigo maligna  
melanosomes 3.20, 58.1  
absence, piebaldism 58.42  
compound 62.6  
development 58.3  
electron microscopy 10.29–30  
ellipsoidal 58.10  
in freckles 58.10  
Laugier-Hunziker syndrome 58.14  
racial differences 3.21, 9.2, 58.10  
size and number, racial differences 3.21  
transfer to keratinocytes 4.7, 58.4–5  
transport to dendrite of melanocytes  
58.4  
variations in skin colour and 58.10  
in warts 33.47
- melanotic lesions, mucosal 54.6–7  
*see also* melanotic macules  
melanotic macules 69.27, 69.98  
dermal 54.7–9  
labial 54.2, 54.6, 54.7  
pigmented (mucosal) 54.2, 54.6–7  
*see also* melanoacanthoma  
melanotic progonoma 56.52–3  
 $\alpha$ -melanotrophin 58.7  
 $\beta$ -melanotrophin 58.7  
 $\gamma$ -melanotrophin 58.7  
melasma 58.25, 58.34–5  
laser therapy 78.11, 80.11  
race and 9.16  
rarity with HRT 58.34  
topical therapy 73.26–7, 73.27, 73.28  
melatonin  
adverse effects 70.5  
hair growth and 66.9  
receptors 3.21
- Meleda, mal de 19.3, 19.94, 19.100–1  
Meleney's ulcer 47.57  
Meliaceae 26.81  
melioidosis 30.50–1, 62.80  
Melkersson-Rosenthal syndrome 42.74,  
48.16, 61.23, 69.37, 69.60, 69.125  
Meloidae 38.2, 38.26  
melorheostosis 18.33, 62.103  
melphalan  
adverse effects 75.125  
isolated limb perfusion in recurrent  
melanoma 54.54  
Meltzer's triad 49.33  
membrane co-factor protein *see* CD46  
membrane-coating granules (Odland  
bodies) 3.1, 3.8, 3.11, 4.2, 4.3  
membrane inhibitor of reactive lysis  
(CD59) 14.4  
MEN *see* multiple endocrine neoplasia  
(MEN)  
men who have sex with men (MSM)  
dermatophytosis 35.32  
genital chlamydial infections 34.29  
gonorrhoea 34.25, 34.26  
herpes simplex infection 33.16  
HIV infection/AIDS 35.2, 35.5, 35.13,  
35.15, 35.30, 35.32  
lymphogranuloma venereum 34.32,  
34.33  
syphilis 34.3, 34.7  
MEN1 gene 62.24, 62.68  
Mendes da Costa syndrome *see*  
erythrokeratoderma variabilis  
Mendes da Costa-van der Valk syndrome  
58.20  
menin 62.24  
meningeal neurosyphilis 34.14  
meningioma 18.95  
cutaneous 56.51–2  
meningism, herpes simplex 33.17  
meningitis  
anthrax 30.41  
cryptococcal 35.33  
in loiasis 37.11  
meningococcal 30.44–5  
recurrent lymphocytic 33.19  
meningococcaemia, purpuric 49.20  
meningococcal infection 30.44–5, 62.105  
purpura in 49.20  
septicaemia 30.44, 49.20, 62.105  
*see also* *Neisseria meningitidis*  
meningocoele 18.95  
meningoencephalitis 30.44  
in sarcoidosis 61.7  
zoster 33.26  
meningoencephalocoele 18.95  
meningothelial heterotopias 56.51–2  
meningovascular syphilis 34.14  
Menkes' syndrome 3.44, 45.14, 45.39  
copper defect 3.44, 45.14, 59.76  
hair in 66.63, 66.64, 66.65  
occipital horn syndrome and 3.44,  
45.14, 45.36, 45.39  
menopausal flushing 8.20, 43.15  
menopause 8.19–21  
age of onset 8.19  
definition 8.19  
female genital changes 71.55  
hormonal and physiological changes  
8.19  
premature 8.19  
skin disorders 8.20  
sweating associated 44.7  
menotrophin 75.117  
menstrual cycle 8.8–9  
allergic contact dermatitis and 26.8  
atopic dermatitis and 24.19  
cutaneous changes 8.8–9  
hormonal influences 8.8  
initiation 8.4  
sebum production changes 42.11  
urticaria and 22.11  
menstrual toxic shock syndrome 71.67  
menstruation, pigmentation changes  
58.25  
mental deficiency 15.23  
mental illness, perceptions of 64.7  
mental nerve 77.2, 77.4, 77.10  
mental neuropathy 62.39  
menthol  
in pruritus 21.17  
topical therapy 73.48  
mepacrine (quinacrine) 13.24, 74.25–6  
adverse effects 75.70  
lichenoid eruptions 41.24  
nail colour changes 65.16  
pigmentation 58.55  
in discoid lupus erythematosus 51.21  
in subacute lupus erythematosus 51.23  
mephenesin 66.94  
mephenytoin, melasma-like  
hyperpigmentation 58.34  
Mepilex 39.28  
Mepitel 39.28  
mepivacaine 77.10  
meprobamate, adverse effects 75.81  
mequinol 73.27  
mercaptans, substituted 73.29  
mercaptobenzothiazole 26.64  
6-mercaptopurine 20.40, 59.63  
mercurials 26.17  
as allergens 26.39  
organic 26.57–8  
mercuric chloride 10.31  
mercury 75.101–2  
as allergen 26.21, 26.39  
exposure to during pregnancy 18.2  
in homeopathic medicines 75.162  
hypersensitivity to 75.34  
as irritant 25.21  
lichen planus pathogenesis and 41.3  
lichenoid eruptions due to 41.24  
pigmentation due to 58.55  
poisoning 69.83–4  
in tattoo pigments, allergic reactions  
58.58  
topical application 75.165  
*see also* dental amalgam  
mercury arc lamps 29.1  
mercury compounds, abuse for skin  
lightening 73.26  
Merkel cell(s) 3.1, 3.15–16, 63.2  
autoantibodies to 3.16  
cytokeratin 20 53.31  
in desmoplastic trichoepithelioma 53.9  
development 3.3, 3.5, 3.16  
glabrous skin 3.16  
hyperplasia 3.16  
immunohistochemistry 53.43  
immunoreactivity 3.15  
neurosecretory granules 3.15  
origin 3.16  
size and structure 3.15–16  
trichoblastoma 53.10  
Merkel cell carcinoma 3.16, 33.37, 53.42–4  
eyelids 67.36  
genetics 15.27  
in trichilemmal cyst 53.4  
*see also* Merkel cell tumours  
Merkel cell polyomavirus 33.37, 53.42  
Merkel cell tumours  
diagnosis 10.20–1  
ear 68.34  
radiotherapy 79.13  
*see also* Merkel cell carcinoma
- Merkel cell-neurite complexes 3.15–16  
Merkel's receptors 4.9, 4.10  
merthiolate 25.21, 26.46, 73.8  
mesalazine 75.56  
mesenchymal cells 3.3–4, 3.49  
dermis formation 3.5  
signalling 3.3–4  
mesenchymal markers 10.22–4  
mesna 75.125  
SLE 51.62  
mesoderm 3.3  
*Mesoknemidokoptes laevis* 38.46  
mesomelic dwarfism-skeletal  
abnormalities-ectodermal  
dysplasia 15.47  
mesperidine, lobular panniculitis with  
crystals after 46.17  
17 $\alpha$ -mestrolone 42.16  
meta-analyses 6.16, 7.4  
appraisal and evaluation 7.7–11  
metabolic disorders 59.1–104  
connective tissue diseases 51.79  
eye and skin involvement 67.30  
oral manifestations 69.117  
in pregnancy 8.11, 8.12  
scleroderma-like lesions 51.79  
metabolic syndrome 46.7  
criteria 46.7  
psoriasis and 6.13  
metachromasia, scleroderma 51.119  
metal halide lamps 29.2  
metal piercings 28.51–2  
metal workers, occupational hazards  
27.20  
metalloelastases 3.44  
metals  
as allergens 26.30–40  
pigmentation due to 58.54–5  
prosthetic implants 26.37  
*see also specific metals*  
metaphyseal chondrodysplasia of  
McKusick 15.93  
metaplasia 10.40  
metastases *see* malignant disease,  
metastatic  
metastatic calcification 59.69–70  
metformin, in hirsutism 66.88–9  
methacrylic acid esters, lichen planus-like  
contact dermatitis 41.23  
methaemoglobinaemia, linear IgA disease  
40.50  
methandienone, dermatomyositis  
51.129  
methanol 25.3, 25.19, 25.20  
methenamine 73.9  
methicillin 75.50  
methicillin-resistant *Staphylococcus aureus*  
(MRSA) 30.9, 38.8, 74.40  
community-acquired 30.9, 30.22  
foreign bodies 28.48  
in HIV infection 35.24  
male genital infection 71.33  
in neuropathic ulcers 63.9  
otitis externa and 68.21  
prevention of spread 77.5, 77.7  
wound infection 14.16  
methimazole 18.102  
methotrexate 13.24, 74.19–23  
adalimumab and, ADEPT study  
74.7  
adverse effects 70.5, 72.29, 74.21,  
75.130–1  
acute toxic effects 20.34, 72.29  
dermatological 75.130  
oral 69.56  
systemic 75.130–1  
toxicity in elderly people 8.28  
alcohol abuse 74.21–2  
in atopic dermatitis 24.31, 74.18–19  
in bullous pemphigoid 74.18–19  
contraindications 74.21  
in cutaneous lupus erythematosus (LE)  
74.19  
in dermatomyositis 51.129  
in dermatoses 74.20

- dose range and evidence level 20.33, 74.19  
 absolute or relative overdose 74.22  
 acute toxicity and overdosage 74.23  
 folate supplementation 74.22–3  
 genetic factors in response to 11.16  
 interactions 72.29  
 intralesional 77.49  
 in liver disease, contraindications 20.34, 74.21  
 management of therapy 74.21–32  
 concurrent therapy 20.33  
 haematological abnormalities. 74.23  
 laboratory control 20.34  
 monitoring schedule 74.22  
 in microscopic polyangiitis 50.36  
 in morphoea 51.75  
 in non-alcoholic steatohepatitis (NASH) 74.21  
 in pregnancy 74.21  
 prescribing safety 72.26, 74.21  
 in psoriasis 20.33–5, 74.18–19  
 in HIV infection 35.17  
 in psoriatic arthritis 20.59  
 in sarcoidosis 61.21, 74.20  
 in SLE 51.62  
 topical 73.23  
 4-methoxyphenol 73.27  
 5-methoxypsoralen, Berloque dermatitis and 58.32  
 8-methoxypsoralen, adverse effects, ocular 67.32  
 methyl aminolevulinic acid (Metvix®) cream 43.6  
 methyl bromide 75.163  
 6-methyl coumarin 26.23  
 methyl-ethylketone 25.20  
 methyl methacrylate 27.9  
 methyl salicylate 75.165  
 methylamfetamine 75.87  
 methylation, genomic imprinting 15.6  
 4-methylbenzylidene camphor 26.62  
 methylcellulose 73.2  
 methylcellulose eye drops 51.138  
 methylchloroisothiazolinone 26.53  
 methylidibromo glutaronitrile 26.55  
 methyldopa  
 adverse effects 70.5, 75.96  
 lichenoid tissue reaction due to 41.25  
 methylene blue 17.12  
 methylene chloride 25.20  
 trans-3-methyl-2-hexanoic acid 44.1  
 methylisothiazolinone 26.53  
 methylphenidate 75.83  
 methylprednisolone, SLE 51.62  
 methylprednisolone aceponate 73.16  
 metoclopramide, adverse effects 70.5  
 metophyma 43.9  
 metoprolol 75.91  
 metronidazole 74.43  
 adverse effects 26.46, 75.59  
 in amoebiasis 37.28  
 in *Demodex* infection in rosacea 43.3  
 in dracunculiasis 37.13  
 in fish odour syndrome 44.20  
 in rosacea 43.3, 43.6  
 in seborrhoeic dermatitis 23.33  
 topical 73.10  
 in rosacea 43.6, 73.9, 73.10  
 in trichomoniasis 37.29  
 Mexican chicken bug 38.24  
 Mexico  
 dermatological care 6.16  
 prevalence of skin disease 6.9  
 mexiletine 75.165  
 Meyerson phenomenon (halo dermatitis) 23.12–13  
 Meyerson's naevus 54.20  
 MGIT 31.6  
 MGUS (monoclonal gammopathy of uncertain significance) 13.15  
 MHA-TP test 34.20  
 MHC *see* major histocompatibility complex (MHC)  
*mi* mutants 58.3  
 mianserin 64.51  
 adverse effects 75.79  
 erythema multiforme 76.3, 76.4  
 Mibelli's porokeratosis 19.91, 66.51  
 disseminated superficial 'actinic' porokeratosis vs 52.36  
 mice *see* mouse  
 Michaelis–Gutmann bodies 55.27  
 Michelin tyre baby 18.36, 18.40, 18.107  
 Michel's transport medium 10.4–5, 39.24  
 miconazole  
 in candidiasis 36.68  
 in dermatophytosis 36.48  
 in napkin dermatitis 17.26  
 topical 73.12  
 miconidin 26.76  
 microabscess  
 Munro 10.41, 65.25  
 papillary tip 10.41  
 Pautrier 10.41  
 microaneurysms, Degos' disease 49.45  
 microangiopathy 47.26  
 thrombotic 49.12  
 microarrays 11.7–8, 11.9  
 high-throughput genetic analysis 15.6  
 microbial recognition, by immune system 12.8–9  
 microcephaly lymphoedema–chorioretinal dysplasia 48.10  
*Microciona prolifera* 38.59  
 microclimate 6.12  
*Micrococcus*  
 classification 30.2  
 in normal skin flora 30.2, 30.3, 30.4  
 bacterial counts 30.3  
 quantitative studies 30.3  
*Micrococcus kristinae* 30.2, 30.3  
*Micrococcus luteus* 30.2, 30.3  
*Micrococcus lylae* 30.2, 30.3  
*Micrococcus sedentarius* 30.2, 30.3, 30.39  
*Micrococcus varians* 30.2, 30.3  
 microcomedones 42.22, 42.23, 42.25, 42.43  
 microconidia 36.3, 36.4, 36.41  
 microcystic adnexal carcinoma 53.35–6  
 microdeletion syndromes 18.2  
 microdeletions 15.2  
 microdontia 69.7  
 microfibril-associated fibrillar proteins (MFAP) 3.45  
 microfibril-associated glycoprotein (MAGP) 3.45  
 microfibrils 3.2, 3.42  
*see also* elastin-associated microfibrils  
 microfilaments 3.9  
 $\beta_2$ -microglobulin, in sarcoidosis 61.20  
 microhaemagglutination, *Treponema pallidum* 34.20  
 microimmunofluorescence (MIF), lymphogranuloma venereum 34.33  
 micronychia 65.9  
 micropapular eruptions, syphilis 34.11, 34.12  
*microphthalmia* mice 2.7  
 microRNA (miRNA) 3.50  
 microsatellite instability (MSI) 57.20  
 Muir–Torre syndrome 52.10, 53.15  
 microscopic polyangiitis (polyarteritis) 50.35–7  
 respiratory tract involvement 62.83  
 microscopy 5.18, 5.20–1  
 capillary *see* capillary microscopy  
 dark-field, syphilis diagnosis 34.3, 34.18–19  
 electron *see* electron microscopy  
 epiluminescence *see* dermoscopy  
 fluorescence 36.7  
 indirect immunofluorescence 16.5–6  
 preparation for 10.32  
 tissue sections 10.31–6  
 microsponges 73.2  
 microsporidiosis, HIV infection 35.35  
*Microsporium* 36.18  
 identification 36.8  
*see also* dermatophytes  
*Microsporium audouinii* 36.19  
 dermatophytide due to 36.36  
 identification 36.37, 36.39  
 investigation 36.6  
 in tinea capitis 36.25–6, 36.27  
 in tinea corporis 36.23, 36.24  
 in tinea faciei 36.29  
*Microsporium canis* 36.19, 36.21  
 in animals 2.12  
 identification 36.37, 36.40  
 investigation 36.6  
 in tinea barbae 36.28  
 in tinea capitis 36.26, 36.27  
 in tinea corporis 36.24, 36.25  
 in tinea faciei 36.29  
*Microsporium equinum*  
 identification 36.39  
 in tinea capitis 36.26  
*Microsporium ferrugineum*  
 identification 36.39  
 investigation 36.6  
 in tinea capitis 36.26, 36.27  
*Microsporium fulvum* 36.26  
*Microsporium gypseum* 36.6, 36.26, 36.39, 36.40  
 in animals 2.12, 2.13  
*Microsporium nanum* 36.6, 36.26, 36.40  
*Microsporium persicolor* 36.19, 36.24, 36.40–1  
*Microsporium vanbreuseghemii* 36.26  
*microphthalmia (mi)* mutants 58.3  
 microtia 68.4  
 microtubules 3.9  
 melanosome, for transfer 58.4  
 microvascular damage, pressure ulcers 28.17  
 microvascular occlusion 49.3, 49.26–48, 50.54–5  
 calcific uraemic arteriopathy 49.47–8  
 classification of disorders 49.27  
 coagulopathies with cutaneous features 49.38–42  
 cryogelling causing 49.32–4  
 emboli causing 49.36–8  
 platelet plugs causing 49.27–31, 49.41  
 reticulocytes causing 49.47  
 vascular coagulopathies causing 49.42–7  
 vessel-invasive organisms causing 49.34–6  
 microvilli 2.2  
 microwave radiation burns 28.90  
 MIDAS syndrome 18.103–4  
 genetics 15.4, 15.85  
 midazolam, in dystrophic EB 39.30  
 midges 38.7  
 biting 38.6, 38.7  
 midgut tumours, carcinoid syndrome associated 43.18  
 midline cervical cleft 18.86  
 Miescher's granulomatous cheilitis 48.16, 61.23, 69.60, 69.125–7  
 Miescher's radial granulomas 46.12  
 MIFT-1 10.21, 20.22  
 migraine, rosacea association 43.1  
 migration  
 atopic dermatitis and 24.2–3  
 risk factor for skin disease 6.12  
 migration index 26.98  
 migration inhibition factor 26.98  
 migratory thrombophlebitis 47.30–1, 62.42–3, 62.66  
 Mikaelian syndrome 15.47  
 Mikulicz cell 30.52  
 Mikulicz syndrome 61.7, 69.57  
 Mikulicz's syndrome 51.49  
*see also* Sjögren's syndrome  
 milfetosine 74.51  
 milia 52.47–8  
 colloid *see* colloid milium  
 definition 5.7, 52.47  
 differential diagnosis 42.36, 52.47–8  
 in dystrophic EB 39.18, 39.21  
 eyelid 67.33  
 hands 25.15, 25.16  
 incidence and aetiology 52.47  
 neonatal 17.5  
 treatment 52.48, 78.14  
 Milian's white atrophy (atrophy blanche) 15.13, 23.35, 47.34, 49.44  
 miliaria 44.13, 44.15–16  
 aetiology and pathology 44.15  
 amputees 28.29  
 causes 25.2  
 clinical features 44.15–16  
 natural history 44.16  
 neonatal 17.7–8  
 in pregnancy 8.10  
 pustular 44.16  
 sports injuries 28.30  
 treatment 44.16  
 miliaria crystallina (sudamina) 17.7–8, 44.15–16  
 miliaria profunda 44.15–16  
 miliaria pustulosa 17.7, 17.8  
 miliaria rubra 17.7–8, 44.15–16  
 miliary eruptions, syphilis 34.11  
 milium *see* milia  
 milk  
 acne and 42.34  
 allergy 22.6  
 milk lines 70.1, 70.2  
 milker's nodule 33.10–11  
 milker's sinuses 28.49  
 millipedes 38.54–5  
 milowood 26.81  
 Milroy's disease 48.8, 48.9–10  
*Mima*  
 in normal skin flora 30.2  
*see also* *Acinetobacter*  
 Mimosaceae 26.80  
 mineral oil  
 as carcinogen 52.4  
 injections in sclerosing lipogranuloma 46.28, 46.29–30  
 in topical treatment 73.6  
 Mineral Oil USP 73.6  
 minimal erythema dose (MED) 29.5, 29.8  
 minocycline 74.41  
 acne vulgaris treatment 42.47, 42.48  
 adverse effects 26.46, 42.50–1, 75.54  
 black galactorrhoea 70.6  
 drug hypersensitivity syndrome 42.51  
 hyperpigmentation 69.97, 75.33, 75.52–3  
 lupus-like reaction 42.51  
 nail colour changes 65.38  
 ocular 67.31–2  
 pigmentation 42.50–1  
 pigmentation due to 58.55–6  
 in dissecting folliculitis of scalp 42.74  
 dose range and evidence level 74.30  
 in hidradenitis suppurativa 42.75  
 in leprosy 32.17  
*Propionibacterium acnes* resistance 42.47, 42.56  
 in rosacea 43.6, 43.7  
 in sarcoidosis 61.21  
 topical, in acne 42.41  
 minoxidil 73.49–51  
 adverse effects 26.18, 73.50, 75.96–7, 75.165–6  
 ear canal hypertrichosis 68.18, 68.21  
 hypertrichosis 66.79  
 in alopecia areata 66.37, 73.50  
 in androgenetic alopecia 66.24, 66.25, 73.49–50  
 indications 73.50  
 mechanism of action 73.50  
 minute keratoses 19.92–3  
 miosis, in Horner's syndrome 63.22  
 MIP-1 $\alpha$  12.16, 12.18, 12.25, 12.39, 12.45, 12.46, 13.4  
 MIP-1 $\beta$  12.46  
 miracidia 37.20, 37.23  
 MIRL (CD59) 14.4  
 miRNA 3.50  
 mirror watching 64.19  
 mirtazapine 21.17, 21.18, 64.51, 75.79

- mites 38.36–54  
 rosacea pathogenesis 43.2–3  
*see also Demodex*  
 MITF gene, Waardenburg's syndrome 58.44  
 Mitf protein 58.3  
 mitochondria  
 DNA damage, UVR-induced 8.21, 29.7  
 radical oxygen species 12.55  
 sebaceous cells 42.3  
 toxicity of antiretroviral drugs 35.22  
 mitochondrial keratoderma with deafness 19.109  
 mitogen-activated protein kinases (MAPKs) 12.8–9  
 ageing and 8.22  
 mitogens, for melanocytes 58.5  
 mitomycin 26.46, 75.128  
 mucous membrane pemphigoid 40.40  
 mitral incompetence 45.30  
 mitral valve prolapse 70.3  
 in Marfan's syndrome 45.30  
 in pseudoxanthoma elasticum 45.22  
 Mitsuda reaction 32.15  
 Mitsuda test 5.24  
 mixed connective tissue disease 51.110–12  
 immunology 51.111  
 oral involvement 69.71  
 respiratory tract involvement 62.82  
 UI-RNP, specific antibody 51.110, 51.112  
 mixed immunobullous disease 40.49  
 mixed tumour of the skin 53.30–2  
 mizolastine 22.29, 75.149  
 adverse effects 22.29  
 MLH1, Muir-Torre syndrome 53.15  
 MLH1 gene 52.10  
 MLS syndrome *see* MIDAS syndrome  
 MMPs *see* matrix metalloproteinases (MMPs)  
 MMR (measles, mumps and rubella) vaccination 33.71  
 MMS *see* Mohs' micrographic surgery  
 MOAHL index 26.3  
 MOAHLFA index 26.3  
*Mobiluncus* spp., vaginal discharge 71.53  
 Mohr's syndrome 68.4  
 Mohs' micrographic surgery 54.43, 77.29–34  
 adjuvant radiotherapy 79.7  
 basal cell carcinoma 52.22, 77.30, 77.32, 77.33  
 eyelids 67.35  
 comparison with traditional surgery 77.29, 77.30, 77.31  
 complications 77.8, 77.9  
 definition 77.29  
 dermatofibrosarcoma protuberans 56.13  
 history 77.29  
 indications and practical aspects 77.32–3  
 nail unit 65.48  
 non-melanoma skin cancer 52.16, 52.17  
 procedure 77.31, 77.32  
 results 77.32  
 squamous cell carcinoma 52.27, 77.32  
 in dystrophic EB 39.30  
 tumours recurring after radiotherapy 79.17–18  
 moisture, pressure ulcers 28.21  
 moisturizing creams 27.9  
 molars, mulberry 34.17  
 Mole Max system™ 54.38  
 molecular biology 11.1–22  
 molecular genetics, keratinizing disorders 19.1–4, 19.94–5  
*see also specific disorders*  
 molecular immunology 13.23  
 molecular mimicry, vasculitis and 50.5  
 molephobia 64.24–5  
 moles (acquired melanocytic naevi) 54.15–21, 54.16  
 Moll's gland 67.2  
 cyst 67.33  
 mollusca fibrosa 15.17  
 molluscipox viruses 33.5, 33.11, 35.30  
 molluscs 38.59  
 in HIV infection 35.30–1  
 pigment cells 2.5  
 molluscum bodies 33.11  
 molluscum contagiosum 33.11–14, 71.34  
 aetiology 33.11  
 agminate form 33.11  
 antibody formation 33.11  
 atopic dermatitis with 24.24, 33.11, 33.12  
 children 33.12  
 clinical features 33.11–12  
 cytodiagnostics 10.29  
 diagnosis 33.12  
 distribution of lesions 33.12  
 ear 68.28  
 eczema associated 23.24  
 epidemiology 33.11  
 eyelids 67.24–5  
 follicular 33.12  
 giant 33.11  
 in HIV infection 33.11, 35.30–1, 35.45, 68.28  
 immune response 33.12, 33.13  
 immunodeficiency and 17.52, 17.53, 33.11  
 MCV-1 and MCV-2 33.11  
 treatment 33.12–13, 35.30–1, 77.50  
 topical imiquimod 73.24  
 molluscum fibrosum gravidarum 8.13  
 molluscum sebaceum *see* keratoacanthoma  
 mometasone furoate 73.16  
 'Mona Lisa smile' 64.36  
 Mondor's disease 38.56, 47.30, 47.31, 48.29, 62.43, 70.16  
 breast carcinoma associated 62.43, 70.16  
 thrombophilia 62.91, 70.16  
 Mongolian spot 17.5, 54.7–8, 58.1, 58.36  
 in phakomatosis pigmentovascularis 18.69  
 race and 9.11  
 skin biopsy 10.43  
 mongolism *see* Down's syndrome  
 monilethrix 15.47, 66.61–3  
 moniliasis *see* candidiasis  
 monkeypox 33.7  
 monkeys, herpes B virus infection from 33.34  
 monoamine oxidase inhibitors 75.79  
 monobenzene 73.27  
 monobenzylether of hydroquinone (monobenzene) 27.15, 73.27  
 hypermelanosis treatment 58.39  
 monochloroacetic acid 77.48  
 wart treatment 33.49  
 monoclonal antibodies 19-DEJ-1 39.25  
 adverse effects 75.146  
 epidermolysis bullosa diagnosis 39.25  
 therapeutic 13.25, 13.26, 57.28  
 monoclonal gammopathy of uncertain significance 13.15  
 monoclonality/tumours, pigmented purpuric dermatoses and 49.23  
 monocyte(s) 12.26–9, 17.48  
 chemotaxis, isotretinoin effect 42.58  
 development/ontogeny 5.1, 5.2  
 emigration 12.74–5  
 in granuloma inguinale 34.37  
 half-life 5.1  
 histiocyte ontogeny 5.1, 5.2  
 malignancies 55.31–4  
 maturation 5.1  
 microscopy 10.34  
 incidence 51.68  
 laboratory abnormalities 51.73–4  
 linear morphoea 51.69–70  
 localized scleroderma in children 51.71  
 ocular lesions 51.70  
 monocyte-macrophage system 12.26–9, 13.5  
 major functions of monocytes/macrophages 12.27  
 major products released 12.27  
 major receptors expressed 12.27  
 role of macrophages in immunity 12.29  
*see also* macrophage(s); monocyte(s)  
 monocytic leukaemia 55.31–2  
 monomethylether of hydroquinone, depigmentation due to 58.50  
 mononeuritis multiplex 61.7, 63.11  
 in HIV infection 63.12  
 mononuclear cells, Sézary-like 57.18  
 mononuclear phagocytes 4.8  
 increased in ageing skin 8.22  
 Langerhans' cells 3.17  
 mononucleosis  
 CMV causing 33.29  
 HHV-6 associated 33.32  
*see also* infectious mononucleosis  
 monosodium glutamate 22.11, 43.16  
 monostotic fibrous dysplasia 68.28  
 monosulfiram 38.41  
 monosymptomatic delusions of malodour 44.19  
 mons pubis 71.54  
 Monsel's solution 10.4, 10.31, 77.50  
 montelukast 12.61, 13.4, 74.31–2  
 adverse effect 75.150  
 in delayed pressure urticaria 22.14  
 dose range and evidence level 74.31  
 Montgomery's disease *see* xanthoma disseminatum  
 mood stabilizers 64.52  
 Moon's molars 69.8  
 Moore-Federman syndrome 51.79  
 Moraceae 26.81  
 morado (pinta) 30.63–4  
*Moraxella* 30.46–7  
 morbakka 38.56  
 morbidity 6.6  
 Morbihan's disease 43.4, 48.13, 48.16  
 morbilli *see* measles  
*Morbilivirus* 33.75  
 morbus Dercum (Dercum's disease) 8.17, 46.46, 46.47–9, 48.20  
 morbus errorum 38.22  
 Morgellons syndrome 64.12, 64.17  
 Moroccan leather skin appearance 45.21, 45.22  
 morphine  
 adverse effects 75.87  
 in burns 28.79  
 pruritus and 21.3  
 morphoea 51.64–78  
 atrophoderma of Pasini and Pierini and 45.8  
*Borrelia* and 30.65, 45.10  
 breast hypoplasia and 70.6, 70.7  
 children, methotrexate and systemic corticosteroids 74.20  
 en coup de sabre 66.48, 66.49  
 generalized 51.76–8  
 aetiology 51.77  
 clinical features 51.77–8  
 differential diagnosis 51.78  
 granuloma annulare and 60.9  
 linear 51.69–70, 66.48, 66.49  
 localized 51.64–75  
 aetiology 51.64–5  
 associated lesions 51.72–3  
 chronic graft-vs-host disease and 51.65  
 clinical features 51.68–9  
 differential diagnosis 51.74  
 drug-associated 51.65  
 frontoparietal lesions 51.70  
 immunohistochemistry 51.67  
 incidence 51.68  
 laboratory abnormalities 51.73–4  
 linear morphoea 51.69–70  
 localized scleroderma in children 51.71  
 ocular lesions 51.70  
 pansclerotic morphoea in children 51.71–2, 51.75  
 pathology 51.67  
 post BCG vaccination 51.65  
 prognosis 51.74  
 superficial morphoea 51.69  
 treatment 51.74–5  
 types 51.64  
 pansclerotic, in children 51.71–2, 51.75  
 pigmentation changes 58.26  
 post-irradiation 62.16, 62.40  
 race and 9.14  
 radiotherapy site 70.6  
 superficial 51.69  
 synonyms 51.64  
 morphoea profunda (deep morphoea), panniculitis in 46.31  
 morpholines, topical 73.12  
 morsicatio buccarum 69.87–8  
 mortality 6.6  
 due to adverse drug reactions 75.2, 75.5  
 Mortimer's malady 61.1  
 Morton Bay stinger 38.56  
 Morton's metatarsalgia (Morton's neuroma) 56.45  
 morula cells 37.31  
 morulae 30.58  
 Morvan's syndrome 63.14  
 mosaic acral keratosis 19.115  
 mosaicism 18.1, 18.3  
 chromosomal abnormalities 15.11  
 epidermal naevi and 18.5  
 functional 15.6  
 gonadal 15.6  
 lichen striatus and 23.41  
 Moschowitz's syndrome (thrombotic thrombocytopenic purpura (TTP)) 49.12, 49.31, 69.114  
 mosquito bites, hypersensitivity 33.31  
 mosquitoes 37.9, 37.27, 38.2, 38.5, 38.6–7  
 mossy foot *see* podocniosis  
 moths 25.21, 38.28–30  
 motor innervation, skin 3.2  
 motor neuropathy 51.132  
 moulds 9.12, 36.2  
 identification 36.9–10  
 saprophytic 36.17–18  
*see also* fungi  
 moult waves 66.27, 66.33  
 moulting  
 animals 2.3  
 seasonal 2.3, 66.8–9  
 waves 66.8  
 mouse  
 coat colour mutants 58.4  
 hypomorphic 11.11  
 knockout 2.7, 11.11  
*microphthalmia* 2.7  
 mites 38.51  
 models  
 assessment of dermatitic potential 27.10  
 multistage carcinogenesis 52.12–13, 52.15  
 neonatal, acantholysis 40.5  
 pigment mutants 58.4  
 strains with cancer induction susceptibility 52.13  
 transgenic 2.7, 11.10–11  
 triple knockout 2.8  
 mouse ear swelling test 26.12  
 mouse fingers 28.27  
 mouth *see* oral cavity  
 mouthwash 69.119–20  
 pigmented melanotic macules 54.6–7  
 movingui 26.80  
 moxibustion 9.8  
 Moynahan's syndrome 66.59–60  
 MPNST (malignant peripheral nerve sheath tumours) 56.53  
 MPS *see* mucopolysaccharidoses (MPS)  
 MRI *see* magnetic resonance imaging (MRI)

- MRSA *see* methicillin-resistant  
*Staphylococcus aureus* (MRSA)
- MSH *see* melanocyte-stimulating hormone (MSH)
- MSH2 gene 52.10
- MSH2 protein, Muir–Torre syndrome 53.15
- MSX1 gene 15.65
- mTOR signalling 48.30
- MTS *see* Muir–Torre syndrome
- MTT assay (dimethylthiazoldiphenyl tetrazolium bromide assay) 25.9
- MUC1 53.41
- MUC5AC 53.41
- Mucha–Habermann disease (pityriasis lichenoides) 57.54–7  
febrile ulceronecrotic 50.50–1  
oral involvement 69.85  
pityriasis lichenoides et varioliformis acuta 50.50–1, 69.85
- mucicarmine 36.90
- mucin 59.21  
abnormal deposits, Degos' disease 49.45  
in basal cell carcinoma 52.21  
in granuloma annulare 60.4  
pretibial deposition 8.17  
stains 53.36  
tear film 67.3
- mucinosis 59.21–9  
areola 70.17  
chronic obesity lymphoedematous 62.8  
classification 59.21  
cutaneous focal 59.25  
focal, oral 69.39  
follicular 57.14, 59.26  
hereditary progressive mucinous histiocytosis 59.25  
lichen myxoedematous 59.21–3  
mucinous naevus 59.25  
papular 62.45  
acral persistent 59.24  
of infancy 59.24  
juvenile and adult 59.24  
in L-tryptophan-induced eosinophilia–myalgia syndrome 59.29  
plaque-like cutaneous 59.25  
reticular erythematous 59.25  
secondary 59.29  
collagen vascular diseases 59.29  
in L-tryptophan-induced eosinophilia–myalgia syndrome 59.29  
papulonodular mucinosis with SLE 59.29  
toxic oil syndrome 59.29  
in SLE 51.40
- mucinous carcinoma 53.36–7
- mucinous cysts, female genital dermatology 71.73
- Muckle–Wells syndrome (cryopyrin-associated autoinflammatory syndrome) 15.95–6, 22.13, 59.57, 74.11
- mucocoele 69.22, 69.65, 69.84, 69.110
- mucocutaneous candidiasis–endocrinopathy syndrome (autoimmune polyglandular (polyendocrine) syndrome) 13.13, 15.31, 36.64, 62.12–14
- mucocutaneous lymph-node syndrome *see* Kawasaki disease
- mucoepidermoid carcinoma, external auditory canal 68.33
- muroid cysts, male genital dermatology 71.35
- mucopolipidoses 59.32
- mucopolysaccharides  
in scleroedema 51.119  
*see also* glycosaminoglycans (GAGs)
- mucopolysaccharidoses (MPS) 59.30–2  
classification 59.31  
clinical features 59.30  
diagnosis and treatment 59.32  
eponyms 59.31
- hypertrichosis in 66.76  
oral involvement 69.117  
prenatal diagnosis 16.3  
sweat gland cellular inclusions 44.18
- Mucor*  
otitis externa and 68.21  
vessel-invasive infection 49.35
- mucormycosis *see* zygomycosis
- mucosa  
in allergic contact dermatitis 26.20–1  
biopsy 10.32  
in sarcoidosis 61.19  
buccal (cheek)  
examination 69.5–6  
lichen planus-like reactions 26.26  
in erythema multiforme 76.7  
examination in fungal infection 36.6  
eyelids 67.2  
in generalized non-Herlitz junctional EB 39.13  
in hereditary haemorrhagic telangiectasia 47.17  
hyperpigmentation, Addison's disease 58.24  
labial 69.5  
in lichen nitidus 41.22  
in lichen planus *see* lichen planus  
in lupus vulgaris 31.17  
in multicentric reticulohistiocytosis 55.24  
oral cavity 69.2  
disorders 69.21–115  
hyperpigmentation 69.95  
in sarcoidosis 61.15  
in Stevens–Johnson syndrome 76.16  
surgical excision in 77.15  
in syphilis  
congenital 34.15  
primary 34.7  
secondary 34.9, 34.10, 34.11  
tertiary 34.14  
in toxic epidermal necrolysis 76.17
- mucosa-associated lymphoid tissue (MALT) 57.2  
lymphomas 57.2, 57.43
- mucosal advancement 77.36
- mucosal barrier injury *see* mucositis
- mucosal melanotic lesions 54.6–7
- mucositis 69.82, 79.10  
plasma cell orificial 69.128
- mucous membrane pemphigoid (MMP) 40.35–41, 67.17–20, 71.66  
aetiology 40.36  
in animals 2.15  
associated diseases. 40.39  
clinical features 40.38–9  
defined 40.35  
differential diagnosis 40.34, 40.40  
epidermolysis bullosa acquisita 40.54  
immunoelectron microscopy 10.29  
immunopathology and immunogenetics 10.18  
linear IgA 40.49  
ocular 67.17–20  
clinical features 67.17, 67.18  
conjunctival biopsy 67.19  
diagnostic criteria 67.19  
differential diagnosis 67.19–20  
direct immunofluorescence 67.17, 67.19  
epidemiology 67.17  
immunopathology 67.20  
indirect immunofluorescence 67.19  
oral involvement 69.65, 69.67–8  
pathogenesis 40.36–8, 67.20  
pathology 40.36–8  
predominantly ocular  
diagnostic criteria 67.19  
diagnostic problems 67.17, 67.19  
prognosis 40.40  
treatment 40.40–1  
*see also* cicatricial pemphigoid
- mucous membranes *see* mucosa
- mucoviscidosis 59.59
- Mucuna pruriens* 21.4
- mucinain 21.4
- multi-chood 68.16  
race and 9.7–8
- Muehrcke's paired white bands 65.15
- Muir–Torre syndrome (MTS) 52.10, 53.15, 53.16, 62.26, 62.35  
sebaceous adenoma association 42.87  
sebaceous carcinoma association 53.17
- mulberry-like erosion 36.87
- mulberry molars 34.17, 69.8
- Muller technique (phlebectomy) 47.39
- Müllerian ducts, atrophy 8.2
- multicentric carcinoma, male genital dermatology 71.42
- multicentric Castleman's disease 56.24
- multicentric reticulohistiocytosis 55.23–5  
bone and joint involvement 62.101, 62.104  
clinical features 55.23–4  
oral involvement 69.59  
paraneoplastic 62.41  
respiratory tract involvement 62.83
- Multiceps* 37.24
- multidrug regimen, in leprosy 32.16–17
- multidrug resistance 1 (*MDR-1*) gene 72.29
- multifactorial disorders, genetics 15.2
- multinucleate giant cells  
Langerhans' cell histiocytosis 55.8  
multicentric reticulohistiocytosis 55.23  
VZV infection 33.24  
*see also* giant cell(s)
- multiorgan syndrome 49.38
- multiple carboxylase deficiency 17.25, 17.30
- multiple decarboxylase deficiency 59.65
- multiple endocrine neoplasia (MEN)  
type 1 62.24, 62.68  
type 2A 59.48, 62.24  
type 2B (type 3) 62.24–5, 69.36
- multiple endocrinopathy syndrome *see* autoimmune polyglandular (polyendocrine) syndrome
- multiple hamartoma syndrome *see* Cowden's syndrome
- multiple hamartoma (and neoplasia) syndrome *see* Cowden's syndrome
- multiple lentiginos (LEOPARD) syndrome *see* LEOPARD syndrome
- multiple mucosal neuroma syndrome 59.48, 62.24
- multiple myeloma 62.92–5  
oral 69.114, 69.116  
sarcoidosis and 61.17
- multiple neurofibromas 15.16, 15.17  
*see also* neurofibroma; neurofibromatosis
- multiple organ failure, pigmentation changes 58.27
- multiple self-healing epithelioma of Ferguson-Smith 52.9–10
- multiple sulphatase deficiency 19.13
- multipotent cells, neural crest 58.3
- multistage carcinogenesis *see* carcinogenesis
- Mulvihill–Smith syndrome 45.60
- MUM-1 10.25
- mumps 69.118  
MMR vaccination 33.71
- Münchhausen's syndrome 64.44  
factitial panniculitis 46.28
- Münchhausen's syndrome by proxy 28.39, 64.44–5
- Munro microabscess 10.41, 65.25
- mupirocin  
in impetigo 30.16  
resistance to 30.9  
topical therapy 73.10
- muriform cells 36.75, 36.76
- murine model  
multistage carcinogenesis 52.12–13, 52.15  
*see also* mouse
- muromonab 13.25
- Murray Valley virus 33.67
- Murray–Puritic–Drescher syndrome (juvenile hyaline fibromatosis) 45.49–50, 69.15
- Musca domestica* 38.6, 38.8
- muscarinic receptors, sweat gland 3.12
- Muscidae 38.6, 38.7, 38.8
- muscle  
atrophy 47.11  
growth between birth and maturity 8.1  
in sarcoidosis 61.7  
in SLE 51.47  
in systemic sclerosis 51.101–2, 51.105  
tumours 56.54–7  
weakness, in leprosy 32.18
- muscle glycogenosis, scleroderma-like lesions 51.79
- muscle herniation of the limbs 28.61–2
- muscular dystrophy 3.35  
with autosomal recessive EB simplex 39.8  
EB simplex with 39.4  
late-onset 3.31
- musculoskeletal system, in dystrophic EB 39.29
- music box spine keratodermas 19.114
- musical instrument injuries 28.25–6
- musk ambrette 26.23, 26.24, 26.41
- mustard gas burns 27.11
- mustards 25.21
- mustine *see* mechlorethamine; nitrogen mustard
- mutagenesis  
UV radiation causing 52.13–14  
*see also* DNA damage
- mutator genes 52.12
- mutating keratoderma with ichthyosis (loricrin keratoderma) 19.3, 19.19, 19.94, 19.98
- myasthenia gravis, with autosomal recessive EB simplex 39.8
- mycelium 36.2
- mycetoma 30.75, 36.72–5  
aetiology 36.72–3  
clinical features 36.73  
definition 36.72  
differential diagnosis 36.73–4  
histology 36.73  
laboratory diagnosis 36.74  
treatment 36.74
- Mycobacterial Growth Indicator Tube (MGIT) 31.6
- mycobacterial infections 74.42  
atypical, in HIV infection 35.25–6  
diagnosis 31.6–7  
epidemiology 31.2–3  
ocular involvement 67.27
- Mycobacterium* 31.1  
cell wall structure 31.1  
characteristics 31.1, 31.2  
epidemiology 31.2–3  
fast growers 31.1, 31.2, 31.38–41  
HIV infection and 31.7  
non-tuberculous 31.1, 31.30–41  
epidemiology 31.2–3  
slow growers 31.1, 31.2, 31.6
- Mycobacterium abscessus* 31.38–40
- Mycobacterium avium* complex 31.36–7, 69.79  
diagnosis of infection 31.6  
ectodermal dysplasias 15.60  
HIV infection and 31.7  
sarcoidosis and 61.2
- Mycobacterium avium-intracellulare*, HIV infection 35.25–6
- Mycobacterium balnei* *see* *Mycobacterium marinum*
- Mycobacterium bovis* 31.8, 31.10, 31.11, 31.28  
in malakoplakia 55.27
- Mycobacterium chelonae* 31.7, 31.38–40, 69.79
- Mycobacterium fortuitum* complex 31.3, 31.7, 31.38–40

- Mycobacterium genavense* 31.41  
*Mycobacterium goodii* 31.38  
*Mycobacterium goodii*  
 diagnosis of infection 31.6  
 HIV infection and 31.7  
*Mycobacterium haemophilum* 31.40–1  
*Mycobacterium immunogenum* 31.38  
*Mycobacterium kansasii* 31.2, 31.33  
 diagnosis of infection 31.6  
 HIV infection and 31.7  
*Mycobacterium leprae* 32.1–2, 32.2–3  
 antibodies to 32.7  
 female genital infections 71.67  
 see also leprosy  
*Mycobacterium malmoeense* 31.41  
*Mycobacterium marinum* 31.30–3  
 diagnosis of infection 31.6  
 differential diagnosis 31.13, 60.9  
 ear infection 68.17, 68.20  
 sarcoidosis and 61.2  
 in sea urchin granuloma 38.58  
 swimming and diving 28.54  
*Mycobacterium mucogenicum* 31.38–40  
*Mycobacterium parascrofulaceum* 31.35  
*Mycobacterium paratuberculosis*, sarcoidosis and 61.2  
*Mycobacterium peregrinum* 31.38  
*Mycobacterium platyepididymum* see *Mycobacterium marinum*  
*Mycobacterium scrofulaceum* 31.7, 31.35–6  
*Mycobacterium simiae* 31.2  
*Mycobacterium smegmatis* 31.38–40  
*Mycobacterium szulgai* 31.36  
*Mycobacterium terrae* 31.7  
*Mycobacterium tuberculosis* 31.1, 31.8, 32.1  
 detection by PCR 31.26  
 female genital infections 71.67  
 in HIV infection 35.25  
 protective immunity to 31.4  
 re-emergence 31.2  
 sarcoidosis and 61.2  
 staining 10.10  
 see also tuberculosis  
*Mycobacterium ulcerans* 31.6, 31.33–5  
 Buruli ulcer 12.9  
*Mycobacterium wolinskyi* 31.38  
*Mycobacterium xenopi* 31.2, 31.7, 31.41  
 mycolactone 31.33, 31.34  
 mycophenolate mofetil 13.24, 20.42, 72.27, 72.29, 74.24–5  
 adverse effects 20.42, 74.24  
 in atopic dermatitis 24.31  
 clinical indications 74.24  
 in lichen sclerosus 51.118  
 in mucous membrane pemphigoid 40.40  
 in pemphigus 40.12  
 in sarcoidosis 61.21  
 in urticarial vasculitis 50.23  
 mycophenolate sodium 74.24  
*Mycoplasma* 30.69–70  
 infection 62.80  
 seal finger and 38.61  
 Stevens–Johnson syndrome and 30.69, 62.80  
*Mycoplasma hominis*, female genital infections 71.68  
 mycoses see fungal infections  
 mycosis fungoides 57.1–13  
 aetiology 57.3  
 allergic contact dermatitis and 26.9  
 classification  
 ISCL EORTC revised staging classification 57.7, 57.11  
 TNM classification 57.6  
 clinical features 57.3–4  
 differential diagnosis 26.30, 57.5  
 pathological differential diagnosis. 57.10–11  
 diffuse progressive hyperpigmentation 58.26  
 ear 68.34  
 follicular mucinosis and 57.14  
 in HIV infection 35.41  
 hypopigmented 9.7  
 invisible 21.10  
 ISCL diagnostic criteria for early MF 57.11  
 molecular pathogenesis 57.19  
 abnormalities of T-cell activation 57.20  
 dysregulated T-cell signalling pathways 57.21  
 gene expression studies 57.21  
 oral involvement 69.58  
 pathology 57.8  
 extracutaneous disease 57.11  
 immunopathology 57.10  
 pigmented purpuric dermatoses and 49.23  
 poikilodermatous 45.13  
 hypopigmentation in 58.52  
 pregnancy and 8.12  
 prognosis 57.7, 57.8  
 pruritus in 21.10  
 race and 9.7  
 skin directed therapies 57.23–5  
 PUVA 57.24  
 radiotherapy and electron beam therapy 57.24–5  
 staging classification, revised 57.7, 57.11  
 systemic therapies 57.25–9  
 combination therapy 57.25–6  
 doxorubicin 57.27  
 extracorporeal photopheresis 57.27  
 histone deacetylase inhibitors 57.28  
 immunotherapy 57.25  
 monoclonal antibody therapy 57.28  
 randomized trials 57.22  
 retinoids 57.25  
 T-cell receptor gene analysis 57.12–13  
 see also Sézary syndrome  
 myelitis, transverse, in zoster 33.26  
 myelocytic leukaemia 57.62  
 myelodysplastic syndrome 62.88–9, 69.57  
 in multicentric reticulohistiocytosis 55.24  
 myelofibrosis, idiopathic, pigmentation changes 58.26  
 myeloma see multiple myeloma  
 myeloma-associated amyloidosis 59.50  
 myelomeningocele 18.95  
 myeloperoxidase 13.4  
 deficiency 13.4, 69.117  
 myeloproliferative disorders 49.29–30  
 cutaneous lesions 49.29–30  
 leg ulcers 47.56  
 MYH-associated polyposis 53.12  
 myiasis 38.2, 38.8–11  
 Mylbris 38.26, 38.27  
 myoblastoma  
 congenital epulis 69.17  
 granular cell 71.73  
 myocarditis, chagasic 37.32  
 myoepithelioma 53.31  
 myofibroblastic tumours 56.2–14  
 myofibroblasts  
 microscopy 10.35  
 in palmar fibromatosis 45.45  
 in wound healing 14.1, 14.7  
 myofibroma, adult 56.9  
 myofibromatosis, infantile 18.35, 56.9  
 myoma, pinna 68.28  
 myonecrosis, clostridial see gas gangrene  
 myopathy  
 inflammatory, HTLV-1 infection 33.65  
 partial lipodystrophy 46.40  
 in sarcoidosis 61.7  
 myopericarditis, vaccinia vaccination 33.6  
 myopericytoma 56.42–3  
 myosin Va, melanosome transfer along melanocyte dendrites 58.4  
*Myroxylon perirae* see balsam of Peru  
 myths, skin and skin disease 64.1  
 myxoedema  
 palmoplantar keratoderma with 19.118  
 see also hypothyroidism; pretibial myxoedema  
 myxofibrosarcoma 56.22  
 myxoid cyst  
 nail 65.17, 65.36–7  
 surgery 77.36, 77.38  
 myxoid degeneration 10.38  
 myxoma  
 cardiac 62.78–9  
 embolism 50.54  
 see also atrial myxoma  
 dermal nerve sheath 56.49–50  
 digital 56.59  
 oral cavity 69.113  
 myxoma syndrome 62.25  
 myxoviruses 33.75  
 N  
 Na-K-ATPase 44.3, 44.4  
 nabumetone 75.77  
 NADPH oxidase 12.54, 13.4, 13.5  
 Naegeli–Franceschetti–Jadassohn syndrome 15.48, 58.19–20  
 Naegeli's syndrome 58.19–20  
 naevi see naevus  
 naevoid basal cell carcinoma syndrome 52.5, 52.6–8, 62.20, 62.21  
 aetiology and incidence 52.6–7  
 basal cell carcinomas 52.6, 52.7, 52.8  
 recurrence 52.8  
 bone and joint involvement 52.7, 62.101  
 clinical features 52.7  
 diagnosis 52.7  
 genetics 52.6–7  
 malignancies in 52.7  
 oral involvement 52.7, 69.39–40  
 pathology 52.7  
 treatment 52.7–8, 73.23  
 naevoid bullous ichthyosiform erythroderma 19.31  
 naevomelanocytes 54.30  
 naevoxanthoendothelioma see juvenile xanthogranuloma  
 naevus 18.1–80  
 acantholytic dyskeratotic epidermal 19.83, 65.18  
 achromic (naevus depigmentosus) 58.42, 58.44–5  
 acne 18.11–13, 42.78  
 acne-free 18.13  
 aetiology 18.2–3  
 apocrine 18.14–15  
 atypical/dysplastic 54.16, 54.19, 54.27–32, 71.47  
 male genitalia 71.47  
 melanoma development 54.28, 54.29–30, 54.31  
 melanoma vs 54.38  
 balloon cell 54.17  
 basal cell with comedones 18.13–14  
 bathing-trunk (giant) 54.11, 54.12  
 Becker's 18.17–19, 62.101, 66.77, 78.10  
 with hypomastia 70.3  
 benign, excision 77.15  
 blue 54.16, 54.25–7, 58.1, 58.37  
 compound 54.26  
 'malignant' 54.26, 54.27  
 oral mucosa 69.29  
 skin biopsy 10.43  
 cartilage (accessory tragus (auricle)) 18.84–5, 68.4  
 cellular (acquired melanocytic) 54.15–21, 54.16  
 cellular blue 54.25–7  
 CHILD 18.21–3, 19.57  
 classification 18.3, 18.4  
 cockade 18.96, 54.20–1  
 collagen 18.31–2  
 combined (blue/cellular blue) 54.26  
 comedo/comedone 18.11–13, 71.38  
 compound 54.10, 54.15, 54.16, 69.29  
 pathology 54.18  
 compound blue 54.26  
 congenital melanocytic 54.10, 54.10–15  
 giant see naevus, giant congenital melanocytic  
 conjunctival 54.18  
 connective tissue 18.30–5  
 deep penetrating 54.26  
 definition 18.1  
 dermal 18.30–40, 54.11  
 dermatitic epidermal (inflammatory linear verrucous) 18.19–21, 20.17  
 desmoplastic 54.22, 54.24  
 dilated pore 18.14  
 dysplastic see naevus, atypical/dysplastic  
 eccrine 18.15–17  
 eccrine angiomatous 18.16  
 elastic 18.32–4  
 epidermal 18.4–40  
 linear 5.11  
 epidermal syndrome 54.11  
 fat 18.37–40  
 faun tail 53.6, 66.77  
 female genitalia 71.72  
 fibrous tissue 18.34–5  
 follicular 18.10–14  
 garment 54.11, 54.12  
 genetic factors 18.2–3  
 giant congenital melanocytic 54.11, 54.12, 54.13, 63.15  
 childhood melanoma 54.48–9  
 hair-follicle 53.6  
 halo (Sutton's) 54.19–20, 54.39, 58.49–50  
 inflammatory linear verrucous epidermal (ILVEN) 18.19–21, 20.17  
 intradermal 54.10, 54.15, 54.16–17, 54.18, 69.29  
 pathology 54.18–19  
 of Ito 54.9, 58.37  
 race and 9.17  
 junctional 54.10, 54.15, 54.17, 69.29  
 pathology 54.18  
 shape/colour variations 54.19  
 linear basal cell 18.13–14  
 linear connective tissue 18.31  
 proteoglycan type 18.34  
 male genitalia 71.11–12, 71.47  
 malignant blue 54.26, 54.27  
 melanocytic 15.12–13, 54.9  
 acquired 54.15–21, 54.16  
 atypical/dysplastic 54.27–32  
 blue/blue-black 54.25–7  
 common acquired 54.16  
 compound 54.11  
 congenital 54.10, 54.10–15  
 dermal 54.11  
 development/evolution 54.18–19  
 female genital region 71.72  
 giant congenital 54.11, 54.12, 54.13, 63.15  
 giant congenital, childhood melanoma 54.48–9  
 laser therapy 78.11  
 male genital region 71.11–12  
 melanoma differential diagnosis 54.19, 54.38–9  
 numbers and melanoma risk 54.33  
 pinna 68.28  
 prevalence 54.9  
 race and 9.17  
 terminology 54.10  
 unusual sites 54.17–19  
 Meyerson's 54.20  
 mucinous 18.34  
 muscle 18.35–7  
 naevocytic (acquired melanocytic) 54.15–21, 54.16  
 nail matrix/bed 54.18  
 non-acne 42.78  
 number  
 melanoma risk 54.33  
 sunscreen use relationship 73.41  
 oral cavity 69.29  
 organoid, syringocystadenoma papilliferum 53.19  
 of Ota 54.8–9, 58.1, 58.36–7  
 bone and joint involvement 62.100  
 eyelid 67.34

- laser therapy 78.10, 78.11, 80.11  
 race and 9.17  
 pigmented  
 of eyelid 67.34  
 hairy *see* naevus, Becker's  
 with premature ageing and short stature 45.60  
 porokeratotic eccrine duct and hair follicle 18.17  
 porokeratotic eccrine ostial and dermal duct 18.11, 18.16–17  
 proteoglycan 18.34  
 pure eccrine 18.15–16  
 reticulate vascular *see* cutis marmorata  
 telangiectatica congenita  
 satellite 54.11, 54.12  
 sebaceous 18.8–10, 42.78, 46.46, 69.23  
 bone and joint involvement 62.100  
 eccrine poroma in 53.23  
 segmental 18.2  
 shave biopsy 77.12  
 speckled and lentiginous 5.14, 54.14, 78.10  
 spider 5.19  
 treatment 77.46  
 spindle cell, of Reed 54.22, 54.23  
 Spitz (spindle and epithelioid cell) 54.14, 54.16, 54.21–5  
 agminate 54.22  
 desmoplastic 54.22, 54.24  
 differential diagnosis 54.23–4, 54.39  
 microscopy 10.35  
 multiple 54.22  
 sites and types 54.22  
 strawberry 18.40–52, 18.96  
 eyelids 67.34  
*see also*  
 haemangioma,  
 infantile/capillary  
 subcutaneous 18.30–40  
 subungual 65.38, 65.39  
 Sutton's *see* naevus, halo (Sutton's)  
 sweat glands 44.9  
 systematized 18.2  
 trichilemmal cyst 53.4  
 true apocrine 18.14  
 true hair-follicle 18.10–11  
 vascular 18.40–80  
 eyelid 67.34  
 race and 9.19  
 verrucous epidermal 18.5–8  
 warty, retinoic acid therapy 73.36  
 white-sponge 35.43, 69.23–4  
 woolly hair 66.71  
 zosteriform 18.2  
 naevus anaemicus 5.19, 18.65  
 with telangiectatic vessels 47.20  
 naevus anelasticus 18.33  
 naevus cells *see* melanocyte(s)  
 naevus comedonicus 18.11–13, 42.78  
 male genital 71.36  
 naevus depigmentosus 58.42, 58.44–5  
 naevus en cocarde 54.20–1  
 naevus flammeus  
 salmon patch 18.62–3  
*see also* port-wine stain  
 naevus follicularis 42.78  
 naevus fusco-caeruleus zygomaticus 54.9  
 naevus fusco-caeruleus  
 ophthalmomaxillaris *see* naevus, of Ota  
 naevus lipomatodes cutaneus superficialis 18.37–8  
 naevus mucinosus 18.34  
 naevus sebaceus of Jadassohn *see* naevus, sebaceous  
 naevus spilus 54.14  
 naevus sudoriferus (pure eccrine naevus) 18.15–16  
 naevus syringocystadenoma papilliferum 18.14–15, 53.19–20, 68.30  
 naevus unilateralis comedonicus 42.78  
 nafarelin, in acne vulgaris 42.53  
 naftifine 26.46, 36.47, 73.12  
 Nager syndrome 68.3  
 nail(s) 3.14–15  
 acrylic 26.16, 26.27, 26.47  
 acrylic gel systems 65.55–6  
 ageing 8.24, 65.7  
 in alopecia areata 66.35, 66.36  
 anatomy and structure 3.14–15  
 in arthritis 65.25  
 atrophy, Cronkhite–Canada syndrome 58.13  
 attachment abnormalities 65.9–12  
 avulsion, surgical 65.44  
 in Bazex syndrome 65.25  
 beading 65.14  
 Beau's line *see* Beau's lines  
 biopsy 65.41–9  
 biting/picking 64.33, 65.50–1  
 black streaks 58.14  
 braces 65.9  
 brittle 8.24  
 buffing 65.56  
 in childhood 65.6–7  
 childhood idiopathic atrophy 41.14  
 clubbing *see* finger(s), clubbing  
 colour changes 65.2, 65.14–18, 65.24  
 cosmetics 65.54–7  
 in crusted scabies 38.44  
 cuticle (eponychium) 3.14  
 in Darier's disease 19.82, 19.83, 65.27–8  
 degloving 65.10  
 dermatitis 65.28–9  
 development 3.3, 3.5, 3.14  
 developmental abnormalities 65.18–20  
 disease, measuring impact 72.20  
 distal ridge 3.14  
 drug-induced changes 65.16, 65.38–9, 75.46  
 pigmentation 75.33  
 dysgenesis with hypodontia 69.6  
 in dystrophic EB 39.21  
 ectodermal dysplasias 15.62, 15.64–6, 15.68–9  
 ectopic 18.92  
 elderly people 65.7  
 embryology 3.3, 3.5  
 exogenous pigment 65.14  
 factitious disorders 64.40  
 factors affecting rate of growth 65.5, 65.6  
 functions 3.3, 3.14, 4.1  
 fungal infection *see* onychomycosis  
 in generalized EB simplex 39.6  
 in generalized non-Herlitz junctional EB 39.13  
 grooves  
 longitudinal 65.12  
 transverse 65.12–13  
 growth  
 ageing and 8.24  
 linear 65.5–6  
 habit tic deformity 65.12, 65.24, 65.25, 65.51  
 in Hailey–Hailey disease 39.34  
 half-and-half 65.15  
 hang 65.51  
 hardeners 65.56  
 in Herlitz junctional EB 39.12  
 in hidrotic ectodermal dysplasia 19.106  
 in HIV infection 35.41–2, 35.42, 65.16, 65.23  
 in hyperthyroidism 62.8  
 hypertrophy 65.51, 65.52, 65.53  
 in hypoparathyroidism 62.12  
 infections 65.21–3, 65.28, 65.56–7  
*see also* onychomycosis  
 ingrowing 65.53–4  
 in childhood 65.6–7, 65.53  
 in HIV infection 35.41  
 treatment 65.48  
 lamellar dystrophy *see* onychoschizia  
 in Langerhans' cell histiocytosis (LCH) 55.11  
 in lichen nitidus 41.22, 65.29  
 in lichen planus 41.14, 41.15, 65.25, 65.29–30  
 in lichen sclerosus et atrophicus 65.29  
 in lichen striatus 65.29  
 linear growth 65.5–6  
 in liver disease 62.64  
 median canaliform dystrophy of Heller 65.12  
 melanoma under 54.44–6  
 mending kits 65.56  
 morphology 65.5  
 ageing and 8.24  
 multicentric reticulohistiocytosis 55.23–4  
 Neapolitan 65.15  
 in Nékam's disease 41.27  
 nutcracker 65.51  
 ostlers' 65.51  
 in pachyonychia congenita 19.3, 19.94, 19.103–4, 59.48  
 in peripheral nerve injury 63.14  
 photo-onycholysis 65.11, 65.16, 75.32  
 pigmentation 9.3  
 drug-induced 75.33  
 pincer (involved/trumpet) 65.8–9  
 pitting 65.13, 65.23–4  
 treatment 73.37  
 in pityriasis rubra pilaris 65.25  
 Plummer's 62.8  
 preformed plastic 65.26, 65.56  
 in pregnancy 8.10  
*Pseudomonas aeruginosa* infection 30.49, 65.10, 65.11, 65.21, 65.22  
 in psoriatic arthritis 20.57  
 pterygium inversum unguis 51.95  
 quitters 65.14  
 racket 65.9  
 in Reiter's syndrome 65.25  
 ridges, lichen planus 41.14  
 ridging 8.24, 65.7, 65.14  
 longitudinal 3.15  
 in sarcoidosis 61.11, 61.15  
 'sausage links' 8.24  
 in scabies 38.39, 38.44  
 in scleroatrophic syndrome of Huriez 45.12  
 sculptured 65.55  
 shedding 65.9–10  
 silicone rubber prostheses 65.56  
 in SLE 51.38  
 splinter haemorrhage 3.15, 49.7  
 spoon-shaped 65.8  
 squamous cell carcinoma 65.21–2, 65.37–8  
 subungual haematoma 65.49–50  
 subungual hyperkeratosis 20.16, 51.12  
 subungual melanoma 65.39–41  
 surgery 65.41–9  
 in syphilis 34.11  
 in systemic sclerosis 51.95  
 Terry's 65.15  
 thickening 65.12  
 trauma  
 acute 65.49–50  
 chronic repetitive 65.50–1  
 delayed 65.49  
 from footwear 65.51, 65.52, 65.53–4  
 malignant melanoma and 65.39  
 from manicure instruments 65.51  
 tumours involving 65.30–41  
 twenty-nail dystrophy 65.13, 65.29, 65.30  
 viral warts 65.30–1  
 washboard 65.12, 65.24  
 white bands 39.35  
 yellow nail syndrome 62.83, 65.12, 65.16–17  
*see also* toenails; *entries beginning subungual; specific nail structures*  
 nail apparatus 3.14–15  
 anatomy and biology 65.1–7  
 arteriovenous abnormalities 65.35–6  
 blood supply 65.4–5  
 development 65.1  
 fibrous tumours 65.31–2  
 function 65.1  
 microscopic anatomy 65.2–4  
 squamous cell carcinoma 65.37–8  
 surgery 65.41–4  
 nail bed 3.14, 3.15, 65.1, 65.2  
 adherent nature 65.5  
 biopsy 65.41, 65.44–5  
 blood supply 65.4  
 colour changes 65.15  
 development 65.5  
 keratinization 65.3  
 laceration 65.49  
 lichen planus 65.29  
 microscopic anatomy 65.2–3  
 naevi 54.18  
 pallor 65.15  
 pigmentation due to antimalarial drugs 58.30  
 role in creation of nail plate 65.5  
 squamous cell carcinoma 52.25  
 nail cream 65.56  
 nail fold 3.14  
 arteriovenous abnormalities 65.35–6  
 biopsy 65.46–7  
 biting 65.50  
 lateral 3.14, 65.1–2  
 microscopic anatomy 65.2  
 proximal/posterior 3.14, 65.1  
 telangiectases 47.14  
 nail fold capillaries  
 dermatomyositis 51.124  
 purpura 49.6  
 nail gel 65.26  
 nail matrix 3.14–15  
 biopsy 65.41, 65.43, 65.45–6  
 blood supply 65.4  
 cell kinetics 65.5  
 cellular structure 3.15  
 definition 65.2  
 melanoma 54.44–6  
 microscopic anatomy 65.2  
 naevi 54.18  
 phenolization 65.48, 65.53  
 nail plate 3.14, 65.1  
 anatomy 65.2, 65.5  
 biopsy 65.41, 65.47–8  
 colour changes 65.14–15  
 effects of ageing 65.7  
 microscopic anatomy 65.3  
 in psoriasis 65.24, 65.25  
 staining 65.54  
 thickness measurement 65.3  
 nail polish/lacquer 65.54–5  
 in psoriasis 65.26  
 nail polish/lacquer removers 65.55  
 Nail Psoriasis Severity Index 65.23, 72.9  
 nail unit 3.14–15  
*see also* nail apparatus  
 nail wall 65.2  
 nail whitener 65.56  
 nail wrapping 65.56  
 nail–patella syndrome 15.8, 15.86–7, 65.19  
 bone and joint involvement 62.100  
 hyperhidrosis and 44.8  
 renal involvement 62.69  
*Naja nigricollis* 38.60  
 nalidixic acid 75.31, 75.60  
 naloxone 21.17  
 NALP-3 inflammasome 12.4  
 naltrexone 29.7  
 in pruritus 21.14, 21.18  
 NAME syndrome 49.37, 54.4, 58.14, 62.25, 62.79, 69.28  
 naming conventions, biological therapies 74.5  
 Nance–Horan syndrome 69.11  
 nano-indentation tests, mechanical injury 28.5  
 NAP-2 (CXCL7) 12.46, 12.74  
 naphthalene 27.12  
 naphthoquinone 66.97  
 napkin(s)  
 candidiasis 36.62, 36.68–9  
 disposable 17.25–6  
 emollient impregnation 17.26  
 frequency of change 17.26  
 washable 17.25, 17.26  
*see also* dermatitis, napkin (diaper)

- napkin dermatitis *see* dermatitis, napkin (diaper)
- napkin psoriasis 17.24, 17.31–2
- nappy rash 71.5  
*see also* dermatitis, napkin (diaper)
- naproxen 75.29, 75.74–5
- NAPSI (Nail Psoriasis Severity Index) 65.23, 72.9
- narrative therapy 64.20
- Naruto Research Institute Otsuka Atrichia (NOA) mouse 2.8
- nasal crease 18.90
- nasal discharge, congenital syphilis 34.15
- nasal planum  
  lupus erythematosus in dogs 2.16  
  vitiligo in dogs 2.23
- nasal vestibule  
  bacterial flora 30.4  
  normal bacterial flora 30.4
- nasolabial folds, dermal fillers 80.4, 80.5
- nasopharyngeal carcinoma, EBV association 33.30
- nasopharyngeal myiasis 38.8
- nasopharynx, lymphoepithelioma 53.41–2
- Nasu–Hakola disease 46.22–3
- National Center for Biotechnology Information (NCBI) 15.1
- National EB Registry (USA) 39.3, 39.19, 39.30
- National Guideline Clearinghouse 7.5, 7.6
- National Institute for Health and Clinical Excellence (NICE) 7.5, 7.6  
  guidance on biological therapies 72.14  
  photodynamic therapy, for non-melanoma skin cancer 52.16
- natural history of diseases 6.13–14
- natural killer *see* NK cells
- natural killer (NK) lymphoma *see* NK-cell lymphoma
- natural moisturizing factors 4.8
- natural rubber latex *see* latex
- naturopathy 75.162
- Naucoridae* 31.34
- Nav 1.7 47.9
- Navajo poikiloderma 15.50
- Naxos disease 3.23, 19.94, 19.107, 66.70
- NBCCS *see* naevoid basal cell carcinoma syndrome
- NBS-LRR (nucleotide-binding site and leucine-rich repeat) proteins 12.9
- NC/Nga mouse 2.8
- NCAM (CD56) 10.21, 10.25, 13.6, 53.43
- NCBI (National Center for Biotechnology Information) 15.1
- NCKX5 3.20
- Nd:YAG laser therapy *see under* laser therapy
- near-miss sudden infant death syndrome 44.6
- Necator americanus* 37.2, 37.14–15
- neck  
  allergic contact dermatitis 26.18  
  atopic dirty 24.20  
  basal cell carcinoma 52.20  
  Casal's necklace 59.63  
  congenital cartilaginous rests (cervical auricle/tab) 18.84, 18.85  
  erythromelanosis follicularis of 58.36  
  fiddler's 28.25, 42.76  
  flushing *see* flushing  
  lichen nuchae 23.40  
  lichen simplex 23.32  
  macrocytic lymphatic malformations 48.27  
  Madelung's 46.46  
  vascular tone 43.14  
  white fibrous papulosis 45.67–8  
  *see also* head and neck
- necklace of Venus 34.10
- necrobiosis 10.40, 60.1  
  facial 68.17  
  xanthomatous granulomas with 55.27–9
- necrobiosis lipoidica 59.79, 60.12–17  
  aetiology 60.12  
  after jejunal bypass surgery 60.15  
  annular 60.13  
  associations 60.15–16  
  ataxia telangiectasia and 60.15  
  'burnt out' 60.13, 60.14  
  clinical features 60.13–15  
  Crohn's disease and 60.15  
  diabetes mellitus and 60.12, 60.13, 60.15  
  differential diagnosis 60.14–15  
  granuloma annulare and 60.9, 60.15  
  granuloma multiforme and 60.14  
  histopathology 60.12–13  
  leg ulcers in 47.57  
  sarcoidosis and 61.17, 61.23  
  scalp 66.5  
  treatment 60.16–17  
  ulcerated 60.13, 60.14  
  ulcerative colitis and 60.15
- necrobiotic xanthogranuloma *see* xanthogranuloma, necrobiotic
- necrolysis 10.40  
  toxic epidermal 71.6
- necrolytic acral erythema, in hepatitis C virus infection 62.59
- necrolytic migratory erythema 62.38, 62.66–7, 71.6, 71.80  
  in dogs 2.17  
  female genital involvement 71.80  
  genitocrural 71.6  
  oral ulceration in 69.85
- necrosis 10.40  
  acute disseminated epidermal 76.1  
  adipose tissue 46.44  
  *see also* subcutaneous fat, necrosis  
  apoptosis vs 12.12  
  avascular bone 51.47  
  burns 28.89  
  carbon monoxide poisoning 28.94  
  caseation 31.8, 31.9, 31.10  
  coagulative, lipocytes 46.18  
  cold-induced injury 28.64  
  coumadin 49.39  
  cutaneous 49.49  
  calciophylaxis differential diagnosis 46.16  
  causes 49.50  
  localized 49.49  
  geographical 56.61  
  heparin causing 49.27–9  
  intravenous drug abuse 28.53  
  in loxoscelism 38.32  
  male genital region 71.24–6, 71.27, 71.31  
  pressure ulcers 28.16, 28.18, 28.22  
  subcutaneous fat *see* subcutaneous fat, necrosis
- necrotizing cellulitis 30.68
- necrotizing crystalline infundibular folliculitis 19.89
- necrotizing fasciitis 30.68–9  
  ear 68.19  
  following human bites 38.61  
  intravenous drug abuse 28.52  
  neonatal 17.44–5  
  ocular involvement 67.27
- necrotizing gingivitis 69.14, 69.77–8
- necrotizing infections  
  perianal/perineal 71.92–3  
  subcutaneous 30.68–9
- necrotizing infundibular crystalline folliculitis 19.89
- necrotizing sarcoid granulomatosis 50.52, 62.83
- necrotizing sialometaplasia 69.84–5
- necrotizing subcutaneous infections 30.68–9
- necrotizing venulitis 14.18
- nectin–afadin complex 3.23
- nectins 3.23
- nedocromil 13.26
- need, for dermatological care 6.15–16
- needle-stick injuries 77.7
- needs assessment, in dermatology 6.14
- neem oil 38.5  
  in head louse infection 38.20  
  in scabies 38.41
- nefopam 75.87
- 'negative-pressure' tests, purpura 49.5
- negative pressure therapy 28.23
- neglect  
  mechanical injury 28.34, 28.38–9  
  of self care 64.12
- NEH *see* neutrophilic eccrine hidradenitis
- Neisseria catarrhalis*, in external auditory meatus 30.4
- Neisseria flora*, in external auditory meatus 30.4
- Neisseria gonorrhoeae* 30.45–6, 34.24–5  
  child abuse and 28.37, 71.57  
  detection and culture 34.28  
  disseminated infections 34.26  
  in paroxysmal nocturnal haemoglobinuria 49.30  
  perianal/perineal infections 71.93  
  symptoms and treatment of infection 71.71  
  vaginal discharge 71.53  
  *see also* gonorrhoea
- Neisseria meningitidis* 13.15, 30.44–5  
  in paroxysmal nocturnal haemoglobinuria 49.30  
  *see also* meningococcal infection
- Nékam's disease 41.27–8, 73.44
- nelfinavir, adverse effects 35.22
- Nelson's syndrome 62.4  
  pigmentation 58.8
- Nematocera 38.5–6
- nematocysts 38.55, 38.56, 38.57
- nematodes 37.2–3, 37.3–20
- NEMO gene 15.58, 17.81–2  
  mutation 48.10
- neovascularization 47.1
- Neofibularia nolitangere* 38.59
- neomycin  
  adverse effects 26.17, 26.18, 26.45, 26.46, 68.24  
  in fish odour syndrome 44.20  
  in impetigo 30.16  
  topical 73.10
- neonatal acne 42.75
- neonatal cephalic pustulosis 42.75
- neonatal juvenile xanthogranuloma 55.16
- neonatal lupus erythematosus 17.16–18, 51.49–51, 62.78, 62.109  
  aetiology 51.49  
  clinical features 51.49–50  
  prognosis 51.51  
  treatment 51.50
- neonatal mouse model, acantholysis 40.5
- neonatal onset multisystem disease 22.24
- neonatal progeroid syndrome 46.37
- neonatal pseudohydrocephalic progeroid syndrome of Wiedemann–Rautenstrauch 45.60
- neonatal purpura 49.20, 49.49, 49.51  
  causes 49.49, 49.51
- neonatal purpura fulminans 17.33, 17.46, 49.39, 49.51  
  causes 49.51
- neonatal suction blisters 28.24
- neonate(s) 17.1–85  
  acne 42.75  
  acropustulosis 17.9–10, 50.62  
  adnexal polyp 17.15, 70.8  
  atrophic lesions 17.15  
  bacterial infection 17.42–6  
  bacterial skin flora 30.3–4, 30.4–5  
  breast abscess/mastitis 17.43  
  bullae and/or erosions 17.43  
  bullous dermolysis 39.23–4, 39.25  
  bullous impetigo 17.42, 30.14  
  candidiasis 17.25, 17.46–7  
  chemical burns 17.14  
  chrysalis babies 19.27  
  CMV infection 33.29  
  cold injury 17.35–6  
  complications  
    of medical procedures 17.11–14  
    of phototherapy 17.12–13  
    of prematurity 17.11
- congenital erosive and vesicular dermatosis healing with reticulated supple scarring 17.11
- congenital syphilis evaluation 34.21
- contact dermatitis 17.22–8
- dysmature/small for dates 17.1, 17.6
- eccrine sweat glands 17.2
- ecthyma gangrenosum 17.45
- eczematous eruptions 17.22–31
- electrocardiographic monitoring 17.14
- eosinophilic pustulosis 17.10
- epidermolysis bullosa, management 39.27–8
- fungal infection 17.46–8
- gas exchange 17.2
- hair loss and growth 17.4
- harlequin colour change 17.4
- herpes simplex 33.15, 33.17, 33.20
- HIV infection 17.42
- iatrogenic dystrophic calcification 17.14
- infections 17.39–48  
  bacterial 17.42–6  
  candidiasis 17.25, 17.46–7  
  CMV 33.29  
  fungal 17.46–8  
  herpes simplex 33.15, 33.17, 33.20  
  HIV infection 17.42  
  *Staphylococcus aureus* 17.42–4  
  varicella (VZV) 33.23  
  viral 17.39–42
- intravenous medication 17.14
- listeriosis 17.45, 30.42
- low birth-weight 17.1
- lupus erythematosus *see* neonatal lupus erythematosus
- maternal pemphigus vulgaris  
  antibodies 40.5
- mechanical injury 28.39
- milia 17.5
- miliaria 17.7–8
- miniature puberty 17.5, 17.6
- multifocal/benign haemangiomas 18.53
- multifocal/diffuse (miliary) haemangiomas 18.53–4
- necrotizing fasciitis 17.44–5
- needle marks 17.14
- nomenclature 17.1
- normal bacterial skin flora 30.3–4, 30.4–5
- occipital alopecia 17.4
- overheating 17.2
- pemphigus foliaceus 40.15
- pemphigus vulgaris 17.18–19
- percutaneous absorption 17.2
- perianal dermatitis 17.22
- peripheral cyanosis 17.4
- phototherapy 17.12–13
- phototoxic reactions 17.12
- physiological scaling 17.4
- pneumothorax 17.14
- postmature/post-term 17.1, 17.6
- premature/preterm 17.1  
  appearance 17.6  
  barrier function 17.2  
  complications 17.11
- primary immunodeficiency disorders 17.48–85
- purpura fulminans 17.33, 17.46
- pustular eruptions 17.8
- pustulosis  
  cephalic 17.47  
  *Malassezia* 17.47–8  
  of transient myeloproliferative disorder 17.10–11
- routine skin care in napkin area 17.26
- scalp trauma 66.53
- scarring  
  due to delivery procedures 17.12  
  following intrauterine procedures 17.11–12
- sclerema neonatorum 17.38–9
- sebaceous glands 17.2, 17.4–5, 42.3
- sebum secretion 17.2
- skin 8.1–4

- appearance 17.4–6  
 barrier function 17.1–2  
 disease 8.1–4  
 disorders 17.1–15  
 function 17.1–4  
 small for gestational age 17.1  
 staphylococcal scalded skin syndrome 17.42–3  
*Staphylococcus aureus*  
 carriage 30.4–5, 30.6  
 infection 17.42–4  
 subcutaneous fat disorders 17.34–9  
 subcutaneous fat necrosis 17.36–7, 46.12  
 toxic erythema 17.6–7  
 transcutaneous oxygen monitoring 17.13–14  
 transepidermal water loss 17.2  
 transient neonatal pustular melanosis 9.12, 17.8–9  
 transient porphyriaemia 17.13  
 transillumination blisters 17.14  
 transplacental transfer of maternal autoantibodies 17.15–19  
 umbilical artery catheterization 17.13  
 umbilical dermatology 71.100  
 umbilicus 30.4–5  
 varicella zoster virus infection 33.23  
 viral infection 17.39–42  
 VZV infection prophylaxis 33.27  
 neoplasms *see* malignant disease  
 neoplastic vaginal discharge 71.54  
 neoprene 26.68  
 neopterin, in sarcoidosis 61.20  
*Neotestudina rosatii* 36.73  
*Neotrombicula* 38.50  
 NEP (neutral endopeptidase) 12.64, 63.2  
 nephelometry 13.18  
 nephrocalcinosis 62.71  
 nephrogenic fibrosing dermopathy *see* nephrogenic systemic fibrosis  
 nephrogenic rest 18.96  
 nephrogenic systemic fibrosis (NSF) 45.53, 51.82–3, 62.73, 75.151–2  
 nephrolithiasis 62.71  
 nephrotic syndrome 69.116  
 dyslipidaemias 59.92  
 NER (nucleotide excision repair) 15.71–2, 15.75–6  
 nerve block 77.2–4, 77.10  
 in curettage 77.40  
 head and neck 77.2–4  
 nerve growth factor (NGF) 12.64, 64.5  
 mast cell development 3.19  
 pruritus and 21.5  
 in wound healing 63.4  
 nerves  
 A $\alpha$  fibres 63.1  
 A $\beta$  fibres 4.9, 63.5  
 A $\delta$  fibres 4.9, 63.1, 63.2, 63.5  
 in complex regional pain syndrome 47.10  
 adrenergic fibres 63.3–4  
 ageing effect 8.24  
 biopsy, in leprosy 32.15  
 C fibres 4.9, 63.1, 63.2  
 capsaicin-sensitive 12.64  
 in complex regional pain syndrome 47.10  
 mast cells and 21.4  
 pruritus and 21.2  
 sweat gland innervation 3.12  
 cholinergic fibres 63.3  
 destruction in zoster 33.24  
 in leprosy 32.4, 32.5, 32.6, 32.12, 32.17  
 complications of damage 32.13, 32.14, 32.18  
 lepromatous 32.10, 32.11  
 tuberculoid 32.8–9  
 post-ganglionic fibres 63.3  
 supply to skin 3.12, 3.15–16  
 nervousism 64.3  
 nervous system diseases  
 pigmentation changes 58.26  
*see also* central nervous system (CNS); neurological disorders
- Netherton's syndrome (NS) 19.3, 19.37–42, 66.65–7  
 immunodeficiency and 17.70  
 prenatal diagnosis 16.3  
*SPINK5* 12.25, 12.50  
 tacrolimus therapy 73.32  
 nettle 22.2  
 nettle rash *see* urticaria  
 Neu-Laxova syndrome 17.20–1, 19.59–60  
 neural cell adhesion molecule (CD56) 10.21, 10.25, 13.6, 53.43  
 neural crest 3.3, 3.16, 18.4  
 abnormalities, Waardenburg's syndrome 58.43  
 melanoblast development 58.3  
 multipotent cells 58.3  
 neural dysfunction, pressure ulcers 28.17  
 neural tube defects (spinal dysraphism) 18.95–8, 63.15–17  
 neuralgia  
 post-herpetic *see* post-herpetic neuralgia  
 trigeminal 69.119  
 neurilemmoma *see* schwannoma  
 neuritis, retrobulbar, in sarcoidosis 61.7  
 neuro-Behçet's disease 50.60, 50.82  
 neuro-immuno-cutaneous system 63.4  
 neuro-Sweet's syndrome 50.60  
 neurocutaneous syndromes, eye and skin involvement 67.30  
 neurodermatitis 64.27  
 circumscribed *see* lichen simplex  
 disseminated *see* atopic dermatitis  
 neuroectoderm 3.3  
 neuroendocrine carcinoma, primary, of skin *see* Merkel cell carcinoma  
 neuroendocrine system, immune system interactions 64.8–9  
 neuroepithelioma, peripheral 56.54  
 neurofibroma  
 breast 70.17  
 cutaneous 15.17  
 diffuse 56.49  
 female genital region 71.73  
 multiple 15.16, 15.17  
*see also* neurofibromatosis  
 pigmented 54.26  
 pinna 68.28  
 plexiform 56.48–9  
 in pregnancy 8.12  
 solitary 56.47–8  
 neurofibromatosis  
 in adolescence 8.7  
 breast 70.17  
 female genital region 71.73  
 genetics 15.2, 15.6, 15.14, 15.15–21  
 McCune-Albright syndrome vs 58.18  
 mechanical injury 28.8  
 pigmentation 58.23  
 segmental 15.20  
 type 1 56.48, 62.20, 62.23  
 oral involvement 69.41–2  
 pigmentation 66.93  
 respiratory tract involvement 62.80  
 urinary tract involvement 62.69  
 type 2 62.20, 62.23  
 neurofibromatosis-Noonan syndrome 15.20–1  
 neurofibrosarcoma 56.53  
 neurogenic hypothesis, vitiligo 58.47  
 neurohormones, targeting sebocytes 42.4  
 neuroimmunology 63.4  
 neurokinin A 63.2, 63.3  
 immune function and 63.4  
 triple response of Lewis and 63.5  
 in wound healing 63.4  
 neurokinin B, menopausal flushing 8.20  
 neurolabyrinthitis 34.16  
 neuroleptics *see* antipsychotic drugs  
 neurolipomatosis 18.40  
 neurological abnormalities/involvement  
 in Degos' disease 49.46  
 genetics 15.17–18, 15.73  
 in secondary syphilis 34.11  
 in SLE 51.45–6  
 in Sneddon's syndrome 49.43  
 in systemic sclerosis 51.102  
 in xeroderma pigmentosum 15.73  
 neurological disorders  
 congenital ichthyoses and 19.60, 19.61  
 CHIME syndrome 19.60  
 Conradi-Hünemann-Happle syndrome 19.49–51  
 IBIDS/PIBIDS syndrome 19.47–9  
 ichthyosis follicularis with alopecia and photophobia 19.58, 19.60  
 KID/HID syndrome 19.54–7, 19.60  
 multiple sulphatase deficiency 19.13  
 Refsum's disease 19.45, 19.46  
 Sjögren-Larsson syndrome 19.44  
 X-linked recessive ichthyosis 19.11  
 erythrokeratoderma with 19.71–2  
 oral involvement 69.119  
*see also* nervous system diseases  
 neuroma  
 amputation stump (traumatic) 56.45  
 epithelial sheath 56.52  
 Morton's 56.45  
 multiple mucosal 56.45  
 solitary circumscribed (palisaded encapsulated) 56.45–6  
 neuromediators 12.62–8  
 sources and target cells 12.63  
 stress 12.63  
 neuromedin N 12.25  
 neuromuscular disease, with autosomal recessive EB simplex 39.8  
 neurone-specific enolase 10.21, 53.43  
 pruritus and 21.2, 21.8  
 neuropathic pain 12.62, 47.9  
 treatment 47.10  
 neuropathic ulcers *see* ulcer(s), neuropathic  
 neuropathy  
 autonomic 44.7  
 cold-induced 63.14  
 diabetic 44.7, 59.78  
 in HIV infection 63.12  
 keratoderma with 19.110  
 painful, erythromelalgia 47.9  
 neuropeptide Y 4.10, 63.3  
 in atopic dermatitis 24.17  
 GnRH release inhibited by 8.4  
 neuropeptides 63.2–3, 64.9  
 in atopic dermatitis 24.17  
 immune function and 63.4  
 peripheral nerves 4.10  
 secretory 63.3  
 wound healing and 63.4  
 neuropilin-1 14.6  
 neurosecretory granules, Merkel cells 3.15  
 neurosyphilis 34.14, 63.15, 69.119  
 asymptomatic 34.14  
 congenital 34.16  
 differential diagnosis 34.14  
 gummatous 34.14  
 meningeal 34.14  
 tabetic 34.14  
 treatment 34.22, 34.23  
*see also* syphilis  
 neurotensin 12.25  
 neurotheisometer 63.9  
 neurothekeoma  
 cellular 56.50  
 dermal nerve sheath myxoma 56.49–50  
 neurotic excoriation 23.46  
 Neurotip® 63.9  
 neurotransmitters 63.2  
 peripheral nerves 4.10  
 sweat glands 3.12  
 neurotrophin-4, pruritus and 21.5  
 neurotropic virus 33.1  
 neurovascular disorders, of extremities 47.9–12  
 neutral endopeptidase (NEP) 12.64, 63.2  
 neutral lipid storage disease (NLS) with ichthyosis 19.52–4  
 neutropenia 17.75–6  
 chronic benign 69.117  
 cyclical/cyclic 13.13, 17.75, 69.33, 69.117  
 familial 69.33  
 severe congenital (Kostmann's syndrome) 17.48, 17.75  
 neutrophil(s) 12.21–2  
 abnormalities/deficiencies 12.22–3  
 acne pathogenesis 42.26  
 basement-membrane zone 40.46  
 collagenases 3.41  
 defensins 12.5–7  
 depression of activities 12.22  
 dermatitis herpetiformis and 40.59  
 emigration 12.22  
 function 13.4–5, 17.48  
 tests 13.23, 17.55–6  
 increased in ageing skin 8.22  
 in infective panniculitis 46.27–8  
 in irritant contact dermatitis 25.5  
 microscopy 10.34  
 oral health and 69.3  
 pattern recognition receptors 13.5  
 recruitment 12.21–2  
 rolling activated 12.74  
 scavenger receptors 13.5  
 in subcorneal pustular dermatosis 40.21  
 synthesis of cytokines 12.21–2  
 in urticaria 22.3, 22.5  
 in vasculitis 50.6–7  
 in wound healing 14.1, 14.2–3  
 neutrophil activating peptide-2 (NAP-2) 12.46, 12.74  
 neutrophil/macrophage colony-forming unit (NM-CFU) 5.1  
 neutrophil-specific granule deficiency 17.75–6  
 neutrophilia 62.86  
 neutrophilic bullous disorders 50.95  
 neutrophilic dermatosis 50.62–95  
 acute febrile *see* Sweet's syndrome  
 bone and joint involvement 62.101, 62.103  
 classification 50.62–4  
 of the dorsal hands 50.80–1  
 extracutaneous 50.81–2  
 inflammatory bowel disease and 62.51  
 oral involvement 69.15–16  
 pustular 50.88–90  
 respiratory tract involvement 62.83  
 rheumatoid 50.92–3  
 TNF antagonists 74.7  
 neutrophilic eccrine hidradenitis 44.16–17, 50.62, 50.93–5  
 annular lesions 62.112  
 in chemotherapy 75.123  
 neutrophilic panniculitis 46.32, 50.90–1  
 neutrophilic pustulosis 50.89  
 neutrophilic sebaceous adenitis 50.62–3  
 nevirapine 74.50, 75.68  
 nevus fuscoceruleus  
 ophthalmomaxillaris *see* naevus, of Ota  
 New World screw-worms 38.8  
 newborn *see* neonate(s)  
 NF *see* neurofibromatosis  
 NF-1 gene 58.23  
 NF-2 gene 58.23  
 NF- $\kappa$ B 12.8, 20.40, 46.16  
 activation  
 in cylindroma 53.28  
 by UV radiation 8.21, 8.22  
 ectodermal dysplasias 15.57–61  
 NF1 *see* neurofibromatosis, type 1  
 NF1 gene 62.23  
 NF1-like syndrome 15.21  
 NF2 (neurofibromatosis type 2) 62.20, 62.23  
 NF2 gene 62.23  
 NGF *see* nerve growth factor (NGF)  
 niacin *see* nicotinic acid  
 niacinamide, in erythema elevatum diutinum 50.27  
 nicardipine 75.95

- NICE *see* National Institute for Health and Clinical Excellence (NICE)
- Nicholas Favre disease *see* lymphogranuloma venereum (inguinale)
- nickel  
allergy 26.30–3  
chemistry 26.30  
clinical features 26.31–2  
effects of earrings 68.7  
incidence and prevalence 26.30  
patch tests 26.32  
pimecrolimus therapy 73.32  
prognosis 26.32  
therapy 26.32  
urticaria and 22.11  
in alloys 26.37  
avoidance 26.32  
dietary intake 26.22, 26.31  
dimethylglyoxime test 26.99, 27.8  
EU directive 26.30, 26.99  
exclusion from diet 26.22, 26.32, 26.102  
occurrence and sources 26.30–1  
oral provocation tests 5.25  
prevention of dermatitis due to 27.9  
in shoes 26.68  
systemic reactions to 26.22
- nickel patch test reagent, sensitization by, hair regrowth and 73.39
- Nicolau's syndrome 75.155
- nicorandil 69.83, 75.95  
male genital dermatology 71.27
- nicotinamide  
pemphigus foliaceus 40.16  
supplements in carcinoid syndrome 43.19  
tetracycline and 74.30  
dose range and evidence level 74.30  
topical therapy 73.51  
acne vulgaris 42.43
- nicotine  
eccrine gland secretion 44.18  
finger staining 62.46  
replacement 47.5
- nicotine acid esters 25.18
- nicotine patches 26.46
- nicotinic acid 59.63  
adverse effects 75.113  
effect on lipid profile 59.93  
flushing associated 43.16  
topical therapy 73.51
- nidogens 3.28–9, 3.31
- nidus 18.61
- Niemann–Pick C1-like protein 59.93
- Niemann–Pick cells 59.40
- Niemann–Pick disease 44.18, 69.117  
pigmentation 58.24  
types A and B 59.40
- nifedipine 74.52  
adverse effects 69.21, 70.5, 75.95  
systemic sclerosis 51.108  
in wound healing 14.24
- nifurtimox 37.32
- Nigerian satinwood 26.80
- night sweats 44.7
- Nijmegen breakage syndrome 13.13, 17.68
- Nikolsky sign 28.4, 40.8  
in toxic epidermal necrolysis 76.17
- nimesulide 75.77
- nipple 70.1  
atopic dermatitis 70.9–10  
basal cell carcinoma 70.15  
benign papillomatosis 70.12–13  
in breast cancer 70.13  
cracked 8.13, 70.10  
cyclist's 70.10–11  
dermatitis/eczema  
due to mechanical injury 28.14  
friction dermatitis 25.17  
Paget's disease vs 53.39  
discharge 53.38  
erosive adenomatosis 70.12–13  
Paget's disease vs 53.39  
florid papillomatosis 70.12–13
- guitar 70.11  
hyperkeratosis 19.93, 70.8–9  
inverted 70.8  
jogger's 70.10–11  
mechanical injury 28.14, 28.25, 28.31  
melanoma 70.15  
neurofibromatosis 70.17  
Paget's disease *see under* Paget's disease  
papillary adenoma 70.12–13  
piercing 70.11  
rudimentary 70.3  
sebaceous glands 42.1  
seborrhoeic warts 70.15  
sore, in puerperium 8.13  
supernumerary 18.92–3, 70.2–3  
tassel ornaments 70.11  
variations in 70.1  
'wide-set' 70.2
- niridazole 75.71
- NISCH syndrome 19.62
- nitrazepam 75.81
- nitric oxide (NO) 12.56, 13.4  
actions and mechanism of 73.51  
depletion, paroxysmal nocturnal haemoglobinuria 49.30  
neutralization 25.23  
pathophysiological role in skin. 12.56  
role in wound healing 14.1, 14.25  
topical therapy 73.51
- nitric oxide (NO) cream, molluscum contagiosum 33.12
- nitric oxide synthase (NOS) 12.54
- nitrite 73.51
- nitritoid reactions 43.15
- nitroblue tetrazolium reduction test 13.23
- nitroethane 25.20
- nitrofurantoin 75.59
- nitrogen mustard  
adverse effects 75.124–5, 75.136  
allergic contact dermatitis 26.46  
carmustine (BCNU) and 57.23  
CD30+ lymphoproliferative disorder 57.30  
topical 75.136  
*see also* mechlorethamine
- nitroglycerin patches 26.25, 26.46
- nitrosamines 27.5
- nitrosoureas, adverse effects 70.5, 75.126
- nitrous oxide cryoprobe, vulval lichen sclerosus 51.118
- nits 38.16, 38.19, 66.62
- NK-cell lymphoma  
CD4+/CD56+ haematodermic neoplasm 57.39–40  
EBV association 33.31
- NK cells 12.18, 13.6  
deficiency 13.6  
EBV infection 33.31  
increased activity, epidermodysplasia verruciformis 33.57  
receptors 13.6
- NK/T-cell lymphoma (nasal type) 57.40–1
- NK T cells 13.6, 13.31
- NNT (number needed to treat) 7.8–9, 7.12
- NO *see* nitric oxide
- no-see-ums 38.6
- Nocardia* 50.55  
actinomycetoma due to 36.72, 36.73, 36.74  
infections, amikacin 74.42  
*Nocardia asteroides* 30.76  
*Nocardia brasiliensis* 30.76  
*Nocardia minutissima see Corynebacterium minutissimum*  
*Nocardia otitidis caviarum* 30.76  
nocardiosis 30.76–7  
nociceptors 4.7, 4.9, 21.2
- NOD-like receptor (NLR) family 12.4, 12.9, 12.12
- NOD (nucleotide-binding oligomerization domain) proteins 12.4, 12.9, 12.12
- NOD receptors 12.4, 12.9
- NOD2 mutations, Blau syndrome 12.12
- NOD2 gene *see* CARD15 gene
- nodal diffuse large B-cell lymphoma 57.47–9
- nodular dermatofibrosis, in dogs 2.17–18
- nodular fasciitis 45.50, 56.4–5, 69.112
- nodule(s)  
in acne vulgaris 42.31, 42.37  
apple-jelly 5.19, 31.11, 31.16, 37.37, 61.13  
athlete's 28.31  
coppery red, in tertiary syphilis 34.12  
cutaneous epithelioid angiomatous 56.28  
in cutaneous polyarteritis nodosa 50.37–8  
in cysticercosis 37.25  
definition 5.7  
dermal tumour 54.36  
differential diagnosis 32.15  
elastotic of the ear 45.28  
fibrous digital 45.50  
glial heterotopic 18.89–90, 56.52  
in infective panniculitis 46.27  
in leprosy 32.9  
in lupus panniculitis 46.25  
in oil granuloma (sclerosing lipogranuloma) 46.29  
onchocercal 37.4, 37.6–7  
prayer 9.13–14, 9.15  
subepidermal calcified 56.2  
viral infections, milker's nodule 33.10  
weathering 68.10, 68.11  
yellow-tinged facial 53.15, 53.16
- nodulectomy, in onchocerciasis 37.7
- Noggin 3.3
- noma 69.14, 69.77–8
- noma neonatorum 17.45–6
- nomenclature 5.1
- NOMID (neonatal onset multisystem disease) 22.24
- non-accidental injury *see* child abuse
- non-alcoholic steatohepatitis (NASH) 74.21
- non-bullous ichthyosiform erythroderma (NBIE) 19.17–21
- non-clostridial gas gangrene 59.78
- non-epidermolytic palmoplantar keratoderma 19.94, 19.97
- non-esterified fatty acids (NEFA) 46.3
- non-Hodgkin's lymphoma  
oral 69.55  
perianal/perineal involvement 71.99  
sarcoïdal reaction in 61.23
- non-melanoma skin cancer (NMSC) 52.1–48  
cancer susceptibility modifying genes 52.10–11  
chemoprevention in high-risk patients 52.17–18  
chronic injury and scarring and 52.11  
definitions 52.1–2  
detection and diagnosis 52.15  
environmental risk factors 52.3–6  
chemical carcinogens 52.4–5  
HPV 52.5–6  
PUVA 52.4  
UV radiation 52.3  
UVA 52.3  
UVB phototherapy 52.4  
X-rays and thermal radiation 52.5  
epidemiology 52.2–6  
epidermodysplasia verruciformis and 52.5  
familial cancer syndromes 52.6  
high-risk, management 52.17–18  
host susceptibility factors 52.6  
immunosuppression association 52.11  
intermediate-risk, management 52.17  
low-risk, management 52.17  
management 52.15–18  
destructive vs excisional 52.16  
high-risk patients 52.17–18  
optimal treatment by risk level 52.17  
specific treatments 52.16–17  
treatment selection 52.15–16
- molecular and cellular biology 52.12–15  
cancer as genetic disease 52.12  
HVP role 52.14  
multistage carcinogenesis 52.12–13  
UV radiation causing mutations 52.13–14
- molecular genetic analysis 52.12
- mortality and morbidity 52.2
- multiple lesions, management 52.17–18
- pre-malignant lesions and 52.2, 52.11  
disorders associated 52.2–12  
epithelial lesions 52.29–38  
squamous cell carcinoma development 52.25
- radiation-induced, long latent period 52.5
- risk factors 52.10–11
- risk in pre-malignant epithelial lesions 52.29
- treatment plan 52.17
- UVR associated 29.7  
*see also* basal cell carcinoma (BCC); squamous cell carcinoma (SCC); *other specific cancers*
- non-naevoid melanoepithelioma, type 1 52.39–40
- non-nucleoside reverse transcriptase inhibitors (NNRTIs) 35.7  
action 74.49–50  
in HIV infection 35.6, 35.7  
side-effects 35.21
- non-perfused pig ear model 25.9
- non-specific balanoposthitis 71.24
- non-steroidal anti-inflammatory drugs (NSAIDs)  
adverse effects 75.72–8, 75.166  
allergic contact dermatitis 26.46  
anaphylactoid reactions 75.25  
erythema multiforme 76.4  
fixed eruption 75.29  
lichenoid tissue reaction 41.24, 41.25  
photosensitivity 29.20, 29.21, 75.31  
Stevens–Johnson syndrome 76.4, 76.11  
toxic epidermal necrolysis 76.13  
urticaria 22.8, 22.10, 75.26  
vasculitis 50.17, 50.18
- bleeding time, effect 49.6
- in mastocytosis 22.35
- skin testing for reactions to 75.173
- topical 73.25, 75.166  
as photosensitizers 26.24
- non-syphilitic spirochaetal ulcerative balanoposthitis 71.31
- non-venereal (epidemic) treponematoses 30.62–4
- Noonan's syndrome (NS) 62.77  
ear defects in 68.4  
genetics 15.14–15, 15.20–1  
lymphoedema 48.10  
oral involvement 69.41
- noradrenaline (norepinephrine) 12.65, 63.3, 64.9  
peripheral nerves 4.10
- norethisterone 26.46
- normal flora *see* bacteria, flora (normal skin)
- normolipaemic plane xanthomatosis 62.45
- northern blotting 11.5–6
- northern fowl mite 38.51
- nortriptyline 64.51  
in post-herpetic neuralgia 63.7
- Norwegian acne 42.79
- Norwegian scabies *see* scabies, crusted (Norwegian)
- NOS (nitric oxide synthase) 12.54
- nose  
'Cyrano nose' 18.46  
'Dudley nose' 2.23  
fibrous papule 56.2–3  
glioma 56.52  
radiotherapy 79.10  
saddle-nose deformity 34.14, 34.17

- sarcoidosis 61.9, 61.15  
 self-healing epitheliomas 52.9  
 'snow nose' 2.23  
 swelling, rhinophyma *see* rhinophyma  
 notalgia paraesthetica 21.15, 23.42, 58.31, 63.23  
 Notch signalling 3.6–7  
 hair greying and 3.21  
 melanoma development 3.21  
 NOTCH3 protein/*NOTCH3* gene 50.47  
*Notoedres cati* 2.10, 38.36, 38.46  
 Nottingham Eczema Severity Score (NESS) 64.10, 72.9  
 Nottingham Health Profile 72.16  
 novolac 26.73  
 NRL *see* latex  
 NS *see* Netherton's syndrome (NS); Noonan's syndrome (NS)  
 NSAIDs *see* non-steroidal anti-inflammatory drugs  
 nuchal stain 18.62–3  
 nuclear factor B essential modulator (NEMO) 58.15  
 nuclear factor κB (NF-κB) *see* NF-κB  
 nuclear factor of activated T-cells (NFAT) 73.31  
 nuclear lamins 3.9  
 in partial face-sparing lipodystrophy 46.41  
 nuclear matrix proteins 3.9  
 nucleic acid amplification tests (NAATs)  
 genital chlamydial infections 34.30  
 gonorrhoea detection 34.28  
 lymphogranuloma venereum 34.33  
 nucleoside reverse transcriptase inhibitors (NRTI) 35.7  
 HIV-associated lipodystrophy 46.42  
 HIV infection 35.5, 35.7  
 side-effects 35.21, 35.22  
 nucleotide-binding oligomerization domain (NOD) proteins 12.4, 12.9, 12.12  
 nucleotide-binding site and leucine-rich repeat (NBS-LRR) proteins 12.9  
 nucleotide excision repair (NER) 15.71–2, 15.75–6  
 numb chin syndrome 62.39  
 number needed to treat 7.8–9, 7.12  
 nummular dermatitis, mechanical injury 28.14  
 nurse specialist 72.26  
 nursing measures, pressure ulcers 28.20  
 nutrition, in severe generalized dystrophic EB 39.29  
 nutritional disorders 59.58–76  
 nutritional status  
 child abuse 28.38–9  
 pressure ulcers 28.18, 28.21–3  
 NV (nodular vasculitis) 31.24–5, 50.31–3  
 nylon fibres, sarcoidal reaction to 61.22–3  
 nymphohymenal tears 71.56, 71.66  
 nystatin 26.46, 74.46  
 adverse effects 75.65  
 in candidiasis 36.68  
 topical 73.12
- O**  
 oak moss 26.77  
 oast house disease 66.95  
 oat cell carcinoma of bronchus, pigmentation changes 58.25  
 obesity 8.16–19, 46.2, 46.5–8  
 adolescent 8.4  
 aetiology 8.16, 46.5–7  
 associated diseases 46.5, 46.6  
 cutaneous 8.17–18  
 diabetes mellitus 46.5, 46.7  
 cellulite vs 46.9  
 in childhood 46.5  
 cutaneous pathophysiology 8.17  
 delayed-type hypersensitivity response in 8.17  
 Dercum's disease 46.48  
 epidemiology 46.5  
 foot shape changes 8.17  
 lymphoedema and 48.20–1  
 macrophages in visceral adipose tissue 46.4  
 measurement 8.16  
 melanoma and 8.17  
 perianal/perineal dermatology 71.85  
 pressure and pain sensitivity 8.17  
 prevention and treatment 46.7–8  
 risk factors 8.16  
 screening, BMI use 46.5  
 sweating and 8.17, 44.7  
 syndromes with cutaneous features 8.18  
 treatments 8.17–18  
 venous leg ulcers and 47.43, 47.47  
 visceral adipocyte dysfunction 46.6, 46.6–7  
 Objective Severity Assessment of Atopic Dermatitis 72.10  
 observational studies 6.19  
 obsessive–compulsive disorder (OCD) 42.70, 64.18, 64.30  
 occipital horn syndrome 3.44, 45.14, 45.15, 45.36, 45.39  
 occludins 3.24  
 occlusion  
 microvascular *see* microvascular occlusion  
 role in irritant contact dermatitis 25.8, 25.12  
 occlusive dressings 73.4  
 occlusive thromboarteriopathy 50.44–5  
 occupation  
 arthropod infestation/attack and 38.2  
 atopy and 27.2  
 disorders associated with 5.6  
 epidemiology of occupational dermatoses and 27.2–3  
 exposure to depigmenting chemicals 27.15  
 hazards associated with 27.18–21  
 history-taking 5.5  
 nickel allergy and 26.30, 26.32  
 risk of skin disease and 6.12, 27.2  
 occupational acne 27.12–15, 42.34, 42.77  
 occupational causes, connective tissue diseases 51.80  
 Occupational Contact Dermatitis Disease severity Index 72.10  
 occupational dermatoses 27.1–23  
 acne 27.12–15, 42.34, 42.77  
 ageing and 27.2  
 argyria 58.54  
 atopic dermatitis 24.33–4  
 Bowen's disease 52.32  
 chemical burns 27.11–12  
 chemical depigmentation 58.50–1  
 clinical features 27.3  
 contact dermatitis  
 allergic 26.4–5, 26.14, 26.20, 26.79, 27.4, 27.5, 27.7  
 irritant 25.13, 25.14, 27.4, 27.5–7  
 contact urticaria 22.20, 26.105, 27.5  
 definition 27.1  
 depigmentation 27.15  
 diagnosis 27.4–5  
 eczematous 27.1–11  
 epidemiology 26.3, 27.1–4  
 fungal infections from animals 2.12  
 HPV infection 33.40, 33.47  
 incidence 27.2  
 investigations 27.7–9  
 iron salts and accidental tattoos 58.57  
 irritants and sensitizers 27.3, 27.18–21  
 leukoderma 27.1, 58.50  
 management 27.10  
 medicolegal aspects 27.17–18  
 milker's nodule 33.10  
 mite-associated 38.46–7, 38.48  
 non-eczematous 27.11–15  
 non-melanoma skin cancers 52.4  
 orf 33.9  
 paronychia 65.21  
 period of exposure and 27.3  
 prevention 27.9–10  
 skin protection programme 25.26  
 primary 27.2  
 prognosis 27.9  
 psychogenic 64.25–6  
 scleroderma 27.16, 27.17  
 scrotal cancer 52.4, 52.25  
 skin cancer 27.15–16  
 stress and 27.2  
 vibration white finger 27.17  
 vitiligo 27.15, 58.9  
 warts 33.40, 33.47  
 occupational exposures, UVR and standard erythema dose 29.4  
 OCD (obsessive–compulsive disorder) 42.70, 64.18, 64.30  
 ochronosis 62.105, 75.33  
 endogenous 73.27  
 exogenous 73.27, 75.165  
 pigmentation 58.54  
*see also* alkaptonuria  
 Ockelbo disease 33.66  
 octopus 38.59  
*Octopus apollyon* 38.59  
 octreotide  
 in carcinoid syndrome 43.19  
 long-acting depot 43.19  
 2-*n*-octyl-4-isothiazolin-3-one 26.54  
 ocular disorders  
 congenital ichthyoses and 19.60  
 CHIME syndrome 19.60  
 Conradi–Hünemann–Happle syndrome 19.49–51  
 harlequin ichthyosis 19.26, 19.27  
 IBIDS/PIBIDS syndrome 19.47–9  
 ichthyosis follicularis with alopecia and photophobia 19.58–9, 19.60  
 KID/HID syndrome 19.54–7  
 Refsum's disease 19.45, 19.46  
 Sjögren–Larsson syndrome 19.44  
 X-linked recessive ichthyosis 19.10  
 keratoderma with oculocutaneous tyrosinaemia 19.95, 19.111–12  
*see also* eye(s); visual impairment  
 ocular rosacea 43.4, 43.5, 67.6, 67.7  
 clinical features 67.9  
 epidemiology 67.6  
 treatment 43.7, 67.11  
 oculo-dentodigital (ODD) syndrome 15.48  
 oculo-osteocutaneous syndrome 15.31  
 oculoauriculovertebral spectrum 18.82–3, 68.4  
 oculocerebral syndrome with hypopigmentation 58.42  
 oculocerebrocutaneous syndrome 18.37, 18.104  
 oculocutaneous albinism *see* albinism, oculocutaneous (OCA)  
 oculodermal melanocytosis *see* naevus, of Ota  
 oculoglandular complex 37.32  
 oculomandibulodycephaly with hypotrichosis 15.41, 18.81–2, 45.8  
 oculomucocutaneous syndromes 69.47  
*see also specific syndromes*  
 oculotrichodysplasia 15.48  
 ODD (oculo-dentodigital) syndrome 15.48  
 odds ratio 6.18, 7.8, 7.9, 7.15  
 Odland bodies 3.1, 4.2, 4.3  
*Odontacarus* 38.50  
 odonto-onycho-hypohidrotic dysplasia with mid-line scalp defect 15.38  
 odonto-onychodermal dysplasia 15.48  
 odontogenic keratocysts 69.39  
 odontomicronychia dysplasia 15.48  
 odontotrichomelic syndrome 15.53  
 odour(s)  
 body *see* body odour  
 workplace 64.26  
*Oeciacus* 38.24  
 oedema  
 acute haemorrhagic of childhood/infancy 17.33–4, 49.18–19, 50.30  
 brawny 48.14  
 causes 48.7, 48.19  
 chronic 48.7  
 chronic ankle 48.7  
 chronic upper facial erythematous 43.4  
 filtration (increased capillary function) 48.7  
 following ear piercing 68.7  
 genetics 15.14  
 lymphatic failure causing 48.5  
 penile 28.39, 71.30, 71.49  
 periorbital 48.23, 67.5  
 pitting 47.29, 47.33, 48.7, 48.14  
 post-cellulitis 30.20  
 in pregnancy 8.11  
 premenstrual 8.8  
 skin colour and 5.16  
 solid facial 42.74, 48.13, 48.16, 48.23  
 in triple response 22.12  
 vulval 71.81  
*see also* lymphoedema  
 oedema toxin 30.41  
 Oedemeridae 38.27  
 oesophagus  
 aperistalsis 51.99  
 blistering 39.19  
 carcinoma, keratoderma with 19.94, 19.106, 19.107  
 cutaneous markers of disorders 62.48  
 diverticula, in dermatomyositis 51.125  
 in dystrophic epidermolysis bullosa 39.19, 39.28  
 in lichen planus 8.9  
 spasm 39.28  
 strictures 39.19, 39.28  
 in systemic sclerosis, cobblestone appearance 51.92  
 oestradiol 26.46, 42.12  
 hair growth and 66.9  
 secretion, menstrual cycle 8.8  
 Oestridae 38.9  
 oestriol 8.9  
 oestrogen(s) 74.33  
 in breast growth/development 8.4, 70.1  
 cellulite association 46.9–10  
 in gynaecomastia 70.4  
 hair growth and 66.9, 66.11  
 male breast cancer and 70.14  
 in menopause 8.19  
 in menstrual cycle 8.8  
 in oral contraceptives, acne treatment 42.53  
 pigmentation changes and 58.7, 58.25  
 postmenopausal period 8.19  
 at puberty 8.4  
 receptors 42.12  
 receptors in skin, in menopause 8.19  
 sebaceous gland activity control 42.12  
 secretion 8.2  
 skin ageing and 80.3–4  
 spider telangiectases and 47.14, 47.15  
 synthesis 8.8, 8.19  
 transplacental passage 70.4  
 oestrogen therapy  
 acne vulgaris 42.53  
 adverse effects 70.5, 75.117–18  
 hypermelanosis 58.29  
 Marfan's syndrome 45.31  
 menopausal flushing 8.20, 43.15  
 in prevention of ageing 80.3–4  
 topical, menopausal women 8.19  
*see also* oral contraceptives  
 oestrone 8.19  
*Oestrus* 38.9  
 OFD *see* orofacioidigital (OFD) syndrome  
 office workers, occupational hazards 27.20  
 ofloxacin 32.17  
 Ofuji's disease 35.18  
 eosinophilic pustular folliculitis 17.10, 30.28–9  
 oil(s)  
 cooking, contamination 27.13  
 cutting 27.13

- diesel 27.13  
 folliculitis due to 27.14, 27.16  
 grape seed 27.13  
 hyperkeratoses due to 27.16  
 as irritants 25.20  
 machine 27.6  
 soluble 25.20, 27.4, 27.5, 27.6  
 sweet almond 27.13  
 vegetable, comedogenicity 27.13
- oil acne 42.77  
 oil beetles 38.26  
 oil granuloma 46.29–30  
 oil-in-water emulsions (O/W) 73.7  
 Oil of Cade 73.42  
 oil of eucalyptus 38.5  
 oil of wintergreen 75.165  
 Oily Cream BP 73.2, 73.7  
 oily creams 73.7  
 Ointment of Wool Alcohols BP 73.7  
 ointments 73.2, 73.5  
 quantity applied 73.3–4  
 OKT3 75.146  
 olanzapine 64.16, 64.52, 75.83  
 in acne excoriée 42.70  
 old age *see* elderly people  
 Old World screwworms 38.8  
 older patients *see* elderly people  
 oleic acid 73.5  
 oleogranuloma (oil granuloma) 46.29–30  
 oleoma (oil granuloma) 46.29–30  
 olfactory delusions 64.16–17  
 oligodontia 69.6, 69.7  
 oligohydramnios 18.1  
 oligosaccharidoses 59.33  
 oligosaccharides, abnormal, detection 59.33  
*Olindias sambaquiensis* 38.56  
 olive oil 73.6  
 Ollier's disease 18.72, 65.34  
 Olmsted's syndrome 19.94, 19.101–2, 69.25  
 olsalazine 75.56  
 omalizumab 74.11, 75.146  
 Omenn's syndrome 17.59  
 omeprazole, adverse effects 70.5, 75.157  
 OMIM (Online Mendelian Inheritance in Man) 11.2, 15.1  
 ommochromes 2.5  
 omphalith 71.100  
 omphalitis 17.44  
 omphalocele 71.100  
 omphalomesenteric duct anomalies 18.93–4  
 Omsk virus 33.67  
 onchocerciasis 37.3, 37.4–8, 38.5  
 genital involvement in males 71.33  
 in HIV infection 35.36  
 ocular involvement 67.27  
 onchodermatitis, acute papular 37.5  
 onco genes 11.17–18  
 ondansetron 75.79  
 onion  
 allergic contact dermatitis due to 26.77  
 as irritant 25.21  
 in naturopathy 75.162  
 'onion-skin cysts' 46.29  
 Online Mendelian Inheritance in Man (OMIM) 11.2, 15.1  
 ONPPD (*o*-nitro-*p*-phenylenediamine) 26.60  
*Onychocla canadensis* 36.53  
 onychocryptosis *see* nail(s), ingrowing  
 onychodermal band 3.15, 65.2  
 onychodysplasia, congenital of the index fingers 65.20  
 onychodystrophy, Naegeli's syndrome 58.19  
 onychogryphosis 65.5, 65.12, 65.51, 65.52, 65.53  
 onycholysis 65.10–11  
 in allergic contact dermatitis 26.27  
 dermatophyte-associated 36.35  
 drug-induced 75.46  
 in hyperthyroidism 62.8  
 idiopathic 65.10  
 manicure instrument-associated 65.51  
 in pregnancy 8.10  
 in *Pseudomonas* infection 30.49, 65.10, 65.11  
 in psoriasis 65.24  
 treatment 73.37  
 secondary 65.11  
 treatment 65.10–11  
 onychomadesis 65.10, 65.13  
 onychomatricoma 65.32–3  
 onychomycosis  
*Candida* 36.63, 36.64, 36.65, 36.69  
 in childhood 65.7  
 definition 36.53  
 dermatophyte-associated (tinea unguium) 36.34–5, 36.50  
 differential diagnosis 65.25, 65.28  
 distal and lateral subungual 36.34, 36.63  
 in elderly people 65.7  
 endonyx 36.35  
 genetics 15.10  
 in HIV infection 35.33, 35.41  
 laboratory investigation 36.6, 36.8  
 non-dermatophyte moulds as cause 36.53–6  
 proximal subungual 36.35  
 in psoriasis 65.24  
*Scopulariopsis brevicaulis* 36.53–4  
*Scytalidium* 36.51–2  
 superficial white 36.34, 36.50, 36.53, 36.55  
 totally dystrophic 36.35  
 treatment 73.12  
*Trichophyton equinum* 2.12  
 onychopapilloma 65.18  
 onychophagia 64.33, 65.50  
 onychoptosis defluvium 65.10  
 onychorrhexis 65.12  
 onychoschizia 65.13–14  
 in childhood 65.6  
 onychotillomania 64.33, 65.50  
 onychotrichodysplasia and neutropenia 15.49  
 O'Nyong-Nyong virus infection 33.66, 33.67  
 open epicutaneous test 26.11–12  
 ophiasis 66.35  
 ophthalmia neonatorum 34.25, 34.27  
 ophthalmia nodosa 38.29  
 ophthalmoganglionic complex 37.32  
 ophthalmomyiasis 38.8, 38.9  
 opilacoo *see* trypanosomiasis, American/South-American  
 opioid peptides  
 flushing in rosacea and 43.2  
 pruritus and 21.3, 21.4, 21.8, 21.9, 24.18  
 opioid receptors 21.4  
 opioid therapy  
 adverse effects 75.86–8  
 post-herpetic neuralgia 63.7  
 topical, dystrophic epidermolysis bullosa 39.30  
 Opitz syndrome 69.37  
 Opitz-Firas syndrome 69.37  
 Opitz-Kaveggia syndrome 15.96  
 opportunistic infections 30.1  
 in HIV infection, in pregnancy 8.13  
 in HTLV-1 infection 33.65  
*see also specific infections; specific pathogens*  
 opsonins 13.2, 13.4  
 optic nerves, in sarcoidosis 61.7  
 optical whiteners 26.65, 26.67  
 lymphatic system 69.4  
 oral allergy syndrome 22.20, 26.105, 69.108  
 oral care, in dystrophic epidermolysis bullosa 39.28  
 oral cavity 69.5  
 abscess 69.109  
 in acanthosis nigricans 69.34  
 in acrodermatitis enteropathica 69.31  
 allergic contact dermatitis 26.20–1  
 in amyloidosis 69.114–15, 69.116, 69.117  
 anatomical variants 69.6–7  
 angio-oedema 69.107–8  
 bacterial infections 69.77–9  
 in Behçet's disease 50.58, 50.59, 69.44, 69.118  
 biology 69.1–3  
 blisters 69.14, 69.22  
 in blue rubber-bleb naevus syndrome 69.30  
 burns 69.43, 69.88  
*Candida albicans* carriage 36.56, 36.58, 69.88  
 candidiasis 36.60–1, 36.64, 69.13, 69.22, 69.88–9  
 treatment 36.68  
 in cardiovascular disease 69.117  
 complications of bone marrow transplantation 69.82–3  
 in connective tissue disorders 69.117  
 in Cowden's syndrome 69.38  
 in Crohn's disease 62.49, 69.116  
 in Darier's disease 69.25–6  
 dermoid cyst 69.34–5  
 in discoid lupus erythematosus 69.65, 69.71  
 drug reactions 69.83, 69.97, 69.116, 75.46–7  
 in dystrophic epidermolysis bullosa 39.18–19  
 in epidermolysis bullosa 69.31–2  
 epithelium 69.1  
 erythema 69.22  
 erythema multiforme 69.65, 69.69–70  
 erythroplasia (erythroplakia) 69.50  
 examination 69.5–7  
 fibroepithelial polyp (fibrous lump) 69.20  
 fibroma 69.20  
 focal mucinosis 69.39  
 fungal infections 69.79–80, 69.118  
 in gastrointestinal disease 69.116  
 in Goltz(-Gorlin) syndrome 69.33–4  
 in graft-versus-host disease 69.83  
 haemangioma 69.13, 69.22, 69.29, 69.30  
 in haematological disease 69.116  
 in hereditary angio-oedema 69.33  
 in hereditary haemorrhagic telangiectasia 69.29, 69.117  
 in herpes zoster 69.74–5, 69.118  
 in HIV infection 69.19, 69.56, 69.81, 69.97–8, 69.118  
 immunity in 69.3  
 in immunodeficiency 69.117  
 in Kawasaki disease 69.84, 69.118, 69.121  
 keratoacanthoma 69.54–5  
 keratoses 69.90–3  
 in KID syndrome 69.26  
 in Kindler syndrome 69.40  
 in Klippel-Trenaunay-Weber syndrome 69.30  
 in Langerhans' cell histiocytosis (LCH) 55.11, 69.118  
 leiomyoma 69.113  
 in leishmaniasis 69.81  
 lentiginosis 69.28  
 in leukocyte adhesion deficiency 69.16  
 lichen planus 26.26, 69.61–3, 69.65  
 lichen sclerosis et atrophicus 69.63–4  
 lipoma 69.113  
 in liver disease 69.115  
 in localized epidermolysis bullosa simplex (Weber-Cockayne EBS) 39.6  
 lumps/swellings 69.33–6, 69.109–15  
 lymphangioma 69.34  
 lymphatic system 69.4  
 in Maffucci's syndrome 69.13, 69.29, 69.30  
 malignant disease 69.13, 69.22, 69.42, 69.49–456, 69.98–9, 69.116  
 metastatic 69.55–6  
 melanoma 54.6, 54.47  
 in metabolic disorders 69.117  
 mucosa 69.2  
 disorders 69.21–115  
 hyperpigmentation 69.95  
 mucous membrane pemphigoid 69.65, 69.67–8  
 multiple myeloma 69.114, 69.116  
 myxoma 69.113  
 naevi 69.29  
 in neurofibromatosis type I 69.41–2  
 in neurological disorders 69.119  
 nodular fasciitis 69.112  
 in Noonan's syndrome 69.41  
 oedema within 48.16  
 papilloma 69.110–11  
 in Papillon-Léfevre syndrome 69.16  
 paracoccidioidomycosis 36.87, 69.118, 69.121  
 pemphigus vulgaris 69.64–6  
 in Peutz-Jeghers syndrome 69.27, 69.28, 69.116  
 pigmentation/pigmented lesions 9.3, 69.21–2, 69.26–9, 69.95–100, 75.47  
 plasmacytoma 69.114  
 protozoal infestations 69.81  
 in psoriasis 69.94  
 in psychiatric disease 69.115  
 purpura 49.5, 69.21–2, 69.99–9100  
 pyoderma gangrenosum 50.70  
 pyogenic granuloma 69.20  
 red lesions 69.29–231, 69.100–6  
 in renal disease 69.116  
 rhabdomyoma 69.112  
 rhabdomyosarcoma 69.112  
 sarcoidosis 69.109, 69.118  
 sebaceous adenoma 69.23  
 soreness 69.85  
 in Sturge-Weber syndrome 69.13, 69.29, 69.30  
 submucous fibrosis 69.106–7  
 in Sweet's syndrome 69.49  
 in syphilis 34.18, 69.78, 69.90, 69.91, 69.118  
 primary 34.7, 34.8  
 secondary 34.11, 34.12  
 tertiary 34.14  
 in systemic disease 69.115–19  
 in systemic lupus erythematosus 69.71  
 tattoos 69.95–6  
 telangiectases 69.22, 69.101  
 in toxic epidermal necrolysis 69.70–1  
 in tuberculosis 69.79, 69.118  
 in tuberous sclerosis 69.41, 69.118  
 ulcers 69.22, 69.33, 69.42–9  
 aetiology 69.14, 69.42  
 in Behçet's disease 50.58, 50.59, 69.44, 69.118  
 Crohn's disease and 62.50  
 drug-induced 69.83  
 eosinophilic 69.43  
 herpeticiform 69.45  
 in HIV infection 35.42  
 local factors 69.43  
 major aphthous (Sutton's) *see* Sutton's disease  
 minor aphthous (Mikulicz) 69.44–5  
 in systemic disease 69.56–84  
 ulcerative colitis and 62.50  
 varicella 33.24, 69.74  
 vasculitides 69.81–2  
 verrucous carcinoma 52.26  
 vesiculobullous disorders 69.64–71  
 vesiculoerosive disorders 69.31–3  
 viral infections 69.72–7, 69.118  
 in Waldenström's macroglobulinaemia 69.114  
 warts 69.111  
 white lesions 69.13, 69.87–95  
*see also* leukoplakia  
 in Wiskott-Aldrich syndrome 69.31  
 in xeroderma pigmentosum 69.42  
 oral commissures 69.2  
 oral contraceptives  
 acne vulgaris treatment 42.53  
 adverse effects 69.97, 75.118  
 hyperpigmentation 58.25, 75.33  
 allergic contact dermatitis and 26.8  
 female genital dermatology and 71.52  
 flushing management 43.15

- hidradenitis suppurativa and 30.80, 30.81  
interactions with antibiotics 75.55  
telogen effluvium and 66.28  
oral dysaesthesia 26.20, 26.39, 62.85, 69.86–7  
oral hairy leukoplakia, EBV and 33.31  
oral lesions, genetics 15.17  
oral leukokeratosis, focal keratoderma with 19.103  
oral-facial-digital syndrome, type I 62.69–70  
orange peel appearance, skin 46.9  
orange tawny 38.50  
orbicularis oris 69.1  
orbital oedema, genetics 15.14  
orchitis, in lymphatic filariasis 37.9  
orf 33.8–10, 69.121  
clinical features, diagnosis and treatment 33.9  
organelles, defects in Chédiak–Higashi syndrome 58.41  
organic solvents 25.3, 25.20, 27.17  
scleroderma-like lesions 51.80  
organoid naevus syndrome 18.27–30, 54.11  
'orgasm cutanéé' 64.23, 64.27  
oriental sore 37.34–9  
orlistat 8.18  
ornamental piercings 28.51–2  
*Ornithobilharzia* 37.22  
*Ornithodoros* 38.35  
*Ornithonyssus* 38.51  
ornithosis 30.71–2, 62.80, 62.107  
orofacial granulomatosis 26.20–1, 69.59–61  
orofacioidigital (OFD) syndrome  
type I 15.49, 69.37  
type II 69.37  
orokeratosis striata lichenoides (Nékam's disease) 41.27–8, 73.44  
oropharyngeal infection, gonococcal 34.25  
oropharynx, in HIV infection 35.42–4  
Oropouche viruses 33.67, 33.70  
orosomucoid 13.19  
Oroya fever 30.57–8, 35.25  
orthomyxoviruses 33.3, 33.75  
orthopoxviruses 33.5, 33.7, 33.8  
Orthoptera 38.28  
Osler–Rendu–Weber disease *see*  
hereditary haemorrhagic  
telangiectasia (HHT)  
Osler's nodes 62.78  
osmidrosis 44.19–20  
Osnabrueck Hand Eczema Severity Index 72.10  
ossification, skin 59.70  
osteoarthritis, venous leg ulcers and 47.46  
osteochondritis, in congenital syphilis 34.16  
osteochondroma, subungual 65.33  
osteocytes, origin 12.30  
osteodystrophy, Albright's hereditary 15.6  
osteoctasia 45.23  
osteogenesis imperfecta 45.40–1, 69.8  
bone and joint involvement 62.100  
collagen gene mutations 3.35  
purpura in 49.15  
osteoid osteoma 65.34  
osteolysis, massive *see* Gorham's  
(Gorham–Stout) disease  
osteoma  
external auditory canal 68.28, 68.29  
genetics 15.26  
jaw 69.39  
osteoid 65.34  
pinna 68.28  
osteoma cutis 42.78, 51.69, 56.61–2, 62.99, 62.101  
osteoma mucosae 69.108–9  
osteomyelitis 62.99  
chronic recurrent multifocal 62.104  
diabetic foot ulcers and 47.58  
in invasive otitis externa 68.26  
in neuropathic ulcer 63.9  
pressure ulcers and 28.19–20  
in tertiary syphilis 62.105  
osteomyelitis syphilitica 34.16  
osteonectin 14.3  
osteopathy 72.32  
osteopoikilosis 18.33, 51.98, 62.99, 62.102  
osteopontin 49.47  
osteoporosis, cutaneous atrophy and 45.3  
Ota, naevus of *see* naevus, of Ota  
otalgia 68.1, 68.22  
psychogenic 68.35  
otitis externa 68.20–7  
acute diffuse 68.22  
acute localized 68.27  
allergic and 'ide' reactions 68.24  
in animals 2.11  
benign non-necrotizing 68.24  
bullous 68.22  
chronic 68.22–3  
clinical features 68.22–3  
complications 68.24  
contact dermatitis and 26.17  
differential diagnosis 68.23–4  
environmental factors 68.21  
genetic and constitutional factors 68.20–1  
granular 68.22  
histopathology 68.22  
hypertrophic 68.24, 68.25  
incidence 68.20  
infective 68.20  
invasive (malignant/necrotizing) 30.49, 68.25–7, 68.28  
mycotic 36.7–8, 36.17, 68.27–8  
necrotic 36.17  
pathogenesis 68.20  
*Pseudomonas aeruginosa* infection and 30.49, 68.21, 68.22, 68.25  
reactive 68.20, 68.23  
recurrent 68.24  
seborrhoeic 68.23  
secondary sensitization 68.24  
secondary trauma 68.24  
traumatic 68.21  
treatment 68.24–5  
*Otodectes cynotis* 2.11, 38.46  
otodontal dysplasia 69.11  
otomycosis 36.7–8, 36.17, 68.27–8  
otophyma 43.9  
Oudtshoorn disease 19.66, 19.68–9  
ovarian disorders  
hirsutism and 66.82  
purpura in 49.18  
ovarian follicles 8.19  
ovarian tumours, hirsutism and 66.82  
ovary  
androgen production, inhibition 42.53  
atrophic 8.19  
ovulation 8.8  
'owl eye' intranuclear inclusions, CMV 33.29  
22-oxa-calcitriol *see* maxacalcitol  
oxalic acid 25.20  
oxaliplatin 75.134  
oxerutins 48.25  
oxiconazole, topical 73.12  
oxidative burst 13.4, 13.5  
oxidative stress 12.55  
oxidizing agents as irritants 25.21  
oxprenolol 75.91  
oxybenzone 26.23, 26.24  
oxybutinin 44.12  
oxycodone 63.7  
*Oxycopsis vittata* 38.27  
oxygen  
hyperbaric therapy 14.25  
gas gangrene 30.44  
lymphoedema 48.23  
neonatal transcutaneous monitoring 17.13–14  
in photosensitivity reactions 29.20  
role in wound healing 14.1, 14.25  
transcutaneous oxygen tension (tcPO<sub>2</sub>) 4.11, 47.3, 47.26  
oxygen perfusion, pressure ulcers 28.18  
oxygen tension, *Propionibacterium acnes*  
growth and acne 42.25  
oxyhaemoglobin 5.15  
in erythema 25.22  
oxymetazoline, flushing management in  
rosacea 43.6  
Oxyopidae 38.32  
oxyptentifylline, flushing and 43.15  
oxyphenbutazone 75.28, 75.77  
oxytalan fibers 3.42  
oxytetracycline 74.41  
acne vulgaris treatment 42.47, 42.48  
adverse effects, ocular 67.31–2  
oxyuriasis 37.13–14  
*Oxyuris infestation*, perianal/perineal  
inflammation 71.84  
**P**  
P antigen, erythrocyte 33.63  
P-cadherin  
gene mutations 3.24  
in Hailey–Hailey disease 39.33  
P-selectin 13.4  
P value 6.18, 7.11, 7.19, 7.20–1  
p16 gene mutations, cancer and 52.12  
p16 protein, in melanoma pathogenesis 54.33  
p38 mitogen-activated protein kinase  
(p38MAPK) 40.6  
p53 15.61  
inactivation by E6 protein of HPV 33.39  
proliferating trichilemmal tumour and 53.5  
UV-induced melanocyte growth arrest and 58.7  
UVR-induced activation 29.5  
p53 gene  
ectodermal dysplasias and 15.61  
mutations  
cancer and 52.12, 52.32  
UVR-induced 29.7  
p59 protein 73.17  
p63 gene 10.24  
mutations in ectodermal dysplasias 15.61  
p63 protein 3.6, 10.24, 15.61  
p73 gene, ectodermal dysplasias and 15.61  
p73 protein 15.61  
PABA (*p*-aminobenzoic acid) 26.23, 26.62  
PACAP (pituitary adenylate cyclase-activating peptide) 12.63–4, 63.3  
pacemakers, electrosurgery and 77.46  
pachyderma 37.6  
pachydermatoglyphy 62.31–2  
pachydermatous eosinophilic dermatitis,  
differential diagnosis 24.27  
pachydermia oralis 35.43, 69.23–4  
pachydermodactyly 45.48–9  
mechanical injury and 28.15  
pachydermoperiostosis 15.87, 15.88–9, 45.41–2, 62.2, 62.101  
pachyonychia congenita (PC) 59.48, 65.20  
genetics 15.49  
Jackson–Lawler type (PC-2) *see* Jackson–Lawler syndrome (pachyonychia congenita type 2)  
Jadassohn–Lewandowsky type (PC-1) *see* Jadassohn–Lewandowsky syndrome (pachyonychia congenita type 1)  
keratins in 65.3  
mechanical injury and 28.13  
oral involvement 69.24  
prenatal diagnosis 16.3  
Pacinian corpuscles 4.9, 4.10, 63.2, 63.14  
paclitaxel 75.135–6  
*Paederus* 38.26–7  
PAF *see* platelet-activating factor (PAF)  
Paget cells 53.38–9  
pagetoid dyskeratosis 69.91  
male genital dermatology 71.46  
pagetoid reticulosis 57.15  
pagetoid vulval intraepithelial neoplasia 71.75  
Paget's disease  
extramammary 53.40–1, 62.16–17  
diagnosis 10.21  
external ear 68.30  
female genitalia 71.78–9  
male genitalia 71.46–7  
perianal/perineal 71.98  
pseudoxanthoma elasticum and 45.23  
topical 5-FU 73.23  
topical imiquimod 73.24  
nipple 53.38–40, 62.16, 70.10, 70.14  
breast cancer and 53.38, 53.39, 70.14  
pagoda red 10.10  
pain  
abdominal, in Henoch–Schönlein  
purpura 50.20  
arterial ulceration 47.52  
chronic skin 63.23–4  
complex regional pain syndrome 44.8, 63.20–2  
congenital insensitivity to 63.19  
in cryosurgery 77.39  
deafferentation 63.6  
in erythromelalgia 47.9  
in furunculosis 30.24  
lightning 63.11, 63.15  
mediation 4.9  
oral 69.85  
plantar warts 33.44  
in post-herpetic neuralgia 63.6  
quality of 5.4  
referred, to ear 68.35  
sensitivity, in obesity 8.17  
threshold, increased with age 8.24  
zoster 33.25, 33.26  
pain management  
burns 28.79  
in dystrophic epidermolysis bullosa 39.30  
venous leg ulcers 47.49  
pain syndromes  
male genitalia 71.51–2  
perianal/perineal 71.99  
vulval 71.81–2  
painful bruising syndrome 49.16, 64.33–4  
painful fat syndrome 48.20  
painful swelling, male genitalia 71.49  
painters, occupational hazards 27.20  
paints (topical therapy) 73.2  
Pakistan, prevalence of skin disease 6.10  
Pal-E 48.4  
palate  
cleft *see* cleft lip/palate  
tertiary syphilis 34.14  
palisaded neutrophilic and  
granulomatous dermatitis 51.131, 62.103–4  
palladium 26.37–8  
pallor 62.85  
'porcelain-white' 49.45  
vasoconstrictor assay for corticosteroids 73.16  
palmar arteries 65.4  
palmar crease erythema 62.85  
palmar dermatitis, mechanical injury and 28.14  
palmar erythema, in pregnancy 8.10  
palmoplantar hyperkeratosis and alopecia 15.49  
palmoplantar keratoderma (PPK) 19.3, 19.93–119, 59.48  
acquired 19.116–19  
cicatrizing 19.94, 19.95, 19.101–2, 19.108–9  
classification 19.93–4  
congenital and perioral 19.94, 19.101–2  
deafness and 19.3, 19.94, 19.108–10  
diffuse 19.94, 19.95–7

- extracutaneous features 19.94–5,  
19.106–12  
filiform 19.114  
focal 19.3, 19.94, 19.95, 19.102–5,  
62.20–1  
hereditary 69.16  
hidrotic ectodermal dysplasia 19.94,  
19.106  
hyperhidrosis and 44.8  
malignancy and 19.106, 19.116–17  
marginal papular 19.114–15  
miscellaneous syndromes 19.115–16  
in Naegeli's syndrome 58.19  
Nékam's disease and 41.27  
periodontitis with *see* Papillon-Lefèvre  
syndrome  
porokeratotic 19.112–13  
punctate 19.95, 19.112–13  
striate 19.3, 19.94, 19.95, 19.105–6,  
19.107  
transgradient 19.94, 19.95, 19.98–101  
palmoplantar keratoderma variants *see*  
palmoplantar keratoderma  
(PPK), focal  
palmoplantar pits, naevoid basal cell  
carcinoma syndrome 52.7  
palmoplantar porokeratosis (of Mantoux)  
19.91  
palmoplantar pustulosis (PPP)  
acitretin therapy 74.35  
bone and joint involvement 62.101–2,  
62.103  
palmoplantar skin, structure 3.9  
palms  
biopsy 10.32  
erythema, paraneoplastic 62.41  
hairy malformation 18.14  
hyperhidrosis 44.7–8, 77.37  
hyperkeratotic eczema 23.16, 26.29  
hyperpigmentation 9.2  
keratosis punctata 9.10  
lichen nitidus 41.22  
lichen planus 26.29, 41.7, 41.8, 41.14  
liver 62.64  
melanocytic naevi 54.17–18  
melanoma 54.44, 54.45  
recurrent focal palmar peeling 23.19  
seed-like keratoses 62.33  
tripe 62.31–2  
vesicular eczema *see* pompholyx  
*see also* hand(s)  
*Palomena prasina* 38.25  
palpation of skin 5.17–18  
palpebral arteries 67.2  
palpebral fornices, superior and inferior  
67.2  
PAMPs *see* pathogen-associated  
molecular patterns (PAMPs)  
PAN *see* polyarteritis nodosa (PAN)  
panatropy  
of Gower 45.11  
local 45.11  
sclerotic 45.11  
pancornulins 3.10  
pancreas  
cystic fibrosis 59.59  
disorders *see* pancreatic disease  
pancreatic cancer 54.33, 54.34  
enzymic panniculitis in 46.18  
flushing and 43.16  
pancreatic disease 62.65–8  
subcutaneous fat necrosis 46.18–20,  
62.65–6  
*see also specific diseases*  
pancreatic enzymes, panniculitis due to  
46.18–20  
pancreatic panniculitis 46.18–20  
pancreatitis 69.116  
acute 62.65  
enzymic panniculitis after 46.18  
pancuronium 75.153  
pancytopenia with congenital defects *see*  
Fanconi's anaemia/syndrome  
panda sign 49.4, 49.15  
Paneth's cells 4.5  
pangeria *see* Werner's syndrome  
panhypopituitarism 46.35  
pannexins 3.24  
panniculitis 46.10–12, 46.12–34, 51.14–15,  
51.87  
acute  
infectious id 46.32  
mechanical injury 28.27  
in animals 2.16  
 $\alpha$ 1-antitrypsin deficiency 46.20–1  
autoimmune 46.15  
calcifying, with renal failure 46.16–17  
cellular proliferative disease 46.23  
chronic ulcerative, drug-induced 46.28  
classification 46.11  
cold 17.35, 46.21  
complement deficiency with 46.27  
connective tissue 46.31–2, 51.87  
crystal deposition association 46.16–17  
cytophagic histiocytic 46.23–5  
Degos' disease 49.45  
in dermatomyositis 46.31–2, 51.124  
drug-induced 35.22  
chronic ulcerative 46.28  
enzymic (pancreatic) 46.18–20  
eosinophilic 46.12  
factitial 46.28–9, 46.29  
fasciitis–panniculitis syndrome 46.30,  
46.31  
granulomatous 46.14, 46.27  
granulomatous lipophagic 46.32  
in HIV infection 35.25  
idiopathic nodular 46.13–14  
infective 46.27–8  
lipoatrophic (connective tissue/  
autoimmune) 46.15  
lipophagic 46.15  
lobular 46.11, 46.13–25  
plasma cell 46.14  
unusual causes 46.14  
vasculitis with 31.24–5, 50.31–3  
lupus 46.25–7, 50.49  
lymphoedema and 48.13  
migrating 37.17  
mixed (septal and lobular) 46.11,  
46.25–32  
neutrophilic 46.32, 50.90–1  
nodular 46.13, 46.24  
complement deficiency 46.27  
cystic 46.22  
infectious causes 46.14  
oedematous scarring vasculitic 46.32–3  
paraneoplastic 62.40  
post-steroid 46.16  
'primary' lipophagic 46.15  
pustular 51.132  
pustular neutrophilic 46.32  
relapsing febrile nodular 46.13  
sclerosing (lipodermatosclerosis)  
46.30–1  
self-inflicted 46.28–9  
septal 46.11, 46.12, 46.32  
viral infections and 33.76  
subacute nodular migratory 46.12  
ulcerative 46.20  
vasculitis with 46.11, 46.32–4  
panniculitis-like T-cell lymphomas,  
subcutaneous (SPTL) *see under* T-  
cell lymphomas  
pannus 67.4  
panobinostat 11.16  
panophthalmitis 38.29  
pansclerotic morphea of children 51.71–  
2, 51.75  
*Panstrongylus megistus* 37.31  
Panton–Valentine leukocidin 30.8,  
30.23–4  
pao ferro 26.81  
PAP (postaxial polydactyly) 18.92  
PAPA syndrome 42.82, 50.53, 50.66,  
62.104  
papatasi fever 38.5  
papaya 25.21  
paper money skin 62.64  
Papilionaceae 26.80  
papillary hidradenoma 71.72  
papillary hyperplasia 69.112  
papillary tip microabscess 10.41  
papillary vessels, actinic keratosis 52.31  
papilloedema, in sarcoidosis 61.7  
papilloma  
basal cell *see* seborrhoeic keratosis  
carcinogen-induced in murine model  
52.12, 52.13  
conjunctiva 33.47  
definition 5.7  
focal dermal hypoplasia syndrome  
15.84  
histopathology 10.40–1  
HPV causing 33.37–8  
nasal inverting 33.47  
oral 69.110–11  
progression to cancer, murine model  
52.13  
papillomatosis  
acanthotic chronic 62.54  
confluent and reticulate 5.10, 19.121–2,  
36.13–14  
in eczema 23.4  
external auditory canal 68.29  
florid  
cutaneous 19.93  
oral 69.53  
histopathology 10.41  
respiratory 33.47  
reticulate 73.44  
in seborrhoeic keratosis 52.39  
in viral warts 33.41  
vulval 33.46  
papillomaviruses, epidermodysplasia  
keratoderma 19.95, 19.115  
papillomaviruses 33.2, 33.37  
canine oral 33.42  
human *see* human papillomavirus  
(HPV)  
 $\beta$ -papillomaviruses, epidermodysplasia  
verruciformis and 52.6  
Papillon-Lefèvre syndrome 13.13, 15.50,  
19.94, 19.110, 19.111  
late-onset 69.16  
oral involvement 69.16, 69.33  
papovaviruses 33.2  
papular acantholytic dermatosis (transient  
and persistent acantholytic  
dermatoses) 19.86–8  
papular acrodermatitis of childhood *see*  
Gianotti-Crosti syndrome  
papular atrichia 66.59  
papular keratoderma, marginal 19.95,  
19.114–15  
papular mucinosis *see* mucinosis, papular  
papular-purpuric gloves and socks  
syndrome 33.63, 49.20, 69.99  
viral infections associated 33.63, 33.76,  
35.31  
papules  
in acne, early 42.25, 42.31  
in acne conglobata 42.82  
benign lymphangiomatous 48.28–9  
common warts 33.42  
definition 5.7  
fissured ('split'), in syphilis 34.11, 34.16  
infantile pedal 17.15  
in Gianotti-Crosti-like syndrome 33.77  
in juvenile xanthogranuloma 55.16  
in Langerhans' cell histiocytosis 55.9  
in leprosy 32.9  
lichen nitidus 41.21, 41.22  
lichen planus 41.4, 41.6  
milker's nodule 33.10  
'moist' in syphilis 34.10  
necrotizing, cryptococcosis 35.33  
in orf 33.9  
papular xanthoma 55.19–20  
piezogenic pedal 28.61  
psoriasiform, in syphilis 34.10, 34.11  
rheumatoid 50.52  
'sago grain,' plantar warts 33.43  
secondary syphilitic 34.7, 34.9, 34.10,  
34.10–11  
papuloerythroderma of Ofuji 9.13, 23.50–  
1, 62.38  
papulosis  
Bowenoid *see* Bowenoid papulosis  
clear cell, genitocrural dermatology  
71.6  
malignant atrophic *see* Degos' disease  
(malignant atrophic papulosis)  
papulosquamous infections, in animals  
2.21  
papulovesicles, hydroa vacciniforme  
29.15  
papulovesicular acrolocated syndrome *see*  
Gianotti-Crosti syndrome  
para-aminosalicylic acid 74.45  
parabens 26.54–5, 73.8, 75.159  
paracellin-1 (claudin 16), gene mutations  
3.25  
paracetamol 75.72–3  
parachlorometacresol 26.56–7, 73.8  
parachlorometaxyleneol 26.56, 73.14  
parachlorophenylalanine 43.19  
*Paracoccidioides brasiliensis* 36.87, 36.88  
paracoccidioidomycosis 36.87–8, 69.118,  
69.121  
in HIV infection 35.34  
male genitalia 71.32  
'paradoxical healing,' tertiary syphilis  
34.13  
paraffin, acnegenicity 27.13  
paraffin implants, scleroderma 51.82  
paraffinoma 28.43–4, 46.28, 46.29–30  
classical 46.28, 46.29  
orbital/palpebral 46.28  
paragonimiasis 37.23  
*Paragonimus* 37.23  
parahydroxybenzoic acid esters 73.8  
parakeratosis  
in actinic keratosis 52.30–1  
Crohn's disease and 62.49  
granular, in obesity 8.17  
histopathology 10.41  
in irritant contact dermatitis 25.4  
in lichen planus 41.4  
mechanical injury and 28.11  
reversal in psoriasis, coal tar and  
73.42  
parakeratosis pustulosa 65.23, 65.25  
parakeratosis variegata 57.58  
paralysis  
in leprosy 32.18  
tick 38.35  
*Paramyxovirus* 33.75  
paramyxoviruses 33.3, 33.75  
paraneoplastic disorders 62.29–46  
genodermatoses 62.19–29  
paraneoplastic pemphigus 40.22–4  
clinical features 40.4  
immunopathology and  
immunogenetics 40.4  
parangi *see* yaws  
paranitrophenyl phosphatase 44.3  
paranoia 64.17  
paraphenylenediamine 26.17, 26.25, 26.26,  
26.60–2, 26.64, 66.97  
sensitization to 26.95  
substituted, lichen planus-like contact  
dermatitis and 41.23  
in temporal henna tattoos 58.57  
paraphimosis 71.8–9, 71.20–1  
parapoxviruses 33.5, 33.8–9, 33.10  
paraproteinaemia 69.114  
diffuse plane xanthomatosis with 55.22  
paraneoplastic 62.44  
purpura in 49.19  
xanthomata and 59.92  
paraproteins 13.17, 62.92–5  
in necrobiotic xanthogranuloma 55.28  
parapsoriasis 57.57  
large plaque, early stage mycosis  
fungoides 57.13  
small plaque 57.13  
parapsoriasis-en-plaque, benign 23.7–8,  
57.57  
pararosaniline chloride *see* gentian violet

- parasites 37.1–44  
 hosts 37.1  
 life histories 37.1–3  
*see also specific parasites*  
 parasitic diseases  
 animals 2.9–11  
 comparison with humans 2.21  
 ocular involvement 67.27  
 perianal/perineal involvement 71.92  
*see also specific diseases*  
 parasitosis, delusional 21.12, 64.13–16, 65.50, 68.16  
 parasympathetic nervous system 63.1, 63.3  
 parathormone, pruritus and 21.8  
 parathyroidectomy 49.48  
 parathyroidism, genetics 15.81  
 paratoluenediamine 66.97  
 paratyphoid 30.47–8  
 paravaccinia (milker's nodule) 33.10–11  
 parchment pulps 23.6  
 Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD) 72.20  
 parietal emissary vein 77.2, 77.3  
 Parinaud's oculoglandular syndrome 30.57  
 Parker's stain 36.7  
 Parkes–Weber syndrome 18.61–2, 47.24  
 lymphoedema with 48.21  
 parkinsonism 69.119  
 seborrheic dermatitis and 23.29  
 Parkinson's disease  
 restless legs syndrome and 47.12  
 sweating in 44.7  
 paronychia  
 bacterial (acute) 30.32, 65.21  
*Candida* 9.18, 36.63, 36.64, 36.69, 65.21  
 in childhood 65.6  
 chronic 36.63, 65.21–2, 65.28  
 herpetic 33.17, 65.22–3  
 in HIV infection 35.41  
 mechanical injury and 28.25  
 in psoriasis 65.25  
*Scytalidium* 36.52  
 syphilis differential diagnosis 34.7  
 syphilitic 34.11, 34.16  
 treatment 65.22  
 parotid duct 69.5  
 operations, gustatory hyperhidrosis following 44.10  
 parotid gland examination 69.5  
 Paroven® 48.25, 75.98  
 paroxetine 64.50  
 adverse effects 75.79  
 in pruritus 21.12, 21.17, 21.18  
 paroxysmal nocturnal haemoglobinuria (PNH) 13.4, 49.30–1  
 Parrot's nodes 34.17  
 Parrot's pseudoparalysis 34.16  
 Parry–Romberg syndrome 45.11–12, 51.70  
 PARs *see* proteinase-activated receptor(s)  
*Parthenium* 26.10, 26.20, 26.75, 26.76  
 parthenolide 26.75  
 parvovirus B19 6.12–13, 33.62  
 antibodies to 33.63  
 genotypes 33.62  
 parvovirus B19 infection 6.12–13, 33.62–4  
 clinical features 33.63, 33.76  
 diagnosis and treatment 33.63  
 in HIV infection 35.31  
 pathogenesis 33.63  
 in pregnancy 33.63  
 purpura in 49.20  
 parvoviruses 33.2, 33.62–4  
 PARV4 and PARV5 33.62  
 PAS stain *see* periodic acid-Schiff (PAS)  
 staining  
 PASI (Psoriasis Area and Severity Index) 7.11–12, 20.41, 72.9, 72.14  
 Pasini's syndrome 39.21–2, 45.50  
 passive haemagglutination test 75.174  
 passive transfer test 5.23  
 paste bandages 73.2, 73.42  
 in eczema 23.38  
 in lichen simplex 23.41  
 pastes 73.2  
 drying (cooling) 73.2  
 protective (fatty) 73.2  
*Pasteurella canis* 30.54  
*Pasteurella dagmatis* 30.54  
*Pasteurella multocida* 30.18, 30.54, 38.60–1  
 in cats 2.12  
*Pasteurella stomatis* 30.54  
 Pastia's lines 30.34  
 Patau's syndrome (trisomy 13) 15.11, 18.102–3, 62.77, 68.4  
 patch test 5.22, 13.22, 26.84–93  
 acrylic resins 26.73  
 allergen storage 26.86  
 aluminium 26.40  
 in atopic dermatitis 24.11  
 atopy 23.37  
 children 26.8–9  
 chromium 26.36  
 clothing 26.67  
 cobalt 26.34  
 colophony 26.83  
 complications 25.17, 26.94–5  
 compound allergy 26.89  
 concentrations 26.85–6, 26.92–3  
 contact dermatitis around venous leg ulcer 47.44–5  
 cosmetic vehicles 26.58, 26.59  
 cosmetics 26.48–9  
 cross-reactions 26.96  
 dose 26.86  
 drugs 26.45, 75.168–9, 75.170  
 ear battery 68.24  
 in eczema 23.37  
 epoxy resins 26.71  
 exposure time 26.86–7  
 false-negative reactions 26.89, 27.7  
 false-positive reactions 26.87–8, 27.7  
 footwear 26.69  
 formaldehyde 26.50  
 formaldehyde resins 26.74  
 fragrances 26.40, 26.42  
 gold 26.38  
 hair dyes 26.61  
 history 26.2  
 ICDRG scoring system 26.87  
 indications 26.84  
 irritants 25.9–10  
 late reactions 26.87, 26.95  
 mercury 26.39  
 methods 26.84–6  
 MOAHL index 26.3  
 MOAHLFA index 26.3  
 multiple primary hypersensitivities 26.96  
 multiple reactions 26.95–7  
 nickel 26.32  
 non-invasive measurement techniques 26.88  
 non-specific hyperreactivity 26.95  
 occupational dermatoses 27.7–8  
 open 26.97  
 palladium 26.38  
 plant allergens 26.77–8  
 predictive 26.11–12  
 in pregnancy 26.85  
 preservatives/biocides 26.50, 26.51, 26.52, 26.53–4, 26.55, 26.56, 26.57  
 propolis 26.83  
 quenching 26.89  
 quick 75.169  
 readings and interpretation 26.87–8  
 relevance 26.88  
 rubber 26.64–5  
 selection of test substances 26.91–2  
 sensitivity 26.12  
 site 26.86  
 standardized protocol 26.2  
 test materials 26.85  
 ultraviolet filters 26.62  
 unexplained positive reactions 27.7  
 vehicles 26.85, 26.92–3  
 woods 26.83  
 patched gene 11.11, 11.17, 11.18, 52.6, 52.12, 53.2  
 mutation in naevoid basal cell carcinoma syndrome 52.19, 62.21  
 patent urachal duct 71.100  
 Paterson–Brown–Kelly syndrome 62.48  
 pathergy  
 in Behçet's disease 50.59  
 in pyoderma gangrenosum 50.68  
 pathogen-associated molecular patterns (PAMPs) 12.4, 12.9  
 acne aetiology 42.25  
 'patient-centred care' 72.1  
 patient education, in atopic dermatitis 24.28  
 patient expectations 72.1–3  
 Patient Generated Index 72.16, 72.22  
 Patient Health Questionnaire-9 64.48  
 patient information, drug therapy 72.7  
 Patient-Orientated Eczema Measure (POEM) 72.9, 72.10, 72.14  
 patient reported outcomes (PROs) 64.10  
 patient self-help groups 6.14, 64.7, 72.33–4  
 pattern-recognition receptors (PRRs) 12.9, 13.5  
 Paul–Bunnell test 33.30  
 Paussidae 38.27  
 Pautrier-like microabscesses, in Langerhans' cell histiocytosis 55.8  
 Pautrier microabscesses 10.41, 57.9, 57.38, 57.54  
 in adult T-cell leukaemia-lymphoma (ATLL) 57.37–8  
 PAX3 gene 2.7, 58.3, 58.44  
 PBC *see* primary biliary cirrhosis  
 PC *see* pachyonychia congenita (PC)  
 PCBs *see* polychlorinated biphenyls  
 PCDFs (polychlorinated dibenzofurans) 27.12–13  
 PCMC (chlorocresol) 26.56–7, 73.8  
 PCMX (chloroxylenol) 26.56, 73.14  
 PCOS *see* polycystic ovary syndrome (PCOS)  
 PCR *see* polymerase chain reaction  
 PCT *see* porphyria cutanea tarda  
 PCV (plasma cell vulvitis) 71.61  
 PDE (phosphodiesterase), in atopic dermatitis 24.15–16  
 PDGF *see* platelet-derived growth factor  
 peanut agglutinin 55.9  
 Langerhans' cell histiocytosis cells 55.8, 55.9  
 pearly penile papules 71.11  
 peau d'orange 45.26, 45.53, 48.7, 62.15, 70.14  
 in rosacea 43.3  
 PECAM-1 *see* CD31  
 PECL (cutis laxa and post-inflammatory elastolysis) 45.19–20  
 PEComa 56.60  
 pectus excavatum 45.30  
 pederin 38.26  
 Pediatric Symptom Checklist 72.23  
 pediculicides, in head louse infection 38.19–20  
 pediculosis capitis *see* lice, head  
*Pediculus*, in primates 2.10  
*Pediculus capitis* *see* lice, head  
*Pediculus humanus* *see* lice, clothing/body  
 peeling skin syndromes 19.66–9  
 pegfilgrastim 50.76  
*Pelagia noctiluca* 38.56  
 pelargonium 25.21  
 pellagra 59.63  
 aetiology 29.21  
 eczema and 23.27  
 epidemiology 6.1  
 pigmentation changes 58.28  
 pelvic inflammatory disease (PID)  
 chlamydial infections causing 34.29–30  
 gonococci causing 34.26  
 pelvic malignancy, lymphoedema 48.8  
 PELVIS syndrome 18.47, 18.96  
 Pemberton sign 62.8, 62.44  
 PEMKB (pseudoepitheliomatous micaceous and keratotic balanitis) 71.37–8  
 pemphigoid 40.26–35  
 bullous *see* bullous pemphigoid  
 cicatricial *see* mucous membrane pemphigoid (MMP)  
 drug-induced 67.20  
 ear 68.16  
 genital involvement  
 in females 71.66  
 in males 71.28  
 genitocrural involvement 71.5  
 mucous membrane *see* mucous membrane pemphigoid (MMP)  
 oral cavity 69.22  
 perianal/perineal involvement 71.91  
 stump 28.29  
 pemphigoid gestationis 8.13, 8.14, 21.14, 40.41–5  
 aetiology 40.41–2  
 associated diseases 40.44  
 clinical features 40.43  
 defined 40.41  
 differential diagnosis 40.45  
 immunopathology and immunogenetics 10.18, 10.19  
 pathogenesis/pathology 40.42–3  
 prognosis 40.44  
 transplacental 17.19  
 treatment 40.45  
 pemphigoid nodularis 40.33–4  
 pruritus in 21.15  
 pemphigoid vegetans 40.34  
 oral involvement 69.68  
 pemphigus 40.3–24  
 aetiology 40.3–4  
 in animals 2.15  
 autoantibodies to Merkel cells 3.16  
 azathioprine therapy 40.12, 40.16, 74.15  
 clinical features 40.4  
 defined 40.3  
 diagnosis, direct immunofluorescence of IgG 40.8  
 drug-induced 40.18–19, 75.20, 75.38–9  
 ear 68.16  
 familial benign chronic *see* Hailey–Hailey disease  
 genital involvement  
 in females 71.66  
 in males 71.28  
 genitocrural involvement 71.5  
 immunopathology 10.18, 10.19  
 loss of desmosomes 40.15  
 oral 69.22  
 paraneoplastic 40.22–4, 62.44–5, 76.19  
 in animals 2.15  
 antibodies to desmosomal proteins 3.22  
 B cell malignancies and 62.90  
 oral 69.66–7  
 overlap with lichen planus pemphigoides 41.20–1  
 respiratory tract involvement 62.83–4  
 pathology 40.7–8  
 peristomal 62.54  
 in pregnancy 40.9  
 presentation as paronychia 65.21  
 prognosis 40.9  
 treatment 40.11–12  
 corticosteroids 40.11–12  
 immunosuppressive agents 40.12  
 infliximab 40.6, 40.12  
 prognosis 40.9  
 rituximab 74.9  
 topical or intralesional steroids 40.11  
*see also specific types*  
 pemphigus erythematous (Senear–Usher syndrome) 40.4, 40.16, 51.41  
 in animals 2.15  
 cytodagnosis 10.29  
 differential diagnosis 40.16

- pemphigus foliaceus 40.13–17  
 aetiology 40.13  
 in animals 2.10, 2.12, 2.15  
 anti-DG1 antibodies 40.13–14  
 antigen 40.13  
 clinical features 40.4, 40.15–16, 40.18  
 cytodagnosis 10.29  
 defined 40.13  
 desmogleins 40.2  
 differential diagnosis 40.15, 40.16  
 endemic 40.17–18  
 erythroderma and 23.48  
 evolving into pemphigus vulgaris 40.13  
 immunogenetics 40.4  
 immunopathology 40.4  
 apoptotic mechanisms in keratinocytes 12.12  
 pathogenesis 40.13  
 pathology 40.15  
 prognosis 40.16, 40.18  
 race and 9.14  
 treatment 40.16, 40.18  
 rituximab 74.9
- pemphigus herpetiformis 40.15–16
- pemphigus neonatorum 17.42
- pemphigus syphiliticus 34.16
- pemphigus vegetans 40.3–13  
 aetiology 40.4, 40.10  
 clinical features 40.4  
 cytodagnosis 10.29  
 defined 40.10  
 differential diagnosis 39.35, 40.11  
 Hallopeau and Neumann types 40.10  
 oral 69.67
- pemphigus vulgaris 40.3–13  
 aetiology 40.3–4  
 in animals 2.15  
 clinical features 40.4, 40.8–9  
 cytodagnosis 10.29  
 desmoglein antibodies 40.5–6  
 desmogleins 40.2  
 differential diagnosis 40.11, 40.34, 40.40  
 immunopathology and immunogenetics 40.4  
 maternal antibodies 40.5  
 neonatal 17.18–19  
 non-desmoglein antibodies 40.6  
 oral lesions 69.64–6  
 race and 9.14  
 treatment, rituximab 74.9
- peniclovir  
 action 74.49  
 herpes simplex therapy 33.20, 33.21  
 topical 73.15
- penetration enhancers 73.7–8
- penetration injury, foreign bodies 28.40, 28.49–52
- D-penicillamine therapy  
 adverse effects 75.102–4  
 copper deficiency 3.44  
 dermatomyositis 51.121  
 elastosis perforans serpiginosa 45.65  
 gigantomastia 70.3  
 gynaecomastia 70.5  
 pemphigus 75.38  
 pseudopseudoxanthoma elasticum 45.25  
 scleroderma 45.52  
 systemic sclerosis 51.108
- penicillin(s) 74.39–41  
 adverse effects 75.48–9  
 allergy 26.46, 34.23, 74.39  
 anaphylaxis 75.5, 75.25, 75.48–9  
 syphilis treatment and 34.22, 34.23  
 urticaria 22.8, 22.10, 75.26  
 amino 74.40  
 in cellulitis/erysipelas 30.20  
 penicillinase-resistant 74.40  
 penicillinase-sensitive 74.39  
 resistance, *Staphylococcus aureus* 74.40  
 skin testing for reactions to 75.170–2  
*see also specific penicillins*
- penicillin G 74.39  
 syphilis management 34.22, 34.23
- penicillin V 74.40  
 in recurrent cellulitis and lymphoedema 48.24
- penicilliosis 36.88–9  
 in HIV infection 35.34
- Penicillium*  
 in otitis externa 68.21  
 in otomycosis 68.27
- Penicillium marneffei* 36.88–9
- penile acne 71.27
- penile calcinosis 71.36
- penile carcinoma 71.40–3
- penile haematoma 71.14
- penile horn 71.37
- penile intraepithelial neoplasia (PIN) 71.38–9, 71.40  
 HPV and 33.54–5
- penile lymphoedema 71.28, 71.49–50
- penile melanosis 58.15, 71.49
- penile necrosis 71.24–6
- penile oedema 28.39, 71.30, 71.49
- penile rupture 71.14
- penile thrombophlebitis 71.14
- penile ulceration, in herpes simplex 33.16, 33.17
- penile warts 33.44, 33.45
- penis  
 amoebiasis 37.28  
 apocrine cystadenoma 18.94  
 Bowen's disease of 52.36  
 fibromatosis (plastic induration/fibrous sclerosis) 45.47–8, 56.11–12  
 granuloma inguinale 34.36  
 lichen nitidus 41.22  
 lichen planus 41.7, 41.9  
 median raphe cyst 18.94–5  
 plastic surgery 71.50  
 pyoderma gangrenosum 50.70  
 saxophone 30.70  
 syphilis 34.7
- Penrose drain 65.42, 65.43
- pentachlorophenols 25.21
- pentaerythrotol tetranitrate 75.97
- pentamidine isethionate 37.31, 37.39, 75.72
- Pentatomidae 38.25
- pentazocine 75.87–8  
 lobular panniculitis with crystals after 46.17, 46.18  
 scleroderma and 27.17, 45.52
- pentazocine ulcers 28.45, 28.53
- pentoxifylline 14.24  
 in dermatomyositis 51.129  
 in systemic sclerosis 51.108  
 in venous leg ulcers 47.49
- pentraxins 13.4  
 in vasculitis 50.7
- PEODDN (porokeratotic eccrine ostial and dermal duct naevus) 18.11, 18.16–17
- PEP syndrome *see* POEMS syndrome
- peppermint oil 26.17, 38.5
- peptidase D deficiency 45.39–40, 47.54
- peptidases 38.1
- peptide histidine methionine 63.3
- peptidoglycan 30.8
- PeptoBismol 75.157
- per protocol analysis 7.11
- perchloroethylene, scleroderma-like lesions and 51.80
- perchloroethylene 25.20
- perennial allergic conjunctivitis (PAC) 67.15  
 clinical features 67.13  
 perfloxacin 32.17, 75.33
- perforating collagenosis (folliculitis) 19.84, 19.88, 19.89, 30.27, 45.63, 59.80, 68.14  
 ear involvement 68.14  
 reactive 19.89, 45.63, 45.64–5, 69.129  
 renal involvement 62.72
- perforating dermatosis 45.63–6  
 acquired reactive 45.63–4  
 chemical-induced 45.64
- perforating folliculitis *see* perforating collagenosis (folliculitis)
- perforating keratotic disorders 19.88–9
- perforins 10.26, 13.6, 13.11
- performing artists, occupational hazards 27.20
- perfumes  
 as allergens 26.40–3  
 Berloque dermatitis and 58.32  
 as photoallergens 26.23, 58.32  
*see also fragrance(s)*
- peri-auricular anomalies 68.4
- periadenitis mucosa necrotica recurrens *see* Sutton's disease
- perianal intraepithelial neoplasia, HPV and 33.54–5
- perianal oil granuloma 46.29
- perianal/perineal area 71.83–100  
 benign tumours 71.83, 71.96  
 candidiasis 36.62  
 cellulitis 30.32–3  
 child sexual abuse and 28.37–8  
 congenital and developmental abnormalities 71.83–4  
 dermatitis 25.16  
 in dystrophic epidermolysis bullosa 39.19, 39.21, 39.28–9  
 general approaches 71.1–4, 71.82–3  
 hidradenitis suppurativa 30.80  
 infections 71.91–6  
 inflammatory dermatoses 71.84–91  
 neonatal dermatitis 17.22  
 Paget's disease 53.40–1  
 premalignant dermatoses and frank malignancies 71.90, 71.96–9  
 pruritus *see* pruritus ani  
 sexually transmitted diseases 71.83, 71.93–5  
 structure and function 71.83  
 syphilitic chancre 34.7  
 trauma and artefact 71.84  
*see also entries beginning anogenital;*  
 perineum
- perianal warts 33.46
- periappendicitis, gonococci causing 34.26
- periarteritis nodosa *see* polyarteritis nodosa
- pericarditis, in sarcoidosis 61.7
- perichondritis, ear 68.7, 68.19–20
- pericytes 3.3, 3.51, 56.42  
 microscopy 10.35
- periderm 3.3
- peridigital dermatosis *see* juvenile plantar dermatosis
- perifollicular elastolysis (PFE), in acne 42.33
- perifolliculitis, in dermatophytosis 36.22
- perifolliculitis capitis abscedens et suffodiens 30.29–230, 42.33, 42.74, 66.47–8  
 features and treatment 42.74
- perihepatitis, acute 34.26
- perilipin 46.2
- perineal syndrome 71.99
- perineum  
 bacterial flora 30.4  
 hidradenitis suppurativa and 30.80  
 watering-can 62.48–9  
*see also perianal/perineal area*  
 perineurioma 56.49
- periodic acid-Schiff (PAS) staining 10.8, 10.9, 10.10, 36.7  
 foreign bodies 28.42
- periodic fever syndromes  
 bone and joint involvement 62.104  
 hereditary 22.24–5
- periodontal ligament 69.2
- periodontitis  
 chronic 69.18  
 in diabetes mellitus 69.18  
 in Down's syndrome 69.17, 69.18  
 early-onset 69.17, 69.18  
 in Ehlers-Danlos syndrome 45.32, 45.36, 69.17, 69.18  
 keratoderma with 19.94, 19.110, 19.111  
 in neutrophil dermatoses 69.15
- in Papillon-Léfavre syndrome 69.16, 69.18  
 in Prader-Willi syndrome 69.17  
 in Unna-Thost syndrome 69.16
- periodontium 69.2  
 disorders 69.12–21  
 in HIV infection 35.43  
 inflammatory *see* periodontitis
- perioral dermatitis 43.11–12  
 acne vs 42.36  
 Gianotti-type 43.12, 43.13  
 granulomatous, in children 43.12, 43.13
- perioral region  
 allergic contact dermatitis 26.17  
 examination 69.3–5
- periorbital oedema 67.5
- periorificial lentiginosis *see* Peutz-Jeghers syndrome
- periostin 14.6
- periostitis  
 in congenital syphilis 34.16  
 venous leg ulcers and 47.46
- peripheral arterial disease *see* arterial disease, peripheral
- peripheral circulation 74.51–2  
 systemic agents 74.51
- peripheral ischaemic disorders 47.1–9  
*see also* arterial disease, peripheral
- peripheral nerve sheath tumour, malignant 56.53
- peripheral nerves  
 injury 63.13–14  
 thickening 32.9, 32.11–12, 32.15
- peripheral neuroectodermal tumours 56.44–54
- peripheral neuropathy 63.11–13  
 aetiology 63.11  
 in chloracne 27.13  
 dysproteinaemia and skin changes with 58.29  
 glove and stocking 32.11, 63.11  
 in HIV infection 63.12  
 hyperhidrosis and 44.7  
 investigation 63.11–12  
 in sarcoidosis 61.7  
 silent 32.17
- peripheral primitive neuroectodermal tumour 56.54
- peripheral sensory neuropathy 51.132
- peripheral T-cell lymphoma 57.34–40  
*see also specific types*
- peripherin 3.9
- Periplaneta* 38.28
- periporitis, swimming-/diving-associated 28.54–5
- periporitis staphylogenes 17.7, 17.43, 30.32, 44.16
- peritoneal dialysis, bacterial infection and 30.7
- periumbilical choristia 71.100
- periungual fibromas 15.22
- periungual warts 33.43, 33.48
- perivascular epithelioid cell tumour 56.60
- perleche *see* cheilitis, angular
- Perls' Prussian blue reaction 10.9, 10.10
- permanent waving (perm) 66.98–9
- permeability constants 4.4
- permeability of skin 4.4–5  
 ageing and 8.23  
 permeability regulation, by tight junctions 3.24
- permethrin  
 in clothing/body louse infection 38.22  
 cream 73.13  
 in *Demodex* infection in rosacea 43.3  
 in head louse infection 38.19  
 in scabies 38.41
- pernio 28.65–6, 74.51–2  
 ear 68.5, 68.10  
 lesions resembling 62.42
- peroxidase-antiperoxidase complex 10.15, 10.16
- peroxisome proliferator-activated receptors *see* PPARs (peroxisome proliferator-activated receptors)

- perphenazine, black galactorrhoea due to 70.6
- persistent acantholytic dermatosis 19.86–8
- persistent avasculopathy syndrome 49.17
- persistent light reaction 26.24, 29.17, 29.21
- persistent pigment darkening (PPD) 58.31
- persistent superficial dermatitis 57.57
- persistent vitelline duct 71.100
- personal experience, value of as evidence 7.3, 7.4
- personality disorders 64.36, 64.42  
borderline type 64.41, 64.46
- perspiration 3.12  
active sweating 3.12  
insensible 3.12  
*see also* sweating
- pertinax bodies 65.2
- Peruvian lily 26.26, 26.76
- pes cavus with lymphoedema 48.10
- pesticides, scleroderma-like lesions 51.80
- PET scanning 5.22
- petechiae 49.4, 62.90  
capillary pressure and Hess test 49.5  
causes 49.7  
definition 5.7, 49.2  
in fat embolism 49.38, 62.99  
in immunodeficiency 17.53  
in infectious mononucleosis 33.30  
oral cavity 69.21, 69.22  
raised intravascular pressure causing 49.14  
size of lesions 49.4
- petechial gloves and socks syndrome 49.20
- petrolatum, comedogenicity 27.13
- Petrolatum USP 26.85, 73.2, 73.6
- petroleum 25.20, 27.13
- Peutz–Jeghers syndrome 54.3, 58.12–13, 62.56–7  
genetics 58.12  
mucocutaneous pigmentation 58.12  
oral involvement 58.12, 69.27, 69.28, 69.116
- Peyer's patches 13.9
- Peyronie's disease 45.47–8, 56.11–12, 71.27
- PFA closure time 49.6
- PFAPA syndrome 50.54
- Pfeiffer's syndrome 15.91
- PFR (phenol formaldehyde resin) 26.73–4
- PG (proteoglycan) *see* proteoglycan(s)
- PG (pyoderma gangrenosum) *see* pyoderma gangrenosum (PG)
- PG-M1 10.24
- PGD *see* preimplantation genetic diagnosis
- PGH (preimplantation genetic haplotyping) 16.1, 16.8–9
- PGL (phenolic glycolipid) 32.1
- PGL-1 antibodies 32.7
- PGP-9.5 21.2
- PHACE syndrome 18.47–8, 18.88
- phacomias, retinal 15.23
- Phaeoannellomyces wernneckii* 36.8, 36.14
- phaeochromocytoma 44.7, 62.35–6, 62.43–4  
granulosis rubra nasi and 44.18  
hyperpigmentation in 58.25
- phaeohyphomycosis 36.77
- phaeomelanins 3.20, 5.15, 66.90  
in animals 2.5, 2.6
- phaeomelanosis 66.90–1
- phagocytes 55.4  
antigen-presentation capacity 55.4  
dermal dendrocyte action 55.3  
receptors 55.4
- phagocytosis 55.4  
*Demodex folliculorum* in rosacea 43.2  
Langerhans' cell role 3.17  
*Treponema pallidum* 34.4
- phagolysosomes 55.4
- phakomatosis pigmentokeratoma 18.27, 18.30
- phakomatosis pigmentovascularis 18.68–9
- pharmaceutical industry, occupational hazards 27.19
- pharmacists 72.7, 72.26  
self-help on skin disease and 6.14
- pharmacodynamics 72.27–30
- pharmacoepidemiology 75.4
- pharmacogenetics 11.16, 72.29–30, 76.10–11
- pharmacokinetics 72.27
- pharmacovigilance 75.3, 75.4
- pharyngitis, herpes simplex 33.17
- phenacetin 75.73
- phenelzine 75.79
- phenindione 75.105
- pheniramine 26.46
- phenobarbital, eccrine gland secretion 44.18
- phenol 75.166, 80.9  
as caustic 33.49, 77.47  
liquefied 77.47  
diluted 33.12  
wart treatment 33.49
- phenol esters 25.3
- phenol formaldehyde resin 26.73–4
- phenolic glycolipid 32.1  
PGL-1 antibodies 32.7
- phenolphthalein 75.158  
hyperpigmentation due to 58.30
- phenols  
as allergens 26.79  
burns 25.11, 27.12  
depigmentation due to 27.15  
hair regrowth and 73.39  
as irritants 25.19, 25.21  
in pruritus 21.17  
substituted  
depigmentation due to 58.50  
hypermelanosis treatment 58.39
- phenoplastics 26.73–4
- phenothiazines 75.82  
adverse effects 70.5, 75.148  
allergy 26.46  
erythema multiforme 76.3, 76.4  
galactorrhoea 70.6  
hypermelanosis 58.29  
hyperpigmentation 69.97  
photosensitivity 75.31  
as photoallergens 26.24
- phenothrin 38.19, 73.13
- phenotypes, online databases 15.1
- phenotypic walking 11.12
- phenoxymethyl penicillin 74.40  
in recurrent cellulitis and lymphoedema 48.24
- phenprocoumon 75.105
- phenyl-benzimidazole sulphonic acid 26.62
- phenylalanine, elevated levels *see* hyperphenylalaninaemia syndromes
- phenylbutazone 49.46  
adverse effects 75.77  
erythema multiforme 26.46  
erythroderma 23.47
- p*-phenylenediamine *see* paraphenylenediamine
- phenylephrine 26.46, 75.98
- phenylketonuria (PKU) 59.94–5  
eczema and 23.27  
hair colour in 66.94  
maternal 18.2
- phenylpyruvic oligophrenia *see* phenylketonuria (PKU)
- phenytoin  
adverse effects 70.5, 75.84–6  
acneiform eruptions due to 42.72  
anticonvulsant hypersensitivity syndrome 76.10  
gingival swelling 69.21  
in HIV infection 35.20  
hypermelanosis 58.29–30  
hypertrichosis 66.79
- melasma-like hyperpigmentation 58.34  
scleroderma 45.52  
eccrine gland secretion 44.18
- pheomelanin, formation 58.5, 58.6
- pheromones 3.3, 44.2  
insect 38.2
- phialides 36.3, 36.4, 36.76
- Phialophora* 36.77  
*Phialophora verrucosa* 36.75, 36.76
- philtrum 69.2
- phimosis 34.7, 34.11, 71.8, 71.20–2, 71.40
- phlebectasia 47.24  
genuine diffuse 47.24
- phlebectomy 47.39
- phlebography 47.36  
ascending 47.36  
descending 47.36
- phlebotomiasis 18.71, 69.29
- Phlebotomus* 37.33, 37.35, 38.5
- phlyctenule 67.4
- PHM (peptide histidine methionine) 63.3
- phobias 64.12, 64.24–5
- phorbol esters 13.23
- Phormia* 38.8
- phosphate metabolism, in chronic renal failure 46.16
- phosphodiesterase, in atopic dermatitis 24.15–16
- phospholipase(s) 31.34, 38.1, 38.14
- phospholipase A2 8.21
- phospholipid(s)  
nail plate 65.3  
stratum corneum 3.11, 4.2
- phospholipid transfer protein (PLTP) 59.83
- phosphonoformate (foscarnet), herpes simplex 33.21
- phosphoric acid 25.19
- phosphorus burns 27.12
- phosphorus sesquisulphide 26.15
- photo-onycholysis 29.6, 65.11, 65.16, 75.32  
doxycycline causing 42.50
- photoactivation 26.23
- photoageing 8.21–2, 8.22, 29.7, 45.26, 80.2  
prevention and reduction 80.3–4  
treatment  
retinoids 73.35, 73.36  
tazarotene 73.37
- photoallergens 29.19, 29.21, 75.32
- photoallergic reactions 26.23–5, 75.32  
drug-induced 29.20–1
- photobiology 29.1–24  
basic principles 29.1–4  
definition 29.1  
emission spectra 29.1–2  
*see also* ultraviolet (UV) radiation
- photobleaching 10.14–15
- photocarcinogenesis 29.7
- photochemotherapy 57.24  
extracorporeal *see* extracorporeal photopheresis (ECP)  
*see also* photodynamic therapy; PUVA therapy
- photodamage  
collagen synthesis increase 3.39  
ecchymotic haemorrhage 49.4  
squamous cell carcinoma and 52.24, 52.27  
*see also* ultraviolet (UV) radiation
- photodermatitis 28.92  
plant-induced 29.21, 58.32, 75.162
- photodermatoses 29.9–23  
acquired, with autoimmune basis 29.9–20  
*see also* actinic prurigo (AP); chronic actinic dermatitis (CAD); hydroa vacciniforme (HV); polymorphic light eruption (PLE); solar urticaria (SU)  
clinical evaluation 29.23  
dermatoses exacerbated by UVR 29.22, 29.22–3, 29.23  
differential diagnosis 29.23  
DNA repair defects *see under* DNA
- drug-/chemical-induced  
photosensitivity  
endogenous *see* porphyria, cutaneous exogenous 29.20–2  
investigations 29.23–4  
management, sunscreen use 73.41  
phototesting and provocation tests 29.23  
race and 9.19  
UVA-induced 29.9  
*see also* photosensitivity
- photodynamic change 78.4
- photodynamic reactions,  
hyperpigmentation 58.32
- photodynamic therapy 20.43, 78.15–16  
acne 42.67  
actinic keratosis 52.32, 78.16  
basal cell carcinoma 78.16  
Bowen's disease 52.34, 78.16  
granuloma annulare 60.10  
molluscum contagiosum 33.12  
naevoid basal cell carcinoma syndrome 52.8  
non-melanoma skin cancer 52.16  
in perioral dermatitis 43.12  
photosensitivity due to 29.21  
pro-drugs 52.16  
psoriasis 20.43  
rosacea 43.6  
sarcoidosis 61.21  
warts 33.49
- photoexacerbation, of skin diseases 29.22, 29.22–3
- photography  
acne 72.10  
occupational hazards 27.20  
psoriasis 72.9
- photoimmunology 13.26–34, 26.10
- photoleukomelanodermitis 75.33
- photomechanical reactions 78.4–5
- photons 29.1  
absorption spectra and, excitation 29.3
- photopatch testing 29.24
- photoperiod and hair growth 66.9
- photopheresis 13.25  
extracorporeal (ECP) 57.67
- photophobia  
in albinism 58.40  
ichthyosis follicularis with alopecia and (IFAP) 19.58–9, 19.60  
in oculocutaneous tyrosinaemia 19.112
- photoplethysmography (PPG) 47.36  
digital 47.36
- photoproducts  
carcinogenesis and 52.14  
DNA damage and repair 52.14  
photoprotection 58.38, 73.41, 80.3  
in actinic prurigo 29.14  
in chronic actinic dermatitis 29.18  
hydroa vacciniforme 29.15  
in polymorphic light eruption 29.12  
in solar urticaria 29.19  
*see also* sunscreens; ultraviolet (UV) radiation, exposure minimisation
- photorecall reactions 75.32
- photosensitivity  
in animals 2.23  
in atopic dermatitis 24.21  
in carcinoid syndrome 43.18  
causes 2.23  
clinical evaluation 29.23  
differential diagnosis 26.29, 26.30, 29.23  
drug-/chemical-induced 29.20–2, 58.56, 75.30–2, 75.52  
acne medications 42.34  
co-trimoxazole 57.53  
endogenous 29.21  
exogenous 29.20–1, 29.21, 29.23  
in HIV infection 35.22  
eye and skin involvement 67.30  
IBIDS/PIBIDS syndrome 19.47–9  
investigations 29.23–4  
in lymphogranuloma venereum 30.70  
persistent 29.21  
*see also* photodermatoses

- photosensitivity dermatitis 29.17  
 photosensitization 29.7  
 photosensitizers 26.23–4, 78.15–16  
 drugs acting as 29.20, 29.21  
*see also* photosensitivity, drug-/chemical-induced  
 plant, in animals 2.23  
 photosensitizing agents, lichenoid photoeruptions and 41.25  
 photostimulation 78.4  
 phototesting procedures 29.23  
 phototherapy  
 atopic dermatitis 21.13, 24.31  
 Darier's disease 19.85  
 dermatographism 22.14  
 eczema 23.38  
 eosinophilic folliculitis in HIV infection 35.18  
 granuloma annulare 60.10  
 hand eczema 23.22  
 mastocytosis 22.36  
 neonatal, complications 17.12–13  
 pityriasis rubra pilaris 19.79–80  
 pruritus 21.18  
 seborrhoeic dermatitis 23.33  
 UVB 29.1  
 UVB narrow-band  
 actinic prurigo 29.14–15  
 chronic actinic dermatitis 29.18  
 polymorphic light eruption 29.12  
 vitiligo 58.48  
 photothermal ablation 78.13–15  
 photothermolytic reactions 78.4–5  
 phototoxic reactions 25.17, 26.16, 26.23  
 drug-induced 5.15, 29.20, 29.21, 29.21, 75.31  
 hyperpigmentation 58.32  
 tests for 25.9  
 topical, dyestuffs causing 29.20–1  
 phototrichography 66.11  
 phototypes, skin 29.6, 29.8  
 chemical peels and 80.9, 80.10  
 phragmoconidia 36.4  
 phrynoderma 19.75–6, 19.84  
 phthalic anhydride 25.20  
 Phthiraptera *see* lice  
 phthiriasis 67.27  
 phthiriasis palpebrarum 38.22, 38.23  
 Phthiriasis pubis *see* lice, pubic (crabs)  
 phycomycosis  
 vulval 71.69  
*see also* zygomycosis  
 phyloerythrins 2.23  
 phymas 43.9–10  
 Physalia 38.55, 38.56, 38.57  
 physical exercise, pressure ulcer risk and 28.21  
 Physician's Global Assessment 72.9  
 physiological livedo reticularis 28.68  
 phytanic acid 19.45–6  
 phytohaemagglutinin A 13.23  
 phytomenadione 45.52  
 photophotodermatitis 29.21, 58.32, 75.162  
 pian *see* yaws  
 pian bois 37.34, 37.35, 37.39–41  
 PIBIDS syndrome 19.47–9  
 PIC3CA gene 18.6  
 pica 62.85  
 picaridin 38.5  
 picatura de pito 37.34, 37.35, 37.39–41  
 Picea 26.81  
 picking of skin, pathological 64.19, 64.27–9  
 PICO 7.2  
 picornaviruses 33.2, 33.71–4  
 picric acid, pigmentation due to 58.56–7  
 piebaldism 58.42–3, 66.93  
 in Waardenburg's syndrome 58.43  
 piedra  
 black 36.5, 36.15–16  
 fungal culture 36.7, 36.8  
 white 30.3, 36.5, 36.16–17  
 fungal culture 36.7, 36.8  
 Piedraia hortae 36.8, 36.15  
 female genital infection 71.69  
 piercings 64.2  
 ornamental 28.51–2  
 piezogenic pedal papules 28.61  
 pigment anomalies, human chimeras with 58.23  
 pigment cells 2.5–7  
 in animals 2.5–7  
 evolution 2.1  
 regulation in fish 2.5–6  
 'pigment type switching' 2.6–7  
 pigmental demarcation lines 58.1, 58.2  
 pigmentary incontinence  
 in lichen planus 41.4  
*see also* incontinentia pigmenti (IP)  
 pigmentation 58.1–59  
 advantages of 58.8  
 ageing and 8.23  
 in anaemia 58.17, 58.27, 62.85  
 ashy colour 58.33  
 blue 58.36  
 naevi 54.25–7  
 blue-black, minocycline causing 58.56  
 blue-grey 58.55  
 drug-induced 58.29  
 bronze 58.53  
 in haemochromatosis 58.28  
 bronzing of skin 58.53  
 brown 58.7, 58.8  
 changes, causes 58.9  
 chemicals causing 58.54, 58.56–7  
 in chronic radiodermatitis 79.16  
 constitutive 58.1, 58.7, 58.9–10  
 disadvantages of 58.9  
 disorders  
 in animals 2.23  
 classification 58.9  
 eye and skin involvement 67.30  
 in HIV infection 35.12  
 localized areas 58.9  
*see also* hyperpigmentation; hypopigmentation; specific disorders  
 endogenous non-melanin 58.53–4  
 evolutionary significance 58.8–9, 73.40  
 exogenous pigments 58.54–9  
 eyelids 67.5  
 facial, grey-brown 58.35  
 facultative/inducible 58.1  
 in fixed drug eruption 75.28  
 genetic causes of variations 58.9–10  
 idiopathic lenticular 69.28  
 of lesions 5.15–17, 5.18  
 in lichen planus 41.7  
 loss *see* depigmentation  
 measurement 72.11  
 melanocytes *see* melanocyte(s)  
 melanocytes and keratinocyte interface 58.2  
 minocycline-induced changes 42.50–1  
 mottled, in epidermolysis bullosa simplex 39.4, 39.8  
 nails 9.3  
 non-melanin 58.53–4  
 normal 5.15, 58.1–2  
 oestrogen effect 58.7  
 oral cavity 9.3, 69.21–2, 69.26–9, 69.95–100, 75.47  
 paraneoplastic 62.33, 62.34  
 patchy, in chloracne 27.13  
 post-inflammatory 9.4  
 post-phototoxic 29.21  
 in pregnancy 8.10  
 race and 9.1, 58.1, 58.10  
 regulation 58.1, 58.7–8  
 endocrine factors 58.7  
 paracrine/autocrine factors 58.7–8  
 UV radiation response 58.7  
 in response to sun exposure 58.8, 58.10  
 reticulate  
 dermatopathia pigmentosa reticularis 58.20  
 Naegeli's syndrome 58.19  
 post-inflammatory 58.31  
 slate-brown, drug-induced 58.30  
 slate-grey 58.36  
 in incontinentia pigmenti (IP) 58.16  
 subungual 54.45  
 variations 58.10  
 pigmented cosmetic dermatitis 58.35  
 pigmented flexural lichen planus 71.59–60  
 pigmented iris hamartomas (Lisch nodules) 15.16, 15.17, 58.18, 58.23, 62.23  
 pigmented neuroectodermal tumour of infancy 56.52–3  
 pigmented peribuccal pigmentation of Brocq 58.35–6  
 pigmented purpuric dermatoses 49.22–6  
 chronic, infectious 49.23  
 differential diagnosis 50.54  
 familial 49.25  
 granulomatous 49.25  
 idiopathic 49.22, 49.23  
 lichenoid 49.22, 49.25  
 linear and quadrant 49.25  
 morphological patterns and pathology 49.22  
 progressive *see* Schamberg's disease  
 secondary 49.23–4  
 systemic causes 49.23–4  
 treatment 49.26  
 venous 49.23  
 pigmented purpuric lichenoid dermatosis of Gougerot and Blum 49.22, 49.25  
 pigments, animal 2.5  
 pigs  
 bullous pemphigoid 2.14–15  
 flea infestations 2.10  
 PI3K 62.61  
 PIK3CA gene, mutations 52.38  
 pilar cyst *see* trichilemmal cyst  
 pilar sheath acanthoma 53.3  
 pilary canal 42.1  
 pili annulati 66.69–70, 66.91  
 pili incarnati 30.22–3  
 pili multigemini (pili bifurcati) 66.73–4  
 pili torti 66.62, 66.63–4, 66.65  
 developmental delay and 15.50  
 onychodysplasia and 15.50  
 pili trianguli et canalliculi 66.71–2  
 pilocarpine 3.12, 26.46  
 pilodental dysplasia with refractive errors 15.50  
 piloerection 28.53  
 pilomatricarcinoma 53.14  
 pilomatricoma (pilomatricoma) 53.12–13  
 pinna 68.28  
 superficial 53.13  
 pilonidal cysts 71.87  
 pilonidal sinus  
 anogenital 28.49–50  
 male genital dermatology 71.26–7  
 perianal/perineal dermatology 71.87, 71.88  
 umbilical dermatology 71.101  
 pilosebaceous duct  
 cornified plug, acne aetiology 42.24, 42.25  
 junction with epithelium, basal cell carcinoma 52.21  
 pilosebaceous follicle, inflammation, epidermoid cyst 52.45  
 pilosebaceous naevoid disorders 42.78  
 pilosebaceous unit 3.1, 3.13–14, 53.1  
 in acne 42.17  
 androgen effects on 42.21  
 classes 3.13  
 development 3.13  
 hamartoma 53.7–8  
 hyperkeratosis 53.2  
 microenvironment, acne pathogenesis 42.25  
 outflow obstruction 42.24, 42.25  
 pimecrolimus 20.42, 51.23, 51.118, 73.31, 73.32, 74.17  
 adverse effects 26.46, 75.146–7  
 in allergic contact dermatitis 26.102  
 in atopic dermatitis 24.30, 73.32  
 in eczema 23.38  
 in Fox-Fordyce disease 44.22  
 in granuloma annulare 60.10  
 in perioral dermatitis 43.12  
 in seborrhoeic dermatitis 23.33, 35.16  
 structure 73.32  
 systemic exposure 73.32  
 topical 73.32  
 in rosacea 43.6  
 pimozone 21.12, 64.52  
 in acne excoriée 42.70  
 adverse effects 64.16  
 in delusional parasitosis 64.16  
 PIN *see* penile intraepithelial neoplasia  
 pinch-pulling 28.25  
 pinch sign, positive 5.18  
 pindolol 75.91  
 pine processionary caterpillar 38.28–9  
 pineapple 25.21  
 pinene 26.82  
 Pink disease 69.83–4, 75.101–2  
 Pinkus tumour 52.48  
 as trichoblastoma variant 53.10  
 pinna  
 accessory 68.4  
 ageing changes 68.5–6  
 altitude injury 68.11  
 anatomy and physiology 68.1, 68.2  
 angiosarcoma 68.34  
 basal cell carcinoma 68.32, 79.9, 79.10  
 benign tumours 68.28–9  
 calcification 59.69, 62.5  
 chondroma 68.28  
 conditions resembling benign tumours 68.29  
 contusion and haematoma 68.6–7  
 development 68.3  
 developmental defects 68.3–5  
 examination 68.3  
 fibroma 68.28  
 granular cell tumour 68.28  
 haemangioma 68.28  
 hypertrichosis 68.1, 68.2, 68.5  
*see also* ear(s), hairy  
 infection 68.19–20  
 laceration and avulsion 68.7  
 lymphangioma 68.28  
 malignant melanoma 68.33–4  
 melanocytic naevi 68.28  
 myoma 68.28  
 neurofibroma 68.28  
 osseo-integrated implants 68.16  
 osteoma 68.28  
 piercing 68.7–9  
 complications 26.17, 61.23, 68.7–8  
 pilomatricoma 68.28  
 premalignant epithelial neoplasms 68.30  
 radiation injury 68.11  
 restoration following loss 68.16  
 schwannoma 68.28  
 seborrhoeic keratosis 68.28  
 solar damage 68.10–11  
 solar keratosis 68.30  
 squamous cell carcinoma 68.30–2  
 squamous cell papilloma 68.28  
 trauma 68.6–14  
 trichoepithelioma 68.28  
 trichofolliculoma 68.28  
 variations in shape 68.4–5  
 Winer's pore 68.28  
*see also* ear(s)  
 pinprick sensation in leprosy 5.18  
 pinta 30.63–4  
 late, hyperpigmentation after 58.31  
 pintids 30.63  
 Pinus 26.79, 26.81  
 pinworms 37.13–14  
 perianal/perineal infection 71.92  
 piperazine 75.71, 75.149  
 piperidine 75.149  
 piroxicam 75.75–6  
 Pit-1 49.47

- pitch  
acnogenicity 27.13, 27.14  
carcinogenicity 27.16, 73.42
- pits  
ear 18.83–4, 68.4  
lip *see under* lip(s)  
preauricular 68.4
- pitted keratolysis 30.39–40, 44.8
- pituitary adenylate cyclase-activating peptide (PACAP) 12.63–4, 63.3
- pituitary dysfunction  
Langerhans' cell histiocytosis (LCH) 55.12  
*see also* hyperpituitarism; hypopituitarism
- pituitary hormones  
in pregnancy 8.9  
sebaceous gland activity and 42.11–12
- pituitary–adrenal axis  
suppression, steroid therapy 73.20, 74.4  
tests of 74.3
- pityriasisiform scale 5.7
- pityriasis alba 23.27–8, 58.10  
hypopigmentation in 58.52  
pityriasis rosea vs 33.81  
vitiligo vs 58.48
- pityriasis amiantacea 20.14, 20.16, 66.57
- pityriasis capitis 66.56–7
- pityriasis circinata, pityriasis rosea vs 33.81
- pityriasis circinata et marginata 33.80
- pityriasis folliculorum 38.53
- pityriasis lichenoides 50.50–1, 57.54–7  
in liver disease 62.64  
pityriasis rosea vs 33.81  
vasculitis and 50.3
- pityriasis lichenoides chronica 50.50  
race and 9.5–6
- pityriasis lichenoides et varioliformis acuta 50.50–1, 69.85
- pityriasis nigra 36.8, 36.14–15
- pityriasis rosea 33.78–81  
aetiology 33.78–9  
breast 70.17  
clinical features 33.79–80  
diagnosis 33.80–1  
differential diagnosis 23.32, 33.80–1  
drug-induced 33.79, 33.80  
drug-induced reactions resembling 33.80, 75.24  
HHV-6 association 33.79, 33.81  
HHV-7 association 33.33, 33.79, 33.81  
HHV-8 association 33.79  
pathology 33.79  
race and 9.6  
second attacks/eruptions 33.79  
secondary syphilis vs 34.11  
treatment 33.81
- pityriasis rotunda 9.10, 19.65, 62.32
- pityriasis rubra pilaris (PRP) 19.76–81, 19.84  
erythroderma and 23.48  
hands 23.20  
nail involvement 65.25  
TNF antagonists as treatment 74.7
- pityriasis versicolor 36.10–13  
in adolescence 8.7  
aetiology 36.10–11  
clinical features 36.11  
definition 36.10  
differential diagnosis 23.32, 36.11  
ear involvement 68.20  
histology and pathogenesis 36.11  
hypopigmentation in 58.52  
laboratory diagnosis 36.7, 36.12  
race and 9.6  
treatment 36.12  
vitiligo vs 58.48
- Pityrosporum see Malassezia*
- pizotifen, in erythromelalgia 47.10
- pizzicato paronychia 28.25
- PKU *see* phenylketonuria (PKU)
- placenta, melanoma metastases 54.57
- placental alkaline phosphatase 55.9  
Langerhans' cell histiocytosis cells 55.8, 55.9
- placental hormones 8.9
- plague 30.54–5  
bubonic 30.55, 38.11  
pneumonic 30.55
- plagues of Egypt 38.27
- plakins 3.22, 40.4  
antibodies 40.23  
in paraneoplastic pemphigus 40.23
- plakoglobin 3.23, 40.1–2
- plakophilin 40.2  
deficiency 39.2, 39.4  
gene mutations 39.5–6
- plakophilin-1 3.22  
deficiency, epidermolysis bullosa simplex 39.4, 39.5–6
- Planck's constant 29.1
- plant alkaloids, photosensitivity in animals and 2.23
- plant growers, occupational hazards 27.19
- plantar dermatitis, mechanical injury 28.14
- plantar keratodermas *see* palmoplantar keratoderma (PPK)
- plants  
allergic contact dermatitis and 26.10, 26.15–16, 26.74–9  
irritant contact dermatitis and 25.17–18, 25.21  
mites on 38.48  
patch testing 26.77–8
- plaque(s)  
atheromatous 47.1  
atherosclerotic 49.36  
definition 5.7  
differential diagnosis 32.15  
in incontinentia pigmenti (IP) 58.16  
vernal 67.14
- plaque-like cutaneous mucinosis 59.25
- plasma cell(s) 13.7, 13.10  
infiltration, in syphilis 34.5  
microscopy 10.34
- plasma cell vulvitis (PCV) 71.61
- plasma exchange *see* plasmapheresis
- plasma proteins  
abnormalities, purpura and 49.19  
mutations, amyloidosis and 59.57
- plasma skin rejuvenation 80.13
- plasma viscosity 13.19
- plasmacytoid dendritic cells, type 1  
interferon-producing 3.19
- plasmacytolympoma 31.21
- plasmacytoma, oral 69.114
- plasmacytosis, idiopathic 69.19–20
- plasmapheresis 13.25  
in cryoglobulinaemic vasculitis 50.25  
in dermatomyositis 51.129  
in hereditary angio-oedema 22.22  
in necrobiotic xanthogranuloma 55.28  
in pemphigus 40.12  
in SLE 51.62  
in solar urticaria 29.20  
in systemic sclerosis 51.108  
in urticaria 22.29–30
- plasmids 11.4, 11.9–10
- plasmin, in wound healing 14.4
- plasminogen, in wound healing 14.4
- plasminogen activation inhibitor-1 (PAI-1) 46.7
- plasminogen activator  
activity 12.50, 40.6  
receptors 12.50  
urokinase, blocking acantholysis 40.14
- Plasmodium* 37.1, 37.27
- plastic surgery  
in body dysmorphic disorder 64.19  
to penis 71.50
- plastics, as allergens 26.69–74
- plastics industry, occupational hazards 27.20
- platelet(s) 12.32–4, 49.7–8  
adherence and activation 49.8  
aggregation 49.8  
abnormal 49.45  
in arterial disease and atherosclerosis 47.1–2
- autoantibodies 49.9, 49.11  
consumption, haemangioma 49.12  
count  
decreased *see* thrombocytopenia  
elevated 49.29  
*see also* thrombocytosis  
in heparin-induced thrombocytopenia 49.27  
in Hermansky–Pudlak syndrome 58.41  
in idiopathic thrombocytopenic purpura 49.9  
normal 49.5  
purpura investigation 49.5  
destruction, drug-/toxin-induced 49.11  
dysfunction  
drug-induced 49.4  
renal disease and 49.18  
simple macular haemorrhage 49.4  
*see also* platelet disorders  
function abnormalities 49.8, 49.12–14  
drug-induced 49.12–13  
due to skin diseases 49.13  
inherited 49.8  
purpura due to 49.12–14  
hyper-activity 49.14  
in immune defence and inflammatory processes 12.33  
immune destruction 49.9  
membrane glycoproteins  
autoantibodies 49.9  
inhibitors 49.11, 49.13  
neutralization procedure 49.40  
plug formation 49.8  
plugging 49.26  
microvascular occlusion due to 49.27–31, 49.41  
shape, microspicules 12.32  
'sticky,' in deep-vein thrombosis 47.28  
in wound healing 14.1, 14.2–3
- platelet-activating factor (PAF) 12.59, 13.4, 75.174
- platelet-derived growth factor (PDGF) 12.31  
in giant cell arteritis 50.43  
in mucous membrane pemphigoid pathogenesis 67.20  
wound healing and 14.3, 14.27
- platelet disorders 62.90–2  
purpura due to 49.7–12, 49.8  
elevated counts 49.8  
functional abnormalities 49.8  
*see also* thrombocytopenia; thrombocytosis
- platelet factor 4 (PF4) 49.11  
antibodies 49.27
- platelet function analysers (PFA) 49.6
- platelet-specific integrins, glycoprotein 11b–111a (GP11b–111a) 12.32
- platelet–endothelial cell adhesion molecule-1 *see* CD31
- platelet–neutrophil interaction 12.32
- platinum 26.40
- PLC *see* pityriasis lichenoides chronica
- PLE *see* polymorphic light eruption (PLE)
- PLEC1* gene mutations, in epidermolysis bullosa simplex 39.4
- plectin 3.30, 3.31, 39.4  
gene mutations 3.31  
monoclonal antibodies to 39.25
- pleomorphism 10.41
- plethysmography 47.36, 47.47
- pleuromutilins 73.10
- PLEVA (pityriasis lichenoides et varioliformis acuta) 50.50–1, 69.85
- plexiform fibrohistiocytic tumour 56.20
- plica polonica 38.19
- PLLA (poly-L-lactic acid) 80.5, 80.6
- 'plucked chicken' skin 62.85
- plumbers, occupational hazards 27.20
- plumber's itch *see* larva migrans, cutaneous
- Plummer–Vinson syndrome 62.48
- PMD 38.5
- pneumatosis cystoides intestinalis 51.100
- Pneumocystis carinii (jiroveci)* 17.50, 17.52, 17.58, 36.92  
ear polyps due to 68.28  
pneumonia, in AIDS/HIV infection 35.4–5, 35.21, 35.35
- pneumonia  
encapsulating 17.74  
giant-cell, in measles 33.75  
*Mycoplasma* 30.69  
*Pneumocystis carinii (jiroveci)*, in AIDS/HIV infection 35.4–5, 35.21, 35.35  
in psittacosis 30.72  
respiratory syncytial virus (RSV) 33.76
- pneumothorax, neonatal 17.14
- Pneumovirus* 33.75
- PNH (paroxysmal nocturnal haemoglobinuria) 13.4, 49.30–1
- podoconiosis 48.13  
race and 9.8
- podophyllin  
adverse effects 33.49, 75.166  
burns 27.11  
contraindications 33.49  
pregnancy 8.11  
mechanism of action 33.49, 73.25  
wart treatment 33.49, 73.25
- podophyllotoxin 73.25  
mechanism of action 33.49  
wart treatment 33.49, 73.25
- podophyllum 73.25
- Podophyllum emodi* 75.160
- podoplanin 10.24, 48.4, 48.5  
skin biopsy, in lymphoedema 48.19
- podopompholyx 23.16
- POEM (Patient-Orientated Eczema Measure) 72.9, 72.10, 72.14
- POEMS syndrome 45.54, 51.80, 58.29, 62.13, 62.44, 62.45, 62.94  
bone and joint involvement 62.101  
cutaneous abnormalities 33.34  
flushing in 43.16  
glomeruloid haemangioma 56.24
- Pogonomyrmex* 38.14
- Pogosta disease 33.66
- POHL* gene 15.72
- poikiloderma  
acquired 45.13  
definition 5.7, 45.13–14  
hereditary acrokeratotic of Weary 45.13  
hereditary sclerosing of Weary 45.13  
in megaloblastic anaemia 62.85
- poikiloderma congenitale 15.51, 15.80–2, 45.13, 45.61, 62.27  
bone and joint involvement 62.100  
greying of hair 66.92
- poikiloderma of Civatte 45.13, 58.35, 80.10, 80.11
- poikiloderma with neutropenia 15.50
- poikilodermatous epidermolysis bullosa 51.79
- poikilodermatous parapsoriasis 57.58
- poikilodermatous syndromes, genetics 15.78–83
- point estimate 7.9
- poison bun sponge 38.59
- poison ivy  
allergy to 26.16, 26.17, 26.75  
erythema multiforme-like reactions and 26.25, 76.5
- poison oak 26.75
- poison sumac 26.75
- pokeweed mitogens 13.23
- Poland syndrome 70.2, 70.3
- poldine methylsulphate 44.11, 73.9
- polidocanol 47.39, 75.156
- poliomyelitis virus 33.71
- poliosis 66.93
- poliovirus 33.1
- Polistes* 38.14
- pollen allergy  
atopic dermatitis and 24.10  
oral allergy syndrome and 22.20  
urticaria and 22.9

- pollinosis *see* pollen allergy  
 Pollitt syndrome 15.51, 15.55  
 pollution, atopic dermatitis and 24.5  
 poly-L-lactic acid (PLLA) 80.5, 80.6  
 polyA tail 11.3  
 polyarteritis nodosa (PAN) 5.10, 50.33–5  
 aetiology and pathogenesis 50.7, 50.33  
 breast involvement 70.11  
 clinical features 50.33–4  
 Crohn's disease and 62.49  
 cutaneous 50.37–9  
 definition 50.33  
 diagnosis 50.34  
 differential diagnosis 50.14, 50.32  
 hepatitis B virus infection and 33.60–1,  
 50.33, 50.34, 50.35, 62.59  
 hepatitis C virus infection and 50.33,  
 62.59  
 histopathology 50.33, 50.34  
 leg ulcer association 47.55  
 male genital dermatology 71.29  
 microscopic *see* microscopic  
 polyangiitis (polyarteritis)  
 ocular involvement 67.25  
 oral involvement 69.81, 69.117  
 respiratory tract involvement 62.83  
 treatment 50.35  
 in viral infections 33.77  
 polyarthralgia/polyarthritides  
 in multicentric reticulohistiocytosis  
 55.23  
 in parvovirus B19 infection 33.63  
 in Ross River virus infection 33.66  
 in sarcoidosis 61.6–7  
 in SLE 51.42  
 polybrominated biphenyls 27.13  
 polychlorinated biphenyls 27.12–13  
 congenital poisoning 18.2  
 polychlorinated dibenzofurans 27.12–13  
 polychondritis, relapsing, panniculitis  
 with 46.32  
 polycyclic hydrocarbons 27.16  
 polycystic ovary syndrome (PCOS) 66.80,  
 66.81–2  
 acne association 42.20, 42.21–2, 42.73  
 investigation and assessment 66.86  
 management 66.86  
 polycythaemia rubra vera (PRV) 62.86  
 disseminated pustular dermatosis 50.89  
 pruritus in 21.10, 62.86  
 polycythaemia vera 49.29  
 polydactyly 18.92  
 polyenes 74.46  
 topical 73.12  
 polyethylene glycols (PEGs) 27.12  
 cetylethers (cetomacrogols) 73.7  
 in topical therapy 73.7  
 polyfibromatosis syndrome 45.45  
 polyhydric alcohols 73.2  
 polyhydroxy acid 46.43  
 polymastia 70.2–3  
 polymerase chain reaction (PCR) 10.11,  
 11.6  
 in analysis of inherited disorders 15.7  
 in fungal infection diagnosis 36.9  
 in granuloma inguinale diagnosis 34.37  
 in HSV detection 33.19  
 in lymphogranuloma venereum  
 diagnosis 34.33  
 in normal skin flora analysis 30.2  
 real-time 11.6  
 reverse transcription 11.6  
 in syphilis diagnosis 34.19  
 in tuberculosis diagnosis 31.26  
 in viral infection diagnosis 33.4  
 in VZV detection 33.27  
 polymorphic eruption of pregnancy  
 (PUPPP) 8.13, 8.14, 21.14  
 polymorphic light eruption (PLE) 29.9–  
 13, 44.16  
 actinic prurigo association 29.14  
 in adolescence 8.7  
 aetiology 29.11  
 clinical features 29.10, 29.11–12  
 definition 29.9, 29.11  
 diagnosis 29.12, 29.23  
 differential diagnosis 29.10, 29.12, 51.7  
 hereditary/familial 29.13  
 investigations 29.10, 29.12  
 pathology 29.11  
 persistent, variant 29.14  
 race and 9.19  
 small papular 29.12  
 treatment 29.10, 29.12  
 treatment-induced flares 29.12  
 polymorphic reticulosis  
 oral involvement 69.58  
 respiratory tract involvement 62.83  
 polymorphism  
 definition 10.41  
 fungi 36.4, 36.56  
 genetic, functional impact 15.6  
 single nucleotide, in analysis of  
 inherited disorders 15.7  
 polymorphonuclear granulocytes  
 12.20–4  
*see also* basophil(s); eosinophil(s);  
 neutrophil(s)  
 polymyalgia rheumatica, giant cell  
 arteritis and 50.43, 50.44  
 polymyositis  
 paraneoplastic 62.36  
 in pregnancy 8.12  
 in sarcoidosis 61.7  
 polymyxin B, topical therapy 73.10  
 polymyxin E (colistin) 74.43  
 polymyxins 26.46  
 polyomaviruses 33.37, 53.42  
 polyostotic fibrous dysplasia 47.55, 66.52,  
 68.28  
 in McCune–Albright syndrome 58.18  
 polypharmacy 72.28  
 polyposis  
 genetics 15.25–6  
 MYH-associated 53.12  
 polyposis, skin pigmentation, alopecia  
 and fingernail changes  
 (Cronkhite–Canada syndrome)  
 15.50, 58.13–14, 62.57–8  
 polyps  
 adnexal polyp of neonatal skin 70.8  
 fibroepitheliomatous *see* skin tags  
 gastrointestinal 62.56–8  
 oral 69.20  
 in Peutz–Jeghers syndrome 58.12–13  
*see also* Peutz–Jeghers syndrome  
 umbilical 18.93–4, 71.100  
 polythelia (supernumerary nipple) 18.92–  
 3, 70.2–3  
 polythene gloves 73.4  
 corticosteroid therapy and 73.20  
 polyvinyl chloride 45.51–2, 62.47  
 disease 51.80  
 polyvinyl pyrrolidone (PVP) 28.44  
 foreign-body reaction to 61.22  
 pomade 27.13, 27.14, 42.73, 66.99  
 pomade acne 42.31, 42.73–4  
 pompholyx 23.16–19, 26.32  
 definition 23.1  
 differential diagnosis 26.29  
 occupational 27.4, 27.5  
 in palmoplantar hyperhidrosis 44.8  
 prevalence 23.3  
 Pontiac fever 30.67  
 pool palms 28.14  
 popliteal pterygium syndrome 15.94,  
 18.91  
 popliteal vessel occlusion 47.5  
 population studies 6.2  
 PORCN gene 15.84  
 pore-forming proteins 13.2  
 porfimer sodium, photosensitivity due to  
 29.21  
 Porifera (sponges) 38.59  
 porocarcinoma 53.32–3  
 porokeratosis 15.91, 19.90–2  
 Crohn's disease and 62.49  
 in HIV infection 35.39  
 linear 18.25–6  
 male genital dermatology 71.37  
 of Mibelli 19.91, 66.51  
 disseminated superficial 'actinic'  
 porokeratosis vs 52.36  
 pathology 52.36  
 perianal/perineal dermatology 71.97  
 punctate 18.17  
 scaling in 5.7, 5.12–13  
 skin biopsy 10.42  
 superficial actinic  
 disseminated 52.35–6  
 treatment 73.23  
 poroma, eccrine 53.22, 53.23–4  
 intradermal 53.22–3  
 malignant 48.14, 53.32–3  
 porphyria 59.1–20  
 acute attacks 59.7–9, 59.19–21  
 clinical features 59.3–8  
 treatment 59.8  
 aetiology 59.7  
 laboratory testing 59.8–10  
 congenital erythropoietic *see* congenital  
 erythropoietic porphyria (CEP)  
 cutaneous disease  
 with acute attacks 59.19–21  
 bullous porphyria 59.5–6  
 congenital erythropoietic porphyria  
 59.10–12  
*see also* congenital erythropoietic  
 porphyria (CEP)  
 erythropoietic protoporphyria *see*  
 erythropoietic protoporphyria  
 (EPP)  
 hepatoerythropoietic protoporphyria  
 59.13–15  
 hereditary coproporphria 59.19  
 major biochemical findings 59.9  
 pathogenesis 59.3–6  
 porphyria cutanea tarda (PCT) *see*  
 porphyria cutanea tarda (PCT)  
 variegata porphyria 59.19–20, 62.46,  
 66.79  
 without acute attacks 59.10–18  
 diagnosis, spectrofluorimetry 59.9  
 drug-induced 75.32, 75.37  
 erythropoietic 69.117  
 haem enzyme deficiencies 59.5  
 hepatoerythropoietic 66.79  
 hypertrichosis in 66.79  
 long-term management 59.8  
 ocular involvement 67.25  
 uroporphyrinogen decarboxylase  
 (UROD) in 59.5  
*see also specific types*  
 porphyria cutanea tarda (PCT) 59.12–15,  
 62.64  
 alcohol and 45.52  
 differential diagnosis 26.29  
 drug-induced 75.32, 75.37  
 ear 68.17–18  
 fibrin cuff-theory and 47.27  
 haemochromatosis and 62.61  
 hair colour in 66.95  
 hepatitis C virus infection and 33.61–2,  
 62.59–60  
 in HIV infection 35.20  
 hypertrichosis in 66.79  
 paraneoplastic 62.46  
 pigmentation changes 58.26  
 in pregnancy 8.12  
 sarcoidosis and 61.18  
 porphyria variegata 59.19–20, 62.46, 66.79  
 porphyrinaemia, transient neonatal 17.13  
 porphyrins, phototoxicity 59.2  
*Porphyromonas* 30.60  
 port-wine stain 18.63–5  
 clinical features 18.63–4  
 eyelids 67.34  
 in Klippel–Trenaunay syndrome 47.23  
 pathology and pathogenesis 18.63  
 race and 9.19  
 spinal dysraphism and 63.15  
 in Sturge–Weber syndrome 18.65–7  
 treatment 18.64–5, 78.6–7  
 Portuguese man-of-war (*Physalia*) 38.55,  
 38.56, 38.57  
 posaconazole 36.68, 36.83, 36.86, 74.47  
 positron emission tomography 5.22  
 post-herpetic neuralgia 33.24, 33.26, 63.6–  
 8, 67.26  
 elderly people 8.28  
 management 33.28, 73.49  
 prevention 63.6–7  
 post-inflammatory elastolysis and cutis  
 laxa (PECL) 45.19–20  
 post-inflammatory hyperpigmentation  
 58.29, 58.30–1  
 anogenital 71.2–3  
 post-inflammatory hypopigmentation  
 58.51–2  
 anogenital 71.2–3  
 post-ionizing radiation keratosis 52.37  
 post-marketing surveillance studies 7.4  
 post-phlebotic syndrome *see* post-  
 thrombotic syndrome (PTS)  
 post-phlebitis subcutaneous calcinosis  
 47.46  
 post-radiation vascular proliferation,  
 atypical 48.31  
 post-steroid panniculitis 46.16  
 post-thrombotic limb 47.33  
 post-thrombotic syndrome (PTS) 47.23,  
 47.26, 47.35, 47.40–1  
 deep-vein thrombosis and 47.29, 47.40  
 venous ulceration 47.42  
 post-transplant lymphoproliferative  
 disease (PTLD) 57.51  
 EBV association 33.31  
 postaxial polydactyly 18.92  
 posterior lid margin disease (PLMD)  
 67.12  
 posthitis 71.8–9  
 postmenopausal syndrome 21.13  
 postnatal growth 8.1  
 postural exercises, lymphoedema  
 management 48.23  
 postvaccinal encephalitis, cowpox 33.7  
 potassium, in sweat 44.5  
 potassium arsenite 52.4  
 potassium hydroxide 25.20, 27.12  
 in molluscum contagiosum 33.12  
 potassium iodide 74.48  
 in granuloma annulare 60.10  
 in sporotrichosis 36.72  
 potassium *p*-aminobenzoate, in lichen  
 sclerosis 51.118  
 potassium permanganate 73.15  
 in allergic contact dermatitis 26.101  
 in eczema 23.37–8  
 in flexural candidiasis 36.68  
 as irritant 25.21  
 in tinea pedis 36.49  
 treatment of burns 25.23  
 Potter's syndrome 18.1  
 Potts, Sir Percival 52.4  
 povidine, panniculitis due to 46.28  
 povidone–iodine 30.7, 75.165  
 in impetigo 30.16  
 in wound cleansing 14.21  
 powders 73.2  
 inorganic and organic types 73.8  
 topical therapy 73.8  
 power 7.22  
 poxvirus officinalis (vaccinia virus) 33.6  
 poxviruses 33.2, 33.5–14  
 genera 33.5  
 spread 33.5  
*see also specific poxviruses*  
 PPARs (peroxisome proliferator-activated  
 receptors) 12.10, 12.28  
 ligands (endogenous) 42.4  
 PPAR- $\gamma$  12.60, 46.3  
 mutations in partial face-sparing  
 lipodystrophy 46.41  
 in sebaceous gland development 3.5  
 sebaceous glands 42.4  
 subtypes, in sebaceous glands 42.4  
 PPD (*p*-phenylenediamine) *see*  
 paraphenylenediamine  
 PPD (purified protein derivative) 31.6  
 PPP *see* palmoplantar pustulosis (PPP)

- practolol 75.91  
 Prader–Willi syndrome 46.5, 58.42  
 hypopigmentation in 58.42  
 periodontitis in 69.17, 69.18  
 pramipexole 63.25  
 pravastatin 75.156–7, 75.157  
 prayer nodules 9.13–14, 9.15, 28.11  
 prayer sign 45.62  
 praziquantel  
 in cysticercosis 37.25  
 in paragonimiasis 37.23  
 in schistosomiasis 37.22  
 prazosin, in systemic sclerosis 51.108  
 pRb protein, inactivation by E7 protein of HPV 33.39  
 pre-adipocyte 46.1, 46.3  
 preaxial polydactyly 18.92  
 prebiotic supplements, in atopic dermatitis 24.31, 24.34  
 precocious puberty, in McCune–Albright syndrome 58.18  
 predendritic cells, type 1 interferon-producing plasmacytoid 3.19  
 predictive value 6.19  
 PrediSkin™ 25.9  
 prednisolone  
 in acne fulminans 42.84  
 in acne vulgaris 42.53, 42.66  
 in atopic eye disease 67.16  
 breastfeeding and 40.45  
 in bullous pemphigoid 40.35  
 in cicatrizing conjunctivitis 67.23  
 in dermatomyositis 51.129  
 in discoid lupus erythematosus (DLE) 51.20  
 interactions 72.29  
 in Langerhans' cell histiocytosis (LCH) 55.13  
 in polymorphic light eruption 29.12  
 prednisone vs 74.2  
 pulsed steroid therapy 74.3  
 in pyoderma faciale 43.14  
 in systemic lupus erythematosus (SLE) 51.61, 51.62  
 see also corticosteroids  
 prednisone, prednisolone vs 74.2  
 pregabalin, in zoster and post-herpetic neuralgia 33.28  
 pregangrene 47.2  
 pregnancy **8.9–16**  
 acrodermatitis enteropathica and 8.12  
 AIDS and 8.13  
 alcohol use in *see* fetal alcohol syndrome  
 allergen avoidance in 24.34  
 allergic contact dermatitis and 26.8  
 atopic dermatitis and 8.12, 24.19  
 autoimmune disorders and 8.11, 8.12  
 autoimmune progesterone dermatitis in 8.15, 8.19, 75.119  
 breast changes 70.1  
 condylomata acuminata and 8.11  
 connective tissue disorders and 8.11, 8.12  
 dermatomyositis and 8.12  
 dermatoses associated with 8.13  
 dermatoses modified by 8.11–12  
 drug therapy in 18.2, 72.28  
 antihistamines 22.29  
 co-trimoxazole 74.39  
 corticosteroids 74.3  
 erythromycin 42.51  
 methotrexate contraindications 74.21  
 retinoids 74.38, 75.113  
 thalidomide 51.21  
 eccrine, apocrine and sebaceous gland activity 8.10  
 Ehlers–Danlos syndrome and 8.12, 45.34  
 eosinophilic granuloma and 8.12  
 epulis 8.11, 69.20–1  
 erythema multiforme in 8.12  
 erythema nodosum and 50.83  
 erythrokeratoderma variabilis and 8.12  
 Fox–Fordyce disease and 8.10  
 generalized pustular psoriasis of pregnancy 20.50–1  
 gigantomastia in 70.3  
 gingivitis in 8.11, 69.20–1  
 gonorrhoea management 34.28  
 haemolytic–uraemic syndrome and 49.31  
 hair in 8.10, 66.9, 66.27  
 hirsutism in 66.82  
 hormonal changes 8.9–10  
 HPV infection and 8.11  
 infections and immunity 8.11  
 inflammatory dermatoses specific to 8.13–15  
 Langerhans' cell histiocytosis and 8.12  
 Lassa fever in 33.69  
 leprosy and 8.11  
 local anaesthesia in 77.10  
 Lyme disease in 30.65  
 Marfan's syndrome and 45.31  
 mask of *see* melasma  
 maternal drug exposure 72.28  
 melanoma 8.12, 54.56–7  
 metabolic disorders in 8.11, 8.12  
 mosquito bites during 38.2  
 mycosis fungoides and 8.12  
 nails in 8.10  
 neurofibromata and 8.12  
 papular dermatitis of 8.15  
 partial lipotrophy and 46.39  
 parvovirus B19 infection and 33.63  
 patch testing in 26.85  
 pemphigoid gestationis **40.41–5**  
 pemphigus 40.9  
 pigmentation in 8.10, 58.25  
 pityriasis rosea in 33.80  
 polymyositis and 8.12  
 porphyria cutanea tarda and 8.12  
 prevention, isotretinoin use 42.59, 42.59–60  
 prurigo of pregnancy 8.14–15, 23.45  
 pruritic urticated papules and plaques of pregnancy 8.13, 8.14, 21.14  
 pruritus gravidarum 8.13  
 pruritus in 21.14–15  
 pseudoxanthoma elasticum and 8.12, 45.23  
 psoriasis and 8.12  
 pyoderma faciale in 43.14  
 restless legs syndrome in 47.12  
 rubella in 33.71  
 sarcoidosis and 61.8  
 scabicide use 38.42  
 scleroderma and 8.12  
 sebaceous gland activity 42.12  
 sexually transmitted diseases and outcomes 34.1  
 skin changes 8.10–11  
 skin tags 8.13  
 SLE and 8.12  
 spider telangiectases in 8.10, 47.14, 47.15  
 Stevens–Johnson syndrome and 8.12  
 striae distensae (striae gravidarum) 8.13  
 syphilis and 34.11  
 syphilis management in 34.22–3  
 thalidomide and 51.21  
 thrombocytopenia in 49.12  
 thrombotic thrombocytopenic purpura and 49.31  
 toxic erythema (toxaemic rash; PUPPP) 8.13, 8.14, 21.14  
 trace element excess/deficiency 18.2  
 tumours and 8.11, 8.12  
 urticaria and 22.11  
 vascular changes 8.10–11  
 warts and 8.11  
 pregnenolone 8.9  
 prehospital management, burns 28.75–6  
 preimplantation genetic diagnosis 16.1, 16.7–9  
 epidermolysis bullosa (EB) 39.31  
 preimplantation genetic haplotyping 16.1, 16.8–9  
 prelymph 48.5  
 prelymphomatous eruption 23.8  
 premalignant dermatoses  
 male genital dermatology 71.37–9  
 perianal/perineal dermatology 71.96–9  
 premalignant epithelial lesions 52.2, **52.29–38**  
 cancer risk 52.29  
 HPV infection and 52.6  
 inflammatory reaction in 52.29  
 risk factors and aetiology 52.29  
 see also actinic keratosis; Bowen's disease  
 premalignant fibroepithelial tumour (of Pinkus) 52.48  
 as trichoblastoma variant 53.10  
 prematurity, ichthyosis prematurity syndrome 19.18–19  
 premelanosomes 66.93  
 premenstrual flushing 8.8  
 premenstrual syndrome 8.8–9, 42.34  
 prenatal diagnosis **16.1–11**  
 DNA-based 16.1–3, 16.4  
 epidermolysis bullosa (EB) 39.27, 39.31  
 ethical aspects 16.10–11  
 fetal ultrasound 16.7  
 fetoscopy and fetal skin biopsy 16.5–7  
 non-invasive 16.9–10  
 preimplantation 16.7–9  
 prescribing  
 electronic 72.26  
 errors 72.26  
 topical therapy **73.1–5**  
 presenting complaint, history-taking 5.4–5  
 preseptal cellulitis 67.4  
 preservatives  
 as allergens 26.49–58  
 food 75.159  
 as irritants 25.20  
 in topical therapy 73.8  
 pressure  
 in palpation 5.17  
 sensitivity, in obesity 8.17  
 pressure erythema 47.33  
 pressure ulcers 14.13–15, **28.16–23**, 47.57  
 in amputees 28.27–8  
 classification 28.18–19  
 clinical features 28.18–19  
 complications 28.19–20  
 epidemiology 28.16–17  
 following spinal cord injury 63.17  
 management 28.22–3  
 pathogenesis and pathophysiology 28.17  
 pathology 28.18  
 perianal/perineal 71.84  
 prevention 28.20–2  
 risk factors 14.14, 28.17–18, 28.20, 28.21  
 sites 14.13–14  
 treatment 73.10  
 pretibial myxoedema 8.17, 48.13, **62.8–9**  
 pretibial pruritic papular dermatitis, mechanical injury 28.15  
 prevalence 6.18  
 definition 26.2  
 period 6.18  
 point 6.18  
 skin disease 6.11  
 see also *specific diseases*  
 prevalence studies of skin disease 6.6–8  
 examined skin disease 6.6–8  
 self-reported disease 6.6  
 prevention of skin diseases 6.3  
 see also *specific diseases*  
 prevention paradox 6.3, 6.4  
 Prevotella 30.60  
 priapism 71.51  
 prick test *see under* skin testing  
 prickly heat 17.7–8, 44.15–16  
 primary acquired melanosis (PAM) 54.40–1  
 primary biliary cirrhosis (PBC) 62.62  
 lichen planus and 41.16  
 oral involvement 69.115  
 pigmentation changes 58.28  
 sarcoidosis and 61.18  
 primary care 6.14–15  
 primary cutaneous lymphomas *see under* lymphoma(s)  
 primary idiopathic hypertrophic pulmonary osteoarthropathy *see* pachydermoperiostosis  
 primary irritant napkin dermatitis *see* dermatitis, napkin  
 primates  
 alopecia in 2.19  
 flea infestations 2.10  
 primin 26.18, 26.76, 26.77  
 Primula 26.1  
 erythema multiforme-like reactions and 26.25, 76.5  
 sensitization by, hair regrowth and 73.39  
 Primula obconica  
 allergenicity 26.10, 26.16, 26.17, 26.76  
 depigmentation and 26.26, 26.27  
 eyelid oedema due to 26.17  
 lichen planus-like eruption due to 26.26  
 secondary involvement patterns 26.21  
 printers  
 occupational hazards 27.20  
 risk of occupational dermatoses 27.2  
 pro-drugs, photodynamic therapy 52.16  
 pro-haptens 26.11  
 pro-opiomelanocortin (POMC) 12.65, 58.7  
 UVR-induced production 29.5, 29.7  
 probability  
 post-test 7.14  
 pre-test 7.13  
 of skin disease 6.11  
 probenecid, adverse effects in HIV infection 35.20  
 probiotic supplements, in atopic dermatitis 24.31, 24.34  
 procainamide 75.90  
 procaine 77.10  
 procaine penicillin, syphilis management 34.22, 34.23  
 procarbazine 75.126  
 procoagulant tendency 49.38  
 procollagen 80.2  
 type III (PIIINP) 20.33, 20.35  
 proctitis, gonococcal 34.25, 34.26  
 proctocolitis, ulcerative, in lymphogranuloma venereum 34.33  
 profilaggrin 3.10  
 in epidermis 4.2  
 profilins 22.20  
 progeria 8.21, 45.58–9, 51.79, 66.59  
 bone and joint involvement 62.100  
 greying of hair 66.92–3  
 progesterone  
 autoimmune progesterone dermatitis 8.9, 75.119  
 in breast development 70.1  
 menstrual cycle 8.8  
 pigmentation changes associated with 58.25  
 in pregnancy 8.9  
 receptors 42.11  
 sebaceous gland activity 42.11  
 topical  
 in acne 42.16  
 in prevention of ageing 80.4  
 progesterone-induced dermatitis, tamoxifen therapy 74.33  
 progestins, in oral contraceptives, acne treatment 42.53  
 proglottids 37.24  
 prognosis, communication to patient 72.4–5  
 programmed cell death *see* apoptosis  
 progressive macular hypomelanosis 9.16  
 progressive multifocal leukoencephalopathy 50.47  
 progressive osseous heteroplasia 45.68

- progressive symmetrical erythrokeratoderma (PSEK) 19.70–1
- prolactin  
in breast development 70.1  
hair growth and 66.9  
hirsutism and 66.83  
in hyperpituitarism 62.2  
in hypopituitarism 62.3  
in pregnancy/after birth 8.10  
prolapse, urethral 71.73  
prolidase deficiency 45.39–40, 47.54  
proline therapy, in prolidase deficiency 45.40
- prolyl hydroxylation reaction, collagen synthesis 3.37
- promethazine 26.44, 74.31
- prominent auricular (Darwin's) tubercle 68.4
- prominent sebaceous glands 71.11
- promonocytes 5.1
- promontory sign 56.35
- Pronematus davisi* 38.48
- propane sulfone 27.11
- n*-propanol, as antiseptic 73.14
- propranolol 44.12
- proparacaine 26.46
- properdin 51.6
- Propionibacterium* 30.3, 30.35, 30.40, 30.59  
erythromycin-resistant 73.10  
growth inhibition by azelaic acid 73.28  
in normal skin flora 30.2, 30.3, 30.4  
subgroups 42.24
- Propionibacterium acnes* 30.3, 30.40, 42.7  
acne aetiology and 42.24–6  
as initiating factor 42.26  
topical drugs affecting 42.40  
in acne fulminans 42.83  
in acne necrotica varioliformis 30.26, 30.27  
antibiotic resistance 42.41–2, 42.43, 42.47, 42.55–6  
causes and MIC levels 42.56  
mutations 42.56  
prevalence 42.56  
specific antibiotics 42.56  
strategies to prevent 42.42
- in axilla 30.4  
biological significance 42.27  
free fatty acid production 30.4, 30.5  
genome 42.24  
lipase action on sebaceous triglycerides 42.6  
in normal skin flora 30.4  
number, acne pathogenesis and 42.24, 42.25  
oxygen tension and 42.25  
progressive macular hypomelanosis and 9.16  
in pyoderma faciale 43.14  
reduced counts, isotretinoin effect 42.58  
in SAPHO syndrome 42.85  
sarcoidosis and 61.2  
skin colonization, immunomodulatory role 42.6  
skin flora 30.4  
substances released by 42.25  
topical therapy 73.10  
Wood's light examination 5.19
- Propionibacterium avidum* 30.3, 30.4, 30.40
- Propionibacterium granulatum* 30.3, 30.40
- propolis 26.82–3, 75.160
- propranolol 75.91  
flushing management 43.15  
lichenoid tissue reaction due to 41.25
- proptosis, in sarcoidosis 61.7
- propylene carbonate 25.19
- propylene glycol 25.19, 25.20, 73.7  
as preservative in topical therapy 73.8  
in scabies 73.14
- propylene glycol diacetate 25.19
- 17 $\alpha$ -propyltestosterone 42.16
- Prosimulium* 38.5
- prostacyclin (PGI<sub>2</sub>) 12.60, 13.4  
formation, platelet aggregation inhibition 49.8  
in systemic sclerosis 51.108
- prostacyclin analogues, in Raynaud's phenomenon 51.108
- prostaglandin(s) 12.60–2, 13.4  
in irritant contact dermatitis 25.5  
pruritus and 21.3, 21.5  
in wound healing 14.3, 14.24
- prostaglandin D<sub>2</sub> (PGD<sub>2</sub>), urticaria and 22.4
- prostaglandin D<sub>2</sub> receptor 1 (DP1) 73.51
- prostaglandin E 21.5
- prostaglandin E<sub>1</sub> (PGE<sub>1</sub>), rest pain and gangrene therapy 47.6
- prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) 21.5  
pigmentation regulation 58.7
- prostate cancer  
androgenetic alopecia and 66.19  
flushing in 43.15  
lymphoedema in 48.8
- prostatitis, gonococci causing 34.26
- prosthetic implants  
metallic 26.37  
osseo-integrated 68.16  
urticaria and 22.11
- prosthetic limbs 25.16
- Protaceae 26.81
- protamine 75.107
- protease(s) 12.49–51, 38.1  
in atopic dermatitis 24.18  
pruritus and 21.3, 21.4–5, 24.18
- protease-activated receptors (PARs) 12.50  
in atopic dermatitis 24.18  
PAR-1, -3 and -4 12.33, 12.49, 12.66
- protease inhibitors 12.50, 35.7, 74.50  
adverse effects 35.21, 35.22, 75.68–9  
in HIV-associated lipodystrophy 46.42  
in HIV infection 35.6, 35.7  
mechanical and thermal injury 28.2
- protein 14.4
- protein A 30.8
- protein C 49.38  
activated *see* activated protein C (APC)  
activation, dysfunction, in purpura 49.20, 49.39  
calciphylaxis (calcific uraemic arteriopathy) 47.8  
concentrates 49.39, 49.40  
deficiency 17.33, 47.28, 49.38, 49.44, 62.91  
acquired severe 49.39–40  
homozygous 49.39  
disease associated with 49.39–40  
resistance 17.33  
severe acquired dysfunction 49.39
- protein contact dermatitis 26.105–6, 27.5
- protein kinase C inhibitor, in psoriasis 20.42
- protein p59 73.17
- protein S 49.38  
acquired severe dysfunction 49.40  
calciphylaxis (calcific uraemic arteriopathy) 47.8  
deficiency 17.33, 47.28, 49.39, 49.44, 62.91, 62.91  
disease associated with 49.39–40  
protein synthesis 11.3
- protein therapeutics 74.4–13
- protein tyrosine phosphatase receptor type D (PTPRD) locus 52.12
- proteinase 3 13.4, 50.39
- proteinase-activated receptor(s) 63.2–3  
pruritus and 21.3, 21.4, 21.5
- proteinase-activated receptor-2 (PAR-2) 3.20, 12.25
- proteoglycan(s) 3.2, 3.34, 3.45–9  
ageing and 80.1  
cell-surface 3.46  
core proteins 3.46  
deposition, changes in 3.49  
functions 3.46–7  
molecular characteristics and distribution 3.48  
structure and synthesis 3.45–6, 3.48  
*see also* glycosaminoglycans (GAGs)  
synthesis in fibroblasts 3.49  
in wound healing 14.1, 14.3, 14.7
- proteoglycan binding, cytokines 12.31
- proteomics 11.8
- Proteus*  
in external auditory meatus 30.4  
genitocrural infection 71.5  
in paronychia 65.21  
wound infection 14.16
- Proteus mirabilis* 42.56
- Proteus syndrome 18.27, 18.78–9, 48.11, 62.26  
aetiology 18.78  
bone and joint involvement 62.100  
clinical features 18.78  
definition 18.78  
diagnosis 18.78–9  
differential diagnosis 18.77  
encephalocraniocutaneous lipomatosis as variant 46.46  
pathology 18.78  
treatment 18.79
- prothrombin 49.38  
G20210A mutation 49.44
- proto-oncogenes 11.17, 52.12
- proton pump inhibitors 75.157
- protoporphyrin, erythropoietic *see* erythropoietic protoporphyria (EPP)
- Prototheca* infection, swimming-/diving-associated 28.54
- protothecosis 36.92
- protozoa 36.1, 37.2
- protozoal infections 37.2, 37.27–44  
female genitalia 71.69  
in HIV infection 35.35–6  
ocular involvement 67.27  
oral involvement 69.81  
urticaria and 22.2, 22.10  
*see also specific infections*
- provocation tests 5.25
- Prox-1 10.24, 48.2, 48.4, 48.5, 48.19
- prozone phenomenon 34.19
- PRP *see* pityriasis rubra pilaris (PRP)
- prurigo 21.1, 23.42–6  
actinic *see* actinic prurigo (AP)  
actinic (Hutchinson's summer) 23.45  
chronic of adults (subacute) 23.44  
definition 23.42  
dermographic 23.45  
early onset of pregnancy 8.14–15  
late-onset of pregnancy (PUPPP) 8.13, 8.14  
nodular (Hyde's) 23.42–4  
of pregnancy 8.14–15, 23.45  
scratch *see* dermographism
- prurigo annularis 8.15
- prurigo diathesique *see* atopic dermatitis
- prurigo gestationis of Besnier 8.14–15
- prurigo nodularis (of Hyde) 21.1, 21.2, 64.27  
differential diagnosis 29.14
- prurigo pigmentosa 23.44–5, 58.31
- pruritic papular eruption, in HIV infection 35.19, 35.45
- pruritic urticarial papules and plaques of pregnancy (PUPPP) 8.13, 8.14, 21.14
- pruritus 21.1–18  
in acne vulgaris 42.32  
in animals 2.9, 2.10, 2.13  
anogenital 71.1–2  
aquagenic 21.10, 21.11–12, 62.86  
assessment 72.10–11  
in atopic dermatitis 8.7, 21.13–14, 24.17–18  
atopic eye disease 67.15  
brachioradial 21.15–16, 62.34, 63.23–4  
central itch 21.3  
in cholestasis 21.9–10  
chronic 21.1  
in chronic renal failure 21.7–9  
classification 21.1  
in clothing/body louse infection 38.22  
in cold-induced injury 28.65  
degree of 5.4  
in diabetes mellitus 21.11  
in eating disorders 21.16  
in elderly people 8.27, 21.12, 21.17  
epidemiology 21.1–2  
female genital dermatology 71.52  
genetics 15.18  
genitocrural dermatology 71.7  
haemodialysis and 21.7–8, 62.72  
in head louse infection 38.19  
in hepatitis C virus infection 62.60  
in HIV infection 21.14, 35.11–12  
in Hodgkin's disease 21.11, 62.89  
hydroxyethyl starch 21.15, 28.44  
in hyperparathyroidism 62.12  
in hyperthyroidism 21.11  
in hypothyroidism 21.11  
in intravenous drug abuse 28.53  
investigation 21.16  
in iron deficiency 21.10  
in lichen planus 41.9, 41.17  
in lichen simplex 23.40  
liver disease and 62.62, 62.63  
male genital dermatology 71.16, 71.34, 71.51  
malignant disease and 21.11  
management 21.16–18  
in mastocytosis 21.10, 22.32, 22.35  
measurement 21.2, 21.16  
in mycosis fungoides 21.10  
neurogenic 21.1, 21.7  
neuropathic 21.1  
in nodular prurigo 23.43  
non-inflamed skin 21.5–7  
in notalgia paraesthetica 21.15  
in onchocerciasis 37.5  
opioids and 21.3, 21.4, 21.8, 21.9, 24.18  
paraneoplastic 62.33–5  
pathophysiology 21.2  
in pemphigoid nodularis 21.15  
perianal/perineal 71.85  
peripheral mediators in skin disease 21.3–5  
in polycythaemia rubra vera 21.10, 62.86  
in polymorphic light eruption (PLE) 29.11  
postmenopausal 21.13  
in pregnancy 21.14–15  
as presenting complaint 5.4  
in primary biliary cirrhosis 62.62  
proteases and 21.3, 21.4–5, 24.18  
pruritoceptive 21.1, 21.7  
psychogenic 21.1, 21.12–13, 64.23–4  
in renal failure 62.72  
in scabies 38.38  
scalp 38.19  
of senescence 21.12, 21.17  
in Sézary syndrome 21.10, 21.11  
solar 21.16  
stigma of 64.2  
swimming-/diving-associated 28.55
- pruritus ani 21.12, 21.15, 37.14, 64.27, 71.83, 71.85–7, 71.92  
allergic contact dermatitis and 26.18, 26.44
- pruritus gravidarum 8.13
- pruritus vulvae 21.12, 21.13, 21.15
- PRV *see* polycythaemia rubra vera (PRV)
- Psalydolytta* 38.26
- Pseudeurotium ovalis* 36.55
- pseudo-ainhum 45.69–70
- pseudo-autosomal regions 15.4
- pseudo-Cushing's syndrome 62.4
- pseudo-Darier sign 18.35
- pseudo-epithelioid 34.36–7
- pseudo-Kaposi's sarcoma 47.22, 49.17–18
- pseudoacne, nasal crease 18.90
- pseudoallergic reactions 22.8, 22.10
- pseudochancres 34.7
- pseudochromhidrosis 44.21
- pseudocowpox (milker's nodule) 33.10–11

- pseudocyst  
 ear/endochondral 24.25, 68.13–14  
 myxoid/mucoid *see* cyst(s), myxoid  
 pseudoepitheliomatous hyperplasia 75.99  
 pseudoepitheliomatous hyperplasia 47.45, 52.25, 52.44–5  
 incontinentia pigmenti vs 58.15  
 pseudoepitheliomatous micaceous and keratotic balanitis (PEMKB) 71.37–8  
 pseudofolliculitis 30.22–3  
 pseudofolliculitis barbae 9.9, 28.50, 78.12  
 acne vs 42.37  
 pseudoglucagonoma syndrome 62.64  
 pseudogynaecomastia 70.4  
 pseudohermaphroditism 66.14, 66.16  
 pseudohyphae 36.2  
 pseudohypoadosteronism 17.8, 44.15  
 pseudohypoparathyroidism 62.12  
 pseudologica fantastica 64.35, 64.44  
 pseudolymphoma 69.58  
 B-cell/T-cell 57.53–4  
 induced by arthropod bites 38.3  
 pseudolymphomatous drug hypersensitivity syndrome 75.27, 75.44  
 pseudomelanoma 54.19  
 pseudomembranous colitis 42.47, 42.51  
*Pseudomonas*  
 anogenital ulcers 71.4  
 in botryomycosis 30.67  
 burn wound infection 28.86  
 genital infection, in females 71.70  
 in HIV infection 35.24  
 perianal/perineal infection 71.93  
 swimming-/diving-associated infections 28.55  
 umbilical infection 71.101  
*Pseudomonas aeruginosa* 30.48–50  
 amikacin therapy 74.42  
 in cellulitis 30.18  
 ear piercing-associated infection 28.51, 68.7  
 ecthyma gangrenosum 49.35  
 ectodermal dysplasias 15.60  
 in erysipelas 30.18  
 female genital infection 71.67  
 genitocrural infection 71.5, 71.7  
 in HIV infection 35.24–5  
 nail infection 30.49, 65.10, 65.11, 65.21, 65.22  
 neonatal infection 17.45–6  
 in normal skin flora 30.3, 68.2  
 in otitis externa 30.49, 68.21, 68.22, 68.25  
 perianal/perineal infection 71.92  
 in perichondritis 68.19  
 septicaemia 30.49, 30.50  
 swimming-/diving-associated infection 28.54–5  
 topical antibiotic therapy 73.10  
 venous leg ulcer infection 47.44  
 wound infection 14.16, 30.49, 30.50  
*Pseudomonas cepacia* 30.48  
*Pseudomonas fluorescens*, mupirocin from 73.10  
*Pseudomonas folliculitis*, swimming-/diving-associated infection 28.54–5  
*Pseudomonas pseudomallei* 30.50–1  
*Pseudomonas pyocyanea* *see* *Pseudomonas aeruginosa*  
 pseudomonilethrix 66.65  
*Pseudonaja* 38.60  
 pseudonits 38.19  
 pseudopelade 66.39  
 lichen planus 41.14  
 pseudopelade of Brocq 66.38, 66.45–6  
 pseudopemphigoid 67.20  
 pseudophotodermatitis 26.75  
 pseudoporphyria 29.7  
 drug-induced 29.21, 75.32, 75.37–8  
 pseudopseudohypoparathyroidism 62.12  
 pseudopseudoxanthoma elasticum 45.25  
 pseudopyogenic reaction 46.13  
 pseudorhagades 69.39  
 pseudosarcoma 56.20–2, 68.34, 79.18  
 pseudoscars 45.6  
 brown 45.6, 45.7  
 discoid 45.6  
 stellate 45.6, 45.7  
 pseudoscleroderma 48.22, 51.79, 51.120  
 pseudosyndactyly  
 in dystrophic epidermolysis bullosa 39.18  
 in generalized non-Herlitz junctional epidermolysis bullosa 39.13  
 pseudothalidomide syndrome 18.70, 66.61  
 pseudotumours, in Ehlers–Danlos syndrome 45.32, 45.33  
 pseudovaginal perineoscrotal hypospadias 66.14  
 pseudoverrucous lesions 62.54  
 pseudoxanthoma elasticum (PXE) 45.21–4  
 aetiology 45.21  
 bone and joint involvement 62.100  
 definition 45.21  
 diagnosis 45.23  
 differential diagnosis 45.16  
 disorders resembling 62.85  
 iron deficiency anaemia in 62.85  
 pathology 45.21–3  
 perforating 45.24–5  
 pregnancy and 8.12, 45.23  
 purpura due to 49.14  
 treatment 45.23  
 psittacosis 30.71–2, 62.80, 62.107  
 PSOR6 gene 2.14  
*Psoralea corylifolia* 75.162  
 psoralen(s) 29.21  
 adverse effects  
 hypertrichosis 66.79  
 ocular 67.32  
 photosensitivity 75.31  
 photochemotherapy *see* PUVA therapy  
 photomutagenic 29.21  
 topically applied, adverse effects 58.48  
 vitiligo treatment 58.48  
 ‘psoriasiform dermatitis of the pawpads’ 2.14  
 psoriasiform-lichenoid dermatosis, in dogs 2.14  
 psoriasis 20.1–60  
 acute pustular 8.12, 76.19  
 in adolescence 8.7, 8.8  
 aetiology 20.2–9  
 nuclear factor-kappa B (NF-kappaB) 12.10  
 peroxisome proliferator-activated receptors (PPARs) 12.10  
 alcohol abuse and 64.47  
 in amputees 28.29  
 amyloidoses and 20.19  
 animal models 2.8  
 biomarkers 20.19  
 breast 70.17  
 career choice and 8.8  
 in children 17.31–2, 20.13, 20.16  
 infantile and juvenile pustular psoriasis 20.51  
 clinical features 20.9–19, 73.44  
 atypical forms 20.16–19  
 common chronic stable plaque 20.10  
 complications 20.18  
 disease associations 20.17–18  
 modification by site 20.14–16  
 onset 20.1, 20.9–10  
 seborrhoeic dermatitis 20.17  
 clinical variants 20.11–14  
 bullous pemphigoid and 40.35  
 erythrodermic 20.12–13, 20.16  
 guttate 20.11  
 pityriasis amiantacea 20.14, 20.16  
 rupoid, elephantine and ostraceous psoriasis 20.12  
 unstable phases 20.12  
 coeliac disease and 62.55  
 course and prognosis 20.20  
 Crohn’s disease and 62.49  
 differential diagnosis 20.19, 26.29  
 in dogs 2.14  
 drug-induced/exacerbated 75.24  
 ear 68.14, 68.23  
 in elderly people 8.28  
 epidemiological aspects 20.1–2  
 environmental risk factors 20.3–4  
 psychogenic factors 20.4  
 sunlight 20.3  
 erythroderma and 23.47  
 erythrodermic, calcipotriol treatment 73.45  
 eyelids 67.5  
 female genital dermatology 71.52, 71.58–9, 71.68  
 flexural (inverse) 8.28  
 following streptococcal infection 30.12  
 friction and 27.6, 28.15  
 generalized pustular *see* generalized pustular psoriasis (GPP)  
 genetics 15.1, 15.2, 15.6, 15.11, 20.3–4  
 replicated genetic loci 20.3–4  
 genitocrural dermatology 71.5  
 guttate, pityriasis rosea vs 33.81  
 hands 23.20, 25.15, 25.16  
 palms 20.15  
 histopathology 20.9  
 Auspitz’s sign 20.11  
 in HIV infection 35.17–18  
 HPV association 33.47  
 hypopigmentation after 58.51  
 Koebner phenomenon/response 5.12, 28.2–3, 28.48  
 localization to tattoos 58.58  
 male genital dermatology 71.18  
 metabolic syndrome association 6.13  
 naevoid 18.24  
 nails 20.15–16, 36.35, 65.10, 65.13, 65.23–7, 65.23–7, 65.28  
 acitretin therapy 74.35  
 calcipotriol therapy 73.45  
 napkin 17.24, 17.31–2  
 ocular involvement 67.5  
 onycholysis in 65.10  
 oral involvement 69.94  
 Paget’s disease of nipple vs 53.39  
 pathogenesis 20.2–9  
 pathogenetic mechanisms 20.5–9  
 immunology and inflammation 20.7  
 Koebner phenomenon 20.8  
 perianal/perineal involvement 71.84  
 peristomal 62.54  
 pityriasis rubra differentiated 19.77  
 plaque, chronic, topical corticosteroid use 73.19  
 pregnancy and 8.12  
 psoriasis area severity index (PASI) score 7.11–12, 20.41  
 psoriatic arthritis *see* psoriatic arthritis  
 psychological factors 64.4, 64.9  
 pustular 20.44–54, 50.62, 62.12  
 acrodermatitis continua 20.46–8  
 acute 8.12, 76.19  
 acute generalized exanthematous psoriasis 20.52  
 acute generalized pustular psoriasis (von Zumbusch) 20.49–50  
 circinate, annular and linear pustular psoriasis 20.52  
 generalized *see* generalized pustular psoriasis (GPP)  
 infantile and juvenile pustular psoriasis 20.51  
 palmoplantar pustulosis 20.44–6  
 subcorneal pustular dermatosis of Sneddon and Wilkinson 20.52–4  
 quality of life assessment 64.10, 72.14, 72.19–20, 72.24  
 race and 9.14  
 remissions 20.20  
 Salford Psoriasis Index 20.21  
 sarcoidosis and 61.18  
 scalp 23.32  
 seborrhoeic dermatitis and 23.32  
 severity assessment 72.9, 72.14  
 skin-directed therapies 20.21–8  
 calcipotriol 73.45  
 calcitriol 73.45  
 coal tar and UV 73.42  
 corticosteroids  
 intralesional 20.25  
 topical 20.25  
 dithranol 73.29  
 lasers 20.43, 78.8  
 occlusive dressings alone 20.28  
 penetration enhancers 73.7  
 photodynamic therapy 20.43  
 pimecrolimus 73.32  
 psoralen photochemotherapy *see* under PUVA therapy  
 retinoic acid 73.36  
 tacalcitol 73.44–5  
 tacrolimus 73.32  
 tar 20.21–2  
 tazarotene 73.37  
 topical calcineurin inhibitors 20.25, 20.42  
 topical mechlorethamine 73.24  
 topical methotrexate 73.23  
 UV phototherapy 20.28–33  
 vitamin D analogues 73.43  
 wood tars 73.42  
 sweat retention in 44.13  
 systemic therapies 20.33–41  
 ABT-874 74.10  
 acitretin 20.37, 74.35  
 adalimumab 20.41, 74.5  
 alefacept 20.41, 74.6, 74.8–9  
 anti-IL12/23 74.10  
 azidothymidine 20.42  
 biological 72.14  
 biological therapies directed against cytokines 20.41–2, 74.10  
 certolizumab 74.5  
 ciclosporin 20.38–9, 74.16  
 Dead Sea Clinic 20.29  
 dialysis and related therapies 20.44  
 etanercept 20.41, 74.5  
 etretinate 20.37  
 fumaric acid 20.40, 74.29  
 gluten-free diet 20.43  
 golimumab 74.5  
 hydroxycarbamide 20.36, 74.18  
 infliximab 20.41, 74.5  
 liarozole 20.42  
 methotrexate 20.33–5, 74.18–19  
 mycophenolate mofetil 20.42, 74.24–5  
 retinoic acid metabolism blockers 20.42–3, 74.37  
 somatostatin 20.42  
 sulfasalazine 20.42  
 T-cell inhibitors 74.6  
 ustekinumab 74.10  
 vitamin A analogues 20.27–8  
*see also* retinoids  
 vitamin D analogues 20.26  
 treatment  
 concordance with 72.5, 72.6, 72.7  
 risk–benefit analysis 72.3  
 skin-directed *see* psoriasis, skin-directed therapies  
 systemic *see* psoriasis, systemic therapies  
 umbilical involvement 71.101  
 Zumbusch-type 20.49, 20.51  
 Psoriasis Area and Severity Index (PASI) 7.11–12, 20.41, 72.9, 72.14  
 Psoriasis Disability Index (PDI) 72.19–20  
 Psoriasis Family Impact questionnaire 72.24  
 psoriasis susceptibility loci (PSORS) 12.14  
 psoriasis vulgaris 20.10  
 treatment, tacrolimus 73.32  
 psoriatic arthritis 20.54–9  
 aetiology and pathogenesis. 20.54  
 clinical features 20.54–5  
 differential diagnosis 20.58  
 histopathology 20.58  
 lymphoedema in 48.13  
 MMPs and 12.53

- Moll and Wright classification 20.54–5  
 nail involvement 20.57  
 pathogenetic mechanisms 20.55  
 prognosis 20.59  
 radiological changes 20.58  
 treatment 20.58–60  
   disease-modifying antirheumatic drugs (DMARDs) 20.59  
   methotrexate 20.59  
   surgery and infection 20.59–60  
 psoriatic nail dystrophy, acitretin therapy 74.35  
 psoriatic onycho-pachydermo-periostitis 65.25, 65.26  
 PSORIQoL 72.20  
*Psoroptes* 38.46  
*Psoroptes cuniculi* 2.11  
*Psoroptes ovis* 2.10  
 Psoroptidae 38.46  
 psychiatric disorders 64.46, 64.54  
   classification 64.11–12  
   oral manifestations 69.115  
 psychiatric liaison 64.3–4, 64.15  
 psychiatric treatments 64.49–54  
   alternative therapies 64.54  
   drug therapy 64.50–2  
   see also psychotherapies  
 psychocutaneous disorders  
   body awareness 64.17–22  
   dermatological beliefs 64.12–17  
   factitious 64.34–45  
   group/mass reactions 64.25–6  
   harmful habits 64.26–34  
   organic diseases associated with 64.13, 64.17  
   phobias 64.24–5  
   pruritus 64.23–4  
 psychodermatology 64.2–4  
 Psychodidae (sandflies) 37.33, 37.39, 38.2, 38.5, 38.7  
*Psychodopygus* 37.33  
 psychological factors  
   congenital naevi 54.14  
   in diagnosis 5.5  
 psychological importance of skin 64.1–2  
 psychological methods, wart treatment 33.50  
 psychoneuroimmunology 64.3, 64.8–9  
 psychosocial factors, acne and 42.35  
 psychosocial questionnaires, acne impact 42.35  
 Psychosomatic Scale for Atopic Dermatitis (PSS-AD) 72.20  
 psychosomatics 64.3, 64.4–5  
 psychotherapies 64.8, 64.52–4  
   body dysmorphic disorder 64.20  
   cognitive behavioural therapy 64.53  
   dynamic 64.53–4  
   psychocutaneous disorder 64.28  
   self-mutilation 64.46  
   therapeutic relationship 64.52–3  
 psychotropic agents 75.78  
 PTBPPR (*p*-tertiary butylphenol formaldehyde resin) 26.68, 26.69, 26.73–4  
*PTCHI* gene mutation, in naevoid basal cell carcinoma syndrome 52.19, 62.21  
 PTD (toluene-2,5-diamine) 26.60, 26.61  
*PTEN* gene 18.6, 62.25, 62.26  
   mutations  
     in Cowden's syndrome 53.5  
     induced by UVR, melanoma and 29.7  
*PTEN* hamartoma tumour syndrome 62.25–6  
 pterins 2.5  
*Pterocarpus soyauxii* 26.81  
 pterygium 65.11  
   in lichen planus 65.29  
   ventral 51.95, 65.11–12  
 pterygium inversum unguis 51.95, 65.11–12  
 pterygoid sign 69.4–5  
*Pthirus gorillae* 2.10, 38.15  
*Pthirus pubis* see lice, pubic (crabs)  
 ptosis 67.5  
   in Horner's syndrome 63.22  
*PTPN11* gene 15.15, 15.20–1  
 PTSAgs (pyrogenic toxin superantigens) 30.31  
 pubarche 8.5  
 puberty 8.2, 8.4–8  
   age for 8.4  
     nutrition affecting 42.34  
   delayed 8.6  
   dermatoses of 8.6–8  
   gynaecomastia in boys 70.4  
   hair growth 8.4, 66.13  
   hormonal events and cutaneous changes 8.4–5  
   initiation, hormonal changes 8.4  
   leptin 'gate' for 8.4  
   miniature 17.5, 17.6  
   partial/incomplete 8.5  
   precocious 8.5  
     classification 8.5  
     in McCune–Albright syndrome 58.18  
   sebum composition changes 42.5  
   skin changes during 8.6, 8.7  
 pubic hair  
   genitocrural dermatology 71.8  
   patterns and distribution 71.10, 71.11  
 pubic lice see under lice  
 public health, skin disease problem 6.4–8  
 publication bias 7.7, 7.8  
 PubMed Clinical Queries 7.6  
 puerperium 8.9–16  
*Pulex irritans* 2.10, 38.11  
 Pulicidae 38.11  
 pulmonary fibrosis, psoriasis and 20.18  
 pulmonary stenosis, genetics 15.20  
 pulmonary symptoms, genetics 15.23, 15.24  
 pulsed-dye laser (PDL) therapy see under laser therapy  
 pulseless disease 50.44–5  
 pulses, peripheral ischaemic disease 47.2  
 punch biopsy, panniculitis 46.11  
 punctate keratoderma 19.95, 19.112–13  
 punkies 38.6  
 pupils  
   Argyll Robertson 33.26, 63.15  
   in Ross's syndrome 44.14  
 PUPPP (pruritic urticarial papules and plaques of pregnancy) 8.13, 8.14, 21.14  
 puretic syndrome 45.49–50, 69.15  
 purified protein derivative 31.6  
 purine nucleoside phosphorylase deficiency 17.60  
 purpura 49.1–51, 62.90  
   abnormal blood vessels causing 49.14–15  
   acral 49.4, 49.32  
   actinic (Bateman's/senile) 49.15  
   aetiology 49.2–4, 49.3  
     see also specific causes  
   ageing association 49.15  
   allergic contact dermatitis and 26.26  
   in amyloidosis 49.15, 49.18  
   anaphylactoid see Henoch–Schönlein purpura  
   annular, mechanical injury 28.31  
   autoimmune thrombocytopenic see idiopathic thrombocytopenic purpura (ITP)  
   bland retiform 49.39–40  
   chronic, partial lipodystrophy 46.40  
   classification 49.1, 49.2–4  
   clinical patterns 49.4  
   cocarde 49.19  
   contact 49.21  
   corticosteroid-induced 49.15  
   Crohn's disease and 62.51  
   in cryoglobulinaemia 49.33  
   in cutaneous small vessel vasculitis 50.14, 50.15  
   decreased blood vessel support causing 49.14–15  
   definition 49.1, 49.2  
   diagnosis 49.4–5  
   distribution/body sites 49.4–5  
   drug-induced 75.23  
     non-thrombocytopenic 49.21  
     thrombocytopenic 49.11  
   dysproteinaemic 49.19–20  
   ear 68.18  
   in endocrine disorders 49.18  
   exercise-induced 49.18, 50.23  
   Favre-Chaix's 49.22  
   generalizations about 49.7  
   genetic tests 49.6–7  
   genital/'bathing trunk' 49.20  
   gravitational 49.17–18  
   in Henoch–Schönlein purpura 50.20  
   histological testing 49.5  
   idiopathic thrombocytopenic see idiopathic thrombocytopenic purpura (ITP)  
   immune thrombocytopenic see idiopathic thrombocytopenic purpura (ITP)  
   infection-associated 49.20–1  
   inflammatory 49.2, 49.3, 49.4, 49.7, 49.16  
     drug-/toxin-induced 49.21  
     infections causing 49.20  
     see also Henoch–Schönlein purpura  
   inflammatory retiform 49.3, 49.32  
   investigations 49.5–7  
     indications/factors suggesting 49.4  
     laboratory tests 49.5–7  
   itching (eczematide-like) 49.22, 49.24–5  
   lower legs 49.7, 49.17  
   in malignant disease 62.14–15  
   in malnutrition 49.18  
   multifactorial, systemic diseases 49.18  
   nail fold capillaries 49.6  
   neonatal see neonatal purpura  
   non-inflammatory 49.3–4, 49.26  
   non-inflammatory retiform 49.3–4  
   non-palpable 49.4–7  
   non-thrombocytopenic  
     systemic diseases causing 49.18  
     toxin-/drug-induced 49.21  
     vascular causes 49.3, 49.14–21  
   occlusion/ischaemia causing 49.3  
     see also microvascular occlusion  
   oral cavity 69.21–2, 69.99–9100  
   in ovarian disorders 49.18  
   palpable 49.2, 49.4, 49.32, 62.91  
   pathogenic mechanisms 49.2–4  
   pathophysiology 49.4–5  
   perifollicular 49.15  
   periobital 49.4, 49.15  
   physical and artefactual causes 49.16  
   pigmented dermatoses see pigmented purpuric dermatoses  
   platelet defects causing 49.7–12, 49.8  
     functional abnormalities 49.8, 49.12–14  
   thrombocytopenia see thrombocytopenia  
   thrombocytosis 49.8, 49.14  
   post-infectious cockade 17.33–4, 49.18–19, 50.30  
   post-transfusion 49.11  
   psychogenic/factitious 64.12, 64.33–4, 64.38  
   raised intravascular pressure causing 49.14  
   in renal failure 62.72  
   reticulate 62.91  
   retiform 49.44, 49.48  
     bland (sepsis-related purpura fulminans) 49.39–40  
   retiform pattern 49.2, 49.7, 49.39  
   rubella 33.71  
   senile 49.15  
   simple macular haemorrhage 49.2, 49.3, 49.4–7  
     diagnosis 49.4–5  
     lesion size 49.3, 49.4  
     size of lesions 49.3, 49.4  
   in skin diseases 49.17  
   solar 49.17  
   sport injury 28.31, 28.54  
   suction injury 28.24  
   thrombotic thrombocytopenic (TTP) 49.12, 49.31, 69.114  
   toxin-induced 49.11, 49.21  
   trauma association 49.14, 49.16  
   ulcerative colitis and 62.51  
   in urticaria 22.25  
   vulval, chronic 71.61–2  
   Waldenström's macroglobulinaemia 49.13, 49.19  
   in Wegener's granulomatosis 50.40  
   see also ecchymoses/bruising  
 purpura annularis telangiectodes (Majocchi's disease) 49.22, 49.25  
 purpura en cocarde avec oedeme 17.33–4, 49.18–19, 50.30  
 purpura fulminans 49.51  
   in children 49.51  
   neonatal 17.33, 17.46, 49.39, 49.51  
   causes 49.51  
   post-infectious 49.39–40, 49.40  
   sepsis-related 49.39–40  
 purpura progressiva pigmentosa see pigmented purpuric dermatoses  
 purpura pulicosa 49.17  
 purpura rheumatoide see Henoch–Schönlein purpura  
 purpura simplex 49.15–16, 49.22  
 purpura telangiectatica arciformis 49.25  
 pustular dermatitis atrophicans, legs 30.22  
 pustular dermatosis 40.19–22  
 pustule(s) 10.41  
   definition 5.7  
   drug-induced 50.62, 75.34  
   Kogoj's spongiform 10.41  
   malignant 30.41  
   in pyoderma faciale 43.13–14  
   subcorneal 10.41  
   in viral infections 33.4, 33.7  
 pustulosis  
   acitretin therapy 74.35  
   acute generalized exanthematous see acute generalized exanthematous pustulosis  
   neonatal cephalic 42.75  
   neutrophilic 50.89  
 PUVA lentigo 54.2, 54.4–5, 58.33  
 PUVA therapy 20.29–31  
   acne induction 42.34  
   actinic prurigo 29.15  
   adverse effects  
     acne 27.13  
     lentiginos 54.2, 54.4–5, 58.33  
     ocular 67.32  
     seborrhoeic dermatitis 23.30  
   alopecia areata 66.37  
   atopic dermatitis 24.31  
   carcinogenic hazard 20.31  
   chronic actinic dermatitis 29.18  
   clinical indications 20.30–1  
   cohort study (US) 6.6  
   combined therapy 20.30  
   dermographism 22.14  
   eczema 23.38  
   effect on contact allergic reactions 26.9  
   effect on skin properties 28.8  
   extracorporeal photophoresis and, in pemphigus 40.12  
   granuloma annulare 60.10  
   Hailey–Hailey disease 39.36  
   hand eczema 23.22  
   Langerhans' cell histiocytosis (LCH) 55.13  
   livedoid vasculopathy 49.44  
   male genital dermatology 71.40, 71.49  
   mastocytosis 22.35–6  
   necrobiosis lipoidica 60.16  
   non-melanoma skin cancer and 52.4  
   patient selection 20.30  
   pemphigus 40.12  
   pigmented purpuric dermatoses 49.26  
   polymorphic light eruption 29.12

- psoriasis 20.29–31  
 in HIV infection 35.17  
 of nails 65.26  
 responses to 64.4  
 sarcoidosis 61.21  
 solar urticaria 29.20  
 with topically applied psoralens 20.32  
 trimethylpsoralen (TMP) bath PUVA 20.32  
 using other psoralens 20.32  
 vitiligo 58.48  
*see also* psoralen(s)  
 PVP *see* polyvinyl pyrrolidone (PVP)  
 PWS *see* port-wine stain  
 PXE *see* pseudoxanthoma elasticum (PXE)  
*Pyemotes* 38.48  
 pyknosis 10.41  
 pyloric atresia, congenital 3.31  
 pyloric stenosis  
 epidermolysis bullosa simplex with 39.4, 39.8  
 junctional epidermolysis bullosa with 39.9–10, 39.11, 39.14  
 pyoderma  
 in animals 2.10  
 chancriform 30.77  
 definition 5.7  
 erythromycin therapy 74.42  
 folliculitis and atopy with 23.27  
 malignant 50.69  
 secondary, in dogs 2.13  
 staphylococcal  
 in dogs 2.11  
 erythromycin 74.42  
 streptococcal 30.14, 30.15, 30.16, 30.33  
 pyoderma faciale (rosacea fulminans) 42.84–5, 43.13–14  
 isotretinoin treatment 42.62  
 scarring 43.14  
 pyoderma gangrenosum (PG) 50.64–74, 51.132  
 aetiology and pathogenesis 50.65–7  
 atypical 50.68–9  
*see also* neutrophilic dermatosis, of the dorsal hands  
 bone and joint involvement 62.102  
 breast 50.70, 70.11  
 bullous 46.32, 50.68–9  
 classic/ulcerative 50.68  
 clinical features 50.68–70  
 Crohn's disease and 50.65, 62.50–1  
 definition 50.64  
 diagnosis 50.70  
 differential diagnosis 50.71  
 diseases associated 50.65  
 ear involvement 68.17  
 factitial panniculitis vs 46.28  
 genital involvement 50.70  
 in males 71.25  
 hepatitis B virus infection and 62.59  
 histopathology 50.67–8  
 history 50.64  
 leg ulcers in 47.57  
 in liver disease 62.64  
 nomenclature 50.64  
 ocular involvement 50.70  
 oral involvement 50.70  
 paraneoplastic 62.41  
 perianal/perineal involvement 71.95  
 peristomal 50.69, 50.72  
 pustular 50.68  
 pyoderma vegetans vs 30.77, 30.78  
 respiratory tract involvement 50.70  
 sarcoidosis and 61.18  
 superficial/vegetative 50.69  
 treatment 50.72–4, 73.24  
 ciclosporin 74.17  
 TNF antagonists 74.7  
 ulcerative colitis and 50.65, 62.50–1  
 upper limbs/trunk/face 50.69–70  
 variants 50.64  
 vasculitis and 50.49, 50.67  
 pyoderma gangrenosum acne 42.85  
 pyoderma gangrenosum-like disease, in animal models 2.8  
 pyoderma vegetans 30.77–8, 50.89  
 pyodermatitis–pyostomatitis vegetans 50.70, 62.51  
 pyodermite vegetante of Hallopeau 30.77  
 pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome 42.82, 50.53, 50.66, 62.104  
 pyogenic granuloma 56.25–6, 71.100  
 in acne 42.32, 42.79  
 curettage 77.40, 77.41  
 eccrine poroma vs 53.23  
 nail involvement 65.35  
 oral cavity 69.20, 69.102  
 pyorrhoea 69.18  
 pyostomatitis vegetans 50.70, 62.50, 69.59  
 pyrantel pamoate 37.14, 37.15  
 pyrazinamide 74.45  
 adverse effects 31.27, 75.62  
 in tuberculosis 31.27  
*Pyrenochaeta unguis hominis* 36.55  
 pyrethroids 38.19, 38.20, 73.13–14  
 pyridostigmine 26.46  
 pyridoxine 59.62, 75.113  
 pyrimethamine  
 adverse effects 75.70  
 Stevens–Johnson syndrome 76.11  
 in toxoplasmosis 37.44  
 pyrin domain (PYD) 12.9  
 pyritinol 75.89  
 pyrogallol 66.97  
 pyrogenic toxin superantigens 30.31  
 pyrrolizidine alkaloids, photosensitivity in animals and 2.23  
*Pythium insidiosum* 36.92
- Q**  
 Q-switched ruby laser, congenital naevi treatment 54.14  
 QFT (Quantiferon-TB Gold) 31.6  
 Quality Adjusted Life Year (QALY) 72.22  
 quality of life (QOL) 72.13–24  
 acne and 42.35  
 clinical decisions and 72.2, 72.14, 72.24  
 definitions 64.10, 72.13  
 disability and 64.10  
 measurement 64.10, 72.13–24  
 children and families 64.10, 72.20, 72.23–4  
 clinical use 72.24  
 correlation with clinical indices 72.14  
 dermatology-specific 72.17–19  
 disease-specific 72.19–21  
 general health 72.16–17  
 patient-specific 72.22  
 practical clinical use 72.24  
 value of 72.13–14, 72.16  
 Quality of Reporting of Meta-Analyses 7.7, 7.16  
 Quantiferon-TB Gold 31.6  
 quartz 27.17  
 quaternary ammonium compounds 25.20, 73.14  
 quaternium-15 26.50, 26.51  
 Questionnaire on Experience with Skin complaints (QES) 72.20  
 quetiapine 64.52, 75.83  
 quills 2.3  
 quinacrine *see* mepacrine  
 Quincke's oedema *see* angio-oedema  
 quinidine, adverse effects 75.90  
 hypermelanosis 58.30  
 quinine  
 adverse effects 75.71, 75.159  
 hypermelanosis 58.30  
 lichenoid tissue reaction 41.24  
 rash 37.27  
 as food additive 75.159  
 as photoallergen 26.24  
 quinizarin 44.4  
 quinoline mix 68.24  
 quinolone antibiotics 74.41, 75.59–60  
 quinones 26.25
- QUOROM (Quality of Reporting of Meta-Analyses) 7.7, 7.16
- R**  
 R-spondin family 3.5, 3.14  
 13-*cis*-RA *see* isotretinoin  
 Rab protein, Rab27A, melanosome transfer 58.4  
 Rab3a, melanosome transfer to keratinocytes 58.4  
 rabbit botfly 38.9  
 rabbit-ear model 42.23, 42.73  
 rabbitfish 38.59  
 rabies 38.61  
 vaccination  
 alopecia after in dogs 2.18  
 dermatomyositis after, in dogs 2.15  
 Rabson–Mendenhall syndrome 45.63  
 Rac, melanocyte dendrite formation 58.4  
 race 9.1–19  
 acanthosis nigricans and 9.15  
 acne and 9.4–5, 42.19, 42.24  
 acne nuchae keloidalis and 9.9  
 actinic prurigo and 9.19  
 adult T-cell leukaemia/lymphoma and 9.13  
 ainhum and 9.12–13  
 allergic contact dermatitis and 9.13, 26.8  
 atopic dermatitis and 9.13  
 bacterial skin flora and 30.3–4  
 basal cell carcinoma and 9.18  
*Candida* paronychia and 9.18  
 capsaicin dermatitis and 9.13  
 cellulitis and 9.18  
 cerumen and 68.2  
 classification 9.1, 9.2  
 contact dermatitis and 9.13  
 definitions 9.1  
 dermatosis papulosa nigra and 9.11  
 dermatosis pustulosa cruris et atrophicans and 9.13  
 discoid lupus erythematosus and 9.15  
 dissecting cellulitis and 9.9–10  
 effect on normal bacterial skin flora 30.3–4  
 epidermal structure and function and 9.2  
 erythema dyschromicum perstans and 9.16–17  
 facial Afro-Caribbean childhood eruption and 9.12  
 focal acral hyperkeratosis and 9.10  
 fungal infection and 9.12  
 hair and 9.2, 66.13  
 hair styling practices and 9.7  
 HTLV-1 associated infective dermatitis and 9.12  
 idiopathic guttate hypopigmentation and 9.11  
 Kaposi's sarcoma and 9.18–19  
 keloids and 9.15  
 keratoderma and 9.10  
 keratosis punctata and 9.10  
 knuckle pads and 9.15  
 lichen nitidus and 9.5  
 lichen planus and 9.5  
 lichen simplex chronicus and 9.13–14  
 lichen striatus and 9.5  
 Lyme disease and 9.18  
 malignant melanoma and 9.18  
 melanocytic naevi and 9.17  
 melanosomes differences 3.21, 9.2, 58.10  
 melasma and 9.16  
 Mongolian spot and 9.11  
 morphoea and 9.14  
 mudi-chood and 9.7–8  
 mycosis fungoides and 9.7  
 naevus of Ito and 9.17  
 naevus of Ota and 9.17  
 nail pigmentation and 65.39  
 oculocutaneous albinism and 9.16  
 otitis externa and 68.20–1  
 papuloerythroderma of Ofuji and 9.13  
 pemphigus foliaceus and 9.14  
 pemphigus vulgaris and 9.14  
 photodermatoses and 9.19  
 pigmentation and 9.1, 58.1, 58.10  
 pigmentation significance 58.9  
 pityriasis lichenoides chronica and 9.5–6  
 pityriasis rosea and 9.6  
 pityriasis rotunda and 9.10  
 pityriasis versicolor and 9.6  
 podoconiosis and 9.8  
 polymorphic light eruption and 9.19  
 primary cutaneous amyloidosis and 9.17  
 progressive macular hypomelanosis and 9.16  
 pseudofolliculitis barbae and 9.9  
 psoriasis and 9.14  
 rosacea and 9.14  
 sarcoidosis and 9.14  
 seborrhoeic dermatitis and 9.6  
 sickle cell disease and 9.12  
 skin bleaching and 9.8  
 skin structure and function variations 9.1–4  
 squamous cell carcinoma and 9.18  
 stratum corneum variations 9.2, 9.13  
 syphilis and 9.6  
 systemic sclerosis and 9.14  
 tinea capitis and 9.8  
 transient neonatal pustular melanosis and 9.12  
 vascular naevi and 9.19  
 vitiligo and 9.6–7  
 vulvodynia and 9.19  
 warts and 9.18  
 radiant exposure 29.1  
 radiation  
 contaminating 29.3  
 electromagnetic *see* electromagnetic radiation  
 infrared *see* infrared radiation  
 ionizing *see* ionizing radiation  
 solar simulated (SSR) 29.5  
 thermal, non-melanoma skin cancer associated 52.5  
 ultraviolet *see* ultraviolet (UV) radiation  
 visible 29.1  
 radiation reaction *see* radiodermatitis  
 radical oxygen species (ROS) 12.54–6  
 radiculoneuropathy, herpes simplex 33.17  
 radio-isotope scanning 5.22  
 radio repair, occupational hazards 27.20  
 radioallergosorbent test 13.16  
*see also* CAP fluorimmunoassay  
 radioccontrast media  
 adverse effects 75.25, 75.150–2  
 histamine liberation 22.8  
 radiocurability 79.3  
 radiodermatitis 47.52  
 acute 79.14–16  
 alopecia due to 66.53–4  
 chronic 66.53–4, 79.16–17  
 chronic, telangiectases in 79.16  
 loss of eccrine function in 44.18  
 male genital dermatology 71.18  
 perianal/perineal 71.90  
 radiofrequency 80.14  
 radiofrequency ablation (RFA), varicose veins 47.39  
 radiofrequency devices, cellulite management 46.10  
 radiography  
 foreign bodies 28.42  
 sarcoidosis 61.20  
*see also* X-ray(s)  
 radioimmunoassay 13.19  
 radionecrosis 79.16–17, 79.18  
 radiopharmaceuticals 75.152  
 radioresponsiveness 79.3  
 radiosensitivity 79.3, 79.4

- radiotherapy  
acrodermatitis continua (of Hallopeau) 79.4  
adjuvant 79.7  
adverse effects 44.18, 62.47  
angiosarcoma 56.37, 56.38  
  carcinogenesis 79.4, 79.18–19  
  mucositis 69.82, 79.10  
  non-melanoma skin cancer 52.5  
angiosarcoma following 56.37, 56.38  
atypical vascular proliferation following 56.41–2  
basal cell carcinoma 79.5–7, 79.8–12, 79.13  
benign disease 79.4–5, 79.18  
Bowen's disease 79.12  
choice of 79.5–7  
comparison with surgery 79.5–7  
contraindication, in naevoid basal cell carcinoma syndrome 52.7  
cutaneous T-cell lymphoma 79.13  
Darier's disease 79.4  
dermatofibrosarcoma protuberans 56.13, 79.13  
dose 79.7–8  
electron beams 79.1–2, 79.9  
eyelid 79.8–9  
face 79.10, 79.11  
fractionation 79.3, 79.8  
Hailey–Hailey disease 79.4  
hand eczema 23.22  
immunosuppressive effects 13.25  
implants 79.2, 79.5  
infantile haemangioma 18.51–2  
inner canthus 79.9  
juvenile xanthogranuloma 55.16  
Kaposi's sarcoma 56.36, 79.13  
Kasabach–Merritt syndrome/phenomenon 18.57  
keloids 45.55, 79.4–5  
kilovoltage 79.1, 79.2  
Langerhans' cell histiocytosis 55.13  
late sequelae 79.4  
lentigo maligna 79.12–13  
lentigo maligna melanoma 79.12–13  
lichen planus association 41.3  
lips 79.10, 79.11  
lymph nodes, lymphoedema after 48.13  
male genital region 71.44  
malignant melanoma 54.55, 54.56, 79.12  
megavoltage 79.1  
Merkel cell carcinoma 79.13  
metastatic carcinoma 79.13  
moulds 79.2  
mycosis fungoides 57.24  
in necrobiotic xanthogranuloma 55.28  
non-melanoma skin cancer 52.5, 52.16  
palliative 79.5, 79.6  
photon beams 79.1, 79.2  
postoperative 79.7  
sarcoidosis 61.21  
squamous cell carcinoma 52.27, 68.31, 79.5–7, 79.8–12, 79.13  
technique 79.3  
tinea capitis 79.4  
treatment modalities 79.1–2  
treatment regimens 79.7–8  
tumour recurrence following 79.17–18  
wart treatment 33.50  
whole-brain, melanoma metastatic to brain 54.55  
Raeder's syndrome 63.22  
RAG-1 gene/enzyme 13.6, 13.8  
RAG-2 gene/enzyme 13.6, 13.8  
ragweed 26.10, 26.20, 26.75  
ragwort, photosensitivity in animals and 2.23  
'rain scald' (dermatophilosis), in horses 2.12  
raised limb bands *see* amniotic bands/adhesions  
ramipril 75.93  
Ramsay–Hunt syndrome 33.26, 68.20, 69.74  
  management 33.28  
  zoster and 33.26  
random effects models 7.9  
randomization, RCTs 7.10–11  
randomized controlled trials (RCT) 7.1  
  applicability 7.13  
  appraisal and evaluation 7.11–15  
  importance of results 7.12–13  
  individual trials 7.10–13  
  results applied to patients 7.13  
  masking 7.11  
  outcome variables 7.12  
  randomization 7.10–11  
  surrogate endpoints 7.12  
  validity 7.10–13  
  value of 7.3, 7.4  
  *see also* systematic reviews  
ranitidine  
  adverse effect 75.150  
  in hand eczema 23.22  
  sebaceous gland activity inhibition 42.16  
  in urticaria 22.28  
RANTES 13.4  
  in atopic dermatitis 24.4  
  in HIV infection 35.4, 35.18  
  in lichen planus 41.1  
  thymus and activation-regulated chemokine (TARC/CCL17) 12.33, 12.44, 12.46  
  in vasculitis 50.10  
  vitamin D action 73.43  
ranula (mucocoele) 69.22, 69.65, 69.84, 69.110  
*Ranunculus* 25.21  
RAPADALINO syndrome 15.80  
rapamycin (sirolimus) 13.25, 74.25, 75.138  
  mammalian target of rapamycin (mTOR) 74.5  
rapeseed oil, toxic oil epidemic syndrome (Spain) 51.82  
raphe cysts, male genital region 71.35  
rapid plasma reagin (RPR) test 34.19  
Rapp–Hodgkin syndrome 15.51  
Rapunzel syndrome 64.32  
RAR-selective retinoids 20.27  
RARs *see* retinoic acid receptors (RARs)  
RAS (recurrent aphthous stomatitis) 69.44–6, 69.48  
RASA1 gene mutation 47.21  
rash(es)  
  in actinic prurigo 29.14  
  in adult T-cell leukaemia–lymphoma 33.64  
  in chronic actinic dermatitis 29.17  
  in congenital syphilis 34.16  
  in coxsackievirus infections 33.71–2  
  in echovirus infections 33.73  
  in erythema infectiosum (fifth disease) 33.62, 33.63  
  factitious 64.42–3  
  in HIV infection 35.10  
  in infectious mononucleosis 33.30  
  in Lassa fever 33.69  
  macular 33.4  
  maculopapular 5.7, 33.4  
  maculopapular–petechial 33.4  
  maculopapular–vesicular 33.4  
  in Marburg and Ebola diseases 33.70  
  in measles 33.75  
  papular 33.4  
  papulovesicular 33.4  
  papulovesiculopustular 33.4  
  in pityriasis rosea 33.79  
  in polymorphic light eruption (PLE) 29.11, 29.23  
  roseolar (macular syphilide) 34.8–10  
  in rubella 33.70  
  in scarlet fever 30.34  
  in secondary syphilis 34.8, 34.10, 34.11  
  urticarial, viral infections 33.4  
  in varicella 33.23, 33.24  
  vesicular, viral infections 33.4  
  vesiculopapular 33.4  
  in viral infections 33.3–4, 33.4  
RAST 13.16  
  *see also* CAP fluoroimmunoassay  
rat-bite fevers 30.67  
rat skin transcutaneous electrical resistance test 25.9  
Raynaud's phenomenon 63.4, 74.51–2  
  aetiology and pathology 28.68–9  
  anticentromere antibodies 51.103  
  clinical features 28.69–70  
  cold-induced injury 28.68–71  
  development of SLE 51.36  
  diagnosis 28.70  
  differential diagnosis 28.57–8, 28.66, 51.106  
  following fish stings 38.59  
  hyperhidrosis and 44.8  
  occupational, vibration white finger 27.17  
  onset of systemic sclerosis 51.94  
  paraneoplastic 62.41  
  telangiectases in 47.14  
  treatment 28.70  
  prostacyclin analogue iloprost 51.108  
  vascular lesions 51.132  
Raynaud's syndrome, oesophageal aperistalsis 51.99  
RCTs *see* randomized controlled trials (RCT)  
reactive oxygen species (ROS)  
  dithranol mechanism of action 73.29  
  skin ageing and 80.2  
  UVA-1 forming 29.1  
reactive perforating collagenosis 19.89, 45.63, 45.64–5, 69.129  
reboxetine 64.51  
recessive alleles 15.3–4  
RecQ helicase 58.23–4  
RECQL4 gene 15.80–1  
rectal carcinoid tumours 43.18  
rectum, syphilitic lesions 34.7, 34.8  
recurrent aphthous stomatitis 69.44–6, 69.48  
recurrent focal palmar peeling 23.19  
recurrent scarlatiniform erythema 30.34  
red, white and blue sign 38.32  
red-back spider 38.31  
red bug 38.50  
red-cell aplasia 33.63  
Red Cross 72.31  
red fingers syndrome 62.59  
red-man syndrome 23.48–9, 75.60  
red poultry mite 38.51  
red sponge 38.59  
Redd African padauk 26.81  
redox status, rosacea 43.2  
reducing agents as irritants 25.21  
5 $\alpha$ -reductase 42.3, 42.10, 44.18, 66.14, 66.15  
  acne aetiology and 42.21, 42.23  
  deficiency 66.14  
  isoforms 42.10, 42.21, 42.23  
  in sebocytes 42.10  
5 $\alpha$ -reductase inhibitors  
  in hirsutism 66.88  
  isotretinoin as 42.16  
  progesterone as 42.11, 42.16  
Reduviidae 37.31, 38.25–6  
Reed syndrome (hereditary leiomyomatosis and renal cell carcinoma syndrome) 2.17, 62.29, 62.69  
Reed–Sternberg cells, in Hodgkin's disease 57.29  
Reed–Sternberg-like cells 57.30  
referrals  
  psychiatry 64.15  
  rates, for specialist care 6.15  
reflex sympathetic dystrophy *see* complex regional pain syndrome (CRPS)  
reflux 47.25, 47.35  
  venous *see* venous reflux  
refractory errors, in albinism 58.40  
Refsum's disease 19.3, 19.45–7  
regional diversity of skin 3.3  
regional ileitis *see* Crohn's disease  
registers of skin disease 6.6  
regulated upon activation normal T cell expressed and secreted *see* RANTES  
Reiter's syndrome 34.30, 34.31, 50.62  
  bone and joint involvement 62.101, 62.105  
  female genital involvement 71.59  
  HIV infection 35.17  
  male genital involvement 71.18  
  nail involvement 65.25  
  ocular involvement 67.25  
  oral involvement 69.71, 69.118  
rejuvenation techniques 80.4–14  
relapsing fever 30.64  
relapsing linear acantholytic linear dermatosis *see* Hailey–Hailey disease  
relapsing polyarthralgia 45.42–4  
  bone and joint involvement 62.104  
  following ear piercing 68.8  
  neutrophilic dermatoses associated 50.91–2  
  panniculitis with 46.32  
  paraneoplastic 62.40  
  respiratory tract involvement 62.82  
  vasculitis and 50.48–9, 50.54, 50.91–2  
relative risk 6.18  
relaxin 3.41  
relaxin family peptide receptor-1 (RFPR1) 3.41  
REM syndrome 59.25  
renal disease 62.68–75  
  ichthyosis and 19.61  
  purpura due to 49.18  
  in SLE 51.44  
  in systemic sclerosis 51.101  
  'wire-loop' lesions 51.34  
  *see also* kidneys, disorders; *specific diseases*  
renal failure 27.11  
  calcifying panniculitis with 46.16–17  
  chronic *see* chronic renal failure  
  cutaneous signs 62.72–3  
  end-stage, restless legs syndrome 47.12  
  pigmentation changes 58.27  
renal transplantation *see* kidneys, transplantation  
renal tumours, genetics 15.23  
reoviruses 33.3  
repeatability 6.19  
repifermin 14.27  
reports, histopathology 10.36  
reptiles  
  glands 2.4  
  pigment cells 2.6  
  scales and skin 2.3  
  skin infections 2.12  
research, health services 6.14–17  
research papers, appraisal and evaluation 7.10, 7.13, 7.15, 7.16–23  
reserpine, systemic sclerosis 51.108  
  contraindications 51.108  
resins  
  acrylic 26.72–3  
  as allergens 26.69–74  
  epoxy  
    allergic contact dermatitis and 26.16, 26.20, 26.70–2  
    depigmentation due to 26.26  
    filter-paper test 27.8  
    scleroderma-like lesions 51.80  
  formaldehyde 26.49, 26.65, 26.68, 26.69, 26.73–4  
  resol 26.73  
  resorcin, acne vulgaris treatment 42.43  
  resorcinol 25.19, 73.13, 75.166  
  shampoo 73.13  
resource allocation 72.13  
respiratory papillomatosis 33.47  
respiratory syncytial virus (RSV) 17.58, 33.75, 33.76

- respiratory tract  
 blastomycosis 36.84  
 coccidioidomycosis 36.85  
 cryptococcosis 36.89, 36.90  
 disorders 62.80–5  
   *see also specific disorders*  
 drugs acting on 75.98–9  
 histoplasmosis 36.82  
 in infantile haemangioma 18.46  
 infections 62.80  
   herpes simplex virus 33.17  
 lymphoid structure 13.9  
 neutrophilic dermatoses 50.81, 50.82  
 paracoccidioidomycosis 36.87  
 pyoderma gangrenosum 50.70  
 sarcoidosis 61.6, 61.7  
 in SLE 51.43, 62.82  
 in Wegener's granulomatosis 50.39–40  
 xanthoma disseminatum 55.21  
*see also lungs*  
 rest pain 47.2, 47.7  
   management 47.6  
 restaurant personnel, occupational  
   hazards 27.20  
 resting stress lines (Langer's lines) 77.2,  
   77.13  
 restless legs syndrome 47.11–12, 63.24–5  
 restriction enzymes 11.4  
 restriction fragment length polymorphism  
   (RFLP) 15.7, 32.1  
 restrictive dermopathy 17.20, 45.51  
 Restylane 80.6  
 RET gene 62.24  
 retapamulin 73.10  
 rete ridges 3.16  
   ageing and 8.23  
   glucocorticoid-induced atrophy 45.4  
   lichen nitidus 41.22  
   saw-tooth appearance in lichen planus  
   41.4  
   warts (common/plantar) 33.41  
 reticular degeneration 10.38  
 reticular erythematous mucinoses 59.25  
 reticular pigmented anomaly of the  
   flexures 15.94–5, 58.22  
 reticulate acropigmentation 58.21–2  
 reticulate acropigmentation of Dohi  
   15.95, 58.21–2  
 reticulate acropigmentation of Kitamura  
   58.21  
 reticulate body, *Chlamydia* 34.29  
 reticulin, in sarcoidosis 61.3, 61.4  
 reticulocytes, occlusion due to 49.47  
 reticulocytoma/reticulohistiocytoma cutis  
   *see multicentric*  
   reticulohistiocytosis  
 reticuloendothelial system 12.26  
   sarcoidosis 61.7  
 reticuloendotheliosis, non-lipid *see*  
   Langerhans' cell histiocytosis  
   (LCH)  
 reticulohistiocytoma (solitary epithelioid  
   histiocytoma) 55.23, 55.24  
 reticulohistiocytoma cutis *see multicentric*  
   reticulohistiocytosis  
 reticulohistiocytosis  
   diffuse cutaneous 55.24  
   malignant 55.32–3  
   multicentric giant-cell *see multicentric*  
   reticulohistiocytosis  
 reticulosis  
   aleukaemic 55.32–3  
   histiocytic (malignant) 55.32–3  
   histiocytic medullary 55.32–3  
   virus-induced 55.30–1  
 retiform parapsoriasis 57.58  
 retina  
   acute retinal necrosis syndrome 33.26  
   angioid streaks 45.21, 45.22  
   anlage tumour 56.52–3  
   detachment 24.25  
   phacomias 15.23  
 retinacula cutis 45.2  
 retinal necrosis syndrome, acute 33.26  
 retinitis, CMV 33.29  
 retinoblastoma, familial 54.48  
 retinochoroiditis 61.7  
 retinoic acid (tretinoin; vitamin A acid)  
   73.35, 73.35–6  
   in acne 42.39–40, 42.40  
   in actinic elastosis 45.27  
   adverse effects 42.49, 75.113, 75.166  
   retinoid dermatitis due to 73.27  
   depigmenting action 73.27  
   in dystrophic EB 39.29  
   formulations 42.39  
   hair regrowth and 73.39  
   hypermelanosis treatment 58.39  
   isomers 73.35  
   metabolism blocking agents 20.42–3,  
   74.37  
   in molluscum contagiosum 33.12  
   photocarcinogenesis control 29.7  
   in prevention of ageing 80.3  
   receptors 73.35  
   for solar lentiginosis 73.26  
   in systemic sclerosis 51.108  
   topical 57.23, 73.34, 73.35–6, 75.166  
   in acne vulgaris 73.34  
   in chemically-induced skin tumours  
   73.36  
   indications 73.35–6  
   in keloids 45.55  
   in osteoma cutis 42.78  
   wart treatment 33.49  
 9-cis-retinoic acid (13cRA) *see* alitretinoin  
   (9-cis-retinoic acid)  
 13-cis-retinoic acid (13cRA), squamous  
   cell carcinoma 52.28  
 retinoic acid metabolism blocking agents  
   20.42–3, 74.37  
 retinoic acid nuclear receptors (RAR,  
   RXR) 3.39  
 retinoic acid receptor (RAR)-selective  
   retinoids 20.27  
 retinoic acid receptors (RARs) 42.14,  
   73.35, 73.36, 73.37  
   acne treatment and 42.40, 42.58  
   RAR- $\alpha$  and RAR- $\beta$  42.40, 42.58  
 retinoic acid-responsive elements (RARE)  
   3.39  
 retinoid acid-binding protein (RAR) 42.40  
 retinoid dermatitis 73.27  
 retinoid X receptors (RXRs) 73.35, 73.36  
   hair growth and 66.11  
 retinoids 20.27, 20.37–8, 73.34–9, 74.33–8  
   adverse effects 74.37, 75.108–13  
   on cancer suppression 74.33  
   on cell differentiation 74.33  
   effects on mood 64.49, 75.112–13  
   hair loss 66.29–30  
   on neutrophil migration 74.33  
   photosensitivity 42.50  
   systemic 75.111–12  
   teratogenicity 42.50, 72.28, 74.38  
   binding proteins and regulation  
   73.34–5  
   chemical peels and 80.9  
   collagen gene expression control 3.39  
   endogenous 73.34–5  
   naturally occurring 73.35  
   *see also* retinol  
   in epidermodysplasia verruciformis  
   33.58  
   in hand eczema 23.22  
   in hidradenitis suppurativa 30.81  
   in HPV-associated dysplasia/neoplasia  
   33.55  
   immunostimulation 74.33  
   mechanism of action 73.34–5  
   metabolism 73.35  
   in naevoid basal cell carcinoma  
   syndrome 52.8  
   in ocular rosacea 43.7  
   oral  
     non-melanoma skin cancer 52.18  
     ocular side effects 67.31  
     wart treatment 33.50  
   photosensitivity with 42.50  
   in pregnancy 74.38, 75.113  
 in psoriatic nail involvement 65.26  
 RAR-selective 20.27  
 receptors and binding to 73.35  
 safety precautions 74.37  
 sebaceous gland activity control  
   42.14–15  
 synthetic 73.34, 73.35  
 systemic  
   epidermolytic/non-epidermolytic  
   epidermal naevi 18.7  
   teratogenicity 73.35  
   *see also* retinoids, oral  
 teratogenicity 42.50, 72.28, 73.35, 74.38  
 topical 57.23  
   in acne 42.39–41, 42.48, 73.34, 73.35,  
   73.36  
   in chloracne 42.77  
   indications 73.34  
   mechanism of action 42.40  
 retinol 73.34, 73.35  
   indications 73.34  
   allergy to 26.46  
   cosmetic uses 73.35  
   deficiency, wound healing and 14.18  
   excess 66.29  
   intoxication 75.108  
   metabolism 73.35  
   in prevention of ageing 80.3  
   topical application 73.35  
   *see also* vitamin A  
 retinopathy, antimalarials causing 67.31  
 retrobulbar neuritis, in sarcoidosis 61.7  
 retroviral entry inhibitors 74.50  
 retroviruses 33.2, 33.64–6  
   HTLV-1-associated adult T-cell  
   leukaemia-lymphoma 57.37–8  
   replication 33.64  
   Tax protein 33.64  
   *see also* HIV infection  
 revascularization  
   claudication 47.5–6  
   rest pain and gangrene 47.6  
 reverse genetics 11.1  
 reverse transcriptase 11.6, 33.1, 33.64  
 reverse transcription, HIV 35.3, 35.6  
 reverse transcription polymerase chain  
   reaction 11.6  
 reversible posterior leukoencephalopathy  
   syndrome 50.47  
 rexinoids 73.36  
 Reye's syndrome, in varicella 33.25  
 Reynold's syndrome 62.62  
 RFLP (restriction fragment length  
   polymorphism) 15.7, 32.1  
 rhabdomyocytes, microscopy 10.35  
 rhabdomyolysis, in varicella 33.25  
 rhabdomyoma 56.57  
   cardiac 15.23  
   fetal 18.37  
   oral 69.112  
 rhabdomyosarcoma  
   cutaneous 56.57  
   ear 68.34  
   oral 69.112  
 rhabdoviruses 33.3  
 rhagades 34.15, 69.122  
   in Hailey-Hailey disease 39.34  
 Rhagionidae 38.6  
 rheography, light-reflection 47.36  
 rheumatic fever 51.138, 62.78  
   erythema marginatum in 51.138,  
   62.107  
   streptococcal infection and 30.12  
 rheumatism, fibroblastic 62.103  
 rheumatoid arthritis 62.103  
   cutaneous atrophy and 45.3  
   dermatological manifestations 51.130–3  
   leg ulceration associated 47.55  
   lymphoedema in 48.13  
   pigmentation changes 58.26  
   pustular neutrophilic panniculitis 46.32  
   treatment  
     flushing associated 43.15  
     TNF antagonists 74.7  
   vascular lesions 51.132  
   vasculitis and 50.48  
 rheumatoid disease, dermatological  
   manifestations 51.130–3  
   fibroblastic rheumatism 51.133  
   pseudosclerodermatous changes 51.130  
 rheumatoid factor 13.10  
   activity of type II/III cryoglobulins  
   49.32  
   detection 13.20–1  
   in syphilis 34.21  
 rheumatoid neutrophilic dermatosis  
   51.131  
 rheumatoid nodules 51.130–2  
 rheumatoid ulcers 47.55  
 rhinitis, congenital syphilis 34.15  
 rhino mouse model 42.23  
 rhinoceros 2.3  
 Rhinocladia aquaspersa 36.75  
 rhinoentomophthoromycosis 36.78–9  
 Rhinoestrus 38.9  
 rhinophyma 43.9–10  
   electrosurgery 77.46  
   giant, symmetrical lipomatosis with  
   46.46  
   laser therapy 78.14  
   malignancy association 43.9  
   treatment 43.6  
 rhinoscleroma 30.51–3, 69.121  
 rhinosporidiosis 36.78  
 Rhinosporidium 36.78  
 Rhipicephalus 38.34, 38.35  
 Rhizoglyphus 38.47  
 Rhizomucor 36.91  
 Rhizopus 36.91, 68.27  
   vessel-invasive infection 49.35  
 Rho, melanocyte dendrite formation 58.4  
 rhodamine RB200 10.12  
 rhodium 26.40  
 Rhodnius prolixus 37.31  
 rhodopsin, formation reduction 67.31  
 Rhodotorula 69.105  
 Rhus 26.1  
 rhytides 80.2  
 ribavirin  
   adverse effects 75.67  
   in cryoglobulinaemic vasculitis 50.25  
   Lassa fever 33.69  
   measles 33.76  
 riboflavinemia, pigmentation 58.53  
 riboflavine 59.62  
 RICE therapy 38.32  
 Richner-Hanhart oculocutaneous  
   syndrome 19.95, 19.111–12, 59.97  
 rickets 69.116, 69.117  
   vitamin D-resistant 66.11  
 Rickettsia akari 30.74  
 Rickettsia conorii 30.73  
 Rickettsia rickettsii 30.73  
 Rickettsia tsutsugamushi 30.74  
 rickettsial infections 30.72–4, 38.35, 38.51  
   vasculitis and 50.55  
 rickettsialpox 30.74  
 Riehl's melanosis 58.35  
 rifampicin 74.44, 74.45  
   adverse effects 31.27, 75.62  
   in leprosy 32.16, 32.17  
   resistance to 31.27, 32.1–2  
   in tuberculosis 31.27  
 rifamycins 74.44  
 Rift Valley fever 33.67, 33.70  
 Riga-Fede disease 69.43  
 rilanocept, cryopyrin-associated  
   autoinflammatory syndromes  
   74.11  
 Riley-Day syndrome (type III hereditary  
   sensory autonomic neuropathy)  
   44.7, 62.80, 63.18  
 Riley-Smith syndrome (Bannayan-Riley-  
   Ruvalcaba syndrome) 18.60,  
   62.26, 62.57, 69.38  
 ring block 77.10  
   for nail biopsy 65.42  
 ringworm  
   beard 36.28–9, 36.49  
   body *see* tinea corporis (tinea circinata)  
   face *see* tinea faciei (tinea faciale)

- foot *see* tinea pedis  
 groin *see* tinea cruris  
 hand (tinea manuum) 26.29, 36.32–3, 36.50  
 nails (tinea unguium) 36.34–5, 36.50  
 scalp *see* tinea capitis (tinea tonsurans)  
 steroid-modified *see* tinea incognita  
 treatment and management 36.46–51  
 rio-palisander 26.81  
 RISC (RNA-induced silencing complex) 11.8, 11.9
- risk  
 attributable 6.18  
 relative 6.18  
 risk factors, for skin disease 6.11–13, 6.18  
 causative 6.11  
*see also individual risk factors*  
 risk-benefit analysis 72.3–4  
 risperidone 64.16, 64.52  
 ritonavir, adverse effects 35.22  
 rituximab 13.25  
 adverse effects 75.146  
 in angio-oedema 22.22  
 in cryoglobulinaemic vasculitis 50.25  
 in cutaneous small vessel vasculitis 50.16  
 in dermatomyositis 74.10  
 dosing schedule 74.9  
 indications 74.10  
 in pemphigus 40.12, 74.9  
 in vasculitides 74.10  
 in Wegener's granulomatosis 50.41  
 river blindness *see* onchocerciasis  
 RLS (restless legs syndrome) 47.11–12, 63.24–5
- RNA  
 amplification, syphilis diagnosis 34.19  
 double-stranded (dsRNA) 11.7  
 fetal 16.9–10  
 interference (RNAi) 11.7, 11.9  
 manipulation 11.4–5  
 microRNA (miRNA) 11.7  
 short hairpin (shRNA) 11.10  
 small interfering (siRNA) 11.7, 11.9, 11.10  
 structure and function 11.2–3  
 RNA-induced silencing complex 11.7, 11.9  
 RNA interference (RNAi) 11.7, 11.9  
 RNA polymerases 11.3, 11.6  
 RNA viruses *see* virus(es), RNA  
 Ro antigen 13.19  
 road workers, occupational hazards 27.20  
 Roberts syndrome 18.70, 66.61  
 Robi comb 38.20  
 Robinson syndrome 15.35  
*Rochalimea see Bartonella*  
*Rochalimea henselae see Bartonella henselae*  
 Rocky Mountain spotted fever 30.73, 38.34, 38.35  
 purpura 49.20  
 rocuronium 75.153  
 rodent bites 38.61  
 rodent botfly 38.9  
 rodent ulcer *see* basal cell carcinoma (BCC)  
 Romaña's sign 37.32  
 Rombo syndrome 52.9  
 rope sign 62.103–4  
 ropinirole 63.25  
 ropivacaine 77.10  
 in nail biopsy 65.42  
 roquinimex 75.148  
 ROS *see* reactive oxygen species (ROS)  
 rosacea 43.1–9  
 antimicrobial peptide expression increased 3.16  
 cathelicidin peptides, pathogenic role 12.5  
 clinical features 43.1, 43.3  
 complications 43.3–4  
 corticosteroid-induced 43.10, 73.19  
 definition 43.1  
 Demodex and 38.53, 43.2–3, 43.5, 43.6  
 differential diagnosis 43.5, 51.9, 61.5  
 acne vs 42.36, 43.5  
 perioral dermatitis vs 43.11  
 epidemiology 43.1  
 erythema 43.3, 43.4, 43.6  
 erythematotelangiectatic 43.1, 43.2, 43.6  
 eye involvement 43.4, 43.5, 43.7  
 flushing 43.1, 43.2, 43.3  
 aggravating factors 43.3  
 management 43.6  
 gastrointestinal symptoms with 43.2  
 granulomatous 43.2, 43.5  
 acne agminata as variant 43.13  
 acne vs 42.37  
*Helicobacter pylori* role in 43.2  
 eradication effect 43.2, 43.6, 43.7  
 histopathology 43.4–5  
 in HIV infection 43.3  
 inflammatory lesions 43.1, 43.3, 43.4, 43.5  
 inflammatory papulopustular 43.4  
 lymphoedema and 43.4, 48.13, 48.16  
 management 43.6–7  
 migraine association 43.1  
 nomenclature 43.1  
 ocular *see* ocular rosacea  
 papulopustular 43.2, 43.4, 43.5, 43.6  
 pathogenesis 43.1–3  
 peau d'orange 43.3  
 prognosis 43.5  
 progression 43.3  
 race and 9.14  
 salivary gland involvement 43.4  
 sarcoidal reaction in 61.23  
 seborrhoeic dermatitis and 23.29  
 severity assessment 72.10  
 solid facial oedema 42.74  
 steroid 43.10, 73.19  
 telangiectasia 43.4, 43.6  
 treatment 43.5–6  
 antibiotics 43.2, 43.6, 43.7  
 isotretinoin 43.6, 74.34  
 metronidazole 43.3, 43.6  
 topical antibiotics 73.9, 73.10  
 rosacea fulminans *see* pyoderma faciale (rosacea fulminans)  
 Rosai-Dorfman disease *see* sinus histiocytosis with massive lymphadenopathy (SHML; Rosai-Dorfman disease)  
 rose spots 30.48  
 Roselli-Gulienetti syndrome 15.33  
 Rosenberg Self-esteem Scale 64.7  
 Rosenthal-Kloepfer syndrome 15.89  
 roseola infantum 33.32  
 roseolar rash (macular syphilide) 34.8–10  
 Ross River virus 33.66–7, 33.67  
 Ross's syndrome 44.11, 44.13–14  
 rotenone 38.41  
 Roth spots 62.78  
 Rothman-Makai syndrome 46.15  
 Rothmund-Thomson syndrome *see* poikiloderma congenitale  
 rotigotine 63.25  
 roustabout's breast 70.15  
 rove beetles 38.26–7  
 Rowell's syndrome 51.14, 76.7  
 RSP04 gene 11.9, 11.10  
 RT-PCR 11.6  
 RTS (Rothmund-Thomson syndrome) *see* poikiloderma congenitale  
 rubber  
 as allergen 26.63–5  
 dermatitis due to 71.17  
 in footwear 26.63, 26.68–9  
 sensitizers in 26.64  
 sources of exposure 26.63  
 synthetic 26.65  
 vulcanization 26.63  
*see also latex*  
 rubber dermatitis, male genital dermatology 71.17  
 rubber workers, occupational hazards 27.20  
 rubbing (the skin) 5.18, 64.27  
 in response to pruritus 21.5  
 rubella 33.70–1  
 aetiology and clinical features 33.70–1  
 congenital 17.41–2, 18.2, 33.71  
 diagnosis, prophylaxis 33.71  
 MMR vaccination 33.71  
 in pregnancy 33.71  
 TORCH syndrome 33.76–7  
 rubeosis 59.77  
 Rubinstein-Taybi syndrome 15.92–3, 18.70  
 Rud's syndrome 19.11  
 rue 26.16  
 Ruffini corpuscles 4.9, 4.10  
 Ruffini organs 3.15  
 rule of hand, quantity of topical therapy 73.3  
 Rule of Nines 14.10, 28.77, 28.78  
 Rule of Tens 72.14  
 ruminations, depressive 64.12  
 Rumpel-Leede sign 49.5  
 rupatadine 74.31–2  
 Russell bodies 30.52  
 Russell's sign 64.22  
 rust-red flour beetle 38.27  
 rusters 28.93  
 Rutaceae, phytophotodermatitis due to 29.21  
 rutosides 47.39–40, 75.98  
 Ruvalcaba-Myhre-Smith syndrome (Bannayan-Riley-Ruvalcaba syndrome) 18.60, 62.26, 62.57, 69.38  
 RXRs *see* retinoid X receptors (RXRs)
- S  
 S100 protein 10.21–2, 10.24  
 juvenile xanthogranuloma 55.15–16  
 Langerhans' cell histiocytosis cells 55.9  
 melanoma vs Paget's disease of nipple 53.39  
 sinus histiocytosis with massive lymphadenopathy 55.29  
 S100A6, expressed by dermal dendrocytes 55.4  
 S100beta protein, melanoma 54.51  
 SAA (serum amyloid A) 13.4, 13.19  
 Sabinas brittle hair and mental deficiency syndrome 15.51  
*Saccharomyces* 69.105  
 sacculus rotundus 13.7  
 sacral herpes zoster *see* zoster  
 SACRAL syndrome 18.47, 18.96  
 SADBE *see* squaric acid dibutylester  
 saddle-nose deformity 34.14, 34.17  
 Saethre-Chotzen syndrome 15.91  
 SAHA syndrome 42.73, 66.82  
 St John's wort 72.29, 75.160, 75.162  
*Saksenaeva vasiformis* 36.91  
 salabrasion of tattoos 58.59  
 Salamon syndrome 15.56  
 salbutamol 75.98  
 Salford Psoriasis Index 64.10, 72.9, 72.20  
 salicylamide 75.73  
 salicylic acid  
 in acne vulgaris 42.43, 42.68  
 adverse effects 75.166  
 as allergen 26.62  
 application and cautions 33.48  
 dithranol with 73.30  
 in hand eczema 23.22  
 as irritant 25.19  
 isotretinoin interaction 42.65  
 in molluscum contagiosum 33.12  
 as penetration enhancer 73.7  
 in pityriasis amiantacea 66.57  
 in pityriasis capitis 66.57  
 topical 5-FU with 73.23  
 topical corticosteroids with 73.20  
 wart treatment 33.48  
 salicylic acid peel, in acne vulgaris 42.68  
 salicylism 19.8, 75.166  
 saline, as local anaesthetic 77.11  
 saliva 69.3  
 salivary gland examination 69.5  
 salivary gland involvement, rosacea 43.4  
 salivary gland swelling, HIV infection 35.42  
 salmeterol 75.98  
 salmon patch 18.62–3  
*Salmonella* 30.47–8  
 aortitis due to 50.55  
 salt-split, lamina lucida 40.47  
 Salticidae 38.32  
 saltpetre disease 45.25  
 sampling error 6.18  
 San Joaquin valley fever *see* coccidioidomycosis  
 sand-worm eruption *see* larva migrans, cutaneous  
 sandflies 37.33, 37.39, 38.2, 38.5, 38.7  
 sandfly fever 38.5  
 Sandhoff disease 44.18  
 Sanfilippo's syndrome *see* mucopolysaccharidoses  
 santos palisander 26.81  
 SAP (SLAM-associated protein) 13.6  
 SAP (serum amyloid P) component 59.42–3  
 saphenofemoral junction (SFJ) 47.25  
 saphenous nerve, damage 47.38  
 saphenous vein  
 greater (GSV) 47.25, 47.30, 47.38  
 ligation and stripping 47.38  
 short (SSV) 47.25, 47.30, 47.39  
 SAPHO syndrome 20.17, 42.85, 62.101  
 saquinavir 75.68  
 photosensitivity due to 35.22  
 sarcoid  
 equine 2.21–2  
 micropapular of face, acne vs 42.37  
 sarcoid-like granulomatous dermatitis (granulomatous perioral dermatitis) 43.12, 43.13  
 'sarcoid of Darier-Roussy' 61.13  
 sarcoidal reactions 61.13, 61.21–3  
 sarcoidosis 61.1–23  
 Addison's disease and 61.17  
 aetiology 61.2–3  
 alopecia and 61.9, 61.14  
 associated diseases 61.17–18  
 bone and joint involvement 61.6–7, 61.11, 62.101, 62.104  
 breast 70.12, 70.14  
 cardiac involvement 61.7, 62.78  
 childhood 61.16  
 chronic urticaria and 61.17  
 connective tissue disorders/disease and 61.17  
 course and prognosis 61.18–19  
 Crohn's disease and 61.23  
 Cushing's syndrome/disease and 61.17  
 cutaneous 61.8–17  
 angiulopoid 61.9  
 annular 61.9  
 atrophic 61.14  
 classification 61.8  
 clinical features 61.8–9  
 erythrodermic 61.14  
 hyperpigmentation in 61.14  
 hypopigmentation in 61.14  
 ichthyosiform 61.14  
 lichenoid 61.14, 61.15  
 lupoid 61.14  
 lupus erythematosus-like 61.14  
 maculopapular and erythematous 61.10, 61.11  
 nodular 61.10, 61.12  
 papular (small nodular) 61.10, 61.12  
 plaque 61.10, 61.12, 61.13  
 pruriginous 61.14  
 pseudotumoral 61.14  
 psoriasiform 61.14  
 ulcerated 61.16  
 verrucous 61.16  
 definition 61.1  
 diabetes insipidus and 61.7, 61.17  
 differential diagnosis 61.5  
 ear involvement 61.9, 68.17  
 early/intermediate/late 61.6

- with endocrine autoimmune conditions 62.13
- epidemiology 61.2
- erythema nodosum and 50.83
- extrapulmonary manifestations 61.6
- general symptoms 61.6
- genetic and familial factors 61.3
- gout and 61.18
- granuloma annulare and 60.9, 61.17
- Hashimoto's thyroiditis and 61.17
- hepatic involvement 61.7–8
- histological features 61.5
- histopathology 61.3–4
- history 61.1–2
- HIV infection and 61.6
- hypercalciuria and hypercalcaemia in 61.8
- hyperthyroidism and 61.17
- hypomelanosis in 58.52
- hypothyroidism and 61.17
- immunology 61.5–6
- inclusion bodies 61.4
- infection and 61.17
- investigations 61.19–20
- leg ulceration 47.55
- lip involvement 69.129
- localization to tattoos 58.58
- main features 61.1
- malignant disease and 61.17
- mortality 61.19
- mucosal involvement 61.15
- muscle involvement 61.7
- myxoedema and 61.17
- nail involvement 61.11, 61.15
- nasal
- rosacea vs 43.5
- see also lupus pernio
- necrobiosis lipoidica and 61.17, 61.23
- nervous system involvement 61.7
- ocular involvement 61.7, 67.25
- mucous membrane pemphigoid vs 67.20
- oral involvement 69.109, 69.119
- paraneoplastic 62.40
- porphyria cutanea tarda and 61.18
- pregnancy and 61.8
- primary biliary cirrhosis and 61.18
- psoriasis and 61.18
- pulmonary 61.6, 61.7
- pyoderma gangrenosum and 61.18
- race and 9.14
- renal involvement 61.7, 62.71
- respiratory tract involvement 62.83
- reticuloendothelial involvement 61.7
- scalp 66.5
- scar 61.10, 61.12–13
- staging 61.6
- subcutaneous 61.13–14
- syphilis and 61.18
- treatment 61.20–1
- methotrexate 74.20
- TNF antagonists 74.7
- vasculitis and 61.17
- sarcoidosis–lymphoma syndrome 61.17, 62.40
- sarcoids, feline 2.22
- sarcoma
- (acral) myxoinflammatory fibroblastic 56.15
- clear cell 56.53–4
- epithelioid 56.60–1
- Ewing's, extraosseous 56.54
- follicular dendritic cell 55.31
- granulocytic 69.57
- histiocytic 55.31
- interdigitating dendritic cell 55.31
- Kaposi see Kaposi's sarcoma
- Langerhans' cell 55.31
- low-grade fibromyxoid 56.22–3
- proximal-type epithelioid 56.61
- see also specific forms of sarcoma
- Sarcophaga* 38.8
- Sarcophagidae* 38.8
- Sarcoptes scabiei* 37.1, 38.36–7, 38.43, 38.46
- see also scabies
- Sarcoptes scabiei* var. *canis* 2.10
- sarcoptic mange 2.10, 38.36, 38.46
- Sarcoptidae 38.36–46
- see also scabies
- sartans see angiotensin II receptor antagonists
- Satchmo's syndrome 28.26
- saw-toothing 10.41
- sawah itch 37.22
- SC phocomelia (Roberts syndrome) 18.70
- scab 14.10, 77.17
- definition 5.7
- scabicides 38.41–2, 38.44
- scabies 38.36–46
- animal 38.46
- breast 70.17
- canine 38.4
- clinical features 38.38–40
- crusted (Norwegian) 38.2, 38.37, 38.39, 38.43–6
- erythroderma and 23.48
- keratoderma caused by 19.117
- diagnosis 38.40–1
- differential diagnosis 24.26, 26.29, 26.30
- elderly people 8.29, 38.40
- epidemiology 6.2, 38.37–8
- feline 2.10
- hands 25.15, 25.16
- HIV infection and 35.36
- identification of mites 5.20
- immunology 38.38
- in infancy and childhood 38.39–40, 38.42
- institutional outbreaks 38.44–5
- keratoderma caused by 19.117
- male genital region 71.34
- morphology and biology of mite 38.36–7
- Panama 6.2, 6.3
- persistent nodules 38.42
- prevention 6.3
- syphilis vs 34.7
- treatment 38.41–3, 73.13–14
- scabies incognita 38.39
- scalded skin syndrome see toxic epidermal necrolysis (TEN)
- scalds
- wound management 28.84–5
- see also burns
- scale, definition 5.7
- scales
- bird 2.3
- elasmoid 2.2
- fish 2.2
- placoid 2.2
- reptile 2.3
- scalp
- allergic contact dermatitis 26.17–18
- aplasia cutis congenita
- with epidermal naevi 18.100
- with limb reduction abnormalities 18.68, 18.99–100
- non-syndromic 18.98–9
- apocrine tubular adenoma 53.21
- biopsy 10.32, 10.43
- in androgenetic alopecia 66.23
- in chronic telogen effluvium 66.31
- in cicatricial alopecia 66.39
- in folliculitis decalvans 66.47
- in trichobezoar 64.32
- cellulitis
- isotretinoin 74.34
- see also perifolliculitis capitis abscedens et suffodiens
- cicatricial pemphigoid 66.49
- congenital melanocytic naevus 54.12
- crusted scabies 38.44
- cylindroma 53.28
- discoid lupus erythematosus 66.43–5
- dissecting cellulitis 42.74
- isotretinoin treatment 42.62
- see also perifolliculitis capitis abscedens et suffodiens
- dissecting folliculitis 42.33, 42.74
- dysaesthesia 63.23
- dystrophic EB 39.18
- erosive pustular dermatosis 66.49–50
- follicular lichen planus 41.11
- folliculitis 42.74
- folliculitis decalvans 30.25, 66.46–7
- granuloma annulare 66.5
- hair
- density 66.2
- see also hair
- hypotrichosis simplex 66.60
- Langerhans' cell histiocytosis 55.9
- lichen planopilaris 41.11, 66.39, 66.41–3
- lichen planus 41.11, 66.39, 66.41–3
- lichen sclerosus 66.50
- lichen sclerosus et atrophicus 66.50
- linear morphea 66.48, 66.49
- medical trauma 66.53
- metastases to 62.18
- necrobiosis lipoidica 66.5
- porokeratosis of Mibelli 66.51
- post-irradiation tumours 52.20
- pressure ischaemia 66.53
- pruritus 38.19
- psoriasis 20.14, 20.28, 23.32
- ringworm see tinea capitis (tinea tonsurans)
- sarcoidosis 66.5
- scabies 38.39, 38.44
- scaling disorders 66.56–7
- scarring follicular tumours 66.50–1
- scleroderma 66.48
- sebaceous carcinoma 53.17
- sebaceous glands 42.1
- seborrhoeic dermatitis 23.30, 66.56–7
- syringocystadenoma papilliferum 53.19–20
- thickened 66.58–9
- trichilemmal cysts 52.46
- scalp–ear–nipple syndrome 15.52
- Scanpor tape 26.85
- scar lymphoedema 48.17
- scar sarcoid, in zoster 33.26
- scar tissue
- amputees 28.27
- differential diagnosis 28.36
- pressure ulcers 28.18
- torture injuries 28.33
- see also scar(s) and scarring
- scar(s) and scarring 14.1
- in acne see acne vulgaris
- adverse/excessive 14.2
- after cryotherapy for warts 33.49
- assessment of severity 14.8
- atrophic 45.6
- dystrophic EB 39.18
- generalized non-Herlitz junctional EB 39.13
- treatment in acne 42.68–9
- atrophic macular, in acne 42.32
- cigarette paper 45.33
- in syphilis 34.12, 34.13
- congenital reticulate 45.6
- definition 5.8, 14.7
- dermabrasion 42.69
- excision 42.68
- features 14.7–8
- hypertrophic 14.2, 14.15, 45.54–6
- acne 42.32
- following surgery 77.8, 77.15
- laser therapy 78.8
- treatment 73.36
- treatment in acne 42.69
- ice-pick, in acne 42.33
- keloid see keloids
- lymphoedema 48.17
- mature 14.7
- non-melanoma skin cancer after 52.11
- prevention/reduction 14.8
- pyoderma faciale 43.14
- remodelling 14.7
- sarcoidosis 61.10, 61.12–13
- self-healing epitheliomas 52.9
- surgical
- complications 77.8, 77.9
- orientation 77.2, 77.11, 77.13
- vaccinia vaccination 33.6
- see also scar tissue
- SCARF syndrome 45.15
- scarlet fever (scarlatina) 30.16, 30.33–5
- staphylococcal 30.7–8, 65.21
- scarring see scar(s) and scarring
- scatter factor (SF), melanocyte mitogen 58.5
- scattering of light, colours in animals and 2.5
- scavenger receptors (SR) 12.10
- macrophage–monocyte 13.5
- neutrophil 13.5
- SCART1 and SCART2 12.10
- SCC see squamous cell carcinoma (SCC)
- Scedosporium apiospermum* 68.25
- in mycetoma 36.73, 36.74
- in otomycosis 36.17
- scent glands, mammals 42.2
- SCF (stem-cell factor) 3.19, 12.24, 12.31
- Schamberg's disease 49.22, 49.24, 49.25
- pigmentation in 58.53
- treatment 49.26
- Schamroth's window 65.7
- Schaumann bodies 61.4
- Scheie's syndrome see mucopolysaccharidoses (MPS)
- Schilder's disease, pigmentation changes 58.26
- Schimke immuno-osseous dysplasia 58.23
- Schimmelpenning's syndrome 18.27
- Schindler disease 59.34
- Schinz syndrome 15.55
- Schinz-Giedion midface-retraction syndrome 15.52
- schistocytes 49.12
- Schistosoma haematobium*, female genital dermatology 71.69
- schistosomiasis 37.3, 37.20–2
- perianal/perineal involvement 71.95–6
- schizophrenia 64.17, 64.18
- diagnostic test 43.16
- schizotripandides 37.32
- schizotrypanosomiasis see trypanosomiasis, American/South-American
- Schizotrypanum cruzi* (*Trypanosoma cruzi*) 37.31–2
- Schmidt's syndrome 62.13
- Schnitzler's syndrome 22.23–4, 50.53, 62.94
- Schnyder's syndrome 19.71–2
- Schoengastia* 38.50
- schoolchildren, infections (skin) 8.3
- schools, epidemic hysteria 64.25–6
- Schöpf-Schulz-Passarge syndrome 15.52, 19.111, 53.18
- Schwann cells, microscopy 10.35
- schwannoma 56.46–7
- ancient 56.46
- cellular 56.47
- epithelioid 56.47
- glandular 56.47
- malignant 56.53
- melanotic 56.47
- neuroblastoma-like 56.47
- pacinian 56.47
- pinna 68.28
- plexiform 56.47
- Sci-70 antibodies 51.104
- SCID see severe combined immunodeficiency (SCID)
- Scl-70 (topoisomerase 1), localized scleroderma 51.74
- SCLE see subacute cutaneous lupus erythematosus (SCLE)
- SCLE-like marginally scaled erythema 51.135
- sclerae, blue 45.34, 45.40, 45.41
- scleredema see scleroedema
- scleredema diabeticorum 59.79
- sclerema neonatorum 17.38–9, 46.16
- scleroatrophic syndrome of Huriez 45.12
- scleroatrophy, keratoderma with 19.94, 19.99–100

- scleroderma 51.64  
 aetiology 51.64–5  
 bone and joint involvement 62.101, 62.103  
 chemical-induced 45.51–3, 75.43  
 in children 51.71  
 collagen formation 12.31  
 drug-induced 45.52, 75.42–3  
 exogenous/iatrogenic 51.81–3  
 drug-associated 51.81  
 induced by silicone or paraffin implants 51.82  
 occupational 27.16, 27.17  
 paraneoplastic 62.40  
 pigmentation changes 58.26  
 in pregnancy 8.12  
 pseudoscleroderma 51.79, 51.120  
 respiratory tract involvement 62.80, 62.82  
 scalp 66.48  
 silicone breast implants and 51.82, 70.7  
 silicosis and 51.80  
 skin biopsy 10.42  
 systemic *see* systemic sclerosis  
 Thibierge–Weissenbach type 47.14  
 vasculitis and 50.48  
*see also* morphoea  
*Scleroderma domesticum* 38.14  
 scleroderma-like lesions  
 resulting from epoxy resin 51.80  
 resulting from organic solvents 51.80  
 resulting from pesticides 51.80  
 sclerodermatomyositis, in childhood 51.126  
 sclerodermiform reactions, vitamin K/B<sub>12</sub> 28.44–5  
 scleroedema 51.118–20  
 aetiology 51.118  
 associated conditions 51.119  
 of Buschke 51.79  
 clinical features 51.119  
 differential diagnosis 51.120  
 histology 51.118  
 metachromasia 51.119  
 treatment 51.120  
 scleroedema (of Buschke) 30.12, 62.45  
 scleroma (rhinoscleroma) 30.51–3, 69.121  
 scleromalacia perforans 51.131  
 scleromyxoedema 51.79, 59.21–3, 62.45  
 bone and joint involvement 62.101, 62.105  
 respiratory tract involvement 62.83  
 scleromyxoedema-like illness of renal disease *see* nephrogenic systemic fibrosis  
 sclerosants 47.38  
 sclerosing lipogranuloma *see* lipogranuloma, sclerosing  
 sclerosing lymphangitis, male genital dermatology 71.14  
 sclerosis, definition 5.8  
 sclerotherapy  
 varicose veins 47.24, 47.38  
 venous malformations 18.71  
 sclerotic cells 36.75, 36.76  
 sclerotic fibroma 56.3  
 SCN9A gene mutations 47.9  
 SCOFF questionnaire 64.22  
 Scoggins type dyskeratosis congenita 15.36  
 scolex 37.24  
 Scolioidea 38.14  
 scombroid fish poisoning, flushing 43.16  
 scopolamine 26.46  
*Scopulariopsis brevicaulis*  
 identification 36.8  
 onychomycosis due to 36.53–4  
 SCORAD (scoring atopic dermatitis) 64.10  
 scorbutus, deficiency *see* vitamin C  
 Scorpiones (scorpions) 38.33  
 scorpionfish 38.59  
 SCORTEN prognosis score 76.18–19  
 Scotchcast boot 47.57  
 scratch prurigo *see* dermatographism  
 scratching 21.1, 21.2, 21.5  
 arthropod bites/stings 38.3  
 measurement 21.2  
 in palpation of lesions 5.18  
*see also* pruritus  
 screening 6.19  
 scrofuloderma 31.8, 31.10, 31.14–15, 31.28  
 ear involvement 68.20  
 following BCG vaccination 31.29  
 histopathology 31.9  
 perianal/perineal dermatology 71.95  
 scrotal angiokeratomas 71.12  
 scrotal cancers 71.43–4  
 squamous cell carcinoma 52.25  
 scrotal carcinoma 27.15–16, 52.4  
 scrotal tongue *see* tongue  
 scrotum  
 acute 71.28  
 angiokeratoma of Fordyce 18.59  
 biopsy 10.32  
 blue scrotum sign 62.65  
 calcinosis 59.69, 71.35–6  
 candidiasis 36.62  
 ‘dirty’ brown spots 35.33  
 gangrene 71.15  
 lichen simplex 9.14, 71.16  
 scrub itch 38.50–1  
 scrub typhus 38.50  
 scumpox 33.17  
 scurvy *see* vitamin C, deficiency  
 scutula 36.27  
 Scyphozoa 38.56  
*Scytalidium*  
 diagnosis 36.8  
 differential diagnosis 36.31  
 infection caused by 9.12, 36.51–3  
 SD (standard deviation) 7.17  
 SDZ ASM 981 *see* pimecrolimus  
 SE (standard error) 7.18–19  
 sea anemones 38.55–8  
 sea bathing 28.55  
 sea chervil 38.58  
 sea mats 26.10, 38.58  
 sea urchins 38.58–9, 61.22  
 seabather’s eruption 37.22, 38.56  
 seal bites 38.61  
 seal finger 38.61  
 seasonal allergic conjunctivitis (SAC) 67.15  
 clinical features 67.13  
 seatworm 37.13–14  
*see also* *Enterobius vermicularis*  
 sebaceoma 53.15–17  
 sebaceous activity, in late childhood and puberty 8.2  
 sebaceous adenitis, neutrophilic 50.62–3  
 sebaceous cells *see* sebocytes (sebaceous cells)  
 sebaceous cyst 52.45  
*see also* epidermoid (‘sebaceous’) cysts  
 sebaceous duct 42.1  
 development 42.3  
 hypercornification, in acne 42.22, 42.23, 42.24  
 sebaceous glands 3.1, 42.1–89, 44.2, 66.2, 66.3  
 acini 42.1  
 acne *see* acne vulgaris  
 activity  
 excess, in acne 42.20  
 inhibition 42.15–17  
 isotretinoin reducing 42.58  
 measurement 42.7–9  
 adenoma 42.87, 53.15–17, 68.28, 69.23  
 ageing and 8.24, 80.1  
 androgen metabolism and enzymes for 42.10  
 carcinoma 42.87–8, 53.15, 53.17–18, 67.10  
 ear 68.34  
 eyelids 67.35–6  
 cell culture 42.12  
 cell dynamics 42.1, 42.3  
*see also* sebocytes  
 development 3.5, 42.3  
 distribution 42.1–2  
 ear 68.1  
 ectopic (Fordyce spots) 42.1, 42.86, 45.21, 69.2, 69.5, 69.22–3  
 embryology 3.3  
 endocrine control of activity 42.9–14, 42.76  
 acne aetiology and 42.20–2  
 adrenocortical hormones 42.11  
 androgens 42.9–11, 42.12  
 in cell culture 42.12  
 oestrogens 42.12  
 pituitary hormones 42.11–12  
 in pregnancy and lactation 42.12  
 progesterone 42.11  
 eyelids 67.2  
 free/unrelated to hair follicles 42.1  
 functions 42.6–7  
 histochemistry 42.3–5  
 homogeneous/heterogeneous outflow 42.21  
 hyperplasia 42.86–7  
 female genital region 71.55  
 hypertrophy, ACTH causing 42.11  
 immunocytochemistry 42.3–5  
 inhibition of activity 42.15–17  
 isolation methods 42.8  
 mammals 42.2  
 mitotic activity 42.8  
 neonatal 17.2, 17.4–5  
 nipple 70.1  
 in pregnancy 8.10  
 prepubertal period 42.5, 42.9  
 proliferative regions 42.1  
 prominent 71.11  
 regulation 42.3  
 retinoid control of activity 42.14–15  
 secretion, measurements 42.7–9  
 size  
 decreased by oestrogens 42.12  
 estimation 42.8  
 isotretinoin reducing 42.14, 42.58  
 testosterone administration effect 42.10  
 species-to-species variations 42.8  
 structure 42.1–3  
 tumours 42.87, 53.15–18  
 multiple benign 53.15  
*see also* sebaceous glands, carcinoma  
 ultrastructure 42.3–5  
 vitamin E secretion 42.7  
 sebaceous glands of Zeis 67.2  
 sebaceous keratoacanthoma 53.15  
 sebaceous naevus of Jadassohn *see* naevus, sebaceous  
 sebaceous naevus syndrome (epidermal naevus syndrome) 18.27–30, 54.11  
 sebaceous pilosebaceous unit 3.13  
 sebocystomatosis *see* steatocystoma multiplex  
 sebocytes (sebaceous cells)  
 activity, inhibitors 42.15–17  
 apoptosis 42.15  
 cell culture, isotretinoin effects 42.58  
 dynamics 42.1, 42.3  
 hormonal actions 42.10–12  
 in cell culture 42.12  
 immortalized 42.12, 42.14  
 isolation methods 42.8  
 keratin expression 42.12  
 lipids 42.3, 42.5  
 surface, changes between birth and puberty 42.5–6  
 lipogenesis 42.5  
 hormonal control of 42.10, 42.11, 42.12  
 maturation prolonged by isotretinoin 42.14  
 neurohormones targeting 42.4  
 prepubertal 42.3–4  
 proliferation 42.1  
 glucocorticoids stimulating 42.11  
 reduced by retinoids 42.14  
 5 $\alpha$ -reductase isoform 42.10  
 terminal differentiation 42.3, 42.15  
 testosterone synthesis 42.12  
 ultrastructure 42.3–5  
 sebometer 42.7  
 seborrhoeic dermatitis 23.32, 36.14  
 seborrhoea 42.79  
 acne vulgaris aetiology 42.20–2, 42.30  
 following spinal cord injury 63.17  
 isotretinoin 74.34  
 Meibomian 67.7, 67.11  
*see also* sebum, excess production  
 seborrhoeic dermatitis 23.29–34, 64.47  
 in adolescence 8.7  
 aetiology 23.29–30  
 in candidiasis 36.64  
 clinical features 23.30–2  
 dandruff and 23.29, 23.30  
 definition 23.29  
 diagnosis 23.32  
 differential diagnosis 26.29  
 perioral dermatitis vs 43.11  
 rosacea vs 43.5  
 secondary syphilis vs 34.12  
 in dogs 2.14  
 ear 68.14, 68.23, 68.28  
 elderly people 8.28  
 eyelids 23.11  
 face 23.31  
 female genitalia 71.52, 71.58  
 flexures 23.31–2  
 following spinal cord injury 63.17  
 histopathology 23.30  
 in HIV infection 23.29, 23.30, 23.32, 35.15–16, 68.28  
 haemophilias and drug abusers 35.45  
*Malassezia* and 36.13  
 incidence 23.29  
 infantile 17.28–31, 23.29, 23.34, 24.22, 24.26  
 Langerhans’ cell histiocytosis vs 55.9  
 light-exacerbated 29.22  
 differential diagnosis 29.12  
*Malassezia* and 17.29, 23.29, 23.30, 36.13, 66.56  
 male genital region 71.18  
 morphological variants 23.30  
 parkinsonism and 23.29  
 perianal/perineal dermatology 71.84  
 petaloid 23.31  
 pityriasisform 23.31  
 pityriasis rosea vs 33.80  
 psoriasiform 17.31, 23.31  
 psoriasis and 23.32  
 race and 9.6  
 refractory, HIV infection 35.16  
 scalp 23.30, 66.56–7  
 treatment 23.32–3  
 pimecrolimus 73.32  
 tacrolimus and Kaposi’s sarcoma 35.36–7  
 trunk 23.31  
 seborrhoeic keratosis 52.38–9  
 aetiology and incidence 52.38  
 breast 70.15, 70.16  
 clinical features 52.38–9  
 compound melanocytic naevi vs 54.19  
 cystic 52.39  
 differential diagnosis 52.38, 52.39  
 early SCC vs 52.39  
 eruptive 62.32  
 eyelids 52.39, 67.33  
 laser therapy 78.10, 80.11  
 malignancies associated 52.38  
 melanoma vs 54.38  
 number and size, age-related increase 52.38  
 pathology 52.39  
 pinna 68.28  
 solid variant 52.39  
 treatment 52.39  
 seborrhoeic warts *see* seborrhoeic keratosis  
 sebotrophic factor 8.10  
 sebum  
 in adolescence 8.6, 8.7  
 ageing effects 8.24

- analysis difficulties 42.5  
biological significance 42.27  
biosynthesis 42.5–6  
  *see also* sebum, production  
cholesterol 42.5  
composition 42.5–6  
  in acne 42.22  
  changed by diet/hormones/drugs 42.6  
excess production  
  in acne 42.20, 42.79  
  mechanisms 42.20  
  *see also* seborrhoea  
excretion rate (SER) 42.7, 42.8, 42.22  
  acne aetiology and 42.21, 42.22  
  acromegaly 42.22  
  oral drugs effect on 42.50  
formation 3.5  
functions 42.3, 42.6–7  
fungistatic action 42.7  
linoleic acid reduction, in acne 42.23, 42.26  
lipids 42.5, 42.5, 42.6  
  in acne 42.22, 42.23  
  synthesis regulation 42.12  
neonatal secretion 8.2, 17.2  
outflow obstruction, acne pathogenesis 42.24, 42.25  
in pregnancy 8.10  
production 42.5–6, 42.11  
  age-related changes 42.9–10  
  androgens controlling 42.9–11, 42.12, 42.20, 42.53, 42.79  
  eunuchs 42.10  
  interfollicular variation 42.21  
  measurement 42.7–9  
  men 42.10  
  menstrual cycle effect 42.11  
  in rats vs humans, rates 42.8  
  reduced by all-*trans*-RA 42.14, 42.15  
  reduced by antiandrogens 42.53  
  reduced by isotretinoin 42.14  
  topical drugs affecting 42.40  
  women 42.10  
in seborrhoeic dermatitis 23.29  
triglycerides 42.5, 42.6, 42.22  
vacuoles 42.3  
volume, at birth and adults 42.9  
sebum-absorbent tape (Sebutape®) 42.8  
sebum excretion rate (SER) *see* sebum  
Sebutape® 42.8  
secondary care 6.15  
secosteroids 73.43–8  
Secretan's syndrome 64.37  
Secrétan's syndrome 48.13  
secretory granules 13.4  
secretory leukocyte protease inhibitor 14.3  
secretory protease inhibitor 4.5  
SED (standard erythema dose) 29.4  
sedatives 75.80–2  
sedentary lifestyle, cellulite and 46.10  
sedge pool itch 37.22  
seed ticks 38.35  
SEER programme 54.32  
segmental Hailey–Hailey disease 39.37  
segmental neurofibromatosis 15.20  
Seidlmayer's syndrome (acute haemorrhagic oedema of childhood/infancy) 17.33–4, 49.18–19, 50.30  
Seldinger-type retrograde aortography 47.4  
selectin family 12.70–2  
selectins  
  E-selectin, deficiency 13.9  
  L-selectin 13.4, 13.9, 58.26  
  neutrophils 12.22  
  P-selectin 13.4  
  in wound healing 14.3  
selective serotonin reuptake inhibitors (SSRIs) 64.20, 64.50  
  adverse effects 64.50, 75.79–80  
  doses and indications 64.50  
  in erythromelalgia 47.10  
  psychocutaneous disorders  
  body dysmorphic disorder 64.20  
  pruritus 64.23–4  
  skin picking 64.28  
  trichobezoar 64.32  
  *see also* antidepressants  
selenium disulphide 73.13  
selenium metabolism 59.76  
selenium sulphide  
  in dermatophytoses 36.49  
  indications 73.13  
  in pityriasis capitis 66.56–7  
  in pityriasis versicolor 36.12  
selenium sulphide shampoo 73.13  
self-adhesive hydrocolloid dressings 73.4  
Self Administered PASI (SAPASI) 72.9  
self-destruct theory of Lerner, vitiligo 58.47  
self-efficacy 64.5  
self-esteem 64.5–6, 64.7  
self-flagellation 28.33  
self-harm 64.12, 64.45–6  
  in eating disorders 64.21  
  mouth ulcers and 69.43  
  repetitive 64.46  
  skin injury/disease in adolescents 8.7  
  substance P 12.66  
  suicidal ideation and 64.45–6  
self-healing epitheliomas 52.9–10  
self-help 6.14  
self-help groups 6.14, 64.7, 72.33–4  
self-inflicted skin injury/disease, adolescents 8.7  
self-mutilation  
  mouth ulcers and 69.43  
  *see also* self-harm  
self-reported skin disease 6.6  
semen, delayed hypersensitivity to 26.19  
semicircular lipoatrophy, mechanical injury 28.27  
semilunar valves 47.25  
Senear–Usher syndrome *see* pemphigus erythematosus (Senear–Usher syndrome)  
Sener syndrome 15.52  
senescence  
  of skin 8.21  
  *see also* ageing  
senile comedones *see* comedones  
senile haemangioma (venous lake) 47.16, 69.101  
senile lentiginos (age spots) 8.23, 54.3, 58.39  
senile orbital fat prolapse 67.5  
senile purpura 49.15  
senile warts *see* seborrhoeic keratosis  
senile xerosis *see* asteatotic eczema (eczema craquelé)  
Sensenbrenner syndrome 15.34, 15.91–2  
sensitive skin 25.2, 25.18–19  
  formulating products for 25.10  
sensitivity  
  analysis 7.9  
  clinical 26.12  
  to cold 28.65–71  
  latent 26.12  
  patch-test 26.12  
  threshold of 26.12  
  in xeroderma pigmentosum 15.72  
sensitivity factor attachment protein receptor (SNARE) 58.4  
sensitization  
  allergic contact dermatitis and 26.1, 26.5–6, 26.6–7, 26.9–10  
  assessment of potential 26.11–12  
  to earrings 68.7–8  
  following patch/photopatch testing 26.94–5  
  risk 26.12  
sensitizers/sensitizing agents  
  children 8.3  
  occupational 27.3, 27.18–21  
  in old age 8.28  
  topical 73.39–40  
  universal 73.39  
sensorineural hearing loss, enamel hypoplasia and nail defects 15.52  
sensory evoked potentials 63.5  
sensory functions of skin 4.1, 4.9–10  
  ageing effect 8.24  
sensory nerve endings, skin 3.2  
sensory perception, pressure ulcers 28.21  
sentinel node biopsy 54.51–2  
  atypical spitzoid tumours 54.25  
  breast cancer 48.8  
  malignant melanoma 54.39, 54.50, 54.51–2, 54.53  
  Merkel cell carcinoma 53.43  
  micrometastases, detection 53.43  
  squamous cell carcinoma in dystrophic EB 39.30  
separation artefact 10.30  
SEPs (sensory evoked potentials) 63.5  
sepsis, purpura fulminans 49.39–40  
septa 36.2, 36.3  
septal panniculitis *see under* panniculitis  
Septi-Check 31.6  
septicaemia  
  *Candida* 36.68  
  following ear piercing 68.7  
  meningococcal 30.44, 49.20, 62.105  
  *Pseudomonas* 30.49, 30.50  
  in toxic epidermal necrolysis 76.17–18  
SERCA2, in Darier's disease 39.32, 39.33  
serglycin 3.46  
serine–threonine kinase gene (*STK11/LKB1*) 58.12, 58.13  
serological tests, viral infections 33.4, 33.5  
seroma 48.29–30  
serotonin (5-HT) 38.1  
  carcinoid tumours 43.18  
  metabolic pathway 43.18  
  release during vascular injury 12.32  
serotonin antagonists, diarrhoea  
  management in carcinoid syndrome 43.18, 43.19  
*Serratia marcescens*, neutrophilic eccrine hidradenitis and 44.17  
sertaconazole, topical 73.12  
sertindole 64.52  
sertraline 64.50  
serum amyloid A (SAA) 13.4, 13.19  
serum amyloid P component (SAP) 59.42–3  
serum opacity factor 30.12  
serum sickness 22.7, 22.18, 75.17, 75.27–8  
  in hepatitis B virus infection 33.60, 62.59  
serum sickness-like syndrome 22.18  
Serrville–Martorell syndrome 47.24  
sesquiterpene lactones 26.25, 26.75, 26.77  
*Sessinia* 38.27  
setae 38.28, 38.29  
Setleis' syndrome 15.40, 18.103, 45.6  
severe combined immunodeficiency (SCID) 13.13, 17.49–50, 17.57–60, 69.117  
  mouse model 2.14  
  mutations 13.8, 13.11  
  RAG-1/RAG-2 defects 13.8  
Severity Scoring in Atopic Dermatitis (SCORAD) 72.6, 72.9–10, 72.11, 72.14, 72.22  
Seveso 27.13, 75.162  
sex determination 8.2  
sex hormone(s) 74.32  
  female, melanoma and 54.56–7  
  therapeutic 74.32  
sex hormone-binding globulin (SHBG) 42.53, 66.14, 66.81  
sex hormone-related conditions, hair loss in, in animals 2.18  
sex-linked genes  
  chromosomal abnormalities 15.12–14  
  definition 15.4  
sexual abuse  
  differential diagnosis 51.117  
  female genital dermatology 71.57  
  Kobner phenomenon 51.117  
  mechanical injury 28.34, 28.37–8  
  perianal/perineal dermatology 71.84  
  *see also* child abuse  
sexual contacts  
  management in gonorrhoea 34.28  
  management in syphilis 34.23  
sexual development 8.2–3, 8.3  
  delayed 8.3  
sexual dysfunction, following spinal cord injury 63.17  
sexually transmitted infections (STIs) 34.1–37  
  adverse pregnancy outcomes 34.1  
  chancroid 34.34–5  
  child sexual abuse 28.37–8  
  chlamydial *see* chlamydial infections, genital  
  donovanosis 34.36–7  
  female genital dermatology 71.70–2  
  global burden 34.1  
  gonorrhoea *see* gonorrhoea  
  herpes simplex 33.15, 33.16, 33.17  
  incidence 34.1  
  lymphogranuloma venereum 34.23–34  
  male genital dermatology 71.33–5  
  perianal/perineal dermatology 71.83, 71.93–5  
  screening, in syphilis management 34.22  
  syphilis *see* syphilis  
  treatment and prevention 34.1, 34.2  
  *see also individual infections*  
Sézary cells, in erythrodermic chronic actinic dermatitis 29.18  
Sézary syndrome 57.17–22  
  atopic dermatitis and 24.25  
  clinical features 57.17  
  defined 57.17  
  dysregulated T-cell signalling pathways 57.21  
  electron microscopy 10.30  
  erythroderma and 23.48  
  in HIV infection 35.41  
  immunopathology 57.10, 57.17–18  
  molecular pathogenesis 57.19  
  abnormalities of T-cell activation 57.20  
  pruritus in 21.10, 21.11  
  specific chromosomal abnormalities 57.20  
  treatment 57.22–9  
  *see also* mycosis fungoides  
Shabbir's syndrome 39.15  
shagreen patches 15.22, 18.31  
shake lotions 73.2  
shale tars 73.42  
shammah 69.50  
shampoos 66.96  
  antieczema 29.22  
  formulations 66.96  
  medicated 26.18  
  in pityriasis capitis 66.56–7  
  safety 66.96  
  in seborrhoeic dermatitis 23.32–3  
sharks 2.2  
shave therapy, venous leg ulcers 47.51  
shaving, wart transmission 33.40  
SHBG (sex hormone-binding globulin) 42.53, 66.14, 66.81  
Shea butter 73.6  
shear force, pressure ulcers 28.17, 28.21  
sheep nostril fly 38.9  
sheep shearing, breast disorders associated 70.15  
sheep tick 38.34, 38.35  
sheet metal workers, occupational hazards 27.20  
shell nail syndrome 65.8  
SHFM (split-hand split-foot syndrome) 15.61, 15.65  
Shimpo's syndrome *see* POEMS syndrome  
shingles *see* zoster  
shoemakers, occupational hazards 27.21  
shoes *see* footwear

- shop assistants, occupational hazards 27.21
- short anagen syndrome 66.27
- short-arm deletion syndromes 15.12
- short bowel syndrome
- biotin deficiencies 59.64
  - genitocrural dermatology 71.7
- short stature 8.3
- disorders associated 8.3
  - Langerhans' cell histiocytosis 55.12
  - pituitary 62.3
  - with premature ageing and pigmented naevi 45.60
- short-limbed dwarfism with immunodeficiency 17.64–5
- syndromes of 8.3
- SHORT syndrome 46.37
- shoulder, surgical excision in area 77.15
- shrinking lungs syndrome 62.82
- Shulman's syndrome 51.86
- Shwachman-(Diamond) syndrome 17.75
- ichthyosiform erythroderma in 19.61
- sialidosis 59.32, 59.34
- prenatal diagnosis 16.3
- Siamese fighting fish 13.31
- SIAoscopy (spectrophotometric image analysis of pigmented lesions) 5.20
- Siascope 54.38
- Siberian tick typhus 38.34, 38.35
- sibutramine 75.89
- Sicariidae 38.31, 38.32
- sick building syndrome 64.26
- sick-cell syndrome 45.23
- sickle cell disease 62.85–6
- leg ulceration 47.56, 49.47
  - oral involvement 69.116
  - pigmentation in 58.53
  - race and 9.12
  - treatment 49.47
  - venous leg ulcers 47.43
- sickness behaviour 64.8
- Sickness Impact Profile (SIP) 72.16
- sickness role 64.35–6
- SIFT (skin integrity function test) 25.9
- 'sign of the groove' 34.33
- signal recognition particle (SRP) 51.128
- signalling
- imiquimod and Toll-like receptors 73.24
  - innate immunity and antimicrobial peptides 3.16, 3.17
  - Langerhans' cells migration 55.4
  - melanocyte development 58.3
  - melanocytes 3.21
  - skin development 3.3–5
  - stem cells 3.6–7
- 'signature' mutations 52.13
- signe de la bandera* 66.94
- sildenafil 75.99
- flushing associated 43.15
- silicates, sarcoidal reaction to 61.22
- silicon dioxide 27.17
- silicone
- foreign body reactions to 28.46
  - organic 25.21
  - panniculitis due to 46.28
- silicone breast implants 51.82, 51.90, 51.111, 70.7–8
- foreign body reactions 28.46
  - scleroderma 51.82
- silicone gels and dressing 73.51
- silicosis, associated with scleroderma 51.80
- silver
- pigmentation due to 58.54
  - see also* argyria
- silver acetate 58.54
- silver nitrate 73.16, 77.47, 77.50
- hair dye 66.97
  - wart treatment 33.49
- silver sulfadiazine 14.11, 14.21, 73.11, 74.39, 75.166
- burns 28.85–6
  - epidermolysis bullosa management 39.28
- 'silvery hair' syndrome 58.42
- Simonart's bands 69.37
- simple lymphatic drainage (SLD) 48.23
- simulation of skin disease 64.42–3
- Simuliidae (blackflies) 37.4, 38.5–6, 38.7
- Simulium* 38.5–6, 38.7
- skin disease in animals 2.11
- simvastatin 75.156–7
- Sindbis virus 33.66, 33.67
- single-gene disorders *see* genodermatoses
- single nucleotide polymorphism 11.7, 11.13, 11.15
- sinus(es)
- acne vulgaris 42.31, 42.32
  - anogenital pilonidal 28.49–50
  - barber's hair 28.49
  - branchial (cervical) 18.85–6
  - cloacal 71.83
  - definition 5.8
  - dental 42.37
  - dermal
    - congenital 63.16
    - dorsal 18.95–6
  - dermoid, congenital 18.88–9
  - dorsal dermal 18.95–6
  - genitoperineal raphe 18.94–5
  - hair, of breast 70.15
  - hair as a foreign body 28.49–50
  - lips 18.3, 18.90–2, 69.40–1
  - milker's 28.49
  - pilonidal 71.87, 71.88, 71.101, 78.12
  - preauricular 18.83–4, 68.4
  - pressure ulcers 28.20
  - umbilical-urachal 18.94
- sinus histiocytosis with massive lymphadenopathy (SHML; Rosai-Dorfman disease) 55.29–30
- extranodal 55.29
  - with neutrophilic predominance 50.62
  - pure cutaneous 55.29
- sinusoidal haematolymphoid malignancy 55.32–3
- Siphonaptera *see* flea(s)
- Siphonophora 38.55
- Siphunculina* 38.6
- Sipple syndrome (MEN type 2A) 62.24
- Sipple's syndrome (multiple mucosal neuroma) 56.45
- sirolimus (rapamycin) 13.25, 74.25, 75.138
- sissoo 26.80
- Sister Mary Joseph's nodule 62.18, 62.66
- Sistrunk procedure 48.25
- sitosterolaemia 59.91
- Six Area Six Sign Atopic Dermatitis (SASSAD) score 72.10
- Sjögren-Larsson syndrome (SLS) 19.3, 19.42–5
- prenatal diagnosis 16.3
- Sjögren's syndrome 51.134
- aetiology 51.134–5
  - annular erythema in 62.109
  - associated with SLE 51.138
  - in childhood 51.136
  - classification criteria 51.134
  - clinical features and pathology 51.135–6
  - diagnosis 51.137
  - with endocrine autoimmune conditions 62.13
  - hyperglobulinaemic purpura 51.136
  - immunity and 13.2
  - immunoglobulins in 13.7, 51.105
  - laboratory abnormalities 51.136–7
  - ocular involvement 67.25
  - ocular mucous membrane pemphigoid vs 67.20
  - primary biliary cirrhosis and 62.62
  - respiratory tract involvement 62.82
  - sarcoidosis and 61.7
  - in systemic sclerosis 51.105
  - treatment 51.137–8
  - chloroquine 51.138
  - vasculitis and 50.49, 50.52–3
- SJS *see* Stevens-Johnson syndrome (SJS)
- SKALP/elafin 3.10
- skeletal abnormalities
- genetics 15.17
  - ichthyosis and 19.61
- skeletal anomalies-ectodermal dysplasia-growth and mental retardation 15.53
- skeletonization, arteriovenous fistulae 47.21
- skin
- anatomy/organization 3.1–53
  - ageing effects 8.22–5
  - barrier function *see* barrier function of skin
  - blood supply 3.2, 3.3, 3.50–2
  - congenital localized absence (Bart's syndrome) 18.101, 39.17, 39.18, 39.22
  - corticosteroid-induced thinning 73.17
  - development *see* embryology, of skin
  - dimensions 3.1
  - functions 2.8, 3.2–3, 4.1–11
  - as immune system 2.8, 3.16–19
  - from infancy to old age 8.1–29
  - maintenance 3.5–7
  - objective assessment 72.11
  - psychological significance 64.1–2
  - regional variation 3.3
  - surface area, between birth and maturity 8.1
  - water content, changes with ageing 8.22, 8.27
- skin-ache syndrome 63.24
- skin appendage tumours 53.1–44
- see also* adnexal tumours
- skin-associated lymphoid tissue (SALT) 57.2
- skin bioequivalents, use in dystrophic EB 39.29–30
- skin biopsy 10.1–2
- actinic granuloma 45.29
  - actinic keratosis 10.42
  - amyloidosis 10.42
  - argyria 10.42
  - artefacts 10.7, 10.8, 10.30–1
  - atrophy 10.42–3
  - blue naevus 10.43
  - café-au-lait spots 10.42
  - connective tissue disease 10.42–3
  - consent to 10.2
  - contraindications 10.2, 10.3
  - curettage 10.4
  - dermal deposits 10.42
  - dermatitis artefacta 64.40
  - diagnostic 10.2
  - elliptical incisional/excisional 10.3, 77.11
  - epidermolysis bullosa 39.21, 39.24
  - fetal 16.5–7
  - freckles 10.42
  - frozen sections 10.6
  - fungal infection 10.42
  - granuloma annulare 10.43
  - haemochromatosis 10.42
  - ichthyosis vulgaris 10.42
  - indications 10.1–2
  - instruments 10.3
  - laboratory methods 10.6–11
  - leprosy 32.15
  - local anaesthesia 10.2
  - lymphoedema 48.19
  - mastocytoma 10.43, 22.34
  - mastocytosis 22.34
  - Mongolian spot 10.43
  - multiple 10.4
  - needle 10.4
  - peripheral neuropathy 63.11–12
  - pigmentary disorders 10.42
  - porokeratosis 10.42
  - punch biopsy 10.3–4, 50.12, 77.11–12
  - sarcoidosis 61.19
  - scalp 10.32, 10.43
  - scleroderma 10.42
  - sections revealing little/no abnormality 10.42–3
- shave biopsy 10.4, 77.12–13
- epidermolysis bullosa 39.24
  - site of 10.32–3
- specimens *see* tissue specimens
- techniques 10.3–4, 77.11–13
- telangiectasia macularis eruptiva perstans 10.43
- urticaria 10.43, 22.3, 22.26
- urticaria pigmentosa 10.43
- urticarial vasculitis 22.26, 50.22
- vasculitis 50.12
- vitiligo 10.42
- skin bleaching 58.38, 73.27
- vitiligo management (hyperpigmented areas) 58.49
- skin-bleaching preparations 9.8
- skin cancer
- acitretin chemoprophylaxis 74.36
  - in animals 2.19–20
  - comparison with humans 2.21
  - in elderly people 8.28–9
  - following chemotherapy 75.124
  - melanoma *see* melanoma, malignant
  - non-melanoma *see* non-melanoma skin cancer (NMSC)
  - occupational 27.15–16
  - registration data 6.6
  - see also specific cancers*
- skin cleansers, as irritants 25.20
- skin colour
- measurement 72.11
  - melanin *see* melanin(s)
  - non-melanin pigmentation 58.53–4
  - see also* pigmentation
- skin-derived precursors (SKPs) 3.7
- Skin Disorders Specialist Library 7.6
- skin equivalents 14.26
- in burns 14.11
- skin failure 4.1, 4.7
- skin flaps 77.23–8
- advancement 77.24–5, 77.28
  - axial pattern 77.23
  - bilobed 77.25
  - complications 77.26, 77.27
  - distant 77.23
  - free 77.23
  - interpolation 77.26, 77.27, 77.28
  - island pedicle 77.26, 77.28
  - local 77.23
  - nasolabial fold 77.25, 77.28
  - pedicle 77.26, 77.27, 77.28
  - random pattern 77.23
  - reticular 77.23
  - rotation 77.24, 77.25, 77.28
  - segmental 77.23
  - transposition 77.25, 77.26, 77.28
- skin flora *see* bacteria, flora (normal skin)
- skin fragility disorders *see* epidermolysis bullosa (EB)
- skin grafts 77.20–3
- acne scars 77.22
  - allografts 14.26
  - animal models 2.7–8
  - autografts 14.26
  - autologous split-thickness, in dystrophic EB 39.29
  - composite 77.20
  - dressings 77.17, 77.20
  - in dystrophic EB 39.29–30
  - epidermal 77.21
  - full-thickness 77.20, 77.21–2
  - hair 66.23–4
  - in vitro* culture *see* skin equivalents
  - lymphatic vessel role after 48.6
  - meshed 47.51, 77.20, 77.23
  - mini-grafts 77.21
  - pinch 14.25, 47.51, 77.20–1
  - punch 77.21, 77.22
  - split-skin 10.19, 14.25, 77.20, 77.23
  - venous leg ulcers 47.49, 47.51–2
  - in vitiligo 58.49, 77.21–2
- skin injury *see* mechanical injury; thermal injury
- skin integrity function test 25.9
- skin lightening agents 73.26, 73.27

- skin phototypes 29.6, 29.8  
 skin sensitivity *see* sensitivity  
 skin snips, in onchocerciasis 37.7  
 skin surface cooling 80.10–11  
 skin tags 52.40–1, 59.79, 62.58  
   female genitalia 71.72  
   peri-auricular 68.4  
   pregnancy 8.13  
 skin tension lines, scar orientation and 77.2, 77.11, 77.13  
 skin testing 5.22–4  
   delayed tests 5.24  
   drugs 75.168–73  
   *in vitro* 26.98, 75.173–5  
   intra-dermal/intracutaneous tests 5.22–4, 26.97  
     drugs 75.168–9  
   leukocyte procoagulant activity 26.98  
   lymphocyte transformation tests 26.98  
   migration inhibition test 26.98  
   modified prick test 5.23  
   patch testing *see* patch test  
   photopatch test 26.84, 26.93–4, 29.24  
   complications 26.94–5  
   cosmetics 26.49  
   indications 26.93  
   protocols 26.93  
   readings 26.94  
   test materials 26.94  
 pre-employment 27.8  
 prick test 5.23, 13.16  
   anaphylaxis and 22.26  
   in atopic dermatitis 24.10–11  
   drugs 75.168–9  
   to food 26.106  
   occupational dermatoses 27.7  
   oral allergy syndrome 22.20  
   urticaria 22.19, 22.26  
 repeat open application tests (ROAT) 26.49, 26.97  
 scratch test 5.23  
   to food 26.106  
 skin window technique 5.23  
 spot tests 26.99  
   in urticaria 75.173  
   usage tests 26.97  
 skin thickening  
   lymphoedema 48.8, 48.14, 48.17  
   mechanical injury 28.28  
 skin thickness  
   in irritant contact dermatitis 25.22  
   measurement 72.11  
 Skindex 72.17, 72.18  
 Skindex-29 64.10  
 skinfold thickness 46.5  
 skin-psyche interactions 64.3–4  
 SLAM (CD150), measles virus receptor 33.75  
 SLAM-associated protein 13.6  
 'slapped cheek' appearance (fifth disease) 5.10, 33.62, 33.63  
   *see also* parvovirus B19 infection  
 SLC24A5 gene 3.20  
 SLD (simple lymphatic drainage) 48.23  
 SLE *see* systemic lupus erythematosus (SLE)  
 sleeping sickness (African trypanosomiasis) 37.2, 37.29–31  
 slit-skin smear  
   in leishmaniasis 37.38  
   in leprosy 32.15  
   in post-kala-azar dermal leishmaniasis 37.42  
 SLP-76 deficiency 48.2  
 SLS *see* Sjögren–Larsson syndrome (SLS)  
 Smad-4 3.4  
 Smad-7 3.4  
 Smad protein family 14.3, 14.7, 14.8, 51.65  
 small proline-rich proteins (SPR1) 3.10  
 small vessel vasculitis 12.32, 62.82  
 smallpox (variola) 33.5, 33.6  
   diagnosis 33.5  
 smear tests, vaginal discharge 71.53  
 Smith–Lemli–Opitz syndrome, prenatal diagnosis 16.3  
 smoker's keratoses 69.90  
 smoker's melanosis 69.96  
 'smoker's patches' 41.9  
 smoking 20.4  
   acne and 42.34–5  
   actinic elastosis and 45.27  
   cessation, claudication treatment 47.5  
   cigars 69.90  
   cold-induced injury 28.64  
   hair colour and 66.95  
   male genital dermatology 71.40  
   mechanical injury 28.8  
   oral keratoses and 69.90  
   oral melanosis and 69.96  
   pigmented melanotic macules 54.6  
   pipes 69.90  
   reverse 69.90, 69.96  
   skin ageing and 80.2  
   skin flap necrosis and 77.26, 77.27  
   telangiectases due to 47.13  
   ulcerative colitis and 50.66  
   wound healing and 14.19  
   wrinkles and 45.2  
 smooth muscle  
   hyperplasia 47.52  
   origin 12.30  
 smooth muscle cells  
   arteriole walls 3.51  
   microscopy 10.35  
 snake(s) 2.9  
   epidermis 2.3  
   glands 2.4  
   mites 38.51  
   skin infections 2.12  
 snake bites 38.60  
 snake envenomation 48.5  
 snakehead 31.31  
 SNARE 58.4  
 Sneddon's syndrome 49.42–4, 50.54  
   clinical features 49.43  
 Sneddon–Wilkinson disease *see* subcorneal pustular dermatosis  
 snip excision 77.34  
 snipe flies 38.6  
 'snow nose' 2.23  
 snowflake sign 16.7  
 SNP (single nucleotide polymorphism) 11.7, 11.13, 11.15  
 snuff-dipper's keratoses 69.90  
 'snuffles,' congenital syphilis 34.15  
 soap  
   avoidance in atopic dermatitis 73.31  
   as irritant 25.20  
   soap substitutes 23.21, 25.25, 73.31  
 Social Exclusion Theory 64.7  
 social factors  
   in diagnosis 5.5  
   venous leg ulcers 47.43–4  
 socio-economic status  
   allergic contact dermatitis and 26.10  
   risk factor for skin disease 6.12  
   syphilis and 34.2  
 sociocultural factors 64.1–2, 64.6, 64.7, 64.18  
 sociosexual communication 4.11  
 soda ash 25.20  
 sodium, in sweat 44.5–6  
 sodium aurothiomalate 74.29–30  
   flushing associated 43.15  
   *see also* gold therapy  
 sodium benzoate 22.26, 25.18, 75.159  
 sodium bicarbonate, in acid burns 27.12  
 sodium carbonate 25.19  
 sodium cromoglycate  
   adverse effects 26.46, 75.99  
   in atopic eye disease 67.15  
   in mastocytosis 22.35  
   mechanism of action 73.51  
   topical therapy 73.51–2  
 sodium hydroxide  
   burns due to 27.12  
   as irritant 25.19, 25.20  
 sodium hypochlorite 25.21  
 sodium lauryl sulphate 25.3, 25.4–5  
   preservatives with 26.50  
   skin irritation thresholds 25.25  
 sodium silicate 25.20  
 sodium stibogluconate 37.39  
 sodium tetrachlorophenate 27.13  
 sodium tetradecyl sulphate (STD) 47.39  
 sodium thiosulphate 49.48  
 sodium valproate 64.52  
   adverse effects 75.86  
   scleroderma 45.52  
   in zoster and post-herpetic neuralgia 33.28  
 sodoku 30.67  
 soframycin, topical 73.10  
 soft palate 69.2  
 soft sore *see* chancroid  
 soft-tissue fillers 75.156  
 soft-tissue infections, HIV infection 35.24  
 soft-tissue tumours 56.1–62  
 soft warts *see* skin tags  
 solar comedones, acne with 42.79  
 solar elastosis, in rosacea 43.4  
 solar keratosis *see* actinic keratosis  
 solar lentigo *see under* lentigines  
 solar purpura 49.17  
 solar simulated radiation (SSR) 29.5  
 solar urticaria (SU) 22.13, 22.16–17, 29.10, 29.19–20  
   clinical features 29.10, 29.19, 29.23  
   definition and aetiology 29.19  
   diagnosis 29.10, 29.23  
   differential diagnosis 29.10, 29.12, 29.23  
   fixed 29.19  
   idiopathic 29.19  
 Solenopsis (fire ant) 38.14  
 soles  
   biopsy 10.32  
   hairy malformation 18.14  
   hyperpigmentation 9.2, 9.3  
   juvenile plantar dermatosis 23.26  
   lichen nitidus 41.22  
   lichen planus 26.29, 41.7, 41.8, 41.14  
   melanocytic naevi 54.17–18  
   melanoma 54.44, 54.45  
   psoriasis 20.15  
   seed-like keratoses 62.33  
   vesicular eczema *see* pompholyx  
   warts *see* wart(s), plantar  
 solid phase assays 13.19  
 solitary epithelioid histiocytoma 55.23, 55.24  
 solitary plaque-like telangiectatic glomangioma 47.20  
 soluble N-ethylmaleimide-sensitivity factor attachment protein receptor (SNARE) 58.4  
 soluble oil dermatitis 27.4, 27.5, 27.6  
 somatic mutation theory 52.10  
 somatic mutations 15.5  
 somatostatin 4.10  
   in atopic dermatitis 24.17  
   effects 12.64–5  
   growth and 8.2  
   in psoriasis 20.42  
 somatotrophin *see* growth hormone  
 sonic hedgehog (Shh) 3.4, 53.2  
   hair growth and 66.10  
 soot, carcinogenicity 27.15–16  
 sorafenib 75.132  
 sorbic acid 25.18, 26.58, 73.8  
 sores, pressure *see* pressure ulcers  
 sortography, Seldinger-type retrograde 47.4  
 SOS1 gene 15.15  
 Southern blotting 11.5–6  
 Southern tick-associated rash illness 38.35  
 sowda 37.5  
 Sox10/SOX10 gene 58.3  
   mutation 2.7  
   Waardenburg's syndrome 58.44  
 SOX18 mutations 48.10  
 soybean oil 38.5  
 Sp1 14.6  
 Spantopsis 38.6  
 Spanish fly *see* cantharidin  
 Sparassidae 38.32  
 spargana 37.26–7  
 sparganum proliferum 37.26  
 SPCA1 39.32, 39.35  
 spearmint oil 26.17  
 specialized burns units 28.80, 28.82  
 specialized support systems 28.20, 28.22  
 specific granules 13.4  
   deficiency 12.23  
 SPECT, invasive otitis externa 68.26  
 spectacle-frame acanthoma 28.29–30, 68.9  
 spectacle frames, dermatitis 26.16, 26.17  
 spectinomycin 74.42  
 spectral irradiance 29.3  
 spectrophotometric image analysis of pigmented lesions 5.20  
 spectroradiometer 29.3  
 spermatogenesis 8.4  
   drug effects on 75.11  
 SPF *see* sun protection factor (SPF)  
 spheroids 45.33  
 spherules 36.85  
 spherulin 36.86  
 sphingolipidoses, classification 59.33  
 sphingolipids 4.2  
 spices, as irritants 25.21  
 spicules 38.28  
 spider angioma 47.14–15, 47.20, 62.64, 78.7  
   in pregnancy 8.10, 47.14, 47.15  
 spider mites 38.48  
 spiders 38.30–3  
 Spiegler–Fendt sarcoïd 57.59  
   differential diagnosis 51.7  
 Spiegler's tumour 53.28–9  
 spina bifida 18.95, 18.96, 63.15–16  
 spinal accessory nerve 77.3–4  
 spinal cord  
   development 63.15  
   implantable stimulator 47.8  
   injury 44.9, 63.17  
   pressure ulcers 28.17  
   tethering 63.15  
 spinal dysraphism 18.95–8, 63.15–17  
 spinal muscular atrophy, with autosomal recessive EB simplex 39.8  
 spindle and epithelioid cell naevus *see* naevus, Spitz  
 spindle cell carcinoma 97.18  
 spindle cell naevus of Reed 54.22, 54.23  
 spindle cell tumours, Kaposi's sarcoma 35.36  
 spines  
   animals 2.3  
   caterpillar 38.29  
   sea urchin 38.58  
 SPINK5 gene 12.25, 24.4, 66.65  
 Netherton's syndrome 12.25, 12.50  
 spinous layer 3.1  
 spiny dogfish 38.59  
 spiradenocarcinoma 53.34  
 spiradenoma 53.2, 53.29–30  
   cylindroma overlap 53.29  
   eccrine 53.29–30  
   malignant 53.30, 53.34  
 spiramycin 75.58  
 Spirillum minor 30.62, 30.67  
 spirochaetes 30.62–6  
   *Treponema pallidum see Treponema pallidum*  
   *Treponema pallidum* differentiation 34.4  
 Spirometra 37.16, 37.24, 37.26–7  
 spironolactone 74.32  
   in acne vulgaris 42.53  
   adverse effects 26.46, 42.53, 70.4, 70.5, 75.97  
   in androgenetic alopecia 66.25  
   in hirsutism 66.88  
   sebaceous gland activity inhibition 42.16  
 spitting cobra 38.60  
 Spitz naevus *see* naevus, Spitz  
 Spitz tumour *see* naevus, Spitz  
 spitzoid tumour, atypical 54.21, 54.25, 54.25  
 spleen, role in immunity 13.8

- splenectomy, idiopathic thrombocytopenic purpura 49.10
- splenomegaly  
in myeloproliferative disorders 49.29  
thrombocytopenia due to 49.11–12
- splinter haemorrhage 65.15, 65.18  
nails 3.15  
in psoriasis 65.24–5
- split-hand split-foot (SHFM) syndrome 15.61, 15.65
- split-skin technique 10.19, 14.25, 77.20, 77.23
- spondylitis, ankylosing *see* ankylosing spondylitis
- sponges 38.59
- spongiosis 10.41, 23.1  
in eczema 23.3–4  
eosinophilic 40.11, 40.15  
in irritant contact dermatitis 25.4  
neutrophilic 50.63, 50.89, 50.90  
in seborrhoeic dermatitis 23.30
- spontaneous gangrene 71.100
- spooning 49.16, 62.85
- sporangiophore 36.3
- Sporothrix schenckii* 36.70, 36.71–2
- sporotrichosis 36.70–2  
aetiology 36.70  
clinical features 36.70–1  
cutaneous 36.70–1  
definition 36.70  
differential diagnosis 36.71  
fixed 36.71  
histology 36.70, 36.71  
in HIV infection 35.26, 35.34  
laboratory diagnosis 36.71–2  
lymphangitic 36.71  
systemic 36.70, 36.71  
treatment 36.72
- sports injuries, mechanical injury 28.30–2, 28.53–6
- spotted fevers 30.73–4
- Spreng/Sprouty family, proteins 48.2
- spruce 26.81
- spurge 25.21, 26.16
- 'spy in the tube' 72.5
- squalene  
in sebum 42.5, 42.22  
in acne 42.22, 42.23  
toxicity 73.12
- squalene epoxidase 73.12
- Squalus acanthias* 38.59
- squamous cell carcinoma (SCC) 52.2, 52.24–9  
actinic keratosis progression 52.29, 52.30, 52.31  
aetiology 52.24  
after chemotherapy 75.124  
aggressive cutaneous, management 52.27, 52.28  
alleleotype analysis 52.12  
anaplastic 52.26  
basal cell carcinoma ratio 52.2, 52.26  
Bowen's disease progression 52.27, 52.29  
burns 28.91  
canine 2.19  
chemical carcinogens 52.4–5  
clinical course 52.25  
clinical features 52.24–5  
*de novo* 52.26  
definition 52.24  
diagnosis 52.27  
differential diagnosis, keratoacanthoma vs 52.26, 52.27, 52.43  
diseases associated 52.24  
in dystrophic epidermolysis bullosa 39.17, 39.19, 39.30  
early 52.31  
seborrhoeic keratosis vs 52.39  
in epidermodysplasia verruciformis 33.57–8  
in epidermolysis bullosa  
dystrophic 39.17, 39.19, 39.30  
Herlitz junctional EB 39.12  
erythema ab igne and 52.24  
extension 52.26  
external auditory canal 68.32–3  
eyelids 67.35, 67.36  
feline 2.19  
female genital region 51.116, 71.63, 71.66, 71.76  
genetics 11.18, 52.12  
in Hailey–Hailey disease 39.35  
HIV infection and 35.39  
HPV infection and 33.55, 52.5–6, 52.6, 52.14  
immunosuppression for organ transplants and 52.26–7  
*in situ*, Bowenoid papulosis of genitalia as 52.37  
incidence 52.2, 52.24  
inflammatory reaction 52.25, 52.26  
intermediate stages not always found 52.29  
invasive 52.25  
lichen planus complication 41.15  
lips 69.42, 69.49–50, 79.10, 79.11  
loss of heterogeneity events 52.12  
lupus vulgaris and 31.18, 31.21  
lymph node involvement 79.10–11  
lymphangioma circumscriptum and 48.26  
male genital region 71.22, 71.39–46  
management principles 52.17  
mechanical injury 28.62  
metastases 52.26, 52.27  
in dystrophic EB 39.19, 39.30  
prediction of 52.26  
risk factors 52.27  
mitotic figures 52.26  
mortality 52.2  
nail apparatus 65.37–8  
oral 69.49–53  
*p53* gene mutations 52.12  
papillomatous 52.25  
pathology 52.25–6  
perianal/perineal 71.97  
photodamage associated 52.24  
pilonidal sinus 28.50  
pinna 68.30–2  
precancerous conditions 52.25, 52.28  
presentation as paronychia 65.21–2  
pressure ulcers 28.20  
prevention 52.28  
in dystrophic EB 39.31  
by sunscreens 29.9  
prolidase deficiency and 47.54  
PUVA associated 52.4  
race and 9.18  
radiation-induced 79.18  
recessive dystrophic EBV and 52.11  
recurrence/recurrent 52.27, 79.17–18  
risk factors 52.24  
scrotal 27.15–16, 52.25  
sites 52.25  
sun exposure patterns 52.3  
sunscreens use and 73.41  
in transplant recipients 62.74–5, 79.13  
treatment 52.27–8  
adjuvant chemotherapy 52.28  
curettage 77.41, 77.44  
destructive therapies 52.27  
Mohs micrographic surgery 52.27, 77.32  
radiotherapy 52.27, 68.31, 79.5–7, 79.8–12, 79.13  
surgery 77.15, 79.5, 79.6  
ulceration 52.25  
ultraviolet radiation and 29.7, 52.3, 52.24, 52.27  
UVB phototherapy associated 52.4  
verrucous 52.26  
vulva 51.116  
well-differentiated 52.25–6  
*see also* non-melanoma skin cancer (NMSC)
- squamous cell papilloma, pinna 68.28  
'squamous eddies' 53.2
- squamous hyperplasia, male genital dermatology 71.37
- squaric acid dibutylester (SADE) 66.37  
sensitization by 73.39  
squirting papilla 23.30
- SSR (sympathetic skin response) 63.4
- SSRIs *see* selective serotonin reuptake inhibitors (SSRIs)
- SSSS *see* staphylococcal scalded skin syndrome (SSSS)
- St John's wort 72.29, 75.160, 75.162
- stab wounds, torture injuries 28.33
- stable fly 38.6, 38.7
- staining  
antigen non-specific 10.14  
artefacts due to 10.31  
fungi 10.8, 10.9, 10.10, 36.7, 36.70  
immunoenzyme methods 10.16–17  
immunofluorescence methods 10.13–14  
tissue specimens 10.8–11
- standard deviation 7.17
- standard error 7.18–19
- standard erythema dose (SED) 29.4
- stanazolol 49.34  
acneiform eruptions due to 42.72  
prophylactic, in hereditary angio-oedema 22.22  
in sclerosing panniculitis (lipodermatosclerosis) 46.30–1  
in venous leg ulcers 47.49
- Staphylinidae 38.26–7
- staphylococcal blepharitis *see* blepharitis, staphylococcal
- staphylococcal erythrogenic toxin 30.8
- staphylococcal pyoderma *see* pyoderma, staphylococcal
- staphylococcal ring 2.11
- staphylococcal scalded skin syndrome (SSSS) 28.92, 30.14, 30.30  
desmoglein 1 (Desgl1) disruption 3.22  
differential diagnosis 76.15, 76.19  
in HIV infection 35.24  
neonatal 17.42–3
- Staphylococcus*  
burns, infections 28.85, 28.92  
classification 30.2–3  
coagulase-negative 30.4, 30.10–11  
normal skin flora 30.3  
coagulase-positive *see Staphylococcus aureus*  
in ecthyma 30.17  
erythrogenic toxin 30.8  
exotoxins 24.8  
damage to desmogleins 40.2  
infections  
animals 2.11–12  
of eyes 67.26–7  
in HIV infection 35.24  
male genital 71.29–30  
perianal/perineal 71.85, 71.91–2  
topical antibiotic therapy 73.9, 73.10, 73.11  
neutrophilic eccrine hidradenitis and 44.17  
in normal skin flora 30.2, 30.3, 68.2  
pyoderma *see* pyoderma, staphylococcal
- Staphylococcus albus*, paronychia due to 65.21
- Staphylococcus aureus* 30.6–10  
in acne necrotica varioliformis 30.26, 30.27  
animal infections 2.11, 2.12  
antibiotic resistance 30.9  
antibodies to 30.8  
atopic dermatitis and 24.8, 24.10, 24.12, 30.7, 30.8–9  
bacterial interference 30.7  
blepharitis 30.32, 67.6, 67.11  
in botryomycosis 30.67  
breast abscess and 70.13  
in carbuncle 30.24  
carriage/carriers 30.6–7  
gastrointestinal 30.7  
nasal 30.4, 30.6–7  
neonatal 30.4–5, 30.6  
suppression 30.7  
in cellulitis 30.17–18  
in chancroid pyoderma 30.77  
colonization of diseased skin 30.7  
reduced by corticosteroids 73.18  
cutaneous infection 30.8–9  
in dermatitis vegetans 30.77  
dissemination 30.4  
ear infection 68.19, 68.21, 68.22  
in ectodermal dysplasias 15.60  
in erysipelas 30.17–18  
exotoxins 24.8  
female genital infection 71.67, 71.70  
fissure of lower lip 30.32  
folliculitis 30.22, 42.74, 67.11  
foreign bodies 28.52  
in furunculosis 30.23  
gastrointestinal carriage 30.7  
genitocrural dermatology 71.5, 71.17  
in hidradenitis suppurativa 30.79–80  
HIV infection and 30.7, 30.8, 35.24, 35.45  
in impetigo 30.14, 30.15  
intravenous drug abuse and 28.52  
in invasive otitis externa 68.25  
Kawasaki disease and 50.45  
in malakoplakia 55.27  
methicillin-resistant (MRSA) *see* methicillin-resistant *Staphylococcus aureus* (MRSA)  
mupirocin-resistant 39.28  
nasal carriage 30.4, 30.6–7  
neonatal carriage 30.4–5, 30.6  
neonatal infection 17.42–4  
in neuropathic ulcers 63.9  
normal skin flora 30.1, 30.4  
elderly men 30.4  
in normal skin flora 30.3, 30.4  
in otitis externa 68.21, 68.22  
paronychia due to 30.32, 65.21  
perianal/perineal infections 71.92  
in perioritis staphylogenes 30.32  
production of biologically active substances 30.7–8  
resistance to infection 30.8  
scalp folliculitis 42.74  
in scarlet fever 30.7–8, 65.21  
skin free fatty acid effect on 42.7  
in staphylococcal scalded skin syndrome 30.30  
strain 502A 30.7  
in subacute bacterial endocarditis 62.78  
in superficial folliculitis 30.22  
surface components 30.7  
in sycosis 30.25  
therapy, topical antibiotics 73.9, 73.10  
in toxic shock syndrome 30.31  
in tropical ulcer 30.60  
umbilical infections 30.4–5, 30.6  
venous leg ulcer infections 47.44  
in Wegener's granulomatosis 50.39, 50.55  
wound infection 14.16  
*see also* methicillin-resistant *Staphylococcus aureus* (MRSA)
- Staphylococcus capitis* 30.3
- Staphylococcus colnii* 30.3
- Staphylococcus epidermidis* 30.3, 30.11, 42.24  
acne aetiology and 42.24  
blepharitis 67.6, 67.11  
cellulitis 30.18  
folliculitis 42.36, 42.84  
growth inhibition by azelaic acid 73.28  
in invasive otitis externa 68.25  
in miliaria rubra 44.15  
in normal skin flora 30.3, 68.2  
in pyoderma faciale 43.14
- Staphylococcus haemolyticus* 30.3
- Staphylococcus hominis* 30.3
- Staphylococcus hyicus* 2.11, 2.12
- Staphylococcus intermedius*, animal infections 2.12
- Staphylococcus pseudintermedius* 2.11, 2.12
- Staphylococcus saccharolyticus* 30.2
- Staphylococcus saprophyticus* 30.3, 30.11

- Staphylococcus simulans* 30.3  
*Staphylococcus warneri* 30.3  
*Staphylococcus xylosus* 30.3  
 starch pastes 73.2  
 starch powders 73.2, 73.8  
 starch/iodine test 44.4, 44.5  
 stargazers 38.59  
 STARI (Southern tick-associated rash illness) 38.35  
 starvation  
   acne and 42.34  
   gynaecomastia and 70.4  
   sebum synthesis rate 42.6  
 STAT kinase 13.11  
 STAT3 66.10  
 statins 59.93  
   adverse effects 75.156–7  
   claudication management 47.5  
 statistical methods 7.19–22  
 statue eye 40.39  
 stavudine, photosensitivity due to 35.22  
 stearyl alcohols 73.7  
 stearyl amine 25.20  
 steatocystoma multiplex 42.88, 52.47  
   familial 42.88  
   histogenesis 52.45  
   isotretinoin treatment 42.62  
 steatopyga 46.46  
 Steel factor (mast cell growth factor/stem cell factor (M/SCF)) *see* stem-cell factor (SCF)  
 stele 66.7  
 stellae 66.21, 66.38  
 stellate bodies 61.4  
   bullous dermolysis of the newborn 39.23, 39.25  
 stellate cells 3.3  
 stem cell(s) 3.5–6, 13.7  
   bulge 3.6  
   CD34<sup>+</sup> pluripotent 3.19  
   embryonic (pluripotent) 3.7  
   epithelial 3.5–6  
     asymmetrical division 3.6, 3.7  
   haematopoietic *see* haematopoietic stem cell(s)  
   hair follicle 3.6, 3.7, 66.3, 66.9  
   markers 3.6  
   melanocyte 3.21  
   multipotent, in fat 3.52–3  
   pluripotent, fibroblasts induced to be 3.50  
   proliferation 3.6, 3.7  
   sebocyte 3.6  
   signalling 3.6–7  
   strategies for burns 28.86–7  
   transplantation 13.26, 76.7  
     *see also* haematopoietic stem cell(s)  
   wound healing and 14.26  
 stem-cell factor (SCF) 3.19, 12.24, 12.31  
 adverse effects 75.144  
*Stenella araguata* 36.14  
*Stenotrophomonas maltophilia* 30.51  
 Stensen's duct *see* parotid duct  
 stenting  
   claudication management 47.5  
   varicose veins 47.39  
*Stephania tetrandra* 75.160  
 Sterculiaceae 26.81  
 stereotactic radiosurgery (SRS), melanoma metastatic to brain 54.55  
 steric hindrance 40.6  
 sternal clefts 18.88  
 sternocleidomastoid muscle 77.2, 77.3  
 sternocostoclavicular hyperostosis 62.101  
 steroid nasal spray, rosacea associated in children 43.10  
 steroid phobia 73.17  
 steroid receptor(s) 73.16, 73.17  
 steroid receptor superfamily 73.43  
 steroid rosacea 43.10, 73.19  
 steroid sulphatase deficiency 19.9, 19.11–12  
 steroid therapy *see* corticosteroids  
 steroid ulcers 47.56  
 sterol, synthesis in epidermis 3.11  
 Stevens–Johnson syndrome (SJS) 69.69, 76.8–22  
   aetiology 76.9–15  
   in animals 2.17  
   cheilitis in 69.121  
   clinical features 76.16–17  
   conjunctival damage 67.20  
   definition 76.1  
   diagnosis 76.19–20  
   drug-induced 42.51, 76.4, 76.11–12  
     antiretroviral drugs causing 35.7  
   genetic markers 72.30  
   HIV infection 35.7, 35.20  
   immunology 76.9–10  
   incidence 76.8–9  
   male genital involvement 71.25  
   *Mycoplasma* and 30.69, 62.80  
   ocular complications 67.20, 67.21, 76.16  
     management 67.22–3  
   pathology 76.15  
   perianal/perineal involvement 71.91  
   pharmacogenetics 76.10–11  
   post-measles vaccination 33.75  
   pregnancy and 8.12  
   prevention 76.22  
   prognosis 76.18–19  
   terminology 76.1  
   treatment 76.20–2  
   in varicella 33.25  
 Stewart–Bluefarb syndrome 47.22  
 Stewart–Treves syndrome 48.15, 48.31, 56.37, 56.38  
 Stickler syndrome 15.46  
 stiff baby syndrome 19.14  
 stiff skin syndromes, infantile 45.50–1  
 stigma 64.2, 64.6–8  
   leprosy and 32.1  
   skin disease in old age 8.25  
 Stigma Scale of mental illness 64.7–8  
 stigmata 49.16  
 stilbenes 26.79  
 stilboestrol, adverse effects 70.5  
 stillbirths, congenital syphilis 34.15  
 Still's disease  
   adult-onset 51.134, 62.104  
   bone and joint involvement 62.104  
   erythema marginatum in 62.107  
   hyperferritinaemia and purpura 49.6  
   juvenile 51.133  
   leg ulceration associated 47.55  
   pigmentation changes 58.26  
 stinger suits 38.57  
 stinging sensation  
   delayed-type 25.19  
   immediate-type 25.19  
 stingrays 38.59  
 stings  
   arthropod 38.1–5, 38.13–15  
   Cnidaria 38.55–8  
   fish 38.59–60  
   Hymenoptera 38.13–15  
   Mollusca 38.59  
   swimming and diving 28.55  
   *see also* insect bite reactions  
 stinking mayweed 25.21  
*STK11* gene 58.12, 58.13  
 stoma  
   cutaneous complications 62.53–4  
   peristomal pyoderma gangrenosum 50.69, 50.72  
 stomach, cutaneous markers of disorders 62.48  
 stomatitis  
   angular *see* cheilitis, angular  
   blackberry 30.53  
   chronic ulcerative with epithelial antinuclear antibodies 69.64  
   denture-related (candidiasis) 36.60, 69.88, 69.102–4  
   drug-induced 75.47  
   herpes simplex 69.13, 69.72–4  
   monoclonal plasmacytic ulcerative 69.84  
   necrotizing ulcerative, in HIV infection 35.43  
   recurrent aphthous 69.44–6, 69.48  
   vesicular 33.74  
     coxsackievirus infections 33.71, 33.72  
     hand, foot and mouth disease 33.71  
 stomatitis nicotina 69.90  
*Stomoxys calcitrans* (stable fly) 38.6, 38.7  
 stonefish 38.59  
 storax 26.40  
 storiform patterning 10.38, 10.41–2  
 stork bite/mark (salmon patch) 18.62–3  
 Stormorken's syndrome 19.62  
 strangulation of the penis 28.38, 71.14  
 stratum basale 3.8  
   structure 3.8  
 stratum compactum 4.2  
 stratum corneum 3.1, 3.8, 3.10, 4.4  
   absorption through 4.4–5  
   ageing 4.11  
   assembly/formation 3.10–11  
   bacterial flora 30.2  
   barrier function 3.2–3, 4.2, 4.3  
   composition 3.10–11  
   corticosteroid diffusion 73.16  
   ear 68.1  
   effects of wetness 17.23  
   glabrous skin 3.3  
   in irritant contact dermatitis 25.2, 25.8–9  
   mechanical function and properties 4.8  
   mechanical injury 28.5, 28.6–7  
   neonatal 17.1–2  
   precursors and formation 3.10  
   racial variations 9.2, 9.13  
   structure 3.1, 3.8, 3.10  
   two-compartment model 4.2  
 stratum corneum tryptic enzyme (SCTE) 12.5, 43.2  
 stratum dysjunctum 4.2  
 stratum germinativum (basale) 3.8  
 stratum granulosum 3.8, 3.10  
   ear 68.1  
 stratum intermedium 42.3  
 stratum lucidum 3.9  
 stratum spinosum 3.8, 4.2  
   structure 3.8  
 straw itch 38.48  
 strawberry naevus *see* naevus, strawberry  
 streblodactyly 45.47  
 Strengthening the Reporting of Observational Studies in Epidemiology 7.17  
*Streptobacillus moniliformis* 30.67  
 streptocerciasis 37.8  
 streptococcal pyodermas, erythromycin 74.42  
 streptococcal toxic shock-like syndrome 30.12, 30.35  
*Streptococcus* (streptococci) 30.11–14  
    $\alpha$ -haemolytic 30.11, 30.13  
    $\beta$ -haemolytic 30.11, 30.67  
   ear infection 68.19  
   erythema nodosum and 50.83  
   eye infection 67.27  
   normal skin flora 30.1  
   in cellulitis 30.17, 30.18  
   in cutaneous disease 30.11  
   in erysipelas 30.17  
   erythema elevatum diutinum and 50.25  
   eye infections 67.27  
   female genital infection 71.67  
    $\gamma$ -haemolytic 30.11  
   genitocrural infection 71.5  
   group A  
     in HIV infection 35.24–5  
     *see also Streptococcus pyogenes*  
   group B 30.13, 30.17, 30.33, 30.69  
     vulva 30.4  
   group C 30.12–13, 30.17, 30.69  
   group D 30.13, 30.69  
   group F 30.13, 30.80  
   group G 30.12–13, 30.17  
   group L 30.13  
   in Henoch–Schönlein purpura 50.20  
   in impetigo 30.14, 30.15–16  
   intertrigo due to 30.33  
   in normal skin flora 30.2  
   perianal/perineal infection 71.92  
   pyoderma due to 30.14, 30.15, 30.16, 30.33  
     erythromycin 74.42  
   serology 30.13  
   urticaria following infection 22.8  
*Streptococcus faecalis*, female genital infection 71.68  
*Streptococcus milleri* 30.80  
   female genital infection 71.67  
   perianal/perineal infection 71.88  
*Streptococcus pneumoniae*  
   in ectodermal dysplasias 15.60  
   in erysipelas 30.18  
   in orbital cellulitis 30.18  
*Streptococcus pyogenes* 30.4, 30.11–12  
   in blepharitis 30.32  
   burns 28.85  
   carriage 30.11–12  
     management 30.12  
   complications of infection 30.12  
   control of epidemics 30.12  
   in dermatitis vegetans 30.77  
   in ecthyma 30.17  
   exotoxins 30.11  
   growth inhibition by free fatty acids on skin 30.4  
   in HIV infection 35.24  
   initiation of infection 30.12  
   Kawasaki disease and 50.45  
   M proteins 30.11  
   male genital infection 71.30  
   in nasal vestibule 30.4  
   perianal infection 30.32–3  
   scarlet fever and 30.16, 30.34  
   skin strain 30.12  
   superinfection of chromic acid burns 27.12  
   T proteins 30.11  
   throat strain 30.12  
   topical therapy 73.10  
   toxic shock syndrome and 30.31  
   umbilicus 30.5  
   vulvovaginitis 30.32  
*Streptococcus viridans* 30.13  
   in subacute bacterial endocarditis 62.78  
 streptodornase, in wound debridement 14.22  
 streptokinase 75.107  
   in wound debridement 14.22  
*Streptomyces* 30.39  
*Streptomyces somaliensis* 36.72, 36.73  
*Streptomyces tsukubaensis* 73.31  
 streptomycin 74.42, 74.44  
   adverse effects 26.46, 31.27, 75.58  
   in tuberculosis 31.27  
 stress 64.4, 64.5  
   acne and 42.35  
   alopecia areata and 66.32  
   atopic dermatitis and 24.19  
   herpes simplex recurrence 33.18  
   immune response and 64.8–9  
   lichen planus association 41.3  
   neuromediators 12.63  
   nodular prurigo and 23.42  
   occupational dermatoses and 27.2  
   oxidative stress 12.55  
   role in pompholyx 23.17  
   urticaria and 22.11–12  
   workplace 64.26  
   wound healing and 14.1  
 stress lines (skin tension lines) 77.2, 77.11, 77.13  
 stretch marks *see* striae  
 stretching of skin 4.8, 5.18  
 striae 4.8, 5.11, 45.4–6  
   aetiology 45.5  
   clinical features 45.5  
   corticosteroid-induced 45.3, 45.5, 73.18  
   definition 45.5  
   diagnosis 45.5  
   elastotic 45.25–6  
   in liver disease 62.64  
   pathology 45.5  
   treatment 45.6

- striae distensae (striae gravidarum) 8.13  
sports injury 28.31
- striate keratoderma 19.3, 19.94, 19.95,  
19.105–6, 19.107
- strimmer's dermatitis 29.21, 58.32  
*see also* phytophotodermatitis
- string test 37.15
- STROBE (Strengthening the Reporting of  
Observational Studies in  
Epidemiology) 7.17
- stromelysins 12.52, 14.11
- Strongyloides stercoralis* 37.2, 37.14,  
37.15–16  
disseminated infection 49.36  
perianal/perineal infection 71.96
- strongyloidiasis 22.10, 37.15–16  
disseminated 49.36  
purpura 49.20
- strontium sulphide 73.29
- structure of skin 3.1–3.53
- stucco keratosis 52.40  
treatment 73.24
- students, medical 72.2
- stump pemphigoid 28.29
- STUMPs (atypical spitzoid tumours of  
unknown malignant potential)  
54.24, 54.39
- Sturge–Weber syndrome 18.65–7  
bone and joint involvement 62.100  
ocular involvement 18.66  
oral involvement 69.13, 69.29, 69.30
- styes 67.6, 67.26–7
- styrene 25.21
- subacute cutaneous lupus erythematosus  
(SCLE) 51.2, 51.22–7  
aetiology 51.22  
autoantibody status 51.22  
clinical features 51.23–4  
urticarial lesions and vasculitis  
51.38–9  
drug associations 51.24  
histopathology 51.22–3  
Ro/SS-A antibodies 51.49  
treatment 51.23–4
- subareolar duct papillomatosis *see* nipple,  
erosive adenomatosis
- subclavian artery, occlusion 47.2
- subcorneal pustular dermatosis 40.19–22,  
50.62, 50.95, 62.49  
differential diagnosis 40.21
- subcutaneous fat 3.52–3, 46.1–49  
absence 54.11  
atrophy *see* lipoatrophy  
blood supply 46.2, 46.11  
compromised, encapsulated fat  
necrosis 46.22  
brown 3.52, 46.1  
central accumulation, HIV  
lipodystrophy 46.42  
cold injury, panniculitis 46.21  
composition 46.2  
deeper (lamellar) layer 46.2  
drug/oil-induced injury 46.28  
embryology 46.1  
fibrosis after injury 46.11  
functions 3.3, 3.52, 46.1, 46.2  
gynoid vs android distribution 46.2  
histology 46.1–2  
hyaline necrosis 46.26  
hypertrophy 46.34, 46.41, 70.3, 70.4  
increased deposition 46.41  
inflammation, macrophage associated  
46.4, 46.6, 46.11  
inflammatory disorders 46.10–11  
*see also* panniculitis
- lobules 46.2  
encapsulated fat necrosis 46.22  
loss *see* lipoatrophy; lipodystrophy  
lymph drainage 46.2  
macrophages in 46.4, 46.6, 46.11  
measurement methods 46.5  
mechanical injury 28.27  
necrosis 46.11, 46.13, 46.21–3, 46.44  
following hypothermic cardiac  
surgery in infancy 17.37–8
- lipomembranous (membranocystic)  
46.22–3  
of newborn 17.36–7, 46.12  
nodular cystic (encapsulated) 46.22  
obesity 8.17  
in pancreatic disease 46.18–20,  
62.65–6  
neonatal disorders 17.34–9  
physiology 46.2–4  
'pseudoherniation' 46.10  
superficial (areolar) layer 46.2  
traumatic injury  
blunt trauma 46.28–9  
cellular events after 46.11  
*see also* panniculitis
- subcutaneous nodules  
lipoma 46.44  
panniculitis 46.11
- subcutaneous panniculitis-like T-cell  
lymphoma (SPTL) 57.33
- subcutaneous panniculitis-like T-cell  
lymphoma of  $\alpha/\beta$  T-cell  
phenotype (SPTL-AB) 46.23,  
46.24, 46.25
- subcutaneous panniculitis-like T-cell  
lymphoma of  $\gamma/\delta$  T-cell  
phenotype (SPTL-GD) 46.23,  
46.24, 46.25
- subcutis *see* subcutaneous fat
- subepidermal calcified nodules 56.2
- subepidermal immunobullous diseases  
40.25–62  
clinical features 40.26  
immunopathology and  
immunogenetics 40.27  
variants 40.26  
*see also* bullous pemphigoid; *specific  
diseases*
- subepidermal nodular fibrosis *see* fibrous  
histiocytoma (FH)
- subfascial endoscopic perforator surgery  
47.39
- submandibular duct 69.5
- submandibular gland examination 69.5
- submucous fibrosis 69.106–7
- substance abuse 64.13, 64.14, 64.18  
*see also* alcohol abuse
- substance P 4.10, 12.64, 12.66, 63.2, 63.3,  
64.5, 64.9  
in atopic dermatitis 24.17  
capsaicin stimulating release 73.49  
flushing in rosacea 43.2  
immune function and 63.4  
pruritus and 21.3, 21.4  
triple response of Lewis and 63.5  
in urticaria 22.5  
in wound healing 63.4
- subungual exostosis 62.101, 65.33–4
- subungual haematoma 65.49–50
- subungual hyperkeratosis 20.16, 51.12,  
65.12, 65.15, 65.24
- subungual keratoacanthoma 65.38
- subungual keratotic tumours 65.38
- subungual melanoma *see* melanoma,  
malignant
- subungual onychomycosis  
distal and lateral 36.34, 36.63  
proximal 36.35
- subungual osteochondroma 65.33
- subungual pigmentation 54.45
- subungual warty dyskeratoma 65.18
- succinylcholine 75.153
- sucker-daddy syndrome 28.24
- sucking blister 17.4
- suckling pads 17.5
- sucralfate 17.26
- suction injury 28.23–5, 28.39
- suction pads 28.24
- suction tests, mechanical injury 28.5
- sucupira 26.80
- Sudeck's atrophy 47.11, 63.21  
*see also* complex regional pain  
syndrome
- sudorific nervous system 3.12
- sugar, in wound treatment 14.21
- Sugio–Kajii syndrome 15.65–6
- suicide 64.48–9  
acne and 42.35, 42.63  
assessment of risk 64.48–9  
body dysmorphic disorder 64.19, 64.48  
rate of in UK 64.48  
with self-harm 64.45–6
- Suidasia nesbitti* 38.47
- SUKA (subungual keratoacanthoma)  
65.38
- sulconazole  
in dermatophytosis 36.47, 36.48  
topical 73.12
- sulcus terminalis 69.2
- sulfadiazine 44.17–18
- sulfadoxine, adverse effects 75.56–7  
Stevens–Johnson syndrome 76.11
- sulfaguanidine 44.17–18
- sulfamethoxypyridazine 74.28, 75.56  
linear IgA disease 40.51
- sulfapyridine 74.28
- sulfasalazine  
adverse effects 75.33, 75.56  
in cicatrizing conjunctivitis 67.22–3  
in lichen sclerosus 51.118  
in psoriasis 20.42  
in psoriatic arthritis 20.59  
in urticaria 22.29
- sulfones 74.28, 74.45
- sulindac 75.76
- sulphapyridine, in cicatrizing  
conjunctivitis 67.22–3
- sulphasalazine *see* sulfasalazine
- sulphatases 3.45–6
- 17 $\beta$ -sulphinyl steroids 42.16
- sulphites 22.11, 75.159
- sulphonamides 74.38–9  
adverse effects 26.17, 74.38–9, 75.55–8,  
75.61  
mechanisms 76.10  
in cicatrizing conjunctivitis 67.23  
as photoallergens 26.24  
in toxoplasmosis 37.44
- sulphonated oils 25.20
- sulphonylureas 75.156
- sulphur  
acne vulgaris treatment 42.43  
depletion 59.72  
granules 30.75  
metabolism 59.72–4  
in scabies 38.41
- sulphur-deficient brittle hair, IBIDS/  
PIBIDS syndrome 19.47–9
- sulphur granules 30.75
- sulphur-rich L granules 3.10
- sulphuric acid, burns 27.12
- sulpiride 64.52
- sultones 26.27
- Sulzberger–Garbe disease 23.11–12
- Sumatra, prevalence of skin disease 6.10
- summer penile syndrome 38.51
- sun exposure  
avoidance  
epidermodysplasia verruciformis  
33.58  
naevoid basal cell carcinoma  
syndrome 52.7  
*see also* photoprotection; sunscreens;  
ultraviolet (UV) radiation,  
exposure minimisation
- cancers in HIV infection and 35.39, 35.40
- malignant melanoma 6.12, 29.7, 54.32–  
3, 54.34, 73.41
- Merkel cell number change 3.15
- minimization 29.8–9
- non-melanoma skin cancers 29.7
- simple lentigo 54.3
- telangiectases due to 47.13
- see also* sunlight; ultraviolet (UV)  
radiation
- sun protection factor (SPF) 29.8, 58.31,  
73.40–1, 80.3  
calculation 73.40  
high-SPF sunscreens 29.9  
*see also* sunscreens
- sun tan 73.40  
false 73.49  
*see also* tanning
- sunbathing, non-melanoma skin cancers  
and 52.3
- sunbeds/sunlamps 29.4  
DNA damage 58.31  
usage, malignant melanoma risk 54.33  
*see also* tanning
- sunburn 4.7, 29.4, 58.7  
avoidance/prevention 29.8  
exaggerated, drugs associated 29.20,  
29.21  
malignant melanoma risk 54.33  
sensitivity to 29.5  
treatment 29.8
- sunburn cells 29.5
- sunlight 29.4  
acne improvement and cautions  
42.34  
actinic lichen planus 41.13  
feel-good and health factors 29.6–7  
UVR source 29.1  
vitamin D synthesis 29.6  
*see also* sun exposure; ultraviolet (UV)  
radiation
- sunscreens 29.8–9, 52.3, 73.40–1  
actinic keratosis reduction 52.32  
in ageing prevention 80.3  
allergic contact dermatitis to 26.62–3  
chemical 73.40  
classification 73.40–1  
contact sensitization by 29.9  
dermatitis due to 73.40  
dihydroxyacetone in 73.49  
efficacy and mechanism of action 29.8  
endogenous 73.40  
exogenous 73.40  
high-SPF 29.9  
ideal, characteristics 73.40  
in lipsticks and lipsalves 69.119  
melanoma prevention 54.34, 73.41  
mineral oxide micropigments 29.8  
misuse/abuse 73.40  
naevi number and 73.41  
organic micropigments 29.8, 29.9  
photoallergic reactions to 29.20  
photodermatoses management 73.41  
physical 73.40  
polymorphic light eruption treatment  
29.12  
prescribable 29.9  
resistance to water (substantivity) 29.8,  
73.40  
SPF rating *see* sun protection factor  
(SPF)  
UVR interaction with 73.40  
vehicles for 73.2
- sunset yellow 22.11, 75.158
- superantigens 17.50–1  
in Kawasaki disease 30.78
- staphylococcal 73.20  
corticosteroid mechanism of action  
and 73.17  
*S. aureus* 24.8, 24.12, 30.8  
streptococcal 30.11  
in vasculitis 50.4, 50.5–6
- superficial acral fibromyxoma 56.6
- superficial necrolytic dermatitis (SND),  
dogs 2.17, 2.20
- superficial papillary adenomatosis *see*  
nipple, erosive adenomatosis
- superficial spreading carcinoma  
(squamous cell) 71.41–2
- superficial spreading carcinoma, male  
genital 71.41–2
- superficial spreading melanoma *see*  
melanoma, malignant
- superficial white onychomycosis (SWO)  
36.34, 36.50, 36.53, 36.55
- superglue (cyanoacrylates) 26.72, 65.28
- superior vena cava obstruction 62.44
- supernumerary digit 18.92
- supernumerary nipple 18.92–3, 70.2–3
- superoxide anion 13.4

- superoxide dismutase, reduced levels, rosacea 43.2
- support groups 64.7, 72.33–4  
atopic dermatitis 72.23
- suppressor of cytokine signalling (Socs)  
protein pathway 12.35
- suprabasal cleavage  
in EB 39.2  
in Hailey–Hailey disease 39.33
- supraorbital nerve 77.2, 77.4, 77.10
- supratrochlear nerve 77.10
- suramin  
adverse effects 75.135  
in African trypanosomiasis 37.31  
in onchocerciasis 37.7
- surface-active agents 25.20
- surfactants 26.59, 66.96
- surgery 77.1–50  
adjuvant radiotherapy 79.7  
in burns 28.84–6  
comparison with Mohs micrographic surgery 77.29, 77.31  
comparison with radiotherapy 79.5–7  
complications 77.8–10  
critical anatomical areas 77.1–5  
dressings 7.17–18  
equipment and sterilization 77.5, 77.6, 77.7  
excision 77.13–14, 77.15–16  
elliptical 77.13–14  
snip 77.34  
wedge 77.35  
haemostasis 77.50  
head and neck 77.2–5  
hydrodissection 77.2, 77.34  
incision and scar orientation 77.2  
in infantile haemangioma 18.51  
Kasabach–Merritt syndrome/  
phenomenon 18.57  
legs 77.5  
minor procedures 77.50  
nail apparatus 65.41–9  
in non-melanoma skin cancer 52.17  
in pressure ulcers 28.23  
relaxing incisions 77.34–5  
safety measures and protocols 77.7  
snip excision 77.34  
sutures 77.14–15  
tissue expansion 77.35  
undermining levels 77.5  
wedge excision 77.35  
wound closure 77.16–17  
*see also* skin biopsy
- Sutton's disease 69.45  
female genitalia 71.65
- Sutton's naevus (halo naevus) 54.19–20, 58.49–50
- Sutton's ulcer, female genital dermatology 71.65
- sutures 77.14–15
- suxamethonium 75.153
- swallow bug 38.24
- swamp cancer 36.92
- sweat  
apocrine 44.19  
odour 30.4  
assessment of production 44.4, 44.5  
chloride in 44.5  
coloured 44.20–1  
composition 3.12, 44.5–6  
in cystic fibrosis 44.6  
glucose in 44.6  
immunoglobulin E (IgE) in 44.6  
lactate in 44.5, 44.6  
mammals 2.4  
odour 30.4  
production 3.12  
retention  
apocrine 44.21–2  
eccrine 44.13  
in psoriasis 44.13  
sodium in 44.5–6  
urea in 44.5, 44.6
- sweat dermatitis, frictional 28.14
- sweat ducts  
carcinoma, sclerosing/syringomatous 53.35–6  
intraepidermal, development 3.5
- sweat glands 3.12–13  
abscess 17.43  
adenocarcinoma 53.40  
apocrine (epitrichial) *see* apocrine sweat glands  
apoeccrine 3.12, 44.1, 44.3  
axillary 44.1  
carcinoma 53.32  
apocrine/follicular 53.33–7  
eccrine 53.32–3, 53.33–7  
comparative anatomy and physiology 44.1–3  
ear 68.1  
eccrine (atrichial) *see* eccrine sweat glands  
ectodermal dysplasias 15.59, 15.62, 15.64–6, 15.69  
embryology 3.3  
intermediate (apoeccrine) 3.12  
naevi 44.9  
odour production 44.2, 44.8, 44.19–20  
secretion inhibition 73.9  
tumours 53.18–37  
apocrine 53.18–22  
eccrine 53.22–7  
eccrine or apocrine/follicular 53.27–32  
miscellaneous 53.37–42
- sweating 3.12  
acne and 42.34  
ageing effect 8.24  
atopic dermatitis and 24.18–19  
cholinergic, ageing effect 8.24  
control of 3.12, 44.2, 44.5–7  
flushing with (wet flushing) 43.14  
following spinal cord injury 63.17  
gustatory, treatment 73.9  
innervation and control 3.12  
mental/emotional 3.12  
mental stimuli 44.5  
obesity and 8.17  
thermal 3.12  
thermoregulatory 4.7, 44.2, 44.4, 44.5  
*see also* hyperhidrosis  
'sweating sickness' 44.7
- Sweden, prevalence of skin disease 6.9
- 'sweet itch' 2.11
- Sweet's disease-like annular erythema 51.135
- Sweet's syndrome 46.34, 50.74–80  
acral, of dorsal hands 50.80–1  
aetiology and pathogenesis 50.74, 50.75, 50.76–7  
annular lesions 62.112  
atypical 46.32  
bone and joint involvement 62.103  
childhood 50.63  
classic/idiopathic 50.74  
clinical features 50.78–9  
conditions associated 50.74, 50.75  
Crohn's disease and 50.75, 62.51  
definition 50.74  
diagnosis 50.79  
differential diagnosis 50.70  
drug-induced 50.74, 50.75  
histopathology 50.77–8  
history and nomenclature 50.74  
infection and 50.75  
neutrophilia in 62.86  
oral involvement 69.49  
paraneoplastic 50.74, 50.75, 62.41  
photoaggravated/photoinduced 50.78  
pustulosis in 50.89  
scrofuloderma and 31.14  
subcutaneous 50.90–1  
treatment 50.79–80  
ulcerative colitis and 50.75, 62.51  
vasculitis and 50.3, 50.77–8
- swelling, male genital 71.49–50
- swimmer's itch (cercarial dermatitis) 28.55, 37.20, 37.22–3, 38.56, 38.57
- swimmer's shoulder 28.31
- swimming  
mechanical injury 28.31, 28.53–6  
skin hazards 30.49
- Swiss-cheese-like pseudocystic spaces 46.28, 46.28, 46.29
- Swiss type ectodermal dysplasia 15.29
- SWO (superficial white onychomycosis) 36.34, 36.50, 36.53, 36.55
- Sybert's keratoderma 19.94, 19.99
- sycosis 30.25–6  
in HIV infection 35.28  
mycotic 30.25
- Sydney funnel-web spider 38.31
- Syk protein 48.2
- symblepharon 67.4, 67.18  
in dystrophic EB 39.19
- symmetrical dyschromatosis of the extremities 58.21–2
- symmetrical interdigital keratoderma 19.115–16
- symmetrical lividity of the feet 44.8
- symmetrical progressive leukopathy 58.52
- sympathectomy  
in complex regional pain syndrome 63.21  
gustatory hyperhidrosis following 63.22  
Horner's syndrome following 63.22  
in hyperhidrosis 44.12, 77.37  
in thromboangiitis obliterans 47.8  
transthoracic endoscopic 43.15
- sympathetic nervous system 63.1  
injury 63.20  
lesions, hyperhidrosis and 44.9, 44.10  
sweating and 3.12
- sympathetic skin response 63.4
- sympathomimetics, adverse effects 26.17
- Symphoromyia* 38.6
- symptoms, history-taking 5.4
- Symtrack itch rating system 21.2
- synaptophysin 10.21
- synbiotic supplements, in atopic dermatitis 24.31, 24.34
- syndactyly, with ectodermal dysplasia and cleft lip/palate 66.52
- syndecan-1 3.16, 3.45
- syndecan-4 3.16, 3.45
- syndecans 3.45
- syndromes  
definition 5.2  
overlap 5.2
- synergistic bacterial gangrene 71.67
- synergistins 75.60
- synophrys 67.3
- syphilide  
corymbose 34.11  
lichenoid 34.11  
macular (roseolar rash) 34.8–10  
nodular (tubercular) 34.12–13  
nodulocutaneous 34.13  
papular 34.9, 34.10, 34.10–11  
papulosquamous 34.11  
pustular ulcerative 34.11  
serpiginous nodulo-squamous 66.52
- syphilis 34.1–24  
acquired 34.6–15  
alopecia 34.11, 66.29, 66.52  
anetoderma in 45.17  
antibodies 34.20, 34.21  
detection 34.19–21  
atypical, in HIV infection 35.25  
biopsy specimens 34.18, 34.19  
bone and joint involvement 34.16, 62.100, 62.105  
cardiovascular 34.14, 34.16  
treatment 34.22  
causative organism 34.3–4  
congenital 17.25, 17.46, 34.15–18  
diagnosis 34.21  
early 34.15–16, 34.18  
late 34.16, 34.18  
prevention 34.24  
stigmata 34.16–17
- transmission 34.5, 34.12  
treatment 34.16, 34.23, 34.23
- control 34.24
- dactylitis in 34.16
- definition 34.1
- diagnosis 34.18–21  
biological false-positive tests 34.20–1  
CSF examination 34.21  
dark-field microscopy 34.3, 34.18–19  
latent syphilis 34.12  
molecular amplification tests 34.19  
rapid point-of-care tests 34.20  
serological screening 34.20–1, 34.24  
serological tests (STS) 34.16, 34.19–21  
specimens 34.18
- differential diagnosis 34.7–8, 34.11–12, 61.5, 61.10
- ear involvement 68.20
- endemic 30.63
- female genital involvement 71.71
- follow-up 34.23
- histopathology 34.5
- HIV co-infection 34.3, 34.14  
treatment 34.23
- incidence 34.2, 34.2–3, 34.15
- incubation period 34.5
- latency 34.5, 34.11
- latent 34.12, 34.23  
diagnosis, CSF examination 34.21
- leukoderma in 58.31
- male genital involvement 71.33–4  
management 34.22–4  
failure 34.23  
in pregnancy 34.22–3  
of sexual contacts 34.23
- medico-social background 34.2
- in men who have sex with men (MSM) 34.3, 34.7
- meningovascular 34.14
- natural history 34.5
- neurosyphilis *see* neurosyphilis
- ocular involvement 67.27
- oral involvement 69.78, 69.90, 69.91, 69.118
- parenchymatous 34.14
- pathogenesis 34.4
- perianal/perineal involvement 71.93  
in pregnancy 34.15, 34.24
- primary 34.6–8  
diagnosis 34.18  
differential diagnosis 34.7–8  
sites 34.7  
treatment 34.22
- prognosis 34.23–4
- race and 9.6
- reinfections 34.23
- risk factors 34.24
- sarcoidal reaction in 61.22
- screening 34.24
- secondary 34.8–12  
diagnosis 34.18  
differential diagnosis 34.11–12, 61.10  
hair loss in 34.11, 66.29, 66.52  
papules 34.7, 34.9, 34.10–11  
pityriasis rosea vs 33.80  
post-inflammatory hypermelanosis after 58.31  
renal involvement 62.71  
sarcoidosis and 61.18
- secondary prevention 34.24
- stages 34.5
- stigmata 34.16
- tattoo localization and 58.58
- tertiary (late) 34.12–14  
diagnosis 34.18, 34.19  
differential diagnosis 31.10, 34.14  
follow-up 34.23  
gumma 34.13–14  
leg ulcers 47.56  
management 34.22  
mucous membrane lesions 34.14  
osteomyelitis in 62.105  
scalp involvement 66.52  
scars 45.6

- tests for 34.18–21  
*see also* syphilis, diagnosis  
 transmission 34.5, 34.12  
 treatment 34.2  
*see also* syphilis, management  
 untreated, course of 34.5  
 vaccine development problem 34.24
- syringobulbia 63.14  
 syringocystadenoma *see* syringoma  
 syringocystadenoma papilliferum 18.14–15, 53.19–20, 68.30
- syringocystoma *see* syringoma  
 syringofibroadenoma, eccrine 53.22, 53.24–5
- syringoid eccrine carcinoma 53.36  
 syringoma 53.25–6, 71.72  
 chondroid 53.2, 53.30–2  
 malignant 53.31  
 eruptive 53.25  
 eyelid 67.33, 78.14  
 female genitalia 71.72  
 genetics 15.10  
 male genitalia 71.36  
 malignant 53.35–6
- syringomyelia 63.14–15  
 post-traumatic 63.17
- syringosquamous metaplasia 44.17, 75.123
- systematic reviews 6.16, 7.4  
 appraisal and evaluation 7.7–11  
 Cochrane Database of Systematic Reviews 7.5  
 information resources 6.20
- systemic agents 74.1–54  
 anti-inflammatory agents 74.2–3  
 antiallergic agents 74.31  
 antifungal drugs 74.46–8  
 antimicrobials 74.38–50  
 antiparasitic agents 74.50–1  
 antiviral drugs 74.48–50  
 biological therapies 74.4–13  
 Chinese herbal medicine 74.52  
 drugs to improve peripheral circulation 74.51  
 immunomodulating agents 74.25–30  
 immunosuppressive agents 74.14–24  
 levels of evidence of efficacy 74.1  
 protein therapeutics 74.4–13  
 retinoids 74.33–8  
 sex hormones and related compounds 74.32  
*see also specific agents for further references*
- systemic capillary leak syndrome 22.23
- systemic disease and the skin 62.1–113  
 in animals 2.17–18  
 bone and joint disorders 62.99–106  
 cardiac disease 62.75–80  
 endocrine disorders 62.2–14  
 eye involvement 67.24, 67.25  
 gastrointestinal disorders 62.47–58  
 haematological disorders 62.85–96  
 liver disorders 62.58–65  
 pancreatic disorders 62.65–8  
 renal disorders 62.68–75  
 respiratory disorders 62.80–5  
*see also individual diseases and disease groups (e.g. liver, disorders)*
- systemic lupus erythematosus (SLE) 51.27–63  
 aetiology 51.28  
 abnormal cell-mediated immunity 51.30  
 autoantibodies 51.29, 51.32  
 environmental factors 51.30  
 genetic/environmental factors 51.32  
 infections, stress and hormonal factors 51.31  
 viral involvement 51.31  
 age of onset 51.27  
 alopecia 66.29  
 anetoderma in 45.17  
 in animals 2.16  
 annular erythema in 62.109  
 antinuclear antibody-negative SLE 51.56  
 ARA criteria for diagnosis 51.27  
 association with other diseases 51.56–7  
 autoantibodies 51.29, 51.32, 51.63  
 bone and joint involvement 62.102  
 bullous *see* bullous systemic lupus erythematosus  
 cardiac involvement 51.43, 62.78  
 in childhood 51.48  
 clinical features 51.35–48  
 avascular bone necrosis 51.47  
 bullous SLE 51.41  
 calcification 51.47  
 cardiac involvement 51.43  
 cutaneous features 51.36  
 eyes/ears 51.46–7, 68.17  
 gastrointestinal tract 51.44–5  
 hair changes 51.38, 66.29, 66.30  
 hepatic lesions 51.45  
 hypertension 51.43  
 IgG anticardiolipin antibody 51.63  
 lupus anticoagulant 51.63  
 lymphadenopathy 51.48  
 mucinosis 51.40  
 muscle changes 51.47  
 neurological and psychiatric disease 51.45–6  
 other cutaneous changes 51.40  
 polyarthritis with inflammation 51.42  
 pulmonary infiltration 51.43  
 renal changes 51.44  
 rheumatoid-like deformity 51.42  
 thyroid disease 51.45  
 vasculitis 51.39
- cryoglobulinaemia with 49.32  
 diagnosis 51.27  
 differential diagnosis 51.59  
 discoid lupus erythematosus vs 51.2  
 rosacea vs 43.5  
 drug-associated 51.31–2, 51.63  
 ear involvement 51.46–7, 68.17  
 in the elderly 51.48  
 genetic counselling 51.61  
 genetics 15.13  
 hair changes 51.38, 66.29, 66.30  
 HPV infections 33.59  
 idiopathic thrombocytopenic purpura and 49.9  
 idiotypes and anti-idiotypes 51.29  
 immunohistology 51.34  
 incidence 51.27  
 laboratory investigations 51.52  
 lip involvement 69.128  
 lupus panniculitis 46.25  
 ocular involvement 51.46–7, 67.25  
 oral involvement 69.71  
 paraneoplastic 62.39–40  
 pathological features 51.33  
 pathology  
 DLE and 51.34  
 Libman–Sacks endocarditis 51.33  
 pemphigus foliaceus and 40.16  
 pigmentation changes 58.27  
 in pregnancy 8.12, 51.48  
 prognosis 51.59–60  
 respiratory tract involvement 51.43, 62.82  
 treatment 51.61–3  
 azathioprine 74.15  
 ciclosporin 51.62  
 corticosteroids 51.61  
 danazol 51.62  
 dietary measures 51.62  
 extracorporeal photochemotherapy 51.62  
 hydroxychloroquine 51.61  
 immunosuppressive drugs 51.61  
 methotrexate 51.62  
 plasmapheresis 51.62  
 prednisolone 51.61, 51.62  
 specific treatment as for DLE 51.62  
 TNF antagonists 74.8  
 vasculitis and 50.48, 51.39
- systemic sclerosis *see* systemic sclerosis  
 scleroderma 51.87–110  
 aetiology 51.88  
 HLA-DR typing 51.90  
 microchimerism 51.90  
 other factors 51.90  
 associations 51.105–6  
 autoimmunity 51.89, 51.105  
 in childhood 51.105  
 classification 51.91  
 clinical features 51.94–105  
 bone changes 51.97  
 calcinosis 51.97  
 cardiac involvement 51.101, 62.78  
 central nervous system 51.102  
 cutaneous changes 51.94–5  
 dental changes 51.102  
 eye changes 51.103  
 hepatic involvement 51.101  
 involvement of the gastrointestinal tract 51.99  
 joint involvement 51.102  
 morphoeic patches 51.106  
 muscle involvement 51.101–2, 51.105  
 osteopoikilosis 51.98  
 pulmonary involvement 51.98  
 renal involvement 51.101  
 tendon involvement 51.102  
 terminal absorption of the phalanges 51.97  
 without skin involvement 51.97
- diagnosis 51.91  
 differential diagnosis 51.106  
 dermatomyositis vs 51.128  
 ocular mucous membrane pemphigoid vs 67.20  
 genetic factors 51.90  
 immunoglobulin/complement absence from dermal–epidermal junction 51.92  
 incidence 51.87  
 laboratory abnormalities 51.103–4  
 anticentromere antibodies 51.103  
 methotrexate 74.20  
 natural history 51.94  
 paraneoplastic 62.40  
 pathology 51.91  
 pigmentation changes 58.26  
 in pregnancy 51.105  
 prognosis 51.107  
 progressive 62.99  
 bone and joint involvement 62.103  
 race and 9.14  
 Sjögren's syndrome in 51.105  
 treatment 51.107–9  
 variations 51.104–5
- T**  
 T4 endonuclease V 15.74  
 liposomal formulation 73.23  
 T-cell inhibitors, psoriasis 74.6  
 T-cell leukaemia–lymphoma *see* adult T-cell leukaemia–lymphoma (ATLL)  
 T-cell lymphomas 57.3–40  
 adult T-cell leukaemia–lymphoma (HTLV-1-associated) 57.37–9  
*see also* adult T-cell leukaemia–lymphoma (ATLL)  
 aggressive epidermotropic CD8+ (provisional) 57.35–6  
 bexarotene 57.23, 74.37  
 CD4+/CD56+ haematodermic neoplasm (blastic NK-cell lymphoma) 57.39–40  
 CD4+ small/medium sized pleomorphic 57.36–7  
 CD30+ lymphoproliferative disorders 57.29–34  
 anaplastic large cell lymphoma 57.31–3  
 lymphomatoid papulosis 57.29–30  
 EBV association 33.31
- extranodal NK/T-cell lymphoma (nasal type) 57.40–1  
 follicular mucinosis 57.14  
 gamma/delta (provisional entity) 57.36  
 granulomatous slack-skin disease 57.15–16  
 hydroa vacciniforme and 29.15  
 mycosis fungoides 57.3–13, 57.22–9  
 pagetoid reticulosis 57.15  
 peripheral T-cell lymphoma 57.34–40  
 primary cutaneous CD30+ lymphoproliferative disorders 57.29–34  
 secondary 57.51–3  
 angioimmunoblastic T-cell lymphoma 57.51–2  
 post-transplant lymphoproliferative disorder (PTLD) 57.51–2  
 Sézary syndrome 57.17–29  
 subcutaneous, panniculitis in 46.23  
 subcutaneous panniculitis-like (SPTL) 46.26, 57.33  
 of  $\alpha/\beta$  T-cell phenotype (SPTL-AB) 46.23, 46.24, 46.25  
 of  $\gamma/\delta$  T-cell phenotype (SPTL-GD) 46.23, 46.24, 46.25  
 WHO–EORTC classification 57.2  
*see also* lymphoma(s)
- T-cell receptors 4.8, 13.6–7  
 development 13.7, 13.8, 17.49  
 gd 13.6  
 gene analysis 57.12–13  
 T lymphocytes 13.6–7, 13.7, 17.49, 64.9  
 activation 4.8, 13.10–11, 17.50, 24.13  
 Langerhans' cell role 3.17, 3.18  
 adverse drug reactions and 75.18–19  
 ageing effect 8.24  
 in allergic contact dermatitis 26.6  
 anergy 17.50  
 antigen presentation to 13.9–10, 17.50–1, 55.4  
 in atopic dermatitis 24.6–8, 24.11  
 blister formation 40.26  
 CD8+ class I pathway 12.13  
 clonal proliferation, cytophagic histiocytic panniculitis 46.23  
 cytokines released 35.4, 35.18, 35.22, 42.26  
 acne pathogenesis 42.26  
 cytotoxic (Tc/CD8<sup>+</sup>) 12.13, 13.7  
 activation 4.8  
 commercially available antibodies to 10.25  
 development 13.8  
 in HIV infection 35.3–4  
 increased in pruritic papular eruption in HIV 35.19  
 increased in psoriasis in HIV infection 35.17  
 in lichen planus 41.1  
 reduced in Langerhans' cell histiocytosis 55.6  
 subtypes 13.11  
 Tc1 13.11  
 Tc2 13.11  
 in delayed-type hypersensitivity reactions 26.5  
 depression/anergy  
 in Langerhans' cell histiocytosis (LCH) 55.6, 55.7  
 in measles 33.75  
 in dermis 3.18–19  
 development 13.7, 13.8, 17.49–50  
 differentiation 35.4  
 EBV infection 33.31  
 in eczema 23.5  
 extrathymic generation 13.8  
 $\gamma\delta$  13.6  
 in Behçet's disease 50.56  
 in Langerhans' cell histiocytosis 55.8  
 in vasculitis 50.6  
 in granuloma annulare 60.4  
 helper (Th/CD4<sup>+</sup>) 13.7, 64.9  
 acne scarring and 42.27  
 activation 4.8

- in atopic dermatitis 24.6–7  
 autoreactive, antiphospholipid syndrome 49.41  
 commercially available antibodies to 10.25  
 defective in psoriasis in HIV infection 35.17  
 destruction in HIV infection 35.4, 35.5, 35.10  
 development 13.8  
 differentiation 24.13–14, 35.4  
 in HIV infection 35.4  
 in lichen planus 41.1  
 polymorphic light eruption 29.11  
 reconstitution by HAART 35.4  
 subtypes 13.11  
 in urticaria 22.3  
 in vasculitis 50.6  
*see also Th1 cells, Th2 cells, Th3 cells (below)*
- helper (Th/CD4<sup>+</sup>) count  
 AIDS-defining complication 35.5  
 eosinophilic folliculitis in HIV infection 35.18  
 in HIV infection 35.5  
 immunogenotyping 10.30  
*in vitro* function tests 13.23  
 intraepidermal 4.8  
 in leprosy 32.7  
 in lymph nodes 13.8–9  
 microscopy 10.34  
 natural killer (NK) 13.6  
 induction by UV radiation 13.31  
 in pyoderma gangrenosum 50.65  
 quantification 17.56–7  
 receptors *see* T-cell receptors  
 reduction  
 in familial haemophagocytic lymphohistiocytosis 55.25–6  
 in HIV infection 35.4, 35.5  
 in HPV infection 33.42  
 regulatory (Treg) 13.11, 31.4  
 in atopic dermatitis 24.7  
 deficiency 13.11  
 induction by UV radiation 13.30–1  
 role in skin immunological function 4.8  
 in sarcoidosis 61.4, 61.5  
 in sensitization 26.12  
 in spleen 13.8  
 in Stevens–Johnson syndrome 76.9  
 suppressor 13.30  
 Th1 cells 13.11, 17.50  
 in acne pathogenesis 42.25, 42.26  
 in atopic eye disease 67.15  
 cytokines 35.4, 42.26  
 in HIV infection 35.4  
 mucous membrane pemphigoid 67.20  
 NFAT regulation of, immunomodulators and 73.31  
 Th2 cells 13.11, 17.50  
 in atopic eye disease 67.15  
 cytokines 35.4, 35.18, 35.22  
 in HIV infection 35.4, 35.22  
 NFAT regulation of, immunomodulators and 73.31  
 response, Langerhans' cells 3.17  
 Th3 cells 13.11  
 in toxic epidermal necrolysis 76.9  
 trafficking 13.9  
 in tuberculosis 31.4  
 UV radiation effects on 13.30–1  
 in vasculitis 50.6–7  
 in vitiligo 58.46  
 in wound healing 14.3  
 t-PA (tissue plasminogen activator) 47.6  
 t-test 7.19–20  
*Tabanid*, skin disease in animals 2.11  
*Tabanidae* 38.6, 38.7  
*Tabanus* (horse flies) 37.11, 38.6, 38.7  
 tabes dorsalis 34.16, 63.11, 63.15  
 tabetic neurosyphilis 34.14  
 tacalcitol 73.43, 73.44–5  
 adverse effects 26.46  
 doses 73.44  
 indications 73.44–5  
 in psoriasis 20.26, 73.44  
 in seborrhoeic dermatitis 23.33  
 structure 73.44  
 Tacaribe complex viruses 33.69  
 tâche noire 38.35  
 tachykinins 63.2  
 substance P 12.64  
 tachyphylaxis, corticosteroid-induced 73.19  
 tacrolimus (FK506) 13.25, 20.42, 51.23, 51.118, 73.31–2, 74.17  
 adverse effects 26.46, 73.31, 75.146–7  
 in allergic contact dermatitis 26.102  
 in atopic dermatitis 24.30, 73.31  
 in children 73.31  
 in chronic actinic dermatitis 29.18  
 in eczema 23.38  
 in granuloma annulare 60.10  
 in granuloma faciale 50.29  
 indications 73.31, 73.32  
 Kaposi's sarcoma association 35.36–7  
 in pyoderma gangrenosum 50.72  
 in sarcoidosis 61.21  
 in seborrhoeic dermatitis 23.33  
 structure 73.32  
 systemic exposure 73.31–2  
 topical 73.31–2  
 indications 73.31, 73.32  
 in lichen planus 41.18  
 in rosacea 43.6, 43.10  
 tacrolimus-binding proteins 74.18  
*Taenia saginata* 37.24  
*Taenia solium* 37.1, 37.3, 37.24, 37.25  
 taeniasis 37.24  
 larval (cysticercosis) 37.3, 37.24, 37.25  
 tags *see* skin tags  
 Takayasu's arteritis 50.44–5  
 talc 73.2, 73.8  
 granuloma 71.100  
 sarcoidal reaction to 61.22  
 talking therapies 64.4  
 tall oil rosin 26.79  
 talon noir (black heel) 28.16, 28.31, 49.16  
 tamoxifen  
 adverse effects 75.119  
 dermatomyositis and 51.121  
 in gynaecomastia 70.5  
 in progesterone-induced dermatitis 74.33  
 tanapox 33.14  
 tanapox virus 33.5  
 Tangier disease 59.91  
 tanners, occupational hazards 27.21  
 tanning 58.1, 58.10, 58.31–3  
 delayed 4.7, 58.31  
 delayed effects 29.5  
 DNA damage 58.31  
 immediate effects 29.5  
 immediate pigment darkening (IPD) 58.31  
 persistent pigment darkening (PPD) 58.31  
 phases 58.31  
 UV light 58.31–3  
*see also* sun tan  
 tanning devices, UVR exposure 29.4  
 tanning salon exposure 58.31  
*see also* sunbeds/sunlamps  
 Tanzania, prevalence of skin disease 6.10  
 TAP proteins 13.10  
 tapeworms (cestodes) 37.2, 37.3, 37.24–7  
 tar 73.41–3  
 as carcinogen 52.4  
 carcinogenicity mechanism 73.42  
 coal *see* coal tar  
 dithranol with 73.30  
 shale 73.42  
 sources 73.41–2  
 topical corticosteroids with 73.20  
 wood 73.42  
 tar acne 42.77  
 tar keratosis 52.37  
 TAR syndrome (thrombocytopenia–absent radii syndrome) 18.70  
 tarantula 38.30  
 target lesions 76.1, 76.6, 76.7  
 tartrazine 5.25, 22.11, 22.26, 75.26, 75.158  
 tattoos 58.57–9, 64.2  
 accidental/traumatic 58.57  
 allergic contact dermatitis and 26.10  
 allergic reactions 58.58  
 amalgam 69.95–6  
 complications 28.48–9, 58.58  
 decorative 58.57–9  
 history and prevalence 58.57  
 granulomatous reactions to 26.27, 26.39  
 henna 26.60, 58.57  
 infections associated 58.58  
 lichenoid reaction 58.58  
 lips 69.96  
 oral cavity 69.95–6  
 pigments 26.27  
 reactions 28.48–9  
 lichen planus and 41.16  
 sarcoïdal 61.13, 61.22  
 removal 58.59, 78.10  
 infrared coagulation 77.47  
 skin disease localization 58.58  
 techniques and materials 58.58  
 temporary 26.25, 26.26, 58.57  
 treatment (reactions) 58.59  
 taurodontia, absent teeth and sparse hair 15.53  
 taurodontism 69.8, 69.9–10  
 taxanes 75.135–6  
 Tay's syndrome (IBIDS/PIBIDS syndrome) 19.47–9  
 tazarotene 20.27, 73.35, 73.37, 75.113  
 adverse effects 73.37  
 tazarotenic acid 73.37  
 TCDD 27.12, 27.13  
 TCOF1 gene 18.80–1  
 TDO (trichodontoosseus) syndrome 15.54, 15.65, 69.11  
 TDT (thermal damage time) 78.5, 78.12  
 tea tree oil (TTO)  
 acne vulgaris treatment 42.43  
 adverse effects 26.45, 26.47, 70.5, 75.160, 75.162  
 in head louse infection 38.20  
 as insect repellent 38.5  
 in scabies 38.41  
 teak 26.81  
 tear film 67.11  
 lipid 67.2, 67.11  
 precorneal 67.2, 67.3  
 functions 67.3  
 lipids 67.2, 67.3  
 mucin 67.3  
 removal, lacrimal pump 67.3  
 tear substitutes 67.31  
*Tectona grandis* 26.81  
*Tedania ignis* 38.59  
 TEE (transepithelial elimination) 45.63, 45.64, 45.65, 68.14  
 teeth 69.2  
 abnormal enamel  
 generalized non-Herlitz junctional EB 39.13  
 Herlitz junctional EB 39.12  
 junctional EB with pyloric stenosis 39.14  
 late-onset junctional EB 39.15  
 abnormalities in dogs 2.18  
 care, in severe generalized dystrophic EB 39.28  
 caries, in dystrophic EB 39.19  
 in congenital syphilis 34.16–17, 69.8  
 discoloration 69.8, 69.9, 75.55  
 early loss 69.7–8  
 in ectodermal dysplasia 15.58–9, 15.62, 15.64–6, 15.68, 69.10–12  
 eruption 69.2, 69.3  
 delayed 69.7  
 premature 69.7  
 examination 69.6  
 Hutchinsonian incisors 69.8, 69.78  
 Hutchinson's 34.17  
 hypoplasia 69.8, 69.9  
 impaction 69.7  
 in incontinentia pigmenti 69.6  
 in Langerhans' cell histiocytosis 55.11  
 loosening 69.7–8  
 loss 69.6  
 malformation 69.8, 69.9  
 missing 69.7  
 mulberry (Moon's) molars 69.8  
 natal 69.7  
 neonatal 69.7  
 notation 69.3  
 peg-shaped 69.8  
 premature eruption 55.11  
 screwdriver 34.17  
 supernumerary (supplemental) 69.6, 69.7  
 taurodont 69.8, 69.9–10  
 Turner's 69.8  
 wisdom 69.7  
*see also* dentition  
 teething 69.7  
*Tegetaria agrestis* 38.32  
 teichoic acid 30.7, 30.8  
 teicoplanin 30.9, 74.43  
 telangiectases/telangiectasia 47.12, 47.12–21  
 aetiology 47.13  
 in ageing skin 8.21, 80.2, 80.11  
 ankles 47.14  
 in basal cell carcinoma 52.19  
 breast 70.13  
 calcium channel blockers with 47.15–16  
 capillary 47.37  
 in chronic radiodermatitis 79.16  
 cold-induced injury 28.68, 28.70  
 development 47.12–13  
 essential 47.19, 47.20  
 facial 47.14  
 generalized essential 47.19  
 gingival 69.13  
 in granulosis rubra nasi 44.18  
 hereditary acrolabial 70.13  
 hereditary benign 47.20  
 hereditary haemorrhagic *see* hereditary haemorrhagic telangiectasia (HHT)  
 lupus erythematosus profundus 51.16  
 macular 47.12  
 male genital region 71.51  
 nail-fold 47.14  
 in necrobiosis lipoidica 60.13, 60.14  
 oral cavity 69.22, 69.101  
 paraneoplastic 62.44  
 post-radiotherapy 70.14  
 primary 47.13, 47.16–20  
 ribs, lower border 47.14  
 in rosacea 43.4, 43.6  
 secondary 47.13, 47.13–16  
 spider *see* spider angioma  
 systemic sclerosis 51.95, 51.96  
 thermal injury 28.72  
 treatment 47.20–1  
 laser therapy 78.7–8  
 nicotinic acid 73.51  
 venous 47.39  
 vessel classification 47.13  
 telangiectasia macularis eruptiva perstans 22.32–3, 47.13, 47.14  
 skin biopsy 10.43  
 telangiectatic erythema and stunted growth, congenital 15.76–7  
 telecanthus 67.4  
 teledermatology 72.2  
 telemedicine 5.25–6  
 teleomorph 36.2  
 television repair, occupational hazards 27.20  
 telogen 3.7, 3.13, 66.8, 66.9, 66.10  
 in androgenetic alopecia 66.20  
 telogen effluvium 66.16, 66.20, 66.27–31  
 acute 66.27–8  
 chronic 66.22, 66.30–1  
 chronic diffuse 66.28–30  
 definition 66.27  
 delayed anagen release 66.27–8

- diagnosis 66.28  
in HIV infection 66.2  
immediate anagen release 66.27  
pathogenesis 66.27  
postpartum (telogen gravidarum) 66.9, 66.27–8  
short anagen syndrome 66.27  
skin biopsy 10.43  
telogen gravidarum 66.9, 66.27–8  
telomerase 58.21  
temazepam 75.81  
temporin, photosensitivity due to 29.21  
temozolomide, melanoma management 54.54  
brain metastases 54.54, 54.56  
temperature  
cold *see* cold (cold temperature)  
hair growth and 66.9  
limb, erythromelalgia 47.9  
role in irritant contact dermatitis 25.8  
sensitivity to 4.7, 4.9  
*see also* body temperature;  
thermoregulation  
temperature set point 44.5  
temporal arteritis *see* giant cell arteritis  
temporalis muscle, examination 69.4  
temporomandibular joint  
examination 69.4–5  
herniation 68.29  
in multicentric reticulohistiocytosis 69.59  
in psoriatic arthritis 20.57  
TEN *see* toxic epidermal necrolysis (TEN)  
tenascin 14.3, 14.4  
tenascin-X 45.32  
deficiency 45.32, 45.33, 45.34, 45.37  
tendon(s)  
in systemic sclerosis 51.102  
xanthomata 59.84  
tendon sheath  
fibroma 56.10  
giant cell tumour 56.15–16, 65.36  
Tenebrionidae 38.27  
teniposide, familial haemophagocytic lymphohistiocytosis 55.26  
tenofovir 75.67  
tenosynovitis, gonococci causing 34.27  
tensile strength of skin 45.14  
tensile tests, mechanical injury 28.5  
teratogens 18.1, 75.11  
aplasia cutis congenita due to 18.102  
drugs 72.28, 75.11  
acitretin 72.28  
isotretinoin 42.59, 42.63, 72.28  
retinoids 42.50, 72.28, 73.35, 74.38  
systemic retinoids 73.35  
teratoma 18.88  
terbinafine 73.12, 74.47  
adverse effects 75.64, 75.65–6  
in chromoblastomycosis 36.76  
in dermatophytoses 36.47–8, 36.49, 36.50  
failure to respond to 36.50–1  
in pityriasis versicolor 36.12  
in *Scytalidium* infection 36.52  
in sporotrichosis 36.72  
TERC gene 15.78–9, 58.21  
terconazole, topical 73.12  
terephthalylidene dicamphor sulphonate acid 73.40  
terfenadine 22.29, 75.148–9  
terminal pilosebaceous unit 3.13  
terminology, diagnosis and 5.1  
terpenes 26.41, 26.79  
TERT gene 15.78–9  
4-tertiary butylcatechol, depigmentation due to 58.50  
*p*-tertiary butylcatechol 27.15  
*p*-tertiary butylphenol 27.15  
depigmentation due to 58.50  
*p*-tertiary butylphenol formaldehyde resin 26.68, 26.69, 26.73–4  
testes  
fetal 8.2  
at puberty 8.4  
tumours 70.4  
testosterone  
absorption, reduced with age 8.23  
acne aetiology and 42.20, 42.21, 42.22  
acneiform eruptions due to 42.72  
activity in skin 42.10  
administration, effect on sebaceous glands 42.10, 42.20  
adverse effects 75.119  
in androgenetic alopecia 66.13–14, 66.19  
effect on sebum composition 42.6  
in females, acne aetiology and 42.20  
hair growth and 66.9, 66.13  
hirsutism and 66.81, 66.83  
metabolism 8.2, 42.10, 42.21  
inhibition 42.16  
oestrogen synthesis 8.8  
at puberty 8.4  
reduced, by oral contraceptives in acne 42.53  
synthesis 8.2, 8.8, 66.14  
at puberty 8.4  
sebocytes 42.12  
transdermal delivery 26.46  
testosterone 5 $\alpha$ -reductase 44.18  
*see also* 5 $\alpha$ -reductase  
tetanus  
prophylaxis in burns 28.79  
tungiasis and 38.13  
tetanus toxoid, grease-gun injuries and 46.29  
tetracaine 75.153, 77.10  
tetrachlorethylene 75.71  
tetrachloroazobenzene 27.13  
2,3,7,8-tetrachlorodibenzo-*p*-dioxin 27.12, 27.13  
tetrachlorophenols 25.21  
tetrachlorosalicylanilide 26.24  
tetracosactide (tetracosactrin)  
in lichen planus 41.18  
in lieu of systemic steroids 74.3–4  
tetracyclines 74.41–2  
acne vulgaris treatment 42.46–7, 42.48  
adverse effects 42.50, 74.41, 75.52–5  
allergy 26.46, 75.53  
fixed eruption 75.28  
hyperpigmentation 75.52–3  
lichenoid eruptions 41.24  
nail colour changes 65.16  
photosensitivity 75.31, 75.52  
systemic 75.54  
tooth discoloration 69.8, 69.9, 75.55  
dose range and evidence level 74.30  
drug interactions 75.54, 75.55  
gastrointestinal absorption 75.54  
isotretinoin contraindication 42.64, 42.65  
nicotinamide and 74.30  
in pemphigus 40.12  
in perioral dermatitis 43.12  
in pregnancy 75.55  
*Propionibacterium acnes* resistance 42.56  
resistance 45.26, 74.41  
rosacea treatment 43.6, 43.7  
topical 73.11  
in acne 42.41  
*P. acnes* resistance 42.42  
toxicity 74.41  
tetrahydrobiopterin, defective metabolism, vitiligo pathogenesis 58.47  
tetramelic deficiencies, ectodermal dysplasia, deformed ears and other abnormalities 15.53  
Tetranychidae 38.48  
tetraphocomelia–thrombocytopenia syndrome 18.70  
TEWL *see* transepidermal water loss (TEWL)  
textile workers, occupational hazards 5.6, 27.21  
textiles *see* clothing  
TG1 (keratinocyte transglutaminase) 3.10  
thalassaemia 62.85–6  
pseudoxanthoma elasticum and 45.23  
thalidomide 13.24, 64.27, 72.28, 74.30–1  
actinic prurigo therapy 29.15  
adverse effects 68.4, 75.64  
in aphthous ulceration in HIV infection 35.42–3  
in complex regional pain syndrome 63.21  
in discoid lupus erythematosus 51.21  
dose range and evidence level 74.31  
in erythema multiforme 76.7  
irreversible peripheral neuropathy 74.30  
in Langerhans' cell histiocytosis 55.13  
in leprosy reactions 32.18  
pregnancy and 51.21  
in sarcoidosis 61.21  
thallium poisoning 75.160  
thallus 36.2  
thanatophoric dwarfism/dysplasia, prenatal diagnosis 16.3  
*Thaumetopoea* 38.28–9  
thaumetopoein 38.29  
thelalgia 70.11  
thelarche 8.4, 8.5  
*Thelazia callipaeda* 37.18  
*Thelyphassa* 38.27  
theobroma oil 73.6  
theque 10.42, 54.10  
therapeutic cupping 28.24  
therapeutic outcome, factors influencing 72.25–8  
Theraphosidae 38.30  
therapy *see* treatment  
Theridiidae 38.31  
thermal damage time 78.5, 78.12  
thermal injury 28.63–94  
burns 28.74–94  
cold-induced 28.63–71  
heat and infrared radiation 28.71–4  
Koebner response 28.2–3, 28.73  
Nikolsky sign 28.4  
overview 28.1–4  
response determinants 28.2  
thermal radiation, non-melanoma skin cancer associated 52.5  
thermal relaxation time 78.4, 78.5, 78.12  
thermokinetic selectivity 78.5  
thermoreceptors 4.7, 4.9  
thermoregulation 4.1, 4.7, 63.3  
in anhidrosis 44.13  
role of blood vessels 3.50–1  
role of skin 3.3, 4.1, 4.7  
role of sweat glands 4.7, 44.2, 44.4, 44.5  
variations in 44.7  
thesauriosis 61.22  
*Thespesia populnea* 26.81  
thiabendazole 74.51  
in cutaneous larva migrans 37.17  
in dracunculiasis 37.13  
in scabies 38.41  
in tinea nigra 36.15  
thiambutosine 74.46  
thiazide diuretics *see* diuretics  
thiazolidinediones, HIV lipodystrophy 46.42  
Thibierge–Weissenbach type, scleroderma 47.14  
Thiersch grafts, localized morphea 51.65  
thimble jellyfish 38.56  
thimerosal 25.21, 26.46, 73.8  
thinners 25.20  
thinning of skin, corticosteroid-induced 73.17  
thioacetazone 75.62  
thioalcohols 73.29  
thioflavine T method 10.10  
thioglycollates 25.21, 73.29  
6-thioguanine 20.40  
thiomersal 25.21, 26.46, 73.8  
thiopurine methyltransferase (TPMT) 11.16, 13.24, 72.29, 74.14–15  
deficiency 74.15  
thioridazine 75.82  
thiotepa  
adverse effects 75.33, 75.125–6  
eccrine gland secretion 44.18  
thiothixene 75.82  
thiouracils, adverse effects 75.121  
vasculitis 50.17, 50.18  
thiourea, as photoallergen 26.24  
Thompson buried dermis flap operation 48.25  
thonzylamine 75.149  
thoracic duct 13.8, 48.5  
Thost–Unna keratoderma 19.97  
threadworm 37.13–14  
*see also* *Enterobius vermicularis*  
Three Item Severity Score 72.10  
3T3 NRU PT test 25.9  
thrips 38.26  
thrombin 49.38  
inhibitors 49.28  
receptors, PAR-1, -3 and -4 12.49  
thromboangiitis obliterans (Buerger's disease) 47.4, 47.6–8, 50.54  
male genital dermatology 71.28  
thrombophlebitis migrans in 47.30  
thrombocytes *see* platelet(s)  
thrombocythaemia 49.14, 49.29–30  
in erythromelalgia 47.9, 47.10  
thrombocytopenia 49.2, 49.7  
antiphospholipid syndrome 49.41  
in bone marrow diseases 49.11–12  
in congenital syphilis 34.16  
drug-/toxin-induced 49.11, 75.23  
gestational/incidental 49.12  
in haemangioma 49.12  
heparin-induced 49.11, 49.27–9  
in HIV infection 35.10  
infection-associated 49.11  
platelet counts 49.5, 49.8  
in pregnancy 49.12  
purpura due to *see* thrombocytopenic purpura  
secondary 49.11–12  
simple macular haemorrhage 49.4  
symptomatic 49.11–12  
thrombocytopenia–absent radii syndrome 18.70  
thrombocytopenic purpura 49.7–12  
autoimmune/immune *see* idiopathic thrombocytopenic purpura (ITP)  
idiopathic *see* idiopathic thrombocytopenic purpura (ITP)  
in infectious mononucleosis 33.30  
secondary/symptomatic 49.11–12  
thrombotic 49.12, 49.31, 69.114  
in varicella 33.25  
thrombocytosis  
bleeding and purpura 49.5, 49.14  
essential 49.29  
myeloproliferative 49.29–30  
purpura due to 49.8  
thrombolysis 47.6  
thrombomodulin 49.38  
thrombomodulin–protein C/S anticoagulant pathway 49.38–9  
thrombophilias 47.42, 49.7, 62.91–2  
venous pigmented purpuric dermatoses 49.23  
thrombophlebitis  
penile 71.14  
superficial 47.30  
breast and chest wall (Mondor's disease) 48.29  
thrombophlebitis migrans 47.30–1, 62.42–3, 62.66  
thrombopoietin receptor, mutation 49.29  
thrombosis 47.28  
antiphospholipid antibodies causing 49.41  
calf vein 47.29  
capillary, venous leg ulceration and 47.42  
deep vein *see* deep-vein thrombosis (DVT)  
in heparin-induced thrombocytopenia 49.27

- iliac 47.28  
 lethal cutaneous and gastrointestinal arteriolar *see* Degos' disease  
 non-inflammatory hyaline 49.33  
 in paroxysmal nocturnal haemoglobinuria 49.30  
 pathogenic mechanism 49.38  
 prevention, in myeloproliferative disorders 49.29  
 thrombotic thrombocytopenic purpura 49.31  
 venous *see* deep-vein thrombosis (DVT); venous thrombosis  
 thrombospondin 1 (TSP-1) 12.33  
 thrombospondins 14.3  
 in Ehlers–Danlos syndrome 45.33  
 thrombotic microangiopathy 49.12  
 thrombotic thrombocytopenic purpura (TTP) 49.12, 49.31, 69.114  
 thromboxanes (TX) 12.60, 13.4  
 in wound healing 14.3  
 thrush  
 oral (acute pseudomembranous candidiasis) 36.60, 36.64, 36.68, 69.88–9  
 vulvovaginal 36.61–2, 36.68  
*Thuja plicata* 26.80  
 thumb  
 deformity and alopecia 15.53  
 racket 65.9  
 thumb sign 45.30  
 thumbnail, Beau's line 59.75  
 thunder flies (thrips) 38.26  
 Thy-1 12.69  
 thymic stromal lymphopoietin (TSLP) 12.36, 24.14  
 thymidine kinase 73.15  
 virus drug resistance 33.21  
 thymidylate synthase 11.16  
 thymine 11.2  
 thymol, topical therapy 73.48–9  
 thymoma, candidiasis and 36.65  
 thymus  
 ageing and 13.15  
 developmental failure 13.8  
 T cell development 13.7, 13.8  
 thymus and activation-regulated chemokine (TARC/CCL17) *see* RANTES  
 thyroglossal cysts 62.11  
 thyroglossal duct 18.86–7  
 thyroid  
 cancer 62.11  
 function, urticaria and 22.2, 22.26  
 lingual 69.35–6  
 medullary carcinoma 62.44  
 flushing associated 43.16  
 in pregnancy 8.9  
 in SLE 51.45  
 thyroid acropachy 62.9–10, 62.101  
 thyroid transcription factor-1 10.24  
 thyroiditis, autoimmune, granuloma annulare and 60.9  
 thyrotoxicosis *see* hyperthyroidism  
 thyrotrophin, human chorionic 8.9  
 thyroxine  
 adverse effects 75.120–1  
 hair growth and 66.9, 66.11  
 in urticaria 22.29  
 Thysanoptera 38.26  
 TIA-1 10.26  
 tiabendazole, adverse effects 75.71  
 tiaprofenic acid 26.46, 75.75  
 tibia, sabre 34.16  
 tibial–peroneal vessel occlusion 47.5  
 tic de lèvres 69.127–8  
 ticilimumab, melanoma management 54.54  
 tick-borne encephalitis 33.67  
 tickle sensation 21.1  
 ticks 30.73, 37.1, 38.33–6  
 ehrlichiosis and 30.58  
 Lyme disease and 30.64, 62.106  
 paralysis due to 38.35  
 relapsing fever and 30.62–3  
 removal 38.35–6  
 ticlopidine 75.108  
 Tietz's syndrome 58.43  
 tight junctions 3.24–5  
 tight skin contracture syndrome (restrictive dermatopathy) 17.20, 45.51  
 TIME system 14.19  
 time trade off (TTO) 72.22  
 TIMPs *see* tissue inhibitors of metalloproteinases (TIMPs)  
 tin ear syndrome 68.6  
 tincture of benzoin 26.41  
 tinctures 73.2  
 tinea, male genitalia 71.32  
 tinea amiantacea 36.27  
 tinea barbae 36.28–9, 36.49  
 tinea capitis (tinea tonsurans) 36.25–8, 36.47, 36.49  
 alopecia and 66.16  
 alopecia areata vs 66.35  
 race influences on 9.8  
 radiation epilation 79.4  
 scalp scaling 66.56  
 tinea corporis (tinea circinata) 5.12–13, 36.23–5, 36.49  
 in HIV infection 35.32  
 tinea cruris 36.33–4, 36.49–50, 71.6–7  
 tinea faciei (tinea faciale) 36.28, 36.29–30, 36.49  
 in HIV infection 35.32  
 tinea flava *see* pityriasis versicolor  
 tinea imbricata 36.24, 36.25, 36.29  
 tinea incognita 25.15, 36.35–6, 36.50  
 in HIV infection 35.32  
 topical corticosteroids causing 73.18  
 tinea manuum 26.29, 36.32–3, 36.50  
 tinea nigra 36.8, 36.14–15  
 tinea nodosa *see* piedra, black  
 tinea pedis 26.29, 36.30–2  
 eczematous 23.25  
 lymphoedema and 48.22  
 prevention 36.46–7  
 swimming and diving 28.54  
 treatment 36.49  
 tinea tonsurans *see* tinea capitis (tinea tonsurans)  
 tinea unguium 36.34–5, 36.50  
 tinea versicolor *see* pityriasis versicolor  
 tinidazole 75.59  
 tioconazole  
 in dermatophytosis 36.48, 36.50  
 topical 73.12  
 tiopronin 75.104  
 TIRAP/Mal 12.8  
*see also* Toll-like receptors  
 tirofiban 49.13  
 tissue engineering 14.26  
 tissue expansion 28.60–1, 77.35  
 in androgenetic alopecia 66.24  
 in congenital naevi 54.14  
 tissue inhibitors of metalloproteinases (TIMPs) 3.41  
 hair growth and 66.10  
 TIMP-1–4 12.51  
 tissue macrophages *see* histiocytes  
 tissue plasminogen activator 47.6  
 in vasculitis 50.4  
 tissue specimens  
 artefacts 10.7, 10.8, 10.30–1  
 blocking and sectioning 10.6, 10.7, 10.31  
 care of 10.4–5  
 fixatives and transport media 10.4–5, 10.6, 10.31  
 information provided with 10.4  
 microscopy 10.31–6  
 preparation 10.6–7  
 for immunoenzyme methods 10.16–17  
 for immunofluorescence methods 10.12–13  
 routine processing 10.7, 10.8  
 staining 10.8–11, 10.31  
 tissue-engineered skin equivalents *see* skin equivalents  
 titanium, implants 26.37, 28.52  
 titanium dioxide 73.8  
 as sunscreen 73.40  
*Tityus* 38.33  
 tixocortol pivalate 26.45, 73.18  
 TMEP *see* telangiectasia macularis eruptiva perstans  
 TNF *see* tumour necrosis factor (TNF)  
 TNF-receptor-associated periodic syndrome 22.25, 50.53, 62.69, 62.104  
 TNM classification of tumours 69.51  
 toadfish 38.59  
 tobacco  
 chewing 69.50, 69.90  
 melanosis and 69.96  
 oral keratoses and 69.90  
*see also* smoking  
 tobramycin 26.17, 26.45, 75.58  
 tocopherol 59.61  
 toe(s)  
 clubbing of 15.87–8  
 congenital malalignment of the great toe 65.7  
 fibro-osseous pseudotumour 56.5  
 toe clefts  
 bacterial flora 30.4  
 erythrasma 30.37, 30.38  
 normal bacterial flora 30.4  
 toenails  
 ingrown, in HIV infection 35.41  
 lichen planus 41.14  
 torture injuries 28.33  
*see also* nail(s)  
 togaviruses, and *Togaviridae* 33.2, 33.66, 33.66–8, 33.67, 33.70  
 detection, blood samples 33.4–5  
 Toker's cells 53.40  
 Toll/IL-1 receptor (TIR) domain 12.8  
 Toll-like receptors 12.8–9, 13.5, 17.48, 32.6–7  
 acne aetiology 42.25  
 pathway deficiencies 17.82  
 potential uses 12.8  
 TLR-7 73.24  
 Toll signalling, non-melanoma skin cancer treatments and 52.17  
 tolmetin 75.77  
 tolnaftate 26.46, 36.49  
 topical, indications 73.12  
 toluene 25.20  
 toluene-2,5-diamine 26.60, 26.61  
 toluidine blue 10.9  
 toluidine blue unheated serum test (TRUST) 34.19  
 tongue 69.2  
 antibiotic sore (acute erythematous (atrophic oral) candidiasis) 36.60, 69.88, 69.102–4  
 black hairy 69.95  
 brown hairy 69.95  
 cellulitis 30.18  
 central papillary atrophy (median rhomboid glossitis) 36.61, 69.88, 69.105–6  
 circumvallate papillae 69.2  
 depapillation 69.22  
 examination 69.6  
 filiform papillae 69.2  
 foliate papillae 69.2  
 fungiform papillae 69.2  
 furred 69.95  
 geographical 69.22, 69.37, 69.100–1  
 treatment 73.36  
 in hereditary haemorrhagic telangiectasia 47.17  
 in lichen planus 41.8, 41.9  
 in lymphangioma 69.34  
 red starberry 30.34  
 scrotal (fissured/plicated) 48.16, 69.6, 69.37, 69.100, 69.125  
 tertiary syphilis vs 34.14  
 strawberry 30.78–9, 69.101  
 in syphilitic chancre 34.7  
 in tertiary syphilis 34.14  
 tie (ankyloglossia) 69.36–7  
 white strawberry 30.34  
 tonofilaments 10.19  
 in Dowling–Meara EB simplex 39.25  
 tonsillitis  
 bilateral syphilitic 34.11  
 lingual 69.35  
 tonsils  
 atrophy 13.9  
 lingual 69.2, 69.6, 69.35  
 syphilitic chancre 34.7  
 tonus of skin 4.8  
 toombak 69.50  
 tooth and nail syndrome 15.56  
 toothpaste 69.119–20  
 allergy to 26.17, 26.21  
 tophi, gouty 62.105  
 ear 68.17  
*see also* gout  
 topical anaesthetic  
 in zoster and post-herpetic neuralgia 33.28  
*see also* local anaesthesia  
 topical immune response modifiers, non-melanoma skin cancer 52.17  
 topical negative pressure therapy 28.23  
 topical therapy 72.27, 73.1–52  
 absorption 73.4, 73.4  
 adverse effects 25.21, 75.163–7  
 advice for patients 73.4  
 chemotherapy, nitrogen mustard (mechlorethamine) and carmustine (BCNU) 57.23  
 concordance with 72.6  
 corticosteroids *see* corticosteroids  
 drug concentration 73.1–2  
 efficacy 73.2  
 formulation 73.5–9  
 frequency of application 73.3  
 hazards and adverse effects 73.4  
 odour 73.5  
 penetration enhancement 73.7–8  
 prescribing 73.1–5  
 preservatives 73.8  
 quantity applied 73.3–4  
 retinoids *see* retinoids  
 self-treatment failures 73.4  
 for skin diseases 73.9–52  
 traditional remedies 73.48–9  
 vehicles for 26.59, 73.2–3  
 choice 73.2–3  
 constituents 73.6  
 corticosteroid therapy 73.20  
 formulation 73.5–9  
 role 73.5  
 types 73.2  
*see also individual drugs and drug groups*  
 topoisomerase 1 (Scl-70), localized scleroderma 51.74  
 TORCH syndrome 33.76–7, 49.20, 49.51  
 Torre syndrome *see* Muir–Torre syndrome  
 torsional tests, mechanical injury 28.5  
 tortoises, skin disease 2.12  
*Tortoiseshell* gene 2.6–7  
 torture injuries 28.32–4  
*Torulopsis*, female genital infections 71.68  
*Torulopsis glabrata* *see* *Candida glabrata*  
 torus mandibularis 69.6  
 torus palatinus 69.6  
 total skin irradiation 57.24–5  
 touch  
 light touch sensation 5.18  
 psychological importance of 64.2  
 sense of 4.9  
 touch corpuscles 3.16  
 touch domes 3.16  
 touch pads 3.3  
 Touraine-Solente-Golé syndrome *see* pachydermoperiostosis  
 tourniquet  
 fingers 65.42, 65.43

- self-inflicted injury, lymphoedema after 48.13
- tourniquet syndrome 71.14  
hair-thread 28.50
- Touton giant cell
- Erdheim–Chester disease 55.18  
juvenile xanthogranuloma 55.15  
xanthoma disseminatum 55.21
- Townes–Brocks syndrome 18.82, 68.3
- toxaemic rash of pregnancy (PUPPP) 8.13, 8.14
- toxic epidermal necrolysis (TEN) 74.11, 76.8–22  
aetiology 76.9–15  
in animals 2.16  
antiretroviral drug causing 35.7, 35.20  
clinical features 69.70, 76.17  
Nikolsky sign 40.8  
complications 76.17–18  
definition 76.1  
diagnosis 69.70–1, 76.19–120  
drug-induced 42.51, 76.12–15  
genetic risk 72.30  
genitocrural involvement 71.6  
GVHD 51.83  
immunology 76.9–10  
incidence 76.8–9  
investigation 76.17  
ocular complications 67.20–1, 67.21  
ocular involvement 76.18  
oral involvement 69.70–1  
pathology 76.15, 76.16  
pharmacogenetics 76.10–11  
prevention 76.22  
prognosis 76.18–19  
renal involvement 62.71  
staphylococcal 30.30  
terminology 76.1  
treatment 69.71, 76.20–2
- toxic erythema of the newborn 17.6–7
- toxic oil syndrome 27.17, 45.52, 75.43, 75.159  
epidemic syndrome, of Spain 51.82  
secondary mucinosis 59.29
- toxic pustuloderma *see* acute generalized exanthematous pustulosis
- toxic shock syndrome 30.31  
differential diagnosis 76.19  
streptococcal 30.12, 30.35
- toxic shock syndrome toxin 1 24.8, 30.7, 30.31  
Kawasaki disease and 50.45
- Toxicodendron* 26.10, 26.22, 26.75, 26.77  
*see also* poison ivy
- toxins  
thrombocytopenia due to 49.11  
*see also individual microbial genera*
- Toxocara* 37.17–18
- toxocariasis 22.10, 37.17–18  
Well's syndrome vs 46.33
- Toxoplasma gondii* 33.76, 37.27, 37.44
- toxoplasmin test 5.24
- toxoplasmosis 18.2, 37.44
- TP63-related phenotypes, ectodermal dysplasias 15.61–5
- TPA, carcinogenesis in murine model 52.13
- TPHA test 34.20
- TPI test 34.20
- TPMT *see* thiopurine methyltransferase (TPMT)
- TPPA test 34.20
- trabecular cell carcinoma of skin *see* Merkel cell carcinoma
- trace elements, excess/deficiency in pregnancy 18.2
- trachyonychia 65.13, 65.25, 66.35
- traditional Chinese herbal medicine, systemic agents 74.52
- traditional Indian medicines, carcinogens in 52.5
- traditional remedies, topical 73.48–9
- tragi 68.1–2
- TRAIL/TRAIL receptors 50.42
- tramadol 63.7
- tranexamic acid, in hereditary angio-oedema 22.22, 22.29
- trans*-3-methyl-2-hexanoic acid 44.1
- transcription factors 11.3  
melanocyte development 58.3
- transcription-mediated amplification assay (TMA), gonorrhoea detection 34.28
- transdermal drug delivery systems 26.46, 72.27, 75.167
- transepidermal water loss (TEWL) 27.11, 44.5, 72.11  
ageing and 4.11  
in atopic dermatitis 24.22  
definition 4.11  
irritant contact dermatitis and 25.2, 25.6, 25.7  
measurement 4.10–11, 25.22  
neonatal 17.2  
race and 9.2
- transepithelial elimination 45.63, 45.64, 45.65, 68.14
- transferrin 13.19, 36.21, 36.58
- transforming growth factor- $\alpha$  (TGF- $\alpha$ )  
sebaceous cell activity control 42.12  
in wound healing 14.4
- transforming growth factor- $\beta$  (TGF- $\beta$ )  
12.29, 12.31–2, 12.35–6, 12.42–3  
ageing skin and 8.22  
collagen gene expression control 3.39  
elastin-associated microfibrils 3.45  
hair growth and 66.11, 66.15  
mucous membrane pemphigoid pathogenesis 67.20  
in telangiectasia 47.13  
in wound healing 14.3, 14.4, 14.8
- transgenic animals 2.7, 2.8, 11.10–11
- transglutaminases 3.10, 4.2  
coeliac disease 40.59
- transgradient palmoplantar keratodermas 19.94, 19.95, 19.98–101
- transient acantholytic dermatosis 19.86–8, 62.33
- transient amplifying cells 66.3
- transient bullous dermolysis of the newborn 39.23–4
- transient myeloproliferative disorder, neonatal pustulosis and 17.10–11
- transient neonatal porphyriaemia 17.13
- transient receptor potential ion channels 21.2
- transillumination blisters 17.14
- transitional cells 3.9
- translators 72.3
- translocation abnormalities 15.2
- transplantation recipients 62.98  
bone marrow *see* bone marrow, transplantation  
immunosuppression  
non-melanoma skin cancers after 52.11, 52.26–7, 79.13  
squamous cell carcinoma after 52.11, 52.26–7  
immunosuppressive therapy 57.51  
Kaposi's sarcoma 56.34  
kidney *see* kidneys, transplantation  
liver 47.18  
post-transplant lymphoproliferative disorder 33.31, 57.51–2  
skin cancer in 79.13  
skin changes in 62.74–5  
solid organ, warts and HPV infections 33.59
- transverse cervical nerve 77.3
- transverse myelitis, in zoster 33.26
- transverse nasal groove 18.90
- Trantas' dots 67.15
- TRAP (TNF-receptor-associated periodic syndrome) 22.25, 50.53, 62.69, 62.104
- trauma  
chronic, non-melanoma skin cancer after 52.11  
eczema following 23.28–9
- lymphoedema after 48.13  
mechanical *see* mechanical injury  
post-inflammatory hypermelanosis after 58.31  
purpura due to 49.14, 49.16  
thermal *see* thermal injury
- traumatic ulcerative granulomatous disease 69.43
- traumiterative dermatitis (cumulative irritant contact dermatitis) 25.1, 25.5, 25.12–13, 25.14, 25.15
- travel, hazards associated 5.6
- trazodone 64.51  
adverse effects 75.79  
erythema multiforme 76.3, 76.4
- Treacher Collins syndrome (mandibulofacial dysostosis) 18.80–1, 68.4
- treatment  
concordance with 72.5–7, 72.25–6  
determination of efficacy 7.1–2  
determination of outcomes 7.12  
general principles 72.25  
risk–benefit analysis 72.3–4  
topical *see* topical therapy  
transdermal drug delivery 26.46
- trematodes 37.2, 37.3, 37.20–3
- trench fever 30.56
- trench foot 28.64  
trench mouth 69.77
- trepine punches, panniculitis 46.11
- Treponema* 30.59, 30.60, 30.62, 34.3–4
- Treponema pallidum* 34.1  
antigen tests 34.20, 34.21  
enzyme immunoassays 34.20  
female genital infection 71.71  
identification, dark-field microscopy 34.3, 34.18–19  
immune response evasion 34.4  
immunogens 34.4  
microbiology 34.4  
morphology 34.3–4, 34.18  
movement 34.3–4  
inhibition 34.20  
Nichol's strain 34.3, 34.20  
pathogenesis 34.4  
Reiter strain 34.3, 34.21  
repeat protein genes (TPR) 34.4  
serological tests 34.16, 34.19–21  
*see also* syphilis
- Treponema pallidum* haemagglutination test (TPHA) 34.20
- Treponema pallidum* immobilization (TPI) test 34.20
- Treponema pallidum*  
microhaemagglutination (MHA-TP) 34.20
- Treponema pallidum* particle agglutination (TPPA) test 34.20
- Treponema pallidum* ssp. *carateum* 30.63
- Treponema pallidum* ssp. *endemicum* 30.63
- Treponema pallidum* ssp. *pertenue* 30.63
- Treponema phagedenis* (Reiter's strain) 34.3, 34.21
- treponematoses  
non-venereal (epidemic) 30.62–4  
ocular involvement 67.27  
*see also specific diseases*
- treponemicides 34.22
- tretinoin *see* retinoic acid (tretinoin; vitamin A acid)
- TREX1 gene 11.15
- triage, burns 28.80
- triamcinolone, intralesional 73.20, 77.48  
adverse effects 45.3–4  
in hand eczema 23.22  
in keloids 45.55  
in necrobiosis lipoidica 60.16  
in psoriatic nails 65.26  
in sarcoidosis 61.21
- triamcinolone acetonide 73.16  
intralesional, childhood acne 42.76
- triamcinolone hexacetonide, psoriasis, intralesional therapy 20.25
- Triatoma infestans* 37.31
- Triatoma sanguisuga* 38.25
- Triatomidae 37.31
- Triatominae 38.25–6
- triazinate 75.136
- triazoles 74.47
- tribal scarification marks, sarcoidosis 61.13
- tribavirin *see* ribavirin
- Tribolium* 38.27
- tribromosalicylanilide 26.23, 26.24
- trichiasis 67.4, 67.21  
management 67.22
- trichilemmal carcinoma 53.6  
ear 68.34
- trichilemmal cyst 52.45, 52.46, 53.4  
cylindroma vs 53.29  
naevus 53.4  
proliferating 53.4–5
- trichilemmal tumour, proliferating 53.4–5
- trichilemmoma 53.5–6  
desmoplastic 53.5  
eyelid 67.33
- Trichinella spiralis* 37.3
- trichinosis/trichiniasis/trichinellosis 37.19–20
- trichloroacetic acid 77.47–8, 80.9  
wart treatment 33.49
- trichlorethylene, scleroderma-like lesions 51.80  
resulting from perchlorethylene 51.80
- trichloroacetic acid, molluscum contagiosum 33.12
- trichloroethylene 25.4, 25.20, 75.162
- trichlorophenols 25.21
- 2,4,5-trichlorophenoxyacetic acid 27.13
- tricho-dento-osseous syndrome 69.11
- tricho-odonto-onychial dysplasia 15.54
- tricho-odonto-onycho-dermal syndrome 15.54
- tricho-onycho-dental (TOD) dysplasia 15.54, 69.11
- trichoadenoma 53.3–4
- trichobezoar 64.31–2
- Trichobilharzia* 37.22
- trichoblastic fibroma 53.10–11
- trichoblastoma 53.8, 53.10–11  
adamantinoid 53.11  
giant 53.10
- trichochrome B 58.7
- trichochromes 58.5, 58.6  
synthesis 58.5, 58.6
- trichoclasia 66.62
- 'trichocyte,' secondary pathway, differentiation 3.13
- trichodental dysplasia 15.53
- trichodental syndrome 69.11
- trichodentoosseus (TDO) syndrome 15.54, 15.65
- trichodiscoma 53.14
- trichoepithelioma 53.8–9  
desmoplastic 53.9–10, 53.35  
eyelid 67.33  
laser therapy 78.14  
pinna 68.28  
solitary giant 53.10  
syringoma vs 53.26
- trichofolliculoma 53.7–8  
pinna 68.28
- trichography, telogen effluvium 66.27, 66.28
- trichohyalin granules 3.13
- tricholemmoma, eyelid 67.33
- trichomalacia 66.62
- trichomegaly 67.4
- Trichomonas* 37.27, 37.29  
male genital infections 71.35
- Trichomonas vaginalis*, vaginal discharge 71.53, 71.69
- trichomoniasis 37.29
- trichomycosis  
female genital dermatology 71.67  
genitocrural dermatology 71.7
- trichomycosis axillaris (trichomycosis nodosa) 30.39
- trichomycosis nodularis *see* piedra, black

- trichomycosis pubis 71.31  
trichonodosis 66.62  
trichonychodental (TOD) syndrome 15.54, 69.11  
trichooculodermovertebral syndrome 15.31  
trichophylin test 5.24  
*Trichophyton* 36.18  
  hand infection 23.20, 23.21, 25.15  
  identification 36.8  
*Trichophyton concentricum* 36.22  
  identification 36.41  
  in tinea corporis 36.49  
  in tinea faciei 36.29  
  in tinea imbricata 36.24  
*Trichophyton equinum* 2.12, 36.41  
*Trichophyton erinacei* 2.12  
*Trichophyton gourvillii* 36.26, 36.27  
*Trichophyton megninii*  
  identification 36.41  
  in tinea barbae 36.28  
  in tinea capitis 36.26  
  in tinea corporis 36.22  
  in tinea unguium 36.35  
*Trichophyton mentagrophytes* 2.12, 36.19, 36.20, 36.21  
  in animals 2.12  
  dermatophytide reaction 23.9  
  identification 36.41–2  
  nomenclature 36.2  
  in tinea barbae 36.28  
  in tinea capitis 36.26, 36.27  
  in tinea corporis 36.24  
  in tinea cruris 36.33  
  in tinea faciei 36.29  
  in tinea manuum 36.32  
  in tinea pedis 36.30, 36.31  
  in tinea unguium 36.34  
*Trichophyton rubrum* 36.20–1, 36.21, 36.22  
  female genital infections 71.68–9  
  genitocrural infections 71.6–7  
  hand infection 25.15  
  in HIV infection 35.32, 35.33, 35.41  
  identification 36.42, 36.43  
  investigation 36.5  
  perianal/perineal infections 71.92  
  in tinea barbae 36.28  
  in tinea capitis 36.26  
  in tinea corporis 36.23, 36.24, 36.25  
  in tinea cruris 36.33  
  in tinea faciei 36.29  
  in tinea manuum 36.32  
  in tinea pedis 36.30, 36.31, 36.49  
  in tinea unguium 36.34, 36.35  
  topical therapy 73.12  
*Trichophyton schoenleinii* 36.19, 36.20  
  identification 36.42, 36.44  
  investigation 36.6  
  in tinea barbae 36.28  
  in tinea capitis 36.25–6, 36.27, 36.49  
*Trichophyton simii* 36.19, 36.44  
*Trichophyton soudanense* 36.19  
  identification 36.44  
  in tinea capitis 36.26, 36.27  
  in tinea unguium 36.34, 36.35  
*Trichophyton tonsurans* 36.19, 36.20  
  dermatophytide due to 36.36  
  identification 36.44, 36.45  
  in tinea barbae 36.28  
  in tinea capitis 36, 36.26, 36.27, 49  
  in tinea faciei 36.29  
  in tinea unguium 36.34  
*Trichophyton verrucosum* 36.20, 36.22  
  in cattle 2.9, 2.12  
  dermatophytide due to 36.36  
  identification 36.45  
  investigation 36.5  
  in tinea barbae 36.28  
  in tinea capitis 36.26, 36.27  
  in tinea corporis 36.24  
  vaccine 36.29  
*Trichophyton violaceum* 36.20, 36.21  
  identification 36.45–6  
  in tinea barbae 36.28  
  in tinea capitis 36.26, 36.27, 36.49  
  in tinea incognito 36.36  
  in tinea manuum 36.32  
  in tinea pedis 36.30  
  in tinea unguium 36.34  
*Trichophyton yaoundei* 36.26, 36.27, 36.46  
trichoptilosis 66.62  
trichorhinophalangeal syndromes (TRPS) 15.55, 15.65–6  
trichorrhexis invaginata (TI; bamboo hair) 19.37, 19.38, 19.39–40, 66.65–7  
trichorrhexis nodosa 15.55, 66.62, 66.67–8, 66.75, 66.91  
  proximal 66.68  
trichoschisis 66.62, 66.68  
*Trichosporon*  
  cutaneous lesions 36.92  
  genitocrural infections 71.5  
  identification 36.8  
  in white piedra 36.16  
*Trichosporon beigelii*, female genital dermatology 71.69  
trichosporosis  
  female genitalia 71.69  
  genitocrural 71.7  
  perianal/perineal 71.95  
trichostasis spinulosa 66.73  
trichothiodystrophy (TTD) 59.72, 66.65, 66.68–9  
  aetiology and pathogenesis 19.47–8  
  collodion membrane 19.14  
  differential diagnosis 19.24  
  TTD-E, TTD-F, TTD-A syndromes 19.47–9  
  xeroderma pigmentosa pathogenesis studies 52.10  
trichotillomania 64.30–1, 66.54–6  
  aetiology 66.54–5  
  clinical features 66.55  
  differential diagnosis 66.35–6, 66.55  
  eyebrows 67.4  
  pathology 66.54  
  psychopathology 66.54–5  
  treatment 66.55  
trichrome stains 10.9  
triclocarban 73.15  
triclosan 26.58, 73.15  
tricone repair 77.16  
tricyclic antidepressants 64.28, 64.32, 64.50–1  
  adverse effects 70.5, 75.78–9  
  in zoster and post-herpetic neuralgia 33.28  
  see also antidepressants  
trifluoperazine 75.82  
  acne excoriée 42.70  
trifluorothymidine, herpes simplex 33.21  
trifluridine 26.46  
trigeminal nerve  
  block 77.2–4  
  maxillary division, zoster 33.26  
  zoster 33.25–6, 33.28  
trigeminal trophic syndrome 63.13  
triggering receptors expressed by myeloid cells (TREM2) 12.28  
triglyceride rich lipoproteins (TRLs) 59.90  
triglycerides 46.2  
  hydrolysis 46.3  
  medium chain (MCTs) 48.27  
  in sebum 42.5, 42.22  
  storage in fat cells 46.2, 46.6  
trimethadione 75.86  
trimethoprim 74.39, 75.57–8  
  acne vulgaris treatment 42.47, 42.48  
  adverse effects 42.51  
  ocular 67.32  
  hidradenitis suppurativa 42.75  
  *Propionibacterium acnes* resistance 42.56  
trimethoprim–sulfamethoxazole see co-trimoxazole  
trimethylaminuria 44.20  
trimipramine 64.51  
trinitrotoluene 66.95  
triparanol 75.157  
tripe palms (acanthosis palmaris) 19.120, 62.31–2  
triple A syndrome 62.13  
triple H syndrome 62.13  
triple response of Lewis 22.12, 63.5  
tripotassium dicitratobismuthate 75.157  
trisodium phosphate 25.19, 25.20  
trisomy 13 15.11, 18.102–3, 62.77, 68.4  
trisomy 18 15.11, 62.77, 66.77  
trisomy 21 see Down's syndrome  
Triton tumour (neuromuscular hamartoma) 18.37, 56.44  
tromantadine 26.46  
Trombiculidae (harvest mites) 30.74, 38.2, 38.50–1  
trombidiosis 38.50–1  
  tropical acne 27.14, 42.79  
tropical bedbug 38.24  
tropical countries, pigmentation significance 58.9  
tropical elephantiasis 37.8–10, 48.12  
tropical fowl mite 38.51  
tropical immersion foot 30.49  
tropical phagedena see ulcer(s), tropical (phagedenic)  
tropical sore 47.57  
tropical ulcer see ulcer(s), tropical  
tropicamide 26.46  
tropisetron 75.79  
tropoelastin 3.43  
Trousseau's sign (migratory thrombophlebitis) 47.30–1, 62.42–3, 62.66  
TRP (transient receptor potential) ion channels 21.2  
TRPS (trichorhinophalangeal syndromes) 15.55, 15.65–6  
TRT (thermal relaxation time) 78.4, 78.5, 78.12  
TRUE test 26.85  
Tryp1 (DHICA oxidase) 58.5, 58.6  
*Trypanosoma* 37.2, 37.27, 37.29  
*Trypanosoma cruzi* 37.31–2  
*Trypanosoma gambiense* 37.29–31  
*Trypanosoma rhodesiense* 37.29–31  
trypanosomiasis  
  African 37.2, 37.29–31  
  American/South-American 37.2, 37.31–3  
  in HIV infection 35.35  
  ocular involvement 37.32  
  vectors 38.6, 38.25  
tryptase 12.25, 12.49  
  in atopic dermatitis 24.18  
  in mastocytosis 22.33, 22.34  
  release from mast cells 63.3  
  in urticaria 22.4  
tryptophan 27.17, 45.52, 59.63  
  eosinophilia–myalgia syndrome and 59.29, 75.43  
  hair colour and 66.91  
  metabolism 43.18  
L-tryptophan-induced eosinophilia–myalgia syndrome 59.29, 75.43  
TSC see tuberous sclerosis complex (TSC)  
TSC1 gene 62.23  
TSC2 gene 62.23  
tsetse flies 37.2, 37.29, 38.6  
TSLP (thymic stromal lymphopoietin) 12.36, 24.14  
TSLs (streptococcal toxic shock-like syndrome) 30.12, 30.35  
TSST-1 see toxic shock syndrome toxin 1  
TST (tuberculin skin test) 5.24, 31.6, 31.8, 31.21  
tsutsugamushi disease (scrub typhus) 38.50  
TTD see trichothiodystrophy (TTD)  
TTF-1 (thyroid transcription factor-1) 10.24  
tubercle 31.8–10, 32.4, 32.5  
  naked 61.3  
tubercles of Montgomery 70.1  
tuberculids 31.10, 31.21–6  
  aetiology 31.21  
  definitions 31.21  
  nodular 31.10, 31.24–5  
  papulonecrotic 31.10, 31.22–4  
  tuberculin skin test 5.24, 31.6, 31.8, 31.21  
tuberculosis 31.1, 31.7–30, 62.80  
  congenital 17.46, 31.20  
  cutaneous 31.10–30  
  classification 31.10, 31.11  
  malignant disease and 31.18, 31.19, 31.21  
  diagnosis 31.6, 31.26  
  differential diagnosis 31.10, 61.5  
  epidemiology 31.2, 31.7–8  
  extremely/extensively drug-resistant (XDR) 31.1, 31.2, 31.27–8  
  female genital region 71.67  
  fish 31.31  
  gangrenous 31.20  
  granuloma annulare and 60.1  
  histopathology 31.8–10, 61.5  
  HIV infection and 31.2, 31.7, 31.8, 31.20, 31.27  
  immunology 31.3–6  
  latent 31.6  
  leg ulcers 47.57  
  lymph node infection 48.12  
  lymphadenitis 35.25, 35.45  
  male genital region 71.31  
  miliary 31.9, 31.10, 31.15–16  
  multidrug-resistant (MDR) 31.1, 31.2, 31.27  
  natural history 31.8  
  nodular vasculitis and 50.31, 50.32  
  notification 31.26  
  ocular involvement 67.27  
  oral involvement 69.79, 69.118  
  orificial 31.9, 31.10, 31.15  
  perianal/perineal 31.10, 71.95  
  perioral 31.10  
  primary 31.8  
  primary complex 31.8  
  primary inoculation 31.8, 31.10, 31.11–12  
  prognosis 31.26  
  re-emergence 31.2  
  re-infection 31.8  
  reactivation 31.30  
  with TNF-antagonist therapy for psoriasis 74.4, 74.7  
  secondary 31.8  
  sweating in 44.7  
  Takayasu's arteritis and 50.44  
  treatment 31.26–8  
  vegetating 31.20  
  warty 31.9, 31.10, 31.12–13, 31.28  
  see also *Mycobacterium tuberculosis*  
tuberculosis colliquativa cutis see scrofuloderma  
tuberculosis cutis orificialis 31.9, 31.10, 31.15  
tuberculosis verrucosa cutis (warty tuberculosis) 31.9, 31.10, 31.12–13, 31.28  
tuberous sclerosis complex (TSC) 62.23–4, 66.65  
  in adolescence 8.7  
  bone and joint involvement 62.100  
  genetics 15.6, 15.21–5  
  hypomelanotic macules of 58.44  
  lesions, acne lesions vs 42.37  
  non-symmetrical lipomatosis with 46.46  
  oral involvement 69.41, 69.118  
  poliosis in 66.93  
  renal involvement 62.69  
  respiratory tract involvement 62.80  
tubo-ovarian abscess 34.26  
tubocurarine 75.153  
tubulin 3.9  
tularaemia 30.53–4, 38.6, 38.35  
tulipalins 26.16, 26.76  
tuliposides 26.76  
tulips 26.16, 26.76  
Tulle dressings 47.48  
tumbu fly 38.8, 38.9, 38.10  
tumoral calcinosis 59.69

- tumour(s)  
 benign vs malignant 52.2  
 definition 5.8, 52.1  
 formation, genetics 15.5–6  
 metastases 52.1  
 obesity and 8.17  
 in pregnancy 8.11, 8.12  
 soft-tissue 56.1–62  
 vascular 18.40–60  
*see also* malignant disease; *specific tumours*
- tumour-like lesions, female genital 71.72–4
- tumour necrosis factor (TNF) 12.42–3  
 adverse effects 75.144  
 anti-TNF monoclonal antibodies 74.5  
 biological therapies 74.5–10  
 in ectodermal dysplasias 15.57–61  
 in linear IgA disease 40.45  
 pathogenesis of chronic inflammatory disease states 74.5  
 recurrent melanoma management 54.54  
 TNF- $\alpha$  12.42–3, 13.5, 17.49, 64.9  
 hair growth and 66.11  
 in lichen planus 41.1  
 receptor activation, UV radiation 8.21  
 in SAPHO syndrome 42.85  
 sebocytes expressing 42.4–5  
 in SJS/TEN lesions 76.9  
 skin barrier function and 25.3  
 in tuberculosis 31.4  
 in vasculitis 50.4, 50.6, 50.10  
 in wound healing 14.3  
 TNF- $\beta$  12.42  
 TNF- $\gamma$  42.26  
 TNF-receptor-associated periodic syndrome (TRAPS) 12.42  
 TNF receptors  
 keratinocyte apoptosis 12.42  
 soluble 74.5  
 types 12.42
- tumour necrosis factor (TNF) antagonists 20.41, 74.5–10  
 in Behçet disease 74.8  
 clinical indications 74.6  
 in hidradenitis suppurativa 74.7  
 in inflammatory bowel disease 74.7  
 in pityriasis rubra pilaris 74.7  
 in psoriasis 74.5  
 and reactivation of tuberculosis 74.4  
 in pyoderma gangrenosum 74.7  
 in rheumatoid arthritis 74.7  
 in sarcoidosis 74.7  
 side effects 74.6  
*see also* tumour necrosis factor tumour-suppressor genes 15.2, 52.12  
 two-hit progression to tumour formation 15.5
- tungiasis 38.12–13  
 Tungidae 38.11, 38.12–13  
 Tuomaala syndrome 15.31  
 turban tumour 53.28–9  
 turbimetry 13.18  
 Turcot's syndrome, genetics 15.25  
 turf toe 28.31  
*Turicella otidis* 68.2  
 turmeric 38.41  
 Turner phenotype 70.2  
 Turner sign (Grey Turner sign) 62.65  
 Turner's syndrome 62.77  
 acquired melanocytic naevi number 54.15  
 ear defects in 68.4  
 genetics 15.12–13  
 lymphoedema 48.10  
 macrocystic lymphatic malformations 48.27  
 Turnpenny type ectodermal dysplasia 15.37  
 turpentine 25.20, 26.79, 26.82–3, 75.163  
 turtles 2.3  
 skin disease 2.12  
 twenty-nail dystrophy 65.13, 65.29, 65.30  
 twin spotting 15.7
- twin studies  
 acne aetiology 42.18  
 atopic dermatitis 24.3  
 twistometry 4.11  
 two-hit hypothesis 11.17, 52.6–7  
 Tydeidae 38.48  
 tylosis 62.20–1, 69.24–5, 69.116  
 with oesophageal cancer 19.106  
 tympanic membrane 68.1, 68.2  
 Tyndall effect 54.26  
 typhoid 30.47–8  
 typhus  
 arthropod vectors 44.7  
 epidemic 30.72–3  
 murine (endemic) 30.73  
 purpura 49.20  
 scrub 30.74  
 sporadic 30.73  
 tick 30.73
- typhus amstelodamensis 15.92  
*see also* de Lange syndrome (Cornelia de Lange)
- typhus maculatus 58.20  
*Tyrophagus* 38.47  
 tyrosinaemia 59.97  
 oculocutaneous (type II) 59.97  
 keratoderma with 19.95, 19.111–12  
 prenatal diagnosis 16.3  
 tyrosinase 73.28  
 gene, albinism 58.39  
 inhibition 73.27  
 melanin synthesis 58.5, 58.6, 58.7  
 tyrosine, melanin synthesis 58.5, 58.6  
 tyrosine kinase pathway, stem cell signalling 3.6  
 tyrosine kinase receptors 63.18, 63.19  
 in piebaldism 58.42  
 Tyson's glands of prepuce 42.1  
 Tzanck smear 5.21, 10.28–9, 35.28  
 Tzank preparation 40.8
- U**  
 U1-RNP, specific antibody 51.110, 51.112  
 Uber lipoidgranulomatose 55.18–19  
 UCA (urocanic acid) 4.7, 13.32, 29.6  
 UK, prevalence of skin disease 6.9  
 UK National Patient Safety Agency 72.26  
 UK Sickness Impact Profile 72.17
- ulcer(s)  
 acute genital 71.65–6  
 acute tuberculous (orificial tuberculosis) 31.9, 31.10, 31.15  
 anogenital 71.3–4  
 arteritic 51.132  
 burns 28.91  
 Chiclero's 37.35, 37.39–41  
 decubitus/pressure *see* pressure ulcers  
 definition 5.8  
 diabetic 14.1, 14.13  
 foot 47.57–8, 63.8–9  
*see also* ulcer(s), neuropathic  
 in dystrophic EB 39.18  
 female genital 71.65–7  
 foot  
 diabetes 47.57–8, 63.8–9  
 lichen planus 41.14  
 genetics 15.13  
 gingival 69.14  
 hypertensive 47.52–4  
 hypopyon 67.9  
 in immunodeficiency 17.52  
 in infantile haemangioma 18.45, 18.49  
 intravenous drug abuse 28.45, 28.53  
 ischaemic 47.2, 47.3  
 'kissing' 34.7  
 leg 14.12–13, 47.41–58, 51.132  
 aetiology 14.12, 47.54–7  
 allergens 47.45  
 allergic contact dermatitis and 26.19, 26.43–4  
 arterial 14.13, 47.52–4  
 in autoimmune disease 47.55  
 chronic 8.28, 47.41  
 decubitus 47.57  
 definition and epidemiology 47.41  
 elderly people 8.28  
 in granulomatous diseases 47.57  
 in haematological disease 47.56  
 in haemoglobinopathies 62.85  
 in hydroxyurea deficiency 47.54–5  
 hyperhidrosis and 44.9  
 hypertensive (Martorell's) 47.53–4  
 infections associated 47.56–7  
 in livedoid vasculopathy (vasculitis) 47.55  
 in prolidase deficiency 47.54  
 in pyoderma gangrenosum 47.57  
 recurrent 47.50–1  
 in rheumatoid arthritis 47.55  
 in sickle cell anaemia 47.56, 49.47  
 silver sulfadiazine therapy 73.11  
 in SLE 47.55  
 vasculitic/vasculopathy 47.55  
 venous *see* venous ulceration  
 leprosy 47.56  
 lip, due to calibre-persistent artery 69.129  
 Lipschutz *see* Lipschütz ulcers  
 male genital 71.24–6  
 Meleney's 47.57  
 neuropathic (neurotrophic/perforating) 47.57, 62.99, 63.8–11, 63.15, 63.20  
 diabetes 47.57  
*see also* ulcer(s), diabetic  
 oral cavity *see under* oral cavity  
 parastomal 62.54  
 penetrating (ulcus terebrans) 52.19  
 pentazocine 28.45, 28.53  
 perianal/perineal 71.94  
 in prolidase deficiency 47.54  
 rheumatoid 47.55  
 rodent *see* basal cell carcinoma (BCC)  
 'snail-track' 34.11  
 steroid 47.56  
 streptococcal 30.33  
 syphilitic chancre 34.6–7  
 treatment  
 hydroxycarbamide (hydroxyurea) 47.54–5  
 topical 73.10  
 in trigeminal trophic syndrome 63.13  
 tropical (phagedenic) 30.60–1, 47.57  
*Staphylococcus aureus* in 30.60  
 tuberculous 47.57  
 tumours associated 47.45  
 venous stasis (gravitational) 14.1  
 in Wegener's granulomatosis 50.40  
*see also* pressure ulcers
- ulcerative colitis 62.50–3  
 angio-oedema and 62.50  
 erythema multiforme and 62.50  
 erythema nodosum and 62.50  
 gangrene and 62.51  
 linear IgA disease and 62.51–2  
 lobular panniculitis and 46.14  
 necrobiosis lipoidica and 60.15  
 purpura and 62.51  
 pustular neutrophilic dermatoses in 50.89  
 pyoderma gangrenosum and 50.65, 62.50–1  
 reactive lesions 62.50  
 smoking and 50.66  
 Sweet's syndrome and 50.75, 62.51  
 urticaria and 62.50  
 vasculitis and 62.51
- ulcus cruris 47.35  
*see also* venous ulceration
- ulcus molle *see* chancroid
- ulcus terebrans 52.19
- ulerythema oophryogenes 66.51
- ulerythema sycosiforme (lupoid sycosis) 30.25
- Ullrich–Turner syndrome *see* Noonan's syndrome (NS)
- ulnar mammary syndrome 15.55
- ultrasound 5.22  
 colour Doppler duplex  
 chronic venous insufficiency 47.35  
 venous leg ulceration 47.47
- compression (CUS), deep-vein thrombosis 47.29
- fetal 16.7
- foreign bodies 28.42
- HIV lipodystrophy 46.42
- in mastocytosis 22.34
- in muscle hernias 28.62
- skin thickness measurement 72.11
- spinal 63.15
- ultraviolet filters, as allergens/  
 photoallergens 26.23, 26.24, 26.62–3
- ultraviolet (UV) phototherapy  
 carcinogenic hazard 20.31  
 psoriasis 20.28–33  
 broad-band vs narrow-band 20.28  
 TL-01 lamps 20.28  
 UVB, non-melanoma skin cancer and 52.4
- ultraviolet protection factor (UPF) 29.8
- ultraviolet (UV) radiation 29.1–3  
 abnormal cutaneous effects *see* photodermatoses  
 acne and 42.34, 42.67  
 ageing due to *see* photoageing  
 antigen induced by 29.11, 29.17, 29.19  
 barrier function of skin and 4.6–7  
 basal cell carcinoma and 29.7, 52.3  
 carcinogenicity 27.16  
 cutaneous effects of exposure 29.5–7, 45.2  
 acute systemic effects 29.6–7  
 early effects 29.5–6  
 late effects 29.7  
 definitions and units 29.1  
 dermatoses exacerbated by 29.22, 29.22–3, 29.23  
 direct/indirect effects on skin 8.21  
 diseases associated with exposure *see* photodermatoses  
 DNA damage *see* DNA damage  
 DNA photoproducts 29.4  
 DNA repair defects and 52.13–14  
*see also* DNA damage, repair defects  
 dosimetry (radiometry) 29.2–3  
 calibration 29.3  
 environmental exposure to 29.4  
 exposure minimisation 29.8–9  
 clothing 29.8  
 squamous cell carcinoma 52.28  
 sunscreens *see* sunscreens  
*see also* photoprotection; sun exposure, avoidance  
 exposure quantification 29.4  
 feel-good and health factors 29.6–7  
 filters, as allergens/photoallergens 26.23, 26.24, 26.62–3  
 genetic changes due to 52.13  
 immunological effects 13.26–34, 26.10, 52.14  
 immunomodulatory effects 29.6  
 immunosuppression due to 8.22, 52.14  
 non-melanoma skin cancers 52.14  
 reduced by sunscreens 73.41  
 intensity increased by reflection 29.8  
 interactions with atmosphere 29.3  
 interactions with matter 29.3–4  
 interactions with skin 29.4  
 lentiginos 54.2  
 malignant melanoma and 6.12, 29.7, 54.32–3, 54.34  
 matrix metalloproteinase activation 8.21, 8.22  
 mechanical injury 28.8, 28.53  
 melanocyte growth arrest due to 58.7  
 melanocyte response 58.7  
 melanosome transfer to keratinocytes 58.4  
 modification, optical components 29.2  
 mutagenic effects 52.13–14  
 nature of 29.1  
 non-melanoma skin cancers 52.3, 52.13–14, 52.19  
 photodermatitis 28.92  
 plant-induced 29.21, 58.23, 75.162

- pigmentation 58.7  
solar elevation affecting 29.8  
sources 29.1–2  
spectrum 29.1, 29.2  
squamous cell carcinoma and 29.7, 52.3, 52.24, 52.27  
tanning with 58.31–3  
  *see also* tanning  
thermal injury 28.72  
transmission to dermis 29.4  
UVA 8.21, 29.1, 52.3, 52.13  
  absorbers 29.9  
  actinic prurigo 29.14  
  adverse effects 73.40  
  carcinogenic potential 52.3  
  chronic actinic dermatitis 29.16–17, 29.18  
  discoid lupus erythematosus 51.5  
  hydroa vacciniforme 29.15  
  hyperpigmentation associated 58.10  
  immunosuppressive effects 13.26, 13.33  
  interactions with atmosphere 29.3  
  long-wave, sunscreens and 73.40  
  mutations induced by 52.13–14  
  penetration of skin 4.7  
  photoageing 29.7  
  polymorphic light eruption 29.11  
  pseudoporphyria 29.7  
  skin penetration 80.2  
  solar urticaria 29.19  
  sources 29.1  
  sunscreens protection from 29.8, 29.9, 73.40  
UVA-1 (340–400 nm) low-dose  
  broadband 29.1  
  lichen sclerosus 51.118  
  morphoea 51.75  
  SLE 51.62  
UVA-II 29.1  
UVB 8.21, 29.1, 52.3, 52.13  
  actinic prurigo 29.14  
  chronic actinic dermatitis 29.18  
  coal tar with 73.42  
  Hailey–Hailey disease aggravation 39.33  
  immunosuppressive effects 13.26–34  
  interactions with atmosphere 29.3  
  melanocyte response 58.7  
  mutations induced by 52.13  
  penetration of skin 4.6–7  
  photoageing 29.7  
  polymorphic light eruption 29.11  
  repair of damage 52.13, 52.14  
  skin penetration 80.2  
  solar urticaria 29.19  
  sources 29.1  
  suberythematous, in Hailey–Hailey disease 39.36  
  sunscreens protection from 73.40  
UVB phototherapy, non-melanoma skin cancer and 52.4  
UVC 29.1, 52.3, 52.13  
  sources 29.1  
  vitamin D synthesis 29.6  
  wavelengths 29.1, 29.2, 29.5  
  *see also* sun exposure; sunlight  
Umbelliferae, phytophotodermatitis due to 29.21  
umbilical artery catheterization 17.13, 71.84  
umbilical cord, inflammation 34.15  
umbilical dermatology 71.100–2  
  congenital and developmental abnormalities 18.93, 71.100  
  general approaches 71.1–4, 71.100  
  inflammatory dermatoses 71.101  
  trauma and artefact 71.100–1  
  tumours and implantations 71.101  
umbilicus  
  bacterial flora 30.4–5, 30.6  
  developmental anomalies 18.93, 71.100  
  granuloma 18.93  
  polyp 18.93–4, 71.100  
  structure and function 71.100  
  unseen, monoclonal antibodies to 39.25  
  *Uncinaria stenocephala* 37.16  
  uncircumcised males 71.13  
  uncombable hair, retinal pigmentary dystrophy, dental abnormalities and brachydactyly 15.56  
  uncombable hair syndrome 66.71–2  
  uncoupling protein-1 (UCP-1) 46.1  
  undecylenic acid 26.46, 73.13  
  undifferentiated vulval intraepithelial neoplasia 71.74  
  unheated serum reagin (USR) test 34.19  
  unilateral naevoid telangiectasia syndrome 47.19  
  uniparental disomy 11.18, 15.7, 16.2, 52.12  
  universal acquired melanosis 58.22  
  Unna–Thost syndrome 69.16  
  Ununo Enyi (granuloma multiforme) 60.14, 60.17  
  upper eyelid dermatosis syndrome 67.5  
  upper limb  
    lymphoedema 48.12, 48.13  
    *see also* arms  
  urachal duct 71.100  
  urachus, anomalies 18.94  
  uraemia 44.20  
    calciophylaxis (calcific uraemic arteriopathy) 47.8  
  urate crystals, lobular panniculitis 46.17  
  urea  
    as penetration enhancer 73.7  
    in sweat 44.5, 44.6  
  urea frosting 62.72  
  *Ureaplasma urealyticum* 30.69  
    female genital infection 71.68  
  urethra  
    caruncles 71.73  
    prolapse 71.73  
    stenosis in males, lichen sclerosus 51.116  
  urethritis  
    anterior, chlamydial 34.29, 34.30  
    gonococcal 34.25, 34.26  
  urinary tract  
    anomalies associated with  
      supernumerary nipples 70.2  
    developmental anomalies 17.24  
    in menopause 8.19  
  urine  
    napkin dermatitis and 17.23  
    output in burns 28.78  
    urocanic acid (UCA) 4.7, 13.32, 29.6  
  UROD (uroporphyrinogen decarboxylase) 59.5  
  urokinase 75.107  
    blocking acantholysis 40.14  
  uroporphyrinogen decarboxylase (UROD) 59.5  
  urostomy *see* stoma  
  *Urtica dioica* 22.2  
  urticants 25.18  
  urticaria 22.1–30  
    acute 22.2, 22.7–9  
    allergic 22.7–8  
    idiopathic 22.7  
    in infectious mononucleosis 33.30  
    intermittent 22.2  
    investigation 22.26  
    non-allergic (intolerance reactions) 22.8  
    pityriasis rosea vs 33.80  
    pseudoallergic 22.8  
    after streptococcal infection 30.16  
    alcohol-induced 22.8  
    allergic 22.7–8  
    allergic contact 22.19–120, 26.104–6  
      female genitalia 71.58  
    aquagenic 22.13, 22.17  
    associated with dental amalgam 22.11  
    associated with prosthetic implants 22.11  
    associations 22.2–3  
    atopic dermatitis and 24.23  
    autoantibodies in 13.21–2, 22.9  
  candidiasis and 22.10  
  childhood 22.6–7  
  cholinergic 22.13, 22.15, 22.16  
  chronic 22.2, 22.9–12  
    aggravating factors 22.10–12  
    autoimmune 22.9  
    autoimmune, ciclosporin therapy 74.16  
    idiopathic 22.9  
    infection and 22.10  
    intermittent 22.2  
    investigation 22.26–7  
    papular 23.44  
    pseudoallergic 22.10  
    psychological factors 64.4–5  
    sarcoidosis and 61.17  
  classification 22.2  
  celiac disease and 22.2  
  cold 22.4, 22.5, 22.16  
    acquired 22.16  
    challenge test 22.13  
    familial 22.16, 22.24  
    following jellyfish stings 38.56  
    histamine and 21.4  
    idiopathic 22.16  
    secondary to serum cryoproteins 22.16  
    systemic 22.16  
  contact 22.2, 22.19–20, 26.25  
  allergic/immune 22.19–120, 26.104–6  
  allergic/immune, of female genitalia 71.58  
  causes 22.20  
  non-allergic/non-immune 22.20, 25.1, 25.18, 25.24  
  occupational 27.5  
  definitions 22.1–2  
  delayed pressure 22.3, 22.13, 22.14–15  
  diagnosis 22.25  
  differential diagnosis 22.25  
  drug-induced 22.8, 22.10, 75.16–17, 75.17, 75.25, 75.26  
  factitious 2.12–13, 22.14  
  familial cold 22.16, 22.24  
  with familial Mediterranean fever 62.69  
  female genital region 71.58  
  food/food additive-associated 22.8, 22.10–11, 26.105  
  genetics 22.3  
  heat 22.15–16  
  *Helicobacter pylori* and 22.2, 22.10  
  in hepatitis B virus infection 22.8, 62.59  
  histology 22.3–4  
  historical background 22.2  
  history taking 22.25  
  idiopathic 22.2  
  infection and 22.2, 22.8, 22.10, 22.11  
  lesions in SLE 51.38  
  localized heat 22.13, 22.15–16  
  male genital region 71.16  
  mechanical injury 28.53  
  menstrual cycle and 22.11  
  natural history 22.27  
  nickel allergy and 22.11  
  ordinary 22.2, 22.5–12  
    aetiology 22.7–12  
    childhood 22.6–7  
    clinical features 22.5–6  
  papular 22.23, 38.2, 38.3  
    due to fleas 38.3, 38.11  
  paraneoplastic 62.38  
  parasite infection and 22.2, 22.10  
  in parvovirus B19 infection 33.63  
  pathophysiology 22.4–5  
  physical 22.12–18  
    challenge tests 22.13  
    classification 22.12  
  pregnancy and 22.11  
  prevalence 22.3  
  in schistosomiasis 37.21  
  skin biopsy 10.43, 22.3  
  skin testing 75.173  
  solar *see* solar urticaria (SU)  
  stress and 22.11–12  
  thyroid disorders and 22.2, 22.26  
  treatment 22.27–30  
    antihistamines 74.31  
    doxepin 74.32  
  ulcerative colitis and 62.50  
  vibratory 22.13, 22.15  
  weal-less 21.6  
  urticaria-like follicular mucinosis 59.28  
  ‘urticaria-like’ plaques 51.131  
  urticaria multiformis endemica (harara) 38.5, 38.7  
  urticaria pigmentosa 22.30, 22.31–2  
    Darier’s sign in 22.14, 22.31–2  
    in dogs 2.22  
    histopathology 22.34  
    hypermelanosis with 58.38  
    KIT gene mutations 3.20  
    skin biopsy 10.43  
  urticular fever 37.21  
  urticular papular and plaque eruption 26.25–6  
  USA, prevalence of skin disease 6.9  
  ustekinumab 20.42, 74.10  
  uta 37.40  
  UV radiation *see* ultraviolet (UV) radiation  
  uveitis 67.4  
    anterior 61.6, 61.7, 67.4  
    in Behçet’s disease 50.59–60  
    granuloma annulare and 60.9  
    hypopyon 50.60  
    intermediate 67.4  
    posterior 50.59–60, 61.7, 67.4  
    in sarcoidosis 61.6, 61.7  
  V  
  VAC (vacuum-assisted closure) 28.23  
  vaccination/vaccines  
    adverse effects 75.138–40, 76.3, 76.4, 76.12, 76.13  
    anthrax 30.41  
    BCG *see* BCG vaccination  
    Canvaxin whole-cell vaccine 54.54  
    hepatitis B *see under* hepatitis B virus (HBV)  
    HPV infection 33.42  
    HSV infection 33.21  
    leprosy 32.19  
    Lyme disease 62.106  
    malignant melanoma 54.54  
    measles 33.75  
    MMR 33.71  
    rabies *see under* rabies  
    rubella 33.71  
    *Trichophyton verrucosum* 36.29  
    vaccinia 33.6, 33.7  
    vasculitis and 50.5, 50.18, 50.55  
    VZV infections (varicella/zoster) 33.27, 63.7  
  vaccinia 33.6–7, 69.121  
    accidental (autoinoculation) 33.6  
    generalized 33.6  
    progressive 33.6  
    vaccination 33.6, 33.7  
  vacuoles, sebum 42.3  
  vacuum-assisted closure (VAC) 28.23  
  vagabond’s disease 38.22  
  pigmentation changes 58.28–9  
  vagina  
    *Candida albicans* carriage 36.56  
    lichen planus 41.9  
    in menopause 8.19  
  vaginal discharge 71.52, 71.53–4, 71.69  
  vaginal intraepithelial neoplasia, treatment 73.24  
  vaginal stenosis 8.12  
  vaginitis, in trichomoniasis 37.29  
  valaciclovir  
    action 74.49  
    in herpes B virus infection 33.34  
    in herpes simplex 33.20, 33.21  
    in herpes zoster 63.6, 67.26  
    in zoster 33.27, 33.28  
  valdecoxib 75.77

- valganciclovir  
   in CMV infection 33.29  
   in HHV-8 infection 33.34  
 validity 6.18–19  
   external 6.19  
   internal 6.18–19  
 valley fever *see* coccidioidomycosis  
 valproate *see* sodium valproate  
 Valsalva manoeuvre 49.4  
 valves, semilunar, of veins 47.25  
 valvuloplasty 47.51  
 Van der Bend chamber 26.85  
 van der Woude syndrome **15.93–4**, 18.3,  
   18.90, 18.91, 69.40, 69.41  
 van Gieson stain 10.9  
 van Lohuizen's syndrome *see* cutis  
   marmorata telangiectatica  
   congenita  
 vancomycin 26.46, 74.43, 75.60–1  
   in drug-induced linear IgA disease  
   40.49, 76.7  
   in MRSA infection 30.9  
 vanilloid receptors 21.2, 63.2, 73.49  
 vanishing bone disease *see* Gorham's  
   (Gorham–Stout) disease  
 vanishing creams 73.7  
 vanishing penis syndrome 71.13  
 variant Creutzfeldt–Jakob disease,  
   sterilization of surgical  
   equipment and 77.7  
 varicella **33.22–8**  
   aetiology and epidemiology 33.22–3  
   antibodies 33.23  
   chronic 33.25  
   clinical features 33.24–5  
   complications 33.24–5  
   cytodiagnosis 10.29, 33.27  
   diagnosis 33.27  
   encephalitis 33.24  
   fetal damage 33.23, 33.24  
   fetal varicella syndrome 17.40–1, 18.2,  
   18.102  
   fever in 33.24  
   haemorrhagic 33.24  
   immune response 33.23, 33.27  
   in immunocompromised patients  
   33.23, 33.24, 33.25, 33.27  
   incubation period 33.24  
   maternal 33.23  
   mortality 33.24, 33.25  
   oral involvement 33.24, 69.74  
   pathology 33.23–4  
   persistent verrucous 35.45  
   prevention 33.27  
   scars 45.6  
   subclinical 33.23  
   treatment 33.27–8  
   vaccination 33.27  
   vesicles 33.24  
 varicella gangrenosa 33.25  
 varicella zoster virus (VZV) **33.22–8**  
   detection (antigen, DNA, proteins)  
   33.27  
   in HIV infection 35.28–39  
   infection  
     disseminated, in HIV infection 35.29  
     female genitalia 71.69  
     *see also* varicella; zoster  
   Oka strain 33.27  
   reactivation 33.22, 33.23  
     in HIV infection 35.28–39  
     *see also* zoster  
   replication 33.23–4  
   transmission 33.23  
   vaccine 8.28, 33.27, 63.7  
   viraemia 33.22, 33.23  
 varices, hands 47.16  
 varicography 47.36  
 varicose eczema 26.19  
   differential diagnosis 26.29  
 varicose veins 47.13, **47.37–40**  
   arteriovenous shunting 47.21  
   clinical features and diagnosis 47.37  
   in pregnancy 8.10–11  
   prevalence and classification 47.37  
   primary 47.37  
   recurrent 47.1, 47.38  
   reticular 47.37  
   secondary 47.37  
   surgery 47.38–9, 47.51  
     lymphoedema after 48.13  
   treatment 47.37–40  
     complications 47.38  
     sclerotherapy 47.24  
   truncal 47.37  
 varicosity 47.23, 47.35  
   female genital dermatology 71.55  
   venous 47.35, 47.37  
     *see also* varicose veins  
 variegated porphyria (VP) 59.19–20, 62.46,  
   66.79  
 variola (smallpox) 33.5, 33.6  
 vasa vasorum, occlusion 34.5  
 vascular cell adhesion molecule-1  
   (VCAM-1) 13.9  
   in polymorphic light eruption 29.11  
   in vasculitis 50.7, 50.8  
 vascular changes, in pregnancy 8.10–11  
 vascular coagulopathies 49.42–7  
 vascular diseases  
   eye and skin involvement 67.30  
   pigmented purpuric dermatoses and  
   49.23  
   *see also specific diseases*  
 vascular endothelial growth factor  
   (VEGF) 48.2  
   in giant cell arteritis 50.43  
   hair growth and 66.10  
   increased, UV radiation associated 8.21  
   in infantile haemangioma 18.41  
   keratinocytes 12.16  
   MHC and 12.16  
   over-expression in psoriasis 20.5  
   in rosacea 43.1–2  
   VEGF-A 48.2  
   VEGF-C 48.2  
   VEGF-D 48.2  
   in wound healing 14.2, 14.6  
 vascular endothelial growth factor  
   receptor-1 (VEGFR-1) 14.6, 48.2  
 vascular endothelial growth factor  
   receptor-2 (VEGFR-2) 14.6  
 vascular endothelial growth factor  
   receptor-3 (VEGFR-3) 10.24, 48.2  
   gene mutation 48.10  
   lymphatic vessel marker 48.4, 48.5,  
   48.19  
 vascular malformations 18.41, 18.60–75  
   arteriovenous 18.61–2, 18.79  
   capillary 18.62–70, 18.79  
   venous 18.70–4  
 vascular permeability  
   dengue haemorrhagic fever 33.68  
   mast cell activation effect 3.20  
 vascular permeability factor *see* vascular  
   endothelial growth factor  
   (VEGF)  
 vascular proliferation, atypical post-  
   radiation 48.31  
 vascular reactivity, abnormal, rosacea  
   pathogenesis 43.1–2  
 vascular spider *see* spider angioma  
 vascular system  
   in Behçet's disease 50.60  
   in Ehlers–Danlos syndrome 45.32,  
   45.34–5  
   head and neck 77.2, 77.3  
   skin 3.2, 3.3  
 vascular tone, face and neck 43.14  
 vascular tumours **18.40–52**  
   benign 56.25–31  
   indeterminate malignancy 56.31–7  
   malignant 56.37–41  
   reactive 56.23–5  
   *see also* haemangioma  
 vasculature, inflammation and 12.68  
 vasculitis 50.1–56, 51.1  
    $\alpha_1$ -antitrypsin deficiency and 50.11,  
   50.53  
 ANCA-associated 74.8  
   TNF antagonists in 74.8  
   in animals 2.16  
   annular lesions 62.112–13  
   arterial ulceration 47.52  
   Behçet's disease and 50.3, 50.49, 69.47  
   bone and joint involvement 62.102  
   breast 70.11  
   cerebral 50.46–7  
   of Churg and Strauss *see* Churg–Strauss  
   syndrome  
   classification 50.1–3  
   Crohn's disease and 62.51  
   cryoglobulinaemic 50.23–5, 50.54  
   cutaneous  
     in scabies 38.39  
     small vessel/leukocytoclastic 50.4,  
     **50.13–17**  
   cystic fibrosis and 50.53  
   definition 50.1  
   differential diagnosis 50.54–5  
   drug-induced 49.21, 50.17–19, 50.49,  
   75.17, 75.40–1  
   effector cells 50.6–7  
   eosinophilic (recurrent cutaneous  
   eosinophilic necrotizing) 50.27–  
   8, 62.112  
   evaluation 50.12–13  
   exercise-induced 49.18, 50.23  
   familial Mediterranean fever and  
   50.53–4  
   genetic factors 50.11–12  
   hepatitis C and 33.61  
   hyper-IgD syndrome and 50.53  
   hypereosinophilic syndrome and 50.53  
   hypocomplementaemic *see* vasculitis,  
   urticarial  
   immune complex 49.18, 49.19, 49.32  
   cryoglobulins causing 49.32, 49.33  
   IgA *see* Henoch–Schönlein purpura  
   in immunodeficiency 17.53  
   infection and 50.5–6, 50.49, 50.55–6  
   laboratory 50.2  
   leg ulceration associated 47.55  
   leukocytoclastic 46.32, 49.18, 50.48  
   livedo *see* livedoid vasculopathy  
   lymphocytic 50.47–50  
   mimics 50.49  
   nodular 31.24–5, **50.31–3**  
   nomenclature 50.1–3  
   panniculitis with 46.11, **46.32–4**  
   paraneoplastic 50.4, 50.49, 50.54,  
   62.41–2  
   in parvovirus B19 infection 33.63  
   pathogenesis 50.3–12  
   pustular 50.89  
   pyoderma gangrenosum and 50.49,  
   50.67  
   relapsing polycondritis and 50.48–9,  
   50.54  
   renal involvement 62.71  
   respiratory tract 62.82–3  
   in rheumatoid arthritis 51.132  
   sarcoidosis and 61.17  
   segmental hyalinizing *see* livedoid  
   vasculopathy  
   Sjögren's syndrome and 50.49, 50.52–3  
   in SLE 50.48, 51.39  
   small vessel 12.32, 62.82  
   Sweet's syndrome and 50.3, 50.77–8  
   in systemic disease 50.52–4  
   ulcerative colitis and 62.51  
   urticarial 22.18–19, 50.21–3, 50.48  
   histopathology 22.3, 50.22  
   hypocomplementaemic 13.22, 22.19,  
   50.22  
   with monoclonal gammopathy  
   (Schnitzler's syndrome) 22.23–4,  
   50.53, 62.94  
   normocomplementaemic 50.22  
   vaccination and 50.5, 50.18, 50.55  
   Wiskott–Aldrich syndrome and 50.54  
 vasculogenesis 47.1  
 vasculopathy  
   crystal globulin 49.38  
   leg ulceration associated 47.55  
   livedoid *see* livedoid vasculopathy  
   progressive, Degos' disease 49.45  
   sickle cell 49.47  
 Vaseline 73.6  
 vasoactive intestinal peptide (VIP) 3.12,  
   4.10, 63.3, 64.9  
   in atopic dermatitis 24.17  
   immune function and 63.4  
   production by tumours 62.68  
   in urticaria 22.5  
   in wound healing 63.4  
 vasoactive intestinal peptide (VIP)–  
   secretin-peptide family, PACAP  
   12.64  
 vasoconstriction  
   cold-induced 28.63, 28.65, 63.4  
   corticosteroid-induced 73.19–20  
   responses in atopic dermatitis 24.15  
 vasoconstrictor assay, topical  
   corticosteroids 73.16  
 vasodilatation  
   antidromic 63.5  
   cold-induced 63.4–5  
   in eczema 23.4  
   inflammatory response 12.4  
   minoxidil action 73.49  
   nicotinamide inducing 73.51  
   prolonged, telangiectases 47.13  
   rebound, corticosteroid-induced  
   73.19–20  
 vasodilators, in flushing pathogenesis  
   43.14  
 vasopressin 75.98  
 Vater–Pacini corpuscles 3.15  
 VCAM-1 *see* vascular cell adhesion  
   molecule-1  
 VCSS classification, chronic venous  
   insufficiency 47.33  
 VDRL test 34.19, 34.21  
 vecuronium 75.153  
 vegetable oils, in topical treatment 73.5–6,  
   73.6, 73.8  
 vegetation, definition 5.8  
 VEGF *see* vascular endothelial growth  
   factor (VEGF)  
 VEGFR-1 (vascular endothelial growth  
   factor receptor-1) 14.6, 48.2  
 VEGFR-2 (vascular endothelial growth  
   factor receptor-2) 14.6  
 VEGFR-3 *see* vascular endothelial growth  
   factor receptor-3  
 vehicles  
   cosmetics 26.58–60  
   for topical therapy *see under* topical  
   therapy  
 veil cells 3.51  
 veiled cells 55.3, 55.4  
 veins  
   anatomy 47.25  
   deep 47.25  
     incompetence 47.41  
     insufficiency 47.33  
   disorders *see* venous disorders  
   pathophysiology 47.25–8  
   perforating (perforators) 47.25  
   eczema and 47.34  
   insufficiency 47.33, 47.34, 47.39  
   physiology 47.25  
   'sunburst' 47.39, 47.40  
   superficial 47.25  
   insufficiency 47.32–3, 47.42  
   valve incompetence 47.25  
   varicose *see* varicose veins  
 veldt sore 47.56  
 vellus cyst, eruptive 53.7  
 vellus hair 3.13  
 velocardiiofacial syndrome 13.8  
 Venereal Disease Research Laboratory  
   (VDRL) antigen test 34.19, 34.21  
 venesection, in polycythaemia rubra vera  
   62.86  
 Venezualan haemorrhagic fever 33.66,  
   33.67, 33.69  
 venlafaxine 64.20, 64.51

- veno-occlusive priapism 71.51  
 Venofer 39.29  
 venom  
 Cnidaria 38.55  
 fish 38.59–60  
 Hymenoptera 22.8, 38.14  
 Mollusca 38.59  
 scorpion 38.33  
 sea urchin 38.58  
 snake 38.60  
 spider 38.31, 38.32  
 venous ankle flare 47.14, 47.33  
 venous disorders **47.25–41**  
 chronic 47.13  
 chronic insufficiency *see* chronic venous insufficiency (CVI)  
 deep vein incompetence 47.41  
 lymphoedema association 48.12, 48.13  
 physiology/pathophysiology 47.25–8  
 mechanisms 47.26–8  
 post-thrombotic syndrome *see* post-thrombotic syndrome (PTS)  
 varicose veins *see* varicose veins  
*see also* venous thrombosis; *specific disorders*  
 venous hypertension 47.25, 47.26, 47.37  
 chronic, lipodermatosclerosis 46.30–1  
 elderly people 8.28  
 in livedoid vasculopathy 49.44  
 post-thrombotic syndrome 47.40  
 venous leg ulceration and 47.42  
*see also* venous pressure, elevated  
 venous insufficiency  
 acroangiodermatitis (of Mali) and 49.17  
 in arteriovenous fistulae 47.21  
 chronic *see* chronic venous insufficiency (CVI)  
 deep veins 47.33  
 lymphoedema association 48.12, 48.13  
 perforating (perforators) veins 47.33, 47.34, 47.39  
 superficial 47.32–3, 47.42  
 venous lake (venous varix) 47.16, 69.101  
 venous macrocirculation 47.25  
 venous malformations 18.70–4, **47.23–5**  
 disorders associated 47.23–5  
 solitary 47.23  
 venous microcirculation 47.26–8  
 venous outflow obstruction 47.26  
 deep-vein 47.32  
 venous pressure 47.25  
 ambulatory, normal lowering 47.25  
 elevated 47.25, 47.26, 47.27, 47.41  
 pigmented purpuric dermatoses and 49.22  
*see also* venous hypertension  
 measurement 47.36  
 venous reflux 47.25–6, 47.32–3  
 investigations 47.35  
 superficial 47.37  
 venous return 47.25  
 venous stasis  
 lipomembranous fat necrosis and 46.22–3  
 purpura due to 49.14  
 venous surgery, for varicose veins 47.38  
 venous thrombosis 47.25, **47.28–32**  
 Mondor's disease *see* Mondor's disease  
 in paroxysmal nocturnal  
 haemoglobinuria 49.30  
 recurrent 47.7  
 superficial 47.30  
*see also* deep-vein thrombosis (DVT)  
 venous tone 47.25  
 venous ulceration 47.35  
 fibrin cuff-theory 47.26–7, 47.27  
 leg **47.41–52**  
 arterial disease coexistence 47.42  
 associated conditions 47.43–6  
 clinical features 47.42–3  
 complications 47.43–6  
 diagnosis 47.47  
 epidemiology 47.41–2  
 failure to heal 47.42  
 haemorrhage 47.45  
 healing, pathology 47.42  
 infections 47.44, 47.49  
 malignant changes 47.45–6, 47.50  
 management 47.47–50  
 measurement 47.49  
 pathogenesis 47.42  
 recurrent 47.50–1, 47.51  
 social factors 47.43–4  
 surgery 47.51–2  
*see also* ulcer(s), leg  
 lipodermatosclerosis 47.34  
 pathogenic theories 47.26–7  
 venous varicosity 47.35, 47.37  
*see also* varicose veins  
 venous vessels 3.51  
 venules 3.51  
 chronically dilated 47.12  
 dilatation, telangiectasia 47.12, 47.13  
 leg, laser therapy 78.8  
 venulitis  
 cutaneous necrotizing 50.4, **50.13–17**  
 in urticarial vasculitis 22.18  
 verapamil 75.95  
 Verbenaceae 26.81  
 vermilionectomy 77.36  
 vernal keratoconjunctivitis (VKC) 67.14, 67.15, 67.16  
 clinical features 67.13  
 vernal plaque 67.14  
 vernix caseosa 17.2, 17.4, 17.6, 17.11, 30.3–4, 42.3  
 Verocay bodies 56.46  
 verruca necrogenica 31.12  
 'verruca socks' 33.48  
 verrucae 28.54  
 verruciform xanthoma  
 female genital dermatology 71.73  
 male genital dermatology 71.36  
 verrucous carcinoma 33.55, 52.26  
 external auditory canal 68.33  
 female genital dermatology 71.76–7  
 male genital dermatology 71.22, 71.42, 71.44–6  
 oral cavity 69.53  
*see also* Buschke–Löwenstein tumour  
 verrucous hyperplasia, mechanical injury and 28.28  
 verrucous perforating collagenoma 45.65  
 verruga peruana 30.57–8  
 versican 3.46  
 gene 3.48  
 vertebral collapse, in Langerhans' cell  
 histiocytosis (LCH) 55.12  
 vertebrates  
 epidermis and dermis 2.2–3  
 pigment cells 2.5  
 vertical growth carcinoma, male genital  
 dermatology 71.42  
 vertical traction, in evaluation of  
 mechanical properties of skin 28.5  
 very late antigen-1 13.9  
 vesicles 10.37  
 in carbon monoxide poisoning 28.93–4  
 in CMV infection 33.29  
 definition 5.8  
 fluid, viral infection diagnosis 33.4  
 in foot and mouth disease 33.74  
 in hand, foot and mouth disease 33.71  
 in herpangina (coxsackievirus infection) 33.71  
 in herpes simplex 33.16, 33.18  
 intradermal, incontinentia pigmenti 58.15  
 in Kaposi's varicelliform eruption 33.35  
 in varicella 33.24  
 in viral infections 33.4  
 in zoster 33.25  
 vesico-urachal diverticulum 18.94  
 vesicular bodies 4.2  
 vesicular stomatitis virus **33.74**  
 vesiculobullous systemic lupus  
 erythematosus 40.56–8  
 Vespa 38.14  
 Vespidae/Vespoidea 38.14  
 Vespula 38.14  
 vestibular papillae, female genital  
 dermatology 71.55  
 vestibular papillomatosis, female genital  
 dermatology 71.55  
 vestibulodynia 71.82  
 veterinarians, occupational hazards 27.3, 27.5, 27.21  
 veterinary dermatology 2.8–19  
 Viagra *see* sildenafil  
 vibration injury **28.56–60**  
 vibration tests, mechanical injury 28.5  
 vibration white finger 27.17, 28.26, 28.56, **28.57–8**  
 vibratory angio-oedema 28.58  
*Vibrio alginolyticus* 30.18  
*Vibrio cholerae* 6.11  
*Vibrio vulnificus* 30.59  
 vibrissae 66.2, 66.6  
 vidarabine 35.28, 74.48  
 vigabatrin 75.86  
 villi 10.42  
 vimentin 3.9, 3.51, 10.22, 69.39  
 VIN *see* vulval intraepithelial neoplasia (VIN)  
 vinblastine 75.132  
 vincristine  
 adverse effects 70.5, 75.132  
 in infantile haemangioma 18.51  
 in Kasabach–Merritt syndrome/  
 phenomenon 18.57  
 vinegar  
 in alkali burns 27.12  
 in jellyfish stings 38.57  
 vinyl chloride 27.17, 45.51–2  
 vinyl chloride disease 51.80  
 violin spider 38.32  
 VIP *see* vasoactive intestinal peptide (VIP)  
 VIP–secretin-peptide family, PACAP 12.64  
 viral infection **33.1–81**  
 acne association 42.79  
 in animals 2.22  
 antibody production 33.4  
 in atopic dermatitis 24.12–13, 24.24  
 bystander activation hypothesis and 50.6  
 cutaneous problems 33.76–81  
 cytodiagnostics 10.29  
 Degos' disease aetiology 49.45  
 ear 68.20  
 electron microscopy 10.30  
 erythema multiforme and 33.76, 76.2  
 erythema nodosum and 33.76  
 exanthems 33.3–4, 33.4  
 eyes 67.24–5  
 female genital dermatology 71.69–70  
 Gianotti–Crosti syndrome *see*  
 Gianotti–Crosti syndrome  
 granuloma annulare and 60.1  
 haemorrhagic fevers **33.66–70**  
 diagnosis 33.68  
 idiopathic thrombocytopenic purpura  
 association 49.9, 49.10  
 insect-borne **33.66–70**  
 laboratory diagnosis 33.4–5  
 specimens 33.4  
 latent 33.3  
 lips 69.121  
 lytic 33.3  
 neonatal 17.39–42  
 oral cavity 69.72–7, 69.118  
 papular–purpuric gloves and socks  
 syndrome 33.76  
 pathogenesis 33.1–3  
 pathology **33.1–5**  
 permissive cells 33.1  
 persistent cells 33.3  
 polyarteritis nodosa in 33.77  
 purpura associated 49.20–1  
 reactivation 33.3  
 sarcoidal reaction in 61.22  
 sarcoidosis and 61.17  
 serological tests 33.4, 33.5  
 TORCH syndrome 33.76–7  
 vasculitis and 50.49, 50.55  
*see also* individual viral infections  
 viral warts *see* human papillomavirus (HPV)  
 Virchow's triad 47.28  
 virus(es)  
 assembly and release 33.3  
 attachment 33.1  
 classification 33.2–3  
 culture 33.4  
 detection methods 33.4  
 DNA 33.1, 33.2, 33.4, 33.14  
 double-stranded DNA 33.1, 33.2, 33.5  
 single-stranded DNA 33.2  
 in lichen planus pathogenesis 41.2–3  
 neurotropic 33.1  
 proteins 33.3  
 replication 33.1, 33.3, 33.4  
 RNA 33.1, 33.2, 33.3–4  
 diseases/infections 33.75  
 negative-sense 33.1, 33.3  
 positive-sense (mRNA) 33.1, 33.2–3  
 RNA tumour 33.1  
*see also* specific viruses  
 virus-associated haemophagocytic  
 syndrome 55.30–1  
 virus-induced histiocytic medullary  
 reticulosis 55.30–1  
 virus-induced histiocytosis with  
 erythrophagocytosis 55.30–1  
 visceral leishmaniasis **37.41–3**  
 viscous extension/slip 4.8  
 vision, colour, in animals 2.6  
 visual impairment  
 in giant cell arteritis 50.43, 50.44  
 in infantile haemangioma 18.45–6  
 in leprosy 32.13–14  
 in onchocerciasis 37.4, 37.5, 37.7  
 vitallium 26.37  
 vitamin(s) **59.60–7**  
 vitamin A 64.49  
 analogues *see* retinoids  
 deficiency 59.60, 67.31  
 pigmentation changes 58.28  
 derivatives, in sebaceous gland activity  
 reduction 42.16  
 intoxication 59.60  
 isotretinoin interaction 42.65  
 measles treatment 33.76  
 oral, acne vulgaris treatment 42.66  
*see also* retinol  
 vitamin A acid *see* retinoic acid (tretinoin);  
 vitamin A acid)  
 vitamin B complex 59.62  
 vitamin B supplements, high-dose,  
 pyoderma faciale and 42.84  
 vitamin B<sub>1</sub> 75.113  
 vitamin B<sub>3</sub> *see* nicotinic acid  
 vitamin B<sub>6</sub> 59.62, 75.113  
 vitamin B<sub>12</sub> 59.62–3  
 deficiency 62.85  
 hair colour changes in 66.94  
 oral involvement 69.56, 69.85–6,  
 69.116, 69.117  
 pigmentation changes in 58.27  
 in systemic sclerosis 51.102  
 sclerodermiform reaction 28.44–5  
 vitamin C 59.65–6  
 adverse effects 75.114  
 analogues 80.3  
 deficiency 59.65–6, 59.66  
 bone and joint involvement 62.101,  
 62.105  
 differential diagnosis 50.54  
 epidemiology 6.1  
 gingival involvement 69.21, 69.117  
 purpura in 49.4, 49.15  
 wound healing and 14.18  
 dithranol with 73.30  
 supplements  
 in miliaria 44.16  
 in wound healing 14.24

- vitamin D 59.61  
analogs 73.43–8  
  in psoriasis 20.26, 73.43  
  sensitization by 73.43  
calciotropic activity 73.43  
cutaneous calciphylaxis and 49.48  
cytokine release 73.43  
deficiency 29.6, 29.9, 54.34  
in psoriasis 73.43  
receptor 73.43  
  hair growth and 66.11  
  response elements 73.43  
  synthesis 4.1, 29.6, 54.34, 73.43  
  pigmentation hindering 58.9  
  therapeutic actions, mechanisms 73.43  
  Williams–Beuren syndrome and 45.25
- vitamin D<sub>3</sub> 29.6
- vitamin E 59.61  
adverse effects 75.114, 75.167  
allergy to 26.46  
secretion by sebaceous glands 42.7  
topical 75.167
- vitamin K  
adverse effects 45.52, 75.114  
allergy to 26.46  
antagonists 47.29  
deficiency, wound healing and 14.18  
prophylaxis 49.51  
sclerodermiform reaction to 28.44–5
- vitamin K-dependent coagulant factors 49.39
- Vitamin K epoxide reductase (VKORC1) 72.29
- vitelline duct 71.100  
anomalies 18.93–4
- vitiligo 58.46–9, 59.79  
in Addison's disease 62.5  
aetiology 58.46–7  
with alopecia areata 66.35  
in animals 2.23  
assessment 72.11  
autoantibodies 58.46  
breast 70.17  
clinical features 58.47–8  
complete 58.48  
diagnosis 58.48  
diascopy 5.19  
differential diagnosis 36.11  
disorders associated 58.46, 58.48  
electron microscopy 10.29–30  
with endocrine autoimmune conditions 62.13  
female genital dermatology 71.63  
hair colour and 58.48, 66.93  
in HIV infection 35.12  
incidence 58.46  
koebnerization 26.26, 26.27, 28.3  
male genital dermatology 71.49  
neurogenic hypothesis 58.47  
occupational 27.15, 58.9  
pathology 58.47  
piebaldism vs 58.42  
quality of life 64.10  
race and 9.6–7  
segmental 58.48  
self-destruct theory of Lerner 58.47  
skin biopsy 10.42  
skin grafts 77.21–2  
spontaneous repigmentation 58.48  
treatment 58.48–9, 73.26, 73.27  
trichrome 58.48  
in Vogt–Koyanagi–Harada syndrome 58.46  
Wood's light examination 5.19
- vitronectin 13.4, 14.3, 14.4
- VLA-1 (very late antigen-1) 13.9
- Vogt–Koyanagi–Harada syndrome (VKHS) 58.45–6, 66.93  
  premature greying of hair 58.48
- Vohwinkel's syndrome 19.3, 19.19, 19.94, 19.98, 19.108, 45.70
- Voight's lines 5.17, 9.2, 9.3
- volcano lesion 37.38
- volume expanders, platelet function disorders 49.12–13
- vomiting  
  self-induced 64.22  
  sweating following 44.7  
  urticaria and 22.5
- von Frey's syndrome 44.10, 44.11
- von Hippel–Lindau syndrome 62.20, 62.22, 62.69
- von Kossa method 10.10
- von Recklinghausen's disease *see* neurofibromatosis, type 1
- von Willebrand factor 49.12, 49.29  
  receptor, GPIIb/IIIa, expressed by dermal dendrocytes 55.4  
  in wound healing 14.3
- von Willebrand's disease, bleeding time 49.6
- voriconazole 36.68, 36.69, 36.86, 74.47, 75.66
- vorinostat 57.28
- Vörner's keratoderma (epidermolytic palmoplantar keratoderma) 19.94, 19.95–7
- VP (variegate porphyria) 59.19–20, 62.46, 66.79
- VP-16 *see* etoposide
- vulva  
  allergic contact dermatitis 26.18–19  
  amoebiasis 37.28  
  angiokeratoma 18.60  
  bacterial flora 30.4  
  cancer, lymphoedema 48.8  
  cicatrical pemphigoid, differential diagnosis 51.117  
  elephantiasis 30.70  
  hidradenoma papilliferum 53.20–1  
  lichen planus 41.9  
  lichen sclerosus 51.113–18  
  lymphangiectasia 48.28  
  lymphoedema 48.16  
  normal bacterial flora 30.4  
  Paget's disease 53.40–1  
  pruritus 21.12, 21.13, 21.15  
  pyoderma gangrenosum 50.70  
  squamous cell carcinoma 51.116  
  syphilitic chancre 34.7
- vulval epithelium 71.52, 71.53
- vulval intraepithelial neoplasia (VIN) 71.74–6  
  differentiated 71.75
- vulval lentiginos 71.80
- vulval lymphangiectasia 71.81
- vulval lymphoedema 71.81
- vulval melanosis 71.79–80
- vulval oedema 71.81
- vulval pain syndromes 71.81–2
- vulval papillomatosis 33.46
- vulval phycomycosis 71.69
- vulval purpura, chronic 71.61–2
- vulvar intraepithelial neoplasia (VIN) HPV and 33.54–5  
  treatment 73.24
- vulvar pemphigoid 40.34
- vulvitis 71.59, 71.61  
  in trichomoniasis 37.29
- vulvodynia 71.81–2  
  contact allergy and 26.19  
  race and 9.19
- vulvovaginal melanosis 58.15
- vulvovaginal–gingival lichen planus (VVG-LP) 41.9, 41.10, 71.60
- vulvovaginitis  
  atrophic 8.20  
  *Candida* 36.61–2, 36.68  
  streptococcal 30.32
- VWF (vibration white finger) 27.17, 28.26, 28.56, 28.57–8
- V–Y plasty 77.35
- W**  
W-plasty 77.35
- Waardenburg's syndrome 58.43–4, 69.12  
  clinical features and variants 58.43  
  genes, dog coat colour and 2.7  
  genetics 2.7, 58.44
- piebaldism in 66.93  
piebaldism vs 58.42
- Wachters' keratoderma (focal palmoplantar keratodermas) 19.3, 19.94, 19.95, 19.102–5
- Wade–Fite stain 10.10
- waist circumference 46.5
- Walbaum–Dehane–Schlemmer syndrome 15.56
- Waldenström's macroglobulinaemia 22.24, 49.13
- oral involvement 69.114
- purpura in 49.19
- Waldeyer's oropharyngeal ring 13.9, 69.2
- Wallace's line 5.15, 5.16
- walnut hair dye 66.97
- warble fly 38.9
- warfarin  
  adverse effects 75.105, 75.167  
  cutaneous calciphylaxis associated 49.48  
  platelet function abnormalities and 49.13  
  surgical complications and 77.9
- warfarin necrosis 49.39
- male genital dermatology 71.27
- warmth receptors 4.9
- wart(s) 33.39–54  
  acne vs 42.37  
  affecting eyelids 67.24  
  anatomist's/prosector's 31.10, 31.12  
  anogenital 33.39  
  'acuminate' 33.44  
  in children 33.40–1, 33.46  
  clinical features 33.44–6  
  epidemiology 33.39–40, 34.2  
  flat warts 33.46  
  genital lymphangiectasia vs 48.28  
  in HIV infection 33.59, 35.29–30  
  immunity impairment 33.42  
  incubation period 33.40, 33.41  
  infectivity and transmission 33.40  
  malignant condylomas vs 33.42  
  maternal, infectivity 33.40  
  non-sexual transmission 33.40–1  
  pathology 33.42  
  prevalence 34.2  
  recurrence 33.46  
  sexual transmission 33.40, 33.41  
  sites 33.44  
  terminology 33.44  
  transmission in adults 33.40  
  transmission in children 33.40–1  
  treatment 33.49, 33.50, 33.51, 73.25  
  *see also* condylomata acuminata
- in atopic dermatitis 24.24
- butchers' 33.47
- clinical features 33.42–6  
  common 33.40  
  around genitalia 33.43  
  clinical features 33.42–3  
  malignant change 33.43  
  pathology 33.41  
  transmission 33.40  
  cryotherapy 33.49–50  
  curettage 33.49, 77.40  
  deep palmoplantar 33.41  
  digitate 33.44  
  duration 33.44, 33.46  
  electrosurgery 33.49, 77.46  
  epidemiology 33.39–40  
  in epidermodysplasia verruciformis 33.57  
  filiform 33.44, 33.45  
  genital, imiquimod therapy 73.24  
  hands 33.48  
  in HIV infection and AIDS 33.59  
  in immunodeficiency 17.52, 33.58–9  
  incubation period 33.40, 33.41  
  laser therapy 33.50, 78.8  
  mosaic plantar 5.14, 33.44, 33.48  
  Murray Williams' 23.39  
  nail involvement 33.43, 33.48, 65.30–1  
  non-melanoma skin cancer and 52.11
- non-melanoma skin cancer associations in EV 52.5
- occlusion 33.48
- oral cavity 33.47, 33.48, 69.111
- pathology 33.41–2
- perianal 33.46, 33.59, 35.45  
  treatment 73.25
- periungual 33.43, 33.48
- phobias 64.24
- pigmented 33.47
- plane (flat) 33.42, 33.59  
  clinical features 33.43, 33.45  
  imiquimod therapy 73.24
- plantar 33.40  
  clinical features 33.43–4  
  pathology 33.41  
  transmission 33.40  
  in transplant recipients 33.59  
  treatment 33.48, 33.49, 33.50
- race and 9.18
- regression 33.42, 33.43, 33.44, 33.48
- sarcoidosis and 61.17
- satellite 33.44
- seborrhoeic *see* seborrhoeic keratosis
- senile *see* seborrhoeic keratosis
- soft *see* skin tags
- surgery 33.49
- tar 27.16
- transmission 33.40  
  iatrogenic 33.40, 33.50
- in transplant recipients 33.59, 62.74
- treatment 33.48–54  
  bleomycin 73.23  
  imiquimod 73.24  
  sensitizing agents 73.39  
  topical 5-FU 73.23
- vaccination 33.50  
  *see also* human papillomavirus (HPV)
- 'wart paint' 33.48
- Warthin–Starry technique 10.10, 34.19, 35.25
- warts, hypogammaglobulinaemia, infection, myelokathexis syndrome 17.81, 33.59
- warty dyskeratoma 69.26
- WAS *see* Wiskott–Aldrich syndrome
- washing, compulsive 64.24
- washing powders 25.20
- WASP (Wiskott–Aldrich syndrome protein) 17.62
- wasps  
  hypersensitivity to 22.8, 38.1, 38.3, 38.14–15  
  social 38.14  
  solitary 38.14  
  venom 38.14
- Wassermann reaction 51.2
- water  
  evaporation from skin surface 3.12  
  as irritant 25.19
- water-in-oil (W/O) emulsions 73.7
- Waterhouse–Friderichsen syndrome 62.5
- waterless cleansers 25.20
- Watson's syndrome 15.20
- wattle 18.84
- wax(es)  
  ear *see* cerumen  
  emulsifying 73.7  
  in topical therapy 73.7
- wax esters, in sebum 42.5, 42.22
- waxy keratoses of childhood 19.93
- weal and flare reaction, in solar urticaria 29.19
- weals  
  amplification and prolongation 22.4  
  caused by physical stimuli 22.12  
  definition 5.8, 22.1  
  in delayed pressure urticaria 22.14  
  immediate weal skin tests 5.22, 5.23–4  
  intradermal injection skin testing 5.22–3  
  measurement 5.23  
  resolution 22.4  
  urticarial 22.5, 22.6, 22.25
- wear and tear, in telangiectases 47.13

- wear and tear dermatitis 23.20  
cumulative irritant contact dermatitis  
25.1, 25.5, 25.12–13, 25.14, 25.15
- Weber-Christian syndrome 46.13, 46.15, 46.24
- Weber-Cockayne syndrome 39.4, 39.6, 39.30–1  
friction blisters in 28.13
- weed-wacker dermatitis 58.32  
*see also* phytophotodermatitis
- weeverfish 38.59
- Wegener's autoantigen 13.4, 50.39
- Wegener's granulomatosis (WG) 45.42, 50.39–41  
aetiology and pathogenesis 50.5–6, 50.7, 50.39, 50.55  
breast involvement 70.11  
cardiac involvement 62.78  
clinical features 50.39–40  
cutaneous small vessel vasculitis in 50.13  
differential diagnosis 50.69–70  
ear involvement 68.17  
genetic factors 50.11  
ocular involvement 67.25  
oral involvement 69.58, 69.118  
in parvovirus B19 infection 33.63  
relapse 30.7  
respiratory tract involvement 62.83  
treatment  
  cyclophosphamide 74.17  
  TNF antagonists 74.5, 74.8
- Weibel-Palade bodies 3.51–2  
electron microscopy 10.30  
P-selectin 12.71
- weight loss  
cellulite management 46.10  
lymphoedema management 48.23  
in obesity 46.7–8
- Weil's disease 30.66
- Weir Mitchell's disease 47.9
- Weir-Mitchell type, partial lipoatrophy 46.39–40
- welders, occupational hazards 27.21
- well being, concept of 64.4
- Wells' syndrome (eosinophilic cellulitis) 46.12, 46.33–4, 62.87
- Werlhof's disease *see* idiopathic thrombocytopenic purpura (ITP)
- Wermer syndrome 62.24, 62.68
- Werner's syndrome 15.77, 15.81, 45.57–8, 51.79, 58.23–4, 62.27–8  
atrophy of acral parts 51.79  
bone and joint involvement 62.100  
greying of hair 66.92
- West Nile fever/virus 33.67, 38.5
- western blotting 11.5  
*Treponema pallidum* 34.20
- Western equine encephalitis virus 33.66, 33.67
- western red cedar 26.80
- wet-wrap technique  
in atopic dermatitis 24.30  
in eczema 23.38
- wetting agents 25.20
- Weyer acrofacial dysostosis 15.56
- WG *see* Wegener's granulomatosis (WG)
- whales 2.3
- Wharton's duct 69.5
- Whiff test 71.53
- WHIM syndrome 17.81, 33.59
- whiplash rove beetles 38.27
- whipping injuries 28.32
- Whipple's disease 59.59, 61.23, 62.55  
arthralgia in 62.105
- whirlpools 28.54–5
- Whitaker's syndrome 13.13, 15.31, 36.64, 62.12–14
- white atrophy 15.13, 23.35, 47.34, 49.44
- white blood cells  
trapping, in venous disorders 47.27  
*see also* entries beginning leukocyte
- 'white clots' 49.28
- white finger 27.17, 28.26, 28.56, 28.57–8
- white folded gingivostomatosis 35.43, 69.23–4
- white ovoid macules 15.22
- White Soft Paraffin BP 73.2  
in eyelash louse infection 38.23
- white-spot disease *see* lichen sclerosus
- 'white spotting' 58.42
- white-tailed spiders 38.32
- whiteheads 42.22, 42.30, 42.36
- Whitfield's ointment 25.18, 36.47, 36.48, 36.49  
composition and indications 73.13
- whitlow  
herpetic 33.17, 65.22–3  
syphilis differential diagnosis 34.7
- WHO, Adverse Reactions Database 75.3, 75.4
- whole-body occlusion, corticosteroid therapy 73.20
- Wickham's striae, lichen planus 41.6
- Widmer classification, chronic venous insufficiency 47.32
- widow spiders 38.31
- Wiener's pore (dilated pore) 53.3
- wigs 26.18, 66.24
- Wilkinson's triangle 26.24
- Williams syndrome 3.44, 45.25
- willingness to pay (WTP) 72.22
- Wilson's disease 59.76
- Wimberger's sign 34.15
- Winchester syndrome 45.50, 66.76
- Winer's pore, pinna 68.28
- 'wire-loop' lesions, kidneys 51.34
- Wiskott-Aldrich syndrome 13.13, 62.28, 62.95–6, 69.117  
bacterial infection and 30.8  
genetics 13.11  
immunodeficiency and 17.62–3  
oral involvement 69.31  
vasculitis and 50.54
- Wiskott-Aldrich syndrome protein (WASP) 17.62
- witchcraft syndrome 64.40
- witch's milk 17.5
- Witkop syndrome 15.56, 15.65
- Witkop-von Sallmann syndrome 69.25
- Wnt 66.10  
signaling 3.3, 3.4, 3.7  
adherens junctions action 3.23
- Wnt/ $\beta$ -catenin pathway, melanocyte development 58.3
- Wohlfahrtia 38.8, 38.9
- Wolbachia 37.7, 37.9
- wolf spiders 38.32
- Wolffian ducts 8.2
- Wolf-Hirschhorn syndrome 15.12, 18.2, 18.103
- women  
HIV infection 35.44  
risk of adverse drug reactions 75.6  
sebum production 42.10  
*see also* entries beginning female
- wood, allergic contact dermatitis to 26.79, 26.80–1, 26.82–4
- Wood Alcohols BP 73.7
- wood dust 25.21, 26.20
- wood rosin 26.79
- wood tars 73.42
- woodcutters' dermatitis 26.77
- Wood's lamp 29.2  
pigmentation examination 58.9
- Wood's light 5.19–20, 36.6  
in erythrasma 30.38  
in pityriasis versicolor 36.11
- woodworkers, occupational hazards 27.21
- wool 2.3  
fibres as irritant 25.19
- wool fat *see* lanolin
- wool wax alcohols 26.58
- woolly hair, hypotrichosis, everted lower lip and outstanding ears 15.56
- woolly hair, keratoderma and cardiac disease and 19.94, 19.107
- Woringer-Kolopp disease 57.15
- World Bank, skin diseases report 6.16
- World Health Organization (WHO), Adverse Reactions Database 75.3, 75.4
- Woronin bodies 36.3
- wound(s)  
activated fibroblasts 12.31  
acute 14.9  
assessment 14.19–20  
chronic 14.1–2, 14.11–12  
cleansing 14.21–2  
closure 14.10  
compression bandaging 14.20–1, 38.31, 38.60  
debridement 14.22  
desiccation 14.17  
dressings *see* dressings  
embryonic 14.2, 14.9  
fetal 14.2, 14.9  
foreign bodies 14.17  
full thickness 14.10  
granulation tissue (provisional matrix) 14.1, 14.3, 14.6, 14.7  
haematoma formation 14.17  
healing *see* wound healing  
infection 14.16–17  
maggot debridement 14.22, 38.8  
measurement 14.19  
myiasis 38.8, 38.9, 38.10  
non-healing 64.38, 64.43  
open 14.10  
partial thickness 14.10  
*Pseudomonas aeruginosa* infection 14.16, 30.49, 30.50
- surgical  
closure 77.16–17  
complications 77.5, 77.8–9  
dog-ear/pseudo-dog-ear repairs 77.16  
dressings 7.17–18, 77.9  
infection 77.5, 77.8, 77.9  
secondary intention healing 77.12, 77.15, 77.16, 77.18, 77.19  
unequal length edges 77.16
- treatment  
honey role 73.48  
principles 14.19–27
- wound care  
burns 28.78, 28.84–6  
pressure ulcers 28.22–3  
*see also* dressings
- wound-care services 14.21
- wound healing 14.1–27  
angiogenesis 14.6–7  
biological aspects 14.1–9  
clinical aspects 14.9–15  
complications 14.15–19  
defensins 12.7  
effects of age 14.2, 14.9, 14.17–18, 45.2  
in elderly people 14.2, 14.9, 14.17–18  
fibroblast recruitment and matrix synthesis 14.7–8  
hyaluronic acid 3.49  
impaired, corticosteroid-induced 73.19  
improvement, retinoic acid 73.36  
in infancy and childhood 14.2  
inflammation and immune response 14.2–4  
inflammatory cells 14.1, 14.2  
integrins 12.69  
by primary intention 14.9–10  
re-epithelialization 14.4–6, 14.10, 14.17  
by secondary intention 14.10  
  following Mohs micrographic surgery 77.29  
  surgical wounds 77.12, 77.15, 77.16, 77.18, 77.19  
skin innervation and 63.4  
stress and 14.1  
systemic factors affecting 14.18–19  
tertiary 14.10
- wrinkles 8.19, 8.22–3, 8.27  
ageing and 45.2–3  
definition 45.2
- glyphic 45.2  
treatment 8.25, 8.27
- wrinkling, abnormal 28.93
- wrinkly skin syndrome 45.15, 45.61
- wrist sign 45.30
- WRN gene 15.77
- Wuchereria bancrofti* 37.3, 37.9–10
- Wyburn-Mason syndrome 18.62
- X**
- X-linked chronic granulomatous disease 13.4
- X-linked dominant ichthyosis (XLDI; Conradi-Hünemann-Happle syndrome) 19.3, 19.49–52, 62.100
- X-linked dominant (XLD) inheritance 15.4, 15.5
- X-linked dyskeratosis congenita 15.36
- X-linked hypohidrotic ectodermal dysplasia 15.43, 15.58–60
- X-linked ichthyosis  
genetics 15.5, 15.6  
pregnancy/labour in 8.9  
recessive 3.11, 19.3, 19.9–13
- X-linked lymphoproliferative syndrome 13.6, 13.11, 17.64  
vasculitis and 50.49
- X-linked recessive dyskeratosis congenita 15.78–80
- X-linked recessive ichthyosis 3.11, 19.3, 19.9–13
- X-linked recessive (XLR) inheritance 15.3
- X-ray(s) 79.1, 79.2  
in allergic contact dermatitis 26.102  
burns 28.84  
contrast lymphography 48.17  
epilation by 66.53–4  
non-melanoma skin cancer association 52.5  
in Sturge-Weber syndrome 18.66  
venous malformations 18.71  
*see also* radiography
- xanthelasma 59.84  
eyelids 67.33  
treatment 77.46, 77.50, 78.14
- xanthoerythroderma perstans 23.7–8, 57.57
- xanthogranuloma  
adult-onset 68.16  
ear 68.16  
generalized lichenoid variant 55.16  
juvenile 15.20, 67.33  
necrobiotic 55.27–9, 60.14, 62.45  
eyelids 67.33  
solitary giant 55.15  
spindle cell 55.20
- xanthogranulomatous reaction 55.6, 55.15
- xanthoma 59.81–93  
in acquired generalized lipodystrophy (AGL) 46.38  
bone and joint involvement 62.105  
ear 68.17  
eruptive 59.79, 59.85  
eyes 59.84–5  
juvenile *see* juvenile xanthogranuloma  
multiple eruptive in infancy *see* juvenile xanthogranuloma  
in necrobiotic xanthogranuloma 55.27  
palmar 59.85  
papular 55.19–20  
tendons 59.84  
tuberous 59.85  
verruciform 68.16, 69.112–13  
psoriasis in HIV infection vs 35.17
- xanthoma disseminatum 55.15, 55.20–2  
atypical 55.22  
variant 55.21
- xanthoma multiplex/naeviforme *see* juvenile xanthogranuloma
- xanthoma tuberosum, congenital *see* juvenile xanthogranuloma

- xanthomatosis  
cerebrotendinous 59.91  
diffuse normolipaemic plane 55.22  
diffuse plane 55.22
- xanthosiderohistiocytosis 55.21  
disseminated *see* xanthoma  
disseminatum
- xenon arc lamp 29.2
- Xenopsylla cheopis* 30.73, 38.11
- xeroderma, pruritus, in old age and 8.27
- xeroderma pigmentosum (XP) 13.13,  
52.10, 62.20, 62.22  
aetiology 15.70–1  
autosomal dominant 15.73  
clinical diversity 15.72  
clinical features 15.72–3  
diagnosis 15.73, 29.23  
differential diagnosis 15.81  
DNA repair defects 52.10  
genetics 15.5, 15.70–5  
melanoma association 54.48  
neoplasia and 15.72  
neurological complications 15.73  
nucleotide excision repair 15.71–2  
ocular lesions 15.73  
oral involvement 69.42  
pathology 15.72  
pigmentation in 58.24  
prenatal diagnosis 16.3  
skin sensitivity 15.72  
squamous cell carcinoma in 52.28  
treatment 15.73–4, 73.23  
trichothiodystrophy and 66.68  
XP variant 15.71–2
- xeroderma–talipes–enamel defect (XTE)  
syndrome 15.56
- xerosis  
eating disorders and 64.22  
in HIV infection 35.11–12  
pruritus and 21.12  
senile *see* asteatotic eczema (eczema  
craquelé)
- xerostomia 69.3  
drug-induced 75.46  
in HIV infection 35.42  
oral candidosis and 69.88
- XLD *see* X-linked dominant
- XLD (X-linked dominant) inheritance  
15.4, 15.5
- XLR (X-linked recessive) inheritance  
15.3
- XP *see* xeroderma pigmentosum (XP)
- XTE (xeroderma–talipes–enamel) defect  
15.56
- XXXXY syndrome 15.14, 68.4
- XXYY syndrome 15.14
- YYY syndrome 15.14, 42.18
- Y**
- Y-linked genes 15.4
- Yasmin®, acne treatment 42.53
- yatapox 33.5
- yaws 30.36, 30.63, 38.6, 71.31–2, 71.95  
bush 37.34, 37.35, 37.39–41  
'daughter yaws' 30.63  
in HIV infection 35.25  
latent syphilis vs 34.12  
'mother yaw' 30.63
- yeasts 36.2  
black 36.77  
identification 36.9  
lipophilic, overgrowth 42.75  
normal skin flora 35.13, 36.10  
*see also* fungi
- Yellow and White Soft Paraffin BP 73.6
- yellow card scheme 75.3
- yellow fever 33.67, 33.68, 38.5
- yellow-jackets 38.14
- yellow nail syndrome 48.10, 48.21, 62.83,  
65.12, 65.16–17  
in HIV infection 35.41
- Yersinia enterocolitica* 30.55  
in cellulitis 30.18
- Yersinia pestis* 30.54–5
- Yersinia pseudotuberculosis* 30.34, 50.45
- 'yesterday use' question 72.6–7
- yohimbine 75.119
- Yucatan pig model 73.27
- Z**
- Z-plasty 77.16
- zafirlukast 12.61, 13.4
- Zanier–Roubicek syndrome 15.56
- ZAP-70 kinase 13.8
- ZB (Zoon's balanitis) 71.13, 71.18,  
71.19–20
- Zeis gland 67.2  
cysts 67.33
- Zemaphyete 75.161
- Zenker's fluid 10.31
- zidovudine  
action 74.49  
adverse effects 75.67–8  
hypermelanosis 58.29  
nail colour changes 65.38  
in HIV infection 35.5, 35.17  
in HTLV-1 infection 33.65  
in psoriasis 20.42
- Ziehl–Neelsen stain 10.10
- zileuton (Zyflo) 12.61, 13.4
- zinc  
deficiency *see* zinc deficiency  
metabolism 59.75  
oral, acne vulgaris treatment 42.66  
supplements, effects on wound healing  
14.24–5  
topical 14.24  
wart treatment 33.50
- zinc acetate, topical erythromycin with  
42.16, 42.41
- zinc chloride 25.21
- zinc deficiency 59.60, 59.72–4  
acne lesions vs 42.37  
acquired 62.65  
in acrodermatitis enteropathica 69.31  
in animals 2.17  
in breastfed infants 59.73–4  
hair loss in 66.28–9  
napkin dermatitis and 17.25  
necrolytic acral erythema and 62.59  
during pregnancy 18.2  
treatment, oral zinc sulphate 59.75  
venous leg ulcers and 47.44  
wound healing and 14.18
- zinc metalloenzymes 3.41
- zinc oxide 73.8  
dithranol with 73.30  
paste(s) 73.2  
bandaging 47.48  
as sunscreen 73.40
- zinc paste bandaging 47.48
- zinc pyrithione 66.56, 73.13
- zinc pyrithione shampoo 73.13
- zinc-responsive dermatosis 2.17
- zinc–insulin granulomas 28.46
- Zineryt® 42.16
- Zinsser–Engman–Cole syndrome *see*  
dyskeratosis congenita (DKC)
- zirconium granuloma 61.22
- zirconium hydroxychloride 25.19
- Zlotogora–Ogur syndrome 15.33
- Zollinger–Ellison syndrome 62.24,  
62.67–8
- zonisamide 75.86
- zonula occludens proteins 3.24–5
- Zoon's balanitis (ZB) 71.13, 71.18,  
71.19–20
- Zoon's vulvitis 71.61
- zoster 33.3, 33.22–8  
acne and 42.79  
aetiology and epidemiology 33.23  
anogenital region 33.25  
antibodies 33.23  
clinical features 33.25–6  
complications 33.26  
cytodiagnosis 10.29  
diagnosis 33.27  
electron microscopy 10.30  
disseminated 33.25  
ear involvement 68.20, 68.28  
*see also* herpes zoster oticus  
in elderly people 8.28, 33.25, 33.26,  
33.28  
gustatory hyperhidrosis following  
44.10  
in HIV infection 33.25, 68.28  
immune response 33.23  
in immunocompromised patients 33.23  
in infancy 33.23  
in malaria 37.27  
male genital region 71.33  
motor involvement 33.25  
ophthalmic 33.25–6, 33.26, 33.28, 67.26  
in HIV infection 35.28  
oral involvement 69.74–5, 69.118  
orofacial 33.26  
pain 33.25, 33.26  
*see also* post-herpetic neuralgia  
pathology 33.24  
perianal/perineal 71.95  
prevention 33.27  
renal involvement 62.71  
sacral  
male genital region 71.33  
perianal/perineal 71.95  
sensory nerve 33.25, 33.26  
thoracic disease 33.25  
treatment 33.27–8  
trigeminal nerve 33.25–6  
management 33.28  
vaccine 63.7  
*see also* varicella zoster virus (VZV)
- zoster immune globulin 33.27
- zoster sine eruptione 33.25, 67.26
- zosteriform reticulate hyperpigmentation  
58.22–3
- zotepine 64.52
- Zumbusch-type psoriasis 20.49, 20.51
- Zyflo 12.61, 13.4
- Zygomycetes 36.2–3  
vessel-invasive infection 49.35
- zygomycosis 36.91–2  
blood vessel invasion 50.55  
male genital dermatology 71.32  
oral involvement 69.118  
rhinocerebral 69.80  
subcutaneous 36.78–9  
zymodemes 37.27